PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Morrison, SJ; Wandycz, AM; Akashi, K; Globerson, A; Weissman, IL				Morrison, SJ; Wandycz, AM; Akashi, K; Globerson, A; Weissman, IL			The aging of hematopoietic stem cells	NATURE MEDICINE			English	Article							BONE-MARROW CELLS; PROLIFERATIVE CAPACITY; REPOPULATING ABILITY; IRRADIATED MICE; MITOTIC CLOCK; FETAL LIVER; B-CELLS; AGE; PROGENITORS; INVITRO	We have purified hematopoietic stem cells (HSCs) from the bone marrow of old mice and compared their properties to HSCs in young and middle-aged mice. Single, reconstituting HSCs (by limit dilution) from old and young mice exhibited indistinguishable progenitor activities in vivo. HSCs were five times as frequent in the bone marrow of old mice; however, HSCs from old mice were only one-quarter as efficient at homing to and engrafting the bone marrow of irradiated recipients. HSCs in young and middle-aged mice rarely were in the S/C-2/M phases of the cell cycle, but HSCs in old mice were frequently in cycle. We speculate that the unexpected proliferation of HSCs in old mice might be related to the increased incidence of leukemia in old mice. HSCs change with age, but it is unknown whether these changes are determined intrinsically or caused by the aging of their environment.	STANFORD UNIV,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Stanford University; Stanford University; Weizmann Institute of Science			Morrison, Sean/ABD-5326-2021	Morrison, Sean/0000-0003-1587-8329	NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; FARRAR JJ, 1974, J IMMUNOL, V112, P1244; FRANCUS T, 1986, J IMMUNOL, V137, P2411; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARRISON DE, 1983, J EXP MED, V157, P1496, DOI 10.1084/jem.157.5.1496; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; HARRISON DE, 1979, MECH AGEING DEV, V9, P409, DOI 10.1016/0047-6374(79)90082-4; HARRISON DE, 1987, J NUTR, V117, P376, DOI 10.1093/jn/117.2.376; HARRISON DE, 1989, J IMMUNOL, V142, P3833; HARRISON DE, 1984, J EXP MED, V160, P759, DOI 10.1084/jem.160.3.759; HARRISON DE, 1973, P NATL ACAD SCI USA, V70, P4184; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; OGDEN DA, 1976, TRANSPLANTATION, V22, P287, DOI 10.1097/00007890-197609000-00010; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peters SO, 1996, BLOOD, V87, P30; REINCKE U, 1982, SCIENCE, V215, P1619, DOI 10.1126/science.7071580; ROLINK A, 1993, BLOOD, V81, P2290; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHARP A, 1989, MECH AGEING DEV, V48, P91, DOI 10.1016/0047-6374(89)90029-8; SIMINOVITCH L, 1964, J CELL COMPAR PHYSL, V64, P23, DOI 10.1002/jcp.1030640104; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; TSUJI K, 1992, BLOOD, V79, P2855; UCHIDA N, 1994, BLOOD, V83, P3758; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857	35	602	616	2	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1011	1016		10.1038/nm0996-1011	http://dx.doi.org/10.1038/nm0996-1011			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782459				2022-12-27	WOS:A1996VF49700036
J	Braly, P				Braly, P			Preventing cervical cancer	NATURE MEDICINE			English	Editorial Material											Braly, P (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT OBSTET & GYNECOL,NEW ORLEANS,LA 70112, USA.							BORYSIEWICZ IK, 1996, LANCET, V347, P1523; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; *NIH, 1996, CONS DEV C STAT CERV; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PROKOPCZYK B, 1996, P AM ASS CANC RES, V37; SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553	8	19	19	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					749	751		10.1038/nm0796-749	http://dx.doi.org/10.1038/nm0796-749			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673918	Bronze			2022-12-27	WOS:A1996UU68000028
J	Wahl, AF; Donaldson, KL; Fairchild, C; Lee, FYF; Foster, SA; Demers, GW; Galloway, DA				Wahl, AF; Donaldson, KL; Fairchild, C; Lee, FYF; Foster, SA; Demers, GW; Galloway, DA			Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis	NATURE MEDICINE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SIMIAN VIRUS-40; DRUG SENSITIVITY; CELL-LINES; PROTEIN; GROWTH; CANCER; RESISTANCE; RADIATION; AGENTS	The anticancer agent paclitaxel (Taxol(R)) stabilizes tubulin polymerization resulting in arrest in mitosis and apoptotic cell death. Normal human fibroblasts depleted of functional p53 by SV40 T antigen or HPV-16 E6, and primary embryo fibroblasts from p53 null mice showed seven- to ninefold increased cytotoxicity by paclitaxel. Reduced levels of p53 correlated with increased G2/M phase arrest, micronucleation, and p53-independent paclitaxel-induced apoptosis. Surviving cells with intact p53 progressed through mitosis and transiently accumulated in the subsequent G1 phase, coincident with increased p53 and p21(cip1,waf1) protein levels. These results are in contrast to studies linking p53 loss with resistance to DNA damaging anticancer agents.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543; FRED HUTCHINSON CANC RES CTR,CANC BIOL PROGRAM,SEATTLE,WA 98104	Bristol-Myers Squibb; Fred Hutchinson Cancer Center	Wahl, AF (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.				NATIONAL CANCER INSTITUTE [R01CA064795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARCELLOSHOFF MH, 1990, CANCER RES, V50, P3551; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CABANILLAS F, 1989, AM J MED, V87, P167; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1409, DOI 10.1073/pnas.75.3.1409; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELROUBY S, 1993, BLOOD, V82, P3452; ETTINGER DS, 1995, J CLIN ONCOL, V13, P1430, DOI 10.1200/JCO.1995.13.6.1430; FAN SJ, 1995, CANCER RES, V55, P1649; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GIANNI L, 1995, J CLIN ONCOL, V13, P180, DOI 10.1200/JCO.1995.13.1.180; GREGORY RE, 1993, CLIN PHARMACY, V12, P401; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWKINS DS, IN PRESS CANCER RES; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; HORWITZ SB, 1993, MONOGR NATL CANCER I, V15, P55; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LONG BH, 1994, CANCER RES, V54, P4355; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCUDIERO DA, 1988, CANCER RES, V48, P4827; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YOUNES A, 1995, J CLIN ONCOL, V13, P583, DOI 10.1200/JCO.1995.13.3.583; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	44	652	670	0	37	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					72	79		10.1038/nm0196-72	http://dx.doi.org/10.1038/nm0196-72			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564846				2022-12-27	WOS:A1996TP57900040
J	STOKES, CL				STOKES, CL			THE PROS AND CONS OF DRUG TRAFFICKING	NATURE MEDICINE			English	Editorial Material							MONOCLONAL-ANTIBODIES; SPATIAL-DISTRIBUTION; SOLID TUMORS				STOKES, CL (corresponding author), UNIV HOUSTON,DEPT CHEM ENGN,HOUSTON,TX 77204, USA.							BAXTER LT, 1992, CANCER RES, V52, P5838; FUJIMORI K, 1989, CANCER RES, V49, P5656; GHETIE MA, 1994, CURR OPIN IMMUNOL, V6, P707, DOI 10.1016/0952-7915(94)90073-6; JUWEID M, 1992, CANCER RES, V52, P5144; Lauffenburger D.A., 1993, RECEPTORS MODELS BIN; MYRDAL S, 1994, SCANNING, V16, P155; RIPPLEY RK, 1995, BIOPHYS J, V69, P825, DOI 10.1016/S0006-3495(95)79956-8; SHOCKLEY TR, 1992, CANCER RES, V52, P367; SUNG C, 1993, CANCER RES, V53, P2092; VIJAYKUMAR V, IN PRESS PHARMACEUTI; WOLFF J, 1994, GENE THERAPEUTICS ME; YAZDI PT, 1994, CANCER RES, V54, P6387	12	0	0	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1135	1136		10.1038/nm1195-1135	http://dx.doi.org/10.1038/nm1195-1135			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584980				2022-12-27	WOS:A1995TC53700032
J	ALLEN, KN				ALLEN, KN			ASPIRIN - NOW WE CAN SEE IT	NATURE MEDICINE			English	Editorial Material							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; INHIBITION; DRUGS				ALLEN, KN (corresponding author), BOSTON UNIV,SCH MED,DEPT PHYSIOL,STRUCT BIOL GRP,BOSTON,MA 02118, USA.		Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551				GARAVITO RM, 1994, CURR OPIN STRUC BIOL, V4, P529, DOI 10.1016/S0959-440X(94)90215-1; LOLI PJ, 1995, NAT STRUCT BIOL, V2, P637; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0	9	4	4	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					882	883		10.1038/nm0995-882	http://dx.doi.org/10.1038/nm0995-882			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585209				2022-12-27	WOS:A1995RT30300037
J	GRAINGER, DJ; WAKEFIELD, L; BETHELL, HW; FARNDALE, RW; METCALFE, JC				GRAINGER, DJ; WAKEFIELD, L; BETHELL, HW; FARNDALE, RW; METCALFE, JC			RELEASE AND ACTIVATION OF PLATELET LATENT TGF-BETA IN BLOOD-CLOTS DURING DISSOLUTION WITH PLASMIN	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; MOLECULAR-WEIGHT COMPLEX; SMOOTH-MUSCLE CELLS; FACTOR-BETA-1; PROLIFERATION; TGF-BETA-1; SEQUENCES; BINDING; PROTEIN	Transforming growth factor beta 1 (TGF-beta 1) is a platelet-derived cytokine involved in both normal wound healing and scarring. We show that human platelets contain two pools of latent TGF-beta 1, which constitute more than 95% of the total TGF-beta assayed in whole platelets. During clotting, one pool, the large latent TGF-beta complex consisting of latent TGF-beta binding protein (LTBP), the latency-associated peptide (LAP) and the 25-kD mature TGF-beta 1 dimer is released into the serum. A second pool, which contains LAP but not LTBP, is retained in the clot, but can be released by RGD peptide. When the clot is dissolved by plasmin this bound TGF-beta 1 is gradually activated and released. if similar mechanisms operate in vivo, the clot will act as a slow-release capsule of TGF-beta 1 activity during wound healing.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GRAINGER, DJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.							ANSCHER MS, 1993, NEW ENGL J MED, V328, P1592, DOI 10.1056/NEJM199306033282203; ASSOIAN RK, 1986, J CELL BIOL, V102, P1712; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORDER WA, 1991, J CLIN INVEST, V90, P1; CALRETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; GRAINGER DJ, 1993, BIOCHEM J, V294, P109, DOI 10.1042/bj2940109; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; Harpel John G., 1992, Progress in Growth Factor Research, V4, P321, DOI 10.1016/0955-2235(92)90014-9; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; NOH JW, 1993, NEPHRON, V63, P73, DOI 10.1159/000187146; OLSEN D, 1993, J CELL BIOCH E, V17, P106; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646	28	186	194	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					932	937		10.1038/nm0995-932	http://dx.doi.org/10.1038/nm0995-932			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585220				2022-12-27	WOS:A1995RT30300048
J	MEULI, M; MEULISIMMEN, C; HUTCHINS, GM; YINGLING, CD; HOFFMAN, KM; HARRISON, MR; ADZICK, NS				MEULI, M; MEULISIMMEN, C; HUTCHINS, GM; YINGLING, CD; HOFFMAN, KM; HARRISON, MR; ADZICK, NS			IN-UTERO SURGERY RESCUES NEUROLOGICAL FUNCTION AT BIRTH IN SHEEP WITH SPINA-BIFIDA	NATURE MEDICINE			English	Article							NEURAL-TUBE DEFECTS; ANATOMICAL PLASTICITY; AMNIOTIC-FLUID; MENINGOMYELOCELE; MODEL; GASTROSCHISIS; DYSRAPHISM; ETIOLOGY; DAMAGE	We hypothesize that the neurologic deficit associated with open spina bifida is not directly caused by the primary defect but rather is due to chronic mechanical and chemical trauma since the unprotected neural tissue is exposed to the intrauterine environment. We report here that exposure of the normal spinal cord to the amniotic cavity in midgestational sheep fetuses leads to a human-like open spina bifida with paraplegia at birth, indicating that the exposed neural tissue is progressively destroyed during pregnancy. When open spina bifida was repaired in, utero at an intermediate stage, the animals mars had near-normal neurologic function. The spinal cord was deformed but largely preserved. These findings suggest that secondary neural tissue destruction during pregnancy is primarily responsible for the functional loss and that timely in utero repair of open spina bifida might rescue neurologic function.	DAVIES MED CTR,MICROSURG LAB,SAN FRANCISCO,CA 94114; JOHNS HOPKINS MED INST,DEPT PATHOL,BALTIMORE,MD 21287; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,ANIM CARE FACIL,SAN FRANCISCO,CA 94143	California Pacific Medical Center; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	MEULI, M (corresponding author), UNIV CALIF SAN FRANCISCO,CTR FETAL TREATMENT,HSW1601,3RD & PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; BREGMAN BS, 1991, EXP NEUROL, V112, P49, DOI 10.1016/0014-4886(91)90113-Q; BREGMAN BS, 1982, SCIENCE, V217, P553, DOI 10.1126/science.7089581; CAMERON AH, 1956, LANCET, V2, P171; CAMPBELL LR, 1986, TERATOLOGY, V34, P171, DOI 10.1002/tera.1420340206; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COPP AJ, 1993, TRENDS NEUROSCI, V16, P381, DOI 10.1016/0166-2236(93)90001-3; EMERY JL, 1973, J PATHOL, V110, P83, DOI 10.1002/path.1711100110; GILBERT JN, 1986, NEUROSURGERY, V18, P559, DOI 10.1227/00006123-198605000-00008; HARRISON MR, 1980, SURGERY, V88, P174; HEFFEZ DS, 1993, NEUROSURGERY, V32, P1005, DOI 10.1227/00006123-199306000-00021; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; JORDAN M A, 1991, Teratology, V43, P472; Keller-Peck C., 1993, Society for Neuroscience Abstracts, V19, P181; KORENROMP MJ, 1986, LANCET, V1, P917, DOI 10.1016/S0140-6736(86)91022-6; LANGER JC, 1989, J PEDIATR SURG, V24, P992, DOI 10.1016/S0022-3468(89)80200-3; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; LOTGERING FK, 1986, SEMIN PERINATOL, V10, P94; LUTHY DA, 1991, NEW ENGL J MED, V324, P662, DOI 10.1056/NEJM199103073241004; MATSUOKA M, 1993, BIOCHEM PHARMACOL, V46, P159, DOI 10.1016/0006-2952(93)90360-9; MCLAUGHLIN JF, 1985, NEW ENGL J MED, V312, P1589, DOI 10.1056/NEJM198506203122501; MICHEJDA M, 1984, Z KINDERCHIR, V39, P259; NIKU SD, 1994, J UROLOGY, V152, P1025, DOI 10.1016/S0022-5347(17)32648-4; OSAKA K, 1978, J NEUROSURG, V49, P711, DOI 10.3171/jns.1978.49.5.0711; PATTEN BM, 1953, AM J ANAT, V93, P365, DOI 10.1002/aja.1000930304; SCHMIDT W, 1992, ADV ANATOMY EMBRYOLO, P1; SHAW GM, 1994, TERATOLOGY, V49, P143, DOI 10.1002/tera.1420490210; THEVENET A, 1986, ROUX ARCH DEV BIOL, V195, P345, DOI 10.1007/BF00402868; TIBBOEL D, 1986, TERATOLOGY, V33, P267, DOI 10.1002/tera.1420330303	29	251	256	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					342	347		10.1038/nm0495-342	http://dx.doi.org/10.1038/nm0495-342			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585064				2022-12-27	WOS:A1995RN09800030
J	FISHER, LJ; GAGE, FH				FISHER, LJ; GAGE, FH			RADICAL DIRECTIONS IN PARKINSONS-DISEASE	NATURE MEDICINE			English	Editorial Material							FIBROBLAST GROWTH-FACTOR; DOPAMINERGIC-NEURONS; NEUROTROPHIC FACTOR; EXPRESSION; TOXICITY; CULTURE				FISHER, LJ (corresponding author), UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093, USA.							BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Beck Klaus D., 1992, Neurodegeneration, V1, P27; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRUNDIN P, 1993, BASIC CLIN ASPECTS N, V5, P5; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FREED WJ, 1991, RESTOR NEUROL NEUROS, V3, P109, DOI 10.3233/RNN-1991-3301; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; 1993, NEW ENGL J MED, V328, P176	20	5	5	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					201	203		10.1038/nm0395-201	http://dx.doi.org/10.1038/nm0395-201			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585029				2022-12-27	WOS:A1995QX55900019
J	THOMPSON, JD; MACEJAK, D; COUTURE, L; STINCHCOMB, DT				THOMPSON, JD; MACEJAK, D; COUTURE, L; STINCHCOMB, DT			RIBOZYMES IN GENE-THERAPY	NATURE MEDICINE			English	Editorial Material							RNA				THOMPSON, JD (corresponding author), RIBOZYME PHARMACEUT INC,2950 WILDERNESS PL,BOULDER,CO 80301, USA.			Stinchcomb, Dan/0000-0002-3634-7503				BALTIMORE D, 1988, NATURE, V325, P395; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; Kashani-Sabet M, 1992, Antisense Res Dev, V2, P3; LEE SW, 1994, VIROLOGY, V68, P8254; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; YU M, 1994, GENE THER, V1, P13	11	48	52	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					277	278		10.1038/nm0395-277	http://dx.doi.org/10.1038/nm0395-277			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585047				2022-12-27	WOS:A1995QX55900040
J	CAPLEN, NJ; ALTON, EWFW; MIDDLETON, PG; DORIN, JR; STEVENSON, BJ; GAO, X; DURHAM, SR; JEFFERY, PK; HODSON, ME; COUTELLE, C; HUANG, L; PORTEOUS, DJ; WILLIAMSON, R; GEDDES, DM				CAPLEN, NJ; ALTON, EWFW; MIDDLETON, PG; DORIN, JR; STEVENSON, BJ; GAO, X; DURHAM, SR; JEFFERY, PK; HODSON, ME; COUTELLE, C; HUANG, L; PORTEOUS, DJ; WILLIAMSON, R; GEDDES, DM			LIPOSOME-MEDIATED CFTR GENE-TRANSFER TO THE NASAL EPITHELIUM OF PATIENTS WITH CYSTIC-FIBROSIS	NATURE MEDICINE			English	Article							ION-TRANSPORT DEFECT; POTENTIAL DIFFERENCE; CELLS; MICE; EXPRESSION; INVIVO; DNA	We report the results of a double-blind, placebo-controlled trial in nine cystic fibrosis (CF) subjects receiving cationic liposome complexed with a complementary DNA encoding the CF transmembrane conductance regulator (CFTR), and six CF subjects receiving only liposome to the nasal epithelium. No adverse clinical effects were seen and nasal biopsies showed no histological or immuno-histological changes. A partial restoration of the deficit between CF and non-CF subjects of 20% was seen for the response to low Cl- perfusion following CFTR cDNA administration. This was maximal around day three and had reverted to pretreatment values by day seven. In some cases the response to low Cl- was within the range for non-CF subjects. Plasmid DNA and transgene-derived RNA were detected in the majority of treated subjects. Although these data are encouraging, it is likely that transfection efficiency and the duration of expression will need to be increased for therapeutic benefit.	ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,ION TRANSPORT UNIT,LONDON SW3 6LR,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LR,ENGLAND; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON SW3 6LR,ENGLAND; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT CYST FIBROSIS,LONDON SW3 6LR,ENGLAND	Imperial College London; Royal Brompton Hospital; University of Edinburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Imperial College London; Royal Brompton Hospital; Imperial College London; Royal Brompton Hospital; Imperial College London; Royal Brompton Hospital	CAPLEN, NJ (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,NORFOLK PL,LONDON W2 1PG,ENGLAND.		Porteous, David J/C-7289-2013; Porteous, David/AAA-3446-2021; Middleton, Peter G/ABC-5138-2020; Caplen, Natasha J/H-2768-2016	Porteous, David J/0000-0003-1249-6106; Porteous, David/0000-0003-1249-6106; Middleton, Peter G/0000-0003-3361-4941; Caplen, Natasha J/0000-0002-0001-9460	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTON EWFW, 1990, EUR RESPIR J, V3, P922; ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BOUCHER RC, 1994, IN PRESS HUM GENE TH, V5, P501; CAPLEN NJ, 1994, GENE THER, V1, P139; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CRYSTAL RC, 1992, FED REG         1102, V57, P49584; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; HARDCASTLE J, 1991, GUT, V32, P1035, DOI 10.1136/gut.32.9.1035; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MIDDLETON PG, 1994, EUR RESPIR J, V7, P442, DOI 10.1183/09031936.94.07030442; MIDDLETON PG, EUR RESP J; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; VARNEY VA, 1992, AM REV RESPIR DIS, V145, P170; WELSH MJ, 1994, HUM GENE THER, V5, P209, DOI 10.1089/hum.1994.5.2-209; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WILSON JM, 1994, IN PRESS HUM GENE TH; WILSON R, 1987, EUR J RESPIR DIS, V70, P272; YEI SP, 1994, GENE THER, V1, P192; ZABNER J, 1993, CELL, V75, P1	28	649	697	1	51	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					39	46		10.1038/nm0195-39	http://dx.doi.org/10.1038/nm0195-39			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584951				2022-12-27	WOS:A1995QX55700024
J	Gourley, PL				Gourley, PL			Semiconductor microlasers: A new approach to cell-structure analysis	NATURE MEDICINE			English	Article											Gourley, PL (corresponding author), SANDIA NATL LABS,POB 5800,ALBUQUERQUE,NM 87185, USA.							ANDERSEN M, 1977, POLYMER, V18, P867, DOI 10.1016/0032-3861(77)90126-4; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BARER R, 1957, J OPT SOC AM, V47, P545, DOI 10.1364/JOSA.47.000545; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; Born M., 1980, PRINCIPLES OPTICS; *ENG FDN, 1994, NAN BIOS FRONT CHALL; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; Gourley P.L., 1996, P SOC PHOTO-OPT INS, V2679, P132; GOURLEY PL, 1995, P SOC PHOTO-OPT INS, V2387, P148, DOI 10.1117/12.206815; GOURLEY PL, 1994, IEEE SPECTRUM, V31, P31, DOI 10.1109/6.299535; GOURLEY PL, 1994, NATURE, V371, P571, DOI 10.1038/371571a0; GOURLEY PL, 1995, BIOPHOTONICS INT, V2, P48; KESSEL D, 1993, SELECTED PAPERS PHOT; MATSUMOTO B, 1993, CELL BIOL APPL CONF, V38; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; Stryer L., 1988, BIOCHEMISTRY-US; TUCHIN VV, 1992, P C OPT METH BIOM DI, P2; WIEGANDSTEUBING R, 1991, CYTOMETRY, V12, P505; YARIV A, 1985, OPTICAL ELECTRONICS, pCH2	19	26	27	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					942	944		10.1038/nm0896-942	http://dx.doi.org/10.1038/nm0896-942			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705868				2022-12-27	WOS:A1996UZ80400045
J	Saag, MS; Holodniy, M; Kuritzkes, DR; OBrien, WA; Coombs, R; Poscher, ME; Jacobsen, DM; Shaw, GM; Richman, DD; Volberding, PA				Saag, MS; Holodniy, M; Kuritzkes, DR; OBrien, WA; Coombs, R; Poscher, ME; Jacobsen, DM; Shaw, GM; Richman, DD; Volberding, PA			HIV viral load markers in clinical practice	NATURE MEDICINE			English	Editorial Material							VIRUS; INFECTION; PLASMA		STANFORD UNIV,STANFORD,CA 94305; PALO ALTO VET AFFAIRS HLTH CARE SYST,PALO ALTO,CA; UNIV COLORADO,HLTH SCI CTR,BOULDER,CO 80309; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024; W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA; UNIV WASHINGTON,SEATTLE,WA 98195; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093; SAN DIEGO VET AFFAIRS MED CTR,SAN DIEGO,CA	Stanford University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of California System; University of California San Diego	Saag, MS (corresponding author), UNIV ALABAMA,908 20TH ST S,BIRMINGHAM,AL 35294, USA.			Holodniy, Mark/0000-0002-6655-7982				Brambilla D., 1996, P155; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOMBS RW, IN PRESS J INFECT DI; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Hammer S. M., 1996, P175; HAVLIR D, 1995, J INFECT DIS, V172, P1379, DOI 10.1093/infdis/172.5.1379; Heath-Chiozzi Margo, 1996, P162; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; HOLODNIY M, 1995, J VIROL, V69, P3510, DOI 10.1128/JVI.69.6.3510-3516.1995; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; KAPPES JC, 1995, J ACQ IMMUN DEF SYND, V10, P139, DOI 10.1097/00042560-199510020-00005; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELLORS JW, IN PRESS SCIENCE; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBRIEN WA, 1995, BLOOD, V86, P1082; OBRIEN WA, 1996, NEW ENGL J MED, V334, P425; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RABOUD RM, 1995, J ACQUIR IMMUNE D S2, V10, pS67; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WELLES SI, IN PRESS J INFECT DI	33	446	464	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					625	629		10.1038/nm0696-625	http://dx.doi.org/10.1038/nm0696-625			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640545				2022-12-27	WOS:A1996UN69100022
J	Norimura, T; Nomoto, S; Katsuki, M; Gondo, Y; Kondo, S				Norimura, T; Nomoto, S; Katsuki, M; Gondo, Y; Kondo, S			p53-dependent apoptosis suppresses radiation-induced teratogenesis	NATURE MEDICINE			English	Article							MALFORMATIONS; MICE; P53	About half of human conceptions are estimated not to be implanted in the uterus, resulting in unrecognizable spontaneous abortions(1,2), and about 5% of human births have a recognizable malformation(1,3). In order to find clues to the mechanisms of malformation and abortion, we compared the incidences of radiation-induced malformations and abortions in p53 null (p53(-/-)) and wild-type (p53(+/+)) mice. After X-irradiation with 2 Cy on day 9.5 of gestation, p53(-/-) mice showed a 70% incidence of anomalies and a 7% incidence of deaths, whereas p53(+/+) mice had a 20% incidence of anomalies and a 60% incidence of deaths. Similar results were obtained after irradiation on day 3.5 of gestation. This reciprocal relationship of radiosensitivity to anomalies and to embryonic or fetal lethality supports the notion that embryonic or fetal tissues have a p53-dependent ''guardian'' of the tissue(4) that aborts cells bearing radiation-induced teratogenic DNA damage. In fact, after X-irradiation, the number of cells with apoptotic DNA fragments was greatly increased in tissues of the p53(+/+) fetuses but not in those of the p53(-/-) fetuses.	KYUSHU UNIV, MED INST BIOREGULAT, HIGASHI KU, FUKUOKA 812, JAPAN; KINKI UNIV, ATOM ENERGY RES INST, HIGASHIOSAKA, OSAKA 577, JAPAN	Kyushu University; Japan Atomic Energy Agency; Kindai University (Kinki University)	Norimura, T (corresponding author), UNIV OCCUPAT & ENVIRONM HLTH, SCH MED, DEPT RADIAT BIOL & HLTH, YAHATANISHI KU, KITAKYUSHU, FUKUOKA 807, JAPAN.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BOUE A, 1985, ADV HUM GENET, V14, P1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; FUKUNAGA A, 1985, MUTAT RES, V151, P243, DOI 10.1016/0027-5107(85)90076-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERT SF, 1991, DEV BIOL, P193; GONDO Y, 1994, BIOCHEM BIOPH RES CO, V202, P830, DOI 10.1006/bbrc.1994.2005; KONDO S, 1988, INT J RADIAT BIOL, V53, P95, DOI 10.1080/09553008814550461; KONDO S, 1993, HLTH EFFECTS LOW LEV, P73; KONDO S, 1984, PROBLEMS THRESHOLD C, P121; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCKEOWN T, 1976, BRIT MED BULL, V32, P1; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; MOLE RH, 1992, ADV RADIAT BIOL, V15, P217; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NOMURA T, 1990, J EXP MED, V172, P1325, DOI 10.1084/jem.172.5.1325; NOMURA T, 1975, CANCER RES, V35, P264; Nomura T., 1984, CONGENIT ANOM, V24, P329; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	23	206	210	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					577	580		10.1038/nm0596-577	http://dx.doi.org/10.1038/nm0596-577			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616719				2022-12-27	WOS:A1996UJ23000043
J	BenEliyahu, S; Page, GG; Yirmiya, R; Taylor, AN				BenEliyahu, S; Page, GG; Yirmiya, R; Taylor, AN			Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; NK CELLS; RATS; CANCER; INVIVO; ETHANOL; INVOLVEMENT; IMMUNITY; DEFENSE; SPREAD	Alcohol consumption is associated with increased morbidity and mortality related to infectious diseases and malignancy(1-5), although immune mediation of these relationships is controversial. Specifically, the activity of natural killer (NK) cells, which are involved in the resistance to infections and metastasis, can be suppressed in the presence of ethanol in vitro. However, acute consumption or infusion of ethanol in vivo exerts no effects on NK activity assessed in vitro thereafter. Therefore, we have developed and used a method to study the effects of ethanol on NK activity in living rats by using an NK-sensitive metastatic process and selective depletion of NK cells in vivo. Acute ethanol intoxication caused a-marked suppression of NK activity in vivo and a tenfold increase in the number of MADB106 tumor metastases. Ethanol had no effect in rats selectively depleted of NK cells or when an NK-insensitive tumor (C4047) was used. These findings suggest that even acute ethanol intoxication markedly suppresses NK activity in the living organism. This suppression may underlie some aspects of the association between alcoholism, infectious disease and malignancies.	OHIO STATE UNIV, COLL NURSING, COLUMBUS, OH 43210 USA; HEBREW UNIV JERUSALEM, DEPT PSYCHOL, IL-91905 JERUSALEM, ISRAEL; UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROBIOL, LOS ANGELES, CA 90095 USA; W LOS ANGLES DEPT VET AFFAIRS MED CTR, LOS ANGELES, CA 90095 USA	University System of Ohio; Ohio State University; Hebrew University of Jerusalem; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BenEliyahu, S (corresponding author), TEL AVIV UNIV, DEPT PSYCHOL, IL-69978 TEL AVIV, ISRAEL.		Ben-Eliyahu, Shamgar/AAE-5444-2020; Yirmiya, Raz/D-1090-2014	Yirmiya, Raz/0000-0002-4009-7316; Ben-Eliyahu, Shamgar/0000-0003-3832-0678	NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOZZARI T, 1985, J IMMUNOL, V134, P2783; BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; BENELIYAHU S, 1992, PROG NEUROENDOCRINIM, V5, P199; BLANK SE, 1993, ALCOHOL CLIN EXP RES, V17, P561, DOI 10.1111/j.1530-0277.1993.tb00800.x; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHAMBERS WH, 1992, J IMMUNOL, V148, P3658; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GORELIK E, 1982, INT J CANCER, V30, P107, DOI 10.1002/ijc.2910300118; HANNA N, 1984, BIOCHIM BIOPHYS ACTA, V780, P213, DOI 10.1016/0304-419X(85)90004-6; HENDERSON IC, 1980, NEW ENGL J MED, V302, P17, DOI 10.1056/NEJM198001033020104; IRWIN MR, 1993, ADV BIOSCI, V86, P69; JERRELLS TR, 1992, ALCOHOL, V9, P459, DOI 10.1016/0741-8329(92)90081-K; LESLIE I, 1993, ALCOHOL CLIN EXP RES, V17, P725; LEVY S, 1987, J CLIN ONCOL, V5, P348, DOI 10.1200/JCO.1987.5.3.348; LONG GS, 1988, TRANSPLANTATION, V46, P433, DOI 10.1097/00007890-198809000-00020; LOTZOVA E, 1993, NAT IMMUN, V12, P169; MACGREGOR RR, 1986, JAMA-J AM MED ASSOC, V256, P1474, DOI 10.1001/jama.256.11.1474; MATHER GG, 1994, IMMUNOBIOLOGY, V190, P333, DOI 10.1016/S0171-2985(11)80606-6; MEADOWS GG, 1993, ALCOHOL IMMUNITY CAN, P55; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; OCHSHORNADELSON M, 1994, ALCOHOL CLIN EXP RES, V18, P1361, DOI 10.1111/j.1530-0277.1994.tb01437.x; OLDHAM RK, 1990, NAT IMMUN CELL GROW, V9, P297; PAGE GG, 1994, BRAIN BEHAV IMMUN, V8, P241, DOI 10.1006/brbi.1994.1022; PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7; Roselle G, 1993, ALCOHOL IMMUNITY CAN, P3; SCHANTZ SP, 1987, CANCER IMMUNOL IMMUN, V25, P141; VANDENBRINK MRM, 1990, J EXP MED, V171, P197, DOI 10.1084/jem.171.1.197; WATSON RR, 1994, ALCOHOL ALCOHOLISM, V29, P131; WATSON RR, 1988, PROG FOOD NUTR SCI, V12, P189; WELSH RM, 1990, NAT IMMUN CELL GROW, V9, P112; WILTROUT RH, 1985, J IMMUNOL, V134, P4267; WU WJ, 1994, J PHARMACOL EXP THER, V271, P722; YEAGER MP, 1991, ARCH SURG-CHICAGO, V126, P454; YIRMIYA R, 1992, BRAIN BEHAV IMMUN, V6, P74, DOI 10.1016/0889-1591(92)90061-R; YIRMIYA R, 1993, ALCOHOL IMMUNITY CAN, P257	35	103	106	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					457	460		10.1038/nm0496-457	http://dx.doi.org/10.1038/nm0496-457			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597957				2022-12-27	WOS:A1996UD31400049
J	MAYORDOMO, JI; ZORINA, T; STORKUS, WJ; ZITVOGEL, L; CELLUZZI, C; FALO, LD; MELIEF, CJ; ILDSTAD, ST; KAST, WM; DELEO, AB; LOTZE, MT				MAYORDOMO, JI; ZORINA, T; STORKUS, WJ; ZITVOGEL, L; CELLUZZI, C; FALO, LD; MELIEF, CJ; ILDSTAD, ST; KAST, WM; DELEO, AB; LOTZE, MT			BONE-MARROW-DERIVED DENDRITIC CELLS PULSED WITH SYNTHETIC TUMOR PEPTIDES ELICIT PROTECTIVE AND THERAPEUTIC ANTITUMOR IMMUNITY	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; LANGERHANS CELLS; LYMPHOCYTES; GENERATION; MOLECULES; INVIVO	Dendritic cells, the most potent 'professional' antigen-presenting cells, hold promise for improving the immunotherapy of cancer. In three different well-characterized tumour models, naive mice injected with bone marrow-derived dendritic cells prepulsed with tumour-associated peptides previously characterized as being recognized by class 1 major histocompatibility complex-restricted cytotoxic T lymphocytes, developed a specific T-lymphocyte response and were protected against a subsequent lethal tumour challenge. Moreover, in the C3 sarcoma and the 3LL lung carcinoma murine models, treatment of animals bearing established macroscopic tumours (up to 1 cm(2) in size) with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases. These results support the clinical use of tumour peptide-pulsed dendritic cells as components in developing effective cancer vaccines and therapies.	UNIV PITTSBURGH,DEPT CELL THERAPEUT,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT DERMATOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15261; LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	MAYORDOMO, JI (corresponding author), UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261, USA.		Falo, Louis/ABD-1499-2020; Mayordomo, Jose/K-3453-2013	Kast, W Martin/0000-0003-2321-3159; ZITVOGEL, laurence/0000-0003-1596-0998; Celluzzi, Christina/0000-0002-2886-5597; Storkus, Walter/0000-0001-8961-4444	NATIONAL CANCER INSTITUTE [R01CA057840, R01CA067407] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57840, CA67407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; BELLONE M, 1994, EUR J IMMUNOL, V24, P2691, DOI 10.1002/eji.1830241118; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CAUX C, 1991, BLOOD, V78, P635; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; FRASSANITO MA, 1995, CANCER RES, V55, P124; GRABBE S, 1991, J IMMUNOL, V146, P3656; GRABBE S, 1995, IMMUNOL TODAY, V16, P116; GYURE LA, 1987, BRIT J CANCER, V55, P17, DOI 10.1038/bjc.1987.4; HSU FJ, 1994, BLOOD, V84, pA520; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; KAST WM, 1988, J IMMUNOL, V140, P3186; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; KOCH F, 1990, J EXP MED, V171, P159, DOI 10.1084/jem.171.1.159; LANIER LL, 1995, J IMMUNOL, V154, P97; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; RAZIWOLF Z, 1994, EUR J IMMUNOL, V24, P805, DOI 10.1002/eji.1830240405; ROCK KL, 1993, J IMMUNOL, V150, P1244; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; STORKUS WJ, 1995, BIOL THERAPY CANC, P64; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; TAMAKI K, 1979, J IMMUNOL, V123, P784; ZORINA T, 1994, J IMMUNOTHER, V16, P247	38	1016	1073	1	59	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1297	1302		10.1038/nm1295-1297	http://dx.doi.org/10.1038/nm1295-1297			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489412				2022-12-27	WOS:A1995TH78600043
J	BACH, FH; ROBSON, SC; WINKLER, H; FERRAN, C; STUHLMEIER, KM; WRIGHTON, CJ; HANCOCK, WW				BACH, FH; ROBSON, SC; WINKLER, H; FERRAN, C; STUHLMEIER, KM; WRIGHTON, CJ; HANCOCK, WW			BARRIERS TO XENOTRANSPLANTATION	NATURE MEDICINE			English	Editorial Material							XENOGRAFT REJECTION; ENDOTHELIAL-CELLS; P-SELECTIN; EXPRESSION; INJURY; GENE				BACH, FH (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,SANDOZ CTR IMMUNOBIOL,BOSTON,MA 02115, USA.		Robson, Simon C./AAA-8537-2021					BACH FH, 1991, TRANSPL P, V23, P205; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1993, XENO, V1, P8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P541; CANDINAS D, IN PRESS TRANSPLANTN; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; Cooper D K, 1993, Transpl Immunol, V1, P198, DOI 10.1016/0966-3274(93)90047-C; COUGHLAN AF, 1993, TRANSPLANT P, V25, P2930; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; FAINT RW, 1992, BLOOD REV, V6, P83, DOI 10.1016/0268-960X(92)90010-N; FODOR WL, 1995, XENO, V3, P23; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GOODMAN DJ, IN PRESS TRANSPLANTN; GREY ST, 1994, J IMMUNOL, V153, P3664; HOFER E, 1992, IMMUNOL TODAY, V13, P429, DOI 10.1016/0167-5699(92)90067-H; HOFER E, 1994, TRANSPLANT P, V26, P1322; INVERARDI L, 1992, J IMMUNOL, V149, P1416; KOPP CW, IN PRESS TRANSPLANTN; LESNIKOSKI BA, 1995, TRANSPLANT P, V27, P290; LESNIKOSKI BA, IN PRESS TRANSPLANTN; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MILLAN MT, IN PRESS TRANSPLANTN; PARETI FI, 1992, BRIT J HAEMATOL, V82, P81, DOI 10.1111/j.1365-2141.1992.tb04597.x; PEERSCHKE EIB, 1993, J EXP MED, V178, P579, DOI 10.1084/jem.178.2.579; POBER JS, 1991, TRANSPLANTATION, V50, P537; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; ROBSON SC, IN PRESS TRANSPLANTN; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; SCHAAPHERDER AFM, 1994, TRANSPLANTATION, V57, P1376, DOI 10.1097/00007890-199405150-00016; TSUJI T, 1994, J LEUKOCYTE BIOL, V56, P583, DOI 10.1002/jlb.56.5.583; VANHOVE B, 1993, TRANSPLANTATION, V56, P1251; WRIGHTON CJ, 1995, TRANSPLANT P, V27, P288	38	243	252	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					869	873		10.1038/nm0995-869	http://dx.doi.org/10.1038/nm0995-869			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585204				2022-12-27	WOS:A1995RT30300032
J	NELSON, JB; HEDICAN, SP; GEORGE, DJ; REDDI, AH; PIANTADOSI, S; EISENBERGER, MA; SIMONS, JW				NELSON, JB; HEDICAN, SP; GEORGE, DJ; REDDI, AH; PIANTADOSI, S; EISENBERGER, MA; SIMONS, JW			IDENTIFICATION OF ENDOTHELIN-1 IN THE PATHOPHYSIOLOGY OF METASTATIC ADENOCARCINOMA OF THE PROSTATE	NATURE MEDICINE			English	Article							BREAST-CANCER CELLS; IMMUNOREACTIVE ENDOTHELIN; GENE-EXPRESSION; STROMAL CELLS; HUMAN-PLASMA; DISEASE; GROWTH; ANTIGEN; FAMILY; TUMOR	Prostate cancer is the second most common cause of death from cancer in U.S. men, and advanced, hormone-refractory disease is characterized by painful osteoblastic bone metastases. Endothelin-1, more commonly known as a potent vasoconstrictor, is a normal ejaculate protein that also stimulates osteoblasts. We show here that plasma immunoreactive endothelin concentrations are significantly elevated in men with metastatic prostate cancer and that every human prostate cancer cell line tested produces endothelin-1 messenger RNA and secretes immunoreactive endothelin. Exogenous endothelin-1 is a prostate cancer mitogen in vitro and increases alkaline phosphatase activity in new bone formation, indicating that ectopic endothelin-1 may be a mediator of the osteoblastic response of bone to metastatic prostate cancer.	JOHNS HOPKINS MED INST,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21287; JOHNS HOPKINS MED INST,DEPT ORTHOPED SURG,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	NELSON, JB (corresponding author), JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,MARBURG 1,600 N WOLFE ST,BALTIMORE,MD 21287, USA.				NCI NIH HHS [CA 01495, CA 58236] Funding Source: Medline; NIDDK NIH HHS [DK07552] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001495, P50CA058236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007552] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM ASMT, 1992, ENDOCRINOLOGY, V130, P3617, DOI 10.1210/en.130.6.3617; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BATTISTINI B, 1993, LAB INVEST, V68, P600; BROWN KD, 1989, BIOCHEM J, V263, P977, DOI 10.1042/bj2630977; CACOUB P, 1993, NEW ENGL J MED, V329, P1967; CASEY ML, 1992, J CLIN ENDOCR METAB, V74, P223, DOI 10.1210/jc.74.1.223; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; DAHLOF B, 1990, J HYPERTENS, V8, P811, DOI 10.1097/00004872-199009000-00004; ECONOMOS K, 1992, CANCER RES, V52, P554; EISENBERGER MA, 1993, J NATL CANCER I, V85, P611, DOI 10.1093/jnci/85.8.611; ERDOS EG, 1985, LAB INVEST, V52, P437; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KELLY WK, 1993, J CLIN ONCOL, V11, P607, DOI 10.1200/JCO.1993.11.4.607; KOBAYASHI S, 1994, MOL PHARMACOL, V45, P306; KOBAYASHI S, 1994, J UROLOGY, V151, P763, DOI 10.1016/S0022-5347(17)35083-8; KOCHVA E, 1993, TOXICON, V31, P541, DOI 10.1016/0041-0101(93)90111-U; KOCHVA E, 1982, TOXICON, V20, P581, DOI 10.1016/0041-0101(82)90052-6; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; KRUSKAL WH, 1953, J AM STAT ASSOC, V48, P907, DOI 10.2307/2281082; KUSUHARA M, 1990, CANCER RES, V50, P3257; LAM HC, 1991, J CARDIOVASC PHARM, V17, pS390, DOI 10.1097/00005344-199100177-00109; LANGENSTROER P, 1993, J UROLOGY, V149, P495; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; MOLLER S, 1993, J HEPATOL, V19, P285, DOI 10.1016/S0168-8278(05)80584-7; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NAKAMUTA M, 1993, AM J GASTROENTEROL, V88, P248; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OGAWA S, 1993, J CARDIOVASC PHARM, V22, pS364, DOI 10.1097/00005344-199322008-00095; Papandreou C., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P268; PITTET JF, 1991, ANN SURG, V213, P261, DOI 10.1097/00000658-199103000-00014; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POLDERMAN KH, 1993, ANN INTERN MED, V118, P429, DOI 10.7326/0003-4819-118-6-199303150-00006; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REDDI AH, 1980, ENDOCRINOLOGY, V107, P1291, DOI 10.1210/endo-107-5-1291; ROLINSKI B, 1994, RES EXP MED, V194, P9, DOI 10.1007/BF02576362; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; RUBIN SA, 1994, J CLIN ENDOCR METAB, V78, P6, DOI 10.1210/jc.78.1.6; SCHER HI, 1994, SEMIN ONCOL, V21, P630; SCHICHIRI M, 1991, J CLIN INVEST, V87, P1867; SCHREY MP, 1992, CANCER RES, V52, P1786; SCHVARTZ I, 1992, PEPTIDES, V13, P159, DOI 10.1016/0196-9781(92)90157-X; SHIOIDE M, 1993, J CELL BIOCHEM, V53, P176, DOI 10.1002/jcb.240530211; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; SUZUKI N, 1989, J BIOCHEM-TOKYO, V106, P736, DOI 10.1093/oxfordjournals.jbchem.a122925; TAKASAKI C, 1988, NATURE, V335, P303, DOI 10.1038/335303b0; TAKUWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P998, DOI 10.1016/0006-291X(90)90491-5; TAKUWA Y, 1989, AM J PHYSIOL, V257, pE797, DOI 10.1152/ajpendo.1989.257.6.E797; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WARNER TD, 1994, BIOCHEM PHARMACOL, V48, P625, DOI 10.1016/0006-2952(94)90038-8; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAMANE K, 1992, J RHEUMATOL, V19, P1566; YAMASHITA J, 1993, CANCER RES, V53, P464; YAMASHITA J, 1992, CANCER RES, V52, P4046; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YASUDA M, 1990, AM HEART J, V119, P801, DOI 10.1016/S0002-8703(05)80315-1; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YOKOKAWA K, 1991, J CARDIOVASC PHARM, V17, pS398, DOI 10.1097/00005344-199100177-00111	65	501	524	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					944	949		10.1038/nm0995-944	http://dx.doi.org/10.1038/nm0995-944			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585222				2022-12-27	WOS:A1995RT30300050
J	MONROE, KR; YU, MC; KOLONEL, LN; COETZEE, GA; WILKENS, LR; ROSS, RK; HENDERSON, BE				MONROE, KR; YU, MC; KOLONEL, LN; COETZEE, GA; WILKENS, LR; ROSS, RK; HENDERSON, BE			EVIDENCE OF AN X-LINKED OR RECESSIVE GENETIC COMPONENT TO PROSTATE-CANCER RISK	NATURE MEDICINE			English	Article								We used data from a population-based cohort study of blacks, Hispanics, Japanese and whites to examine the frequency of prevalent prostate and breast cancer by family history status of first-degree relatives (parents and siblings). Independent of race, the age-adjusted relative risk for prevalent prostate cancer in subjects with affected brothers was approximately two times that in subjects with affected fathers (P<0.00005). No such excess risk for breast cancer was observed among subjects with affected sisters compared to those with affected mothers (age- and race-adjusted relative risk = 1.10, P = 0.34). The magnitude of the relative risk for prostate cancer in sibling- versus parent-affected groups was significantly different from that of the comparable relative risk for breast cancer (P <0.00005). An excess risk of prostate cancer in men with affected brothers compared to those with affected fathers is consistent with the hypothesis of an X-linked, or recessive, model of inheritance.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT UROL,LOS ANGELES,CA 90033; UNIV HAWAII,CANC RES CTR HAWAII,HONOLULU,HI 96813	University of Southern California; University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System			Coetzee, Gerhard/AAG-8439-2019; coetzee, Gerhard/AAT-6203-2020	Coetzee, Gerhard/0000-0001-8820-8364	NATIONAL CANCER INSTITUTE [R01CA054281, R35CA053890] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53890, R01 CA54281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; COETZEE GA, 1994, J NATL CANCER I, V86, P872, DOI 10.1093/jnci/86.11.872; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; HAYES RB, 1995, INT J CANCER, V60, P361, DOI 10.1002/ijc.2910600315; IRVINE RA, 1995, CANCER RES, V55, P1937; NAROD SA, 1995, NAT MED, V1, P99, DOI 10.1038/nm0295-99; ROSS RK, 1995, CANCER, V75, P1778, DOI 10.1002/1097-0142(19950401)75:7+<1778::AID-CNCR2820751605>3.0.CO;2-J; WHITTEMORE AS, 1995, AM J EPIDEMIOL, V141, P732, DOI 10.1093/oxfordjournals.aje.a117495; WOOLF CM, 1960, CANCER, V13, P739, DOI 10.1002/1097-0142(196007/08)13:4<739::AID-CNCR2820130414>3.0.CO;2-E; 1991, CANCER LOS ANGELES C	11	174	175	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					827	829		10.1038/nm0895-827	http://dx.doi.org/10.1038/nm0895-827			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585188				2022-12-27	WOS:A1995RM63500042
J	BACALLAO, R				BACALLAO, R			FILLING IN THE MATRIX OF KIDNEY-DISEASE	NATURE MEDICINE			English	Editorial Material							COMPUTED-TOMOGRAPHY; GROWTH		NORTHWESTERN UNIV, SCH MED, DEPT MOLEC & CELLULAR BIOL, CHICAGO, IL 60611 USA	Northwestern University	BACALLAO, R (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, CHICAGO, IL 60611 USA.			Bacallao, Robert/0000-0002-5703-5701				BACALLAO R, 1994, J AM SOC NEPHROL, V5, P618; BACALLAO R, 1993, JASN, V4, P881; BURROW CR, 1993, JASN, V4, P813; CARONE FA, 1974, KIDNEY INT, V5, P411, DOI 10.1038/ki.1974.59; CARONE FA, 1993, LAB INVEST, V68, P413; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRANTHAM JJ, 1988, DISEASES KIDNEY, P583; LEVINE E, 1981, AM J KIDNEY DIS, V1, P99, DOI 10.1016/S0272-6386(81)80036-4; SEGAL AJ, 1982, J COMPUT ASSIST TOMO, V6, P777, DOI 10.1097/00004728-198208000-00021; VANADELSBERG JS, 1995, NAT MED, V1, P359, DOI 10.1038/nm0495-359; WARD CJ, 1994, CELL, V77, P881; Wilson P D, 1992, Adv Nephrol Necker Hosp, V21, P125; WILSON PD, 1991, AM J KIDNEY DIS, V17, P634, DOI 10.1016/S0272-6386(12)80338-6; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1993, EUR J CELL BIOL, V61, P131; YE M, 1993, NEW ENGL J MED, V329, P310, DOI 10.1056/NEJM199307293290503	18	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1995	1	4					305	306		10.1038/nm0495-305	http://dx.doi.org/10.1038/nm0495-305			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585058				2022-12-27	WOS:A1995RN09800024
J	SILVERSTEIN, SC				SILVERSTEIN, SC			IN DEFENSE OF INDIRECT COSTS	NATURE MEDICINE			English	Editorial Material											SILVERSTEIN, SC (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.							1995, FED REGISTER, V60, P7104	1	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					196	198		10.1038/nm0395-196	http://dx.doi.org/10.1038/nm0395-196			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585027				2022-12-27	WOS:A1995QX55900017
J	KISILEVSKY, R; LEMIEUX, LJ; FRASER, PE; KONG, XQ; HULTIN, PG; SZAREK, WA				KISILEVSKY, R; LEMIEUX, LJ; FRASER, PE; KONG, XQ; HULTIN, PG; SZAREK, WA			ARRESTING AMYLOIDOSIS IN-VIVO USING SMALL-MOLECULE ANIONIC SULFONATES OR SULFATES - IMPLICATIONS FOR ALZHEIMERS-DISEASE	NATURE MEDICINE			English	Article							BASEMENT-MEMBRANE COMPONENTS; HEPARAN-SULFATE PROTEOGLYCAN; HIGH-AFFINITY BINDING; ENHANCING FACTOR; PRECURSOR PROTEINS; PRP ACCUMULATION; INDUCTION; SAA; AMYLOIDOGENESIS; INFLAMMATION	Amyloid is a term for extracellular protein fibril deposits that have characteristic tinctorial and structural properties. Heparan sulphate, or the heparan sulphate proteoglycan perlecan, has been identified in all amyloids and implicated in the earliest stages of inflammation-associated (AA) amyloid induction. Heparan sulphate interacts with the AA amyloid precursor and the beta-peptide of Alzheimer's amyloid, imparting characteristic secondary and tertiary amyloid structural features. These observations suggest that molecules that interfere with this interaction may prevent or arrest amyloidogenesis. We synthesized low-molecular-weight (135-1,000) anionic sulphonate or sulphate compounds. When administered orally, these compounds substantially reduced murine splenic AA amyloid progression. They also interfered with heparan sulphate-stimulated beta-peptide fibril aggregation in vitro.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; KINGSTON GEN HOSP,SYL & MOLLY APPS RES CTR,KINGSTON,ON K7L 3N6,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DISORDERS,TORONTO,ON M5S 1A8,CANADA; QUEENS UNIV,DEPT CHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada; University of Toronto; Queens University - Canada	KISILEVSKY, R (corresponding author), QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030361] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS30361] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AILLES L, 1993, LAB INVEST, V69, P443; ANCSIN JB, 1992, LAB INVEST, V66, pA106; AXELRAD MA, 1982, LAB INVEST, V47, P139; BRISSETTE L, 1989, J BIOL CHEM, V264, P19327; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; DEAL CL, 1982, ANN NY ACAD SCI, V389, P439, DOI 10.1111/j.1749-6632.1982.tb22161.x; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; GANAPATHI MK, 1991, J IMMUNOL, V1147, P1261; GANOWIAK K, 1994, BIOCHEM BIOPH RES CO, V199, P306, DOI 10.1006/bbrc.1994.1229; HOWARD J, 1990, NEUROSCI LETT, V118, P71, DOI 10.1016/0304-3940(90)90251-4; KAGAN DZ, 1974, PROBL TUBERK, V40, P72; KISILEVSKY R, 1983, LAB INVEST, V48, P53; KISILEVSKY R, 1994, MOL NEUROBIOL, V8, P65, DOI 10.1007/BF02778008; KISILEVSKY R, 1992, CRIT REV CL LAB SCI, V29, P59, DOI 10.3109/10408369209105246; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; LYON AW, 1991, LAB INVEST, V64, P785; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MCADAM KPWJ, 1978, J CLIN INVEST, V61, P390, DOI 10.1172/JCI108949; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NARINDRASORASAK S, IN PRESS LAB INVEST; PERLMUTTER LS, 1990, BRAIN RES BULL, V24, P677, DOI 10.1016/0361-9230(90)90007-M; PERLMUTTER LS, 1991, J NEUROSCI RES, V30, P673, DOI 10.1002/jnr.490300411; PUCHTLER H, 1983, HISTOCHEMISTRY, V77, P431, DOI 10.1007/BF00495799; SIPE JD, 1978, BR J EXP PTH B, P305; SMALL DH, 1992, J NEUROSCI, V12, P4143; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SNOW AD, 1988, LAB INVEST, V57, P687; TATSUTA E, 1982, ANN NY ACAD SCI, V389, P467, DOI 10.1111/j.1749-6632.1982.tb22176.x; TATSUTA E, 1983, J BIOL CHEM, V258, P5414; WOODROW SI, 1994, AMYLOID AMYLOIDOSIS, P195; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951; YOUNG ID, 1989, ACTANEUROPATH, V7, P202	39	319	375	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					143	148		10.1038/nm0295-143	http://dx.doi.org/10.1038/nm0295-143			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585011				2022-12-27	WOS:A1995QX55800025
J	SNYDER, SH; SABATINI, DM				SNYDER, SH; SABATINI, DM			IMMUNOPHILINS AND THE NERVOUS-SYSTEM	NATURE MEDICINE			English	Review							CALCINEURIN PHOSPHATASE-ACTIVITY; MUSCLE SARCOPLASMIC-RETICULUM; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; NITRIC-OXIDE SYNTHASE; CIS-TRANS-ISOMERASE; RYANODINE RECEPTOR; MOLECULAR-CLONING; IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A	The search for immunosuppressant drugs to increase the success of organ transplantation led to the discovery of the immunophilins, proteins that interface with a range of signal transduction systems inside cells, especially in the nervous and immune systems. Here we review how these interesting molecules work and consider their therapeutic potential.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	SNYDER, SH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.			/0000-0002-1446-7256				ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BRAM RJ, 1993, MOL CELL BIOL, V13, P460; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAMERON AM, IN PRESS P NATN ACAD; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DINERMAN JL, 1994, IN PRESS NEUROPHARM; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FERRIS CD, 1991, ANNU REV PHYSIOL, V54, P469; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1989, NATURE, V340, P351; FLANAGAN WM, 1991, NATURE, V352, P754; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GOLD BG, 1994, RESTOR NEUROL NEUROS, V6, P287, DOI 10.3233/RNN-1994-6404; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1994, SCIENCE, V253, P905; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYRAMAN T, 1992, J BIOL CHEM, V267, P9474; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JONES DT, 1987, J BIOL CHEM, V262, P14241; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1994, IN PRESS J NEUROSCI; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NELSON PA, 1993, J IMMUNOL, V150, P2139; OCHIAI T, 1987, TRANSPLANT P, V19, P1284; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OTSU K, 1990, J BIOL CHEM, V265, P13472; PALMER FS, 1991, PHARMACOL REV, V43, P109; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1991, SCIENCE, V253, P283; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; STEINER JP, 1993, SOC NEUR ABST; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TOTTRUP A, 1992, GASTROENTEROLOGY, V102, P409, DOI 10.1016/0016-5085(92)90084-C; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616	82	175	207	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					32	37		10.1038/nm0195-32	http://dx.doi.org/10.1038/nm0195-32			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584950				2022-12-27	WOS:A1995QX55700023
J	Melder, RJ; Koenig, GC; Witwer, BP; Safabakhsh, N; Munn, LL; Jain, RK				Melder, RJ; Koenig, GC; Witwer, BP; Safabakhsh, N; Munn, LL; Jain, RK			During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium	NATURE MEDICINE			English	Article							INDUCED LEUKOCYTE ADHESION; CRANIAL WINDOWS; NECROSIS-FACTOR; E-SELECTIN; EXPRESSION; VESSELS; PERMEABILITY; METASTASIS; KINETICS; INVIVO	Localization of activated natural killer (A-NK) cells in the microvasculature of growing tumors is the result of recognition of the intracellular and vascular cell-adhesion molecules ICAM-1 and VCAM-1 on the tumor endothelium, mediated by lymphocyte function-associated protein LFA-1 and vascular lymphocyte function-associated protein VLA-4. In vitro and in vivo studies of A-NK cell adhesion to endothelial cells showed that vascular endothelial growth factor (VEGF) promotes adhesion, whereas basic fibroblast growth factor (bFGF) inhibits adhesion through the regulation of these molecules on tumor vasculature. Thus, some angiogenic factors may facilitate lymphocyte recognition of angiogenic vessels, whereas others may provide such vessels with a mechanism that protects them from cytotoxic lymphocytes.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Melder, RJ (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,EDWIN L STEELE LAB,100 FRUIT ST,BOSTON,MA 02114, USA.		Munn, Lance L/L-3950-2016; Jain, Rakesh K/I-1384-2017	Munn, Lance L/0000-0003-0698-7232; Jain, Rakesh K/0000-0001-7571-3548	NCI NIH HHS [R35-CA 56591, F32-CA 61631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056591, F32CA061631] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAVENA P, 1991, J EXP MED, V173, P39; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2893; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Dellian M, 1996, AM J PATHOL, V149, P59; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1995, NATURE, V376, P467, DOI 10.1038/376467a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Folkman J, 1995, MOL BASIS CANC, P206; FREEMAN MR, 1995, CANCER RES, V55, P4140; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FUKUMURA D, 1995, CANCER RES, V55, P4824; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; GOTO F, 1993, LAB INVEST, V69, P508; GULLINO PM, 1970, METHOD CANCER RES, P45; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; JAIN RK, 1988, CANCER RES, V48, P2641; JALLAL B, 1995, CANCER RES, V55, P3223; KITAYAMA J, 1994, CANCER IMMUNOL IMMUN, V38, P317, DOI 10.1007/s002620050072; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Melder R J, 1992, Cell Biophys, V20, P161; MELDER RJ, 1990, AIDS RES HUM RETROV, V6, P1011, DOI 10.1089/aid.1990.6.1011; MELDER RJ, 1995, MICROVASC RES, V50, P35, DOI 10.1006/mvre.1995.1036; MELDER RJ, 1988, CANCER RES, V48, P3461; Melder RJ, 1995, BIOPHYS J, V69, P2131, DOI 10.1016/S0006-3495(95)80087-1; MELDER RJ, 1993, CANCER RES, V53, P5867; MELDER RJ, 1991, CELL IMMUNOL, V132, P177, DOI 10.1016/0008-8749(91)90017-6; MUNN LL, 1994, BIOPHYS J, V67, P889, DOI 10.1016/S0006-3495(94)80550-8; MUNN LL, 1995, BIOTECHNIQUES, V19, P622; OHKUBO C, 1991, CANCER RES, V51, P1561; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; REED JA, 1994, AM J PATHOL, V144, P329; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SASAKI A, 1991, JNCI-J NATL CANCER I, V83, P433, DOI 10.1093/jnci/83.6.433; SASAKI A, 1989, CANCER RES, V49, P3742; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WHITESIDE TL, 1994, IMMUNOL SER, V61, P159; WU NZ, 1992, CANCER RES, V52, P4265; YUAN F, 1994, CANCER RES, V54, P4564	39	378	393	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					992	997		10.1038/nm0996-992	http://dx.doi.org/10.1038/nm0996-992			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782456				2022-12-27	WOS:A1996VF49700033
J	OLeary, JJ				OLeary, JJ			Seeking the cause of Kaposi's sarcoma	NATURE MEDICINE			English	Editorial Material							DNA-SEQUENCES; HERPESVIRUS				OLeary, JJ (corresponding author), UNIV OXFORD,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND.							BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; MORFELDT L, 1994, SCAND J INFECT DIS, V26, P749, DOI 10.3109/00365549409008645; NICHOLOFF BJ, 1996, AM J PATHOL, V148, P1323; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	12	13	13	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					862	863		10.1038/nm0896-862	http://dx.doi.org/10.1038/nm0896-862			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705853				2022-12-27	WOS:A1996UZ80400030
J	Weatherall, DJ; Clegg, JB				Weatherall, DJ; Clegg, JB			Thalassemia - A global public health problem	NATURE MEDICINE			English	Editorial Material							ALPHA-THALASSEMIA; PRENATAL-DIAGNOSIS; GENE DELETION; DNA; HEMOGLOBINOPATHIES				Weatherall, DJ (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOL MED, MRC MOL HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND.							CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; CHANG JC, 1979, P NATL ACAD SCI USA, V76, P2886, DOI 10.1073/pnas.76.6.2886; Craig JE, 1996, NAT GENET, V12, P58, DOI 10.1038/ng0196-58; Fawdry AL, 1944, LANCET, V1, P171; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; GROSS F, 1983, B WORLD HEALTH ORGAN, V61, P63; INGRAM VM, 1959, NATURE, V184, P1903, DOI 10.1038/1841903a0; KAN YW, 1978, LANCET, V2, P910; KAN YW, 1976, NEW ENGL J MED, V295, P1165, DOI 10.1056/NEJM197611182952104; LOVE DR, 1993, NEUROMUSCULAR DISORD, V3, P5, DOI 10.1016/0960-8966(93)90037-K; Olivieri NF, 1996, SEMIN HEMATOL, V33, P24; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; ORKIN SH, 1979, P NATL ACAD SCI USA, V76, P2400, DOI 10.1073/pnas.76.5.2400; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OTTOLENGHI S, 1974, NATURE, V251, P389, DOI 10.1038/251389a0; TAYLOR JM, 1974, NATURE, V251, P392, DOI 10.1038/251392a0; WASI P, 1969, ANN NY ACAD SCI, V165, P60, DOI 10.1111/j.1749-6632.1969.tb27777.x; WEATHERA.DJ, 1965, NATURE, V208, P1061, DOI 10.1038/2081061a0; WEATHERALL D, 1995, MOL MED TODAY, V1, P15, DOI 10.1016/1357-4310(95)80014-X; Weatherall DJ, 1981, THALASSEMIA SYNDROME; Weatherall DJ, 1994, MOL BASIS BLOOD DIS, P157; 1993, 1993	22	182	189	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1996	2	8					847	849		10.1038/nm0896-847	http://dx.doi.org/10.1038/nm0896-847			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705845				2022-12-27	WOS:A1996UZ80400022
J	Tripathy, SK; Black, HB; Goldwasser, E; Leiden, JM				Tripathy, SK; Black, HB; Goldwasser, E; Leiden, JM			Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors	NATURE MEDICINE			English	Article							VIRAL-ANTIGEN; T-CELLS; MICE; ERYTHROPOIETIN; TOLERANCE; INDUCTION; INVIVO	The use of replication-defective adenoviruses (RDAd) for human gene therapy has been limited by host immune responses that result in transient recombinant gene expression in vivo. It remained unclear whether these immune responses were directed predominantly against viral proteins or, alternatively, against foreign transgene-encoded proteins. In this report, we have compared the stability of recombinant gene expression in adult immunocompetent mice following intramuscular (i.m.) injection with identical RDAd encoding self (murine) or foreign (human) erythropoietin. Our results demonstrate that immune responses directed against foreign transgene-encoded proteins are the major determinants of the stability of gene expression following i.m. injection of RDAd. Moreover, we demonstrate long-term recombinant gene expression in immunocompetent animals following a single i.m. injection of RDAd encoding a self protein. These findings are important for the design of future preclinical and clinical gene therapy trials.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago			Tripathy, Sujit/AAG-1838-2022; Tripathy, Sujit/AFK-3197-2022	Tripathy, Sujit/0000-0003-0179-9910	NIAMS NIH HHS [AR 42885] Funding Source: Medline; NIDDK NIH HHS [DK 48987] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048987] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR D, 1995, GENE THER, V2, P151; BARR E, 1994, GENE THER, V1, P51; BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; ENGELHARDT JF, 1994, HUM GENE THER, V5, P1217, DOI 10.1089/hum.1994.5.10-1217; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GOLDWASSER E, 1981, BRIT J HAEMATOL, V48, P359, DOI 10.1111/j.1365-2141.1981.tb02726.x; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LIN RH, 1991, J EXP MED, V173, P1433, DOI 10.1084/jem.173.6.1433; MAMULA MJ, 1992, J IMMUNOL, V149, P789; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAWLE FC, 1991, J IMMUNOL, V146, P3977; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; WEIGLE WO, 1962, J EXP MED, V116, P913, DOI 10.1084/jem.116.6.913; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	30	601	627	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					545	550		10.1038/nm0596-545	http://dx.doi.org/10.1038/nm0596-545			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616713				2022-12-27	WOS:A1996UJ23000037
J	Kaslow, RA; Carrington, M; Apple, R; Park, L; Munoz, A; Saah, AJ; Goedert, JJ; Winkler, C; OBrien, SJ; Rinaldo, C; Detels, R; Blattner, W; Phair, J; Erlich, H; Mann, DL				Kaslow, RA; Carrington, M; Apple, R; Park, L; Munoz, A; Saah, AJ; Goedert, JJ; Winkler, C; OBrien, SJ; Rinaldo, C; Detels, R; Blattner, W; Phair, J; Erlich, H; Mann, DL			Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; MULTICENTER AIDS COHORT; HLA; POLYMORPHISM; ANTIGENS; INVITRO; PEPTIDE; REGION	Major histocompatibility complex (MHC) genes (HLA in humans) regulate the immune response to foreign antigens. Molecular and serologic techniques were used to identify products of HLA class I, class II and transporter (TAP) genes (also part of the MHC) in homosexual seroconverters to human immunodeficiency virus type 1 (HIV-1). Comprehensive statistical analysis produced an HLA profile that predicted time from HIV-1 infection to the onset of AIDS. The profile was developed in a cohort of 139 men and evaluated in a second unrelated cohort of 102 men. In the evaluation cohort, the profile discriminated a sixfold difference between groups with the shortest and longest times to AIDS (P = 0.001). These findings support current theory about control of antigen processing by HLA genes and have implications for immunopathogenesis of HIV-1 and other infections.	NCI,BCDP SAIC,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; ROCHE MOL SYST INC,DEPT HUMAN GENET,ALAMEDA,CA 94501; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; NCI,VIRAL EPIDEMIOL BRANCH,DIV CANC ETIOL,ROCKVILLE,MD 20852; FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,HLTH SCI CTR,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; NORTHWESTERN UNIV,SCH MED,DEPT MED,COMPREHENS AIDS CTR,CHICAGO,IL 60611	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Roche Holding; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; Northwestern University	Kaslow, RA (corresponding author), UNIV ALABAMA,SCH PUBL HLTH,DEPT EPIDEMIOL,212C TIDWELL HALL,720 20TH ST S,BIRMINGHAM,AL 35294, USA.		OBRIEN, STEPHEN/ABD-1346-2020; apple, raymond J/I-4506-2012	apple, raymond J/0000-0002-8007-0345; OBRIEN, STEPHEN/0000-0001-7857-0757	NIAID NIH HHS [N01-AI-72631, N01-AI-72632, N01-AI-72634] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072634, N01AI072631, N01AI072632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCABES P, 1993, EPIDEMIOL REV, V15, P303, DOI 10.1093/oxfordjournals.epirev.a036122; AMOS DB, 1980, MANUAL CLIN IMMUNOLO, P978; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; BANNAI M, 1994, EUR J IMMUNOGENET, V21, P1, DOI 10.1111/j.1744-313X.1994.tb00170.x; BECKER Y, 1994, VIRUS GENES, V8, P249, DOI 10.1007/BF01704519; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; CARRINGTON M, 1992, HUM IMMUNOL, V33, P208, DOI 10.1016/0198-8859(92)90073-V; CARRINGTON M, 1993, IMMUNOGENETICS, V37, P266; CARRINGTON M, 1994, HUM IMMUNOL, V41, P234, DOI 10.1016/0198-8859(94)90041-8; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; ERLICH HA, 1989, PCR TECHNOLOGY PRINC, P193; FUKAZAWA T, 1994, J IMMUNOL, V152, P1190; FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81; GOEDERT JJ, 1985, AM J EPIDEMIOL, V121, P629, DOI 10.1093/aje/121.5.629; HESSOL NA, 1994, AM J EPIDEMIOL, V139, P1077, DOI 10.1093/oxfordjournals.aje.a116951; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KASLOW RA, 1994, J INFECT DIS, V169, P1332, DOI 10.1093/infdis/169.6.1332; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KEET IPM, IN PRESS ACQUIR IMMU; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KLITZ W, 1992, EVOL BIOL, V26, P35; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; KUBO RT, 1994, J IMMUNOL, V152, P3913; MANN DL, 1994, AIDS S1, V8, pS53; Miller R. G., 1981, SURVIVAL ANAL; MUNOZ A, 1993, PREVENTION CONTROL N; MUNOZ A, 1995, ACQUIR IMMUNE DEFIC, V8, P496; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; REZZA G, 1994, HIV EPIDEMIOLOGY, P279; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; *SAS I INC, PHREG SAS REL 6 09; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; TIWARI J, 1985, HLA DIS ASS, P383; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; [No title captured]; 1987, MMWR-MORBID MORTAL W, V36, pS3	43	802	817	0	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					405	411		10.1038/nm0496-405	http://dx.doi.org/10.1038/nm0496-405			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597949				2022-12-27	WOS:A1996UD31400041
J	Ju, JY; Glazer, AN; Mathies, RA				Ju, JY; Glazer, AN; Mathies, RA			Energy transfer primers: A new fluorescence labeling paradigm for DNA sequencing and analysis	NATURE MEDICINE			English	Editorial Material									UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley								BENSON SC, 1993, NUCLEIC ACIDS RES, V21, P5720, DOI 10.1093/nar/21.24.5720; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAZER AN, 1983, BIOPHYS J, V43, P383, DOI 10.1016/S0006-3495(83)84361-6; HAMMOND HA, 1994, AM J HUM GENET, V55, P175; JU J, IN PRESS NUCLEIC ACI; JU JY, 1995, ANAL BIOCHEM, V231, P131, DOI 10.1006/abio.1995.1512; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; MATHIES RA, 1992, NATURE, V359, P167, DOI 10.1038/359167a0; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REEVE MA, 1995, NATURE, V376, P796, DOI 10.1038/376796a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; WANG YW, 1995, ANAL CHEM, V67, P1197, DOI 10.1021/ac00103a010	18	85	136	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					246	249		10.1038/nm0296-246	http://dx.doi.org/10.1038/nm0296-246			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574973				2022-12-27	WOS:A1996TU06000048
J	GUY, RH				GUY, RH			A SWEETER LIFE FOR DIABETICS	NATURE MEDICINE			English	Editorial Material							TRANSDERMAL DELIVERY; IONTOPHORESIS		UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GUY, RH (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARM, SAN FRANCISCO, CA 94143 USA.		Guy, Richard H/H-3471-2012	Guy, Richard/0000-0003-3227-9862				AMATO I, 1992, SCIENCE, V258, P892; BURNETTE RR, 1989, TRANSDERMAL DRUG DEL, P247; GLIKFELD P, 1989, PHARMACEUT RES, V6, P988, DOI 10.1023/A:1015957816254; GUY R, 1994, Patent No. 5362307; HELLER J, 1993, PULSATILE DRUG DELIV, P57; LEDGER PW, 1992, ADV DRUG DELIVER REV, V9, P289, DOI 10.1016/0169-409X(92)90027-N; LEDUC S, 1907, IONS MEDICATIONS ION; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; ODRISCOLL C, 1994, CHEM BRIT, V30, P878; PIKAL MJ, 1992, ADV DRUG DELIVER REV, V9, P201, DOI 10.1016/0169-409X(92)90024-K; RAO G, 1993, PHARMACEUT RES, V10, P1751, DOI 10.1023/A:1018926215306; RAO G, IN PRESS PHARM RES; SANTI P, IN PRESS J CONTROL R; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; TAMADA JA, 1995, NAT MED, V1, P1198, DOI 10.1038/nm1195-1198; TURNER APF, 1993, CHEM SENSORS IN VIVO	17	17	17	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1995	1	11					1132	1133		10.1038/nm1195-1132	http://dx.doi.org/10.1038/nm1195-1132			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584978				2022-12-27	WOS:A1995TC53700030
J	WEINSTEIN, BM; STEMPLE, DL; DRIEVER, W; FISHMAN, MC				WEINSTEIN, BM; STEMPLE, DL; DRIEVER, W; FISHMAN, MC			GRIDLOCK, A LOCALIZED HERITABLE VASCULAR PATTERNING DEFECT IN THE ZEBRAFISH	NATURE MEDICINE			English	Article							HEART	We are using the zebrafish, Danio rerio, to identify genes that generate and pattern the vertebrate vasculature. We have isolated a recessive mutation, gridlock(m145) (grl(m145)) in which blood flow to the tail is impeded by a localized vascular defect. Using a novel microangiographic method, we show that the blockade is in the anterior trunk, where the paired lateral dorsal aortae normally merge to form the single midline aorta. Arterial-venous shunts and collateral vessels develop in most mutant embryos, bypassing the lesion and reconstituting caudal blood flow. The grl defect resembles coarctation of the aorta, a human congenital cardiovascular malformation of unknown aetiology, in the location of the lesion and its consequences and in the mutants' dependence on collateral vessels for survival.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	WEINSTEIN, BM (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,149 13TH ST,BOSTON,MA 02129, USA.			Driever, Wolfgang/0000-0002-9551-9141	NHLBI NIH HHS [T32-HL07208, R01-HL49579] Funding Source: Medline; NICHD NIH HHS [R01-HD29761] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029761] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007208, R01HL049579] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COFFIN JD, 1991, ANAT REC, V231, P383; DEHAAN RL, 1959, DEV BIOL, V1, P586, DOI 10.1016/0012-1606(59)90019-3; HUTCHINS GM, 1971, AM J PATHOL, V63, P203; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; NETTER FF, 1978, HEART; OLLEY PM, 1992, NEONATAL HEART DISEA; OSMOND MK, 1991, DEVELOPMENT, V113, P1405; Perloff JK, 1994, CLIN RECOGNITION CON; Pierpont M.E.M., 1987, GENETICS CARDIOVASCU; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; Walker WF, 1992, VERTEBRATE DISSECTIO; Westerfield M, 1994, ZEBRAFISH BOOK; WIELENGA G, 1968, J PATHOL BACTERIOL, V95, P265, DOI 10.1002/path.1700950131; [No title captured]	15	243	257	0	25	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1143	1147		10.1038/nm1195-1143	http://dx.doi.org/10.1038/nm1195-1143			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584985				2022-12-27	WOS:A1995TC53700037
J	ACOTT, TS; WELEBER, RG				ACOTT, TS; WELEBER, RG			VITAMIN-A MEGATHERAPY FOR RETINAL ABNORMALITIES	NATURE MEDICINE			English	Editorial Material							SORSBY FUNDUS DYSTROPHY; TISSUE INHIBITOR; METALLOPROTEINASES				ACOTT, TS (corresponding author), OREGON HLTH SCI UNIV,CASEY EYE INST,PORTLAND,OR 97201, USA.							ACOTT TS, 1994, TXB OPHTHALMOLOGY, V7; APTE SS, 1994, GENOMICS, V19, P88; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; LECO KJ, 1994, J BIOL CHEM, V269, P9352; WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P8, DOI 10.1016/0167-4838(93)90105-Z	13	5	5	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					884	885		10.1038/nm0995-884	http://dx.doi.org/10.1038/nm0995-884			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585210				2022-12-27	WOS:A1995RT30300038
J	HAMILTON, BS; PAGLIA, D; KWAN, AYM; DEITEL, M				HAMILTON, BS; PAGLIA, D; KWAN, AYM; DEITEL, M			INCREASED OBESE MESSENGER-RNA EXPRESSION IN OMENTAL FAT-CELLS FROM MASSIVELY OBESE HUMANS	NATURE MEDICINE			English	Article								Obesity presents a significant challenge to the general health of affluent nations in terms of the number of people affected, the serious associated maladies and the lack of effective treatments(1-3). While common wisdom has held that obesity results from 'gluttony and sloth', a number of studies have indicated physiological causes underlying the pathogenesis of obesity(2), with the degree of adiposity having a strong genetic component(4,5). Recently, the obese gene in the ob/ob mouse was cloned, along with its human homologue(6). The specific production of the obese protein by adipose tissue suggested that it may function in a feedback loop from fat tissue to the hypothalamus to control energy intake and/or energy expenditure, and that it may play a role in the pathogenesis of human obesity(6-8). In this study we report that obese mRNA expression is elevated in ex vivo omental adipocytes isolated from massively obese humans in the absence of an identifiable mutation. Therefore, we speculate that this increased expression may suggest that the massively obese are insensitive to the putative regulatory function(s) of the obese gene product.	SUNNYBROOK HLTH SCI CTR, N YORK, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT SURG, TORONTO, ON M6R 1B5, CANADA; UNIV TORONTO, DEPT NUTR SCI, TORONTO, ON M6R 1B5, CANADA; ST JOSEPHS HLTH CTR, TORONTO, ON M6R 1B5, CANADA	University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario)	HAMILTON, BS (corresponding author), UNIV TORONTO, INST MED SCI, 100 COLL ST, TORONTO, ON M5S 1A8, CANADA.							AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOUCHARD C, 1993, ENDOCR REV, V14, P72, DOI 10.1210/er.14.1.72; CHENG AYM, 1993, OBES SURG, V3, P340, DOI 10.1381/096089293765559016; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; FAUST IM, 1977, SCIENCE, V197, P393, DOI 10.1126/science.877564; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; KOPELMAN PG, 1994, INT J OBESITY, V18, P189; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MARTIN RJ, 1991, AM SCI, V79, P528; RINK TJ, 1994, NATURE, V372, P406, DOI 10.1038/372406a0; RONCARI DAK, 1993, ADV EXP MED BIOL, V334, P269; Sambrook J, 1989, MOL CLONING LABORATO; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TEICHERTKULISZEWSKA K, 1994, BIOCHEM CELL BIOL, V72, P54, DOI 10.1139/o94-009; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	490	529	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1995	1	9					953	956		10.1038/nm0995-953	http://dx.doi.org/10.1038/nm0995-953			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585224				2022-12-27	WOS:A1995RT30300052
J	LUBIN, R; ZALCMAN, G; BOUCHET, L; TREDANIEL, J; LEGROS, Y; CAZALS, D; HIRSCH, A; SOUSSI, T				LUBIN, R; ZALCMAN, G; BOUCHET, L; TREDANIEL, J; LEGROS, Y; CAZALS, D; HIRSCH, A; SOUSSI, T			SERUM P53 ANTIBODIES AS EARLY MARKERS OF LUNG-CANCER	NATURE MEDICINE			English	Article							IMMUNE-RESPONSE; BREAST-CANCER; EPITOPES	The p53 alteration is the most common alteration found in human cancer. It usually involves missense mutations that stabilize the p53 protein, which in turn accumulates, reaching levels detectable by immunohistochemistry. We(1-4) and others(5-8) have demonstrated that this overexpression of mutant p53 protein can induce a specific humoral response in cancer patients. This result was assessed by the presence of p53 antibodies in sera of patients with various types of cancers, whereas normal populations do not exhibit such antibodies. In lung cancer, the prevalence of p53 antibodies is high (30%) and is correlated with a very high rate of p53 mutations in this cancer (60-70%)(2,8). We show that these antibodies are always present at the time of diagnosis, but never appear during tumour development, an observation strengthened by the fact that these antibodies are mostly IgG, corresponding to a secondary immune response. These results suggest that the humoral response is an early event and that p53 antibodies can be used as a precocious marker of p53 alteration before clinical manifestation of the disease.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV PNEUMOL,F-75010 PARIS,FRANCE; HOP ST LOUIS,ANATOMOPATHOL LAB,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gérard/L-7809-2015; ZALCMAN, Gerard/M-8113-2019	ZALCMAN, Gérard/0000-0002-0343-9575; soussi, thierry/0000-0001-8184-3293				ANGELOPOULOU K, 1994, INT J CANCER, V58, P480, DOI 10.1002/ijc.2910580404; BENNETT WP, 1993, CANCER RES, V53, P4817; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; IDHE DC, 1991, CURR PROBL CANCER, V15, P65; LUBIN R, 1993, CANCER RES, V53, P5872; MAO L, 1994, CANCER RES, V54, P1634; PEYRAT JP, 1995, LANCET, V345, P621, DOI 10.1016/S0140-6736(95)90523-5; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TENAUD C, 1994, MODERN PATHOL, V7, P853; WINTER SF, 1992, CANCER RES, V52, P4168	13	282	296	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					701	702		10.1038/nm0795-701	http://dx.doi.org/10.1038/nm0795-701			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585154				2022-12-27	WOS:A1995RQ06600047
J	HENDERSON, D; HURLEY, LH				HENDERSON, D; HURLEY, LH			MOLECULAR STRUGGLE FOR TRANSCRIPTIONAL CONTROL	NATURE MEDICINE			English	Editorial Material							DNA				HENDERSON, D (corresponding author), UNIV TEXAS,COLL PHARM,DRUG DYNAM INST,AUSTIN,TX 78712, USA.							ADAMS EG, 1988, CANCER RES, V48, P109; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; FAN JY, 1995, J MED CHEM, V38, P408, DOI 10.1021/jm00003a003; HO SN, 1994, P NATL ACAD SCI USA, V91, P9203, DOI 10.1073/pnas.91.20.9203; HURLEY LH, 1989, J MED CHEM, V32, P2027, DOI 10.1021/jm00129a001; Li B., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P111; MACLEOD MC, IN PRESS CARCINOGENE; MITSCHER LA, 1992, NUCLEIC ACID TARGETE, P375; POTMESIL M, 1994, CANCER RES, V54, P1431; SUN D, 1994, BIOCHEMISTRY-US, V33, P9578, DOI 10.1021/bi00198a025; Sun D., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P534; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; WALKER S, 1993, J AM CHEM SOC, V115, P7954, DOI 10.1021/ja00071a004	16	70	74	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					525	527		10.1038/nm0695-525	http://dx.doi.org/10.1038/nm0695-525			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585116				2022-12-27	WOS:A1995RN10100033
J	PILOTTO, LS; DOUGLAS, RM				PILOTTO, LS; DOUGLAS, RM			MEASURING NO2 EXPOSURE IN RESPIRATORY-DISEASE	NATURE MEDICINE			English	Editorial Material							NITROGEN-DIOXIDE EXPOSURE; PULMONARY-FUNCTION; AIR-POLLUTION; CHILDREN; PATTERNS; TOXICITY; MICE				PILOTTO, LS (corresponding author), AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT 0200,AUSTRALIA.							ABRAMSON M, 1991, MED J AUSTRALIA, V154, P543, DOI 10.5694/j.1326-5377.1991.tb119453.x; BAUER MA, 1986, AM REV RESPIR DIS, V134, P1203; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172, DOI 10.1164/ajrccm/142.5.1172; Frampton M W, 1991, Semin Respir Infect, V6, P185; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; FRAMPTON MW, 1991, AM REV RESPIR DIS, V143, P522, DOI 10.1164/ajrccm/143.3.522; GARDNER DE, 1979, ENVIRON HEALTH PERSP, V30, P23, DOI 10.2307/3429098; GRAHAM JA, 1987, J TOXICOL ENV HEALTH, V21, P113, DOI 10.1080/15287398709531006; HOUTHUIJS D, 1987, INDOOR AIR, V1, P463; MILLER FJ, 1987, J TOXICOL ENV HEALTH, V21, P99, DOI 10.1080/15287398709531005; MORROW PE, 1989, 23 HLTH EFF I RES RE; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; PILOTTO LS, 1994, THESIS AUSTR NATIONA; ROGER LJ, 1985, TOXICOLOGIST, V5, P70; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258, DOI 10.1164/ajrccm/148.5.1258; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SEIFERT B, 1993, ENV CARCINOGENESIS M, V12; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	19	1	1	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					517	518		10.1038/nm0695-517	http://dx.doi.org/10.1038/nm0695-517			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585112				2022-12-27	WOS:A1995RN10100029
J	HOLT, JT				HOLT, JT			A SENSELESS IMMUNE-RESPONSE TO DNA	NATURE MEDICINE			English	Editorial Material							PROLIFERATION	Antisense oligonucleotides can have dramatic effects, but a recent paper suggests that the mechanism isn't always based on nucleotide sequence interactions.	VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University	HOLT, JT (corresponding author), VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.							GILKESON GS, 1995, J CLIN INVEST, V95, P1398, DOI 10.1172/JCI117793; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KRIEG AM, 1989, J IMMUNOL, V143, P2448; MESSINA JP, 1991, J IMMUNOL, V147, P1759; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0	8	15	15	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					407	408		10.1038/nm0595-407	http://dx.doi.org/10.1038/nm0595-407			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585081				2022-12-27	WOS:A1995RN10000024
J	SCOTT, J; ALMOND, N				SCOTT, J; ALMOND, N			ASSESSING ANIMAL-MODELS OF AIDS	NATURE MEDICINE			English	Editorial Material							BLOOD MONONUCLEAR-CELLS; SIV VACCINE; NEF GENE; INFECTION; CHIMPANZEES; PROTECTION; HIV-1; CHALLENGE; PRIMATES; ANTIBODY				SCOTT, J (corresponding author), NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND.			Almond, Neil/0000-0001-6105-0616				ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; AHMED S, 1994, AIDS RES HUM RETROV, V10, P195; [Anonymous], 1995, VACCINE, V13, P295; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; ISRAEL ZR, 1994, J VIROL, V68, P1843, DOI 10.1128/JVI.68.3.1843-1853.1994; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; RUD EW, 1994, J GEN VIROL, V75, P529, DOI 10.1099/0022-1317-75-3-529; SHIBATA R, 1991, J VIROL, V65, P3514, DOI 10.1128/JVI.65.7.3514-3520.1991; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WARREN JT, 1993, J MED PRIMATOL, V22, P203	15	31	36	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1995	1	4					295	297		10.1038/nm0495-295	http://dx.doi.org/10.1038/nm0495-295			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585052	Bronze			2022-12-27	WOS:A1995RN09800018
J	VANADELSBERG, JS; FRANK, D				VANADELSBERG, JS; FRANK, D			THE PKD1 GENE PRODUCES A DEVELOPMENTALLY-REGULATED PROTEIN IN MESENCHYME AND VASCULATURE	NATURE MEDICINE			English	Article							POLYCYSTIC KIDNEY-DISEASE; EXTRACELLULAR-MATRIX; GROWTH; MEMBRANES; EPITHELIA; CYSTS	Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common human genetic diseases. In addition to polycystic kidneys, the disease can cause cystic changes in liver and other organs, cardiac valvular insufficiency and cerebral arterial aneurysms. Using antibodies raised against the predicted gene product of PKD1, which is mutated in about 85% of ADPKD cases, we show that PKD1 is a 530-kD protein localized to the extracellular matrix of kidney, liver and cerebral blood vessels. We discovered that the PKD1 protein was highly expressed in the mesenchyme of developing kidney and liver, transiently localized in the developing glomerulus and juxtaglomerular apparatus and restricted to perivascular, extraglomerular areas in adult renal cortex. These data suggest that the PKD1 protein plays a role in renal and hepatic morphogenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University	VANADELSBERG, JS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020999, R37DK020999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; [Anonymous], 1994, CELL, V77, P881; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; CARONE FA, 1993, LAB INVEST, V68, P413; CARONE FA, 1994, LAB INVEST, V70, P645; CHAPMAN AB, 1990, NEW ENGL J MED, V323, P1091, DOI 10.1056/NEJM199010183231602; DALGAARD OZ, 1957, ACTA MED SCAND, V328, P10; Davies J, 1993, Semin Cell Biol, V4, P213, DOI 10.1006/scel.1993.1025; DOUILLARD JY, 1983, METHOD ENZYMOL, V92, P168; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; Gabow P A, 1989, Adv Nephrol Necker Hosp, V18, P19; GABOW PA, 1990, HEPATOLOGY, V11, P1033, DOI 10.1002/hep.1840110619; GABOW PA, NW ENGL J MED; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; GRANTHAM JJ, 1987, KIDNEY INT, V32, P187, DOI 10.1038/ki.1987.191; GRNTHAM JJ, 1995, J CLIN INVEST, V95, P195; LEIER CV, 1984, ANN INTERN MED, V100, P683, DOI 10.7326/0003-4819-100-5-683; MILUTINOVIC J, 1980, AM J MED, V68, P741, DOI 10.1016/0002-9343(80)90266-1; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1642; SCHEFF RT, 1980, ANN INTERN MED, V92, P202, DOI 10.7326/0003-4819-92-2-202; VANADELSBERG J, 1994, CELL, V76, P1053, DOI 10.1016/0092-8674(94)90382-4; Wilson P D, 1992, Adv Nephrol Necker Hosp, V21, P125; WILSON PD, 1991, AM J KIDNEY DIS, V17, P634, DOI 10.1016/S0272-6386(12)80338-6; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1992, J CELL PHYSIOL, V150, P360, DOI 10.1002/jcp.1041500220	28	31	31	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					359	364		10.1038/nm0495-359	http://dx.doi.org/10.1038/nm0495-359			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585067				2022-12-27	WOS:A1995RN09800033
J	STEARNS, T				STEARNS, T			THE FORM AND THE SUBSTANCE	NATURE MEDICINE			English	Editorial Material							CENTROSOMES; OOCYTES	By careful microscopic examination of in vitro fertilization (pages 47-52) Simerly et al. demonstrate the paternal origin of the human centrosome and reveal steps at which fertilization may fail.			STEARNS, T (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Stearns, Tim/0000-0002-0671-6582				FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; SIMERLY C, 1995, NAT MED, V1, P47, DOI 10.1038/nm0195-47; STEARNS T, 1994, CELL, V776, P623	6	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					19	20		10.1038/nm0195-19	http://dx.doi.org/10.1038/nm0195-19			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584942				2022-12-27	WOS:A1995QX55700017
J	Zavazava, N; Kronke, M				Zavazava, N; Kronke, M			Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN FAS LIGAND; BIOCHEMICAL-CHARACTERIZATION; MONOCLONAL ANTIBODY; HUMAN SERUM; CELL-LINE; ANTIGENS; TRANSPLANTATION; PEPTIDES; LIVER	Soluble HLA class I molecules (sHLAs) have been identified in the serum of patients with inflammatory diseases, allografts and autoimmune diseases and in serum of healthy individuals. The biological significance of these molecules, particularly after allogeneic organ transplantation, has been enigmatic. Here we show that primary alloreactive CD8(+) T cells interact with sHLA and undergo apoptosis in the absence of a second signal. Ligation of CD28 rescued T cells from death, implying that sHLAs induce apoptosis through selective stimulation of the T-cell receptor. CD95-L was upregulated after cytotoxic T lymphocytes were incubated with sHLAs, and cell death was blocked by a neutralizing anti-CD95-L antibody, suggesting that sHLAs induce endogenous mutual killing of activated T cells. These results provide a molecular basis for the capacity of sHLAs to downregulate T-cell responses, which may be especially relevant to organ transplantation.			Zavazava, N (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,MICHAELISTR 5,D-24105 KIEL,GERMANY.							ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ALTMAN J, 1992, TRANSPLANT P, V224, P967; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CHARLTON RK, 1970, SCIENCE, V170, P636, DOI 10.1126/science.170.3958.636; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; DOBBE LME, 1988, IMMUNOGENETICS, V27, P203, DOI 10.1007/BF00346587; DUKE R, 1989, J EXP MED, V169, P765; EMERSON SG, 1981, J IMMUNOL, V127, P482; EMERSON SG, 1980, J EXP MED, V152, P783, DOI 10.1084/jem.152.4.783; GONWA TA, 1988, TRANSPLANTATION, V46, P690, DOI 10.1097/00007890-198811000-00013; HAGA JA, 1991, J BIOL CHEM, V266, P3695; HAUSMANN R, 1993, CLIN EXP IMMUNOL, V91, P183; JU ST, 1990, J IMMUNOL, V144, P23; KANE K, 1989, J IMMUNOL, V142, P4253; KANE KP, 1989, NATURE, V340, P157, DOI 10.1038/340157a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KRANGEL MS, 1984, J IMMUNOL, V132, P2984; KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; PARHAM P, 1983, IMMUNOGENETICS, V18, P1, DOI 10.1007/BF00401351; PARHAM P, 1987, NATURE, V325, P625, DOI 10.1038/325625a0; PARHAM P, 1979, J IMMUNOL, V123, P342; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; PUPPO F, 1995, IMMUNOL TODAY, V16, P124, DOI 10.1016/0167-5699(95)80127-8; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL T, 1989, NEW ENGL J MED, V10, P1092; STARZL T, 1993, IMMUNOL TODAY, V326, P326; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; VANROOD JJ, 1970, NATURE, V226, P366, DOI 10.1038/226366a0; ZAVAZAVA N, 1993, TISSUE ANTIGENS, V42, P20, DOI 10.1111/j.1399-0039.1993.tb02161.x; ZAVAZAVA N, 1994, HUM IMMUNOL, V40, P174, DOI 10.1016/0198-8859(94)90065-5; ZAVAZAVA N, 1991, TRANSPLANTATION, V51, P838, DOI 10.1097/00007890-199104000-00019; ZAVAZAVA N, 1991, J IMMUNOGENET, V17, P387	41	244	255	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1005	1010		10.1038/nm0996-1005	http://dx.doi.org/10.1038/nm0996-1005			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782458				2022-12-27	WOS:A1996VF49700035
J	Gao, SJ; Kingsley, L; Li, M; Zheng, W; Parravicini, C; Ziegler, J; Newton, R; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Chang, Y; Moore, PS				Gao, SJ; Kingsley, L; Li, M; Zheng, W; Parravicini, C; Ziegler, J; Newton, R; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Chang, Y; Moore, PS			KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma	NATURE MEDICINE			English	Article							HERPESVIRUS	A major controversy regarding Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8)(1,2) is whether or not it is a ubiquitous infection of humans(3,4). Immunoassays based on KSHV- and Epstein-Barr virus (EBV)-coinfected cell lines show that most US AIDS-KS patients have specific antibodies to KSHV-related antigens(2,5,6). We have developed a sensitive indirect immunofluorescence assay (IFA) based on an EBV-negative, KSHV-infected cell line, BCP-1. When we used this IFA assay, KSHV-related antibodies were found in 71-88% of serum samples from US, Italian and Ugandan AIDS-KS patients, as well as all serum samples examined from HIV-seronegative KS patients. Although none of the US blood donors examined were KSHV seropositive by IFA, intermediate and high seroprevalence rates were found in Italian and Ugandan control populations. Antibody kinetics showed that more than half of the AIDS-KS patients who were examined IgG-seroconverted before KS development, and antibody levels did not decline after seroconversion. For these patients, seropositivity rates increased linearly with time, suggesting that the rate of infection was constant and that the risk of developing KS once infected with KSHV is not highly dependent on the duration of infection. These data strongly suggest that KSHV is not ubiquitous in most populations and that the virus may be under strict immunologic control in healthy KSHV-infected persons.	COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; UNIV PITTSBURGH, DEPT INFECT DIS & MICROBIOL, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15213 USA; LUIGI SACCO HOSP, DEPT PATHOL, I-20157 MILAN, ITALY; WHO, INT AGCY RES CANC, F-69372 LYON, FRANCE; UNIV OXFORD, RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, OXFORD OX2 6HE, ENGLAND; JOHNS HOPKINS UNIV, DIV EPIDEMIOL, SCH PUBL HLTH, BALTIMORE, MD 21205 USA; NW UNIV MED, COMPREHENS AIDS CTR, CHICAGO, IL 60611 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90095 USA	Columbia University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Milan; Luigi Sacco Hospital; World Health Organization; International Agency for Research on Cancer (IARC); Radcliffe Infirmary; University of Oxford; Johns Hopkins University; University of California System; University of California Los Angeles			Moore, Patrick S./F-3960-2011; Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Kingsley, Lawrence/0000-0002-7000-8556; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035040, U01AI035039] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI 35039, U01-AI 35040] Funding Source: Medline; PHS HHS [U64CCU210852-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; GAIDANO G, IN PRESS LEUKEMIA; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GEDDES M, 1994, BRIT J CANCER, V69, P333, DOI 10.1038/bjc.1994.60; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; WABINGA HR, 1993, INT J CANCER, V54, P5; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277	14	681	713	1	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					925	928		10.1038/nm0896-925	http://dx.doi.org/10.1038/nm0896-925			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705864				2022-12-27	WOS:A1996UZ80400041
J	Wilson, JM; Kalasinsky, KS; Levey, AI; Bergeron, C; Reiber, G; Anthony, RM; Schmunk, GA; Shannak, K; Haycock, JW; Kish, SJ				Wilson, JM; Kalasinsky, KS; Levey, AI; Bergeron, C; Reiber, G; Anthony, RM; Schmunk, GA; Shannak, K; Haycock, JW; Kish, SJ			Striatal dopamine nerve terminal markers in human, chronic methamphetamine users	NATURE MEDICINE			English	Article							RAT-BRAIN; NEURONS	Methamphetamine is a drug that is significantly abused worldwide. Although long-lasting depletion of dopamine and other dopamine nerve terminal markers has been reported in striatum of nonhuman primates receiving very high doses of the psychostimuiant(1-3), no information is available for humans. We found reduced levels of three dopamine nerve terminal markers (dopamine, tyrosine hydroxylase and the dopamine transporter) in post-mortem striatum (nucleus accumbens, caudate, putamen) of chronic methamphetamine users. However, levels of DOPA decarboxylase and the vesicular monoamine transporter, known to be reduced in Parkinson's disease(4,5), were normal. This suggests that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in our study. However, the dopamine reduction might explain some of the dysphoric effects of the drug, whereas the decreased dopamine transporter could provide the basis for dose escalation occurring in some methamphetamine users.	CLARKE INST PSYCHIAT,HUMAN NEUROCHEM PATHOL LAB,TORONTO,ON M5T 1R8,CANADA; ARMED FORCES INST PATHOL,DIV FORENS TOXICOL,WASHINGTON,DC 20306; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322; TORONTO GEN HOSP,DEPT PATHOL NEUROPATHOL,TORONTO,ON M5G 2C4,CANADA; NO CALIF FORENS PATHOL,SACRAMENTO,CA 95825; OFF BROWN CTY MED EXAMINER,GREEN BAY,WI 54305; LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70119	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; United States Department of Defense; Emory University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Louisiana State University System			Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NIDA NIH HHS [DA 07182] Funding Source: Medline; NIMH NIH HHS [MH 00967] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000967] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRUNSWICK DJ, 1992, SYNAPSE, V11, P287, DOI 10.1002/syn.890110404; CHAN P, 1994, J NEUROCHEM, V62, P2484, DOI 10.1046/j.1471-4159.1994.62062484.x; DASILVA JN, 1993, SYNAPSE, V14, P128, DOI 10.1002/syn.890140205; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; FISHBEIN DH, 1989, BIOL PSYCHIAT, V25, P1049, DOI 10.1016/0006-3223(89)90293-X; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; HARTMAN JA, 1980, BRAIN RES, V190, P421; HORTNAGL H, 1983, PROG BRAIN RES, V58, P269, DOI 10.1016/S0079-6123(08)60029-1; KISH SJ, 1988, NEW ENGL J MED, V318, P867; KUCZENSKI R, 1980, J PHARMACOL EXP THER, V215, P135; Kuikka J. T., 1995, Journal of Nuclear Medicine, V36, p31P; LARUELLE M, 1995, J NUCL MED, V36, P1182; Miczek K A, 1989, NIDA Res Monogr, V94, P68; MILLER DB, 1994, J PHARMACOL EXP THER, V270, P752; NAUDON L, 1994, NEUROSCI LETT, V173, P1, DOI 10.1016/0304-3940(94)90136-8; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; ORDWAY GA, 1994, J NEUROCHEM, V62, P680; PERSICO AM, 1993, NEUROREPORT, V4, P41, DOI 10.1097/00001756-199301000-00010; PIFL C, 1995, MOL PHARMACOL, V47, P368; PRESTON KL, 1985, BRAIN RES, V338, P243, DOI 10.1016/0006-8993(85)90153-2; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; Riley H., 1960, ATLAS BASAL GANGLIA; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A; SEIDEN LS, 1976, DRUG ALCOHOL DEPEN, V1, P215, DOI 10.1016/0376-8716(76)90030-2; VanderBorght T, 1995, EUR J PHARMACOL, V294, P577; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; WILSON JM, 1994, J NEUROSCI, V14, P2966; WILSON JM, IN PRESS NEUROLOGY; WILSON JM, IN PRESS J NEUROSCI; WISE RA, 1995, PSYCHOPHARMACOLOGY, V117, P130, DOI 10.1007/BF02245178; WOOLVERTON WL, 1989, BRAIN RES, V486, P73, DOI 10.1016/0006-8993(89)91279-1; ZHONG XH, 1995, MOVEMENT DISORD, V10, P10, DOI 10.1002/mds.870100104	35	606	615	1	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					699	703		10.1038/nm0696-699	http://dx.doi.org/10.1038/nm0696-699			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640565				2022-12-27	WOS:A1996UN69100042
J	McHugh, PR				McHugh, PR			Hippocrates a la mode - Commentary	NATURE MEDICINE			English	Editorial Material											McHugh, PR (corresponding author), JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,600 N WOLFE ST,MEYER 4-113,BALTIMORE,MD 21287, USA.							BURLEIGH M, 1994, DEATH DELIVERANCE EU, P275; Edelstein Ludwig, 1967, ANCIENT MED, P6; Hupert N, 1994, HARVARD MED ALUMNI B, V68, P42; Temkin O., 1991, HIPPOCRATES WORLD PA; WOLFE T, 1976, MAUVE GLOVES MADMEN, P111	5	23	24	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					507	509		10.1038/nm0596-507	http://dx.doi.org/10.1038/nm0596-507			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616701				2022-12-27	WOS:A1996UJ23000025
J	Wong, ML; Rettori, V; AlShekhlee, A; Bongiorno, PB; Canteros, G; McCann, SM; Gold, PW; Licinio, J				Wong, ML; Rettori, V; AlShekhlee, A; Bongiorno, PB; Canteros, G; McCann, SM; Gold, PW; Licinio, J			Inducible nitric oxide synthase gene expression in the brain during systemic inflammation	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; ULCERATIVE-COLITIS; RESPONSE SYNDROME; ENCEPHALOPATHY; NEUROTOXICITY; MECHANISMS; CULTURES; DISEASE; NITRATE	Inducible nitric oxide synthase (iNOS) is a transcriptionally regulated enzyme that synthesizes nitric oxide from L-arginine(1) that has a key role in the pathophysiology of systemic inflammation and sepsis. Transgenic animals with a null mutation for the iNOS gene are resistant to hypotension and death caused by Escherichia coli lipopolysaccharide (LPS)(2,3). The regulation of peripheral iNOS has been well studied in sepsis, but little is known about iNOS regulation in the brain during systemic inflammation or sepsis. We show that at baseline there is no detectable iNOS gene expression in the brain, but a detailed neuroanatomical study reveals that early in the course of systemic inflammation there is a profound induction of iNOS messenger RNA in vascular, glial and neuronal structures of the rat brain, accompanied by the production of nitric oxide (NO) metabolites in brain parenchyma and cerebrospinal fluid (CSF). We propose that the spillover of nitrite into the CSF has the potential to be a diagnostic marker for systemic inflammation and sepsis. Pharmacological interventions aimed at regulating iNOS function in the brain might represent a new treatment strategy in sepsis. Brain iNOS may be relevant to the pathophysiology, diagnosis and treatment of systemic inflammation and sepsis.	NIMH,NIH,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; CONSEJO NACL INVEST CIENT & TECN,CENTRO ESTUDIOS FARMACOLOG & BOTANICOS,BUENOS AIRES,DF,ARGENTINA; LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,BATON ROUGE,LA 70808	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center			Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020; Licinio, Julio/L-4244-2013	Wong, Ma-Li/0000-0003-1512-3073; Licinio, Julio/0000-0001-6905-5884				BARRIERE SL, 1995, CRIT CARE MED, V23, P376, DOI 10.1097/00003246-199502000-00026; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CANTEROS G, IN PRES P NATL ACAD; COSTA A, 1993, BRAIN RES, V605, P187, DOI 10.1016/0006-8993(93)91739-F; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dennhardt R, 1989, Prog Clin Biol Res, V308, P751; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LICINIO J, 1995, ENDOCRINOLOGY, V136, P4709, DOI 10.1210/en.136.10.4709; LUNDBERG JON, 1994, LANCET, V344, P1673, DOI 10.1016/S0140-6736(94)90460-X; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; RIVIER C, 1994, J NEUROSCI, V14, P1985; ROSSOR MN, 1996, OXFORD TXB MED, V3, P3971; SANDI C, 1995, EUR J PHARMACOL, V274, P17, DOI 10.1016/0014-2999(94)00700-H; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WONG ML, 1993, METH NEUROSCI, V16, P81; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016	34	250	254	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					581	584		10.1038/nm0596-581	http://dx.doi.org/10.1038/nm0596-581			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616720	Green Published			2022-12-27	WOS:A1996UJ23000044
J	Olson, L				Olson, L			Toward trophic treatment in parkinsonism: A primate step	NATURE MEDICINE			English	Editorial Material											Olson, L (corresponding author), KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN.							Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; Gash DM, 1995, J COMP NEUROL, V363, P345, DOI 10.1002/cne.903630302; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Kotzbauer P. T., 1995, Society for Neuroscience Abstracts, V21, P544; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDSAY RM, 1995, NATURE, V373, P289, DOI 10.1038/373289a0; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; SYDOW O, 1995, EUR J NEUROL, V2, P1; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P9274	18	9	11	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					400	401		10.1038/nm0496-400	http://dx.doi.org/10.1038/nm0496-400			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597946				2022-12-27	WOS:A1996UD31400038
J	Roses, AD				Roses, AD			From genes to mechanisms to therapies: Lessons to be learned from neurological disorders	NATURE MEDICINE			English	Editorial Material									DUKE UNIV,MED CTR,DEANE LAB,DURHAM,NC 27710	Duke University	Roses, AD (corresponding author), DUKE UNIV,MED CTR,CTR HUMAN GENET,DURHAM,NC 27710, USA.							BASSETT AS, 1994, AM J HUM GENET, V54, P864; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; GAMES D, 1995, ANTURE, V373, P523; GOTTESMAN II, 1989, ARCH GEN PSYCHIAT, V46, P867; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; HUANG DY, 1994, NEUROSCI LETT, V182, P55, DOI 10.1016/0304-3940(94)90204-6; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; OHM TG, 1995, NEUROSCIENCE, V66, P583, DOI 10.1016/0306-4522(94)00596-W; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; ROSES AD, 1995, EXP NEUROL, V132, P149, DOI 10.1016/0014-4886(95)90019-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S	17	28	28	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					267	269		10.1038/nm0396-267	http://dx.doi.org/10.1038/nm0396-267			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612215				2022-12-27	WOS:A1996TY64000025
J	Hsu, FJ; Benike, C; Fagnoni, F; Liles, TM; Czerwinski, D; Taidi, B; Engleman, EG; Levy, R				Hsu, FJ; Benike, C; Fagnoni, F; Liles, TM; Czerwinski, D; Taidi, B; Engleman, EG; Levy, R			Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells	NATURE MEDICINE			English	Article							LANGERHANS CELLS; IMMUNIZATION; IMMUNOGENICITY; EXPRESSION; ANTIBODY; INVITRO; SURFACE; TUMORS; GENE	In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with tumor-specific idiotype protein to stimulate host antitumor immunity when infused as a vaccine. Four patients with follicular B-cell lymphoma received a series of three or four infusions of antigen-pulsed dendritic cells followed, in each instance, by subcutaneous injections of soluble antigen two weeks later. All patients developed measurable antitumor cellular immune responses. In addition, clinical responses have been measured with one patient experiencing complete tumor regression, a second patient having partial tumor regression, and a third patient resolving all evidence of disease as detected by a sensitive tumor-specific molecular analysis.	STANFORD UNIV,MED CTR,STANFORD BLOOD CTR,STANFORD,CA 94305	Stanford University	Hsu, FJ (corresponding author), STANFORD UNIV,MED CTR,DIV ONCOL,ROOM M207,STANFORD,CA 94305, USA.		Fagnoni, Francesco F/A-1642-2008	Levy, Ronald/0000-0003-2061-0650	NATIONAL CANCER INSTITUTE [P01CA034233, R01CA033399, P01CA049605, R37CA033399] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49605-07, CA 34233, CA 33399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CAMPBELL MJ, 1990, J IMMUNOL, V145, P1029; CARROLL WL, 1986, J IMMUNOL METHODS, V89, P61, DOI 10.1016/0022-1759(86)90032-3; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN TT, 1994, J IMMUNOL, V153, P4775; FAGNONI FF, 1995, IMMUNOLOGY, V85, P467; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GRABSTEIN K, 1980, SELECTED METHODS CEL, P124; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; HSU FJ, 1993, ANN NY ACAD SCI, V690, P385; HSU FJ, 1995, BLOOD, V86, P3072, DOI 10.1182/blood.V86.8.3072.bloodjournal8683072; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; KANTOR J, 1992, CANCER RES, V52, P6917; KOCH F, 1995, J IMMUNOL, V155, P93; KOTERA Y, 1994, CANCER RES, V54, P2856; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LEVY R, 1982, MALIGNANT LYMPHOMAS, pCH5; LYNCH RG, 1979, IMMUNOL REV, V48, P45, DOI 10.1111/j.1600-065X.1979.tb00298.x; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MALONEY DG, 1992, BLOOD, V80, P1502; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARCHAND M, 1993, DERMATOLOGY, V186, P278, DOI 10.1159/000247375; MARLAND G, 1995, J CELL BIOL SA, V21, P21; MCCABE BJ, 1995, CANCER RES, V55, P1741; MEHTA DA, 1994, J IMMUNOL, V153, P996; MEHTA DA, 1995, EUR J IMMUNOL, V25, P1206; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAMIZAWA M, 1995, J CLIN INVEST, V95, P296, DOI 10.1172/JCI117654; TAO MH, 1993, NATURE, V362	40	1566	1700	1	57	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					52	58		10.1038/nm0196-52	http://dx.doi.org/10.1038/nm0196-52			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564842				2022-12-27	WOS:A1996TP57900037
J	ATKINS, CJ; ZIELINSKI, A; MAKOSINSKI, A				ATKINS, CJ; ZIELINSKI, A; MAKOSINSKI, A			PALPOMETRY - A NOVEL CONCEPT IN PAIN MEASUREMENT	NATURE MEDICINE			English	Editorial Material									UNIV VICTORIA,DEPT ELECT ENGN,VICTORIA,BC V8W 2Y2,CANADA	University of Victoria	ATKINS, CJ (corresponding author), ARTHRIT SOC BRITISH COLUMBIA & YUKON,VICTORIA,BC,CANADA.							ATKINS CJ, 1992, ARTHRITIS RHEUM, V35, P407, DOI 10.1002/art.1780350408; ATKINS CJ, 1995, PAIN, V62, P249, DOI 10.1016/0304-3959(95)00005-D; ATKINS CJ, 1992, RHEUMATOL REV, V1, P217; BENDTSEN L, 1995, CEPHALALGIA, V15, P205, DOI 10.1046/j.1468-2982.1995.015003205.x; BENDTSEN L, 1994, PAIN, V59, P235, DOI 10.1016/0304-3959(94)90076-0; BENNETT RM, 1993, TXB RHEUMATOLOGY, P471; PUTTICK MPE, IN PRESS J MUSCULOSK; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; ZIELINSKI A, 1991, Patent No. 5012817	10	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1138	1139		10.1038/nm1195-1138	http://dx.doi.org/10.1038/nm1195-1138			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584982				2022-12-27	WOS:A1995TC53700034
J	KHAW, BA; TORCHILIN, VP; VURAL, I; NARULA, J				KHAW, BA; TORCHILIN, VP; VURAL, I; NARULA, J			PLUG AND SEAL - PREVENTION OF HYPOXIC CARDIOCYTE DEATH BY SEALING MEMBRANE LESIONS WITH ANTIMYOSIN-LIPOSOMES	NATURE MEDICINE			English	Article							MYOSIN-SPECIFIC ANTIBODY; MYOCARDIAL-INFARCTION; REPERFUSION; SIZE; LOCALIZATION	The hallmark of cell death is the development of cell membrane lesions. Such lesions in the myocardium are usually associated with acute myocardial infarction. Minimizing myocardial necrosis by thrombolytic reperfusion therapy constitutes the only major treatment to date. We envisioned a method to seal these membrane lesions using immunoliposomes as a novel adjunctive approach. An antigen to intracellular cytoskeletal myosin in hypoxic embryonic cardiocytes is used as an anchoring site, and a specific antibody on immunoliposomes as the anchor to plug and to seal the membrane lesions. H9C2 cells were used because they are cardiocytes and are propagated in tissue culture and their viability may be assessed by various methods. Viability assessed by [H-3]thymidine uptake in hypoxic cardiocyte cultures (n = 6 each) treated with antimyosin-immunoliposomes (3.26 +/- 0.483 x 10(6) c.p.m.) was similar to that of normoxic cells (3.68 +/- 0.328 x 10(6) c.p.m.), but was greater than those of untreated hypoxic cells (0.115 +/- 0.155 x 10(6) c.p.m.) or hypoxic cells treated with plain liposomes (1.140 +/- 0.577 x 10(6) c.p.m.). These results were reconfirmed by trypan blue exclusion and by fluorescent, confocal and transmission electron microscopy. They indicated that cell death in hypoxic cardiocytes can be prevented by targeted cell membrane sealing. This concept of cell salvage should be applicable in the prevention of cell death in different biological systems.	MASSACHUSETTS GEN HOSP,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital	KHAW, BA (corresponding author), NORTHWESTERN UNIV,CTR DRUG TARGETING & ANAL,205 MUGAR BLDG,BOSTON,MA 02115, USA.			Vural, Imran/0000-0002-1627-3834				ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7; BLEIFELD W, 1977, CIRCULATION, V55, P303, DOI 10.1161/01.CIR.55.2.303; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; JENNINGS RB, 1983, CIRCULATION, V68, P25; JENNINGS RB, 1960, ARCH PATHOL, V70, P68; KATZUNG BJ, 1975, PFLEUGERS ARCH EUR J, V260, P193; KHAW BA, 1976, J CLIN INVEST, V58, P439, DOI 10.1172/JCI108488; KHAW BA, 1979, CIRCULATION, V60, P1527, DOI 10.1161/01.CIR.60.7.1527; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; NARULA J, 1995, CIRCULATION, V92, P474, DOI 10.1161/01.CIR.92.3.474; PASTERNAK RC, 1994, HARRISONS PRINCIPLES, P1066; REIMER KA, 1983, AM J CARDIOL, V52, pA72; ROBERTS R, 1994, HURSTS HEART ARTERIE, P1107; ROBERTS R, 1979, ISOZYMES CURRENT TOP, P115; ROGERS WJ, 1977, CIRCULATION, V56, P199, DOI 10.1161/01.CIR.56.2.199; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; TANDAN R, 1987, J NEUROL SCI, V79, P189, DOI 10.1016/0022-510X(87)90272-3; TORCHILIN VP, 1992, FASEB J, V6, P2716, DOI 10.1096/fasebj.6.9.1612296; TORCHILIN VP, 1988, LIPOSOMES DRUG CARRI, P63	21	68	70	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1195	1198		10.1038/nm1195-1195	http://dx.doi.org/10.1038/nm1195-1195			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584994				2022-12-27	WOS:A1995TC53700046
J	BOLAND, CR; SATO, J; APPELMAN, HD; BRESALIER, RS; FEINBERG, AP				BOLAND, CR; SATO, J; APPELMAN, HD; BRESALIER, RS; FEINBERG, AP			MICROALLELOTYPING DEFINES THE SEQUENCE AND TEMPO OF ALLELIC LOSSES AT TUMOR-SUPPRESSOR GENE LOCI DURING COLORECTAL-CANCER PROGRESSION	NATURE MEDICINE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISM; FAMILIAL ADENOMATOUS POLYPOSIS; MUTATIONS OCCUR; TUMORIGENESIS; P53; CARCINOMAS; EXPRESSION; COLON; HYPOMETHYLATION; CHROMOSOME-5Q21	Microallelotyping of many regions from individual colorectal tumours was used to determine the sequence and tempo of allelic loss on 5q, 17p and 18q during neoplastic progression. No allelic losses were found in normal tissues surrounding colorectal neoplasms, but losses occurred abruptly on 5q at the transition from normal colonic epithelium to the benign adenoma, and on 17p at the transition from adenoma to carcinoma, indicating an essential role for these losses in tumour progression. Allelic losses were uniform throughout extensively microdissected benign adenomas and carcinomas. However, substantial allelic heterogeneity was found in high-grade dysplasia, the transition lesion between adenoma and carcinoma. Thus, allelic losses on 5q and 17p are associated with abrupt waves of clonal neoplastic expansion, and high-grade dysplasia is characterized by a high degree of allelic heterogeneity.	UNIV MICHIGAN,CTR CANC,ANN ARBOR,MI 48109; UNIV TSUKUBA,INST CLIN MED,TSUKUBA,IBARAKI 305,JAPAN; UNIV MICHIGAN HOSP,MED CTR,DEPT PATHOL,ANN ARBOR,MI 48109; HENRY FORD HOSP,DETROIT,MI 48202; JOHNS HOPKINS UNIV,SCH MED,DEPT INTERNAL MED,BALTIMORE,MD 20105; JOHNS HOPKINS UNIV,SCH MED,DEPT HUMAN GENET,BALTIMORE,MD 20105	University of Michigan System; University of Michigan; University of Tsukuba; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital; Johns Hopkins University; Johns Hopkins University	BOLAND, CR (corresponding author), VET AFFAIRS MED CTR,DEPT INTERNAL MED,4410 KRESGE 3,200 ZINA PITCHE PL,ANN ARBOR,MI 48109, USA.		Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991; Bresalier, Robert/0000-0002-9740-281X	NATIONAL CANCER INSTITUTE [R01CA054358, P30CA046592, R01CA039233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA054358, R01 CA 39233, CA 46592] Funding Source: Medline; NIDDK NIH HHS [DK 34933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AN SF, 1991, J CLIN PATHOL, V44, P924, DOI 10.1136/jcp.44.11.924; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOLAND CR, 1987, MED HYPOTHESES, V22, P237, DOI 10.1016/0306-9877(87)90189-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAMPO E, 1991, CANCER RES, V51, P4436; DELATTRE O, 1989, LANCET, V2, P353; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1989, CANCER CEL, V7, P245; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1994, J CELL SCI S, V18, P7; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1994, CANCER RES, V54, P5059; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MOERKERK P, 1994, CANCER RES, V54, P3376; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHUE M, 1994, CANCER RES, V54, P4798; OLIPHANT AR, 1991, NUCLEIC ACIDS RES, V19, P4794; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P6465, DOI 10.1093/nar/18.21.6465-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P3431, DOI 10.1093/nar/18.11.3431-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YUAN M, 1986, CANCER RES, V46, P4841	45	170	174	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					902	909		10.1038/nm0995-902	http://dx.doi.org/10.1038/nm0995-902			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585215				2022-12-27	WOS:A1995RT30300043
J	LONNQVIST, F; ARNER, P; NORDFORS, L; SCHALLING, M				LONNQVIST, F; ARNER, P; NORDFORS, L; SCHALLING, M			OVEREXPRESSION OF THE OBESE (OB) GENE IN ADIPOSE-TISSUE OF HUMAN OBESE SUBJECTS	NATURE MEDICINE			English	Article							ENERGY-INTAKE; BODY-FAT; TWIN	Obesity is accompanied by complications such as hypertension, non-insulin-dependent diabetes mellitus and atherosclerosis, which in turn cause ischaemic heart disease, stroke and premature death(1-3). The underlying mechanisms behind imbalance in energy intake and energy expenditure that lead to obesity are still controversial. In most populations, obesity is more common among women than men and is a multifactorial phenotype, which may result from a complex network of genetic and nongenetic factors. The relative importance of genetic factors for obesity is under debate(4-7). Genome searches using polymorphic markers in inbred mice with phenotypes that result in extreme obesity(8,9) and studies of human candidate genes are being performed in an attempt to identify genes that contribute to obesity. There is evidence that body weight is physiologically regulated(4,10,11) and it has been postulated that the storage of fat may provide signals to the brain that the body is obese, which in turn may make the subject eat less and burn more fuel(12,13). One of the molecules that may be involved in such signalling is the obese (ob) gene product. Mutations in ob result in profound obesity and type II diabetes in mice(14,15). The mouse ob gene and its human homologue have been cloned and sequenced(8). The gene is expressed in adipose tissue and the product has features of a secreted protein, We have investigated human ob expression in subcutaneous and omental adipose tissue obtained from non-obese and massively obese subjects using in situ hybridization histochemistry and report on overexpression in obese people.	HUDDINGE UNIV HOSP,DEPT MED,KAROLINSKA INST,S-14186 STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,RES CTR,S-14186 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet	LONNQVIST, F (corresponding author), KAROLINSKA HOSP,DEPT MOLEC MED,NEUROGENET UNIT,KAROLINSKA INST,S-17176 STOCKHOLM,SWEDEN.		Schalling, Martin/F-1518-2015	Schalling, Martin/0000-0001-5011-2922; Arner, Peter/0000-0002-6208-6220				ASTRUP A, 1992, EUR J CLIN NUTR, V46, P611; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BODURTHA JN, 1990, PEDIATR RES, V28, P1, DOI 10.1203/00006450-199007000-00001; BOUCHARD C, 1988, ANNU REV NUTR, V8, P259, DOI 10.1146/annurev.nu.08.070188.001355; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BROBECK JR, 1948, YALE J BIOL MED, V20, P545; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FLIER S, 1995, CELL, V80, P15; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERUSSE L, 1988, AM J CLIN NUTR, V47, P629, DOI 10.1093/ajcn/47.4.629; SCHALLING M, 1992, GENE EXPRESSION NEUR, P231; STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51; TREMBLAY A, 1991, AM J CLIN NUTR, V53, P1134, DOI 10.1093/ajcn/53.5.1134; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	23	651	697	1	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					950	953		10.1038/nm0995-950	http://dx.doi.org/10.1038/nm0995-950			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585223				2022-12-27	WOS:A1995RT30300051
J	SUN, L; JIANG, RZ; STEINBACH, S; HOLMES, A; CAMPANELLI, C; FORSTNER, J; SAJJAN, U; TAN, Y; RILEY, M; GOLDSTEIN, R				SUN, L; JIANG, RZ; STEINBACH, S; HOLMES, A; CAMPANELLI, C; FORSTNER, J; SAJJAN, U; TAN, Y; RILEY, M; GOLDSTEIN, R			THE EMERGENCE OF A HIGHLY TRANSMISSIBLE LINEAGE OF CBL(+) PSEUDOMONAS (BURKHOLDERIA) CEPACIA CAUSING CF CENTER EPIDEMICS IN NORTH-AMERICA AND BRITAIN	NATURE MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIELD GEL-ELECTROPHORESIS; CYSTIC-FIBROSIS; COLONIZATION; SALMONELLA; REGION	The rapid increase in Pseudomonas (Burkholderia) cepacia infection in cystic fibrosis (CF) patients suggests epidemic transmission, but the degree of transmissibility remains controversial as conflicting conclusions have been drawn from studies at different CF centres. This report provides the first DNA sequence-based documentation of a divergent evolutionary lineage of P. cepacia associated with CF centre epidemics in North America (Toronto) and Europe (Edinburgh). The involved epidemic clone encoded and expressed novel cable (Cbl) pill that bind to CF mucin. The sequence of the cblA pilin subunit gene carried by the epidemic isolates proved to be invariant. Although it remains to be determined how many distinct, highly transmissible lineages exist, our results provide both a DNA sequence and chromosomal fingerprint that can be used to screen for one such particularly infectious, transatlantic clone.	BOSTON UNIV,SCH MED,MAXWELL FINLAND LAB INFECT DIS,MOLEC GENET SECT,BOSTON,MA 02118; BOSTON CITY HOSP,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; HOSP SICK CHILDREN,DIV BIOCHEM,RES INST,TORONTO,ON M5G 1X8,CANADA; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Boston University; Boston Medical Center; Boston University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047471] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50838] Funding Source: Medline; NIGMS NIH HHS [GM 47471] Funding Source: Medline; PHS HHS [A1 37728] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; ARTHUR M, 1989, INFECT IMMUN, V57, P303, DOI 10.1128/IAI.57.2.303-313.1989; ARTHUR M, 1990, INFECT IMMUN, V58, P471, DOI 10.1128/IAI.58.2.471-479.1990; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GOLDSTEIN R, 1995, J BACTERIOL, V177, P1039, DOI 10.1128/jb.177.4.1039-1052.1995; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; LIPUMA JJ, 1988, J PEDIATR-US, V113, P859, DOI 10.1016/S0022-3476(88)80018-0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NELSON K, 1992, J BACTERIOL, V174, P6886, DOI 10.1128/JB.174.21.6886-6895.1992; PREVOST G, 1992, J CLIN MICROBIOL, V30, P967, DOI 10.1128/JCM.30.4.967-973.1992; RABKIN CS, 1989, REV INFECT DIS, V11, P600; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAJJAN U, 1993, INFECT IMMUN, V61, P3156; SAJJAN US, 1992, J CLIN INVEST, V89, P648, DOI 10.1172/JCI115631; SAJLAN U, 1995, J BACTERIOL, V177, P1030; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH NH, 1990, J BACTERIOL, V172, P603, DOI 10.1128/jb.172.2.603-609.1990; SNELL GI, 1993, CHEST, V103, P466, DOI 10.1378/chest.103.2.466; STEINBACH S, 1994, NEW ENGL J MED, V331, P981, DOI 10.1056/NEJM199410133311504; TABLAN OC, 1985, J PEDIATR-US, V107, P382, DOI 10.1016/S0022-3476(85)80511-4; THOMASSEN MJ, 1985, AM REV RESPIR DIS, V131, P791; THOMASSEN MJ, 1986, AM REV RESPIR DIS, V134, P669; VINOGRAD J, 1962, FORTSCHR CHEM ORG NA, V20, P372	27	179	183	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					661	666		10.1038/nm0795-661	http://dx.doi.org/10.1038/nm0795-661			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585148				2022-12-27	WOS:A1995RQ06600041
J	LUDWIG, S; RAPP, UR				LUDWIG, S; RAPP, UR			CASCADING TOWARDS VASCULAR DISORDER GENE-THERAPY	NATURE MEDICINE			English	Editorial Material							INHIBITION; KINASE; PROLIFERATION; PROTEIN; HEPARIN; CELLS				LUDWIG, S (corresponding author), UNIV WURZBURG,INST MED RADIOBIOL & CELL RES,VERSBACHER STR 5,D-97078 WURZBURG,GERMANY.			Ludwig, Stephan/0000-0003-4490-3052				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594	14	12	12	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					513	515		10.1038/nm0695-513	http://dx.doi.org/10.1038/nm0695-513			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585110				2022-12-27	WOS:A1995RN10100027
J	ROSSANT, J; NAGY, A				ROSSANT, J; NAGY, A			GENOME ENGINEERING - THE NEW MOUSE GENETICS	NATURE MEDICINE			English	Editorial Material							EMBRYONIC STEM-CELLS; SWITCH RECOMBINATION		MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	ROSSANT, J (corresponding author), UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA.		Nagy, Andras/G-6465-2013	Nagy, Andras/0000-0003-4311-0413				ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819	11	77	83	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1995	1	6					592	594		10.1038/nm0695-592	http://dx.doi.org/10.1038/nm0695-592			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585128				2022-12-27	WOS:A1995RN10100045
J	FABRE, JW				FABRE, JW			NUDGING XENOTRANSPLANTATION TOWARDS HUMANS	NATURE MEDICINE			English	Editorial Material							EPITOPES	Transplanting organs across species lines presents tremendous difficulties, but the obstacles are no longer insurmountable (pages 423-127).			FABRE, JW (corresponding author), UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND.							CALNE RY, 1960, LANCET, V1, P417; Carrel A, 1902, LYON MED, V99, P859; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GUSTAFSSON K, 1994, IMMUNOL REV, V141, P59, DOI 10.1111/j.1600-065X.1994.tb00872.x; INVERARDI L, 1994, IMMUNOL REV, V141, P71, DOI 10.1111/j.1600-065X.1994.tb00873.x; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SAWYER GJ, 1995, TRANSPLANT P, V27, P309; SCHWARTZ R, 1958, P SOC EXP BIOL MED, V99, P164; Ullman E, 1914, ANN SURG, V60, P195, DOI 10.1097/00000658-191408000-00006; ULLMANN E, 1902, WIEN KLIN WOCHENSCHR, V11, P281; VONDECASTELLO A, 1902, WIENER KLINISCHE WOC, V12, P317; ZUKOSKI C F, 1960, Surg Forum, V11, P470	13	11	15	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					403	404		10.1038/nm0595-403	http://dx.doi.org/10.1038/nm0595-403			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585079				2022-12-27	WOS:A1995RN10000022
J	BRODEUR, GM				BRODEUR, GM			DO THE ENDS JUSTIFY THE MEANS	NATURE MEDICINE			English	Editorial Material							N-MYC AMPLIFICATION; HUMAN NEUROBLASTOMAS; NEURO-BLASTOMA; TUMOR KARYOTYPE; TRK EXPRESSION; PROGNOSIS; PROTOONCOGENE; CHROMOSOME-1; ASSOCIATION; STAGE				BRODEUR, GM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV CARDIOL,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.							BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1990, CANCER SURV, V9, P673; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FRANKE F, 1986, J CANCER RES CLIN, V111, P266, DOI 10.1007/BF00389243; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KANEKO Y, 1987, CANCER RES, V47, P311; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOGNER P, 1993, CANCER RES, V53, P2044; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209	20	5	7	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					203	205		10.1038/nm0395-203	http://dx.doi.org/10.1038/nm0395-203			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585030				2022-12-27	WOS:A1995QX55900020
J	DIEHL, SR				DIEHL, SR			SAND IN THE SHEETS	NATURE MEDICINE			English	Editorial Material							ALZHEIMERS-DISEASE; GENE	A demonstration of inhibition of beta-sheets in both reactive amyloid, using an in vivo mouse model, and synthetic Alzheimer (beta) amyloid, in vitro (pages 143-148).			DIEHL, SR (corresponding author), NIDR,DEODP,MOLEC EPIDEMIOL & DIS INDICATORS BRANCH,BETHESDA,MD 20892, USA.							BENSON MD, 1994, METABOLIC BASIS INHE, P4159; CAUBHEYY B, 1994, PHILOS T R SOC LONDB, V343, P399; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DUFF KJ, 1994, FLA MED ASS, V91, P625; GHISO J, 1994, MOL NEUROBIOL, V8, P49, DOI 10.1007/BF02778007; HIGGINSLS, 1994, ANN NEUROL, V35, P598; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; MANESS LM, 1994, LIFE SCI, V55, P1643, DOI 10.1016/0024-3205(94)00331-9; McKusick V.A., 1992, MENDELIAN INHERITANC; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PRICE DL, 1994, ANNU REV MED, V45, P435; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; TSUDA T, 1994, ANN NEUROL, V36, P97, DOI 10.1002/ana.410360118	17	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					120	122		10.1038/nm0295-120	http://dx.doi.org/10.1038/nm0295-120			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585005				2022-12-27	WOS:A1995QX55800019
J	Speicher, MR; Ward, DC				Speicher, MR; Ward, DC			The coloring of cytogenetics	NATURE MEDICINE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; HUMAN-CHROMOSOMES; DNA LIBRARIES; YAC CLONES; MULTIPLE; PROBES; SEQUENCES; METAPHASE; CELLS		YALE UNIV,SCH MED,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University	Speicher, MR (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Speicher, Michael R/B-5362-2013	Speicher, Michael R/0000-0003-0105-955X				Boveri T, 1914, FRAGE ENTSTEHUNG MAL, P1; CASPERSS.T, 1970, EXP CELL RES, V60, P315, DOI 10.1016/0014-4827(70)90523-9; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; DAUWERSE JG, 1992, HUM MOL GENET, V1, P593, DOI 10.1093/hmg/1.8.593; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P205; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LeBeau MM, 1996, NAT GENET, V12, P341, DOI 10.1038/ng0496-341; LENGAUER C, 1993, HUM MOL GENET, V2, P505, DOI 10.1093/hmg/2.5.505; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; NEDERLOF PM, 1989, CYTOMETRY, V10, P20, DOI 10.1002/cyto.990100105; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; POPP S, 1993, HUM GENET, V92, P527, DOI 10.1007/BF00420933; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Tjio J. H., 1956, HEREDITAS, V42, P1, DOI [10.1007/978-94-011-6621-8_13, DOI 10.1111/J.1601-5223.1956.TB03010.X]; WIEGANT J, 1993, CYTOGENET CELL GENET, V63, P73, DOI 10.1159/000133507	18	27	29	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1046	1048		10.1038/nm0996-1046	http://dx.doi.org/10.1038/nm0996-1046			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782466				2022-12-27	WOS:A1996VF49700045
J	Kennedy, D				Kennedy, D			The Baltimore affair: Let's not forget what went wrong	NATURE MEDICINE			English	Editorial Material											Kennedy, D (corresponding author), STANFORD UNIV,STANFORD,CA 94305, USA.							1996, NAT MED, V2, P10	1	4	4	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					843	844		10.1038/nm0896-843	http://dx.doi.org/10.1038/nm0896-843			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705843				2022-12-27	WOS:A1996UZ80400020
J	Morse, RP; Evans, EF				Morse, RP; Evans, EF			Enhancement of vowel coding for cochlear implants by addition of noise	NATURE MEDICINE			English	Article							STOCHASTIC RESONANCE; AUDITORY-NERVE; ELECTRICAL-STIMULATION; POTASSIUM CHANNELS; FIBERS; CRAYFISH; PARALLEL; MEMBRANE; NEURONS; RANVIER	Profoundly deaf people, who gain no benefit from conventional hearing aids, can receive speech cues by direct electrical stimulation of the cochlear nerve(1,2). This is achieved by an electronic device, a cochlear implant, which is surgically inserted into the ear. Here we show physiological results from the isolated sciatic nerve of the toad Xenopus laevis, used to predict the response of the human cochlear nerve to vowels coded by a cochlear implant. These results suggest that standard analogue cochlear implants do not evoke the patterns of neural excitation that are normally associated with acoustic stimulation. Adding noise to the stimulus, however, enhanced distinguishing features of the vowel encoded by the fine time structure of neural discharges. On the basis of these results, and those concerning stochastic resonance(3-5), we advocate a cochlear implant coding strategy in which noise is deliberately added to cochlear implant signals.			Morse, RP (corresponding author), UNIV KEELE, DEPT COMMUN & NEUROSCI, KEELE ST5 5BG, STAFFS, ENGLAND.			Morse, Robert/0000-0002-5656-6009				BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; Bilger RC, 1977, ANN OTOL RHINOL  S38, V86, P1, DOI 10.1177/00034894770860S303; BRETAG AH, 1975, PFLUG ARCH EUR J PHY, V354, P257, DOI 10.1007/BF00584649; CLOPTON BM, 1984, HEARING RES, V14, P1, DOI 10.1016/0378-5955(84)90063-7; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; DELGUTTE B, 1984, J ACOUST SOC AM, V75, P866, DOI 10.1121/1.390596; DODGE FA, 1958, J PHYSIOL-LONDON, V143, P76, DOI 10.1113/jphysiol.1958.sp006045; DUBOIS JM, 1981, J PHYSIOL-LONDON, V318, P297; ERLANGER J, 1937, ELECTRICAL SIGNS NER; EVANS EF, 1978, AUDIOLOGY, V17, P369; EVANS EF, 1972, J PHYSIOL-LONDON, V226, P263, DOI 10.1113/jphysiol.1972.sp009984; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; FRANKENHAEUSER B, 1964, J PHYSIOL-LONDON, V171, P302, DOI 10.1113/jphysiol.1964.sp007378; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; GOLDBERG JM, 1973, BRAIN RES, V64, P35, DOI 10.1016/0006-8993(73)90169-8; Hill AV, 1936, PROC R SOC SER B-BIO, V121, P74, DOI 10.1098/rspb.1936.0053; Kiang NY, 1970, SENSORINEURAL HEARIN, P241, DOI DOI 10.1002/9780470719756.CH15; KIANG NYS, 1972, ANN OTO RHINOL LARYN, V81, P714, DOI 10.1177/000348947208100513; Kiang NYS, 1965, DISCHARGE PATTERNS S; KLATT DH, 1980, J ACOUST SOC AM, V67, P971, DOI 10.1121/1.383940; KNAUTH M, 1994, HEARING RES, V74, P247, DOI 10.1016/0378-5955(94)90193-7; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MOSS F, 1995, NATURE, V376, P211, DOI 10.1038/376211a0; PARKIN JL, 1988, LARYNGOSCOPE, V98, P262; ROPER J, 1989, J PHYSIOL-LONDON, V416, P93; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; SCHWARZ JR, 1995, PFLUG ARCH EUR J PHY, V430, P283, DOI 10.1007/BF00374660; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SIMMONS FB, 1966, ARCHIV OTOLARYNGOL, V84, P2; SPOENDLIN H, 1989, HEARING RES, V43, P25, DOI 10.1016/0378-5955(89)90056-7; TYLER RS, 1989, J SPEECH HEAR RES, V32, P887, DOI 10.1044/jshr.3204.887; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; WLSON BS, 1988, COCHLEAR IMPLANT CUR, P395; YOUNG ED, 1979, J ACOUST SOC AM, V66, P1381, DOI 10.1121/1.383532	36	170	174	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1996	2	8					928	932		10.1038/nm0896-928	http://dx.doi.org/10.1038/nm0896-928			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705865				2022-12-27	WOS:A1996UZ80400042
J	Prakash, S; Chang, TMS				Prakash, S; Chang, TMS			Microencapsulated genetically engineered live E-coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats	NATURE MEDICINE			English	Article								Safety concerns about introducing genetically engineered cells into the body have prevented their use in medical treatments. To solve this problem, we prepared polymeric membrane artificial cells (semipermeable microcapsules) containing genetically engineered live cells from the bacteria Escherichia coli DH5. When given orally, the cells remain at all times in the microcapsules and are finally excreted in the stool. During their passage through the intestine, small molecules like urea diffuse rapidly into the microcapsules and are acted on by the genetically engineered cells. This lowers the high plasma urea level to normal in uremic rats with induced kidney failure, and has exciting implications for the use of this and many other types of genetically engineered cells in a number of medical applications.	MCGILL UNIV,FAC MED,ARTIFICIAL CELLS & ORGANS RES CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,FAC MED,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,FAC MED,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,FAC MED,DEPT BIOMED ENGN,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University; McGill University				/0000-0002-4902-2353				AGISHI T, 1980, HEMOPERFUSION KIDNEY, P255; ASABA H, 1980, MIDDLE MOL UREMIA OT, P137; CATTANEO M, 1991, J AM SOC ARTIF INTER, V37, P80; Chang T M, 1995, Biotechnol Annu Rev, V1, P267; CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524; CHANG TMS, IN PRESS METHODS MOL, V63, pCH75; CHANG TMS, 1991, ENCY HUMAN BIOL, V1, P377; CHANG TMS, 1985, COMPREHENSIVE BIOTEC, P53; CHARLES S, 1990, HUMAN PHYSL FDN FRON, P526; COHEN BD, 1972, UREMIA, P1; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DEMETRIOU AA, 1994, SCI AM SCI MED, V1, P58; DRUKKER W, 1983, REPLACEMENT RENAL FU; Esposito R, 1980, SORBENTS THEIR CLIN, P133; FRIEDMAN EA, 1978, STRATEGY RENAL FAILU, P521; FRIEDMAN EA, 1976, KIDNEY INT, V13, pS273; Goosen A.M., 1988, CHEM ENG EDUC, V22, P196; GRIFFIN AM, 1995, MOL BIOL CURRENT INN, P5; GU KF, 1988, BIOTECHNOL BIOENG, V32, P363, DOI 10.1002/bit.260320315; GU KF, 1991, J BIOTECH APPL BIOCH, V12, P227; KJELLSTRAND C, 1981, T AM SOC ART INT ORG, V27, P24; KOLFF WJ, 1990, INT J ARTIF ORGANS, V13, P404, DOI 10.1177/039139889001300703; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; MANGE AP, 1984, BIOSCIENCE, V34, P642, DOI 10.2307/1309530; MARINCS F, 1994, APPL ENVIRON MICROB, V60, P3862, DOI 10.1128/AEM.60.10.3862-3863.1994; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; PRAKASH S, 1995, BIOTECHNOL BIOENG, V46, P621, DOI 10.1002/bit.260460615; PRAKASH S, 1993, BIOMATER ARTIF CELLS, V19, P687; SAARVEDRA MJ, 1995, LANCET, V344, P1046; Sambrook J., 2002, MOL CLONING LAB MANU; SCOOT B, 1989, J GEN MICROBIOL, V135, P1769; Setala K, 1972, Proc Eur Dial Transplant Assoc, V9, P514; SETALA K, 1973, IRCS MED SCI NEPHROL, V73, P35; SHIANSOON P, 1994, LANCET, V343, P950; SPARKS RE, 1979, CLIN NEPHROL, V11, P81; SPARKS RE, 1972, T AM SOC ART INT ORG, V18, P458; SYMMOUR AC, 1954, J BIOL CHEM, V209, P145; WALKER JM, 1977, ARTIF ORGANS, P137	38	150	166	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					883	887		10.1038/nm0896-883	http://dx.doi.org/10.1038/nm0896-883			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705857				2022-12-27	WOS:A1996UZ80400034
J	Allen, KM; Walsh, C				Allen, KM; Walsh, C			Shaking down new epilepsy genes	NATURE MEDICINE			English	Editorial Material											Allen, KM (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,INST MED,DEPT NEUROL,77 AVE LOUIS PASTEUR,BOSTON,MA 02115, USA.							[Anonymous], 1995, CELL, V82, P949; Beck C, 1994, Neurobiol Dis, V1, P95, DOI 10.1006/nbdi.1994.0012; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; FERREIRA A, 1995, P NATL ACAD SCI USA, V92, P9225, DOI 10.1073/pnas.92.20.9225; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; RYAN SG, 1995, NAT GENET, V10, P4, DOI 10.1038/ng0595-4; SERRATOSA JM, 1995, HUM MOL GENET, V4, P1657; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; STEINLEIN O, 1994, GENOMICS, V22, P493, DOI 10.1006/geno.1994.1420; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WAYMIRE KG, 1995, NAT GENET, V11, P45, DOI 10.1038/ng0995-45; ZARA F, 1995, HUM MOL GENET, V4, P1201, DOI 10.1093/hmg/4.7.1201	19	11	11	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					516	518		10.1038/nm0596-516	http://dx.doi.org/10.1038/nm0596-516			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616704				2022-12-27	WOS:A1996UJ23000028
J	Nabel, GJ; Grunfeld, C				Nabel, GJ; Grunfeld, C			Calories lost - Another mediator of cancer cachexia?	NATURE MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; CACHECTIN		UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94114	University of California System; University of California San Francisco	Nabel, GJ (corresponding author), UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.							BALDUCCI L, 1987, Comprehensive Therapy, V13, P60; BEUTLER B, 1988, NUTR REV, V46, P369, DOI 10.1111/j.1753-4887.1988.tb05370.x; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; CERAMI A, 1993, BLOOD PURIFICAT, V11, P108, DOI 10.1159/000170104; FEARON KCH, 1988, ANN SURG, V208, P1, DOI 10.1097/00000658-198807000-00001; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GRUNFELD C, IN PRESS J CLIN INVE; KERN KA, 1988, JPEN-PARENTER ENTER, V12, P286, DOI 10.1177/0148607188012003286; LANGSTEIN HN, 1991, HEMATOL ONCOL CLIN N, V5, P103, DOI 10.1016/S0889-8588(18)30457-X; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MCDEVITT TM, 1995, CANCER RES, V55, P1458; NORTON JA, 1987, CRC CR REV ONCOL-HEM, V7, P289, DOI 10.1016/S1040-8428(87)80003-3; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Todorov P, 1996, NATURE, V379, P739, DOI 10.1038/379739a0	16	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					397	398		10.1038/nm0496-397	http://dx.doi.org/10.1038/nm0496-397			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597944				2022-12-27	WOS:A1996UD31400036
J	Folkman, J				Folkman, J			Tumor angiogenesis and tissue factor	NATURE MEDICINE			English	Editorial Material							VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL-CELLS; FIBRINOGEN		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Folkman, J (corresponding author), CHILDRENS HOSP,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							BURROWS FJ, 1994, J CONTROL RELEASE, V28, P195, DOI 10.1016/0168-3659(94)90166-X; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DEJANA E, 1990, BLOOD, V75, P1509; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KADISH JL, 1979, TISSUE CELL, V11, P99, DOI 10.1016/0040-8166(79)90010-7; LAWSON CA, 1995, CIRCULATION, V92, P804; MODZELEWSKI RA, 1994, CANCER RES, V54, P336; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SENGER DR, 1996, INTEGRINS SIGNALING, P69; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; WEIDNER N, 1995, AM J PATHOL, V147, P9; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	21	240	276	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					167	168		10.1038/nm0296-167	http://dx.doi.org/10.1038/nm0296-167			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574960				2022-12-27	WOS:A1996TU06000035
J	Plummer, SJ; Casey, G				Plummer, SJ; Casey, G			Are we any closer to genetic testing for common malignancies?	NATURE MEDICINE			English	Editorial Material											Plummer, SJ (corresponding author), CLEVELAND CLIN,RES INST,DEPT CANC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; Serova O, 1996, AM J HUM GENET, V58, P42; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	12	10	10	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					156	158		10.1038/nm0296-156	http://dx.doi.org/10.1038/nm0296-156			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574954				2022-12-27	WOS:A1996TU06000029
J	Sacca, L; Fazio, S				Sacca, L; Fazio, S			Cardiac performance: Growth hormone enters the race	NATURE MEDICINE			English	Editorial Material							MORTALITY				Sacca, L (corresponding author), UNIV NAPLES FEDERICO II,DEPT INTERNAL MED,SCH MED,I-80131 NAPLES,ITALY.							BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; CUNEO RC, 1989, LANCET, V1, P838, DOI 10.1016/S0140-6736(89)92290-3; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; FLYVBJERG A, 1991, AM J PHYSIOL, V260, pE568, DOI 10.1152/ajpendo.1991.260.4.E568; FRUSTACI A, 1992, AM J CLIN PATHOL, V97, P503, DOI 10.1093/ajcp/97.4.503; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JORGENSEN JOL, 1989, LANCET, V1, P1221; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555; TIMSIT J, 1990, J CLIN INVEST, V86, P507, DOI 10.1172/JCI114737; WAHLANDER H, 1992, HYPERTENSION, V19, P25, DOI 10.1161/01.HYP.19.1.25; YANG RH, 1995, CIRCULATION, V92, P262, DOI 10.1161/01.CIR.92.2.262	16	48	48	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					29	31		10.1038/nm0196-29	http://dx.doi.org/10.1038/nm0196-29			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564831				2022-12-27	WOS:A1996TP57900031
J	Williams, SK; Jarrell, BE				Williams, SK; Jarrell, BE			Tissue-engineered vascular grafts	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL-CELL; PATENCY				Williams, SK (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT SURG,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.							BELSEN TA, 1982, T AM SOC ART INT ORG, V28, P173; CLOWES AW, 1991, J VASC SURG, V13, P734; DOUVILLE EC, 1987, J VASC SURG, V5, P544, DOI 10.1067/mva.1987.avs0050544; GRAHAM LM, 1980, ARCH SURG-CHICAGO, V115, P1289; HERRING M, 1978, SURGERY, V84, P498; KEMPCZINSKI RF, 1985, J VASC SURG, V2, P424, DOI 10.1067/mva.1985.avs0020424; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; SCHMIDT SP, 1984, J VASC SURG, V1, P434, DOI 10.1067/mva.1984.avs0010434; SHEPARD AD, 1986, SURGERY, V99, P318; SHINDO S, 1987, J VASC SURG, V6, P325, DOI 10.1067/mva.1987.avs0060325; STANLEY JC, 1982, SURGERY, V92, P994; TANNENBAUM G, 1987, Current Surgery, V44, P318; WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210; WILLIAMS SK, 1995, CELL TRANSPLANT, V4, P401, DOI 10.1016/0963-6897(95)00023-Q	14	25	27	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					32	34		10.1038/nm0196-32	http://dx.doi.org/10.1038/nm0196-32			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564834				2022-12-27	WOS:A1996TP57900033
J	TOWBIN, JA; MCQUINN, TC				TOWBIN, JA; MCQUINN, TC			GRIDLOCK - A MODEL FOR COARCTATION OF THE AORTA	NATURE MEDICINE			English	Editorial Material							ENDOTHELIUM		MED UNIV S CAROLINA, DEPT PEDIAT, CHARLESTON, SC 29407 USA; MED UNIV S CAROLINA, DEPT ANAT & CELL BIOL, CHARLESTON, SC 29407 USA	Medical University of South Carolina; Medical University of South Carolina	TOWBIN, JA (corresponding author), BAYLOR COLL MED, DEPT PEDIAT CARDIOL, 1 BAYLOR PLAZA, ROOM 333E, HOUSTON, TX 77030 USA.		Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X				ANDERSON KR, 1979, BRIT HEART J, V41, P28; CLARK EB, 1986, GENETICS CARDIOVASCU; COFFIN JD, 1991, ANAT REC, V231, P383; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; FISHMAN MC, 1994, CIRC RES, V74, P757, DOI 10.1161/01.RES.74.5.757; HUTCHINS GM, 1971, AM J PATHOL, V63, P203; MORRISS MJH, 1990, SCI PRACTICE PEDIAT, P1353; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PEAULT B, 1988, CELL DIFFER DEV, V23, P165, DOI 10.1016/0045-6039(88)90069-3; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; RUDOLPH AM, 1972, AM J CARDIOL, V30, P514, DOI 10.1016/0002-9149(72)90042-2; RUSSELL GA, 1991, J THORAC CARDIOV SUR, V102, P596; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143	14	18	18	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1995	1	11					1141	1142		10.1038/nm1195-1141	http://dx.doi.org/10.1038/nm1195-1141			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584984				2022-12-27	WOS:A1995TC53700036
J	PAPERMASTER, DS				PAPERMASTER, DS			NECESSARY BUT INSUFFICIENT	NATURE MEDICINE			English	Editorial Material											PAPERMASTER, DS (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284, USA.							BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0; DRYJA TP, 1995, INVEST OPHTH VIS SCI, V36, P1197; HENGARTNER MO, 1994, NATURE, V369, P272; Korsmeyer S J, 1993, Important Adv Oncol, P19; LI ZY, 1994, EXP EYE RES, V58, P397, DOI 10.1006/exer.1994.1032; LI ZY, IN PRESS RETINAL DEG, V2; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; PAPERMASTER DS, 1995, INVEST OPHTH VIS SCI, V36, P977; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319	9	20	20	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					874	875		10.1038/nm0995-874	http://dx.doi.org/10.1038/nm0995-874			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585205				2022-12-27	WOS:A1995RT30300033
J	RYAN, US				RYAN, US			COMPLEMENT INHIBITORY THERAPEUTICS AND XENOTRANSPLANTATION	NATURE MEDICINE			English	Editorial Material							RECEPTOR TYPE-1; EXPERIENCES; SURVIVAL				RYAN, US (corresponding author), T CELL SCI INC,115 4TH AVE,NEEDHAM,MA 02194, USA.							ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; BACH FH, 1991, TRANSPL P, V23, P205; BALDWIN WM, 1995, TRANSPLANTATION, V59, P797, DOI 10.1097/00007890-199503270-00001; BANNETT AD, 1987, TRANSPLANT P, V19, P4543; CANDINAS D, IN PRESS TRANSPLANTN; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DALMASSO AP, 1991, TRANSPLANTATION, V32, P530; FODER WL, 1995, XENO, V3, P23; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; PRUITT SK, IN PRESS TRANSPLANTN; PRUITT SK, 1992, TRANSPLANTATION, V52, P868; RYAN US, 1994, XENO, V2, P19; RYAN US, 1988, ENDOTHELIAL CELLS, V1; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; THOMAS LJ, IN PRESS J HEART LUN; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; XIA W, 1992, TRANSPLANT P, V24, P479; XIA W, 1993, TRANSPLANT P, V25, P410	19	43	46	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					967	968		10.1038/nm0995-967	http://dx.doi.org/10.1038/nm0995-967			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585227				2022-12-27	WOS:A1995RT30300055
J	GALLO, RC				GALLO, RC			HUMAN RETROVIRUSES IN THE 2ND DECADE - A PERSONAL PERSPECTIVE	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL LEUKEMIA; TROPICAL SPASTIC PARAPARESIS; HTLV-III; KAPOSIS-SARCOMA; AIDS; ANTIBODIES; GENE; GROWTH; HIV-1	Human retroviruses have developed novel strategies for their propagation and survival. A consequence of their success has been the induction of an extraordinarily diverse set of human diseases, including AIDS, cancers and neurological and inflammatory disorders. Early research focused on their characterization, linkage to these diseases, and the mechanisms involved. Research should now aim at the eradication of human retroviruses and on treatment of infected people.			GALLO, RC (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,ROOM 6A09,37 CONVENT DR,BETHESDA,MD 20892, USA.							BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; BARRESINOUSSI F, 1993, SCIENCE, V220, P868; BARTHOLOMEW C, 1986, LANCET, V2, P99; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CATOVSKY D, 1982, LANCET, V1, P639; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COFFIN JM, 1992, RETROVIRIDAE, V1; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FRANCHINI G, IN PRESS BLOOD; Gallo R., 1991, VIRUS HUNTING, P59; GALLO RC, 1986, SCI AM, V255, P88, DOI 10.1038/scientificamerican1286-88; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GALLO RC, 1991, VIRUS HUNTING, P99; GESSAIN A, 1985, LANCET, V2, P407; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HASELTINE WA, 1988, SCI AM, V259, P52, DOI 10.1038/scientificamerican1088-52; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; LOWER R, 1983, P NATL ACAD SCI USA, V90, P4480; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; OSAME M, 1986, LANCET, V1, P1031; PANTALEO G, 1995, NAT MED, V1, P118, DOI 10.1038/nm0295-118; Pantaleo G, 1993, Semin Immunol, V5, P157, DOI 10.1006/smim.1993.1019; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SIEGAL B, 1990, CANCER, V65, P492, DOI 10.1002/1097-0142(19900201)65:3<492::AID-CNCR2820650320>3.0.CO;2-C; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEMIN HM, 1992, RETROVIRIDAE, V1; TURANO A, 1992, P NATL ACAD SCI USA, V89, P4447, DOI 10.1073/pnas.89.10.4447; Waldmann T A, 1994, Important Adv Oncol, P131; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; ZAGURY JF, 1993, P NATL ACAD SCI USA, V90, P7573, DOI 10.1073/pnas.90.16.7573	56	24	28	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					753	759		10.1038/nm0895-753	http://dx.doi.org/10.1038/nm0895-753			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585176	Bronze			2022-12-27	WOS:A1995RM63500030
J	PLATERZYBERK, C; BONNEFOY, JY				PLATERZYBERK, C; BONNEFOY, JY			MARKED AMELIORATION OF ESTABLISHED COLLAGEN-INDUCED ARTHRITIS BY TREATMENT WITH ANTIBODIES TO CD23 IN-VIVO	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; SOLUBLE CD23; TNF-ALPHA; IGE; RECEPTOR; MICE; ANTIGEN; LOCALIZATION	CD23 is a low-affinity receptor for immunoglobulin E (IgE) expressed by a variety of haematopoietic cells. Proteolytic cleavage of the transnnembrane receptor generates soluble forms, which can be detected in biological fluids. CD23 regulates many functional aspects of immune cells, both in its cell-associated and soluble forms. In view of the increased levels of CD23 in rheumatoid arthritis, we have studied the effect of neutralizing CD23 in type II collagen-induced arthritis in mice, a model for human rheumatoid arthritis. Successful disease modulation is achieved by treatment of arthritic DBA/1 mice with either polyclonal or monoclonal antibodies to mouse CD23. Treated mice show a dose-related amelioration of arthritis with significantly reduced clinical scores and number of affected paws. This improvement in clinical severity is confirmed by histological examination of the arthritic paws. A marked decrease in cellular infiltration of the synovial sublining layer and limited destruction of cartilage and bone is evident in animals treated with therapeutic doses of anti-CD23 antibody. These findings demonstrate the involvement of CD23 in a mouse model of human rheumatoid arthritis.			PLATERZYBERK, C (corresponding author), GLAXO INST MOLEC BIOL SA, DEPT IMMUNOL, CHEMIN AULX 14, CH-1228 GENEVA, SWITZERLAND.							ARMANT M, 1994, J EXP MED, V180, P1005, DOI 10.1084/jem.180.3.1005; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BANSAL A, 1992, CLIN EXP IMMUNOL, V89, P452; BANSAL AS, 1993, IMMUNOLOGY, V79, P285; BANSAL AS, 1994, CLIN EXP RHEUMATOL, V12, P281; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293; BRENNAN FM, 1989, LANCET, V2, P244; CHOMARAT P, 1993, ARTHRITIS RHEUM-US, V36, P234, DOI 10.1002/art.1780360215; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FELDMANN M, 1991, IMMUNOL REV, V119, P105, DOI 10.1111/j.1600-065X.1991.tb00580.x; FIELD M, 1991, RHEUMATOL INT, V11, P45, DOI 10.1007/BF00291144; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; HELLEN EA, 1991, J CLIN PATHOL, V44, P293, DOI 10.1136/jcp.44.4.293; HERBELIN A, 1994, EUR J IMMUNOL, V24, P1869, DOI 10.1002/eji.1830240823; LECOANETHENCHOZ S, IN PRESS IMMUNITY; MARCELLETTI JF, 1991, J IMMUNOL, V147, P4185; PIGUET PF, 1992, IMMUNOLOGY, V77, P510; PLATERZYBERK C, 1994, CLIN EXP IMMUNOL, V98, P442; RAO M, 1987, J IMMUNOL, V138, P1845; REZONZEW R, 1994, CLIN IMMUNOL IMMUNOP, V71, P156, DOI 10.1006/clin.1994.1066; STUART JM, 1984, ANNU REV IMMUNOL, V2, P199, DOI 10.1146/annurev.iy.02.040184.001215; TRENTHAM DE, 1982, ARTHRITIS RHEUM, V25, P911, DOI 10.1002/art.1780250801; VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237; WENDLING D, 1993, J RHEUMATOL, V20, P259; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915; WOOLEY PH, 1993, J IMMUNOL, V151, P6602; WOOLEY PH, 1985, J IMMUNOL, V134, P2366	32	53	58	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					781	785		10.1038/nm0895-781	http://dx.doi.org/10.1038/nm0895-781			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585180				2022-12-27	WOS:A1995RM63500034
J	BUKAWA, H; SEKIGAWA, KI; HAMAJIMA, K; FUKUSHIMA, J; YAMADA, Y; KIYONO, H; OKUDA, K				BUKAWA, H; SEKIGAWA, KI; HAMAJIMA, K; FUKUSHIMA, J; YAMADA, Y; KIYONO, H; OKUDA, K			NEUTRALIZATION OF HIV-1 BY SECRETORY IGA INDUCED BY ORAL IMMUNIZATION WITH A NEW MACROMOLECULAR MULTICOMPONENT PEPTIDE VACCINE CANDIDATE	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY VIRUS-ANTIGEN; CHOLERA-TOXIN; INFECTED INDIVIDUALS; SYNTHETIC PEPTIDES; T-CELL; B-CELL; RESPONSES; ANTIBODY; ADJUVANT; MUCOSAL	Control of pandemic infection of human immunodeficiency virus type 1 (HIV-1) requires some means of developing mucosal immunity against HIV-1 because sexual transmission of the virus occurs mainly through the mucosal tissues. However, there is no evidence as yet that the secretory immunoglobulin A (IgA) antibody induced by immunization with antigens in experimental animals can neutralize HIV-1. We demonstrate here that oral immunization with a new macromolecular peptide antigen and cholera toxin (CT) induces a high titre (1:2(11)) of gut-associated and secretory IgA antibody to HIV-1. Using three different neutralizing assays, we clearly demonstrate that this secretory IgA antibody is able to neutralize HIV-1(III), HIV-1(F2) and HIV-1(MN). Our new approach may prove to be important in the development of a mucosal vaccine that will provide protection of mucosal surfaces against HIV-1.	YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT BACTERIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; OSAKA UNIV,DEPT MUCOSAL IMMUNOL,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294	Yokohama City University; Yokohama City University; Osaka University; University of Alabama System; University of Alabama Birmingham	BUKAWA, H (corresponding author), YOKOHAMA CITY UNIV,SCH MED,DEPT ORAL & MAXILLOFACIAL SURG,KANAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.		Kiyono, Hiroshi/AAC-6735-2022					ACHOUR A, 1990, P NATL ACAD SCI USA, V87, P7045, DOI 10.1073/pnas.87.18.7045; BOUCHER CAB, 1990, J CLIN LAB ANAL, V4, P43, DOI 10.1002/jcla.1860040109; BOURGUIN I, 1993, INFECT IMMUN, V61, P2082, DOI 10.1128/IAI.61.5.2082-2088.1993; BUKAWA H, IN PRESS MICROBIOL I; BURNETT PR, 1994, J IMMUNOL, V152, P4642; DEFOORT JP, 1992, P NATL ACAD SCI USA, V89, P3879, DOI 10.1073/pnas.89.9.3879; DEVOS T, 1991, J IMMUNOL METHODS, V141, P285, DOI 10.1016/0022-1759(91)90155-9; GOUDSMIT J, 1986, LANCET, V2, P177; INAMI S, 1991, AIDS, V5, P1140, DOI 10.1097/00002030-199109000-00015; JACKSON RJ, 1993, INFECT IMMUN, V61, P4272, DOI 10.1128/IAI.61.10.4272-4279.1993; KAARTINEN M, 1978, SCAND J IMMUNOL, V7, P229, DOI 10.1111/j.1365-3083.1978.tb00448.x; KORN AH, 1972, J MOL BIOL, V65, P525, DOI 10.1016/0022-2836(72)90206-9; LAI PK, 1990, AIDS RES HUM RETROV, V6, P205, DOI 10.1089/aid.1990.6.205; LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; LEHNER T, 1994, J VIROL, V68, P1624, DOI 10.1128/JVI.68.3.1624-1632.1994; Lehner T, 1992, VACCINE RES, V3, P319; LYCKE N, 1986, IMMUNOLOGY, V59, P301; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; NAKASHIMA H, 1990, B YAMAGUCHI MED SCH, V37, P169; NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283; NARDELLI B, 1992, J IMMUNOL, V148, P914; OKUDA K, 1994, J INFECT DIS, V169, P227, DOI 10.1093/infdis/169.1.227; Okuda K, 1993, J Clin Lab Immunol, V40, P97; OKUDA K, 1981, P NATL ACAD SCI-BIOL, V78, P4557, DOI 10.1073/pnas.78.7.4557; Okuda Kenji, 1993, Journal of Molecular Recognition, V6, P101, DOI 10.1002/jmr.300060302; OLSON CA, 1989, P NATL ACAD SCI USA, V86, P1031, DOI 10.1073/pnas.86.3.1031; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; Reichlin M, 1980, Methods Enzymol, V70, P159; STAATS HF, 1994, CURR OPIN IMMUNOL, V6, P572, DOI 10.1016/0952-7915(94)90144-9; UBOLYAM S, 1994, LANCET, V344, P485, DOI 10.1016/S0140-6736(94)91825-2; XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309	33	110	111	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					681	685		10.1038/nm0795-681	http://dx.doi.org/10.1038/nm0795-681			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585151				2022-12-27	WOS:A1995RQ06600044
J	KRISHNAN, S; HAENSLER, J; MEULIEN, P				KRISHNAN, S; HAENSLER, J; MEULIEN, P			PAVING THE WAY TOWARDS DNA VACCINES	NATURE MEDICINE			English	Editorial Material											KRISHNAN, S (corresponding author), PASTEUR MERIEUX SERUMS & VACCINS,DEPT RES,MARCY LETOILE,FRANCE.							DONNELLY JJ, 1995, NATURE MED, V1, pR30; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1994, VACCINE, V12, P1541, DOI 10.1016/0264-410X(94)90081-7; ULMER JB, 1992, SCIENCE, V259, P1745; WEBSTER RG, 1994, VACCINE, V12, P1495, DOI 10.1016/0264-410X(94)90071-X; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	7	12	15	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					521	522		10.1038/nm0695-521	http://dx.doi.org/10.1038/nm0695-521			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585114				2022-12-27	WOS:A1995RN10100031
J	HELLMAN, S				HELLMAN, S			THE PATIENT AND THE PUBLIC GOOD	NATURE MEDICINE			English	Editorial Material							CLINICAL RESEARCH; ETHICS	The prevailing view is that a physician can simultaneously husband economic resources to control health care costs and fulfill a doctor's traditional responsibility to put the patient first. I disagree.			HELLMAN, S (corresponding author), UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, 5841 S MARYLAND AVE, MC0011, CHICAGO, IL 60637 USA.							BAUM M, 1989, BRIT MED J, V299, P251, DOI 10.1136/bmj.299.6693.251; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; TOON PD, 1994, LANCET, V343, P585, DOI 10.1016/S0140-6736(94)91527-X	4	11	11	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					400	402		10.1038/nm0595-400	http://dx.doi.org/10.1038/nm0595-400			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585078				2022-12-27	WOS:A1995RN10000021
J	PAN, ZK; IKONOMIDIS, G; LAZENBY, A; PARDOLL, D; PATERSON, Y				PAN, ZK; IKONOMIDIS, G; LAZENBY, A; PARDOLL, D; PATERSON, Y			A RECOMBINANT LISTERIA-MONOCYTOGENES VACCINE EXPRESSING A MODEL TUMOR-ANTIGEN PROTECTS MICE AGAINST LETHAL TUMOR-CELL CHALLENGE AND CAUSES REGRESSION OF ESTABLISHED TUMORS	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; T-CELLS; GENE; TRANSFECTION; SUPPRESSION; INDUCTION; CARCINOMA; IMMUNITY; GROWTH; CANCER	Listeria monocytogenes is an intracellular organism that has the unusual ability to live in the cytoplasm of the cell. It is thus a good vector for targeting protein antigens to the cellular arm of the immune response. Here we use a model system, consisting of colon and renal carcinomas that express the influenza virus nucleoprotein and a recombinant L. monocytogenes that secretes this antigen, to test the potential of this organism as a cancer immunotherapeutic agent. We show that this recombinant organism can not only protect mice against lethal challenge with tumour cells that express the antigen, but can also cause regression of established macroscopic tumours in an antigen-specific T-cell-dependent manner.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	University of Pennsylvania; University of Pennsylvania; Johns Hopkins University; Johns Hopkins University				Paterson, Yvonne/0000-0002-9406-4958				ASHER AL, 1991, J IMMUNOL, V146, P3227; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BERCHE P, 1987, J IMMUNOL, V138, P2266; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CASON J, 1993, VACCINE, V11, P603, DOI 10.1016/0264-410X(93)90302-E; COSSART P, 1989, INFECT IMMUN, V57, P3269; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; FEARON ER, 1988, CANCER RES, V38, P2975; FETTEN JV, 1991, J IMMUNOL, V147, P2697; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; GEOFFROY C, 1991, INFECT IMMUN, V59, P2382, DOI 10.1128/IAI.59.7.2382-2388.1991; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; HAHN H, 1991, REV INFECT DIS, V3, P1221; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; IKONOMIDIS G, 1994, J EXP MED, V180, P2209, DOI 10.1084/jem.180.6.2209; IKONOMIDIS G, IN PRESS VACCINES 95; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KAUFMANN SHE, 1985, INFECT IMMUN, V48, P263, DOI 10.1128/IAI.48.1.263-266.1985; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; KRUISBEEK AM, 1994, CURRENT PROTOCOLS IM; LASSAM N, 1989, J IMMUNOL, V143, P3792; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; PARDOLL DM, 1993, TRENDS PHARMACOL SCI, V14, P202, DOI 10.1016/0165-6147(93)90209-3; PORGADOR A, 1992, CANCER RES, V52, P3679; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; SCHAFER R, 1992, J IMMUNOL, V149, P53; SCHREIBER H, 1993, FUNDAMENTAL IMMUNOLO, pCH32; SLINGLUFF CL, 1994, CURR OPIN IMMUNOL, V6, P733, DOI 10.1016/0952-7915(94)90077-9; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WU TC, 1994, CURR OPIN IMMUNOL, V6, P746, DOI 10.1016/0952-7915(94)90079-5	39	194	238	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					471	477		10.1038/nm0595-471	http://dx.doi.org/10.1038/nm0595-471			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585097				2022-12-27	WOS:A1995RN10000040
J	BODE, L; ZIMMERMANN, W; FERSZT, R; STEINBACH, F; LUDWIG, H				BODE, L; ZIMMERMANN, W; FERSZT, R; STEINBACH, F; LUDWIG, H			BORNA-DISEASE VIRUS GENOME TRANSCRIBED AND EXPRESSED IN PSYCHIATRIC-PATIENTS	NATURE MEDICINE			English	Article							ANTIBODIES; RATS; INFECTION; DISORDERS; HUMANS; CELLS; BRAIN	Borna disease virus (BDV) is a neurotropic, negative and single-stranded enveloped RNA virus that persistently infects various domestic animal species. Infection causes disturbances in behaviour and cognitive functions, but can also lead to a fatal neurologic disease. Human infections seemed likely, since serum antibodies were detected in neuropsychiatric patients. Further proof came from our discovery that peripheral blood monocytes carry viral antigens. Here, we present the first data on different viral genomic transcripts in such patients' cells as well as sequence data of transcripts. Both viral markers seem to coincide with acute episodes of mood disorders, thus pointing to a new human virus infection possibly threatening mental health.	FREE UNIV BERLIN,INST VIROL,D-13353 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT PSYCHIAT,D-12203 BERLIN,GERMANY	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	BODE, L (corresponding author), ROBERT KOCH INST,DEPT VIROL,D-13353 BERLIN,GERMANY.		Bode, Liv/ABD-1599-2021; Steinbach, Falko/V-1682-2019	Bode, Liv/0000-0002-8935-6198; Steinbach, Falko/0000-0003-1236-2837				Bechter K., 1992, NEUROL PSYCHIAT BR, V1, P23; BODE L, 1994, LANCET, V343, P297, DOI 10.1016/S0140-6736(94)91147-9; BODE L, 1995, CURR TOP MICROBIOL, V190, P103; BODE L, 1994, VET REC, V135, P283, DOI 10.1136/vr.135.12.283; Bode L, 1993, Arch Virol Suppl, V7, P159; BODE L, 1988, LANCET, V2, P689; BODE L, 1992, J MED VIROL, V36, P309, DOI 10.1002/jmv.1890360414; BRIESE T, 1994, P NATL ACAD SCI USA, V91, P4362, DOI 10.1073/pnas.91.10.4362; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; CUBITT B, 1994, J VIROL, V68, P1382, DOI 10.1128/JVI.68.3.1382-1396.1994; CUBITT B, 1994, J VIROL, V68, P1371, DOI 10.1128/JVI.68.3.1371-1381.1994; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; DITTRICH W, 1989, BIOL PSYCHIAT, V26, P818, DOI 10.1016/0006-3223(89)90122-4; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOLD PW, 1988, NEW ENGL J MED, V319, P347; GOSZTONYI G, 1993, LAB INVEST, V68, P285; LIPKIN WI, 1990, P NATL ACAD SCI USA, V87, P4184, DOI 10.1073/pnas.87.11.4184; Ludwig H, 1993, Arch Virol Suppl, V7, P111; LUDWIG H, 1988, PROG MED VIROL, V35, P107; LUNDGREN AL, 1993, J VET MED B, V40, P298, DOI 10.1111/j.1439-0450.1993.tb00142.x; NARAYAN O, 1983, SCIENCE, V220, P1401, DOI 10.1126/science.6602380; OLDSTONE MBA, 1991, J VIROL, V65, P6381, DOI 10.1128/JVI.65.12.6381-6386.1991; RICHT JA, 1989, J EXP MED, V170, P1045, DOI 10.1084/jem.170.3.1045; ROTT R, 1985, SCIENCE, V228, P755, DOI 10.1126/science.3922055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER PA, 1994, J VIROL, V68, P63, DOI 10.1128/JVI.68.1.63-68.1994; SIERRAHONIGMANN AM, 1993, J NEUROIMMUNOL, V45, P31, DOI 10.1016/0165-5728(93)90160-Z; STEINBACH F, 1994, J IMMUNOL METHODS, V174, P109, DOI 10.1016/0022-1759(94)90015-9; VANDEWOUDE S, 1990, SCIENCE, V250, P1278, DOI 10.1126/science.2244211; ZIMMERMANN W, 1994, J VIROL, V68, P6755, DOI 10.1128/JVI.68.10.6755-6758.1994; ZIMMERMANN W, 1994, J VIROL METHODS, V46, P133, DOI 10.1016/0166-0934(94)90098-1; 1987, DIAGNOSTIC STATISTIC, P567	32	217	228	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					232	236		10.1038/nm0395-232	http://dx.doi.org/10.1038/nm0395-232			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585039				2022-12-27	WOS:A1995QX55900029
J	MCHUGH, PR				MCHUGH, PR			WITCHES, MULTIPLE PERSONALITIES, AND OTHER PSYCHIATRIC ARTIFACTS	NATURE MEDICINE			English	Editorial Material							SCHIZOPHRENIA	Contemporary psychiatric misdirections derived primarily from standard medical errors of oversimplification, misplaced emphasis, and invention are reviewed. These particular errors, however, were in part prompted and sustained by the sociocultural fads and fashions of the day. The results have been disastrous for everyone - patients, families, the public and psychiatry itself.			MCHUGH, PR (corresponding author), JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,600 N WOLFE ST,MEYER 4-113,BALTIMORE,MD 21287, USA.							BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; KENNY MG, 1986, PASSION A BOURNE MUL; MCHUGH PR, 1992, J ROY SOC MED, V85, P483; MCHUGH PR, 1992, AM SCHOLAR, V61, P497; MCHUGH PR, 1983, PERSPECTIVES PSYCHIA, P57; MCKENNA PJ, 1984, BRIT J PSYCHIAT, V145, P579, DOI 10.1192/bjp.145.6.579; Starkey Marion L, 1949, DEVIL MASSACHUSETTS; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Szasz T.S., 1976, SCHIZOPHRENIA SACRED; TERR LC, 1983, AM J PSYCHIAT, V140, P1543; WERNICKE C, 1906, FUNDAMENTALS PSYCHIA	11	23	24	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					110	114		10.1038/nm0295-110	http://dx.doi.org/10.1038/nm0295-110			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585001				2022-12-27	WOS:A1995QX55800014
J	BEDI, GC; WESTRA, WH; FARZADEGAN, H; PITHA, PM; SIDRANSKY, D				BEDI, GC; WESTRA, WH; FARZADEGAN, H; PITHA, PM; SIDRANSKY, D			MICROSATELLITE INSTABILITY IN PRIMARY NEOPLASMS FROM HIV+ PATIENTS	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; KAPOSIS-SARCOMA; MISMATCH REPAIR; COLORECTAL-CANCER; AIDS; INFECTION; MUTATIONS; CARCINOGENESIS; PATHOGENESIS; SEQUENCES	AIDS is associated with a high risk of certain malignancies, notably Kaposi's sarcoma (KS) and B-cell non-Hodgkin's lymphoma (NHL). The pathogenesis of these malignancies is not fully understood. One mechanism of malignant transformation recently described in colon tumorigenesis results from defects in DNA mismatch repair, manifest as widespread microsatellite instability. We demonstrate a high rate of microsatellite instability in KS and aggressive lymphomas obtained from HIV-infected patients, whereas there is no evidence of instability in similar lesions from HIV-negative patients. Further elucidation of the underlying mechanisms responsible for HIV-associated instability in primary tumours may provide insight into the pathogenesis of these AIDS-related neoplasms.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Astrin S M, 1992, Curr Top Microbiol Immunol, V182, P399; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BOVI PD, 1986, CANCER RES, V46, P6333; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COUTLEE F, 1991, MOL CELL PROBE, V5, P241, DOI 10.1016/0890-8508(91)90046-M; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FARZADEGAN H, 1993, J INFECT DIS, V168, P327, DOI 10.1093/infdis/168.2.327; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GLEBOV OK, 1994, CANCER RES, V54, P3703; GROOPMAN JE, 1986, BLOOD, V67, P612; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Knowles Daniel M., 1993, Current Opinion in Oncology, V5, P845, DOI 10.1097/00001622-199309000-00012; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Levine A M, 1993, Curr Opin Oncol, V5, P819, DOI 10.1097/00001622-199309000-00008; Lipsey Lewis R., 1993, Current Opinion in Oncology, V5, P861, DOI 10.1097/00001622-199309000-00014; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELLICI PG, 1986, J EXP MED, V164, P2049; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; RADMAN M, 1993, NATURE, V366, P722, DOI 10.1038/366722a0; REYNOLDS P, 1993, AM J EPIDEMIOL, V1, P19; SHIBATA D, 1993, BLOOD, V8, P2102; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON J, 1994, ONCOGENE, V9, P1167; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WOOSTER R, 1994, NAT GENET, V6, P1152; 1993, MMWR-MORBID MORTAL W, V41, P10	36	91	92	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					65	68		10.1038/nm0195-65	http://dx.doi.org/10.1038/nm0195-65			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584955				2022-12-27	WOS:A1995QX55700028
J	Fauci, AS				Fauci, AS			Resistance to HIV-1 infection: It's in the genes	NATURE MEDICINE			English	Editorial Material											Fauci, AS (corresponding author), NIAID,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0	11	28	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					966	967		10.1038/nm0996-966	http://dx.doi.org/10.1038/nm0996-966			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782446				2022-12-27	WOS:A1996VF49700023
J	Sigalas, I; Calvert, AH; Anderson, JJ; Neal, DE; Lunec, J				Sigalas, I; Calvert, AH; Anderson, JJ; Neal, DE; Lunec, J			Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer	NATURE MEDICINE			English	Article							ONCOPROTEIN MDM2; GENE; EXPRESSION; PROTEIN; AMPLIFICATION; CELLS; CARCINOMAS; MUTATIONS; SARCOMAS; ONCOGENE	The mdm2 oncogene encodes a 90-kilodalton nuclear phosphoprotein that binds and inactivates the p53 tumor suppressor protein. Here we report the observation of five alternatively spliced mdm2 gene transcripts in a range of human cancers and their absence in normal tissues. Transfection of NIH 3T3 cells with each of these forms gave foci of morphologically transformed cells. A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding, consistent with partial deletion of sequences encoding the p53 binding domain, but retain carboxyterminal zinc-finger domains. These observations suggest a reassessment of the transforming mechanisms of mdm2 and its relation to p53.	UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK				Neal, David/0000-0002-6033-5086				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P188; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLIFFORD SC, 1994, BRIT J CANCER, V69, P680, DOI 10.1038/bjc.1994.130; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; LEACH FS, 1993, CANCER RES, V53, P2231; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7; REIFENBERGER G, 1993, CANCER RES, V53, P2736; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; WABER PG, 1993, CANCER RES, V53, P6028; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	25	254	262	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					912	917		10.1038/nm0896-912	http://dx.doi.org/10.1038/nm0896-912			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705862				2022-12-27	WOS:A1996UZ80400039
J	Duvall, CP				Duvall, CP			One doctor against managed care	NATURE MEDICINE			English	Editorial Material											Duvall, CP (corresponding author), SOC INTERNAL MED,3301 NEW MEXICO AVE NW,SUITE 348,WASHINGTON,DC 20016, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					735	736		10.1038/nm0796-735	http://dx.doi.org/10.1038/nm0796-735			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673910				2022-12-27	WOS:A1996UU68000020
J	Heslop, HE; Ng, CYC; Li, CF; Smith, CA; Loftin, SK; Krance, RA; Brenner, MK; Rooney, CM				Heslop, HE; Ng, CYC; Li, CF; Smith, CA; Loftin, SK; Krance, RA; Brenner, MK; Rooney, CM			Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes	NATURE MEDICINE			English	Article							MARROW TRANSPLANTATION	Adoptive transfer of antigen-specific cytotoxic T lymphocytes (CTLs) offers safe and effective therapy for certain viral infections and could prove useful in the eradication of tumor cells. Whether or not the infused T cells persist for extended periods, retaining their ability to expand in response to antigenic stimulation, is not known. We now report long-term detection of gene-marked Epstein-Barr virus (EBV)-specific CTLs in immunocompromised patients at risk for the development of EBV lymphoproliferative disease. Infusions of CTLs not only restored cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months. Our findings support wider use of antigen-specific CTLs in adoptive immunotherapy.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Heslop, HE (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Heslop, Helen/AAC-9500-2020; Rooney, Cliona/ABD-5475-2021; Wilson, Matthew H/K-3193-2013; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180, R01CA061384, U01CA061384] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180, CA 61384, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; BOYLE MJ, 1991, BLOOD, V78, P3004; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; DOHERTY PC, 1994, CURR OPIN IMMUNOL, V6, P545, DOI 10.1016/0952-7915(94)90139-2; HESLOP HE, 1994, HUM GENE THER, V5, P381, DOI 10.1089/hum.1994.5.3-381; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LUCAS K, 1994, BLOOD, V84, pA98; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MATZINGER P, 1994, NATURE, V369, P605, DOI 10.1038/369605a0; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; REITTIE JE, 1989, BLOOD, V73, P1351; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RILL DR, 1992, BLOOD, V79, P2694; ROONEY CM, 1995, BRIT J HAEMATOL, V89, P98, DOI 10.1111/j.1365-2141.1995.tb08904.x; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Smith C A, 1995, J Hematother, V4, P73, DOI 10.1089/scd.1.1995.4.73; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	25	660	693	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					551	555		10.1038/nm0596-551	http://dx.doi.org/10.1038/nm0596-551			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616714				2022-12-27	WOS:A1996UJ23000038
J	Simons, M; Ware, JA				Simons, M; Ware, JA			Food for starving hearts	NATURE MEDICINE			English	Editorial Material											Simons, M (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV CARDIOVASC, VASC BIOL UNIT, BOSTON, MA 02215 USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734				FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; KOSTYK SK, 1995, AM J PHYSIOL-HEART C, V269, pH1583, DOI 10.1152/ajpheart.1995.269.5.H1583; LI JS, IN PRESS AM J PHYSL; MILLER JW, 1994, AM J PATHOL, V145, P574; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; SELLKE FW, IN PRESS AM J PHYSL; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858	11	20	32	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					519	520		10.1038/nm0596-519	http://dx.doi.org/10.1038/nm0596-519			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616705				2022-12-27	WOS:A1996UJ23000029
J	Ollier, B				Ollier, B			Shock revelations about HLA-DR4 - A shortcut to rheumatoid arthritis?	NATURE MEDICINE			English	Editorial Material							SUSCEPTIBILITY				Ollier, B (corresponding author), UNIV MANCHESTER,SCH EPIDEMIOL & HLTH SCI,MANCHESTER M13 9PT,LANCS,ENGLAND.							Auger I, 1996, NAT MED, V2, P306, DOI 10.1038/nm0396-306; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; MACGREGOR A, 1995, J RHEUMATOL, V22, P1032; OLLIER W, 1992, RHEUM DIS CLIN N AM, V18, P741; ROUDIER J, 1989, P NATL ACAD SCI USA, V86, P5104, DOI 10.1073/pnas.86.13.5104; SALVAT S, 1994, J IMMUNOL, V153, P5321; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602	8	7	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					279	280		10.1038/nm0396-279	http://dx.doi.org/10.1038/nm0396-279			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612222				2022-12-27	WOS:A1996TY64000032
J	Monsein, LH				Monsein, LH			New detachable coils for treating cerebral aneurysms	NATURE MEDICINE			English	Editorial Material							ENDOVASCULAR APPROACH; SACCULAR ANEURYSMS; ELECTROTHROMBOSIS; MORTALITY				Monsein, LH (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT RADIOL,600 N WOLFE ST,B112C HOUCK,BALTIMORE,MD 21287, USA.							Dandy WE, 1938, ANN SURG, V107, P654, DOI 10.1097/00000658-193805000-00003; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008; HILAL SK, 1988, AM J NEURORADIOL, V9, P1030; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; KLEIN GE, 1995, RADIOLOGY, V197, P416; NICHOLS DA, 1995, RADIOLOGY, V197, P58; ROPPER AH, 1984, J NEUROSURG, V60, P909, DOI 10.3171/jns.1984.60.5.0909; SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125; VUNUELA F, 1995, SYLLABUS 1995 COURSE, P5; WEIR B, 1987, ANEURYSMS AFFECTING, P23	11	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					160	161		10.1038/nm0296-160	http://dx.doi.org/10.1038/nm0296-160			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574956				2022-12-27	WOS:A1996TU06000031
J	GLUSHAKOVA, S; BAIBAKOV, B; MARGOLIS, LB; ZIMMERBERG, J				GLUSHAKOVA, S; BAIBAKOV, B; MARGOLIS, LB; ZIMMERBERG, J			INFECTION OF HUMAN TONSIL HISTOCULTURES - A MODEL FOR HIV PATHOGENESIS	NATURE MEDICINE			English	Editorial Material							AIDS				GLUSHAKOVA, S (corresponding author), NICHHD,THEORET & PHYS BIOL LAB,BETHESDA,MD 20892, USA.							BALTIMORE D, 1995, CELL, V82, P175, DOI 10.1016/0092-8674(95)90303-8; BONYHADI ML, 1995, AIDS RES HUM RETROV, V11, P1073, DOI 10.1089/aid.1995.11.1073; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FREEMAN AE, 1986, P NATL ACAD SCI USA, V83, P2694, DOI 10.1073/pnas.83.8.2694; Gougeon M L, 1993, Semin Immunol, V5, P187, DOI 10.1006/smim.1993.1022; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LEIGHTON J, 1957, CANCER RES, V17, P929; MARGOLIS LB, 1995, AIDS RES HUM RETROV, V11, P697, DOI 10.1089/aid.1995.11.697; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RACZ P, 1990, LYMPHOLOGY, V23, P85; ROSENZWEIG M, 1994, LEUKEMIA, V8, pS163; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	12	146	148	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1320	1322		10.1038/nm1295-1320	http://dx.doi.org/10.1038/nm1295-1320			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489416				2022-12-27	WOS:A1995TH78600048
J	STEIN, CA				STEIN, CA			DOES ANTISENSE EXIST	NATURE MEDICINE			English	Editorial Material							OLIGONUCLEOTIDES; DNA				STEIN, CA (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; GAO WY, 1992, MOL PHARMACOL, V41, P223; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; MALTESE JY, 1995, NUCLEIC ACIDS RES, V23, P1146, DOI 10.1093/nar/23.7.1146; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Stein C A, 1993, Antisense Res Dev, V3, P19; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; TAMAMOTO T, 1994, ANTISENSE RES DEV, V4, P119; YAKUBOV L, 1993, J BIOL CHEM, V268, P18818; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x	12	225	229	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1119	1121		10.1038/nm1195-1119	http://dx.doi.org/10.1038/nm1195-1119			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584974				2022-12-27	WOS:A1995TC53700026
J	LOWY, DR; WILLUMSEN, BM				LOWY, DR; WILLUMSEN, BM			RATIONAL CANCER-THERAPY	NATURE MEDICINE			English	Editorial Material							RAS; INHIBITION	As our knowledge of the basis of different cancers gros, so does the arsenal o	UNIV COPENHAGEN, DEPT MOLEC CELL BIOL, DK-1353 COPENHAGEN, DENMARK	University of Copenhagen	LOWY, DR (corresponding author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999				BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; COX AD, 1994, J BIOL CHEM, V269, P19203; DEXTER DL, 1993, INVEST NEW DRUG, V11, P161, DOI 10.1007/BF00874150; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JORDAN VC, 1992, CURR PROB CANCER, V16, P134; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANNE V, 1995, ONCOGENE, V10, P1763; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244	21	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					747	748		10.1038/nm0895-747	http://dx.doi.org/10.1038/nm0895-747			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585173				2022-12-27	WOS:A1995RM63500027
J	OBRIEN, SJ				OBRIEN, SJ			GENOMIC PROSPECTING	NATURE MEDICINE			English	Editorial Material							PREVALENCE	The importance of preserving biodiversity extends beyond the discovery of new drugs to understanding how other species have dealt with medical problems we currently face.			OBRIEN, SJ (corresponding author), NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; Benveniste R. E., 1985, MOL EVOLUTIONARY GEN, P359; BLACK FL, 1992, SCIENCE, V258, P1739, DOI 10.1126/science.1465610; BROWN EW, 1995, J VIROL, V68, P5953; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; FLAM F, 1994, SCIENCE, V266, P1324, DOI 10.1126/science.7973722; GARDNER MB, 1991, TRENDS GENET, V7, P22, DOI 10.1016/0168-9525(91)90017-K; HEENEY JL, 1990, J VIROL, V64, P1964, DOI 10.1128/JVI.64.5.1964-1972.1990; HIRSCH VM, 1994, VIRUS RES, V32, P183, DOI 10.1016/0168-1702(94)90041-8; OBRIEN SJ, 1994, P NATL ACAD SCI USA, V91, P5748, DOI 10.1073/pnas.91.13.5748; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; OBRIEN SJ, 1994, ANNU REV GENET, V28, P467, DOI 10.1146/annurev.ge.28.120194.002343; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; ROBERTS L, 1992, SCIENCE, V256, P1142, DOI 10.1126/science.256.5060.1142; ROELKE ME, 1993, CURR BIOL, V3, P340, DOI 10.1016/0960-9822(93)90197-V; TROWSDALE J, 1993, TRENDS GENET, V9, P117, DOI 10.1016/0168-9525(93)90205-V; Wilkinson D. A., 1994, RETROVIRIDAE, P465	19	11	11	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					742	744		10.1038/nm0895-742	http://dx.doi.org/10.1038/nm0895-742			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585171	Bronze, Green Published			2022-12-27	WOS:A1995RM63500025
J	WALES, MM; BIEL, MA; ELDEIRY, W; NELKIN, BD; ISSA, P; CAVENEE, WK; KUERBITZ, SJ; BAYLIN, SB				WALES, MM; BIEL, MA; ELDEIRY, W; NELKIN, BD; ISSA, P; CAVENEE, WK; KUERBITZ, SJ; BAYLIN, SB			P53 ACTIVATES EXPRESSION OF HIC-1, A NEW CANDIDATE TUMOR-SUPPRESSOR GENE ON 17P13.3	NATURE MEDICINE			English	Article							FINGER ENCODING GENE; HUMAN BREAST-CANCER; CELL LUNG-CANCER; DNA HYPERMETHYLATION; ZINC FINGERS; BINDING-SITE; PROTEIN; MUTATIONS; IDENTIFICATION; CHROMOSOME-17	For several human tumour types, allelic loss data suggest that one or more tumour sup presser genes reside telomeric to the p53 gene at chromosome 17p73.7. in the present study we have used a new strategy, involving molecular analysis of a DNA site hypermethylated in tumour DNA, to identify a candidate gene in this region (77p13.3). Our ap proach has led to identification of HIC-1 (hypermethylated in cancer), a new zinc-finger transcription factor gene which is ubiquitously expressed in normal tissues, but underexpressed in different tumour cells where it is hypermethylated. Multiple characteristics of this gene, including the presence of a p53 binding site in the 5'flanking region, activation of the gene by expression of a wild-type p53 gene and suppression of G418 selectability of cultured brain, breast and colon cancer cells following insertion of the gene, make HIC-1 gene a strong candidate for a tumour suppressor gene in region 17p13.3.	JOHNS HOPKINS MED INST,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS MED INST,HUMAN GENET GRAD PROGRAM,BALTIMORE,MD 21231; UNIV CALIF SAN DIEGO,LUDWIG CANC INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093; JOHNS HOPKINS MED INST,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Issa, Jean-Pierre/0000-0003-2258-5030	NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA43318] Funding Source: Medline; NIGMS NIH HHS [GM07814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; CARNEY DN, 1985, RECENT RESULTS CANC, V99, P157; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; DENG G, 1994, CANCER RES, V54, P499; DIBELLO PR, 1991, GENETICS, V129, P385; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENSEL CH, 1991, ONCOGENE, V6, P1067; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HROMAS R, 1991, J BIOL CHEM, V266, P14183; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MIKI T, 1994, BLOOD, V83, P26; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NEGRINI M, 1994, CANCER RES, V54, P1818; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TAKITA K, 1992, CANCER RES, V52, P3914; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VAN MEIR EG, 1994, CANCER RES, V54, P649; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6	49	352	366	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					570	577		10.1038/nm0695-570	http://dx.doi.org/10.1038/nm0695-570			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585125				2022-12-27	WOS:A1995RN10100042
J	MOULLIER, P; BOHL, D; CARDOSO, J; HEARD, JM; DANOS, O				MOULLIER, P; BOHL, D; CARDOSO, J; HEARD, JM; DANOS, O			LONG-TERM DELIVERY OF A LYSOSOMAL-ENZYME BY GENETICALLY-MODIFIED FIBROBLASTS IN DOGS	NATURE MEDICINE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; BETA-GLUCURONIDASE; SKIN FIBROBLASTS; GENE-TRANSFER; RECOGNITION; STORAGE; LIVER; TRANSPLANTATION; SPLEEN; MOUSE	We have evaluated the feasibility and efficacy of intraperitoneal implants (neo-organs) for protein delivery in large animals. Skin biopsies were taken from four healthy dogs. Primary fibroblast cultures were transduced with a retroviral vector coding for the human beta-glucuronidase. One to six lattices each containing 10(9) skin fibroblasts were implanted into the omentum of the donor animal. Laparotomies performed at regular intervals showed vascularized neo-organs without local inflammation. Human beta-glucuronidase levels equivalent to 0.8 to 3.1% of the endogenous canine activity were detected for up to 340 days on liver biopsy samples. These results indicate that neo-organs can be considered for the long-term delivery of therapeutic proteins or enzymes in humans.	INST PASTEUR,RETROVIRUS & TRANSFERT GENET LAB,CNRS,URA 1157,F-75015 PARIS,FRANCE; UER COCHIN PORT ROYAL BIOCHIM MACROMOL,RECH CHIRURG LAB,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Bohl, Delphine/L-8709-2016	Bohl, Delphine/0000-0001-8262-5642				ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; CARDOSO JE, 1993, HUM GENE THER, V4, P411, DOI 10.1089/hum.1993.4.4-411; DANOS O, 1991, PRACTICAL MOL VIROLO, P17; DWARKI VJ, 1995, P NATL ACAD SCI USA, V92, P1023, DOI 10.1073/pnas.92.4.1023; HAYASHI M, 1963, J HISTOCHEM CYTOCHEM, V12, P293; HOPWOOD JJ, 1990, MOL BIOL MED, V7, P381; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KRIVIT W, 1992, BONE MARROW TRANSPL, V10, P87; MARECHAL V, 1993, BLOOD, V82, P1358; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; NAFFAKH N, IN PRESS P NATN ACAD; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; Pfeffer S R, 1991, Curr Top Microbiol Immunol, V170, P43; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; ULLRICH K, 1978, BIOCHEM J, V170, P643, DOI 10.1042/bj1700643; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0	19	43	46	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					353	357		10.1038/nm0495-353	http://dx.doi.org/10.1038/nm0495-353			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585066				2022-12-27	WOS:A1995RN09800032
J	SCHNEIDER, KA; PATENAUDE, AF; GARBER, JE				SCHNEIDER, KA; PATENAUDE, AF; GARBER, JE			TESTING FOR CANCER GENES - DECISIONS, DECISIONS	NATURE MEDICINE			English	Editorial Material							OVARIAN-CANCER; GENETICS; BREAST; SUSCEPTIBILITY; PHYSICIANS; KNOWLEDGE				SCHNEIDER, KA (corresponding author), DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BURT RW, 1992, CANCER, V70, P1719, DOI 10.1002/1097-0142(19920915)70:4+<1719::AID-CNCR2820701611>3.0.CO;2-Q; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Geller G, 1993, J Law Med Ethics, V21, P238, DOI 10.1111/j.1748-720X.1993.tb01246.x; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; HOLTZMAN NA, 1993, FETAL DIAGN THER, V8, P213, DOI 10.1159/000263890; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; PETERSEN GM, 1993, HUM GENET, V91, P307; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; WALKER AP, 1990, AM J HUM GENET, V46, P1223; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	13	9	9	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					302	303		10.1038/nm0495-302	http://dx.doi.org/10.1038/nm0495-302			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585056				2022-12-27	WOS:A1995RN09800022
J	Moss, F; ChiouTan, F; Klinke, R				Moss, F; ChiouTan, F; Klinke, R			Will there be noise in their ears?	NATURE MEDICINE			English	Editorial Material							STOCHASTIC RESONANCE; CRAYFISH		UNIV FRANKFURT,ZENTRUM PHYSIOL,D-60590 FRANKFURT,GERMANY; BAYLOR COLL MED,HOUSTON,TX 77030	Goethe University Frankfurt; Baylor College of Medicine	Moss, F (corresponding author), UNIV MISSOURI,CTR NEURODYNAM,ST LOUIS,MO 63121, USA.							BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; CHIOUTAN FY, IN PRESS INT J BIFUR; FISEIFIS S, 1996, P 24 GOTT NEUR C, V2, P457; HARTMANN R, 1984, HEARING RES, V13, P47, DOI 10.1016/0378-5955(84)90094-7; Morse RP, 1996, NAT MED, V2, P928, DOI 10.1038/nm0896-928; NICOLIS C, 1993, J STAT PHYS, V70, P3, DOI 10.1007/BF01053950; PLOTZ K, 1996, P 24 GOTT NEUR C, V2, P209; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	11	24	24	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					860	862		10.1038/nm0896-860	http://dx.doi.org/10.1038/nm0896-860			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705852				2022-12-27	WOS:A1996UZ80400029
J	Scorpio, A; Zhang, Y				Scorpio, A; Zhang, Y			Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus	NATURE MEDICINE			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; PYRIDINE-NUCLEOTIDE CYCLE; MYCOBACTERIUM-TUBERCULOSIS; POINT MUTATIONS; SENSITIVITY; POLYMERASE; DNA	Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acquired PZA-resistant M, tuberculosis strains lose pyrazinamidase (PZase). To investigate the molecular mechanism of PZA resistance, we have cloned the gene (pncA) encoding M, tuberculosis PZase. Mutations in pncA were identified in both types of PZA-resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility. These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA-resistant clinical isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT MOLEC MICROBIOL & IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University								BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BONICKE R, 1959, Tuberkulosearzt, V13, P377; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; COLLINS CH, 1985, TUBERCULOSIS BACTERI, P59; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DICKINSON J M, 1970, Tubercle, V51, P389; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; FOSTER JW, 1979, J BACTERIOL, V137, P1165, DOI 10.1128/JB.137.3.1165-1175.1979; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; HEIFETS L, 1992, AM REV RESPIR DIS, V145, P1223, DOI 10.1164/ajrccm/145.5.1223; JERLSTROM PG, 1989, GENE, V78, P37, DOI 10.1016/0378-1119(89)90312-0; Klemens SP, 1996, ANTIMICROB AGENTS CH, V40, P14, DOI 10.1128/AAC.40.1.14; KONNO K, 1967, AM REV RESPIR DIS, V95, P461; KONNO K, 1959, NATURE, V184, P1743, DOI 10.1038/1841743b0; MACKANESS GB, 1956, AM REV TUBERC PULM, V74, P718; MCCLATCHY JK, 1981, ANTIMICROB AGENTS CH, V20, P556, DOI 10.1128/AAC.20.4.556; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUEZ JG, 1995, MICROBIOL-SGM, V141, P2131, DOI 10.1099/13500872-141-9-2131; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SKINNER PS, 1994, ANTIMICROB AGENTS CH, V38, P2557, DOI 10.1128/AAC.38.11.2557; TARSHIS MS, 1953, AM REV TUBERC PULM, V67, P391; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TRIVEDI SS, 1987, TUBERCLE, V68, P221, DOI 10.1016/0041-3879(87)90058-4; WAYNE LG, 1974, AM REV RESPIR DIS, V109, P147; YEAGER RL, 1952, AM REV TUBERC PULM, V65, P523; ZHANG Y, 1992, INFECT IMMUN, V60, P2160, DOI 10.1128/IAI.60.6.2160-2165.1992; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; 1994, B WORLD HEALTH ORGAN, V72, P851	36	534	559	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1996	2	6					662	667		10.1038/nm0696-662	http://dx.doi.org/10.1038/nm0696-662			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640557				2022-12-27	WOS:A1996UN69100034
J	Foncin, JF				Foncin, JF			The true western diet	NATURE MEDICINE			English	Letter											Foncin, JF (corresponding author), LAB MONTYON LA SALPETRIERE,LAB NEUROHISTOL,47 BLVD HOP,F-75651 PARIS 13,FRANCE.								0	1	1	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					255	255		10.1038/nm0396-255b	http://dx.doi.org/10.1038/nm0396-255b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612209	Bronze			2022-12-27	WOS:A1996TY64000005
J	Slusher, BS; Jackson, PF				Slusher, BS; Jackson, PF			A shot in the arm for cocaine addiction	NATURE MEDICINE			English	Editorial Material							HUMAN DOPAMINE TRANSPORTER				Slusher, BS (corresponding author), GUILFORD PHARMACEUT INC,BALTIMORE,MD 21224, USA.							BONESE KF, 1974, NATURE, V252, P20; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; Carroll F. Ivy, 1993, P149; CARROLL FI, 1994, PHARM NEWS, V1, P1; CHRISTENSON JG, 1978, Patent No. 4102979; GIROS B, 1992, MOL PHARMACOL, V42, P383; KITYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; LEUTE RK, 1975, Patent No. 3888866; MULE SJ, 1977, CLIN CHEM, V23, P796; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; 1995, INTRO DEV MEDICATION, P36	13	1	1	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					26	27		10.1038/nm0196-26	http://dx.doi.org/10.1038/nm0196-26			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564829				2022-12-27	WOS:A1996TP57900029
J	WILLIAMS, RS				WILLIAMS, RS			HUMAN GENE-THERAPY - OF TORTOISES AND HARES	NATURE MEDICINE			English	Editorial Material											WILLIAMS, RS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CARDIOL,DALLAS,TX 75235, USA.							GROSSMAN M, 1995, NAT MED, V1, P1148, DOI 10.1038/nm1195-1148; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303	3	7	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1137	1138		10.1038/nm1195-1137	http://dx.doi.org/10.1038/nm1195-1137			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584981				2022-12-27	WOS:A1995TC53700033
J	WURTMAN, RJ; BETTIKER, RL				WURTMAN, RJ; BETTIKER, RL			THE SLOWING OF TREATMENT DISCOVERY, 1965-1995	NATURE MEDICINE			English	Editorial Material									MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	WURTMAN, RJ (corresponding author), MIT,CLIN RES CTR,CAMBRIDGE,MA 02139, USA.							Jobe P C, 1994, Physiologist, V37, P79; Kelly WN, 1994, CAREERS CLIN RES OBS; WILLIAMS GH, 1994, ANAL REV PATIENT ORI	3	42	42	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1122	1125		10.1038/nm1195-1122	http://dx.doi.org/10.1038/nm1195-1122			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584975				2022-12-27	WOS:A1995TC53700027
J	BARANYI, L; CAMPBELL, W; OHSHIMA, K; FUJIMOTO, S; BOROS, M; OKADA, H				BARANYI, L; CAMPBELL, W; OHSHIMA, K; FUJIMOTO, S; BOROS, M; OKADA, H			THE ANTISENSE HOMOLOGY BOX - A NEW MOTIF WITHIN PROTEINS THAT ENCODES BIOLOGICALLY-ACTIVE PEPTIDES	NATURE MEDICINE			English	Article							HYDROPATHIC COMPLEMENTARITY APPROACH; ANGIOTENSIN-II RECEPTOR; MESSENGER-RNA; ENDOTHELIN RECEPTOR; ACETYLCHOLINE-RECEPTOR; RECOGNITION PROPERTIES; BINDING PEPTIDE; OPIATE RECEPTOR; SENSE PEPTIDES; GENETIC-CODE	Amphiphilic peptides approximately fifteen amino acids in length and their corresponding antisense peptides exist within protein molecules. These regions (termed antisense homology boxes) are separated by approximately fifty amino acids. Because many sense-antisense peptide pairs have been reported to recognize and bind to each other, antisense homology boxes may be involved in folding, chaperoning and oligomer formation of proteins. The antisense homology box-derived peptide CALSVDRYRAVASW, a fragment of human endothelin A receptor, proved to be a specific inhibitor of endothelin peptide (ET-1) in a smooth muscle relaxation assay. The peptide was able to block endotoxin-induced shock in rats as well. Our finding of endothelin receptor inhibitor among antisense homology box-derived peptides indicates that searching proteins for this new motif may be useful in finding biologically active peptides.	NAGOYA CITY UNIV, SCH MED, DEPT PHARMACOL, NAGOYA, AICHI 467, JAPAN; NOYORI FUKUSHIMURA HOSP, CHOJU MED INST, TOYOHASHI, AICHI 441, JAPAN; ALBERT SZENT GYORGYI MED UNIV, INST EXPTL SURG, H-6723 SZEGED, HUNGARY; NAGOYA CITY UNIV, SCH MED, DEPT MOLEC BIOL, NAGOYA, AICHI 467, JAPAN	Nagoya City University; Szeged University; Nagoya City University			Boros, Mihály/B-5195-2008					ALOBEIDI FA, 1989, PEPTIDES 89, P530; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAJPAI A, 1991, BIOCHEM BIOPH RES CO, V180, P1312, DOI 10.1016/S0006-291X(05)81338-5; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOROVSKY D, 1994, FASEB J, V8, P350, DOI 10.1096/fasebj.8.3.7908271; Bost K L, 1989, J Mol Recognit, V1, P179; BOST KL, 1985, BIOCHEM BIOPH RES CO, V128, P1373, DOI 10.1016/0006-291X(85)91092-7; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; BRETDIBAT JL, 1994, J NEUROCHEM, V63, P333; CAMPBELLTHOMPSON M, 1993, AM J MED SCI, V305, P365, DOI 10.1097/00000441-199306000-00003; CARR DJJ, 1987, FEBS LETT, V224, P272, DOI 10.1016/0014-5793(87)80468-4; CARR DJJ, 1989, IMMUNOL LETT, V20, P181, DOI 10.1016/0165-2478(89)90077-1; CARR DJJ, 1986, J NEUROIMMUNOL, V12, P329, DOI 10.1016/0165-5728(86)90039-1; CASTRONOVO V, 1991, CANCER RES, V51, P5672; CHAIKEN IM, 1989, PROTEIN RECOGNITION, P257; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLARKE BL, 1990, P NATL ACAD SCI USA, V87, P9708, DOI 10.1073/pnas.87.24.9708; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DEGASPARO M, 1989, BIOCHEM J, V261, P310, DOI 10.1042/bj2610310; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; DRAPER KG, 1989, BIOCHEM BIOPH RES CO, V163, P466, DOI 10.1016/0006-291X(89)92159-1; EBERLE A N, 1989, Peptide Research, V2, P213; EBERLE AN, 1991, J RECEPTOR RES, V11, P13, DOI 10.3109/10799899109066387; ELTON TS, 1988, P NATL ACAD SCI USA, V85, P2518, DOI 10.1073/pnas.85.8.2518; FASSINA G, 1992, INT J PEPT PROT RES, V39, P540; FASSINA G, 1992, BIOCHEM J, V282, P773, DOI 10.1042/bj2820773; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FASSINA G, 1992, PEPTIDES 92; FASSINA G, 1989, METHODS PROTEIN SEQU, P431; FREIRE E, 1991, J MOL BIOL, V222, P687, DOI 10.1016/0022-2836(91)90505-Z; GARTNER TK, 1991, BIOCHEM BIOPH RES CO, V180, P1446; GARTNER TK, 1991, P SOC EXP BIOL MED, V198, P649; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; GOLDSTEIN A, 1989, P NATL ACAD SCI USA, V86, P42, DOI 10.1073/pnas.86.1.42; GROSVENOR CE, 1989, Patent No. 4833166; GUILLEMETTE G, 1989, BIOCHEM J, V261, P309, DOI 10.1042/bj2610309; HAYNES WG, 1993, TRENDS PHARMACOL SCI, V14, P225, DOI 10.1016/0165-6147(93)90012-9; HEYL DL, 1993, PEPTIDE RES, V6, P238; JOHNSON HM, 1988, J IMMUNOL, V141, P2420; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; KELLY JM, 1990, PEPTIDES, V11, P857, DOI 10.1016/0196-9781(90)90204-I; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; KON V, 1992, RENAL FAILURE, V14, P345, DOI 10.3109/08860229209106641; LU FX, 1991, P NATL ACAD SCI USA, V88, P3642, DOI 10.1073/pnas.88.9.3642; MAEMURA K, 1992, GERONTOLOGY, V38, P29; MARKUS G, 1989, ARCH BIOCHEM BIOPHYS, V272, P433, DOI 10.1016/0003-9861(89)90237-3; MCGUIGAN JE, 1992, GASTROENTEROLOGY, V103, P749, DOI 10.1016/0016-5085(92)90002-G; MOFFAT AS, 1991, SCIENCE, V253, P510, DOI 10.1126/science.1857981; MOORE GJ, 1989, BIOCHEM BIOPH RES CO, V160, P1387, DOI 10.1016/S0006-291X(89)80157-3; MULCHAHEY JJ, 1986, P NATL ACAD SCI USA, V83, P9714, DOI 10.1073/pnas.83.24.9714; NAGY GM, 1991, 73 ANN END SOC M, P209; PANEK RL, 1992, BIOCHEM BIOPH RES CO, V183, P566, DOI 10.1016/0006-291X(92)90519-Q; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; RADDING W, 1992, J AUTONOM NERV SYST, V40, P161, DOI 10.1016/0165-1838(92)90027-E; Rassmundsen UB, 1987, BIOCHEM BIOPH RES CO, V149, P930; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCAPOL L, 1992, J CHROMATOGR, V600, P235, DOI 10.1016/0021-9673(92)85553-6; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; SHAHABI NA, 1992, J PHARMACOL EXP THER, V263, P876; SHAI Y, 1989, BIOCHEMISTRY-US, V28, P8804, DOI 10.1021/bi00448a019; SLEGEL S, 1988, NONPARAMETRIC STAT, P40; SOFFER RL, 1987, P NATL ACAD SCI USA, V84, P9219, DOI 10.1073/pnas.84.24.9219; SOKOLOVSKY M, 1994, INT J BIOCHEM, V26, P335, DOI 10.1016/0020-711X(94)90053-1; TROSPHA A, 1992, J MOL RECOGNIT, V5, P43; WEIGENT DA, 1986, BIOCHEM BIOPH RES CO, V139, P367, DOI 10.1016/S0006-291X(86)80123-1; WHITAKER JN, 1989, J NEUROIMMUNOL, V22, P157, DOI 10.1016/0165-5728(89)90047-7; ZAMAI M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P337, DOI 10.1016/0167-4838(93)90025-M; ZHOU SR, 1993, J IMMUNOL, V150, P1629; ZULL JE, 1994, NUCLEIC ACIDS RES, V22, P3373, DOI 10.1093/nar/22.16.3373; ZULL JE, 1990, TRENDS BIOCHEM SCI, V15, P257, DOI 10.1016/0968-0004(90)90048-G	78	93	100	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1995	1	9					894	901		10.1038/nm0995-894	http://dx.doi.org/10.1038/nm0995-894			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585214				2022-12-27	WOS:A1995RT30300042
J	COZZI, E; WHITE, DJG				COZZI, E; WHITE, DJG			THE GENERATION OF TRANSGENIC PIGS AS POTENTIAL ORGAN DONORS FOR HUMANS	NATURE MEDICINE			English	Editorial Material							HYPERACUTE XENOGRAFT REJECTION; DECAY-ACCELERATING FACTOR; COMPLEMENT ACTIVATION; INHIBITION; MECHANISM; MODEL; CELLS		UNIV PADUA,INST MED INTERNA,PADUA,ITALY; UNIV CAMBRIDGE,DEPT SURG,CAMBRIDGE CB2 2AH,ENGLAND	University of Padua; University of Cambridge				Cozzi, Emanuele/0000-0001-7855-5055				ATKINSON J P, 1991, Clinical and Experimental Immunology, V86, P27; BACH FH, 1993, XENO, V1, P8; BRAIDLEY PC, 1994, TRANSPLANT P, V26, P1259; CALNE RY, 1970, TRANSPL P, V2, P550; CARY N, 1993, TRANSPLANT P, V25, P400; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; COOPER DKC, 1994, IMMUNOL REV, V141, P31, DOI 10.1111/j.1600-065X.1994.tb00871.x; Cooper DKC, 1991, XENOTRANSPLANTATION; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; DIAMOND LE, 1994, TRANSPLANT P, V26, P1239; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; JOHNSTON PS, 1992, TRANSPLANTATION, V54, P573, DOI 10.1097/00007890-199210000-00001; KEMP E, 1982, TRANSPLANT P, V14, P116; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; LANGFORD GA, 1994, TRANSPLANT P, V26, P1400; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MIYAGAWA S, 1994, TRANSPLANT P, V26, P1253; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PLATT JL, 1991, TRANSPLANTATION, V52, P214, DOI 10.1097/00007890-199108000-00006; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; SACHS DH, 1990, HUM IMMUNOL, V28, P245, DOI 10.1016/0198-8859(90)90025-K; SANDRIN MS, 1994, TRANSPLANT REV, V8, P134; VANDENBERG CW, 1995, J IMMUNOL, V152, P4095; WALSH LA, 1991, EUR J IMMUNOL, V21, P847, DOI 10.1002/eji.1830210349; WHITE DJG, IN PRESS XENO; WHITE DJG, 1992, TRANSPLANT INT, V5, P648; YANNOUTSOS N, 1995, TRANSPLANT P, V27, P324	30	486	502	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					964	966		10.1038/nm0995-964	http://dx.doi.org/10.1038/nm0995-964			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585226				2022-12-27	WOS:A1995RT30300054
J	SACHS, DH; SYKES, M; GREENSTEIN, JL; COSIMI, AB				SACHS, DH; SYKES, M; GREENSTEIN, JL; COSIMI, AB			TOLERANCE AND XENOGRAFT SURVIVAL	NATURE MEDICINE			English	Editorial Material							NONLETHAL PREPARATIVE REGIMEN		MASSACHUSETTS GEN HOSP EAST,BOSTON,MA 02129; BIOTRANSPLANT INC,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital	SACHS, DH (corresponding author), HARVARD UNIV,SCH MED,BLDG 149-9019,13TH ST,BOSTON,MA 02129, USA.							AKSENTIJEVICH I, 1992, TRANSPLANTATION, V53, P1108, DOI 10.1097/00007890-199205000-00025; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; SACHS DH, 1995, IN PRESS XENOTRANSPL; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; TANAKA M, 1994, TRANSPLANT P, V26, P1326	6	37	38	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					969	969		10.1038/nm0995-969	http://dx.doi.org/10.1038/nm0995-969			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585228	Bronze			2022-12-27	WOS:A1995RT30300056
J	BARBAS, CF				BARBAS, CF			SYNTHETIC HUMAN-ANTIBODIES	NATURE MEDICINE			English	Editorial Material							IMMUNIZATION; LIBRARIES; DIVERSITY; SELECTION				BARBAS, CF (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AKAMATSU Y, 1993, J IMMUNOL, V151, P4651; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P6385, DOI 10.1073/pnas.90.14.6385; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BARBAS CF, 1993, GENE, V137, P57, DOI 10.1016/0378-1119(93)90251-W; BARBAS SM, 1994, J AM CHEM SOC, V116, P2161, DOI 10.1021/ja00084a073; BARBAS SM, 1994, FIBRINOLYSIS, V8, P245, DOI 10.1016/0268-9499(94)90722-6; BARBOS CF, IN PRESS METH COMPAN; BARRE S, 1994, NAT STRUCT BIOL, V1, P915, DOI 10.1038/nsb1294-915; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CROWE JE, 1994, P NATL ACAD SCI USA, V91, P2133; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; GARRARD LJ, 1993, GENE, V128, P103, DOI 10.1016/0378-1119(93)90160-5; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; GRONSKI P, 1991, MOL IMMUNOL, V28, P1321, DOI 10.1016/0161-5890(91)90034-H; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; Karu Alexander E., 1994, Food and Agricultural Immunology, V6, P277, DOI 10.1080/09540109409354839; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; PACK P, 1995, J MOL BIOL, V248, P29; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; RIDDER R, 1995, BIO-TECHNOL, V13, P255, DOI 10.1038/nbt0395-255; SANZ I, 1991, J IMMUNOL, V147, P1720; SMITH JW, 1994, J BIOL CHEM, V269, P32788; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	32	34	96	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					837	839		10.1038/nm0895-837	http://dx.doi.org/10.1038/nm0895-837			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585190				2022-12-27	WOS:A1995RM63500044
J	GOLDMAN, D				GOLDMAN, D			DOPAMINE TRANSPORTER, ALCOHOLISM AND OTHER DISEASES	NATURE MEDICINE			English	Editorial Material							GENE				GOLDMAN, D (corresponding author), NIAAA,NEUROGENET LAB,ROCKVILLE,MD 20852, USA.		Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405				BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BYERLEY W, 1993, HUM HERED, V43, P319, DOI 10.1159/000154151; COOK EH, 1995, AM J HUM GENET, V56, P993; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GELERNTER J, 1994, NEUROPSYCHOPHARMACOL, V11, P195, DOI 10.1038/sj.npp.1380106; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; HAUSER P, 1993, NEW ENGL J MED, V328, P997, DOI 10.1056/NEJM199304083281403; PERSICO AM, 1993, BIOL PSYCHIAT, V34, P265, DOI 10.1016/0006-3223(93)90081-N; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; RUBINSTEIN P, 1981, HUM IMMUNOL, V3, P384; TIIHONEN J, 1995, NAT MED, V1, P654, DOI 10.1038/nm0795-654; TU GC, 1995, BEHAV GENET, V25, P59, DOI 10.1007/BF02197242	12	4	4	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					624	625		10.1038/nm0795-624	http://dx.doi.org/10.1038/nm0795-624			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585136				2022-12-27	WOS:A1995RQ06600029
J	MACIEJEWSKI, JP; WEICHOLD, FF; YOUNG, NS; CARA, A; ZELLA, D; REITZ, MS; GALLO, RC				MACIEJEWSKI, JP; WEICHOLD, FF; YOUNG, NS; CARA, A; ZELLA, D; REITZ, MS; GALLO, RC			INTRACELLULAR EXPRESSION OF ANTIBODY FRAGMENTS DIRECTED AGAINST HIV REVERSE-TRANSCRIPTASE PREVENTS HIV-INFECTION IN-VITRO	NATURE MEDICINE			English	Article							EPSTEIN-BARR VIRUS; SINGLE-CHAIN FV; ESCHERICHIA-COLI; MAMMALIAN-CELLS; GENE-THERAPY; REPLICATION; PROTEIN; TYPE-1; VECTOR; DNA	We have tested a novel strategy of intracellular immunization to block human immunodeficiency virus (HIV) infection. The expression of a specific antibody within a cell was achieved by transduction of genes that encode for immunoglobulin chains with specificity to viral reverse transcriptase. We demonstrated that inhibition of this enzyme makes cells resistant to HIV infection by blocking an early stage of viral replication. If high efficiency transduction with a stable vector into lymphohaematopoietic stem cells or mature lymphocytes can be achieved, gene transfer-mediated intracellular immunization might be a feasible treatment strategy in AIDS.	NHLBI,HEMATOL BRANCH,BETHESDA,MD 20892; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			ZELLA, DAVIDE/AAC-7630-2020; Cara, Andrea/M-4865-2015; Cara, Andrea/AAA-4238-2021	ZELLA, DAVIDE/0000-0001-5576-5770; Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895				BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BIOCCA S, 1984, BIOTECHNOLOGY, V12, P396; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CARA A, 1995, VIROLOGY, V208, P242, DOI 10.1006/viro.1995.1148; CARLSON JR, 1988, MOL CELL BIOL, V8, P2638, DOI 10.1128/MCB.8.6.2638; CARUSO M, 1992, P NATL ACAD SCI USA, V89, P182, DOI 10.1073/pnas.89.1.182; DUAN L, 1994, P NATL ACAD SCI USA, V91, P5015; DUNBAR CE, 1994, STEM CELLS, V12, P563, DOI 10.1002/stem.5530120604; DUNBAR CE, IN PRESS BLOOD; GERNA G, 1984, ANTIMICROB AGENTS CH, V38, P38; GILBOA E, 1986, BIOTECHNIQUES, V4, P584; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7427; MUILINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095; MUROCACHO CA, 1992, J IMMUNOTHER, V11, P231, DOI 10.1097/00002371-199205000-00001; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PENG L, 1994, J GEN VIROL, V75, P1917; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, Antiviral Chemistry and Chemotherapy, V2, P133; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; TALBOTT R, 1993, P NATL ACAD SCI USA, V90, P4226, DOI 10.1073/pnas.90.9.4226; TAVIADORAKI P, 1993, NATURE, V366, P469; TRATSCHIN JD, 1985, MOL CELL BIOL, V5, P3251, DOI 10.1128/MCB.5.11.3251; TRAVIS J, 1993, SCIENCE, V261, P1114, DOI 10.1126/science.8356445; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VERONESE FD, 1976, SCIENCE, V231, P1289; WITHLOW M, 1991, METHOD ENZYMOL, V2, P97; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG JM, 1988, GENE, V62, P171, DOI 10.1016/0378-1119(88)90556-2; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	41	83	84	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					667	673		10.1038/nm0795-667	http://dx.doi.org/10.1038/nm0795-667			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585149				2022-12-27	WOS:A1995RQ06600042
J	ALBANI, S; KEYSTONE, E; NELSON, JL; OLLIER, WER; LACAVA, A; MONTEMAYOR, AC; WEBER, DA; MONTECUCCO, C; MARTINI, A; CARSON, DA				ALBANI, S; KEYSTONE, E; NELSON, JL; OLLIER, WER; LACAVA, A; MONTEMAYOR, AC; WEBER, DA; MONTECUCCO, C; MARTINI, A; CARSON, DA			POSITIVE SELECTION IN AUTOIMMUNITY - ABNORMAL IMMUNE-RESPONSES TO A BACTERIAL DNAJ ANTIGENIC DETERMINANT IN PATIENTS WITH EARLY RHEUMATOID-ARTHRITIS	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; NUCLEOTIDE-SEQUENCE; MOLECULAR MIMICRY; CLASS-II; B-CELL; DISEASE; SUSCEPTIBILITY; GENE	A novel 'multistep molecular mimicry' mechanism for induction of rheumatoid arthritis (RA) by bacterial antigens that activate T lymphocytes previously 'educated' by peptides derived from a class of human histocompatibility antigens is reported here. These antigens have the amino acid sequence QKRAA, which is also present on the Escherichia coli heat-shock protein dnaj. Synovial fluid cells of early RA patients have strong immune responses to the bacterial antigen, but cells from normal subjects or controls with other autoimmune diseases do not. The activated T cells may cross-react with autologous dnaj heat-shock proteins that are expressed at synovial sites of inflammation. Our findings may have direct relevance to new strategies for the immune therapy of RA.	UNIV CALIF SAN DIEGO, SAM & ROSE STEIN INST RES AGING, LA JOLLA, CA 92093 USA; UNIV TORONTO, WELLESLEY HOSP, RHEUMAT DIS UNIT, TORONTO, ON M4Y 1J3, CANADA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV MANCHESTER, ARC, EPIDEMIOL RES UNIT, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV PAVIA, POLICLIN SAN MATTEO, DEPT PEDIAT, I-27100 PAVIA, ITALY	University of California System; University of California San Diego; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Fred Hutchinson Cancer Center; University of Manchester; IRCCS Fondazione San Matteo; University of Pavia	ALBANI, S (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.		/AAG-9576-2020; MONTECUCCO, CARLOMAURIZIO/K-5236-2018	/0000-0002-8839-0933; MONTECUCCO, CARLOMAURIZIO/0000-0001-8263-3925	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007567, R37AR025443, P01AR041897, R01AR025443] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 25443, AR 41897, AR 07567] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBANI S, 1994, J PEDIATR-US, V124, P561, DOI 10.1016/S0022-3476(05)83134-8; ALBANI S, 1992, J CLIN INVEST, V89, P327, DOI 10.1172/JCI115580; ALLEN PM, 1994, CELL, V76, P593, DOI 10.1016/0092-8674(94)90497-9; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; FATENEJAD S, 1993, P NATL ACAD SCI USA, V90, P12010, DOI 10.1073/pnas.90.24.12010; FROUDE J, 1989, CURR TOP MICROBIOL, V145, P5; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HODQUIST KA, 1994, CELL, V76, P17; LIFE PF, 1991, IMMUNOL REV, V121, P113, DOI 10.1111/j.1600-065X.1991.tb00825.x; MULLERFASSBENDER HR, 1993, BRIT J RHEUMATOL, V32, P746; NELSON JL, 1993, NEW ENGL J MED, V329, P466, DOI 10.1056/NEJM199308123290704; NEPOM GT, 1992, RHEUM DIS CLIN N AM, V18, P785; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OLLIER W, 1992, RHEUM DIS CLIN N AM, V18, P741; ROUDIER J, 1991, EUR J IMMUNOL, V21, P2063, DOI 10.1002/eji.1830210914; ROUDIER J, 1989, P NATN ACAD SSI US, V86, P5014; SALVAT S, 1994, J IMMUNOL, V153, P5321; SIEPER J, 1991, ARTHRITIS RHEUM-US, V34, P588, DOI 10.1002/art.1780340511; SILMAN AJ, 1993, BRIT J RHEUMATOL, V32, P903; SPECTOR TD, 1990, RHEUM DIS CLIN N AM, V16, P513; THOMSON W, 1992, EUR J IMMUNOGENET, V19, P169, DOI 10.1111/j.1744-313X.1992.tb00056.x; VANASSELDONK M, 1993, J BACTERIOL, V175, P1637, DOI 10.1128/JB.175.6.1637-1644.1993; VANEDEN W, 1991, IMMUNOL REV, V121, P5; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WINCHESTER R, 1992, RHEUM DIS CLIN N AM, V18, P761; WINFIELD JB, 1992, B RHEUM DIS, V41, P4	32	143	156	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					448	452		10.1038/nm0595-448	http://dx.doi.org/10.1038/nm0595-448			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585093				2022-12-27	WOS:A1995RN10000036
J	KOENIG, S; CONLEY, AJ; BREWAH, YA; JONES, GM; LEATH, S; BOOTS, LJ; DAVEY, V; PANTALEO, G; DEMAREST, JF; CARTER, C; WANNEBO, C; YANNELLI, JR; ROSENBERG, SA; LANE, HC				KOENIG, S; CONLEY, AJ; BREWAH, YA; JONES, GM; LEATH, S; BOOTS, LJ; DAVEY, V; PANTALEO, G; DEMAREST, JF; CARTER, C; WANNEBO, C; YANNELLI, JR; ROSENBERG, SA; LANE, HC			TRANSFER OF HIV-1-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO AN AIDS PATIENT LEADS TO SELECTION FOR MUTANT HIV VARIANTS AND SUBSEQUENT DISEASE PROGRESSION	NATURE MEDICINE			English	Article							INFECTED RHESUS-MONKEYS; CYTO-TOXIC RESPONSES; ADOPTIVE TRANSFER; NEF PROTEIN; VIRUS; CD8+; CELLS; PROTECTION; VACCINE; INVIVO	An HIV-1-seropositive volunteer was infused with an expanded autologous cytotoxic T lymphocyte (CTL) clone directed against the HIV-1 nef protein. This clone was adoptively transferred to determine whether supplementing CTL activity could reduce viral load or improve clinical course. Unexpectedly, infusion was followed by a decline in circulating CD4(-) T cells and a rise in viral load. Some of the HIV isolates obtained from the plasma or CD4(-) cells of the patient were lacking the nef epitope. These results suggest that active CTL selection of viral variants could contribute to the pathogenesis of AIDS and that clinical progression can occur despite high levels of circulating HIV-1-specific CTLs.	MERCK RES LABS, West Point, PA 19486 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; NCI, CTR CLIN, TRANSFUS MED BRANCH, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, BETHESDA, MD 20892 USA	Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOENIG, S (corresponding author), MEDIMMUNE INC, 35 W WATKINS MILL RD, GAITHERSBURG, MD 20878 USA.		Pantaleo, Giuseppe/K-6163-2016					BINDER D, 1991, J IMMUNOL, V146, P4301; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHEN ZW, 1993, J IMMUNOL, V151, P2177; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; CULMANN B, 1991, J IMMUNOL, V146, P1560; DAI L C, 1992, Journal of Virology, V66, P3151; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DILLON SB, 1992, VACCINE, V10, P309, DOI 10.1016/0264-410X(92)90369-U; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; GREEN WR, 1994, J VIROL, V68, P4679, DOI 10.1128/JVI.68.7.4679-4684.1994; HO M, 1993, BLOOD, V81, P2093; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JOHNSON RP, 1992, J EXP MED, V175, P961, DOI 10.1084/jem.175.4.961; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KOENIG S, 1990, J IMMUNOL, V145, P127; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOUP RA, 1989, BLOOD, V73, P1909; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KYBURZ D, 1993, J IMMUNOL, V150, P5051; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; MYERS G, 1988, HIV SEQUENCE DATABAS; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; OLDSTONE MBA, 1993, J VIROL, V67, P4372, DOI 10.1128/JVI.67.7.4372-4378.1993; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; RIDDELL SR, 1992, SCIENCE, V257, P238; RIVIERE Y, 1989, J VIROL, V63, P2270, DOI 10.1128/JVI.63.5.2270-2277.1989; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; Sambrook J, 1989, MOL CLONING LABORATO; SLOBOD KS, 1993, CLIN EXP IMMUNOL, V93, P363, DOI 10.1111/j.1365-2249.1993.tb08186.x; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; WONG RA, 1991, J IMMUNOTHER, V10, P120, DOI 10.1097/00002371-199104000-00006; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	40	318	323	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1995	1	4					330	336		10.1038/nm0495-330	http://dx.doi.org/10.1038/nm0495-330			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585062				2022-12-27	WOS:A1995RN09800028
J	Boland, CR				Boland, CR			Setting microsatellites free	NATURE MEDICINE			English	Editorial Material							COLORECTAL-CANCER; MUTATIONS; IDENTIFICATION				Boland, CR (corresponding author), UNIV CALIF SAN DIEGO,BASIC SCI BLDG,ROOM 4028,LA JOLLA,CA 92093, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; Brentnall TA, 1996, CANCER RES, V56, P1237; Chen XQ, 1996, NAT MED, V2, P1033; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	11	12	18	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					972	974		10.1038/nm0996-972	http://dx.doi.org/10.1038/nm0996-972			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782450				2022-12-27	WOS:A1996VF49700027
J	Roth, JA; Nguyen, D; Lawrence, DD; Kemp, BL; Carrasco, CH; Ferson, DZ; Hong, WK; Komaki, R; Lee, JJ; Nesbitt, JC; Pisters, KMW; Putnam, JB; Schea, R; Shin, DM; Walsh, GL; Dolormente, MM; Han, CI; Martin, FD; Yen, N; Xu, K; Stephens, LC; McDonnell, TJ; Mukhopadhyay, T; Cai, D				Roth, JA; Nguyen, D; Lawrence, DD; Kemp, BL; Carrasco, CH; Ferson, DZ; Hong, WK; Komaki, R; Lee, JJ; Nesbitt, JC; Pisters, KMW; Putnam, JB; Schea, R; Shin, DM; Walsh, GL; Dolormente, MM; Han, CI; Martin, FD; Yen, N; Xu, K; Stephens, LC; McDonnell, TJ; Mukhopadhyay, T; Cai, D			Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer	NATURE MEDICINE			English	Article							CELL-CYCLE CONTROL; RECOMBINANT ADENOVIRUS; EXPRESSION VECTOR; ANTISENSE RNA; MUTATIONS; APOPTOSIS; LESIONS; INDUCTION; GROWTH; TUMORIGENICITY	A retroviral vector containing the wild-type p53 gene under control of a p-actin promoter was produced to mediate transfer of wild-type p53 into human non-small cell lung cancers by direct injection. Nine patients whose conventional treatments failed were entered into the study. No clinically significant vector-related toxic effects were noted up to five months after treatment. In situ hybridization and DNA polymerase chain reaction showed vector-p53 sequences in posttreatment biopsies. Apoptosis (programmed cell death) was more frequent in posttreatment biopsies than in pretreatment biopsies. Tumor regression was noted in three patients, and tumor growth stabilized in three other patients.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT DIAGNOST IMAGING,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT ANESTHESIOL & CRIT CARE,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT RADIOTHERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOMATH,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT VET MED & SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Roth, JA (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CARDIOVASC & THORAC SURG,SECT THORAC MOLEC ONCOL,HOUSTON,TX 77030, USA.		Shin, Dong Moon/G-9649-2013; Ray, Dana M/C-3470-2013; Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Shin, Dong Moon/0000-0002-8245-4174; Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X; Putnam, Joe/0000-0002-7504-2104	NATIONAL CANCER INSTITUTE [R01CA045187, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 45187, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJANI JA, 1990, CANCER INVEST, V8, P147, DOI 10.3109/07357909009017560; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; CASSON AG, 1991, CANCER RES, V51, P4495; CHUNG KY, 1993, CANCER RES, V53, P1676; CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8; CUSACK JC, IN PRESS CANC GENE T; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; FUJIWARA T, 1994, CANCER RES, V54, P2287; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Johnson LG, 1996, HUM GENE THER, V7, P51, DOI 10.1089/hum.1996.7.1-51; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KITAMURA H, 1995, AM J PATHOL, V146, P876; KNOL JA, 1995, CANCER RES, V55, P3687; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU TJ, 1994, CANCER RES, V54, P3662; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Roth JA, 1996, HUM GENE THER, V7, P861, DOI 10.1089/hum.1996.7.7-861; ROTH JA, 1993, HUM GENE THER, V4, P365; SCHNEIDER PM, 1996, J THORAC CARDIOVASC, V111; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAMIYA T, 1995, GENE THER, V2, P531; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WANG JX, 1995, CANCER GENE THER, V2, P9; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P5; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	41	609	638	1	22	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					985	991		10.1038/nm0996-985	http://dx.doi.org/10.1038/nm0996-985			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782455				2022-12-27	WOS:A1996VF49700032
J	Johnson, OL; Cleland, JL; Lee, HJ; Charnis, M; Duenas, E; Jaworowicz, W; Shepard, D; Shahzamani, A; Jones, AJS; Putney, SD				Johnson, OL; Cleland, JL; Lee, HJ; Charnis, M; Duenas, E; Jaworowicz, W; Shepard, D; Shahzamani, A; Jones, AJS; Putney, SD			A month-long effect from a single injection of microencapsulated human growth hormone	NATURE MEDICINE			English	Article							DRUG DELIVERY; PROTEINS; PITUITARY; RELEASE; ZINC; MICROSPHERES; DEGRADATION; POLYMERS; ACID)	An injectable sustained-release form of human growth hormone (hGH) was developed by stabilizing and encapsulating the protein, without altering its integrity, into biodegradable microspheres using a novel cryogenic process. A single injection of microspheres in monkeys resulted in elevated serum levels of recombinant hGH (rhGH) for more than one month. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-3, both of which are induced by hGH, were also elevated for four weeks by the rhGH containing microspheres to a level greater than that induced by the same amount of rhGH administered by daily injections. These results show that, by using appropriate methods of stabilization and encapsulation, the advantages of sustained-release formulations previously demonstrated for low-molecular-weight drugs can now be extended to protein therapeutics.	ALKENNES INC,CAMBRIDGE,MA 02139; GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								AUSTIN PE, 1995, ANN EMERG MED, V25, P328, DOI 10.1016/S0196-0644(95)70289-X; BATTERSBY JE, 1995, ANAL CHEM, V67, P447, DOI 10.1021/ac00098a600; BATTERSBY JE, 1994, INT J PEPT PROT RES, V44, P215; BECK LR, 1980, CONTRACEPT DELIV SYS, V1, P79; CANOVADAVIS E, 1990, INT J PEPT PROT RES, V35, P17; CLELAND JL, 1995, P INT S CONTR REL BI, V22, P143; CLELAND JL, 1995, P INT S CONTR REL BI, V22, P518; COHEN S, 1990, J AM CHEM SOC, V112, P7832, DOI 10.1021/ja00177a074; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; ECKHARDT BM, 1991, PHARM RES-DORDR, V8, P1360, DOI 10.1023/A:1015888704365; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; HUTCHINSON FG, 1985, BIOCHEM SOC T, V13, P520, DOI 10.1042/bst0130520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LAURSEN J, 1995, J CLIN ENDOCR METAB, V80, P2410; LI CH, 1986, ARCH BIOCHEM BIOPHYS, V245, P287, DOI 10.1016/0003-9861(86)90216-X; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MATHIOWITZ E, 1988, J APPL POLYM SCI, V35, P755, DOI 10.1002/app.1988.070350316; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; OGAWA Y, 1988, CHEM PHARM BULL, V36, P2576; OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095; Pearlman R, 1993, Pharm Biotechnol, V5, P1; PIHLAJAMAKI H, 1992, J BONE JOINT SURG BR, V74, P853, DOI 10.1302/0301-620X.74B6.1447246; PITT CG, 1990, INT J PHARMACEUT, V59, P173, DOI 10.1016/0378-5173(90)90108-G; PITT CG, 1980, CONTROLLED RELEASE B, P19; SANDERS LM, 1986, J PHARM SCI, V75, P356, DOI 10.1002/jps.2600750407; Schwendeman S.P., 1996, MICROPARTICULATE SYS, P1; SHAH SS, 1992, J CONTROL RELEASE, V18, P261, DOI 10.1016/0168-3659(92)90171-M; Steiner D., 1995, ENDOCRINOLOGY, P1296; TAUBER M, 1993, J CLIN ENDOCR METAB, V76, P1135, DOI 10.1210/jc.76.5.1135; TESHIMA G, 1992, J CHROMATOGR, V625, P207, DOI 10.1016/0021-9673(92)85204-7; TESHIMA G, 1991, J BIOL CHEM, V266, P13544; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; WILSON ME, 1991, J ENDOCRINOL, V130, P435, DOI 10.1677/joe.0.1300435; WINDE G, 1993, EUR J SURG, V159, P301; WISE DL, 1973, CONTRACEPTION, V8, P227; 1995, PHYSICIANS DESK REFE, P2502; [No title captured]	40	234	298	1	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					795	799		10.1038/nm0796-795	http://dx.doi.org/10.1038/nm0796-795			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673926				2022-12-27	WOS:A1996UU68000036
J	Goudreau, G; Carpenter, S; Beaulieu, N; Jolicoeur, P				Goudreau, G; Carpenter, S; Beaulieu, N; Jolicoeur, P			Vacuolar myelopathy in transgenic mice expressing human immunodeficiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; DEFICIENCY SYNDROME PATIENTS; SPINAL-CORD; HIV-1 INFECTION; AIDS PATIENTS; GLIAL-CELLS; OLIGODENDROCYTES; MACROPHAGES; ENCEPHALOPATHY; IDENTIFICATION	Vacuolar myelopathy is a common neurological complication in AIDS patients. The pathogenesis of this spinal cord white matter disease remains unclear and it is still debated whether infection of spinal cord with the human immunodeficiency virus type 1 (HIV-1) is causing the disease. We have generated transgenic mice expressing the entire HIV-1 genome under the regulation of an oligodendrocyte-specific promoter. These mice develop spinal cord vacuolar lesions similar to those found in AIDS patients. This animal model provides in vivo evidence linking the expression of HIV-1 proteins in oligodendrocytes to the spinal cord damage found in vacuolar myelopathy.	CLIN RES INST MONTREAL,MOLEC BIOL LAB,MONTREAL,PQ H2W 1R7,CANADA; MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA; MCGILL UNIV,DEPT EXPTL MED,MONTREAL,PQ H3G 1A4,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal; McGill University								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ALLINQUANT B, 1991, J CELL BIOL, V113, P393, DOI 10.1083/jcb.113.2.393; ARTIGAS J, 1990, PATHOL RES PRACT, V186, P228, DOI 10.1016/S0344-0338(11)80540-6; ARYA SK, 1986, P NATL ACAD SCI USA, V83, P2209, DOI 10.1073/pnas.83.7.2209; BAGASRA O, IN PRESS AIDS; BERGMANN M, 1993, PATHOL RES PRACT, V189, P58, DOI 10.1016/S0344-0338(11)80117-2; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUDKA H, 1988, J INFECT DIS, V157, P203, DOI 10.1093/infdis/157.1.203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; ESIRI MM, 1991, AIDS, V5, P1081, DOI 10.1097/00002030-199109000-00003; GOLDSTICK L, 1985, NEUROLOGY, V35, P103, DOI 10.1212/WNL.35.1.103; GOSZTONYI G, 1994, J NEUROPATH EXP NEUR, V53, P521, DOI 10.1097/00005072-199409000-00012; GRAFE MR, 1989, ANN NEUROL, V25, P561, DOI 10.1002/ana.410250606; GRAVEL C, 1993, J VIROL, V67, P6648, DOI 10.1128/JVI.67.11.6648-6658.1993; GREEN R, 1975, NATURE, V254, P148, DOI 10.1038/254148a0; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HENIN D, 1992, HUM PATHOL, V23, P1106, DOI 10.1016/0046-8177(92)90028-2; JOLICOEUR P, 1992, J VIROL, V66, P3904, DOI 10.1128/JVI.66.6.3904-3908.1992; KAMIN SS, 1991, HUM PATHOL, V22, P816, DOI 10.1016/0046-8177(91)90211-7; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PETITO CK, 1994, J NEUROPATH EXP NEUR, V53, P86, DOI 10.1097/00005072-199401000-00011; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; ROSENBLUM M, 1989, NEUROLOGY, V39, P892, DOI 10.1212/WNL.39.7.892; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sambrook J., 2002, MOL CLONING LAB MANU; SCALABRINO G, 1995, LAB INVEST, V72, P114; SHARER LR, 1988, J INFECT DIS, V157, P204, DOI 10.1093/infdis/157.1.204; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; THOMAS FP, 1994, J VIROL, V68, P7099, DOI 10.1128/JVI.68.11.7099-7107.1994; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TURNLEY AM, 1991, NATURE, V353, P566, DOI 10.1038/353566a0; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; VAZEUX R, 1987, AM J PATHOL, V126, P403; WEISER B, 1990, P NATL ACAD SCI USA, V87, P3997, DOI 10.1073/pnas.87.10.3997; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; YOSHIOKA T, 1991, MOL CELL BIOL, V11, P5479, DOI 10.1128/MCB.11.11.5479	47	37	37	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					655	661		10.1038/nm0696-655	http://dx.doi.org/10.1038/nm0696-655			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640556				2022-12-27	WOS:A1996UN69100033
J	Longbottom, C; Huysmans, MCDNJ; Pitts, NB; Los, P; Bruce, PG				Longbottom, C; Huysmans, MCDNJ; Pitts, NB; Los, P; Bruce, PG			Detection of dental decay and its extent using ac impedance spectroscopy	NATURE MEDICINE			English	Article							CARIES	Dental caries (decay), the most prevalent of diseases, represents a health problem of immense proportions(1). It principally affects posterior (back) teeth on occlusal (biting) and approximal (adjacent contacting) surfaces. Caries starts as a subsurface demineralization of enamel, may progress to the underlying dentine and, eventually, to cavitation of the surface. Accurate diagnosis before cavitation would permit targeted preventive treatment, thereby significantly improving dental health and reducing the need for expensive drilling and filling. Inaccessibility of caries initiation sites and recent changes in lesion morphology contribute to the relatively poor accuracy of conventional diagnostic methods(2). Among alternative techniques, measurements of electrical resistance(3-5) have shown the most promise. Here we described new experimental technique that demonstrates an outstanding 100% correlation between a.c. impedance measurements of whole teeth and the actual extent of approximal caries in vitro. Only relatively minor modifications should be required to transfer the technique to in vivo applications.	UNIV NIJMEGEN,INST DENT CLIN RES,TRIKON,DEPT CARIOL & ENDODONTOL,NIJMEGEN,NETHERLANDS; UNIV ST ANDREWS,SCH CHEM,ST ANDREWS KY16 9AJ,FIFE,SCOTLAND	Radboud University Nijmegen; University of St Andrews	Longbottom, C (corresponding author), UNIV DUNDEE,SCH DENT,DEPT DENT HLTH,PK PLACE,DUNDEE DD1 4HR,SCOTLAND.		Huysmans, Marie Charlotte/H-8052-2014; Bruce, Peter/AAB-2011-2019	Huysmans, Marie Charlotte/0000-0002-3036-7554; Bruce, Peter/0000-0001-6748-3084; Pitts, Nigel Berry/0000-0001-6184-4213				BRUCE PG, 1994, J ELECTROANAL CHEM, V367, P279, DOI 10.1016/0022-0728(94)03303-X; BRUCE PG, 1993, NATO ASI SER, P87; Bruce PG, 1987, POLYM ELECTROLYTE RE, V1, P237; JOHNSON NW, 1991, DENT CARIES MARKERS, P1; KAY EJ, 1991, THESIS U GLASGOW; LEVENKIND M, 1992, J DENT RES, V71, P426; LEVENKIND M, 1990, J DENT RES, V69, P1806; LONGBOTTOM C, 1992, THESIS U DUNDEE; LUSSI A, 1991, CARIES RES, V25, P296, DOI 10.1159/000261380; MAYUZUMI Y, 1964, J DENT RES, V43, P941; Pitts N B, 1992, Dent Update, V19, P37; PLEPER K, 1990, DTSCH ZAHNARTZI Z, V45, P721; RICKETTS DNJ, 1995, BRIT DENT J, V178, P11, DOI 10.1038/sj.bdj.4808636; RUSSELL M, 1993, CARIES RES, V27, P65, DOI 10.1159/000261518; SCHOLBERG HPF, 1984, ARCH ORAL BIOL, V29, P965, DOI 10.1016/0003-9969(84)90142-0; WHITE GE, 1978, J DENT RES, V57, P195, DOI 10.1177/00220345780570020801	16	48	48	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					235	237		10.1038/nm0296-235	http://dx.doi.org/10.1038/nm0296-235			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574971				2022-12-27	WOS:A1996TU06000046
J	Allan, JS				Allan, JS			Xenotransplantation at a crossroads: Prevention versus progress	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY VIRUSES; PARTICLES				Allan, JS (corresponding author), SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,7620 NW LOOP 410 & MIL DR,SAN ANTONIO,TX 78228, USA.							ALLAN J, 1995, ASM NEWS, V61, P442; Allan Jonathan S., 1995, ILAR J, V37, P37; ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; EBERLE R, 1995, INFECT AGENT DIS, V4, P55; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; FLUGEL RM, 1991, J ACQ IMMUN DEF SYND, V4, P739; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; KALTER SS, 1973, SCIENCE, V179, P1332, DOI 10.1126/science.179.4080.1332; KORALNIK IJ, 1994, J VIROL, V68, P2693, DOI 10.1128/JVI.68.4.2693-2707.1994; LERCHE NW, 1994, LAB ANIM SCI, V44, P217; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MONE J, 1992, AIDS RES HUM RETROV, V8, P1653, DOI 10.1089/aid.1992.8.1653; MORSE SS, 1990, J INFECT DIS, V162, P1, DOI 10.1093/infdis/162.1.1; MURPHY FA, 1994, ADV VIRUS RES, V4, P1; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; THOMPSON C, 1995, LANCET, V346, P369; WARD JA, 1994, LAB ANIM SCI, V44, P222	19	62	63	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					18	21		10.1038/nm0196-18	http://dx.doi.org/10.1038/nm0196-18			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564824				2022-12-27	WOS:A1996TP57900025
J	Lacronique, V; Mignon, A; Fabre, M; Viollet, B; Rouquet, N; Molina, T; Porteu, A; Henrion, A; Bouscary, D; Varlet, P; Joulin, V; Kahn, A				Lacronique, V; Mignon, A; Fabre, M; Viollet, B; Rouquet, N; Molina, T; Porteu, A; Henrion, A; Bouscary, D; Varlet, P; Joulin, V; Kahn, A			Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice	NATURE MEDICINE			English	Article							HUMAN FOLLICULAR LYMPHOMA; CELL-DEATH; GENE; INVOLVEMENT; CDNA	Fas is an apoptosis-signaling cell surface antigen that has been shown to trigger cell death upon specific ligand or antibody binding. Treatment of mice with an anti-fas antibody causes fulminant hepatic failure due to massive apoptosis. To test a putative protective effect of the anti-apoptotic Bcl-2 protein, transgenic mice were generated to express the human bcl-2 gene product in hepatocytes. Early onset of massive hepatic apoptosis leading to death was observed in all nontransgenic mice treated with an anti-Fas antibody. By contrast, hepatic apoptosis was delayed and dramatically reduced in transgenic animals, yielding a 93% survival rate. These results demonstrate that Eel-2 is able to protect from in vivo Fas-mediated cytotoxicity, and could be of significance for preventing fulminant hepatic failure due to viral hepatitis in humans.	UNIV PARIS 05,INST COCHIN GENET MOLEC,U129 INSERM,F-75014 PARIS,FRANCE; CHU COCHIN PORT ROYAL,SERV REANIMAT MED,F-75014 PARIS,FRANCE; CHU BICETRE,SERC ANAT & CYTOL PATHOL,F-94270 LE KREMLIN BICETR,FRANCE; UNIV PARIS 05,INST COCHIN GENET MOLEC,U380 INSERM,F-75014 PARIS,FRANCE; UNIV PARIS 05,INST COCHIN GENET MOLEC,U363 INSERM,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Penard-Lacronique, Virginie/E-5729-2016; Viollet, Benoit/O-6927-2017; Molina, Thierry/ABA-5214-2020; Caude, Alexandra A Henrion/I-2778-2016; Viollet, Benoit/N-2397-2019; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Viollet, Benoit/0000-0002-0121-0224; Molina, Thierry/0000-0002-3929-9754; Caude, Alexandra A Henrion/0000-0002-8170-2260; Viollet, Benoit/0000-0002-0121-0224; Penard-Lacronique, Virginie/0000-0001-9435-7331; JOULIN, Virginie/0000-0003-1091-7819; Bouscary, Didier/0000-0003-3654-5064				ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU VK, 1995, J IMMUNOL, V154, P2023; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LACRONIQUE V, 1995, J BIOL CHEM, V270, P14989, DOI 10.1074/jbc.270.25.14989; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TAKAHASHI H, 1995, P NATL ACAD SCI USA, V92, P1470, DOI 10.1073/pnas.92.5.1470; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHAO M, 1994, HISTOPATHOLOGY, V25, P237, DOI 10.1111/j.1365-2559.1994.tb01323.x; ZORNIG M, 1995, ONCOGENE, V10, P2397	42	351	358	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					80	86		10.1038/nm0196-80	http://dx.doi.org/10.1038/nm0196-80			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564847				2022-12-27	WOS:A1996TP57900041
J	CRANE, GM; ISHAUG, SL; MIKOS, AG				CRANE, GM; ISHAUG, SL; MIKOS, AG			BONE TISSUE ENGINEERING	NATURE MEDICINE			English	Editorial Material							MARROW				CRANE, GM (corresponding author), RICE UNIV,INST BIOSCI & BIOENGN,COX LAB BIOMED ENGN,POB 1892,HOUSTON,TX 77251, USA.		Crane, Genevieve M/AAK-9224-2020; Cartmell, Sarah/J-8506-2012	Crane, Genevieve M/0000-0001-9274-0214; Cartmell, Sarah/0000-0001-6864-0846				CRANE GM, 1995, ANN BIOMED ENG, V23, pS45; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; HOLLINGER J, 1989, J ORAL MAXIL SURG, V47, P1182, DOI 10.1016/0278-2391(89)90009-8; ISHAUG SL, 1994, J BIOMED MATER RES, V28, P1445, DOI 10.1002/jbm.820281210; LEE SC, 1994, J BIOMED MATER RES, V28, P1149, DOI 10.1002/jbm.820281005; OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202; SCHOETERS G, 1992, CELL PROLIFERAT, V25, P587, DOI 10.1111/j.1365-2184.1992.tb01462.x; THMOPSON RC, 1995, ADV POLYM SCI, V122, P245; VACANTI CA, 1993, TRANSPLANT P, V25, P10196; YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005; Yaszemski M J, 1995, Tissue Eng, V1, P41, DOI 10.1089/ten.1995.1.41	11	206	251	2	60	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1322	1324		10.1038/nm1295-1322	http://dx.doi.org/10.1038/nm1295-1322			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489417				2022-12-27	WOS:A1995TH78600049
J	BLALOCK, JE				BLALOCK, JE			GENETIC ORIGINS OF PROTEIN SHAPE AND INTERACTION RULES	NATURE MEDICINE			English	Editorial Material							MESSENGER-RNA; AMINO-ACIDS; COMPLEMENTARY; PEPTIDES; BINDING; SENSE				BLALOCK, JE (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,UAB STN,BIRMINGHAM,AL 35294, USA.			Blalock, J. Edwin/0000-0001-5303-8123				BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BLALOCK JE, 1994, SCIENCE, V265, P1511, DOI 10.1126/science.265.5178.1511-a; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRANDEN C, 1991, INTRO PROTEIN STRUCT, V11; CLARKE BL, 1990, P NATL ACAD SCI USA, V87, P9708, DOI 10.1073/pnas.87.24.9708; Curto E V, 1994, Immunomethods, V5, P98, DOI 10.1006/immu.1994.1043; DRAPER KG, 1989, BIOCHEM BIOPH RES CO, V163, P466, DOI 10.1016/0006-291X(89)92159-1; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FASSINA G, 1992, ARCH BIOCHEM BIOPHYS, V296, P137, DOI 10.1016/0003-9861(92)90555-B; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; JARPE MA, 1994, PEPTIDES DESIGN SYNT, P165; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; McGuigan J E, 1994, Immunomethods, V5, P158, DOI 10.1006/immu.1994.1050; PALLA E, 1993, J BIOL CHEM, V268, P13486; Weigent D A, 1994, Immunomethods, V5, P91, DOI 10.1006/immu.1994.1042; ZHOU SR, 1994, CLIN IMMUNOL IMMUNOP, V70, P251, DOI 10.1006/clin.1994.1037	20	73	78	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					876	878		10.1038/nm0995-876	http://dx.doi.org/10.1038/nm0995-876			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585206				2022-12-27	WOS:A1995RT30300034
J	MAY, RM				MAY, RM			THE RISE AND FALL AND RISE OF TUBERCULOSIS	NATURE MEDICINE			English	Editorial Material								A mathematical approach to the transmission dynamics of tuberculosis offers a			MAY, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.							ANDERSON R M, 1991; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; MAY RM, 1994, HLTH ENV, P150; MCKEOWN T, 1979, ROLE MODERN MED DREA	4	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					752	752		10.1038/nm0895-752	http://dx.doi.org/10.1038/nm0895-752			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585175				2022-12-27	WOS:A1995RM63500029
J	WESSON, DM; KROGSTAD, DJ				WESSON, DM; KROGSTAD, DJ			TRANSFECTION AND MALARIA	NATURE MEDICINE			English	Editorial Material							GENE; DNA; INTEGRATION; EXPRESSION	The introduction of novel genes into mosquitoes and malaria parasites is now feasible, raising hopes for an effective attack on malaria.			WESSON, DM (corresponding author), TULANE UNIV,SCH PUBL HLTH & TROP MED,DEPT TROP MED,NEW ORLEANS,LA 70112, USA.							BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BRAIG HR, 1994, NATURE, V367, P453, DOI 10.1038/367453a0; COLLINS FH, 1995, ANNU REV ENTOMOL, V40, P195, DOI 10.1146/annurev.en.40.010195.001211; FALLON AM, 1991, NATURE, V352, P828, DOI 10.1038/352828a0; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; MORRIS AC, 1995, AM J TROP MED HYG, V52, P456, DOI 10.4269/ajtmh.1995.52.456; Robertson H.M., 1993, Insect Molecular Biology, V2, P125, DOI 10.1111/j.1365-2583.1993.tb00132.x; VADHEIM KL, 1994, MICROB PATHOGENESIS, V17, P339, DOI 10.1006/mpat.1994.1079; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	16	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					745	747		10.1038/nm0895-745	http://dx.doi.org/10.1038/nm0895-745			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585172				2022-12-27	WOS:A1995RM63500026
J	KATSUMATA, M; OKUDAIRA, T; SAMANTA, A; CLARK, DP; DREBIN, JA; JOLICOEUR, P; GREENE, MI				KATSUMATA, M; OKUDAIRA, T; SAMANTA, A; CLARK, DP; DREBIN, JA; JOLICOEUR, P; GREENE, MI			PREVENTION OF BREAST-TUMOR DEVELOPMENT IN-VIVO BY DOWN-REGULATION OF THE P185(NEU) RECEPTOR	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; NEU ONCOGENE PRODUCT; MONOCLONAL-ANTIBODIES; MAMMARY-TUMORS; EFFECTS INVIVO; EXPRESSION; CANCER; PROTOONCOGENE; CELLS; P185NEU	Certain strains of transgenic mice that express the rat neu oncogene (neuT) in mammary epithelial cells develop breast tumours at an average of 44 weeks of age. in this study, intraperitoneal injection of a monoclonal anti-receptor antibody specific for the rat neuT oncogene product dramatically affected tumour development in these transgenic mice in a dose-dependent manner. A significant proportion (50%) of mice, when injected with anti-receptor antibodies, did not develop tumours even after 90 weeks of age. The phosphotyrosine levels of the membrane fraction of breast tissues in the anti-receptor antibody-treated mice were almost completely abolished when a higher dose of antibodies was used. This study demonstrates, for the first time, that immunologic manipulation of an oncogene product can effectively prevent the development of tumours in a rodent transgenic model.	WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA; CLIN RES INST MONTREAL, MOLEC BIOL LAB, MONTREAL, PQ H2W 1R7, CANADA	Washington University (WUSTL); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	KATSUMATA, M (corresponding author), UNIV PENN, DEPT PATHOL & LAB MED, JOHN MORGAN BLDG, ROOM 288, PHILADELPHIA, PA 19104 USA.							BACUS SS, 1992, CANCER RES, V52, P2580; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAZIN VR, 1992, ONCOGENE, V7, P1859; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEPOTTER CR, 1989, HISTOPATHOLOGY, V15, P351; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1988, ONCOGENE, V2, P387; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LESLIE KO, 1992, PATHOL ANNU, V27, P321; MAGUIRE HC, 1990, PATHOBIOLOGY, V58, P297; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MOOI WJ, 1992, EUR J CANCER, V28A, P623, DOI 10.1016/S0959-8049(05)80112-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRESS MF, 1990, ONCOGENE, V5, P953; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TARAKHOVSKY AM, 1990, ONCOGENE, V5, P405; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1990, ONCOGENE, V5, P489; WEINER DB, 1989, ONCOGENE, V4, P1175; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YU DH, 1991, ONCOGENE, V6, P1991; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503	40	103	113	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1995	1	7					644	648		10.1038/nm0795-644	http://dx.doi.org/10.1038/nm0795-644			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585144				2022-12-27	WOS:A1995RQ06600037
J	TIIHONEN, J; KUIKKA, J; BERGSTROM, K; HAKOLA, P; KARHU, J; RYYNANEN, OP; FOHR, J				TIIHONEN, J; KUIKKA, J; BERGSTROM, K; HAKOLA, P; KARHU, J; RYYNANEN, OP; FOHR, J			ALTERED STRIATAL DOPAMINE REUPTAKE SITE DENSITIES IN HABITUALLY VIOLENT AND NON-VIOLENT ALCOHOLICS	NATURE MEDICINE			English	Article							D2-DOPAMINE RECEPTOR GENE; HUMAN BRAIN; TRANSPORTERS; ABUSE; VULNERABILITY; STIMULATION; ASSOCIATION; RELEASE; NEURONS; ALLELE	Animal studies suggest that development of substance dependence is associated with dopaminergic activity in striatum and the limbic system. Several genetic studies indicate that allele A1 is associated with both D-2 receptor density and alcoholism, although these findings have remained controversial. We studied striatal dopamine (DA) re-uptake site densities in 48 subjects (19 healthy controls, 19 habitually impulsive violent alcoholics, acid 10 non-violent alcoholics) with single photon emission computed tomography (SPECT) using iodine-123-labelled 2 beta-carbomethoxy-3 beta(4-iodophenyl)tropane (beta-CIT) as a tracer. Blind quantitative analysis revealed that the striatal DA transporter density was markedly lower in non-violent alcoholics than in healthy controls (P < 0.001), while violent alcoholics had slightly higher DA transporter densities than controls (P < 0.10). The results indicate that both types of alcoholics have alterations in striatal dopaminergic system, though these occur in opposite directions.	UNIV KUOPIO,NIUVANNIEMI HOSP,DEPT CLIN PHYSIOL,SF-70240 KUOPIO,FINLAND; UNIV KUOPIO,NIUVANNIEMI HOSP,DEPT NEUROPHYSIOL,SF-70240 KUOPIO,FINLAND	University of Eastern Finland; University of Eastern Finland	TIIHONEN, J (corresponding author), UNIV KUOPIO,NIUVANNIEMI HOSP,DEPT FORENS PSYCHIAT,SF-70240 KUOPIO,FINLAND.		Tiihonen, Jari/G-3078-2012	Tiihonen, Jari/0000-0002-0400-6798				BERGSTROM KA, 1994, J NUCL BIOL MED, V37, P1425; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BRUCKE T, 1993, J NEURAL TRANSM-GEN, V94, P137, DOI 10.1007/BF01245007; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; DYR W, 1993, ALCOHOL, V10, P207, DOI 10.1016/0741-8329(93)90037-O; FARDE L, 1994, SYNAPSE, V16, P93, DOI 10.1002/syn.890160203; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; GOLDMAN D, 1993, ACTA PSYCHIAT SCAND, V86, P351; HIETALA J, 1994, PSYCHOPHARMACOLOGY, V116, P285, DOI 10.1007/BF02245330; INNIS RB, 1993, P NATL ACAD SCI USA, V90, P11965, DOI 10.1073/pnas.90.24.11965; KALIVAS PW, 1993, BRAIN RES REV, V18, P75, DOI 10.1016/0165-0173(93)90008-N; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KUIKKA JT, 1994, EUR J NUCL MED, V21, P53; KUIKKA JT, 1993, NUCL MED COMMUN, V14, P490, DOI 10.1097/00006231-199306000-00013; KUIKKA JT, 1993, EUR J NUCL MED, V20, P783; LYCKE E, 1969, EXPERIENTIA, V25, P951, DOI 10.1007/BF01898084; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P643; PAIVARINTA P, 1993, THESIS ALKO; ROSSETTI ZL, 1991, EUR J PHARMACOL, V201, P243, DOI 10.1016/0014-2999(91)90353-R; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SORENSEN SM, 1992, J PHARMACOL EXP THER, V260, P872; SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; YOSHIMOTO K, 1991, ALCOHOL, V9, P17	31	179	180	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					654	657		10.1038/nm0795-654	http://dx.doi.org/10.1038/nm0795-654			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585146				2022-12-27	WOS:A1995RQ06600039
J	MELDOLESI, J				MELDOLESI, J			BRINGING CELL-GROWTH RESEARCH TOGETHER	NATURE MEDICINE			English	Editorial Material							PHOSPHOLIPASE-C; STIMULATION		SCI INST SAN RAFFAELE,DIBIT,CTR CYTOPHARMACOL,I-20132 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	MELDOLESI, J (corresponding author), SCI INST SAN RAFFAELE,DIBIT,CTR CNR,I-20132 MILAN,ITALY.							BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P177; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; QIAN NX, 1994, J BIOL CHEM, V269, P17417; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; WALDRON RT, 1994, J BIOL CHEM, V269, P11927	13	7	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					512	513		10.1038/nm0695-512	http://dx.doi.org/10.1038/nm0695-512			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585109				2022-12-27	WOS:A1995RN10100026
J	ROME, LH				ROME, LH			MULTIDRUG-RESISTANCE - LOCKED IN THE VAULT	NATURE MEDICINE			English	Editorial Material							RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; CONTAIN				ROME, LH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.		Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063				CHUGANI DC, 1993, J CELL SCI, V106, P23; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578	5	3	9	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					527	527		10.1038/nm0695-527	http://dx.doi.org/10.1038/nm0695-527			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585117				2022-12-27	WOS:A1995RN10100034
J	LUNDBERG, JON; FARKASSZALLASI, T; WEITZBERG, E; RINDER, J; LIDHOLM, J; ANGGARD, A; HOKFELT, T; LUNDBERG, JM; ALVING, K				LUNDBERG, JON; FARKASSZALLASI, T; WEITZBERG, E; RINDER, J; LIDHOLM, J; ANGGARD, A; HOKFELT, T; LUNDBERG, JM; ALVING, K			HIGH NITRIC-OXIDE PRODUCTION IN HUMAN PARANASAL SINUSES	NATURE MEDICINE			English	Article							SYNTHASE; COLITIS	Nitric oxide (NO) is present in air derived from the nasal airways. However, the precise origin and physiological role of airway-derived NO ale unknown. We report that NO in humans is produced by epithelial cells in the paranasal sinuses and is present in sinus air tn very high concentrations, close to the highest permissible atmospheric pollution levels. In immunohistochemical and mRNA in situ hybridization studies we show that an NO synthase most closely resembling the inducible isoform is constitutively expressed apically in sinus epithelium. In contrast, only weak NO synthase activity was found in the epithelium of the nasal cavity. Our findings, together with the well-known bacteriostatic effects of NO, suggest a role for NO in the maintenance of sterility in the human paranasal sinuses.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT OTORHINOLARYNGOL, DEPT ANESTHESIOL & INTENS CARE, S-17176 STOCKHOLM, SWEDEN; PHARMACIA DIAGNOST AB, S-75182 UPPSALA, SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Pfizer; Pharmacia Corporation	LUNDBERG, JON (corresponding author), KAROLINSKA INST, DEPT PHYSIOL & PHARMACOL, S-17177 STOCKHOLM, SWEDEN.		Alving, Kjell/M-4579-2014	Alving, Kjell/0000-0003-0784-0443; Lundberg, Jon/0000-0002-0174-5210; Lidholm, Jonas/0000-0002-7779-3411				AFZELIUS B A, 1976, Science (Washington D C), V193, P317; ALVING K, 1993, EUR RESPIR J, V6, P1368; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BJORKWALL T, 1950, BACTERIOLOGICAL EXAM; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; KNOPS JL, 1993, OTOLARYNG CLIN N AM, V26, P517; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1994, LANCET, V344, P1673, DOI 10.1016/S0140-6736(94)90460-X; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PUYBASSET L, 1994, BRIT J ANAESTH, V72, P56; RACHMILEWITZ D, 1993, GASTROENTEROLOGY, V105, P1681, DOI 10.1016/0016-5085(93)91063-N; SHECHTMAN FG, 1993, OTOLARYNG CLIN N AM, V26, P509; Stein JJ, 1994, INTERNAL MED; 1988, MMWR-MORBID MORTAL W, V37, pS7	23	480	501	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1995	1	4					370	373		10.1038/nm0495-370	http://dx.doi.org/10.1038/nm0495-370			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585069				2022-12-27	WOS:A1995RN09800035
J	PYPER, JM				PYPER, JM			DOES BORNA-DISEASE VIRUS INFECT HUMANS	NATURE MEDICINE			English	Editorial Material							RATS; ANTIBODIES; DISORDERS				PYPER, JM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT COMPARAT MED,BALTIMORE,MD 21205, USA.							AMSTERDAM JD, 1985, ARCH GEN PSYCHIAT, V42, P1093; BODE L, 1994, LANCET, V343, P297, DOI 10.1016/S0140-6736(94)91147-9; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; DITTRICH W, 1989, BIOL PSYCHIAT, V26, P818, DOI 10.1016/0006-3223(89)90122-4; NARAYAN O, 1983, J INFECT DIS, V148, P305, DOI 10.1093/infdis/148.2.305; ROTT R, 1991, ARCH VIROL, V118, P143, DOI 10.1007/BF01314025; ROTT R, 1985, SCIENCE, V228, P755, DOI 10.1126/science.3922055; SIERRAHONIGMANN AM, 1993, J NEUROIMMUNOL, V45, P31, DOI 10.1016/0165-5728(93)90160-Z; SPRANKEL H, 1978, MED MICROBIOL IMMUN, V165, P1, DOI 10.1007/BF02121228; VANDEWOUDE S, 1990, SCIENCE, V250, P1278, DOI 10.1126/science.2244211	10	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					209	210		10.1038/nm0395-209	http://dx.doi.org/10.1038/nm0395-209			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585033				2022-12-27	WOS:A1995QX55900023
J	Kumar, V; Sercarz, E				Kumar, V; Sercarz, E			Genetic vaccination: The advantages of going naked	NATURE MEDICINE			English	Editorial Material							ENCEPHALOMYELITIS				Kumar, V (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095, USA.							BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; KUMAR V, 1993, J EXP MED, V178, P909, DOI 10.1084/jem.178.3.909; KUMAR V, IN PRESS J NEUROSCI; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Pisetsky DS, 1996, J IMMUNOL, V156, P421; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899	11	65	67	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					857	859		10.1038/nm0896-857	http://dx.doi.org/10.1038/nm0896-857			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705850				2022-12-27	WOS:A1996UZ80400027
J	Shibata, T; Nagano, T				Shibata, T; Nagano, T			Applying very high resolution microfocus X-ray CT and 3-D reconstruction to the human auditory apparatus	NATURE MEDICINE			English	Article							TOMOGRAPHY	Conventional high-resolution X-ray computed tomography (XCT) is an important medical technique because it provides sectional images (tomograms) of internal structures without destroying the specimen. However, it is difficult to observe and to analyze fine structures less than a few cubic millimeters in size because of its low spatial resolution of 0.4 mm. Overcoming this problem would not only enable visualization of human anatomical structures in living subjects by means of computer images but would make it possible to obtain the equivalent of microscopic images by XCT without making microscopic sections of biopsy material, which would allow the examination of the entire body and detection of focal lesions at an early stage. Bonse et al. and Kinney et al. studied absorption contrast microtomography by using synchrotron radiation(1-3) and achieved 8-mu m spatial resolution in human cancellous bone(1). Recently, Momose et al. reported examining the soft tissue of cancerous rabbit liver by a modification of the phase-contrast technique using synchrotron radiation with a spatial resolution of 30 mu m (ref. 4). However, the equipment for synchrotron radiation requires a great deal of space and is very expensive. Aoki et al., on a different tack, reported microtomography of frog embryos by using a conventional laboratory microfocus X-ray source with a spot size of about 2 mu m (ref. 5). As no human tomographic studies by superresolution microfocus XCT (MFXCT) using a normal open-type X-ray source have been reported, we tried using MFXCT with a maximum experimental spatial resolution of 2.5 mu m, especially designed for industrial use, on the auditory ossicles(6) of a human fetus, the smallest and lightest bones in the skeletal system. No XCT studies of fetal auditory ossicles have been reported to date. The fine tomograms with three-dimensional reconstructions obtained showed the existence of an apparently previously undescribed joint between the tympanic ring and the anterior process of the malleus. We hope the early development of this MFXCT for clinical use will make a great contribution to medicine.			Shibata, T (corresponding author), TOKYO WOMENS MED COLL,DEPT ANAT,SHINJUKU KU,KAWADACHO 8-1,TOKYO 162,JAPAN.							AOKI S, 1994, JPN J APPL PHYS 2, V33, pL556, DOI 10.1143/JJAP.33.L556; BARRY JA, 1966, MORRIS HUMAN ANATOMY, P1186; BONSE U, 1994, BONE MINER, V25, P25, DOI 10.1016/S0169-6009(08)80205-X; BRACEWELL RN, 1967, ASTROPHYS J, V150, P427, DOI 10.1086/149346; HINRACHSEN KV, 1990, HUMANEMBRYOLOGIE LEH, P509; KINNEY JH, 1994, NUCL INSTRUM METH A, V347, P480, DOI 10.1016/0168-9002(94)91932-1; KINNEY JH, 1986, 26 SOC PHOT SCI ENG; KUBIK S, 1987, RAUBER KOPSCH ANATOM, V3, P588; Momose A, 1996, NAT MED, V2, P473, DOI 10.1038/nm0496-473; SATO Y, 1956, J OTOLARYNGOL JPN, V59, P953; SLAVKIN HC, 1979, DEV CRANIOFACIAL BIO, P373; SWARTZ JD, 1983, RADIOLOGY, V148, P449, DOI 10.1148/radiology.148.2.6867341; VESALIUS A, 1843, HUMANI CORPORIS FABR	13	31	31	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					933	935		10.1038/nm0896-933	http://dx.doi.org/10.1038/nm0896-933			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705866				2022-12-27	WOS:A1996UZ80400043
J	Fuchs, E				Fuchs, E			Clues to B-cell memory	NATURE MEDICINE			English	Editorial Material											Fuchs, E (corresponding author), JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21287, USA.							Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; VERRALL M, 1994, NATURE, V370, P6, DOI 10.1038/370006a0; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	13	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					743	744		10.1038/nm0796-743	http://dx.doi.org/10.1038/nm0796-743			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673914				2022-12-27	WOS:A1996UU68000024
J	David, K; Ollert, MW; Juhl, H; Vollmert, C; Erttmann, R; Vogel, CW; Bredehorst, R				David, K; Ollert, MW; Juhl, H; Vollmert, C; Erttmann, R; Vogel, CW; Bredehorst, R			Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans	NATURE MEDICINE			English	Article							ANTIGANGLIOSIDE GD2 ANTIBODY; NEURO-BLASTOMA; MEDIATED LYSIS; CELLS	Neuroblastoma (NB) is the most common extracranial solid neoplasm of infancy and is associated with very poor prognosis in patients with advanced disease(1,2). Current therapeutic regimens of advanced NE which combine surgical resection with radiation therapy and/or chemotherapy brought some improvements, but in a significant number of patients, a cure remains elusive(3). Normal human serum of healthy adults contains natural IgM antibodies that are cytotoxic for human NE cells. In this study, we evaluated the anti-NB activity of these natural IgM antibodies in nude rats bearing solid human NE tumors. A single intravenous (i.v.) injection of purified cytotoxic IgM led to uptake of IgM into the tumors with massive perivascular complement activation and accumulation of neutrophil granulocytes after 24 hours. Five consecutive i.v. injections of purified cytotoxic IgM into NB-bearing animals resulted in complete growth arrest of even large and established solid tumors which lasted for several weeks after discontinuation of the injections, whereas tumors of control animals continued to grow exponentially during the observation period. These studies suggest that natural anti-NB IgM may have a potential as a novel therapeutic modality in the treatment of human NE.	CHRISTIAN ALBRECHTS UNIV KIEL,DEPT SURG,D-24105 KIEL,GERMANY; UNIV HAMBURG,HOSP EPPENDORF,DEPT PEDIAT ONCOL,D-20246 HAMBURG,GERMANY	University of Kiel; University of Hamburg	David, K (corresponding author), UNIV HAMBURG,DEPT BIOCHEM & MOLEC BIOL,MARTIN LUTHER KING PL 6,D-20146 HAMBURG,GERMANY.			Ollert, Markus W./0000-0002-8055-0103				BARKER E, 1993, CANCER RES, V53, P362; BARKER E, 1991, CANCER RES, V51, P144; BRUCHELT G, 1989, J BIOLUM CHEMILUM, V3, P93, DOI 10.1002/bio.1170030212; BURCK HC, 1988, HISTOLOGISCHE TECHNI, P104; DIXON FJ, 1958, ARCH PATHOL, V65, P18; HANDGRETINGER R, 1993, HUMAN NEUROBLASTOMA, P24; JUHL H, 1995, CANCER RES, V55, pS5749; KUSHNER BH, 1989, BLOOD, V73, P1936; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUJOO K, 1989, CANCER RES, V49, P2857; OLLERT MW, IN PRESS P NATL ACAD; Ouchterlony O., 1978, HDB EXPT IMMUNOLOGY; Philip T, 1989, NEW DIRECTIONS CANCE, P605; PINKERTON CR, 1993, HUMAN NEUROBLASTOMA, P3; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SIEGEL SE, 1986, ONCOLOGY, P1211; VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0	17	27	30	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					686	689		10.1038/nm0696-686	http://dx.doi.org/10.1038/nm0696-686			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640561				2022-12-27	WOS:A1996UN69100038
J	Breton, S; Smith, PJS; Lui, B; Brown, D				Breton, S; Smith, PJS; Lui, B; Brown, D			Acidification of the male reproductive tract by a proton pumping (H+)-ATPase	NATURE MEDICINE			English	Article							ANHYDRASE-II DEFICIENCY; CARBONIC-ANHYDRASE; HISTOCHEMICAL-LOCALIZATION; SPERM MOTILITY; RAT EPIDIDYMIS; H+-ATPASE; PH; TESTIS; KIDNEY; CELLS	An acidic luminal pH (ref. 1-3) is involved in sperm maturation, and in maintaining sperm in an immotile state in the epididymis and vas deferens(2,4-6). Neutralization by prostatic fluid is one of a complex series of events that triggers sperm motility(2,7,8). Failure of the acidification mechanism might, therefore, result in poor sperm maturation, premature motility and infertility. We have shown that a vacuolar (H+)-ATPase is expressed at high levels on the luminal plasma membrane of specialized cells in the epididymis(9), which closely resemble acid-secreting kidney intercalated cells(10.11). We now show that similar cells are also present in the vas deferens, and that a bafilomycin-sensitive proton flux can be detected using a noninvasive proton-selective vibrating probe. Up to 80% of the net proton secretion in the vas deferens is inhibited by bafilomycin, consistent with a major role of a vacuolar-type (H+)-ATPase in this process. This acidification mechanism is a potential target for novel strategies aimed at modulating the acidification capacity of parts of the male reproductive tract and, therefore, in regulating male fertility.	HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, RENAL UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02129 USA; MARINE BIOL LAB, NATL VIBRATING PROBE FACIL, WOODS HOLE, MA 02543 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Marine Biological Laboratory - Woods Hole				Smith, Peter/0000-0003-4400-6853	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042956] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42956] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOTT TS, 1984, BIOL REPROD, V30, P926, DOI 10.1095/biolreprod30.4.926; ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; AU CL, 1980, J PHYSIOL-LONDON, V309, P419, DOI 10.1113/jphysiol.1980.sp013517; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; BROWN D, 1992, AM J PHYSIOL, V263, pC913, DOI 10.1152/ajpcell.1992.263.4.C913; CALFISCH CR, 1990, AM J PHYSIOL, V258, pE143; CARR DW, 1989, BIOL REPROD, V41, P907, DOI 10.1095/biolreprod41.5.907; CARR DW, 1985, BIOL REPROD, V33, P588, DOI 10.1095/biolreprod33.3.588; COHEN EP, 1992, J AM SOC NEPHROL, V3, P264; COHEN JP, 1976, BIOL REPROD, V14, P339, DOI 10.1095/biolreprod14.3.339; EKSTEDT E, 1991, ACTA ANAT, V141, P257, DOI 10.1159/000147131; EKSTEDT E, 1992, ACTA ANAT, V143, P258, DOI 10.1159/000147258; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; KAUNISTO K, 1995, BIOL REPROD, V52, P1350, DOI 10.1095/biolreprod52.6.1350; LEVINE N, 1978, J REPROD FERTIL, V52, P333, DOI 10.1530/jrf.0.0520333; LEWIS SE, 1988, P NATL ACAD SCI USA, V85, P1962, DOI 10.1073/pnas.85.6.1962; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SLY WS, 1985, PEDIATR RES, V19, P1033, DOI 10.1203/00006450-198510000-00017; SMITH PJS, 1994, METHOD CELL BIOL, V40, P115; STEINMETZ PR, 1986, AM J PHYSIOL, V251, pF173, DOI 10.1152/ajprenal.1986.251.2.F173; USSELMAN MC, 1983, BIOL REPROD, V29, P1241, DOI 10.1095/biolreprod29.5.1241; WONG PYD, 1980, PFLUG ARCH EUR J PHY, V387, P61, DOI 10.1007/BF00580845	23	215	219	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					470	472		10.1038/nm0496-470	http://dx.doi.org/10.1038/nm0496-470			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597961				2022-12-27	WOS:A1996UD31400053
J	Hill, AVS				Hill, AVS			HIV and HLA: Confusion or complexity?	NATURE MEDICINE			English	Editorial Material							INFECTION		UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics			HILL, Adrian V>S>/C-1306-2008					CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; Davenport MP, 1996, MOL MED TODAY, V2, P38, DOI 10.1016/1357-4310(96)88757-0; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; SMERALDI RS, 1986, LANCET, V2, P1187; STEEL CM, 1988, LANCET, V1, P1185; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	10	30	30	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					395	396		10.1038/nm0496-395	http://dx.doi.org/10.1038/nm0496-395			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597943				2022-12-27	WOS:A1996UD31400035
J	Romer, J; Bugge, TH; Pyke, C; Lund, LR; Flick, MJ; Degen, JL; Dano, K				Romer, J; Bugge, TH; Pyke, C; Lund, LR; Flick, MJ; Degen, JL; Dano, K			Impaired wound healing in mice with a disrupted plasminogen gene	NATURE MEDICINE			English	Article							UROKINASE-TYPE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; ACTIVATOR; RECEPTOR; TISSUE; EXPRESSION; CANCER; KERATINOCYTES; LOCALIZATION	Activation of plasminogen (Plg) has been proposed to play a role in proteolytic degradation of extracellular matrices in tissue remodeling events, including wound healing. However, there has been no definitive proof of involvement of Plg in such processes. We now report that healing of skin wounds is severely impaired in mice made deficient in plg by targeted gene disruption. The results demonstrate that plg is required for normal repair of skin wounds in mice and support the assumption that it also plays a central role in other disease processes involving extracellular matrix degradation, such as cancer invasion.	CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of California System; University of California San Francisco	Romer, J (corresponding author), RIGSHOSP,FINSEN LAB,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN O,DENMARK.							BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; HEIPLE JM, 1986, J EXP MED, V164, P826, DOI 10.1084/jem.164.3.826; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; NY T, 1985, ENDOCRINOLOGY, V116, P1666, DOI 10.1210/endo-116-4-1666; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, AM J PATHOL, V138, P1059; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALO T, 1994, LAB INVEST, V70, P176; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	40	475	488	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					287	292		10.1038/nm0396-287	http://dx.doi.org/10.1038/nm0396-287			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612226				2022-12-27	WOS:A1996TY64000036
J	Saam, BT				Saam, BT			Magnetic resonance imaging with laser-polarized noble gases	NATURE MEDICINE			English	Editorial Material							NUCLEAR-SPIN RELAXATION; XE-129; EXCHANGE				Saam, BT (corresponding author), PRINCETON UNIV,DEPT PHYS,JADWIN HALL,POB 708,PRINCETON,NJ 08544, USA.							ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; BHASKAR ND, 1982, PHYS REV LETT, V49, P25, DOI 10.1103/PhysRevLett.49.25; BLACK RD, IN PRESS RADIOLOGY; CATES GD, 1992, PHYS REV A, V45, P4631, DOI 10.1103/PhysRevA.45.4631; CHUPP TE, 1987, PHYS REV C, V36, P2244, DOI 10.1103/PhysRevC.36.2244; DIXON WT, 1984, RADIOLOGY, V153, P189, DOI 10.1148/radiology.153.1.6089263; GATZKE M, 1993, PHYS REV LETT, V70, P690, DOI 10.1103/PhysRevLett.70.690; HAPPER W, 1984, PHYS REV A, V29, P3092, DOI 10.1103/PhysRevA.29.3092; HOULT DI, 1979, J MAGN RESON, V34, P425, DOI 10.1016/0022-2364(79)90019-2; JAMESON CJ, 1988, J CHEM PHYS, V89, P4074, DOI 10.1063/1.454842; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; MILLER KW, 1981, P NATL ACAD SCI-BIOL, V78, P4946, DOI 10.1073/pnas.78.8.4946; SAAM B, 1995, PHYS REV A, V52, P862, DOI 10.1103/PhysRevA.52.862; WAGSHUL ME, IN PRESS MAGN RESON; WEATHERSBY PK, 1980, UNDERSEA BIOMED RES, V7, P277	15	11	11	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					358	359		10.1038/nm0396-358	http://dx.doi.org/10.1038/nm0396-358			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612239				2022-12-27	WOS:A1996TY64000049
J	CARLING, T; KINDMARK, A; HELLMAN, P; LUNDGREN, E; LJUNGHALL, S; RASTAD, J; AKERSTROM, G; MELHUS, H				CARLING, T; KINDMARK, A; HELLMAN, P; LUNDGREN, E; LJUNGHALL, S; RASTAD, J; AKERSTROM, G; MELHUS, H			VITAMIN-D-RECEPTOR GENOTYPES IN PRIMARY HYPERPARATHYROIDISM	NATURE MEDICINE			English	Article							PARATHYROID-HORMONE GENE; BOVINE; CELLS; 1,25-DIHYDROXYVITAMIN-D3; PROLIFERATION; CALCIUM	Vitamin D and parathyroid hormone (PTH) constitute the main regulators of systemic calcium homeostasis. As well as its calcaemic effects, active vitamin D-3 (1,25(OH)(2)D-3) has a direct regulatory role on parathyroid cells. Active vitamin D-3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promotor regions of the PTH gene inhibits transcription(1). Active vitamin D-3 constitutes a principal regulator of parathyroid cell growth(2,3), and polymorphism in the VDR gene has recently been related to bone mineral density and suggested as predisposing to osteoporosis(4). Impaired effects of active vitamin D-3 may contribute to the relatively enhanced secretion and cell proliferation seen in hyperparathyroidism (HPT). Indeed, VDR dysfunction, of essentially unknown character, has been demonstrated in the pathological parathyroid tissue of primary HPT as well as HPT secondary to uraemia(5,6). Consistent with the essential role of active vitamin D-3 in parathyroid regulation, the VDR gene polymorphism was studied in 90 postmenopausal women with primary hyperparathyroidism. The VDR genotype bb was found in 60.0% of HPT patients and in 33.3% of the postmenopausal female controls (P < 0.001). As the b allele has been linked to decreased transcriptional activity or messenger RNA stability(4,7), reduced VDR expression may impede regulatory actions of vitamin D and may contribute to parathyroid tumorigenesis in these patients.	UNIV UPPSALA HOSP,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	CARLING, T (corresponding author), UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN.		Hellman, Per/AAL-9817-2021	Hellman, Per/0000-0002-5322-5073				AKERSTROM G, 1986, HUM PATHOL, V17, P520, DOI 10.1016/S0046-8177(86)80043-0; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ARNOLD A, 1993, J CLIN ENDOCR METAB, V77, P1108, DOI 10.1210/jc.77.5.1108; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; FARROW S, 1994, LANCET, V343, P1242, DOI 10.1016/S0140-6736(94)92147-4; FRIEDMAN E, 1992, CANCER RES, V52, P6804; FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720; HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; KARMALI R, 1989, J ENDOCRINOL, V123, P137, DOI 10.1677/joe.0.1230137; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; KROGER H, 1995, LANCET, V345, P1238, DOI 10.1016/S0140-6736(95)92019-6; MELHUS H, 1994, LANCET, V344, P949, DOI 10.1016/S0140-6736(94)92297-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; NYGREN P, 1988, CALCIFIED TISSUE INT, V43, P213, DOI 10.1007/BF02555137; PALMER M, 1988, EUR J CLIN INVEST, V18, P39, DOI 10.1111/j.1365-2362.1988.tb01163.x; RIGGS BL, 1995, J BONE MINER RES, V10, P991	19	173	176	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1309	1311		10.1038/nm1295-1309	http://dx.doi.org/10.1038/nm1295-1309			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489414				2022-12-27	WOS:A1995TH78600045
J	BLOWER, SM; MCLEAN, AR; PORCO, TC; SMALL, PM; HOPEWELL, PC; SANCHEZ, MA; MOSS, AR				BLOWER, SM; MCLEAN, AR; PORCO, TC; SMALL, PM; HOPEWELL, PC; SANCHEZ, MA; MOSS, AR			THE INTRINSIC TRANSMISSION DYNAMICS OF TUBERCULOSIS EPIDEMICS	NATURE MEDICINE			English	Article							BRIEF EPIDEMIOLOGIC HISTORY; EXOGENOUS REINFECTION; DEVELOPING-COUNTRIES; DISEASE; ARCANA; HIV; SENSITIVITY; MEASLES; MODEL	In developed countries the major tuberculosis epidemics declined long before the disease became curable in the 1940s. We present a theoretical framework for assessing the intrinsic transmission dynamics of tuberculosis. We demonstrate that it takes one to several hundred years for a tuberculosis epidemic to rise, fall and reach a stable endemic level. Our results suggest that some of the decline of tuberculosis is simply due to the natural behaviour of an epidemic. Although other factors must also have contributed to the decline, these causal factors were constrained to operate within the slow response time dictated by the intrinsic dynamics.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND; STANFORD UNIV, SCH MED,DIV INFECT DIS & GEOG MED, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP,MED SERV, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP,DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA	University of Oxford; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	BLOWER, SM (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT EPIDEMIOL & BIOSTAT, BOX 1347, SAN FRANCISCO, CA 94143 USA.				NIAID NIH HHS [K08AI01137-01, AI33831] Funding Source: Medline; NIDA NIH HHS [1R29DA08153] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001137, R01AI033831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ANDERSON R M, 1991; Blower S. M., 1992, BR J ADDICT, V87, P31; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P151; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P426; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P583; GRZYBOWSKI S, 1978, Bulletin of the International Union Against Tuberculosis, V53, P70; LONG ER, 1940, B HIST MED, V8, P819; LURIE MB, 1964, RESISTANCE TUBERCULO, P30; MACDONALD G, 1952, Trop Dis Bull, V49, P813; May R.M., 1986, Biomathematics (Berlin), V17, P405; MAY RM, 1990, PARASITOLOGY, V100, pS89, DOI 10.1017/S0031182000073042; MCKEOWN T, 1962, POP STUD-J DEMOG, V16, P94, DOI 10.2307/2173119; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NEWSHOLME A, 1908, PREVENTION TUBERCULO, P269; RANSOME A, 1898, RES TUBERCULOSIS, P1; RYAN F, 1992, FORGOTTEN PLAGUE; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STYBLO K, 1986, RECENT ADV RESPIRATO, P77; WAALER H, 1962, AM J PUBLIC HEALTH N, V56, P1002; Waaler H T, 1968, Bull Int Union Tuberc, V41, P42; WAALER HT, 1969, B WORLD HEALTH ORGAN, V41, P75; 1990, TUBERCULOSIS STATIST; 1992, TUBERCULOSIS STATIST	33	333	340	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					815	821		10.1038/nm0895-815	http://dx.doi.org/10.1038/nm0895-815			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585186				2022-12-27	WOS:A1995RM63500040
J	DEROOS, A; DOORNBOS, J; VANDERWALL, EE; VANVOORTHUISEN, AE				DEROOS, A; DOORNBOS, J; VANDERWALL, EE; VANVOORTHUISEN, AE			MAGNETIC-RESONANCE OF THE HEART AND GREAT-VESSELS	NATURE MEDICINE			English	Editorial Material							CINE		LEIDEN UNIV HOSP,DEPT CARDIOL,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	DEROOS, A (corresponding author), LEIDEN UNIV HOSP,DEPT DIAGNOST RADIOL,2333 AA LEIDEN,NETHERLANDS.							GEVA T, 1994, CIRCULATION, V90, P348, DOI 10.1161/01.CIR.90.1.348; HELBING WA, IN PRESS AM HEART J; KERSTINGSOMMERH.BA, 1990, AM HEART J, V120, P133; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; MOHIADDIN RH, 1993, CIRCULATION, V88, P264, DOI 10.1161/01.CIR.88.1.264; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; PATTYNAMA PMT, 1993, RADIOLOGY, V187, P261, DOI 10.1148/radiology.187.1.8451425; PFLUGFELDER PW, 1988, AM J ROENTGENOL, V150, P523, DOI 10.2214/ajr.150.3.523; REBERGEN SA, 1993, CIRCULATION, V88, P2257, DOI 10.1161/01.CIR.88.5.2257; REES RSO, 1987, BRIT HEART J, V58, P621; STEFFENS JC, 1994, CIRCULATION, V90, P937, DOI 10.1161/01.CIR.90.2.937; van Rugge FP, 1993, J AM COLL CARDIOL, V22, P431, DOI 10.1016/0735-1097(93)90047-5; WETTER DR, 1995, RADIOLOGY, V194, P765, DOI 10.1148/radiology.194.3.7862976	14	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					711	713		10.1038/nm0795-711	http://dx.doi.org/10.1038/nm0795-711			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585158				2022-12-27	WOS:A1995RQ06600051
J	SCHALLING, M; EKMAN, M; KAAYA, EE; LINDE, A; BIBERFELD, P				SCHALLING, M; EKMAN, M; KAAYA, EE; LINDE, A; BIBERFELD, P			A ROLE FOR A NEW HERPES-VIRUS (KSHV) IN DIFFERENT FORMS OF KAPOSIS-SARCOMA	NATURE MEDICINE			English	Article								Kaposi's sarcoma (KS) is a previously rare, tumour-like lesion of controversial biological nature(1,2). KS has since the early 1980s become frequent in patients with AIDS, particularly in homosexuals(3). KS is also endemic in Central Africa predominantly in otherwise healthy men but also in women and children(1,4). Recently, evidence for the presence of novel, herpes virus DNA sequences in more than 90% of AIDS Kaposi lesions (AKS) was presented(5). This DNA was identified using representational difference analysis (RDA) generating short, unique sequences with variable homology to several herpes virus, but no intact virus was recovered. If these DNA-sequences are also present in other, non-HIV-associated forms of Kaposi's sarcoma this would strongly suggest a specific, aetiopathological involvement of this putative new herpes virus in the pathogenesis of Kaposi's sarcoma, rather than a contamination of yet another opportunistic virus in immunosuppressed AIDS patients.	KAROLINSKA HOSP & INST,DEPT MOLEC MED,NEUROGENET UNIT,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP & INST,IMMUNOPATHOL LAB,S-17176 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Swedish Institute for Infectious Disease Control	SCHALLING, M (corresponding author), KAROLINSKA INST,DEPT MOLEC MED,NEUROGENET UNIT,S-17176 STOCKHOLM,SWEDEN.		Schalling, Martin/F-1518-2015	Schalling, Martin/0000-0001-5011-2922				BAYLEY AC, 1991, CANCER SURV, V10, P53; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, AIDS UPDATES, V7, P1; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6	5	259	271	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					707	708		10.1038/nm0795-707	http://dx.doi.org/10.1038/nm0795-707			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585156				2022-12-27	WOS:A1995RQ06600050
J	RENSEN, PCN; VANDIJK, MCM; HAVENAAR, EC; BIJSTERBOSCH, MK; KRUIJT, JK; VANBERKEL, TJC				RENSEN, PCN; VANDIJK, MCM; HAVENAAR, EC; BIJSTERBOSCH, MK; KRUIJT, JK; VANBERKEL, TJC			SELECTIVE LIVER TARGETING OF ANTIVIRALS BY RECOMBINANT CHYLOMICRONS - A NEW THERAPEUTIC APPROACH TO HEPATITIS-B	NATURE MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; ADENINE-ARABINOSIDE MONOPHOSPHATE; APOLIPOPROTEIN-E; RAT-LIVER; HEPATOCELLULAR-CARCINOMA; PARENCHYMAL-CELLS; VIRUS-INFECTION; REPLICATION; PROTEIN; DISTINCT	Hepatitis B virus (HBV) infection is the world's most important chronic virus infection. No safe and effective treatment is available at present, and clinical exploration of promising antiviral agents, such as nucleoside analogues is hampered because of significant side-effects due to their aspecific body distribution. We are exploring the possibility of the selective delivery of antiviral active drugs to liver parenchymal cells, the main site of infection and replication of HBV. Chylomicrons, which transport dietary lipids into the liver via apolipoprotein E-specific receptors, could serve as drug carriers. However, their endogenous nature hampers their application as pharmaceutical drug carriers. We report here that incorporation of a derivative of the nucleoside analogue iododeoxyuridine into recombinant chylomicrons leads to selective targeting to liver parenchymal cells. Potentially effective intracellular drug concentrations of 700 nM can be achieved, and we therefore anticipate that these drug carrier complexes represent a conceptual advance in the development of an effective and safe therapy for hepatitis B.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,SYLVIUS LABS,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988				BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1981, LANCET, V2, P1129; BIJSTERBOSCH M K, 1990, Advanced Drug Delivery Reviews, V5, P231, DOI 10.1016/0169-409X(90)90018-N; BIJSTERBOSCH MK, 1994, BIOCHEMISTRY-US, V33, P14073, DOI 10.1021/bi00251a016; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HOOFNAGLE JH, 1984, GASTROENTEROLOGY, V86, P150; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; LIN TS, 1994, J MED CHEM, V37, P798, DOI 10.1021/jm00032a013; LOK ASF, 1984, J ANTIMICROB CHEMOTH, V14, P93, DOI 10.1093/jac/14.1.93; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; PRICE PM, 1989, P NATL ACAD SCI USA, V86, P8543; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; SACKS SL, 1982, ANTIMICROB AGENTS CH, V21, P93, DOI 10.1128/AAC.21.1.93; SACKS SL, 1979, JAMA-J AM MED ASSOC, V241, P28, DOI 10.1001/jama.1979.03290270020010; SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490; Shaw J. M., 1991, LIPOPROTEINS CARRIER; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; Tennant Bud C., 1994, P1455; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; UEDA K, 1989, VIROLOGY, V169, P213, DOI 10.1016/0042-6822(89)90057-3; VANBERKEL TJC, 1983, BIOCHEM J, V216, P71, DOI 10.1042/bj2160071; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WELLER IVD, 1983, J ANTIMICROB CHEMOTH, V11, P223, DOI 10.1093/jac/11.3.223; WINDLER E, 1980, J BIOL CHEM, V255, P8303; YOFFE B, 1992, DIGEST DIS SCI, V37, P1, DOI 10.1007/BF01308334	34	122	126	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					221	225		10.1038/nm0395-221	http://dx.doi.org/10.1038/nm0395-221			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585037				2022-12-27	WOS:A1995QX55900027
J	Minna, JD; Gazdar, AF				Minna, JD; Gazdar, AF			Translational research comes of age	NATURE MEDICINE			English	Editorial Material							P53 EXPRESSION VECTOR; LUNG-CANCER CELLS; WILD-TYPE; MUTATIONS; LESIONS; GROWTH; ABNORMALITIES; GENE				Minna, JD (corresponding author), UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75235, USA.							CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; MAO L, 1994, CANCER RES, V54, P1634; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SOZZI G, 1992, CANCER RES, V52, P6079; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; WINTER SF, 1992, CANCER RES, V52, P4168	15	23	29	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					974	975		10.1038/nm0996-974	http://dx.doi.org/10.1038/nm0996-974			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782451				2022-12-27	WOS:A1996VF49700028
J	Kozal, MJ; Shah, N; Shen, NP; Yang, R; Fucini, R; Merigan, TC; Richman, DD; Morris, D; Hubbell, ER; Chee, M; Gingeras, TR				Kozal, MJ; Shah, N; Shen, NP; Yang, R; Fucini, R; Merigan, TC; Richman, DD; Morris, D; Hubbell, ER; Chee, M; Gingeras, TR			Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEOTIDE-SEQUENCE; VIRAL INFECTIVITY; AIDS VIRUS	Naturally occurring mutations in HIV-1-infected patients have important implications for therapy and the outcome of clinical studies. However, little is known about the prevalence of mutations that confer resistance to HIV-1 protease inhibitors in isolates derived from patients naive for such inhibitors. In the first clinical application of high-density oligonucleotide array sequencing, the sequences of 167 viral isolates from 102 patients have been determined, The DNA sequence of USA HIV-1 clade B proteases was found to be extremely variable and 47.5% of the 99 amino acid positions varied. This level of amino acid diversity is greater than that previously known for all worldwide HIV-1 clades combined (40%). Many of the amino acid changes that are known to contribute to drug resistance occurred as natural polymorphisms in isolates from patients who had never received protease inhibitors.	AFFYMETRIX,DEPT BIOL MOLEC,SANTA CLARA,CA 95051; STANFORD UNIV,DIV INFECT DIS,STANFORD,CA 94305; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; VET AFFAIRS MED CTR,SAN DIEGO,CA 92161	Affymetrix; Stanford University; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Merigan, Thomas/AGQ-7464-2022	, Michael/0000-0002-7719-7396; Kozal, Michael/0000-0002-3100-8254; Gingeras, Thomas/0000-0001-9106-3573; Hubbell, Earl/0000-0001-7301-3759	NIAID NIH HHS [1R43-AI 36809, 1U01-AI 30457, R44-AI/GM 36809-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI036809, U01AI030457, R44AI036809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Eckert K A, 1991, PCR Methods Appl, V1, P17; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GINGERAS TR, 1991, J INFECT DIS, V164, P1066, DOI 10.1093/infdis/164.6.1066; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1994, HIV DRUG RES 3 INT W, P16; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5022; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; LIPSHUTZ RJ, 1994, CURR OPIN STRUC BIOL, V4, P376, DOI 10.1016/S0959-440X(94)90106-6; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; Mellors J. W., 1995, International Antiviral News, V3, P8; MEYERS G, 1994, HUMAN RETROVIRUSES A, V3, P97; MEYERS G, 1994, HUMAN RETROVIRUSES A, V1, P79; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; PILLAY D, 1995, REV MED VIROL, V5, P23, DOI 10.1002/rmv.1980050104; POTTS KE, 1994, HIV DRUG RES 3 INT W, P4; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROSE B, 1994, HIV DRUG RES 3 INT W, P17; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; Tabor S., 1995, P NATL ACAD SCI USA, V92, P6639; THEODORE T, 1990, HUMAN RETROVIRUSES A, P162; TISDALE M, 1994, 3RD INT WORKSH HIV D, P14; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0	28	422	574	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					753	759		10.1038/nm0796-753	http://dx.doi.org/10.1038/nm0796-753			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673920				2022-12-27	WOS:A1996UU68000030
J	Shimomura, I; Funahashi, T; Takahashi, M; Maeda, K; Kotani, K; Nakamura, T; Yamashita, S; Miura, M; Fukuda, Y; Takemura, K; Tokunaga, K; Matsuzawa, Y				Shimomura, I; Funahashi, T; Takahashi, M; Maeda, K; Kotani, K; Nakamura, T; Yamashita, S; Miura, M; Fukuda, Y; Takemura, K; Tokunaga, K; Matsuzawa, Y			Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity	NATURE MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CARDIOVASCULAR-DISEASE; INSULIN RESISTANCE; RAPID INHIBITOR; ADIPOSE-TISSUE; MESSENGER-RNA; BODY-FAT; PLASMA; LEVEL; RISK	The presence of obesity increases the risk of thrombotic vascular diseases. The role of fat accumulation and its effect on plasminogen activator inhibitor-1 (PAI-1) levels was investigated in humans and animals. Plasma PAI-1 levels were closely correlated with visceral fat area but not with subcutaneous fat area in human subjects. PAI-1 mRNA was detected in both types of fat tissue in obese rats but increased only in visceral fat during the development of obesity. These data suggest that an enhanced expression of the PAI-7 gene in visceral fat may increase plasma levels and may have a role in the development of vascular disease in visceral obesity.	OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; MITSUBISHI KAGAKU BIOCLIN LABS,ITABASHI KU,TOKYO 174,JAPAN; OTSUKA ASSAY LABS,HIRAI,TOKUSHIMA,JAPAN	Osaka University; Mitsubishi Kagaku Bio-Clinical Laboratories								ALLHAUD G, 1992, ANNU REV NUTR, V12, P207; AUWERX J, 1988, ARTERIOSCLEROSIS, V8, P68, DOI 10.1161/01.ATV.8.1.68; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; DEPRES JP, 1989, DIABETES, V38, P304; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KOOISTRA T, 1989, THROMB HAEMOSTASIS, V62, P723; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; MATSUZAWA Y, 1990, PROGR OBESITY RES, P309; NAKAMURA T, 1994, ATHEROSCLEROSIS, V107, P239, DOI 10.1016/0021-9150(94)90025-6; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SHIMOMURA I, 1993, AM J PHYSIOL, V265, pE44, DOI 10.1152/ajpendo.1993.265.1.E44; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; TOKUNAGA K, 1986, AM J PHYSIOL, V251, pR1221, DOI 10.1152/ajpregu.1986.251.6.R1221; TOKUNAGA K, 1983, INT J OBESITY, V7, P437; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; WIMAN B, 1984, J BIOL CHEM, V259, P3644; WIMAN B, 1990, SEMIN THROMB HEMOST, V16, P207, DOI 10.1055/s-2007-1002671	23	719	746	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					800	803		10.1038/nm0796-800	http://dx.doi.org/10.1038/nm0796-800			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673927				2022-12-27	WOS:A1996UU68000037
J	Bennett, J; Tanabe, T; Sun, DX; Zeng, Y; Kjeldbye, H; Gouras, P; Maguire, AM				Bennett, J; Tanabe, T; Sun, DX; Zeng, Y; Kjeldbye, H; Gouras, P; Maguire, AM			Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy	NATURE MEDICINE			English	Article							PHOSPHODIESTERASE BETA-SUBUNIT; CGMP PHOSPHODIESTERASE; RETINITIS-PIGMENTOSA; MOUSE RETINA; NONSENSE MUTATION; IDENTIFICATION; PREVALENCE; EXPRESSION	Mutations in the beta subunit of the cCMP phosphodiesterase gene (beta PDE) can cause a recessively inherited retinal degeneration in several species, including mice, dogs and humans. We tested the possibility of altering the course of retinal degeneration in the rd mouse through subretinal injection of a recombinant replication-defective adenovirus that contains the murine cDNA for wild-type beta PDE, Ad.CMV beta PDE. Subretinal injection of Ad.CMV beta PDE results in beta PDE transcripts and increased PDE activity and delays photoreceptor cell death by six weeks. The findings demonstrate cell rescue by in vivo gene transfer, thus supporting the feasibility of treating an inherited retinal degeneration by somatic gene therapy.	UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; COLUMBIA UNIV,DEPT OPHTHALMOL,NEW YORK,NY 10032	University of Pennsylvania; Columbia University	Bennett, J (corresponding author), UNIV PENN,SCHEIE EYE INST,FM KIRBY CTR MOL OPHTHALMOL,DEPT OPHTHALMOL,STELLAR CHANCE LABS 310,PHILADELPHIA,PA 19104, USA.				NEI NIH HHS [EY 10964, R01 EY 10820-01] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010820, R21EY010964] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BUNDEY S, 1984, J MED GENET, V21, P417, DOI 10.1136/jmg.21.6.417; BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FLETCHER RT, 1986, J NEUROCHEM, V46, P1240, DOI 10.1111/j.1471-4159.1986.tb00644.x; JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347; KAPLAN J, 1990, HUM GENET, V85, P635; LASANSKY A, 1960, J BIOPHYS BIOCHEM CY, V7, P679, DOI 10.1083/jcb.7.4.679; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; LI TS, 1994, INVEST OPHTH VIS SCI, V35, P2543; LI TS, 1995, P NATL ACAD SCI USA, V92, P7700, DOI 10.1073/pnas.92.17.7700; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Milam AH, 1996, INVEST OPHTH VIS SCI, V37, P753; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Robb R M, 1974, Trans Am Ophthalmol Soc, V72, P650; SAS I.I., 1989, SAS STAT US GUID VER; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	25	272	294	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					649	654		10.1038/nm0696-649	http://dx.doi.org/10.1038/nm0696-649			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640555				2022-12-27	WOS:A1996UN69100032
J	Guleria, I; Teitelbaum, R; McAdam, RA; Kalpana, G; Jacobs, WR; Bloom, BR				Guleria, I; Teitelbaum, R; McAdam, RA; Kalpana, G; Jacobs, WR; Bloom, BR			Auxotrophic vaccines for tuberculosis	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; SALMONELLA-TYPHIMURIUM; TY 21A; IMMUNIZATION; STRAINS; RESISTANCE; IMMUNITY; PROTEIN; TYPHI; LIVE	Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually(1). It remains the largest attributable cause of death in HIV-infected individuals, responsible for 32% of deaths of HIV-infected individuals in Africa(2). The only currently available vaccine for tuberculosis, bacille Calmette-Guerin (BCC) is the most widely used vaccine in the world, being administered to approximately 100 million children each year, Although untoward effects were not seen in several studies of HIV-seropositive children(3), the safety of live attenuated BCC vaccine in HIV-positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCC produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCC could no longer be detected in mice receiving the auxotrophs after 16-32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCC vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged virulent Mycobacterium tuberculosis, several of auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCC. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Guleria, I (corresponding author), ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA.			Kalpana, Ganjam/0000-0003-4111-0604; Jacobs, William/0000-0003-3321-3080; GULERIA, INDIRA/0000-0002-0622-3585	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023545, R37AI023545, R37AI026170, R01AI026170, R22AI026170] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23545, AI 07118, AI 26170] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bloom Barry R., 1994, P531; BRAUN MM, 1992, PEDIATR INFECT DIS J, V11, P220, DOI 10.1097/00006454-199203000-00010; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V272, P766, DOI 10.1001/jama.1994.03520100029017; COLDITZ GA, 1994, ACP J CLUB, V121, P22; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; COOPER AM, 1995, IMMUNOLOGY, V84, P423; CURTISS R, 1987, INFECT IMMUN, V55, P3035, DOI 10.1128/IAI.55.12.3035-3043.1987; DOUGAN G, 1988, J INFECT DIS, V158, P1329, DOI 10.1093/infdis/158.6.1329; FENNELLY GJ, 1995, J INFECT DIS, V172, P698, DOI 10.1093/infdis/172.3.698; FINE PEM, 1989, REV INFECT DIS, V11, pS353; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FLYNN JL, 1995, J IMMUNOL, V155, P2515; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GANJAM K, 1991, P NATL ACAD SCI USA, V88, P5433; GERMANIER R, 1975, J INFECT DIS, V131, P553, DOI 10.1093/infdis/131.5.553; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HOLSETH SK, 1981, NATURE, V291, P238; Lucas Sebastian, 1994, P503; MCADAM RA, 1995, INFECT IMMUN, V63, P1004, DOI 10.1128/IAI.63.3.1004-1012.1995; MILLER IA, 1989, MOL GEN GENET, V215, P312, DOI 10.1007/BF00339734; Murray C.J, 1994, GLOBAL COMP ASSESSME; NORTH RJ, 1993, J EXP MED, V177, P1723, DOI 10.1084/jem.177.6.1723; Orme Ian M., 1994, P113; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STYBLO K, 1991, SELECTED PAPERS, V24, P1; TENDAM HG, 1976, B WORLD HEALTH ORGAN, V54, P255; VONREYN CF, 1987, LANCET, V2, P669; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; WELTMAN AC, 1993, AIDS, V7, P149, DOI 10.1097/00002030-199302000-00001; 1980, INDIAN J MED RES S, V72, P1; 1992, EXPANDED PROGRAM IMM	35	129	142	0	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1996	2	3					334	337		10.1038/nm0396-334	http://dx.doi.org/10.1038/nm0396-334			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612234				2022-12-27	WOS:A1996TY64000044
J	Scholander, C; Treutiger, CJ; Hultenby, K; Wahlgren, M				Scholander, C; Treutiger, CJ; Hultenby, K; Wahlgren, M			Novel fibrillar structure confers adhesive property to malaria-infected erythrocytes	NATURE MEDICINE			English	Article							HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; CYTOADHERENCE; RECEPTOR; MOLECULE-1; CD36	Infections with the malaria parasite Plasmodium falciparum are characterized by sequestration of erythrocytes infected by mature forms of the parasite. Sequestration seems critical for the survival of the parasite, but may lead to excessive binding in the microvasculature and death of the human host. We report here that a novel electron-dense fibrillar structure, containing immunoglobulins M or M and G, is found at the surface of infected erythrocytes that adhere to host cells. In cases of cerebral malaria, fibrillar strands are also seen in the microvasculature at autopsy. Our findings may explain the adhesive mechanism by which malaria-infected erythrocytes cause the vascular obstruction seen in complicated malaria infections.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,S-17177 STOCKHOLM,SWEDEN; HUDDINGE HOSP,KAROLINSKA INST,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet								AIKAWA M, 1988, AM J TROP MED HYG, V39, P3, DOI 10.4269/ajtmh.1988.39.3; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; FUJIOKA H, 1994, EXP PARASITOL, V78, P371, DOI 10.1006/expr.1994.1040; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; HIDAYAT AA, 1993, OPHTHALMOLOGY, V100, P1183, DOI 10.1016/S0161-6420(93)31508-3; HOWARD RJ, 1989, BLOOD, V74, P2603; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MILLER LH, 1972, T ROY SOC TROP MED H, V66, P459, DOI 10.1016/0035-9203(72)90277-5; NAGATAKE T, 1992, AM J TROP MED HYG, V47, P359; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; RIGANTI M, 1990, IMMUNOL LETT, V25, P199, DOI 10.1016/0165-2478(90)90115-7; RINGWALD P, 1993, INFECT IMMUN, V61, P5198, DOI 10.1128/IAI.61.12.5198-5204.1993; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; RUANGJIRACHUPORN W, 1991, PARASITOLOGY, V102, P325, DOI 10.1017/S003118200006426X; TRAGER W, 1966, B WORLD HEALTH ORGAN, V35, P883; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503	20	90	91	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					204	208		10.1038/nm0296-204	http://dx.doi.org/10.1038/nm0296-204			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574966				2022-12-27	WOS:A1996TU06000041
J	Smith, O				Smith, O			Cells, stress and EMFs	NATURE MEDICINE			English	Editorial Material							FREQUENCY ELECTROMAGNETIC-FIELDS; HEAT-SHOCK; EXPOSURE; CANCER											Bassett CAL, 1995, ADV CHEM SER, V250, P261; BLANK M, 1994, BIOELECTROCH BIOENER, V33, P109, DOI 10.1016/0302-4598(94)85001-1; BLANK M, 1995, MOL BIOL CELL, V6, pA466; GOODMAN EM, 1995, INT REV CYTOL, V158, P279; GOODMAN R, 1992, BIOELECTROMAGNETICS, V13, P111, DOI 10.1002/bem.2250130205; GOODMAN R, 1994, BIOELECTROCH BIOENER, V33, P115, DOI 10.1016/0302-4598(94)85002-X; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; LIN H, IN PRESS BIOELECTROC; MATANOSKI GM, 1991, LANCET, V337, P737, DOI 10.1016/0140-6736(91)90325-J; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; STRAHLER JR, 1990, J CLIN INVEST, V85, P200, DOI 10.1172/JCI114413; TAUBES G, 1995, SCIENCE, V269, P1816, DOI 10.1126/science.269.5232.1816-a	13	45	45	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					23	24		10.1038/nm0196-23	http://dx.doi.org/10.1038/nm0196-23			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564827				2022-12-27	WOS:A1996TP57900027
J	COLLINS, S				COLLINS, S			THE LIMIT OF HUMAN ADAPTATION TO STARVATION	NATURE MEDICINE			English	Article							CHRONIC ENERGY DEFICIENCY; SOMALIA; MALNUTRITION; FAMINE	During the height of the 1992-93 famine in Somalia, data were collected from 573 inpatients at the Concern Worldwide Adult Therapeutic Centre in Baidoa, the town at the epicentre of the disaster. These data indicate that a body mass index (BMI, body weight in kilograms divided by height in metres squared) of less than 10 kg m(-2) can be compatible with life, so long as specialized care is provided. Such low levels of BMI may be explained, in part, by the high ambient temperature, the tall phenotype of the Somalis, the gradual reduction in food intake and previous exposure to chronic energy deficiency. Famine oedema occurred with the same prevalence in male and female patients, but male patients had more severe oedema and a poorer prognosis at any given degree of severity. Survival from these extremes of emaciation has never before been recorded, and many of the BMI values documented here are below the level of 12, previously thought to mark the limit of human adaptation to starvation.	INST CHILD HLTH,CTR INT CHILD HLTH,LONDON WC1N 1EH,ENGLAND; CONCERN WORLDWIDE,DUBLIN 2,IRELAND	University of London; University College London								AYKROID WR, 1974, CONQUEST FAMINE; BEATTIE J, 1948, BRIT J NUTR, V2, P47, DOI 10.1079/BJN19480008; BRANCA F, 1993, LANCET, V341, P1478, DOI 10.1016/0140-6736(93)90923-5; BURGER GCE, 1945, LANCET, P282; COLLINS S, 1993, JAMA-J AM MED ASSOC, V270, P637; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1990, EPI INFO VERSION 6 W; DEGOYET CD, 1978, MANAGEMENT NUTRITION; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; FRIEDMAN PJ, 1991, NUTRITION, V7, P223; GOPALAN C, 1975, Progress in Food and Nutrition Science, V1, P207; HENRY CJK, 1990, EUR J CLIN NUTR, V44, P329; HENRY CJK, 1993, ANTHROPOMETRY INDIVI; JAMES WFT, 1992, BODY MASS INDEX OBJE; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; JAMES WPT, 1994, EUR J CLIN NUTR, V49, P883; Keys A, 1950, BIOL HUMAN STARVATIO; Keys Ancel, 1946, JOUR AMER DIETETIC ASSOC, V22, P582; LEYTON GB, 1946, LANCET, V1, P73; LIPSCOMB FM, 1945, LANCET, V1, P313; MCCANCE RA, 1951, STUDIES UNDERNUTRITI; MOLLINSON PL, 1946, BRIT MED J, V5, P4; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; ROSS DA, 1990, INT J EPIDEMIOL, V19, P636, DOI 10.1093/ije/19.3.636; SHETTY PS, 1984, HUM NUTR-CLIN NUTR, V41, P287; WINICK M, 1979, HUNGER DISEASE; 1992, MMWR-MORBID MORTAL W, V41, P913; 1986, WHO B, V64, P929; 1993, FIGURES NUMBER UNCLA	30	39	39	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					810	814		10.1038/nm0895-810	http://dx.doi.org/10.1038/nm0895-810			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585185				2022-12-27	WOS:A1995RM63500039
J	FALO, LD; KOVACSOVICSBANKOWSKI, M; THOMPSON, K; ROCK, KL				FALO, LD; KOVACSOVICSBANKOWSKI, M; THOMPSON, K; ROCK, KL			TARGETING ANTIGEN INTO THE PHAGOCYTIC PATHWAY IN-VIVO INDUCES PROTECTIVE TUMOR-IMMUNITY	NATURE MEDICINE			English	Article							INFILTRATING LYMPHOCYTES; SOLUBLE-PROTEIN; T-CELLS; INVIVO; ASSOCIATION; MELANOMA; SURVIVAL	Cytotoxic T lymphocytes (CTLs) kill neoplastic or virally infected cells after recognizing on their surface antigenic peptides bound to major histocompatibility complex class molecules. These peptides are derived from antigens that are degraded in the cytosol of the affected cell. Because exogenous proteins cannot enter the cytosol, immunizations with killed pathogens or their proteins do not generally elicit CTLs. However, antigens that are internalized into phagocytic cells can enter the cytosol and be processed for class presentation. Here we show that immunization with a purified antigen on an avidly phagocytized particle primes CTLs, which in turn protect animals from subsequent challenge with tumours transfected with the antigen gene. Interestingly, these animals also become immune to other antigens expressed by the tumour. This approach could be exploited to develop tumour and viral vaccines.	UNIV PITTSBURGH,SCH MED,PITTSBURGH CANC INST,PITTSBURGH,PA 15213; DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	FALO, LD (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT DERMATOL,190 LOTHROP ST,PITTSBURGH,PA 15213, USA.		Falo, Louis/ABD-1499-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020248, R01AI031337, R37AI020248] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31337, AI 20248] Funding Source: Medline; PHS HHS [R01-1884] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AEBERSOLD P, 1991, JNCI-J NATL CANCER I, V83, P932, DOI 10.1093/jnci/83.13.932; AUCHINCLOSS H, 1988, TRANSPLANTATION, V45, P1118, DOI 10.1097/00007890-198806000-00024; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; FIDLER IJ, 1976, CANCER RES, V36, P3160; HARDING CV, 1994, J IMMUNOL, V153, P4925; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KOVACSOVICSBANK.M, 1994, EUR J IMMUNOL, V24, P2421; KOVACSOVICSBANK.M, 1995, SCIENCE, V267, P243; KOVACSOVICSBANKOWS, 1993, P NATL ACAD SCI USA, V90, P4942; KUNDIG TM, 1993, J IMMUNOL, V150, P4450; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1993, J IMMUNOL, V150, P438; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SINGLUFF CL, 1994, CURR OPIN IMMUNOL, V6, P733; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZHOU F, 1992, CANCER RES, V52, P6287	26	233	248	1	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					649	653		10.1038/nm0795-649	http://dx.doi.org/10.1038/nm0795-649			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585145				2022-12-27	WOS:A1995RQ06600038
J	ROEDERER, M				ROEDERER, M			T-CELL DYNAMICS OF IMMUNODEFICIENCY	NATURE MEDICINE			English	Editorial Material											ROEDERER, M (corresponding author), STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA.		Roederer, Mario/G-1887-2011					DIMITROV DS, 1995, NATURE, V375, P194, DOI 10.1038/375194b0; DONNENBERG A, 1995, IN PRESS RES IMMUN; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NATURE, V375, P198, DOI 10.1038/375198b0; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; SPRENT J, 1995, NATURE, V375, P194, DOI 10.1038/375194a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	14	45	77	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1995	1	7					621	622		10.1038/nm0795-621	http://dx.doi.org/10.1038/nm0795-621			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585134				2022-12-27	WOS:A1995RQ06600027
J	WEILLER, C; MAY, A; LIMMROTH, V; JUPTNER, M; KAUBE, H; VONSCHAYCK, R; COENEN, HH; DIENER, HC				WEILLER, C; MAY, A; LIMMROTH, V; JUPTNER, M; KAUBE, H; VONSCHAYCK, R; COENEN, HH; DIENER, HC			BRAIN-STEM ACTIVATION IN SPONTANEOUS HUMAN MIGRAINE ATTACKS	NATURE MEDICINE			English	Article							PET IMAGES; PERIAQUEDUCTAL GRAY; LOCALIZATION; SUMATRIPTAN; HEADACHE; SITES; PAIN	Evidence from animal experiments shows that the brain stem is involved in the pathophysiology of migraine. To investigate human migraine, we used positron emission tomography to examine the changes in regional cerebral blood flow as an index of neuronal activity in the human brain during spontaneous migraine attacks. During the attacks, increased blood flow was found in the cerebral hemispheres in cingulate, auditory and visual association cortices and in the brain stem. However, only the brain stem activation persisted after the injection of sumatriptan had induced complete relief from headache and phono- and photophobia These findings support the idea that the pathogenesis of migraine is related to an imbalance in activity between brain stem nuclei regulating antinociception and vascular control.	UNIV ESSEN GESAMTHSCH,DEPT NEUROL,D-45122 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,DEPT NUCL MED,RADIOPHARM SECT,D-45122 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen			Diener, Hans-Christoph/AAF-7275-2019; Coenen, Heinz H./K-3078-2013	Coenen, Heinz H./0000-0002-3810-103X				BEHBEHANI MM, 1979, BRAIN RES, V170, P85, DOI 10.1016/0006-8993(79)90942-9; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; FERRARI MD, 1995, ARCH NEUROL-CHICAGO, V52, P135, DOI 10.1001/archneur.1995.00540260037013; FOWLER PA, 1991, EUR NEUROL, V31, P291, DOI 10.1159/000116756; FOX PT, 1989, J NUCL MED, V30, P141; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Friberg L, 1994, Eur J Neurol, V1, P35, DOI 10.1111/j.1468-1331.1994.tb00048.x; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; GOADSBY PJ, 1991, ANN NEUROL, V29, P91, DOI 10.1002/ana.410290116; GOADSBY PJ, 1988, BASIC MECHANISMS HEA, P413; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HEROLD S, 1985, J CEREB BLOOD FLO S1, V5, pS445; JENSEN TS, 1989, BRAIN RES, V476, P1, DOI 10.1016/0006-8993(89)91529-1; JONES AKP, 1992, SCIENCE, V255, P215, DOI 10.1126/science.1553549; KAUBE H, 1993, BRIT J PHARMACOL, V109, P788, DOI 10.1111/j.1476-5381.1993.tb13643.x; LAMMERTSMA AA, 1989, J CEREBR BLOOD F MET, V9, P461, DOI 10.1038/jcbfm.1989.69; LANCE JW, 1990, HEADACHE, V30, P17, DOI 10.1111/j.1526-4610.1990.hed30s1017.x; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; OLESEN J, 1991, MIGRAINE OTHER HEADA; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; Talairach J., 1988, COPLANAR STEREOTAXIC; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	28	1011	1033	0	61	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					658	660		10.1038/nm0795-658	http://dx.doi.org/10.1038/nm0795-658			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585147				2022-12-27	WOS:A1995RQ06600040
J	YANG, NS; SUN, WH				YANG, NS; SUN, WH			GENE GUN AND OTHER NONVIRAL APPROACHES FOR CANCER GENE-THERAPY	NATURE MEDICINE			English	Editorial Material							PARTICLE BOMBARDMENT; CELLS; EXPRESSION; MELANOMA		NORTHWESTERN UNIV,CHILDRENS MEM HOSP,LURIE CANC CTR,DIV DERMATOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	YANG, NS (corresponding author), AGRACETUS INC,DEPT CANC GENE THERAPY,8520 UNIV GREEN,MIDDLETON,WI 53562, USA.							ANDREE C, 1994, P NATL ACAD SCI USA, V91, P12188, DOI 10.1073/pnas.91.25.12188; BURKHOLDER JK, 1993, J IMMUNOL METHODS, V165, P149, DOI 10.1016/0022-1759(93)90340-D; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FOA R, 1994, NAT IMMUN, V13, P65; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; HWU P, 1994, CANCER DETECT PREV, V18, P43; KERR WG, 1994, J LEUKOCYTE BIOL, V56, P210, DOI 10.1002/jlb.56.2.210; KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0; NABEL GJ, 1994, HUM GENE THER, V5, P57, DOI 10.1089/hum.1994.5.1-57; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NABEL GJ, 1994, HUM GENE THER, V5, P79, DOI 10.1089/hum.1994.5.1-79; OGASAWARA M, 1993, CANCER RES, V53, P3561; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; SUN WH, 1995, P NATL ACAD SCI USA, V92, P2889, DOI 10.1073/pnas.92.7.2889; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568; YANG NS, 1994, PARTICLE BOMBARDMENT, P39; YANG NS, 1994, PARTICLE BOMBARDMENT, P117; YANG NS, 1994, GENE THERAPEUTICS ME, P193	22	132	141	3	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					481	483		10.1038/nm0595-481	http://dx.doi.org/10.1038/nm0595-481			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585098				2022-12-27	WOS:A1995RN10000041
J	PLATT, OS				PLATT, OS			SICKLE-CELL PATHS CONVERGE ON HYDROXYUREA	NATURE MEDICINE			English	Editorial Material							FETAL-HEMOGLOBIN PRODUCTION; ANEMIA; AUGMENTATION				PLATT, OS (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115, USA.							BRIDGES K, 1994, BLOOD, V84, pA413; CASTLE WB, 1976, SEMIN HEMATOL, V13, P159; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1987, BLOOD, V69, P109; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Orringer Eugene P., 1994, P861; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PAULING L, 1994, SICKLE CELL DISEASE; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; PLATT OS, 1987, J CLIN INVEST, V74, P652; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	15	11	11	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					307	308		10.1038/nm0495-307	http://dx.doi.org/10.1038/nm0495-307			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585059				2022-12-27	WOS:A1995RN09800025
J	Nawroz, H; Koch, W; Anker, P; Stroun, M; Sidransky, D				Nawroz, H; Koch, W; Anker, P; Stroun, M; Sidransky, D			Microsatellite alterations in serum DNA of head and neck cancer patients	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MUTATIONS; PLASMA; PROGRESSION; BLOOD; GENE	Microsatellite DNA alterations are an integral part of neoplastic progression and are valuable as clonal markers for the detection of human cancers(1-3). Moreover, recent evidence suggests that senescent tumor cells may release DNA into the circulation, which is subsequently carried by and therefore enriched in the serum and plasma(4,5). We tested 21 patients with primary head and neck squamous cell carcinoma (HNSCC) by polymerase chain reaction (PCR)-based microsatellite analysis of DNA from lymphocytes and paired serum samples. Patients were scored for alterations as defined by the presence of new alleles (shifts) or loss of heterozygosity (LOH) in serum at each of 12 markers and then compared with primary tumor DNA. Six out of 21 patients (29%) were found to have one or more microsatellite alterations in serum precisely matching those in the primary tumors. All six patients had advanced disease (stage III or IV); five of these patients had nodal metastases, three later developed distant metastases, and four died of disease. Microsatellite analysis of serum represents a novel method for the detection of circulating tumor cell DNA. If these results are confirmed in larger studies, microsatellite markers may be useful in assessing tumor burden in cancer patients.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; UNIV GENEVA,FAC SCI,PAVILLON ISOTOPES,LAB PLANT BIOCHEM & PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	Johns Hopkins University; University of Geneva					NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58184-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Califano J, 1996, CANCER RES, V56, P2488; CHEN XQ, 1996, NAT MED, V2, P1034; LEON SA, 1977, CANCER RES, V37, P646; LITT M, 1993, BIOTECHNIQUES, V15, P280; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MERLO A, 1994, CANCER RES, V54, P2098; NAWROZ H, 1994, CANCER RES, V54, P1152; SHAPIRO B, 1983, CANCER, V51, P2216; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318; VANDERRIET P, 1994, CANCER RES, V54, P25; VASIOUKHIN V, 1994, BRIT J HAEMATOL, V86, P774, DOI 10.1111/j.1365-2141.1994.tb04828.x; VASIOUKHIN V, 1994, CHALLENGES MODERN ME, P141; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306	20	543	636	2	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1035	1037		10.1038/nm0996-1035	http://dx.doi.org/10.1038/nm0996-1035			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782464				2022-12-27	WOS:A1996VF49700041
J	Momose, A; Takeda, T				Momose, A; Takeda, T			Seeing how we hear	NATURE MEDICINE			English	Editorial Material							RAY TOMOGRAPHIC MICROSCOPY; SYNCHROTRON-RADIATION; RESOLUTION		UNIV TSUKUBA,INST CLIN MED,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba	Momose, A (corresponding author), HITACHI LTD,ADV RES LAB,HATOYAMA,SAITAMA 35003,JAPAN.		Momose, Atsushi/T-4873-2019					BONSE U, 1994, BONE MINER, V25, P25, DOI 10.1016/S0169-6009(08)80205-X; BONSE U, 1991, J MATER SCI, V26, P4076, DOI 10.1007/BF02402949; FLANNERY BP, 1987, SCIENCE, V237, P1439, DOI 10.1126/science.237.4821.1439; KINNEY JH, 1992, ANNU REV MATER SCI, V22, P121, DOI 10.1146/annurev.ms.22.080192.001005; MOMOSE A, 1995, MED PHYS, V22, P375, DOI 10.1118/1.597472; Momose A, 1996, NAT MED, V2, P473, DOI 10.1038/nm0496-473; Pateyron M, 1996, P SOC PHOTO-OPT INS, V2708, P417, DOI 10.1117/12.237803; Shibata T, 1996, NAT MED, V2, P933, DOI 10.1038/nm0896-933; TAKEDA T, 1994, J COMPUT ASSIST TOMO, V18, P98, DOI 10.1097/00004728-199401000-00021	9	1	1	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					852	853		10.1038/nm0896-852	http://dx.doi.org/10.1038/nm0896-852			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705847				2022-12-27	WOS:A1996UZ80400024
J	Tascon, RE; Colston, MJ; Ragno, S; Stavropoulos, E; Gregory, D; Lowrie, DB				Tascon, RE; Colston, MJ; Ragno, S; Stavropoulos, E; Gregory, D; Lowrie, DB			Vaccination against tuberculosis by DNA injection	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEIN; PLASMID DNA; T-CELLS; PROTECTIVE IMMUNITY; GENE-EXPRESSION; ANTIGEN; INFECTION; MICE; INVIVO; IMMUNIZATION	There are 3 million deaths per annum worldwide due to tuberculosis, and AIDS is compounding the problem. A better vaccine than the live mycobacterium currently in use, bacillus Calmette-Guerin (BCG), is needed. When mice were injected with plasmid DNA encoding a single mycobacterial antigen (65-kDa heat shock protein, hsp65) they made specific cellular and humoral responses to the protein and became immune to subsequent challenge with Mycobacterium tuberculosis. Protection was equivalent to that obtained by vaccinating with live BCG, whereas immunizing with the protein was ineffective. Protection was also obtained with DNA encoding another mycobacterial antigen (36-kDa proline-rich antigen). These results suggest that DNA vaccination might yield improved vaccines to replace BCG.	NATL INST MED RES,DIV MYCOBACTERIAL RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			Lowrie, Douglas/B-8151-2013	Lowrie, Douglas/0000-0003-2689-9627				ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; ANDERSON DC, 1988, J IMMUNOL, V141, P607; BILLINGHAM MEJ, 1990, J EXP MED, V171, P339, DOI 10.1084/jem.171.1.339; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; BOTHAMLEY GH, 1992, LANCET, V339, P315, DOI 10.1016/0140-6736(92)91397-Q; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FYNAN EF, 1995, INT J IMMUNOPHARMACO, V17, P79, DOI 10.1016/0192-0561(94)00090-B; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; JONES RF, 1995, J IMMUNOL METHODS, V179, P137, DOI 10.1016/0022-1759(94)00324-P; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; MULLER I, 1987, INFECT IMMUN, V55, P2037; Orme I M, 1993, Trends Microbiol, V1, P77, DOI 10.1016/0966-842X(93)90109-5; OTTENHOFF THM, 1995, EUR J CLIN INVEST, V25, P371, DOI 10.1111/j.1365-2362.1995.tb01716.x; ROBERTSON JS, 1994, VACCINE, V12, P1526, DOI 10.1016/0264-410X(94)90077-9; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SILVA CL, 1994, IMMUNOLOGY, V82, P244; Silva CL, 1996, INFECT IMMUN, V64, P2400, DOI 10.1128/IAI.64.7.2400-2407.1996; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOLE JER, 1990, INFECT IMMUN, V58, P80, DOI 10.1128/IAI.58.1.80-87.1990; THOLE JER, 1990, MOL BIOL MYCOBACTERI, P37; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER KB, 1992, J IMMUNOL, V184, P1885; WILTROUT RH, 1982, INT J CANCER, V30, P335, DOI 10.1002/ijc.2910300313; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1994, VACCINE, V12, P1534, DOI 10.1016/0264-410X(94)90079-5; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YANG NS, 1992, CRIT REV BIOTECHNOL, V12, P335, DOI 10.3109/07388559209040627; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YOUNG D, 1990, MOL BIOL MYCOBACTERI, P1; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	38	453	477	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					888	892		10.1038/nm0896-888	http://dx.doi.org/10.1038/nm0896-888			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705858				2022-12-27	WOS:A1996UZ80400035
J	Harris, E				Harris, E			Developing essential scientific capability in countries with limited resources	NATURE MEDICINE			English	Editorial Material							MOLECULAR-BIOLOGY; DENGUE				Harris, E (corresponding author), UNIV CALIF SAN FRANCISCO,PROGRAM MOL PATHOGENESIS,APPL MOL BIOL APPROPR TECHNOL TRANSFER PROGRAM,SAN FRANCISCO,CA 94143, USA.							[Anonymous], 1994, SCI PUBL PAN AM HLTH; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Harris E, 1996, BIOCHEM EDUC, V24, P3, DOI 10.1016/0307-4412(95)00154-9; HARRIS E, 1993, BIOCHEM EDUC, V21, P16, DOI 10.1016/0307-4412(93)90004-J; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; 1995, MMWR-MORBID MORTAL W, V44, P839	7	9	9	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					737	739		10.1038/nm0796-737	http://dx.doi.org/10.1038/nm0796-737			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673911				2022-12-27	WOS:A1996UU68000021
J	Weiss, RA				Weiss, RA			Human herpesvirus 8 in lymphoma and Kaposi's sarcoma: Now the virus can be propagated	NATURE MEDICINE			English	Editorial Material											Weiss, RA (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6BJ,ENGLAND.							BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Cesarman E, 1996, NEW ENGL J MED, V334, P272; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; GIRALDO G, 1972, J NATL CANCER I, V49, P1509, DOI 10.1093/jnci/49.6.1509; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	16	35	40	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					277	278		10.1038/nm0396-277	http://dx.doi.org/10.1038/nm0396-277			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612221				2022-12-27	WOS:A1996TY64000031
J	Teller, JK; Russo, C; DeBusk, LM; Angelini, G; Zaccheo, D; DagnaBricarelli, F; Scartezzini, P; Bertolini, S; Mann, DMA; Tabaton, M; Gambetti, P				Teller, JK; Russo, C; DeBusk, LM; Angelini, G; Zaccheo, D; DagnaBricarelli, F; Scartezzini, P; Bertolini, S; Mann, DMA; Tabaton, M; Gambetti, P			Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; PROTEIN; PRECURSOR	Abnormal and excessive accumulation of the amyloid beta-peptide (A beta) in the brain is a major and common characteristic of all Alzheimer's disease (AD) forms irrespective of their genetic background. Insoluble aggregates of A beta are identified as amyloid plaques. These deposits are thought to form when the amount of A beta is. increased in the brain parenchyma as a result of either overexpression or altered processing of the amyloid precursor protein (APP)(1-3). Soluble A beta ending at carboxyl-terminal residue 40 (A beta(40)) and, in lesser amount, the form ending at residue 42 (A beta(42)) are normal products of the APP metabolism in cell cultures. Increased secretion of soluble A beta(42) has been observed in cells transfected with constructs modeling APP gene mutations of familial forms of AD (refs 4, 5). On the basis of these in vitro data it has been hypothesized that the presence of soluble AP, plays a role in the formation of amyloid plaques. Subjects affected by Down's syndrome (DS) have an increased APP gene dosage and overexpress APP. Apparently because of this overexpression, they almost invariably develop amyloid deposits after the age of 30 years, although they are free of them at earlier ages(6,7). Moreover, it has been observed that A beta(42) precedes A beta(40) in the course of amyloid deposition in DS brains. Thus, DS subjects provide the opportunity to investigate in the human brain the metabolic conditions that precede the formation of the amyloid deposits. Here we report that soluble A beta(42) is present in the brains of DS-affected subjects aged from 21 gestational weeks to 61 years but it is undetectable in age-matched controls. It is argued that overexpression of APP leads specifically to A beta(42) increase and that the presence of the soluble A beta(42) is causally related to plaque formation in DS and, likely, in AD brains.	ADV BIOTECHNOL CTR,I-16132 GENOA,ITALY; UNIV GENOA,INST ANAT,I-16132 GENOA,ITALY; GALLIERA HOSP,CTR HUMAN GENET,I-16128 GENOA,ITALY; GALLIERA HOSP,DIV PEDIAT,I-16128 GENOA,ITALY; UNIV GENOA,DEPT INTERNAL MED,I-16132 GENOA,ITALY; UNIV MANCHESTER,DEPT PATHOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Genoa; Ente Ospedaliero Ospedali Galliera; Ente Ospedaliero Ospedali Galliera; University of Genoa; University of Manchester	Teller, JK (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.		Russo, Claudio/AIA-1429-2022; /V-4899-2019; Angelini, Giovanna/C-8476-2013	ANGELINI, giovanna/0000-0003-1474-5452; russo, claudio/0000-0002-2520-2958				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; MANN DMA, 1992, NEURODEGENERATION, V1, P201; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; TAMAOKA A, 1995, BRAIN RES, V679, P151, DOI 10.1016/0006-8993(95)00162-J; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882	23	306	337	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					93	95		10.1038/nm0196-93	http://dx.doi.org/10.1038/nm0196-93			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564851				2022-12-27	WOS:A1996TP57900044
J	MINETA, T; RABKIN, SD; YAZAKI, T; HUNTER, WD; MARTUZA, RL				MINETA, T; RABKIN, SD; YAZAKI, T; HUNTER, WD; MARTUZA, RL			ATTENUATED MULTI-MUTATED HERPES-SIMPLEX VIRUS-1 FOR THE TREATMENT OF MALIGNANT GLIOMAS	NATURE MEDICINE			English	Article							RIBONUCLEOTIDE REDUCTASE; DELETION MUTANT; TYPE-1; SEQUENCES; MICE; NEUROVIRULENCE; PATHOGENICITY; REPLICATION; COMPONENT; LATENCY	We have created a double mutant of the herpes simplex virus (HSV) type 1 (termed G207) with favourable properties for treating human malignant brain tumours: replication-competence in glioblastoma cells (and other dividing cells), attenuated neurovirulence, temperature sensitivity, ganciclovir hypersensitivity, and the presence of an easily detectable histochemical marker. G207 has deletions at both gamma 34.5 (RL1) loci and a lacZ gene insertion inactivating the ICP6 gene (UL39). G207 kills human glioma cells in monolayer cultures. In nude mice harbouring subcutaneous or intracerebral U-87MG gliomas, intraneoplastic inoculation with G207 causes decreased tumour growth and/or prolonged survival. G207 is avirulent upon intracerebral inoculation of mice and HSV-sensitive non-human primates. These results suggest that G207 should be considered for clinical evaluation in the treatment of glioblastomas.	GEORGETOWN UNIV,MED CTR,GEORGETOWN BRAIN TUMOR CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT NEUROSURG,WASHINGTON,DC 20007	Georgetown University; Georgetown University			rabkin, samuel/C-2443-2012	rabkin, samuel/0000-0003-2344-2795	NATIONAL CANCER INSTITUTE [P20CA060176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032677] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60176] Funding Source: Medline; NINDS NIH HHS [NS 32677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIKAWA M, 1988, ATLAS RENAL DISEASE; ASOU H, 1989, NEUROSCI RES, V6, P369, DOI 10.1016/0168-0102(89)90030-8; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARINGER JR, 1994, ANN NEUROL, V36, P823, DOI 10.1002/ana.410360605; BOLOVAN CA, 1994, J VIROL, V68, P48, DOI 10.1128/JVI.68.1.48-55.1994; BOVIATSIS EJ, 1994, GENE THER, V1, P323; CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607; CHOU J, 1986, J VIROL, V57, P629, DOI 10.1128/JVI.57.2.629-637.1986; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; COEN DM, 1989, ANTIMICROB AGENTS CH, V33, P1395, DOI 10.1128/AAC.33.8.1395; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; DOLAN A, 1992, J GEN VIROL, V73, P971, DOI 10.1099/0022-1317-73-4-971; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; HERSHKOVITZ P, 1983, AM J PRIMATOL, V4, P209, DOI 10.1002/ajp.1350040302; Hunt R. D., 1993, Nonhuman primates 1., P82; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; JIA WWG, 1994, J NATL CANCER I, V86, P1209, DOI 10.1093/jnci/86.16.1209; KAPLITT M G, 1991, Molecular and Cellular Neuroscience, V2, P320, DOI 10.1016/1044-7431(91)90062-S; KAPLITT MG, 1994, J NEURO-ONCOL, V19, P137, DOI 10.1007/BF01306455; KATZIN DS, 1967, P SOC EXP BIOL MED, V125, P391, DOI 10.3181/00379727-125-32100; KNIPE DM, 1981, J VIROL, V38, P539, DOI 10.1128/JVI.38.2.539-547.1981; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MARKERT JM, 1993, NEUROSURGERY, V35, P597; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MELENDEZ LV, 1969, LAB ANIM CARE, V19, P38; MESSER A, 1977, BRAIN RES, V130, P12; MINETA T, 1994, CANCER RES, V54, P3963; PRESTON VG, 1984, J GEN VIROL, V65, P1457, DOI 10.1099/0022-1317-65-9-1457; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; YAMADA Y, 1991, J INFECT DIS, V164, P1091, DOI 10.1093/infdis/164.6.1091	35	650	694	1	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					938	943		10.1038/nm0995-938	http://dx.doi.org/10.1038/nm0995-938			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585221				2022-12-27	WOS:A1995RT30300049
J	HALLAHAN, DE; MAUCERI, HJ; SEUNG, LP; DUNPHY, EJ; WAYNE, JD; HANNA, NN; TOLEDANO, A; HELLMAN, S; KUFE, DW; WEICHSELBAUM, RR				HALLAHAN, DE; MAUCERI, HJ; SEUNG, LP; DUNPHY, EJ; WAYNE, JD; HANNA, NN; TOLEDANO, A; HELLMAN, S; KUFE, DW; WEICHSELBAUM, RR			SPATIAL AND TEMPORAL CONTROL OF GENE-THERAPY USING IONIZING-RADIATION	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; ADENOVIRUS TYPE-5; CELLS; TNF	Activation of transcription of the Egr-1 gene by X-rays is regulated by the promoter region of this gene. We linked the radiation-inducible promoter region of the Egr-1 gene to the gene encoding the radiosensitizing and tumoricidal cytokine, tumour necrosis factor-alpha (TNF-alpha) and used a replication-deficient adenovirus to deliver the Egr-TNF construct to human tumours growing in nude mice. Combined treatment with AdS.EgrTNF and 5,000 cGy (rad) resulted in increased intratumoral TNF-a production and increased tumour control compared with treatment with Ad5.Egr-TNF alone or with radiation alone. The increase in tumour control was achieved without an increase in normal tissue damage when compared to tissue injury from radiation alone. Control of gene transcription by ionizing radiation in vivo represents a novel method of spatial and temporal regulation of gene-based medical treatments.	UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637; DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Harvard University; Dana-Farber Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA041068, R01CA037435, R29CA058508, R01CA058508] Funding Source: NIH RePORTER; NCI NIH HHS [CA37435, CA41068, CA58508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN R, 1995, HUM GENE THER, V6, P145, DOI 10.1089/hum.1995.6.2-145; ANDERSON WF, 1994, HUM GENE THER, V5, P1, DOI 10.1089/hum.1994.5.1-1; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; GORCZYCA W, 1993, CANCER RES, V53, P1945; GRIDLEY DS, 1994, ANTICANCER RES, V14, P1107; HALLAHAN D, IN PRESS CANCER J; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1990, INT J RADIAT ONCOL, V19, P69, DOI 10.1016/0360-3016(90)90136-8; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2152; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUANG P, IN PRESS INT J RAD O; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; MANOME Y, 1994, CANCER RES, V54, P5408; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEYN RE, 1993, RADIAT RES, V136, P327, DOI 10.2307/3578544; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PATEL PM, 1993, J IMMUNOTHER, V14, P310, DOI 10.1097/00002371-199311000-00010; SERSA G, 1988, INT J CANCER, V42, P129, DOI 10.1002/ijc.2910420124; TAKAKU F, 1994, ONCOLOGY, V51, P123, DOI 10.1159/000227326; WEICHSELBAUM RR, 1985, P NATL ACAD SCI USA, V82, P4732, DOI 10.1073/pnas.82.14.4732; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; WEICHSELBAUM RR, 1993, CANC MED, P539; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403	34	288	323	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					786	791		10.1038/nm0895-786	http://dx.doi.org/10.1038/nm0895-786			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585181				2022-12-27	WOS:A1995RM63500035
J	PETRYLAK, DP				PETRYLAK, DP			METASTASES SUPPRESSORS AND PROSTATE-CANCER	NATURE MEDICINE			English	Editorial Material							RADICAL PROSTATECTOMY	Even though diagnosis of prostate cancer can be made earlier than in the past, prognosis is still difficult. The discovery of new metastatic markers should aid in treatment design.			PETRYLAK, DP (corresponding author), COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BORING CC, 1995, CA CANC J CLIN, V45, P8; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FISHMAN JR, 1994, J UROLOGY, V152, P202, DOI 10.1016/S0022-5347(17)32862-8; PARTIN AW, 1995, UROLOGY, V45, P831, DOI 10.1016/S0090-4295(99)80091-0; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345	7	4	4	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					739	740		10.1038/nm0895-739	http://dx.doi.org/10.1038/nm0895-739			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585169				2022-12-27	WOS:A1995RM63500023
J	DUNCAN, C; DOUGALL, H; JOHNSTON, P; GREEN, S; BROGAN, R; LEIFERT, C; SMITH, L; GOLDEN, M; BENJAMIN, N				DUNCAN, C; DOUGALL, H; JOHNSTON, P; GREEN, S; BROGAN, R; LEIFERT, C; SMITH, L; GOLDEN, M; BENJAMIN, N			CHEMICAL GENERATION OF NITRIC-OXIDE IN THE MOUTH FROM THE ENTEROSALIVARY CIRCULATION OF DIETARY NITRATE	NATURE MEDICINE			English	Article							HUMAN SALIVA; GASTRIC-CANCER; STOMACH; SUPEROXIDE; PATHWAY; GENES	High concentrations of nitrite present in saliva (derived from dietary nitrate) may, upon acidification, generate nitrogen oxides in the stomach-in sufficient amounts to provide protection from swallowed pathogens. We now show that, in the rat, reduction of nitrate to nitrite is confined to a specialized area on the posterior surface of the tongue, which is heavily colonized by bacteria, and that nitrate reduction is absent in germ-free rats. We also show that in humans increased salivary nitrite production resulting from nitrate intake enhances oral nitric oxide production. We propose that the salivary generation of nitrite is accomplished by a symbiotic relationship involving nitrate-reducing bacteria on the tongue surface, which is designed to provide host defence against microbial pathogens in the mouth and lower gut. These results provide further evidence for beneficial effects of dietary nitrate.	UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,SCH MED,DEPT PATHOL,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PLANT & SOIL SCI,ABERDEEN AB9 2UD,SCOTLAND	University of Aberdeen; University of Aberdeen; University of Aberdeen			Golden, Michael/AAB-8989-2020	Golden, Michael/0000-0002-4039-7538; Leifert, Carlo/0000-0002-2974-3612				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; BODIS S, 1993, BIOCHEM BIOPH RES CO, V194, P347, DOI 10.1006/bbrc.1993.1826; BRAUN C, 1991, J BIOL CHEM, V266, P22785; CALDWELL JR, 1974, JAMA-J AM MED ASSOC, V230, P77, DOI 10.1001/jama.230.1.77; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DONAHOE WE, 1949, PEDIATRICS, V3, P308; DOUGALL HT, 1995, BRIT J CLIN PHARMACO, V39, P460, DOI 10.1111/j.1365-2125.1995.tb04479.x; EDWARDS DAW, 1954, LANCET, P498; FORMAN D, 1985, NATURE, V313, P620, DOI 10.1038/313620a0; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNSALUS RP, 1992, J BACTERIOL, V174, P7069, DOI 10.1128/jb.174.22.7069-7074.1992; HADDOCK BA, 1977, BACTERIOL REV, V41, P47, DOI 10.1128/MMBR.41.1.47-99.1977; HEGESH E, 1982, CLIN CHIM ACTA, V125, P107, DOI 10.1016/0009-8981(82)90187-5; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Ishiwata H., 1975, Journal of the Food Hygienic Society of Japan [Shokuhin Eiseigaku Zasshi], V16, P89; JENSEN ME, 1989, BRIT DENT J, V167, P204, DOI 10.1038/sj.bdj.4806971; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KNIGHT TM, 1990, INT J EPIDEMIOL, V19, P510, DOI 10.1093/ije/19.3.510; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; NEAL KR, 1994, BRIT MED J, V308, P176; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; RIDER BF, 1946, IND ENG CHEM, V18, P96, DOI 10.1021/i560150a003; RUDDELL WSJ, 1976, GUT, V17, P401; Sasaki T, 1979, J FOOD HYG SOC JPN, V20, P363; SOBALA GM, 1989, GASTROENTEROLOGY, V97, P357, DOI 10.1016/0016-5085(89)90071-1; SPIEGELHALDER B, 1976, FOOD COSMET TOXICOL, V14, P545, DOI 10.1016/S0015-6264(76)80005-3; STEVENS A, 1990, THEORY PRACTICE HIST, P290; SUGIMURA T, 1970, CANCER RES, V30, P455; TANNENBAUM SR, 1976, FOOD COSMET TOXICOL, V14, P549, DOI 10.1016/S0015-6264(76)80006-5; TANNENBAUM SR, 1974, JNCI-J NATL CANCER I, V53, P79; WALKER AM, 1979, JAMA-J AM MED ASSOC, V242, P1273, DOI 10.1001/jama.242.12.1273; WENNERHOLM K, 1994, CARIES RES, V28, P48, DOI 10.1159/000261620; WHITTLE BJR, 1989, BRIT J PHARMACOL, V99, P607; Williams D. L. H., 1988, NITROSATION; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; 1987, 20 MIN AGR FISH FOOD, P7	38	487	511	6	54	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					546	551		10.1038/nm0695-546	http://dx.doi.org/10.1038/nm0695-546			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585121				2022-12-27	WOS:A1995RN10100038
J	SIMONS, JN; LEARY, TP; DAWSON, GJ; PILOTMATIAS, TJ; MUERHOFF, AS; SCHLAUDER, GG; DESAI, SM; MUSHAHWAR, IK				SIMONS, JN; LEARY, TP; DAWSON, GJ; PILOTMATIAS, TJ; MUERHOFF, AS; SCHLAUDER, GG; DESAI, SM; MUSHAHWAR, IK			ISOLATION OF NOVEL VIRUS-LIKE SEQUENCES ASSOCIATED WITH HUMAN HEPATITIS	NATURE MEDICINE			English	Article							NON-B-HEPATITIS; C VIRUS; NON-A; NUCLEOTIDE-SEQUENCE; VIRAL-RNA; GENOME; ASSAY; REGION; CHIMPANZEES; ANTIBODIES	Two viruses, GB virus A (GBV-A) and GB virus B (GBV-B), were recently identified in the GB hepatitis agent. Human sera containing antibodies that recognize GBV-A and/or GBV-B recombinant proteins were subjected to polymerase chain reaction studies wi:h degenerate oligonucleotides capable of amplifying a segment of the putative helicase genes from GBV-A, GBV-B or hepatitis C virus. Novel sequences related to members of the Flaviviridae were identified in sera from 12 individuals including 4 individuals with hepatitis. The limited nucleotide sequence identity between GBV-A, GBV-B and HCV sequences suggests that a novel virus, tentatively named GB virus C, may be responsible for some cases of non-A, non-B, non-C, non-D, non-E hepatitis.			SIMONS, JN (corresponding author), ABBOTT LABS,VIRUS DISCOVERY GRP,N CHICAGO,IL 60064, USA.							ALTER HJ, 1994, VOX SANG, V67, P19, DOI 10.1111/j.1423-0410.1994.tb04539.x; BOLLING TJ, 1990, BIOTECHNIQUES, V8, P488; BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254; BROTMAN B, 1985, J INFECT DIS, V151, P618, DOI 10.1093/infdis/151.4.618; BUKH J, 1992, P NATL ACAD SCI USA, V89, P187, DOI 10.1073/pnas.89.1.187; BUKH J, P NATL ACAD SCI USA, V90, P8234; CASTLE E, 1986, VIROLOGY, V149, P10, DOI 10.1016/0042-6822(86)90082-6; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1989, VIROLOGY, V165, P191; DAWSON GJ, 1992, J VIROL METHODS, V38, P175, DOI 10.1016/0166-0934(92)90180-L; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; DEINHARDT F, 1975, AM J MED SCI, V270, P73; DUPUY A, 1989, NUCLEIC ACIDS RES, V17, P3989, DOI 10.1093/nar/17.10.3989; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; FELSENSTEIN J, 1993, PHYLIP INFERENCE PAC; FU JL, 1992, VIROLOGY, V188, P953, DOI 10.1016/0042-6822(92)90560-C; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIBBS JR, 1992, JAMA-J AM MED ASSOC, V267, P2051; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOLMES AW, 1973, NATURE, V243, P419, DOI 10.1038/243419a0; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; IWARSON S, 1994, FEMS MICROBIOL REV, V14, P201, DOI 10.1111/j.1574-6976.1994.tb00089.x; KARAYIANNIS P, 1989, HEPATOLOGY, V9, P186, DOI 10.1002/hep.1840090204; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801; PETERS T, 1993, J MED VIROL, V39, P139, DOI 10.1002/jmv.1890390210; PURCELL RH, 1993, GASTROENTEROLOGY, V104, P955, DOI 10.1016/0016-5085(93)90261-A; ROUX KH, 1994, BIOTECHNIQUES, V16, P812; SAKAMOTO M, J GEN VIROL, V75, P1761; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SCHLAUDER GG, 1994, J VIROL METHODS, V47, P243, DOI 10.1016/0166-0934(94)90022-1; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9; TABOR E, 1979, J INFECT DIS, V140, P794, DOI 10.1093/infdis/140.5.794; TABOR E, 1980, J MED VIROL, V5, P103, DOI 10.1002/jmv.1890050202; TABOR E, 1979, J INFECT DIS, V40, P789; TICEHURST J, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P501; WHITTINGTON RO, 1983, VIRAL IMMUNOLOGICAL, P221; YOSHIZAWA H, 1981, GASTROENTEROLOGY, V81, P107	47	1111	1154	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					564	569		10.1038/nm0695-564	http://dx.doi.org/10.1038/nm0695-564			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585124				2022-12-27	WOS:A1995RN10100041
J	THURSZ, MR; KWIATKOWSKI, D; TOROK, ME; ALLSOPP, CEM; GREENWOOD, BM; WHITTLE, HC; THOMAS, HC; HILL, AVS				THURSZ, MR; KWIATKOWSKI, D; TOROK, ME; ALLSOPP, CEM; GREENWOOD, BM; WHITTLE, HC; THOMAS, HC; HILL, AVS			ASSOCIATION OF HEPATITIS-B SURFACE-ANTIGEN CARRIAGE WITH SEVERE MALARIA IN GAMBIAN CHILDREN	NATURE MEDICINE			English	Article							VIRUS	Severe malaria is a major cause of childhood mortality in sub-Saharan Africa but the factors predisposing children to Severe forms of malaria have not been fully elucidated. In a case-control study of over 1,200 Cambian children hepatitis B virus carriage was significantly increased amongst cases of severe malaria compared to matched controls. We suggest,that this association may relate to impaired clearance of liver stage parasites in the presence of the reduced level of HLA class l antigen expression on hepatocytes Infected by hepatitis B virus. If this association is causal and viral carriage predisposes to severe malaria, widespread vaccination against hepatitis B virus may reduce mortality from severe malaria.	ST MARYS HOSP,SCH MED,ACAD DEPT MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; MRC LABS,FAJARA,GAMBIA	Imperial College London; University of Oxford; MRC Laboratory Molecular Biology	THURSZ, MR (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND.		HILL, Adrian V>S>/C-1306-2008; Thomas, Howard C/A-3152-2009	Torok, Mili Estee/0000-0001-9098-8590; Thursz, Mark/0000-0002-8218-192X; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; DECKER R, 1983, VIRAL HEPATITIS SCI; FOSTER GR, 1993, HEPATOLOGY, V17, P757, DOI 10.1002/hep.1840170502; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; IKEDA T, 1986, HEPATOLOGY, V6, P963; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; RYDER RW, 1984, LANCET, V2, P449; THURSZ MR, IN PRESS NEW ENGL J	11	43	47	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					374	375		10.1038/nm0495-374	http://dx.doi.org/10.1038/nm0495-374			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585070				2022-12-27	WOS:A1995RN09800036
J	EZEKOWITZ, RAB				EZEKOWITZ, RAB			AGALACTOSYL IGC AND MANNOSE-BINDING PROTEINS - BIOCHEMICAL NICETY OR PATHOPHYSIOLOGICAL PARADIGM	NATURE MEDICINE			English	Editorial Material							COMPLEMENT PATHWAY; CLASSICAL PATHWAY; ASSOCIATION; PATTERN; DEFECT; FORMS; CLQ		CHILDRENS HOSP,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute	EZEKOWITZ, RAB (corresponding author), HARVARD UNIV,CHILDRENS HOSP,DEPT PEDIAT,DIV HEMATOL & INFECT DIS,BOSTON,MA 02115, USA.							ANDERS EM, 1994, J GEN VIROL, V75, P615, DOI 10.1099/0022-1317-75-3-615; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; EZEKOWITZ R A B, 1991, Current Biology, V1, P60; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; IKEDA K, 1987, J BIOL CHEM, V262, P7451; LU J, 1990, J IMMUNOL, V144, P2287; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MATSUSHITA M, UNPUB ALLELIC FORM H; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1992, NAT GENET, V2, P50, DOI 10.1038/ng0992-50; SUPER M, 1989, LANCET, V2, P1236; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, CURR BIOL, V2, P1227	20	5	5	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					207	208		10.1038/nm0395-207	http://dx.doi.org/10.1038/nm0395-207			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585032				2022-12-27	WOS:A1995QX55900022
J	FINNEGAN, LP; ROSSOUW, J; HARLAN, WR				FINNEGAN, LP; ROSSOUW, J; HARLAN, WR			A PEPPY RESPONSE TO PEPI RESULTS	NATURE MEDICINE			English	Editorial Material							ENDOMETRIAL CARCINOMA				FINNEGAN, LP (corresponding author), NIH,OFF DIS PREVENT,OFF RES WOMENS HLTH,BETHESDA,MD 20892, USA.							GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; SIMON JA, 1993, FERTIL STERIL, V60, P26; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; WENTZ WB, 1974, GYNECOL ONCOL, V2, P262; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1995, JAMA-J AM MED ASSOC, V273, P199; 1992, ANN INTERN MED, V117, P1038; 1992, ACOG TECHNICAL B, V166	9	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					205	206		10.1038/nm0395-205	http://dx.doi.org/10.1038/nm0395-205			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585031				2022-12-27	WOS:A1995QX55900021
J	LIU, SQ; SAIJO, K; TODOROKI, T; OHNO, T				LIU, SQ; SAIJO, K; TODOROKI, T; OHNO, T			INDUCTION OF HUMAN AUTOLOGOUS CYTOTOXIC T-LYMPHOCYTES ON FORMALIN-FIXED AND PARAFFIN-EMBEDDED TUMOR SECTIONS	NATURE MEDICINE			English	Article							ACTIVATED KILLER CELLS; CANCER; MELANOMA; IMMUNOTHERAPY; INTERLEUKIN-2; PROLIFERATION; RECOGNITION; GROWTH; MICE	Human autologous tumour-specific cytotoxic T lymphocytes (CTL) were generated from peripheral blood on small formalin-fixed paraffin-embedded sections of a gastric cancer. The CTL killed live target cells at an effector/target ratio of 1 within 24 hours and showed the same target specificity as those induced on live cancer cells, The killing activity of the CTL lasted for more than four months in culture and was inhibited by antibodies against CD8 and MHC-class I. These results suggest that adoptive immunotherapy of tumours will be possible with CTL induced on a stable source of tumour antigen.	UNIV TSUKUBA,SCH MED,INST PHYS & CHEM RES,RIKEN,CELL BANK,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,SCH MED,DEPT SURG,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; University of Tsukuba; University of Tsukuba			Saijo, Kaoru/N-5095-2015					AZUMA M, 1992, J IMMUNOL, V149, P1115; CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992; CROWLEY NJ, 1991, J IMMUNOL, V146, P1692; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; FUJINO T, 1994, CANCER RES, V54, P4294; Hay R. K. M, 1994, ATLAS HUMAN TUMOR CE; HEO DS, 1988, J IMMUNOL, V140, P4042; HOLDEN CA, 1986, J IMMUNOL METHODS, V91, P45, DOI 10.1016/0022-1759(86)90100-6; IKARASHI H, 1994, CANCER RES, V54, P190; IOANNIDES CG, 1993, CLIN IMMUNOL IMMUNOP, V66, P91, DOI 10.1006/clin.1993.1012; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LIU SQ, 1994, CANCER IMMUNOL IMMUN, V39, P279; MITRA AB, 1994, CANCER RES, V54, P4481; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUUL LM, 1987, J IMMUNOL, V138, P989; NAKASHIMA M, 1994, CELL IMMUNOL, V155, P53, DOI 10.1006/cimm.1994.1101; PERUSSIA B, 1987, NAT IMMUN CELL GROW, V6, P171; POLLARD K, 1987, J IMMUNOL METHODS, V96, P145, DOI 10.1016/0022-1759(87)90379-6; Rees A D, 1989, Int Immunol, V1, P624, DOI 10.1093/intimm/1.6.624; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SAOTOME K, 1989, TOXICOL IN VITRO, V3, P317, DOI 10.1016/0887-2333(89)90039-8; SLINGLUFF CL, 1994, CANCER RES, V54, P2731; TAKAHASHI H, 1993, SCIENCE, V259, P1460, DOI 10.1126/science.8451642; TJOA, 1994, CANCER RES, V54, P204; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WOLFEL T, 1993, INT J CANCER, V54, P636, DOI 10.1002/ijc.2910540419	30	88	94	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					267	271		10.1038/nm0395-267	http://dx.doi.org/10.1038/nm0395-267			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585045				2022-12-27	WOS:A1995QX55900035
J	PAIGEN, K				PAIGEN, K			A MIRACLE ENOUGH - THE POWER OF MICE	NATURE MEDICINE			English	Review							LIPOPROTEIN				PAIGEN, K (corresponding author), JACKSON LAB,600 MAIN ST,BAR HARBOR,ME 04609, USA.							COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Davisson Muriel T., 1993, V384, P117; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; NISHINA PM, 1992, P NATL ACAD SCI USA, V89, P708, DOI 10.1073/pnas.89.2.708; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PIAGEN B, IN PRESS AM J CLIN N; SLY WS, 1993, NAT GENET, V4, P105, DOI 10.1038/ng0693-105; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	8	141	144	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					215	220		10.1038/nm0395-215	http://dx.doi.org/10.1038/nm0395-215			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585036				2022-12-27	WOS:A1995QX55900026
J	SOMMER, N; LOSCHMANN, PA; NORTHOFF, GH; WELLER, M; STEINBRECHER, A; STEINBACH, JP; LICHTENFELS, R; MEYERMANN, R; RIETHMULLER, A; FONTANA, A; DICHGANS, J; MARTIN, R				SOMMER, N; LOSCHMANN, PA; NORTHOFF, GH; WELLER, M; STEINBRECHER, A; STEINBACH, JP; LICHTENFELS, R; MEYERMANN, R; RIETHMULLER, A; FONTANA, A; DICHGANS, J; MARTIN, R			THE ANTIDEPRESSANT ROLIPRAM SUPPRESSES CYTOKINE PRODUCTION AND PREVENTS AUTOIMMUNE ENCEPHALOMYELITIS	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; PHOSPHODIESTERASE INHIBITOR ROLIPRAM; MAJOR DEPRESSIVE DISORDER; FACTOR-ALPHA PRODUCTION; CENTRAL-NERVOUS-SYSTEM; T-CELL CLONES; MULTIPLE-SCLEROSIS; MYELIN; PROTEIN	In multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) the cytokines tumour necrosis factor-alpha (TNF), lymphotoxin-alpha (LT), and interferon-gamma (IFN-gamma) are of central pathogenetic importance. A therapy capable of stopping neurological deterioration in MS patients is not yet available. Here, we report that rolipram, a selective type IV phosphodiesterase inhibitor, stereospecifically suppresses the production of TNF/LT and less strongly also IFN-gamma in human and rat autoreactive T cells. Moreover, we show that rolipram is an effective treatment for EAE. Rolipram has extensively been studied in humans for the treatment of depression, but has not yet been marketed. The data presented here identify rolipram as potential therapy for multiple sclerosis and provoke the immediate initiation of clinical trials.	UNIV TUBINGEN, DEPT TRANSFUS MED, D-72076 TUBINGEN, GERMANY; UNIV ZURICH HOSP, DEPT INTERNAL MED, CLIN IMMUNOL SECT, CH-8044 ZURICH, SWITZERLAND; UNIV TUBINGEN, INST BRAIN RES, D-72076 TUBINGEN, GERMANY; NINCDS, NEUROIMMUNOL BRANCH, BETHESDA, MD 20892 USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital; Eberhard Karls University of Tubingen; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	SOMMER, N (corresponding author), UNIV TUBINGEN, DEPT NEUROL, HOPPE SEYLER STR 3, D-72076 TUBINGEN, GERMANY.			Weller, Michael/0000-0002-1748-174X				BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; CHUNG IY, 1991, J EXP MED, V173, P801, DOI 10.1084/jem.173.4.801; DAVIS CW, 1984, BIOCHIM BIOPHYS ACTA, V797, P354, DOI 10.1016/0304-4165(84)90257-5; DEZUBE BJ, 1993, J ACQ IMMUN DEF SYND, V6, P787; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FLEISCHHACKER WW, 1992, NEUROPSYCHOBIOLOGY, V26, P59, DOI 10.1159/000118897; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; HEBENSTREIT GF, 1989, PHARMACOPSYCHIATRY, V22, P156, DOI 10.1055/s-2007-1014599; HERVE P, 1992, BLOOD, V79, P3362; ICHIMURA M, 1993, BIOCHEM BIOPH RES CO, V193, P985, DOI 10.1006/bbrc.1993.1722; KAULEN P, 1989, BRAIN RES, V503, P229, DOI 10.1016/0006-8993(89)91669-7; KRAUSE W, 1989, XENOBIOTICA, V19, P683, DOI 10.3109/00498258909042306; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; LINDSEY JW, 1994, ANN NEUROL, V36, P183; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTIN R, 1992, J IMMUNOL, V148, P1359; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; PANITCH HS, 1987, LANCET, V1, P893; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1992, INT IMMUNOL, V4, P615, DOI 10.1093/intimm/4.5.615; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SCHMIECHEN R, 1990, PSYCHOPHARMACOLOGY, V102, P17, DOI 10.1007/BF02245738; SCOTT AIF, 1991, EUR J CLIN PHARMACOL, V40, P127; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; SPENGLER RN, 1989, INFECT IMMUN, V57, P2837, DOI 10.1128/IAI.57.9.2837-2841.1989; STOLL G, 1993, J NEUROIMMUNOL, V45, P175, DOI 10.1016/0165-5728(93)90178-2; SUTTORP N, 1993, J CLIN INVEST, V91, P1421, DOI 10.1172/JCI116346; SWANBORG RH, 1988, METHOD ENZYMOL, V162, P413; UMEHARA F, 1990, LAB INVEST, V62, P147; WACHTEL H, 1986, NEUROPHARMACOLOGY, V25, P1119, DOI 10.1016/0028-3908(86)90159-0	36	308	325	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1995	1	3					244	248		10.1038/nm0395-244	http://dx.doi.org/10.1038/nm0395-244			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585041				2022-12-27	WOS:A1995QX55900031
J	KENNEDY, D				KENNEDY, D			ACADEMIC MISCONDUCT	NATURE MEDICINE			English	Editorial Material											KENNEDY, D (corresponding author), STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305, USA.								0	12	12	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					115	116		10.1038/nm0295-115	http://dx.doi.org/10.1038/nm0295-115			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585002				2022-12-27	WOS:A1995QX55800015
J	ESTRELA, JM; OBRADOR, E; NAVARRO, J; DELAVEGA, MCL; PELLICER, JA				ESTRELA, JM; OBRADOR, E; NAVARRO, J; DELAVEGA, MCL; PELLICER, JA			ELIMINATION OF EHRLICH TUMORS BY ATP-INDUCED GROWTH-INHIBITION, GLUTATHIONE DEPLETION AND X-RAYS	NATURE MEDICINE			English	Article							BUTHIONINE SULFOXIMINE; ADENINE-NUCLEOTIDES; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; ASCITES TUMOR; METABOLISM; ADENOSINE; MODULATION; TISSUES; INVIVO	ATP-induced tumour growth inhibition is accompanied by a selective decrease in the content of the tripeptide glutathione (GSH) within the cancer cells in vivo. Depletion of cellular GSH sensitizes tumours to chemotherapy and radiation, but the usefulness of this depletion depends on whether the levels of GSH can be reduced in the tumour relative to normal tissues. We report here that administration of ATP in combination with diethylmaleate and X-rays leads to complete regression of 95% of Ehrlich ascites tumours in mice. This shows that an aggressive tumour can be eliminated by using a therapy based on modulation of GSH levels in cancer cells.			ESTRELA, JM (corresponding author), UNIV VALENCIA,FAC MED,DEPT FISIOL,AV BLASCO IBANEZ 17,E-46010 VALENCIA,SPAIN.		OBRADOR, ELENA/H-4069-2015; Estrela, Jose/H-4449-2015; MARTINEZ, ANTONIO PELLICER/C-4832-2015	OBRADOR, ELENA/0000-0002-5934-5543; Estrela, Jose/0000-0002-2540-9190; 				Akerboom T P, 1981, Methods Enzymol, V77, P373; Apolant, 1905, BERL KLIN WSCHR, V42, P871; ARRICK BA, 1984, CANCER RES, V44, P4224; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BERGMEYER HU, 1985, METHODS ENZYMATIC AN; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CHAHWALA SB, 1984, J BIOL CHEM, V259, P3717; DELAVEGA MCL, 1994, BIOCHEM J, V298, P99; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; HISATA T, 1980, EUR J BIOCHEM, V105, P155, DOI 10.1111/j.1432-1033.1980.tb04485.x; LEE FYF, 1987, BRIT J CANCER, V56, P33, DOI 10.1038/bjc.1987.148; LOPES MN, 1989, BIOCHEM J, V264, P713, DOI 10.1042/bj2640713; MCCLARD RW, 1980, BIOCHEMISTRY-US, V19, P4699, DOI 10.1021/bi00561a024; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MEISTER A, 1983, SCIENCE, V220, P470; MISTRY P, 1991, PHARMACOL THERAPEUT, V49, P125, DOI 10.1016/0163-7258(91)90026-I; MITCHELL J B, 1987, British Journal of Cancer, V55, P96; MITCHELL JB, 1989, INT J RADIAT ONCOL, V16, P1289, DOI 10.1016/0360-3016(89)90301-5; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PLANET G, 1976, J BIOL CHEM, V251, P583; RAPAPORT E, 1983, CANCER RES, V43, P4402; RAPAPORT E, 1989, P NATL ACAD SCI USA, V86, P1662, DOI 10.1073/pnas.86.5.1662; RAPAPORT E, 1988, EUR J CANCER CLIN ON, V24, P1491, DOI 10.1016/0277-5379(88)90340-9; Rottenberg H, 1979, Methods Enzymol, V55, P547; SNYDER FF, 1976, FEBS LETT, V66, P102, DOI 10.1016/0014-5793(76)80595-9; TERRADEZ P, 1993, BIOCHEM J, V292, P477, DOI 10.1042/bj2920477; WEISMAN GA, 1988, J BIOL CHEM, V263, P12367; YATES RA, 1956, J BIOL CHEM, V221, P743	31	66	68	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					84	88		10.1038/nm0195-84	http://dx.doi.org/10.1038/nm0195-84			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584960				2022-12-27	WOS:A1995QX55700032
J	Brenner, M				Brenner, M			Placental blood transplant: Who will benefit?	NATURE MEDICINE			English	Editorial Material							UMBILICAL-CORD BLOOD; CELLS				Brenner, M (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							APPELBAUM FR, 1994, MED ONCOL, V11, P69; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; Butler D, 1996, NATURE, V382, P99, DOI 10.1038/382099a0; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 1996, NATURE, V382, P108, DOI 10.1038/382108a0; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Laporte JP, 1996, NEW ENGL J MED, V335, P167, DOI 10.1056/NEJM199607183350304	8	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					969	970		10.1038/nm0996-969	http://dx.doi.org/10.1038/nm0996-969			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782448				2022-12-27	WOS:A1996VF49700025
J	Huygen, K; Content, J; Denis, O; Montgomery, DL; Yawman, AM; Deck, RR; DeWitt, CM; Orme, IM; Baldwin, S; DSouza, C; Drowart, A; Lozes, E; Vandenbussche, P; VanVooren, JP; Liu, MA; Ulmer, JB				Huygen, K; Content, J; Denis, O; Montgomery, DL; Yawman, AM; Deck, RR; DeWitt, CM; Orme, IM; Baldwin, S; DSouza, C; Drowart, A; Lozes, E; Vandenbussche, P; VanVooren, JP; Liu, MA; Ulmer, JB			Immunogenicity and protective efficacy of a tuberculosis DNA vaccine	NATURE MEDICINE			English	Article							MYCOBACTERIUM-BOVIS BCG; MAJOR HISTOCOMPATIBILITY COMPLEX; INTERFERON-GAMMA; T-CELLS; MICE; INFECTION; ANTIGEN; LEPROSY; IDENTIFICATION; IMMUNIZATION	Tuberculosis is the most widespread and lethal infectious disease affecting humans. Immunization of mice with plasmid DNA constructs encoding one of the secreted components of Mycobacterium tuberculosis, antigen 85 (Ag85), induced substantial humoral and cell-mediated immune responses and conferred significant protection against challenge with live M. tuberculosis and M. bovis bacille Calmette-Guerin (BCG). These results indicate that immunization with DNA encoding a mycobacterial antigen provides an efficient and simple method for generating protective immunity and that this technique may be useful for defining the protective antigens of M. tuberculosis, leading to the development of a more effective vaccine.	INST PASTEUR, DEPT VIROL, B-1180 BRUSSELS, BELGIUM; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; FREE UNIV BRUSSELS, HOP ERASME, B-1070 BRUSSELS, BELGIUM	Colorado State University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Huygen, K (corresponding author), MERCK RES LABS, DEPT VIRUS & CELL BIOL, WP16-10, W POINT, PA 19486 USA.			Huygen, Kris/0000-0001-7808-0512	NIAID NIH HHS [AI 35182] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035182] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; APPELBERG R, 1993, IMMUNOLOGY, V80, P352; BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BORREMANS ML, 1989, INFECT IMMUN, V57, P3122; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEBRUYN J, 1987, MICROB PATHOGENESIS, V2, P351, DOI 10.1016/0882-4010(87)90077-5; DENIS M, 1990, IMMUNOL LETT, V24, P203, DOI 10.1016/0165-2478(90)90049-V; DENIS O, 1993, INT IMMUNOL, V5, P71, DOI 10.1093/intimm/5.1.71; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GRIFFIN JP, 1994, INFECT IMMUN, V62, P1683, DOI 10.1128/IAI.62.5.1683-1690.1994; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; HUYGEN K, 1993, INFECT IMMUN, V61, P2687, DOI 10.1128/IAI.61.6.2687-2693.1993; HUYGEN K, 1992, INFECT IMMUN, V60, P2880, DOI 10.1128/IAI.60.7.2880-2886.1992; HUYGEN K, 1994, INFECT IMMUN, V62, P363, DOI 10.1128/IAI.62.2.363-370.1994; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994; LAUNOIS P, 1993, J INFECT DIS, V167, P1160, DOI 10.1093/infdis/167.5.1160; MONTGOMERY DL, 1993, DNA CELL BIOL, V12, P777, DOI 10.1089/dna.1993.12.777; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; PARISH CR, 1983, J IMMUNOL METHODS, V58, P225, DOI 10.1016/0022-1759(83)90277-6; SHIVER JW, 1995, VACCINES, P95; Silva CL, 1995, IMMUNOLOGY, V86, P519; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WIKER HG, 1992, MICROBIOL REV, V56, P648, DOI 10.1128/MMBR.56.4.648-661.1992; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	30	562	614	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					893	898		10.1038/nm0896-893	http://dx.doi.org/10.1038/nm0896-893			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705859				2022-12-27	WOS:A1996UZ80400036
J	Alonso, AD; GrundkeIqbal, I; Iqbal, K				Alonso, AD; GrundkeIqbal, I; Iqbal, K			Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules	NATURE MEDICINE			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; ABNORMAL PHOSPHORYLATION; BRAIN; ASSAY	Microtubule-associated protein tau becomes abnormally hyperphosphorylated in Alzheimer's disease (AD) and accumulates as tangles of paired helical filaments in neurons undergoing degeneration. We now show that in solution normal tau associates with the AD hyperphosphorylated tau (AD P-tau) in a nonsaturable fashion, forming large tangles of filaments 3.3 +/- 0.7 nm in diameter. These tangles, which are not detected in identically treated normal tau or AD P-tau alone, are made up of filaments several microns in length and are labeled with tau antibodies. Dephosphorylation with alkaline phosphatase abolishes the ability of AD P-tau to aggregate with normal tau and prevents tangle formation. AD P-tau disassembles microtubules assembled from normal tau and tubulin. These data provide insight into how the hyperphosphorylation of tau might lead to the formation of the neurofibrillary tangles and the degeneration of the affected neurons in AD.			Alonso, AD (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL,1050 FOREST HILL RD,STATEN ISL,NY 10314, USA.				FOGARTY INTERNATIONAL CENTER [R03TW000507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008076, R01AG005892] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00507] Funding Source: Medline; NIA NIH HHS [AG 08076, AG 05892] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALAFUZOFF I, 1987, ACTA NEUROPATHOL, V74, P209, DOI 10.1007/BF00688184; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ALONSO AD, 1995, BRAIN RES MOL BRAIN, V31, P194; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KOPKE E, 1993, J BIOL CHEM, V268, P24374; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; RUBEN GC, 1988, J BIOL CHEM, V263, P2861; RUBEN GC, 1992, BRAIN RES, V590, P164, DOI 10.1016/0006-8993(92)91092-S; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WANG JZ, UNPUB NATURE MED; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WRZOLEK MA, 1992, AM J PATHOL, V141, P343	30	655	678	3	73	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					783	787		10.1038/nm0796-783	http://dx.doi.org/10.1038/nm0796-783			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673924				2022-12-27	WOS:A1996UU68000034
J	Perucho, M				Perucho, M			Microsatellite instability: The mutator that mutates the other mutator	NATURE MEDICINE			English	Editorial Material							CARCINOGENESIS				Perucho, M (corresponding author), BURNHAM INST,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Perucho, Manuel/0000-0002-2169-2662				Casares S, 1995, ONCOGENE, V11, P2303; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; LOEB LA, 1991, CANCER RES, V51, P3075; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Shibata D, 1996, NAT MED, V2, P676, DOI 10.1038/nm0696-676; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	13	165	173	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					630	631		10.1038/nm0696-630	http://dx.doi.org/10.1038/nm0696-630			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640546				2022-12-27	WOS:A1996UN69100023
J	Karalis, K; Goodwin, G; Majzoub, JA				Karalis, K; Goodwin, G; Majzoub, JA			Cortisol blockade of progesterone: A possible molecular mechanism involved in the initiation of human labor	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; GLUCOCORTICOID RECEPTOR; MESSENGER-RNA; PREGNANCY; ANTIPROGESTERONE; EXPRESSION; PLACENTA; PEPTIDE; PLASMA; PARTURITION	In most mammals, labor is heralded by progesterone withdrawal, which is believed to be related to the activation of multiple pathways leading to parturition. In humans, despite no decrease in placental progesterone production, activation of similar pathways preceding labor suggests the presence of an endogenous antiprogestin, which we reasoned might: be cortisol, whose secretion from the fetal adrenal rises markedly at the end of human gestation. We report that in primary cultures of human placenta, cortisol is able to compete with the action of progesterone in the regulation of the corticotropin-releasing hormone (CRH) gene. CRH is a peptide highly expressed in human placenta at the end of gestation, which has been suggested to be involved in regulating the timing of parturition. These findings provide a model for functional progesterone withdrawal at the end of human pregnancy, which may be involved in the initiation of labor.			Karalis, K (corresponding author), CHILDRENS HOSP, DIV ENDOCRINOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024704] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [2MO1 RR 02172] Funding Source: Medline; NICHD NIH HHS [R01 HD 24704-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON ABM, 1975, J ENDOCRINOL, V66, P61, DOI 10.1677/joe.0.0660061; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BERGHORN KA, 1991, ENDOCRINOLOGY, V129, P1424, DOI 10.1210/endo-129-3-1424; BLOCH K, 1945, J BIOL CHEM, V157, P661; CASEY ML, 1993, SEMIN REPROD ENDOCR, V11, P272, DOI 10.1055/s-2007-1018840; CASEY ML, 1988, CLIN OBSTET GYNECOL, V31, P533, DOI 10.1097/00003081-198809000-00005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; Csapo A I, 1977, Ciba Found Symp, P159; EMANUEL RL, 1994, CLIN ENDOCRINOL, V40, P257, DOI 10.1111/j.1365-2265.1994.tb02477.x; FENCL MDM, 1980, NATURE, V287, P225, DOI 10.1038/287225a0; FRIM DM, 1988, J CLIN INVEST, V82, P287, DOI 10.1172/JCI113585; GASPARONI A, 1991, EUR J PEDIATR, V150, P481, DOI 10.1007/BF01958427; GOLAND RS, 1988, AM J OBSTET GYNECOL, V159, P884, DOI 10.1016/S0002-9378(88)80162-5; JAHN GA, 1987, J STEROID BIOCHEM, V28, P371, DOI 10.1016/0022-4731(87)91053-3; JONES SA, 1989, J CLIN ENDOCR METAB, V68, P825, DOI 10.1210/jcem-68-4-825; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V150, P501, DOI 10.1016/S0002-9378(84)90428-9; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; LELAIDIER C, 1994, BRIT J OBSTET GYNAEC, V101, P501, DOI 10.1111/j.1471-0528.1994.tb13150.x; LIGGINS GC, 1994, AUST NZ J OBSTET GYN, V34, P338, DOI 10.1111/j.1479-828X.1994.tb01085.x; LIGGINS GC, 1981, FETAL ENDOCRINOLOGY, P211; LIPPMAN M, 1977, ANN NY ACAD SCI, V286, P101, DOI 10.1111/j.1749-6632.1977.tb29409.x; MAJZOUB JA, 1988, METHODS NEUROSCI, V52, P1160; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015; OKAMOTO E, 1989, HORM METAB RES, V21, P566, DOI 10.1055/s-2007-1009289; PHILIBERT D, 1991, FRONT HORM RES, V19, P1; PRESS MF, 1988, AM J PATHOL, V131, P112; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; ROBINSON BG, 1989, MOL CELL ENDOCRINOL, V62, P337, DOI 10.1016/0303-7207(89)90022-1; RYAN KJ, 1980, MATERNAL FETAL ENDOC, P297; SAWCHENKO PE, 1987, J NEUROSCI, V7, P1093; SCHWARZ BE, 1977, ANN NY ACAD SCI, V286, P304, DOI 10.1111/j.1749-6632.1977.tb29425.x; SIITERI PK, 1963, STEROIDS, V2, P713, DOI 10.1016/0039-128X(63)90044-8; SIITERI PK, 1981, FETAL ENDOCRINOLOGY, V5, P1; SLATER EP, 1988, MOL ENDOCRINOL, V2, P485, DOI 10.1210/mend-2-6-485; SPEEG KV, 1979, ENDOCRINOLOGY, V104, P1364, DOI 10.1210/endo-104-5-1364; STALLA GK, 1989, GYNECOL ENDOCRINOL, V3, P1, DOI 10.3109/09513598909152447; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; TULCHINSKY D, 1972, AM J OBSTET GYNECOL, V112, P1095, DOI 10.1016/0002-9378(72)90185-8; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WESTPHAL U, 1977, ANN NY ACAD SCI, V286, P10, DOI 10.1111/j.1749-6632.1977.tb29402.x	44	186	188	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					556	560		10.1038/nm0596-556	http://dx.doi.org/10.1038/nm0596-556			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616715				2022-12-27	WOS:A1996UJ23000039
J	Ito, T; May, WS				Ito, T; May, WS			Drug development train gathering steam	NATURE MEDICINE			English	Editorial Material							CELLS				Ito, T (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL & HEMATOL,GALVESTON,TX 77555, USA.							CORTES JE, 1995, CANCER-AM CANCER SOC, V76, P2393, DOI 10.1002/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JONES RJ, 1990, BLOOD, V75, P1319; KARP JE, 1994, CANCER RES, V54, P653; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MAY WS, 1987, P NATL ACAD SCI USA, V84, P8483, DOI 10.1073/pnas.84.23.8483; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283	13	12	12	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					403	404		10.1038/nm0496-403	http://dx.doi.org/10.1038/nm0496-403			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597948				2022-12-27	WOS:A1996UD31400040
J	Potts, M				Potts, M			The myth of a male pill	NATURE MEDICINE			English	Editorial Material											Potts, M (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA.							[Anonymous], 1987, JAMA, V257, P796; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650; FELDBLUM PJ, 1994, AM J PUBLIC HEALTH, V84, P1032, DOI 10.2105/AJPH.84.6.1032-a; GRAHAMSMITH F, 1994, POPULATION COMPLEX R, P377; HIEU DT, 1993, LANCET, V342, P213, DOI 10.1016/0140-6736(93)92302-A; *I MED COMM REL OR, 1991, OR CONTR BREAST CANC, P4; PIES C, 1994, INT FAMILY PLANNING, V20, P137; PIKE MC, 1989, BRIT J CANCER, V60, P142, DOI 10.1038/bjc.1989.237	9	24	24	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					398	399		10.1038/nm0496-398	http://dx.doi.org/10.1038/nm0496-398			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597945				2022-12-27	WOS:A1996UD31400037
J	Rade, JJ; Schulick, AH; Virmani, R; Dichek, DA				Rade, JJ; Schulick, AH; Virmani, R; Dichek, DA			Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury	NATURE MEDICINE			English	Article							MUSCLE CELL-PROLIFERATION; THROMBIN; RECEPTOR; HEPARIN; ANGIOPLASTY; RESTENOSIS; INHIBITOR	Catalytically active thrombin, acting locally, is thought to mediate neointima formation after arterial injury. We constructed an adenovirus vector, AdHV-1.2, containing a complementary DNA for the thrombin inhibitor hirudin. AdHV-1.2 directed the synthesis and secretion of biologically active hirudin from vascular cells in vitro. In vivo gene transfer of hirudin into smooth muscle cells of injured rat carotid arteries resulted in peak secretion of at least 34 +/- 23 pg hirudin per vessel per 24 hours, and resulted in a significant (P < 0.05) 35% reduction in neointima formation. Systemic partial thromboplastin times were not affected by local hirudin expression. These results support the hypothesis that local thrombin activity contributes to neointima formation after arterial injury and suggest that local delivery of a highly specific antithrombin may constitute an effective intervention for arterial proliferative disease.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; NHLBI,MOLEC HEMATOL BRANCH,BETHESDA,MD 20892; ARMED FORCES INST PATHOL,DIV CARDIOVASC,WASHINGTON,DC 20307; JOHNS HOPKINS SCH MED,DIV CARDIOL,BALTIMORE,MD 21205	University of California System; University of California San Francisco; The J David Gladstone Institutes; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); United States Department of Defense; Johns Hopkins University; Johns Hopkins Medicine				Dichek, David/0000-0002-5224-2736				BENEZRA M, 1993, BLOOD, V81, P3324; BLOMBACK B, 1958, ARK KEMI, V12, P321; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DANIEL WW, 1991, BIOSTATISTICS F ANAL; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; Eccleston E., 1977, Comparative clinical haematology,, P611; FORTKAMP E, 1986, DNA-J MOLEC CELL BIO, V5, P511, DOI 10.1089/dna.1.1986.5.511; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; HATTON MWC, 1994, THROMB HAEMOSTASIS, V71, P499; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; JOHNSON PH, 1991, HAEMOSTASIS, V21, P41; JUST M, 1991, HAEMOSTASIS, V21, P80; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OKAZAKI H, 1992, CIRC RES, V71, P1285, DOI 10.1161/01.RES.71.6.1285; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHULICK AH, 1995, CIRC RES, V77, P475, DOI 10.1161/01.RES.77.3.475; SCHULICK AH, 1995, CIRCULATION, V91, P2407, DOI 10.1161/01.CIR.91.9.2407; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; SPANNAGL M, 1991, HAEMOSTASIS, V21, P36; STRAUSS BH, 1992, CIRCULATION, V85, P1952, DOI 10.1161/circ.85.5.1533354; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; VANDENBOS AA, 1993, CIRCULATION, V88, P2058, DOI 10.1161/01.CIR.88.5.2058; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; WALSMANN P, 1991, SEMIN THROMB HEMOST, V17, P83, DOI 10.1055/s-2007-1002593; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; 1994, CIRCULATION, V90, P1631; 1992, CIRCULATION, V86, P100	38	135	139	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					293	298		10.1038/nm0396-293	http://dx.doi.org/10.1038/nm0396-293			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612227				2022-12-27	WOS:A1996TY64000037
J	Abkowitz, JL; Catlin, SN; Guttorp, P				Abkowitz, JL; Catlin, SN; Guttorp, P			Evidence that hematopoiesis may be a stochastic process in vivo	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; STEM-CELL CLONES; PROGENITOR CELLS; W/WV MICE; DIFFERENTIATION; GENE; RECONSTITUTION; SEPARATION; NUMBERS; SYSTEM	To study the behavior of hematopoietic stem cells in vivo, hematopoiesis was simulated by assuming that all stem cell decisions (that is, replication, apoptosis, initiation of a differentiation/maturation program) were determined by chance. Predicted outcomes from simulated experiments were compared with data obtained in autologous marrow transplantation studies of glucose 6-phosphate dehydrogenase (G6PD) heterozygous female Safari cats. With this approach, we prove that stochastic differentiation can result in the wide spectrum of discrete outcomes observed in vivo, and that clonal dominance can occur by chance. As the analyses also suggest that the frequency of feline hematopoietic stem cells is only 6 per 10(7) nucleated marrow cells, and that stem cells do not replicate on average more frequently than once every three weeks, these large-animal data challenge clinical strategies for marrow transplantation and gene therapy.	UNIV WASHINGTON, DEPT STAT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Abkowitz, JL (corresponding author), UNIV WASHINGTON, DEPT MED, DIV HEMATOL, BOX 357710, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [R01 HL 46598] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABKOWITZ JL, 1985, J CLIN INVEST, V75, P133, DOI 10.1172/JCI111665; ABKOWITZ JL, 1995, P NATL ACAD SCI USA, V92, P2031, DOI 10.1073/pnas.92.6.2031; ABKOWITZ JL, 1990, P NATL ACAD SCI USA, V87, P9062, DOI 10.1073/pnas.87.22.9062; Arley N., 1943, THEORY STOCHASTIC PR; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BLACKETT NM, 1987, CELL TISSUE KINET, V20, P393, DOI 10.1111/j.1365-2184.1987.tb01324.x; BODINE NM, 1993, BLOOD, V82, P1875; CAPEL B, 1990, BLOOD, V75, P2267; CAPEL B, 1989, P NATL ACAD SCI USA, V86, P4564, DOI 10.1073/pnas.86.12.4564; Coffin J. M., 1990, VIROLOGY, P1437; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GORDON MY, 1994, STEM CELLS, V12, P175, DOI 10.1002/stem.5530120205; GUTTORP P, 1990, IMA J MATH APPL MED, V7, P125; Guttorp P, 1995, STOCHASTIC MODELING; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1992, P NATL ACAD SCI USA, V89, P10134, DOI 10.1073/pnas.89.21.10134; HELLINGA HW, 1994, P NATL ACAD SCI USA, V91, P5803, DOI 10.1073/pnas.91.13.5803; HOGGE DE, 1994, BAILLIERE CLIN HAEM, V7, P49, DOI 10.1016/S0950-3536(05)80006-X; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KARLSSON S, 1991, BLOOD, V78, P2481; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; KIEFER F, 1991, BLOOD, V78, P2577; KIEM HP, 1994, BLOOD, V83, P1467; KURNIT DM, 1985, J CELL PHYSIOL, V123, P55, DOI 10.1002/jcp.1041230110; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LOTHROP CD, 1991, BLOOD, V78, P237; METCALF D, 1993, BLOOD, V82, P3515; MICKLEM HS, 1987, EXP HEMATOL, V15, P251; NASH R, 1988, BLOOD, V72, P2031; NEWTON M, IN PRESS J AM STAT A; OBRIEN SJ, 1986, TRENDS GENET, V2, P137, DOI 10.1016/0168-9525(86)90204-0; OGATA H, 1992, BLOOD, V80, P91; OGAWA M, 1983, BLOOD, V61, P823; ONISHI M, 1993, BLOOD, V81, P3217; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; POSAKONY JW, 1994, CELL, V76, P415, DOI 10.1016/0092-8674(94)90105-8; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; SPAIN LM, 1992, P NATL ACAD SCI USA, V89, P3790, DOI 10.1073/pnas.89.9.3790; STEWART FM, 1993, BLOOD, V81, P2566; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TURHAN AG, 1989, NEW ENGL J MED, V320, P1655, DOI 10.1056/NEJM198906223202504; UCHIDA N, 1994, BLOOD, V83, P3758; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; VOGEL H, 1969, J THEOR BIOL, V22, P249, DOI 10.1016/0022-5193(69)90004-6; WICHMANN HE, 1988, BLOOD CELLS, V14, P411; WOLF NS, 1993, EXP HEMATOL, V21, P614	52	195	201	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1996	2	2					190	197		10.1038/nm0296-190	http://dx.doi.org/10.1038/nm0296-190			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574964				2022-12-27	WOS:A1996TU06000039
J	Dierich, MP; Stoiber, H; Clivio, A				Dierich, MP; Stoiber, H; Clivio, A			A ''complement-ary'' AIDS vaccine	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; HIV; ENHANCEMENT; RECEPTORS; PROTEINS; CELLS	The human immunodeficiency virus uses the human complement system to its advantage. Is it possible to turn the tables with a vaccine?	LUDWIG BOLTZMANN INST AIDS FORSCH,INNSBRUCK,AUSTRIA; UNIV MILAN,LAB INTERDISCIPLINARE TECNOL AVANZATE,MILAN,ITALY	Ludwig Boltzmann Institute; University of Milan	Dierich, MP (corresponding author), INST HYG,A-6020 INNSBRUCK,AUSTRIA.		CLIVIO, ALBERTO/S-9320-2017	CLIVIO, ALBERTO/0000-0002-1423-046X				ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; ATKINSON J P, 1991, Clinical and Experimental Immunology, V86, P27; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BOYER V, 1991, J EXP MED, V173, P1151, DOI 10.1084/jem.173.5.1151; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; EBENBICHLER C, 1991, J EXP MED, V174, P944; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; JOLING P, 1993, J IMMUNOL, V150, P1065; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; MARSCHANG P, 1995, EUR J IMMUNOL, V25, P285, DOI 10.1002/eji.1830250147; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; MORGAN RP, 1994, IMMUNOPATHOLOGY, V15, P369; ORENTAS RJ, 1993, AIDS RES HUM RETROV, V9, P1157, DOI 10.1089/aid.1993.9.1157; PINTER C, 1995, AIDS RES HUM RETROV, V11, P971, DOI 10.1089/aid.1995.11.971; PINTER C, 1995, AIDS RES HUM RETROV, V11, P577, DOI 10.1089/aid.1995.11.577; PINTR C, 1995, IMMUNOBIOLOGY, V193, P98; REISINGER E, 1989, AIDS PHILA, V4, P961; ROBINSON WE, 1990, VIROLOGY, V175, P600, DOI 10.1016/0042-6822(90)90449-2; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; SOLDER B, 1989, LANCET, V2, P271; STOIBER H, 1994, EUR J IMMUNOL, V24, P294, DOI 10.1002/eji.1830240203; STOIBER H, 1995, AIDS, V9, P19, DOI 10.1097/00002030-199501000-00003; STOIBER H, IN PRESS J EXP MED; TREMBLAY M, 1990, J EXP MED, V171, P1791, DOI 10.1084/jem.171.5.1791	26	25	26	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					153	155		10.1038/nm0296-153	http://dx.doi.org/10.1038/nm0296-153			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574953				2022-12-27	WOS:A1996TU06000028
J	FREDERICH, RC; HAMANN, A; ANDERSON, S; LOLLMANN, B; LOWELL, BB; FLIER, JS				FREDERICH, RC; HAMANN, A; ANDERSON, S; LOLLMANN, B; LOWELL, BB; FLIER, JS			LEPTIN LEVELS REFLECT BODY LIPID-CONTENT IN MICE - EVIDENCE FOR DIET-INDUCED RESISTANCE TO LEPTIN ACTION	NATURE MEDICINE			English	Article							OBESITY; FAT	The regulation of body weight and composition involves input from genes(1,2) and the environment(3,4), demonstrated, for example, by the variable susceptibility of inbred strains of mice to obesity when offered a high-fat diets. The identification of the gene responsible for obesity in the ob/ob mouse(6) provides a new approach to defining links between diet and genetics in the regulation of body weight. The ob gene protein product, leptin(7), is an adipocyte-derived circulating protein(6,8). Administration of recombinant leptin reduces food intake and increases energy expenditure in ob/ob mice(7,9,10), suggesting that it signals to the brain the magnitude of fat stores. Information on the regulation of this protein is limited. In several rodent models of obesity including db/db(6,8,11), fa/fa(12), yellow (Ay/a)(13) VMH-lesioned(14) and those induced by gold thioglucose(11), monosodium glutamate(8), and transgenic ablation of brown adipose tissues, leptin mRNA expression(6,8,11-14) and the level of circulating leptin(6,8) are increased, suggesting resistance to one or more of its actions. We have assessed the impact of increased dietary fat on circulating leptin levels in normal FVB mice and FVB mice with transgene-induced ablation of brown adipose tissue(15,16). We find that high-fat diet evokes a sustained increase in circulating leptin in both normal and transgenic mice, with leptin levels accurately reflecting the amount of body lipid across a broad range of body fat. However, despite increased leptin levels, animals fed a high-fat diet became obese without decreasing their caloric intake, suggesting that a high content of dietary fat changes the 'set point(17) for body weight, at least in part by limiting the action of leptin.			FREDERICH, RC (corresponding author), BETH ISRAEL HOSP RES N,DIV ENDOCRINOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [R01 DK43051, P30 DK46200, R37 DK28082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, R01DK043051, P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouchard C, 1994, GENETICS OBESITY; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DUBUC PU, 1977, HORM METAB RES, V9, P95, DOI 10.1055/s-0028-1095550; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HAMANN A, IN PRESS ENDOCRINOLO; HILL JO, 1991, AM J CLIN NUTR, V54, P10, DOI 10.1093/ajcn/54.1.10; HILL JO, 1992, INT J OBESITY, V16, P321; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MIZUNO T, 1995, END SOC ABSTR, P174; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALMON DMW, 1985, INT J OBESITY, V9, P443; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	1331	1361	0	125	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1311	1314		10.1038/nm1295-1311	http://dx.doi.org/10.1038/nm1295-1311			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489415				2022-12-27	WOS:A1995TH78600046
J	WINSLOW, RM				WINSLOW, RM			BLOOD SUBSTITUTES - A MOVING TARGET	NATURE MEDICINE			English	Editorial Material									VET ADM MED CTR,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA)	WINSLOW, RM (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,SAN DIEGO,CA 92103, USA.							BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BOWERSOX JC, 1995, BLOOD SUBSTITUTES PH; CHRISTOPHERSON R, 1991, ANESTHESIOLOGY, V75, pA99; CORASH L, 1995, SICKLE CELL DISEASE, V234, P275; Diamond Lewis K., 1980, BLOOD PURE ELOQUENT, p[659, 664]; FLAIM SF, 1991, INVEST RADIOL S, V26, pS125; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GOULD S, 1995, OCT ANN M NEW ORL LO; HIRSCHL RB, IN PRESS LANCET; HOROWITZ B, 1994, BLOOD COAGUL FIBRIN, V5, pS21, DOI 10.1097/00001721-199412003-00006; KAUFMAN RJ, 1995, BLOOD SUBSTITUTES PH; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; LOGAN JS, 1994, HEMOGLOBINS B, V231, P364; LOOKER DD, 1994, HEMOGLOBINS B, V231, P364; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; MERCURIALI F, 1994, ARTIF CELL BLOOD SUB, V22, P245, DOI 10.3109/10731199409117418; NAKAI K, 1994, ARTIF CELL BLOOD SUB, V22, P559, DOI 10.3109/10731199409117884; OGDEN JE, 1994, METHOD ENZYMOL, V231, P374; REILLY MP, 1994, METHOD ENZYMOL, V231, P403; RIOUX F, 1994, J CARDIOVASC PHARM, V24, P229, DOI 10.1097/00005344-199424020-00006; RUDOLPH AS, 1994, BIOMATERIALS, V15, P796, DOI 10.1016/0142-9612(94)90034-5; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SUIT H, 1995, BLOOD SUBSTITUTES PH; TARTTER PI, 1995, IMMUNOL INVEST, V24, P277, DOI 10.3109/08820139509062778; TOMASULO P, 1995, BLOOD SUBSTITUDES PH; TSAI AG, 1995, BLOOD SUBSTITUTES PH; WINSLOW RM, 1993, MORBID MORTAL WKLY R; WINSLOW RM, 1994, HEMOGLOBINS B, V231, P316; 1988, JAMA-J AM MED ASSOC, V260, P2700	29	39	40	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1212	1215		10.1038/nm1195-1212	http://dx.doi.org/10.1038/nm1195-1212			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584998				2022-12-27	WOS:A1995TC53700050
J	KLEINMAN, A; EISENBERG, L				KLEINMAN, A; EISENBERG, L			MENTAL-HEALTH IN LOW-INCOME COUNTRIES	NATURE MEDICINE			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KLEINMAN, A (corresponding author), HARVARD UNIV,DEPT ANTHROPOL,BOSTON,MA 02118, USA.							[Anonymous], 1995, WORLD MENTAL HLTH PR; 1993, 1993 WORLD BANK DEV	2	3	3	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					630	631		10.1038/nm0795-630	http://dx.doi.org/10.1038/nm0795-630			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585139				2022-12-27	WOS:A1995RQ06600032
J	SRIWATANAWONGSA, V; DAVIES, HFS; CALNE, RY				SRIWATANAWONGSA, V; DAVIES, HFS; CALNE, RY			THE ESSENTIAL ROLES OF PARENCHYMAL TISSUES AND PASSENGER LEUKOCYTES IN THE TOLERANCE INDUCED BY LIVER GRAFTING IN RATS	NATURE MEDICINE			English	Article							I MHC MOLECULES; TRANSPLANTATION ANTIGENS; ALLOGRAFT-REJECTION; KIDNEY ALLOGRAFTS; RECIPIENTS; NONREACTIVITY; SUPPRESSION; CHIMERISM; RESPONSES	Liver allografts in pigs and rodents are uniquely capable of inducing tolerance to themselves and to other grafts of donor tissues, instead of succumbing to the acute rejection that follows transplantation of other allogeneic tissues. We demonstrate here, using normal and chimaeric rat liver grafts, that both the allogeneic liver parenchyma and the intrahepatic leukocytes of donor type contribute to the establishment of long-term tolerance, each component being essential and complementary. The essential role of hepatic parenchyma may be related to its continuous release of soluble transplantation antigens that facilitate tolerogenesis. We suggest that clinical attempts at tolerance induction by the infusion of donor bone marrow-derived leukocytes may likewise be facilitated by the coadministration of soluble transplantation antigens of donor type.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND	Addenbrooke's Hospital; University of Cambridge	SRIWATANAWONGSA, V (corresponding author), CHULALONGKORN UNIV, FAC MED, DEPT SURG, BANGKOK 10330, THAILAND.							BATCHELOR JR, 1979, J EXP MED, V150, P455, DOI 10.1084/jem.150.3.455; BUTCHER GW, 1987, J IMMUNOGENET, V14, P163; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE R, 1991, CLIN TRANSPLANT, V5, P544; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CALNE RY, 1994, TRANSPLANTATION, V57, P1433; DAHMEN U, 1994, TRANSPLANTATION, V58, P1, DOI 10.1097/00007890-199407150-00001; DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; DAVIES HFS, 1983, TRANSPLANT P, V15, P831; DAVIES HFS, 1991, TRANSPLANT P, V23, P2248; DEMETRIS AJ, 1994, TRANSP CL IMMUN SFMM, V25, P325; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; KAMADA N, 1983, SURGERY, V93, P64; KAMADA N, 1981, NATURE, V292, P840, DOI 10.1038/292840a0; KAMADA N, 1983, TRANSPLANTATION, V35, P304, DOI 10.1097/00007890-198304000-00008; KAMADA N, 1980, TRANSPLANTATION, V29, P429, DOI 10.1097/00007890-198005000-00021; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; MILLARD PR, 1971, TRANSPLANT P, V3, P505; PRIESTLEY CA, 1989, TRANSPLANTATION, V48, P1031, DOI 10.1097/00007890-198912000-00028; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; RASMUSSEN A, IN PRESS TRANSPLANTA; SETTAF A, 1988, TRANSPLANTATION, V46, P32, DOI 10.1097/00007890-198807000-00005; SINGH PB, 1988, J EXP MED, V168, P195, DOI 10.1084/jem.168.1.195; SPENCER SC, 1987, IMMUNOGENETICS, V25, P91, DOI 10.1007/BF00364273; SRIWATANAWONGSA V, 1993, TRANSPLANT P, V25, P371; SRIWATANAWONGSA V, IN PRESS TRANSPLANTA; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; SUMIMOTO R, 1990, TRANSPLANTATION, V50, P678, DOI 10.1097/00007890-199010000-00029; ZAVAZAVA N, 1992, TRANSPLANT INT, V5, pS606; ZIMMERMANN FA, 1979, TRANSPLANT P, V11, P571; ZIMMERMANN FA, 1984, TRANSPLANTATION, V37, P406, DOI 10.1097/00007890-198404000-00019	33	117	118	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					428	432		10.1038/nm0595-428	http://dx.doi.org/10.1038/nm0595-428			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585089				2022-12-27	WOS:A1995RN10000032
J	WALGENBACH, KJ; GRATAS, C; SHESTAK, KC; BECKER, D				WALGENBACH, KJ; GRATAS, C; SHESTAK, KC; BECKER, D			ISCHEMIA-INDUCED EXPRESSION OF BFGF IN NORMAL SKELETAL-MUSCLE - A POTENTIAL PARACRINE MECHANISM FOR MEDIATING ANGIOGENESIS IN ISCHEMIC SKELETAL-MUSCLE	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; RABBIT MODEL; INVIVO; DIFFERENTIATION; PROLIFERATION; ISCHEMIA; RECEPTOR; LIMB	To test the hypothesis that induction of endogenous bFGF can lead to angiogenesis in ischaemic skeletal muscle, we studied the expression of bFGF after transposition of a well-vascularized muscle flap onto an ischaemic hindlimb in the rabbit. The results indicated a marked induction of bFGF mRNA throughout the myoblasts of the well-perfused muscle flap but not the myoblasts of the ischaemic muscle. bFGF protein was detected in the muscle flap, particularly in the myoblasts located closest to a newly formed, adjacent interface, and in the interface itself. In contrast, bFGF expression was not induced after transposition of a well-perfused muscle flap onto healthy muscle tissue. These data provide evidence that the juxtaposition of ischaemic skeletal muscle with healthy mesenchymal tissue triggers an increased expression of bFGF in the myoblasts of the well-perfused muscle. This paracrine induction of bFGF, in turn, leads to increased angiogenesis and regeneration of the ischaemic skeletal muscle.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT SURG,DIV PLAST SURG,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Gratas-Rabbia-Ré, Catherine/K-9280-2015	Gratas-Rabbia-Ré, Catherine/0000-0002-9155-6906				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1992, ONCOGENE, V7, P2303; CHLEBOUN JO, 1992, BIOCHEM BIOPH RES CO, V185, P510, DOI 10.1016/0006-291X(92)91654-9; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOSPODAROWICZ D, 1989, J INVEST DERMATOL, V93, P39; GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243; HENDRICKS DL, 1990, J SURG RES, V49, P453, DOI 10.1016/0022-4804(90)90195-8; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NICKOLOFF BJ, 1993, ARCH DERMATOL, V129, P250, DOI 10.1001/archderm.129.2.250; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; PEVEC WC, 1991, J VASC SURG, V13, P385, DOI 10.1067/mva.1991.24915; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Pu L Q, 1994, J Invest Surg, V7, P49, DOI 10.3109/08941939409018282; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VIGNOVICH J, 1993, INT J ONCOL, V2, P637; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313	27	50	50	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					453	459		10.1038/nm0595-453	http://dx.doi.org/10.1038/nm0595-453			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585094				2022-12-27	WOS:A1995RN10000037
J	KARP, JE; BRODER, S				KARP, JE; BRODER, S			MOLECULAR FOUNDATIONS OF CANCER - NEW TARGETS FOR INTERVENTION	NATURE MEDICINE			English	Review							FIBROBLAST GROWTH-FACTOR; NONPOLYPOSIS COLORECTAL-CANCER; NUCLEAR ANTIGEN EXPRESSION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CELL-CYCLE; RETINOBLASTOMA PROTEIN; ATAXIA-TELANGIECTASIA; EXTRACELLULAR-MATRIX; PROSTATE-CANCER				KARP, JE (corresponding author), NCI, BETHESDA, MD 20892 USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AMAN MJ, 1993, BLOOD, V82, P2371, DOI 10.1182/blood.V82.8.2371.bloodjournal8282371; BENEZRA M, 1993, BLOOD, V81, P3324; BOSL GJ, 1994, J NATL CANCER I, V86, P349, DOI 10.1093/jnci/86.5.349; BOVA GS, 1993, CANCER RES, V53, P3869; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; BRUNNER G, 1993, BLOOD, V81, P631; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHENG JQ, 1994, CANCER RES, V54, P5547; CHU EW, 1972, J NATL CANCER I, V48, P771; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, MOL CELL BIOL, V14, P407; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JOLLY KW, 1994, ONCOGENE, V9, P97; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEIM D, 1990, BLOOD, V76, P985; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEACH FS, 1993, CANCER RES, V53, P1986; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCPHERSON JD, 1994, GENOMICS, V19, P188, DOI 10.1006/geno.1994.1042; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MYERS CE, 1991, MOL F ONCOLOGY, P419; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NGUYEN M, 1993, J NATL CANCER I, V85, P241, DOI 10.1093/jnci/85.3.241; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLSON TA, 1994, CANCER RES, V54, P276; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1990, New Biologist, V2, P389; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIN DM, 1993, J NATL CANCER I, V85, P971, DOI 10.1093/jnci/85.12.971; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIEBOS RJ, 1994, P NATL ACAD SCI USA, V91, P5320; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMBAS R, 1994, CANCER RES, V54, P3929; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wakefield L. M., 1990, TUMOR SUPPRESSOR GEN, P217; WALDMANN TA, 1983, ANN INTERN MED, V99, P367, DOI 10.7326/0003-4819-99-3-367; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; WEBER BL, 1994, NEW ENGL J MED, V331, P1523, DOI 10.1056/NEJM199412013312214; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WONG M, 1994, J NATL CANCER I, V86, P177, DOI 10.1093/jnci/86.3.177; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; 1994, NIH942789 NATL CANC	133	101	124	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1995	1	4					309	320		10.1038/nm0495-309	http://dx.doi.org/10.1038/nm0495-309			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585060	Bronze			2022-12-27	WOS:A1995RN09800026
J	LIU, B; FARRINGTON, SM; PETERSEN, GM; HAMILTON, SR; PARSONS, R; PAPADOPOULOS, N; FUJIWARA, T; JEN, J; KINZLER, KW; WYLLIE, AH; VOGELSTEN, B; DUNLOP, MG				LIU, B; FARRINGTON, SM; PETERSEN, GM; HAMILTON, SR; PARSONS, R; PAPADOPOULOS, N; FUJIWARA, T; JEN, J; KINZLER, KW; WYLLIE, AH; VOGELSTEN, B; DUNLOP, MG			GENETIC INSTABILITY OCCURS IN THE MAJORITY OF YOUNG-PATIENTS WITH COLORECTAL-CANCER	NATURE MEDICINE			English	Article							NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; NATURAL-HISTORY; MUTATIONS; CARCINOMA; POLYPOSIS; HOMOLOG	Replication errors (RER) associated with genetic instability have been found in cancers of several different types and particularly in the tumours of patients with hereditary non-polyposis colorectal cancer (HNPCC). We have here determined the prevalence of such instability in relation to age among patients without HNPCC. Colorectal cancers (CRCs) in the majority of patients 35 years of age or younger exhibited instability (58% of 31 patients), whereas CRCs from patients older than 35 uncommonly did (12% of 158, P < 0.0001). Twelve of the patients under 35 with instability were evaluated for alterations of mismatch repair genes, and five were found to harbour germline mutations. These data suggest that the mechanisms underlying tumour development in young CRC patients differ from those in most order patients, regardless of HNPCC status. The results have important implications for genetic testing and management of young CRC patients and their families.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21205; UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	LIU, B (corresponding author), JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231, USA.		Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/Q-2710-2019; Farrington, Susan M/C-7319-2013; Papadopoulos, Nickolas/K-7272-2012	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R37CA035494, P50CA062924, R01CA035494, R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA62924, CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; COSTA LT, 1995, NAT GENET, V9, P9; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAN HJ, 1993, CANCER RES, V53, P5087; HARTWELL L, 1991, ORIGINS OF HUMAN CANCER, P45; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KIM H, 1994, AM J PATHOL, V145, P1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOEB LA, 1974, CANCER RES, V34, P2311; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MILLER BA, 1993, NIH932789 NATL CANC; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RISINGER JI, 1993, CANCER RES, V53, P5100; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; 1990, CANCER REGISTRATION	39	322	328	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					348	352		10.1038/nm0495-348	http://dx.doi.org/10.1038/nm0495-348			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585065				2022-12-27	WOS:A1995RN09800031
J	SMITH, MA; SIEDLAK, SL; RICHEY, PL; MULVIHILL, P; GHISO, J; FRANGIONE, B; TAGLIAVINI, F; GIACCONE, G; BUGIANI, O; PRAPROTNIK, D; KALARIA, RN; PERRY, G				SMITH, MA; SIEDLAK, SL; RICHEY, PL; MULVIHILL, P; GHISO, J; FRANGIONE, B; TAGLIAVINI, F; GIACCONE, G; BUGIANI, O; PRAPROTNIK, D; KALARIA, RN; PERRY, G			TAU-PROTEIN DIRECTLY INTERACTS WITH THE AMYLOID BETA-PROTEIN PRECURSOR - IMPLICATIONS FOR ALZHEIMERS-DISEASE	NATURE MEDICINE			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; BRAIN; PHOSPHORYLATION; DEPOSITION; PLAQUES; INVITRO; BINDING; ALPHA-1-ANTICHYMOTRYPSIN; PATHOLOGY	The simultaneous presence of intracellular neurofibrillary tangles (NFT) and extracellular senile plaques in Alzheimer's disease (AD) suggests that the two lesions could be synergistically interrelated. However, although the main protein components of NFT and senile plaques, (tau) and amyloid beta-protein, respectively, are well characterized, the molecular mechanisms responsible for their deposition in lesions are unknown. We demonstrate, using four independent techniques, that tau directly interacts with a conformation-dependent domain of the amyloid beta-protein precursor (beta PP) encompassing residues beta PP714-723. The putative tau-binding domain includes beta PP717 mutation sites that are associated with familial forms of AD. Our findings strongly suggest that NFT and senile plaques, often thought of as independent structures, may play a role in each other's formation during the pathogenesis of AD.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; IST NAZL NEUROL CARLO BESTA,DIV NEUROPATHOL,I-20133 MILAN,ITALY	New York University; IRCCS Istituto Neurologico Besta	SMITH, MA (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106, USA.		Tagliavini, Fabrizio/AAO-7891-2021; giaccone, giorgio/AAB-9978-2019; Giaccone, Giorgio/J-6212-2012; Smith, Mark A/A-9053-2009; Perry, George/A-8611-2009; Kalaria, Raj/AAX-2630-2020	Tagliavini, Fabrizio/0000-0003-1039-7315; giaccone, giorgio/0000-0002-4803-0802; Perry, George/0000-0002-6547-0172; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R37AG005891, R01AG007552] Funding Source: NIH RePORTER; NIA NIH HHS [AG05891, AG07552] Funding Source: Medline; NINDS NIH HHS [NS 30455] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALZHEIMER A, 1907, ZENTRALBL NERVENHEIL, V18, P177; AUTILIOGAMBETTI L, 1988, FEBS LETT, V241, P94, DOI 10.1016/0014-5793(88)81038-X; CAPUTO CB, 1992, BRAIN RES, V597, P227, DOI 10.1016/0006-8993(92)91478-W; CONNOLLY JA, 1977, P NATL ACAD SCI USA, V74, P2437, DOI 10.1073/pnas.74.6.2437; CRAS P, 1990, AM J PATHOL, V137, P241; DAVIES L, 1988, NEUROLOGY, V38, P1688, DOI 10.1212/WNL.38.11.1688; ELLISMAN M, 1987, ALTERATIONS NEURONAL, P61; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; KALARIA RN, 1991, NEUROPATH APPL NEURO, V17, P189, DOI 10.1111/j.1365-2990.1991.tb00714.x; KALARIA RN, 1992, BRAIN RES, V585, P87, DOI 10.1016/0006-8993(92)91193-I; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; PERRY G, 1993, AM J PATHOL, V143, P1586; PERRY G, 1988, LANCET, V2, P746; PERRY G, 1993, MED HYPOTHESES, V40, P257, DOI 10.1016/0306-9877(93)90051-Q; PERRY G, 1982, MUSCLE CELL MOTILITY, V2; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; REFOLO LM, 1991, J NEUROSCI, V11, P3888; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SHIN RW, 1993, P NATL ACAD SCI USA, V90, P6825, DOI 10.1073/pnas.90.14.6825; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	35	78	81	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					365	369		10.1038/nm0495-365	http://dx.doi.org/10.1038/nm0495-365			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585068				2022-12-27	WOS:A1995RN09800034
J	MALHOTRA, R; WORMALD, MR; RUDD, PM; FISCHER, PB; DWEK, RA; SIM, RB				MALHOTRA, R; WORMALD, MR; RUDD, PM; FISCHER, PB; DWEK, RA; SIM, RB			GLYCOSYLATION CHANGES OF IGG ASSOCIATED WITH RHEUMATOID-ARTHRITIS CAN ACTIVATE COMPLEMENT VIA THE MANNOSE-BINDING PROTEIN	NATURE MEDICINE			English	Article							SERUM IGG; LECTIN; SITE; OLIGOSACCHARIDE; RECOGNITION; DOMAINS; C1Q	The glycosylation of the circulating immunoglobulin-gamma (IgC) antibody molecules changes in rheumatoid arthritis. The extent of the changes correlates with the disease severity and reverses in remission. We demonstrate here that the alteration in glycosylation associated with rheumatoid arthritis can create a new mode for the interaction of IgC with complement through binding to the collagenous lectin mannose-binding protein (MBP). Rheumatoid arthritis is associated with a marked increase in IgC glycoforms that lack galactose (referred to as CO glycoforms) in the Fc region of the molecule and that terminate in N-acetyl glucosamine (GlcNAc). We show, using nuclear magnetic resonance (NMR) and X-ray data, that these terminal GlcNAc residues become accessible for MBP binding. We further demonstrate that multiple presentation of IgG-GO glycoforms to MBP results in activation of the complement. This suggests that a contribution to the chronic inflammation of the synovial membrane could arise from the localization of the IgG-GO glycoforms in the affected joint and from resulting activation of complement.	UNIV OXFORD, DEPT BIOCHEM, INST GLYCOBIOL, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, MRC, IMMUNOCHEM UNIT, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford			Sim, Bob/A-1354-2008; Wormald, Mark R/G-2785-2011	Sim, Bob/0000-0002-2855-7455; Wormald, Mark R/0000-0002-4853-2773				ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; CHANG SC, 1993, THESIS OXFORD; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DWEK RA, 1984, BIOCHEM SOC SYMP, P123; IKEDA K, 1987, J BIOL CHEM, V262, P7451; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KIYOHARA T, 1976, J BIOCHEM, V80, P9, DOI 10.1093/oxfordjournals.jbchem.a131263; MALHOTRA R, 1994, IMMUNOLOGY, V82, P439; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; Malhotra R, 1994, Clin Exp Immunol, V97 Suppl 2, P4; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Morgan B, 1990, COMPLEMENT CLIN ASPE; PAREKH R, 1988, J EXP MED, V167, P1731, DOI 10.1084/jem.167.5.1731; PAREKH R, 1989, J AUTOIMMUN, V2, P101, DOI 10.1016/0896-8411(89)90148-0; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PAREKH RB, 1987, THESIS OXFORD U; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RADEMACHER TW, 1986, BIOCHEM SOC SYMP, P131; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; RADEMACHER TW, 1988, SPRINGER SEMIN IMMUN, V10, P231, DOI 10.1007/BF01857227; ROOK GAW, 1991, J AUTOIMMUN, V4, P779, DOI 10.1016/0896-8411(91)90173-A; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SJOHOLM AG, 1991, APMIS, V99, P1120; SUPER M, 1992, NAT GENET, V2, P50, DOI 10.1038/ng0992-50; TSUCHIYA N, 1993, J IMMUNOL, V151, P1137; VANZEBEN D, 1994, BRIT J RHEUMATOL, V33, P36; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	32	636	696	0	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1995	1	3					237	243		10.1038/nm0395-237	http://dx.doi.org/10.1038/nm0395-237			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585040				2022-12-27	WOS:A1995QX55900030
J	GRAINGER, DJ; KEMP, BR; METCALFE, JC; LIU, AC; LAWN, RM; WILLIAMS, NR; GRACE, AA; SCHOFIELD, PM; CHAUHAN, A				GRAINGER, DJ; KEMP, BR; METCALFE, JC; LIU, AC; LAWN, RM; WILLIAMS, NR; GRACE, AA; SCHOFIELD, PM; CHAUHAN, A			THE SERUM CONCENTRATION OF ACTIVE TRANSFORMING GROWTH-FACTOR-BETA IS SEVERELY DEPRESSED IN ADVANCED ATHEROSCLEROSIS	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; MYOCARDIAL-INFARCTION; TGF-BETA; LIPOPROTEIN; ACTIVATION; PROLIFERATION; PATHOGENESIS; PLASMINOGEN; INHIBITOR; CULTURE	Recent evidence has led us to propose that transforming growth factor-beta (TGF-beta) is a key inhibitor of atherosclerosis. We show here that a population of patients with advanced atherosclerosis all have less active TGF-beta in their sera than patients with normal coronary arteries, with a fivefold difference in average concentration between the two groups. This correlation with atherosclerosis is much stronger than for other known major risk factors and it may therefore have important diagnostic and prognostic significance. Aspirin medication correlates with an increase in active TGF-beta concentration, indicating that therapeutic interventions for TGF-beta are possible.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA; PAPWORTH HOSP NHS TRUST, DEPT CARDIOL, CAMBRIDGE CB3 8RE, ENGLAND	Stanford University; Papworth Hospital	GRAINGER, DJ (corresponding author), UNIV CAMBRIDGE, DEPT BIOCHEM, TENNIS COURT RD, CAMBRIDGE CB2 1QW, ENGLAND.		WILLIAMS, Norman/C-2002-2008	WILLIAMS, Norman/0000-0001-6496-312X; Kemp, Paul/0000-0001-8975-7293				BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; DEBONO D, 1994, BRIT HEART J, V71, P504; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRAINGER D, IN PRESS CLIN CHIM A; GRAINGER DJ, 1993, BIOCHEM J, V294, P109, DOI 10.1042/bj2940109; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; KANNEL WB, 1983, AM J CARDIOL, V52, pB9, DOI 10.1016/0002-9149(83)90649-5; KIRSCHENLOHR HL, 1993, AM J PHYSIOL, V265, pC571, DOI 10.1152/ajpcell.1993.265.2.C571; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LAWRENCE DA, 1991, METHOD ENZYMOL, V198, P327; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	26	357	374	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1995	1	1					74	79		10.1038/nm0195-74	http://dx.doi.org/10.1038/nm0195-74			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584958				2022-12-27	WOS:A1995QX55700030
J	Richardson, SH; Wozniak, DJ				Richardson, SH; Wozniak, DJ			An ace up the sleeve of the cholera bacterium	NATURE MEDICINE			English	Editorial Material							VIBRIO-CHOLERAE; TOXIN; ENTEROTOXIN; SYSTEM; PHAGE				Richardson, SH (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MICROBIOL & IMMUNOL,300 S HAWTHORNE RD,WINSTON SALEM,NC 27157, USA.							CLEMENS J, 1994, CHOLERA MOL GLOBAL P, P425; FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; KOONIN EV, 1992, FEBS LETT, V312, P3, DOI 10.1016/0014-5793(92)81398-6; KURAZONO H, 1995, MICROB PATHOGENESIS, V18, P231, DOI 10.1016/S0882-4010(95)90076-4; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; TRUCKSIS M, 1993, P NATL ACAD SCI USA, V90, P5267, DOI 10.1073/pnas.90.11.5267; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	8	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					853	855		10.1038/nm0896-853	http://dx.doi.org/10.1038/nm0896-853			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705848				2022-12-27	WOS:A1996UZ80400025
J	Chresta, CM; Hickman, JA				Chresta, CM; Hickman, JA			Oddball p53 in testicular tumors	NATURE MEDICINE			English	Editorial Material											Chresta, CM (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND.							BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; FRY AM, 1991, CANCER RES, V51, P6592; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hawkins DS, 1996, CANCER RES, V56, P892; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MONTES DOL, 1995, NATURE, V378, P203; PECKHAM MJ, 1985, BRIT J CANCER, V52, P7, DOI 10.1038/bjc.1985.141; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303	16	18	23	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					745	746		10.1038/nm0796-745	http://dx.doi.org/10.1038/nm0796-745			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673915				2022-12-27	WOS:A1996UU68000025
J	Rothwell, NJ; Luheshi, GN				Rothwell, NJ; Luheshi, GN			Brain TNF damage limitation or damaged reputation?	NATURE MEDICINE			English	Editorial Material											Rothwell, NJ (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,1124 STOPFORD BLDG,MANCHESTER M13 9PT,LANCS,ENGLAND.							Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4	10	37	38	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					746	747		10.1038/nm0796-746	http://dx.doi.org/10.1038/nm0796-746			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673916				2022-12-27	WOS:A1996UU68000026
J	Dimitrov, DS				Dimitrov, DS			Fusin - A place for HIV-1 and T4 cells to meet	NATURE MEDICINE			English	Editorial Material							AIDS				Dimitrov, DS (corresponding author), NCI,NIH,BETHESDA,MD 20892, USA.							BLUMENTHAL R, 1996, HDB PHYSL, V1, pCH14; BURKLY L, 1995, J VIROL, V69, P4267, DOI 10.1128/JVI.69.7.4267-4273.1995; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; REIMANN KA, 1993, AIDS RES HUM RETROV, V9, P199, DOI 10.1089/aid.1993.9.199; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	8	29	42	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					640	641		10.1038/nm0696-640	http://dx.doi.org/10.1038/nm0696-640			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640552	Bronze			2022-12-27	WOS:A1996UN69100029
J	Sarver, N; Cairns, S				Sarver, N; Cairns, S			Ribozyme trans-splicing and RNA tagging: Following the messenger	NATURE MEDICINE			English	Editorial Material							TETRAHYMENA RIBOZYME; BINDING-SITE; SPECIFICITY; SEQUENCE				Sarver, N (corresponding author), NIAID,DIV AIDS,TARGETED INTERVENT BRANCH,BETHESDA,MD 20892, USA.							BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Castanotto D, 1994, Adv Pharmacol, V25, P289, DOI 10.1016/S1054-3589(08)60435-4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	12	11	14	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					641	642		10.1038/nm0696-641	http://dx.doi.org/10.1038/nm0696-641			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640553				2022-12-27	WOS:A1996UN69100030
J	Abraham, EH; Vos, P; Kahn, J; Grubman, SA; Jefferson, DM; Ding, I; Okunieff, P				Abraham, EH; Vos, P; Kahn, J; Grubman, SA; Jefferson, DM; Ding, I; Okunieff, P			Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ANTICANCER ACTIVITIES; ADENINE-NUCLEOTIDES; ANIMAL-MODEL; GENE; CELLS; MICE	Cystic fibrosis (CF) is the most common lethal recessive genetic disease of the Caucasian population. Although reports of cancer frequency in CF have emphasized an elevated observed-to-expected ratio of 6.5 for digestive tract cancers, these studies also show a significantly decreased observed-to-expected ratio for other malignancies including breast cancer. The cystic fibrosis transmembrane conductance regulator (CFTR) functions as an ATP channel(1-3). We found that heterozygous and homozygous CFTR knockout mice had elevated blood ATP concentrations. Elevated extracellular ATP is known to inhibit tumor growth in vivo and in vitro(4-7). Using double mutant mice created by F-2 generation crosses of CFTR knockout and nude mice, we observed reduced breast tumor implantability in CFTR homozygous nude animals. Decreased tumor growth rate was observed in both CFTR heterozygous and homozygous nude animals. Extracellular ATP reduced human tumor cell growth rate in vitro, and a breast transfected with human CFTR that had high extracellular ATP concentrations in vitro correspondingly had a slower growth rate in vivo. The results suggest that both CFTR heterozygosity and homozygosity suppress breast cancer growth and that elevated extracellular ATP can account for this phenomenon.	MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT PHYSIOL & PEDIAT,BOSTON,MA 02111	Harvard University; Massachusetts General Hospital; Tufts Medical Center; Tufts University	Abraham, EH (corresponding author), NCI,RADIAT ONCOL BRANCH,BLDG 10,ROOM B3B69,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ABRAHAM EH, 1992, J GEN PHYSIOL, V100, pA145; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; FROIO J, 1995, ACTA ONCOL, V34, P419, DOI 10.3109/02841869509094001; Jenkins Helen A., 1993, Biochemical Society Transactions, V21, p326S; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MCLESKEY SW, 1994, CANCER RES, V54, P523; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; OKUNIEFF P, 1994, RAD ONCOL INVEST, V1, P346; RAPAPORT E, 1983, CANCER RES, V43, P4402; RAPAPORT E, 1989, P NATL ACAD SCI USA, V86, P1662, DOI 10.1073/pnas.86.5.1662; RAPAPORT E, 1993, DRUG DEVELOP RES, V28, P428, DOI 10.1002/ddr.430280344; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Schiavi SC, 1996, AM J PHYSIOL-CELL PH, V270, pC341, DOI 10.1152/ajpcell.1996.270.1.C341; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SIEGEL D, 1992, CYTOGENET CELL GENET, V61, P184, DOI 10.1159/000133404; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; TAKAHASHI Y, 1992, J EXP MED, V175, P873, DOI 10.1084/jem.175.3.873; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760	22	50	52	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					593	596		10.1038/nm0596-593	http://dx.doi.org/10.1038/nm0596-593			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616723				2022-12-27	WOS:A1996UJ23000047
J	Barton, JC; Bertoli, LF				Barton, JC; Bertoli, LF			Hemochromatosis: The genetic disorder of the twenty-first century	NATURE MEDICINE			English	Editorial Material							IRON OVERLOAD				Barton, JC (corresponding author), BROOKWOOD MED CTR,DEPT MED,BIRMINGHAM,AL 35209, USA.			Barton, James/0000-0003-2876-8276				BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; BARTON JC, 1994, J LAB CLIN MED, V124, P193; BROCK JH, 1994, IRON METABOLISM HLTH, P353; EASON RJ, 1990, AUST NZ J MED, V20, P226, DOI 10.1111/j.1445-5994.1990.tb01024.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; WITTE DL, IN PRESS CLIN CHIM A	10	44	50	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					394	395		10.1038/nm0496-394	http://dx.doi.org/10.1038/nm0496-394			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597942				2022-12-27	WOS:A1996UD31400034
J	Isaka, Y; Brees, DK; Ikegaya, K; Kaneda, Y; Imai, E; Noble, NA; Border, WA				Isaka, Y; Brees, DK; Ikegaya, K; Kaneda, Y; Imai, E; Noble, NA; Border, WA			Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; PROTEOGLYCAN; LIVER; PROTEIN; DNA	There are currently no effective therapies for progressive fibrotic diseases. Recent evidence has implicated overproduction of transforming growth factor-beta 1 (TGF-beta 1) as a major cause of tissue fibrosis. Furthermore, this evidence implies that inhibitors of TGF-beta 1 may be clinically useful as antifibrotic agents. The proteoglycan decorin is a known inhibitor of TGF-beta 1. In a rat model of glomerulonephritis we have shown that fibrosis is mediated by TGF-beta 1. We report here that transfer of decorin cDNA into rat skeletal muscle increases the amount of decorin messenger RNA and protein present in skeletal muscle and decorin protein present in kidney, where it has a marked therapeutic effect on fibrosis induced by glomerulonephritis. Transfected glomerulonephritic rats showed a significant reduction in levels of glomerular TGF-beta 1 mRNA and TGF-beta 1 protein, extracellular matrix accumulation and proteinuria. These results demonstrate the potential of gene therapy as a novel treatment for fibrotic diseases caused by TGF-beta 1.	UNIV UTAH,SCH MED,SALT LAKE CITY,UT 84132; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Utah System of Higher Education; University of Utah; Osaka University; Osaka University					NIDDK NIH HHS [DK 49374, DK 49342, DK 43609] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049342, R37DK043609, R01DK049374, R01DK043609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BLAU HM, 1995, NEW ENGL J MED, V333, P1294; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORDER WA, 1995, J CLIN INVEST, V6, P665; DANKO I, 1994, VACCINE, V12, P1499, DOI 10.1016/0264-410X(94)90072-8; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; DREHER KL, 1990, EUR J CELL BIOL, V53, P296; FELGNER PL, 1993, LAB INVEST, V68, P1; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; KATO K, 1991, J BIOL CHEM, V266, P22071; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noble Nancy A., 1992, Progress in Growth Factor Research, V4, P369, DOI 10.1016/0955-2235(92)90017-C; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; Touchette N, 1996, NAT MED, V2, P7, DOI 10.1038/nm0196-7; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65	32	436	457	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					418	423		10.1038/nm0496-418	http://dx.doi.org/10.1038/nm0496-418			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597951				2022-12-27	WOS:A1996UD31400043
J	Laws, ER				Laws, ER			Imaging brain tumors - Beyond three dimensions	NATURE MEDICINE			English	Editorial Material											Laws, ER (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22908, USA.							Asakura T, 1996, CRIT REV NEUROSURG, V6, P20; Preul MC, 1996, NAT MED, V2, P323, DOI 10.1038/nm0396-323	2	8	8	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					271	272		10.1038/nm0396-271	http://dx.doi.org/10.1038/nm0396-271			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612217				2022-12-27	WOS:A1996TY64000027
J	Renne, R; Zhong, WD; Herndier, B; McGrath, M; Abbey, N; Kedes, D; Ganem, D				Renne, R; Zhong, WD; Herndier, B; McGrath, M; Abbey, N; Kedes, D; Ganem, D			Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture	NATURE MEDICINE			English	Article							EPSTEIN-BARR VIRUS; INFECTION; GENOME; LINES; AIDS	Kaposi's sarcoma (KS) is the leading neoplasm of AIDS patients, and HIV infection is known to be a major risk factor for its development(1,2). However, KS can occur in the absence of HIV infection(3-5) and the risk of KS development varies widely even among HIV-infected patients, with homosexual men with AIDS being 20 times more likely to develop KS than AIDS-afflicted children or hemophiliacs(6). These and other data strongly suggest that a sexually transmitted agent or co-factor may be involved in KS pathogenesis(7). Recently, DNA sequences corresponding to the genome of a novel member of the herpesvirus family have been identified within AIDS-KS biopsies(8), and several reports indicate that these sequences are also present in all forms of HIV-negative KS (ref. 9-13). These and other findings(14) suggest this new agent, referred to as KS-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8), as a candidate for the putative etiologic cofactor. However, the role of this agent in KS remains hotly debated(15). Further progress in understanding its biology has been severely hampered by the lack of a cell culture system for virus growth. Here we report the development of a system for the lytic growth of this virus in a latently infected B cell line and present the first ultrastructural visualization of the virus. This system will facilitate the detailed study of the molecular biology of viral replication, the testing of antiviral drugs and the development of diagnostic tests for viral infection.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA 67381] Funding Source: Medline; NIAID NIH HHS [AI 27763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BENSASSON SA, 1981, INT J CANCER, V28, P131, DOI 10.1002/ijc.2910280204; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN J, 1995, SCIENCE, V268, P1847, DOI 10.1126/science.7604255; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; FREIDMANKIEN AE, 1990, LANCET, V335, P168; GANEM D, 1995, CURR BIOL, V5, P469, DOI 10.1016/S0960-9822(95)00093-5; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; HUMMEL M, 1982, P NATL ACAD SCI-BIOL, V79, P5698, DOI 10.1073/pnas.79.18.5698; KIEFF E, 1990, VIROLOGY, P1902; LENHOFF RJ, 1994, J VIROL, V68, P4565, DOI 10.1128/JVI.68.7.4565-4571.1994; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; ROIZMAN B, 1990, VIROLOGY, P1787; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; ZIEGLER JL, 1984, SEMIN ONCOL, V11, P47; ZURHAUSEN H, 1978, NATURE, V272, P373	28	860	884	1	25	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					342	346		10.1038/nm0396-342	http://dx.doi.org/10.1038/nm0396-342			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612236				2022-12-27	WOS:A1996TY64000046
J	Russell, S				Russell, S			Peptide-displaying phages for targeted gene delivery?	NATURE MEDICINE			English	Editorial Material											Russell, S (corresponding author), MRC CTR,CAMBRIDGE CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; HART SL, 1995, GENE THER, V2, P552; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; WADMAN M, 1995, NATURE, V378, P655, DOI 10.1038/378655a0	8	8	13	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					276	277		10.1038/nm0396-276	http://dx.doi.org/10.1038/nm0396-276			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612220				2022-12-27	WOS:A1996TY64000030
J	Schwartz, O; Marechal, V; LeGall, S; Lemonnier, F; Heard, JM				Schwartz, O; Marechal, V; LeGall, S; Lemonnier, F; Heard, JM			Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein	NATURE MEDICINE			English	Article							DOWN-REGULATION; COATED PITS; HLA; EXPRESSION; ANTIGENS; CHAINS; ASSOCIATION; HEAVY; GENE	Like other pathogenic viruses, HIV-1 down-modulates surface expression of major histocompatibility complex class I (MHC-I) molecules in infected cells, thus impairing lysis by cytotoxic T lymphocytes(1,2). We have observed that this phenomenon depends on the expression of Nef. nef is an early gene of primate lentiviruses(3), which is necessary for maintaining high virus loads and inducing AIDS (ref. 4). Nef is not necessary for viral replication in vitro and stimulates the endocytosis of CD4 (ref. 5-8). We show that the expression of MHC-I at the surface of lymphoid, monocytic and epithelial cells was reduced in the presence of Nef protein from various HIV-1 strains. Whereas MHC-I protein synthesis and transport through the endoplasmic reticulum and cis Golgi apparatus occurred normally in Nef(+) cells, surface MHC-I molecules were rapidly internalized, accumulated in endosomal vesicles and were degraded. The stimulation of MHC-I endocytosis by Nef represents a previously undocumented viral mechanism for evading the immune response.	INST PASTEUR,UNITE IMMUNITE CELLULAIRE ANTIVIRALE,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schwartz, O (corresponding author), INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,URA CNRS 1157,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Schwartz, Olivier/AAZ-3765-2021	Schwartz, Olivier/0000-0002-0729-1475; Le Gall, Sylvie/0000-0003-0385-926X				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BEVAN MJ, 1995, P NATL ACAD SCI USA, V92, P5765, DOI 10.1073/pnas.92.13.5765; BOSKHOV LK, 1992, J IMMUNOL, V148, P881; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DASGUPTA JD, 1988, J IMMUNOL, V141, P2577; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FERRIER P, 1985, J IMMUNOL, V135, P1281; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GUILD BC, 1984, J BIOL CHEM, V259, P9235; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; MACHY P, 1987, NATURE, V328, P724, DOI 10.1038/328724a0; Miller Michael D., 1994, Trends in Microbiology, V2, P294, DOI 10.1016/0966-842X(94)90007-8; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; RINALDO CR, 1994, AM J PATHOL, V144, P637; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	31	845	856	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					338	342		10.1038/nm0396-338	http://dx.doi.org/10.1038/nm0396-338			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612235				2022-12-27	WOS:A1996TY64000045
J	Grandis, JR; Zeng, Q; Tweardy, DJ				Grandis, JR; Zeng, Q; Tweardy, DJ			Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines	NATURE MEDICINE			English	Article							SQUAMOUS CARCINOMA; GROWTH; RECEPTOR; DIFFERENTIATION; EXPRESSION; MODULATION; MARKERS; CLONING	Retinoic acid (RA) has been shown to be effective in eradicating premalignant lesions(1) and preventing second primary malignancies in patients cured of squamous cell carcinoma of the head and neck (SCCHN) in clinical trials(2). The basis for this effect is unclear. We have previously demonstrated that messenger RNA from tumor growth factor-alpha (TCF-alpha) and its receptor, the epidermal growth factor (EGFR), is upregulated in tumors and histologically normal mucosal samples from patients with SCCHN compared with control normal mucosa from patients without cancer, implicating this ligand-receptor pair in an autocrine growth pathway early in the molecular pathogenesis of this disease(3). In this report, we examined the hypothesis that the action of RA on the mucosa of the upper aerodigestive tract is mediated via downregulation of steady-state TGF-alpha and/or EGFR mRNA levels. Following exposure to all-trans-RA, a series of SCCHN cell lines demonstrated a 35.4% reduction in TCF-alpha mRNA expression (P = 0.022) and 58.5% reduction in EGFR mRNA (P = 0.0027). Nuclear run-on analysis indicated that the RA-mediated reduction of TCF-alpha and EGFR steady-state mRNA levels was a result of decreased gene transcription. These results suggest that the clinical effects of RA in SCCHN patients may be due to a downmodulation of TCF-alpha and EGFR mRNA production.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15213; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), UNIV PITTSBURGH,DEPT OTOLARYNGOL,200 LOTHROP ST,SUITE 500,PITTSBURGH,PA 15213, USA.		Tweardy, David/L-3929-2019					BOYLE JO, 1993, CANCER RES, V53, P4477; CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FIELD JK, 1989, ONCOGENE, V4, P1463; GAREWAL HS, 1990, J CLIN ONCOL, V8, P1715, DOI 10.1200/JCO.1990.8.10.1715; GRANDIS JR, 1993, CANCER RES, V53, P3579; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; KIM JS, 1992, J NCI MONOGR, V13, P101; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAWROZ H, 1994, CANCER RES, V54, P1152; SACKS PG, 1989, INT J CANCER, V44, P926, DOI 10.1002/ijc.2910440530; SCHUURING E, 1992, ONCOGENE, V7, P355; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; ZHENG ZS, 1990, CANCER RES, V50, P1201	20	109	109	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					237	240		10.1038/nm0296-237	http://dx.doi.org/10.1038/nm0296-237			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574972				2022-12-27	WOS:A1996TU06000047
J	Taniguchi, H; Toyoshima, T; Fukao, K; Nakauchi, H				Taniguchi, H; Toyoshima, T; Fukao, K; Nakauchi, H			Presence of hematopoietic stem cells in the adult liver	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; MARROW-CELLS; BONE-MARROW; TRANSPLANTATION; CHIMERISM; MICE; PROGENITORS; EXPRESSION; ANTIGENS	Recently, cases have been reported in which a mixed chimeric state of blood cells is established after liver transplantation. Because the established chimerism may have aided in the induction of donor-specific tolerance, the mechanism responsible for this chimerism is of clinical importance. To establish this, we examined cells in adult mouse liver and identified the presence of c-kit(+) Sca-1(+) Lin(lo/-) cells. These cells were capable of forming in vivo as well as in vitro colonies. Furthermore, the cells could reconstitute bone marrow of lethally irradiated recipient mice for at least 12 months. These data obtained from the mouse study strongly suggest that hematopoietic stem cells residing in the donor liver are responsible for mixed chimerism and maintenance of tolerance after liver transplantation.	UNIV TSUKUBA,INST BASIC MED SCI,DEPT IMMUNOL,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST CLIN MED,DEPT SURG,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba								BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BRECHER G, 1982, P NATL ACAD SCI-BIOL, V79, P5085, DOI 10.1073/pnas.79.16.5085; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; Coffman R L, 1982, Immunol Rev, V69, P5; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; EMA H, 1990, BLOOD, V75, P1941; HARDY RR, 1986, HDB EXPT IMMUNOLOGY, pCH31; HOLMES KL, 1986, J IMMUNOL, V137, P679; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAMADA N, 1981, NATURE, V292, P840, DOI 10.1038/292840a0; KAMADA N, 1980, TRANSPLANTATION, V29, P429, DOI 10.1097/00007890-198005000-00021; KORBLING M, 1979, EXP HEMATOL, V7, P277; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; LU L, 1993, BLOOD, V81, P41; MARKUS BH, 1988, TRANSPLANTATION, V46, P372; MORCE HC, 1987, IMMUNOGENETICS, V23, P71; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OKADA S, 1992, BLOOD, V80, P3044; PHILIP AL, 1991, EXP HEMATOL, V19, P994; PHILIP AL, 1992, BLOOD, V80, P663; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; RASMUSSEN A, 1993, 6TH C EUR SOC ORG TR; SAXE DF, 1984, EXP HEMATOL, V12, P277; SCHEID MP, 1979, IMMUNOGENETICS, V9, P423, DOI 10.1007/BF01570435; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1982, HEPATOLOGY, V2, P614; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; STEWART FM, 1993, BLOOD, V81, P2566; TANIGUCHI H, 1995, J IMMUNOL, V155, P5631; TANIGUCHI H, 1995, TRANSPLANT P, V27, P196; TANIGUCHI H, 1994, TRANSPLANT P, V26, P1966; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892	39	260	265	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					198	203		10.1038/nm0296-198	http://dx.doi.org/10.1038/nm0296-198			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574965				2022-12-27	WOS:A1996TU06000040
J	NYSTROMLAHTI, M; KRISTO, P; NICOLAIDES, NC; CHANG, SY; AALTONEN, LA; MOISIO, AL; JARVINEN, HJ; MECKLIN, JP; KINZLER, KW; VOGELSTEIN, B; DELACHAPELLE, A; PELTOMAKI, P				NYSTROMLAHTI, M; KRISTO, P; NICOLAIDES, NC; CHANG, SY; AALTONEN, LA; MOISIO, AL; JARVINEN, HJ; MECKLIN, JP; KINZLER, KW; VOGELSTEIN, B; DELACHAPELLE, A; PELTOMAKI, P			FOUNDING MUTATIONS AND ALU-MEDIATED RECOMBINATION IN HEREDITARY COLON-CANCER	NATURE MEDICINE			English	Article							COLORECTAL-CANCER	By screening members of Finnish families displaying hereditary nonpolyposis colorectal cancer (HNPCC) for predisposing germline mutations in MSH2 and MLH1, we show that two mutations in MLH1 together account for 63% (19/30) of kindreds meeting international diagnostic criteria. Mutation 1, originally detected as a 165-base pair deletion in MLH1 cDNA comprising exon 16, was shown to consist of a 3.5-kilobase genomic deletion most likely resulting from Alu-mediated recombination. Mutation 2 destroys the splice acceptor site of exon 6. A simple diagnostic test based on polymerase chain reaction was designed for both mutations. Our results show that these two ancestral founding mutations account for a majority of Finnish HNPCC kindreds and represent the first report of Alu-mediated recombination causing a prevalent, dominantly inherited predisposition to cancer.	UNIV HELSINKI,DEPT MED GENET,SF-00014 HELSINKI,FINLAND; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HOWARD HUGHES MED INST,BALTIMORE,MD 21231; ROCHE MOLEC SYST INC,ALAMEDA,CA 94501; UNIV HELSINKI,CENT HOSP,DEPT SURG 2,SF-00290 HELSINKI,FINLAND; JYVASKYLA CENT HOSP,SF-40620 JYVASKYLA,FINLAND	University of Helsinki; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital			Mecklin, Jukka-Pekka/AAC-9650-2019; Aaltonen, Lauri/A-5375-2010; Mecklin, Jukka-Pekka/AAB-5378-2020	Aaltonen, Lauri/0000-0001-6839-4286; Mecklin, Jukka-Pekka/0000-0003-4895-2249; Peltomaki, Paivi/0000-0001-8819-2980; Nystrom, Minna/0000-0003-0827-0243	NCI NIH HHS [CA 35494, CA 62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R37CA035494, R01CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; FROGGATT NJ, 1995, LANCET, V345, P727, DOI 10.1016/S0140-6736(95)90900-1; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1994, CANCER RES, V54, P4590; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699	20	257	262	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1203	1206		10.1038/nm1195-1203	http://dx.doi.org/10.1038/nm1195-1203			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584997				2022-12-27	WOS:A1995TC53700049
J	SCHLESSINGER, D				SCHLESSINGER, D			GENOME SEQUENCING PROJECTS	NATURE MEDICINE			English	Editorial Material							REGIONS		WASHINGTON UNIV,SCH MED,CTR MED GENET,ST LOUIS,MO 63110	Washington University (WUSTL)	SCHLESSINGER, D (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110, USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BERGEY DH, 1984, BERGEYS MANUAL DETER, V1, P558; CHEN EY, 1993, GENOMICS, V17, P651, DOI 10.1006/geno.1993.1385; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; FLEISCHMANN RD, 1995, SCIENCE, V268, P496; GILBERT W, 1991, NATURE, V349, P99, DOI 10.1038/349099a0; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Neidhardt F.C., 1987, ESCHERICHIA COLI SAL, VI; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SMITH MW, 1994, NAT GENET, V7, P40, DOI 10.1038/ng0594-40; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	15	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					866	868		10.1038/nm0995-866	http://dx.doi.org/10.1038/nm0995-866			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585203				2022-12-27	WOS:A1995RT30300031
J	KOHL, NE; OMER, CA; CONNER, MW; ANTHONY, NJ; DAVIDE, JP; DESOLMS, SJ; GIULIANI, EA; GOMEZ, RP; GRAHAM, SL; HAMILTON, K; HANDT, LK; HARTMAN, GD; KOBLAN, KS; KRAL, AM; MILLER, PJ; MOSSER, SD; ONEILL, TJ; RANDS, E; SCHABER, MD; GIBBS, JB; OLIFF, A				KOHL, NE; OMER, CA; CONNER, MW; ANTHONY, NJ; DAVIDE, JP; DESOLMS, SJ; GIULIANI, EA; GOMEZ, RP; GRAHAM, SL; HAMILTON, K; HANDT, LK; HARTMAN, GD; KOBLAN, KS; KRAL, AM; MILLER, PJ; MOSSER, SD; ONEILL, TJ; RANDS, E; SCHABER, MD; GIBBS, JB; OLIFF, A			INHIBITION OF FARNESYLTRANSFERASE INDUCES REGRESSION OF MAMMARY AND SALIVARY CARCINOMAS IN RAS TRANSGENIC MICE	NATURE MEDICINE			English	Article							ONCOGENES; CANCER; MYC	For Ras oncoproteins to transform mammalian cells, they must be post-translationally modified with a farnesyl group in a reaction catalysed by the enzyme farnesyl-protein transferase (FPTase). Inhibitors of FPTase have therefore been proposed as anti-cancer agents. We show that L-744,832, which mimics the CaaX motif to which the farnesyl group is added, is a potent and selective inhibitor of FPTase. In MMTV-v-Ha-ras mice bearing palpable tumours, daily administration of L-744,832 caused tumour regression. Following cessation of treatment, tumours reappeared, the majority of which regressed upon retreatment. No systemic toxicity was found upon necropsy of L-744,832-treated mice. This first demonstration of anti-FPTase-mediated tumour regression suggests that FPTase inhibitors may be safe and effective anti-tumour agents in some cancers.	MERCK SHARP & DOHME RES LABS,DEPT SAFETY ASSESSMENT,W POINT,PA 19486; MERCK SHARP & DOHME RES LABS,DEPT MED CHEM,W POINT,PA 19486; MERCK SHARP & DOHME RES LABS,ANIM RESOURCES LAB,W POINT,PA 19486	Merck & Company; Merck & Company; Merck & Company	KOHL, NE (corresponding author), MERCK SHARP & DOHME RES LABS,DEPT CANC RES,W POINT,PA 19486, USA.							ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Clark Geoffrey J., 1995, P17; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DEXTER DL, 1993, INVEST NEW DRUG, V11, P161, DOI 10.1007/BF00874150; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YAMADA H, 1986, BIOCHEM BIOPH RES CO, V140, P167, DOI 10.1016/0006-291X(86)91072-7	17	486	570	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					792	797		10.1038/nm0895-792	http://dx.doi.org/10.1038/nm0895-792			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585182				2022-12-27	WOS:A1995RM63500036
J	LANNFELT, L; BASUN, H; WAHLUND, LO; ROWE, BA; WAGNER, SL				LANNFELT, L; BASUN, H; WAHLUND, LO; ROWE, BA; WAGNER, SL			DECREASED ALPHA-SECRETASE-CLEAVED AMYLOID PRECURSOR PROTEIN AS A DIAGNOSTIC MARKER FOR ALZHEIMERS-DISEASE	NATURE MEDICINE			English	Article							BETA-PROTEIN; CEREBROSPINAL-FLUID; MUTATION	The neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular plaques and intracellular neurofibrillary tangles. A constituent of senile plaques in AD is beta-amyloid, a hydrophobic peptide of 39-43 amino acids(1) and a fragment of the amyloid precursor protein (APP). APP can be metabolized by at least two pathways, one of which involves generation of soluble APP by an unidentified enzyme named alpha-secretase. This cleavage generates alpha-secretase-cleaved, soluble APP (alpha-sAPP), which in this investigation was measured by a new assay in cerebrospinal fluid (CSF) from members of a Swedish AD family with a pathogenic mutation at APP(670/671) (ref. 2). Family members who carry the mutation and are diagnosed with AD had low levels of alpha-sAPP (160 +/- 48 ng ml(-1)), with no overlap compared with non-carriers (257 +/- 48 ng ml(-1)). Carriers of the presymptomatic mutation showed intermediate alpha-sAPP levels. Today there exists no antemortem marker in AD with sufficient sensitivity and specificity, but measurement of alpha-sAPP represents a new and promising diagnostic marker.	SIBIA,LA JOLLA,CA 92037		LANNFELT, L (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN NEUROSCI GERIATR MED,S-14186 HUDDINGE,SWEDEN.							AXELMAN K, 1994, ARCH NEUROL-CHICAGO, V51, P1193, DOI 10.1001/archneur.1994.00540240037013; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HARDY J, 1992, NEUROSCI FACTS, V3, P65; HENRIKSSON T, 1991, J NEUROCHEM, V56, P1037, DOI 10.1111/j.1471-4159.1991.tb02026.x; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; LANNFELT L, 1993, NEUROSCI LETT, V153, P85, DOI 10.1016/0304-3940(93)90083-W; LANNFELT L, 1994, NEUROSCI LETT, V168, P254, DOI 10.1016/0304-3940(94)90463-4; LEVY E, 1991, SCIENCE, V49, P511; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; VANNOSTRAND WE, 1992, ANN NEUROL, V32, P215, DOI 10.1002/ana.410320214; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; WAGNER SL, 1994, ANN NEUROL, V36, P215, DOI 10.1002/ana.410360214	20	142	152	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					829	832		10.1038/nm0895-829	http://dx.doi.org/10.1038/nm0895-829			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585189				2022-12-27	WOS:A1995RM63500043
J	MCMAHON, SB; BENNETT, DLH; PRIESTLEY, JV; SHELTON, DL				MCMAHON, SB; BENNETT, DLH; PRIESTLEY, JV; SHELTON, DL			THE BIOLOGICAL EFFECTS OF ENDOGENOUS NERVE GROWTH-FACTOR ON ADULT SENSORY NEURONS REVEALED BY A TRKA-IGG FUSION MOLECULE	NATURE MEDICINE			English	Article							FACTOR NGF; RAT; INVIVO; AXONS; SKIN	Evidence suggests that nerve growth factor (NGF) may function as a mediator of some persistent pain states. We have used a synthetic protein, trkA-lgG, to sequester endogenous NGF and block the survival effects of NGF on cultured sensory neurons. We show that administration of trkA-lgC produces a sustained thermal and chemical hypoalgesia and leads to a downregulation of the sensory neuropeptide CGRP (calcitonin gene-related peptide) in treated sensory neurons. Acute administration of the molecule blocks the hyperalgesia that develops with carrageenan-induced inflammation. These data suggest that peripherally produced NCF normally acts to maintain the sensitivity of nociceptive sensory neurons and that, in some inflammatory states, an upregulation of NGF is responsible for alterations in pain-related behaviour. Antagonists of NGF may therefore be of clinical use in treating some chronic pain states.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT BIOCHEM,LONDON SE1 7EH,ENGLAND; GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080	University of London; King's College London; Roche Holding; Genentech	MCMAHON, SB (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT PHYSIOL,ST THOMASS CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.			Bennett, David/0000-0002-7996-2696; McMahon, Stephen/0000-0003-4656-5536				Agnati L F, 1984, Acta Physiol Scand Suppl, V532, P5; ALOE L, 1992, ARTHRITIS RHEUM, V35, P351, DOI 10.1002/art.1780350315; ALSALIHI O, 1995, J PHYSIOL-LONDON, V483P, pP154; ANDREEV NY, IN PRESS PAIN; AVERILL S, IN PRESS EUR J NEURO; BADLEY EM, 1993, ANN RHEUM DIS, V52, P6, DOI 10.1136/ard.52.1.6; BENNETT D, IN PRESS 25TH P ANN; Byers MR, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008870; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DIAMOND J, 1987, P NATL ACAD SCI USA, V84, P6596, DOI 10.1073/pnas.84.18.6596; DIAMOND J, 1992, J NEUROSCI, V12, P1467; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; GORIN D, 1990, BRAIN RES, V20, P131; GORIN PD, 1980, BRAIN RES, V198, P27, DOI 10.1016/0006-8993(80)90341-8; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; KOLLASTOS VE, 1994, J COMP NEUROL, V343, P247; LEWIN GR, 1992, EUR J NEUROSCI, V4, P700, DOI 10.1111/j.1460-9568.1992.tb00179.x; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Lindsay RM, 1992, SENSORY NEURONS DIVE, P404; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MCMAHON SB, 1992, SENSORY NEURONS DIVE, P333; MULDERRY PK, 1990, NEUROSCI LETT, V108, P314, DOI 10.1016/0304-3940(90)90660-2; MURPHY RA, 1993, J NEUROSCI, V13, P2853; OTTEN U, 1979, BRAIN RES, V176, P79, DOI 10.1016/0006-8993(79)90871-0; OTTEN U, 1991, NEW PHARMACOTHERAPY, P353; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; RATNER V, 1992, J WOMENS HEALTH, V1, P63; RICH KM, 1984, J COMP NEUROL, V230, P110, DOI 10.1002/cne.902300110; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; SCHMELZER CH, 1992, J NEUROCHEM, V59, P1675, DOI 10.1111/j.1471-4159.1992.tb10998.x; SCHWARTZ JP, 1982, BRAIN RES, V244, P378, DOI 10.1016/0006-8993(82)90102-0; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; VERGE VMK, 1995, J NEUROSCI, V15, P2081, DOI 10.1523/JNEUROSCI.15-03-02081.1995; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; 1994, MMWR-MORBID MORTAL W, V43, P433	43	355	417	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					774	780		10.1038/nm0895-774	http://dx.doi.org/10.1038/nm0895-774			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585179				2022-12-27	WOS:A1995RM63500033
J	HEARST, JE; ELLIOTT, KE				HEARST, JE; ELLIOTT, KE			IDENTIFYING THE KILLER IN CYSTIC-FIBROSIS	NATURE MEDICINE			English	Editorial Material							PSEUDOMONAS-CEPACIA; TRANSMISSION				HEARST, JE (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.							GOLDSTEIN R, 1995, J BACTERIOL, V177, P1039, DOI 10.1128/jb.177.4.1039-1052.1995; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; GOVAN JRW, 1984, ARCH DIS CHILD, V59, P1131; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MARSHALL E, 1995, SCIENCE, V267, P1588, DOI 10.1126/science.7886441; ROSENSTEIN BJ, 1994, LANCET, V343, P746, DOI 10.1016/S0140-6736(94)91832-5; SAJJAN SU, 1992, INFECT IMMUN, V60, P1434, DOI 10.1128/IAI.60.4.1434-1440.1992; SAJJAN U, 1991, GLYCOCONJUGATE J, V8, P209; SAJJAN U, 1993, INFECT IMMUN, V61, P3156; SAJJAN US, 1995, J BACTERIOL, V177, P1030, DOI 10.1128/jb.177.4.1030-1038.1995; SAJJAN US, 1992, J CLIN INVEST, V89, P648, DOI 10.1172/JCI115631; STEINBACH S, 1994, NEW ENGL J MED, V331, P981, DOI 10.1056/NEJM199410133311504; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; WALTERS S, 1993, LANCET, V342, P3; 1993, NEW ENGL J MED, V329, P1308	15	10	10	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					626	627		10.1038/nm0795-626	http://dx.doi.org/10.1038/nm0795-626			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585137				2022-12-27	WOS:A1995RQ06600030
J	LI, LN; HOFFMAN, RM				LI, LN; HOFFMAN, RM			THE FEASIBILITY OF TARGETED SELECTIVE GENE-THERAPY OF THE HAIR FOLLICLE	NATURE MEDICINE			English	Article							SKIN; HISTOCULTURE; TYROSINASE	Loss of hair and hair colour is associated with ageing, and when it involves the scalp hair, it can be distressing to both sexes. Hair loss resulting from cancer chemotherapy is particularly distressing. However, safe, effective therapies directed to hair have only just started to be developed. The hair follicle is a complex skin appendage composed of epidermal and dermal tissue, with specialized keratinocytes, the hair matrix cells, forming the hair shaft. Specific therapy of the hair follicle depends on selective targeting of specific cells of the hair follicle. We have developed the histoculture of intact hair-growing skin on sponge-gel matrices(1-6). We have recently found in histocultured skin that liposomes can selectively target hair follicles to deliver both small and large molecules(3-6). That liposomes can target the hair follicle for delivery has been confirmed independently(7). Two decades ago we introduced the technique of entrapping DNA in liposomes for use in gene therapy(8). In this report we describe the selective targeting of the lacZ reporter gene to the hair follicles in mice after topical application of the gene entrapped in liposomes. These results demonstrate that highly selective, safe gene therapy for the hair process is feasible.	ANTICANC INC,SAN DIEGO,CA 92111	AntiCancer, Inc.								CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; HOFFMAN RM, 1978, FEBS LETT, V93, P365, DOI 10.1016/0014-5793(78)81141-7; LI LG, 1993, IN VITRO CELL DEV-AN, V29A, P192; LI LN, 1994, IN VITRO CELL DEV-AN, V30A, P135; LI LN, 1993, IN VITRO CELL DEV-AN, V29A, P258; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P679; LI LN, 1992, P NATL ACAD SCI USA, V89, P8764, DOI 10.1073/pnas.89.18.8764; LI LN, 1991, P NATL ACAD SCI USA, V88, P1908, DOI 10.1073/pnas.88.5.1908; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; TANAKA S, 1990, DEVELOPMENT, V108, P223; YAROSH D, 1994, J INVEST DERMATOL, V103, P461, DOI 10.1111/1523-1747.ep12395551	12	156	169	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					705	706		10.1038/nm0795-705	http://dx.doi.org/10.1038/nm0795-705			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585157				2022-12-27	WOS:A1995RQ06600049
J	GOODY, RS				GOODY, RS			RATIONAL DRUG DESIGN AND HIV - HOPES AND LIMITATIONS	NATURE MEDICINE			English	Editorial Material							REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; INHIBITORS; INVITRO				GOODY, RS (corresponding author), MAX PLANCK INST MOLEK PHYSIOL, D-44026 DORTMUND, GERMANY.		Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				ABDELMEGUID SS, 1993, MED RES REV, V13, P731, DOI 10.1002/med.2610130605; BUSHMAN F, 1995, SCIENCE, V267, P1443, DOI 10.1126/science.7878462; CASPAR DLD, 1995, STRUCTURE, V3, P327, DOI 10.1016/S0969-2126(01)00163-0; COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; DIVITA G, 1994, J BIOL CHEM, V269, P13080; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RITTINGER K, IN PRESS P NATN ACAD; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653	19	5	5	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1995	1	6					519	520		10.1038/nm0695-519	http://dx.doi.org/10.1038/nm0695-519			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585113				2022-12-27	WOS:A1995RN10100030
J	GREEN, SJ				GREEN, SJ			NITRIC-OXIDE IN MUCOSAL IMMUNITY	NATURE MEDICINE			English	Editorial Material							MAMMALIAN-CELLS				GREEN, SJ (corresponding author), ENTREMED INC,ROCKVILLE,MD 20850, USA.			Green, Shawn J./0000-0003-4361-5454				DUNCAN C, 1995, NAT MED, V1, P546, DOI 10.1038/nm0695-546; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; JONESCARSON J, 1995, NAT MED, V1, P552, DOI 10.1038/nm0695-552; KLOTZ FW, 1995, J IMMUNOL, V154, P3391; LI L, 1991, CANCER RES, V51, P251; MARLETTA MA, 1988, CHEM RES TOXICOL, V1, P249, DOI 10.1021/tx00005a001; MAYER J, 1993, INFECT IMMUN, V61, P491, DOI 10.1128/IAI.61.2.491-497.1993; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OSWALD IP, 1994, P NATL ACAD SCI USA, V91, P999, DOI 10.1073/pnas.91.3.999; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928	19	28	29	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					515	517		10.1038/nm0695-515	http://dx.doi.org/10.1038/nm0695-515			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585111				2022-12-27	WOS:A1995RN10100028
J	BECK, MA; SHI, Q; MORRIS, VC; LEVANDER, OA				BECK, MA; SHI, Q; MORRIS, VC; LEVANDER, OA			RAPID GENOMIC EVOLUTION OF A NONVIRULENT COXSACKIEVIRUS B3 IN SELENIUM-DEFICIENT MICE RESULTS IN SELECTION OF IDENTICAL VIRULENT ISOLATES	NATURE MEDICINE			English	Article							TYPE-3 VACCINE STRAIN; POLIOVIRUS; ATTENUATION; MUTATION	Previous work from our laboratory demonstrated that selenium deficiency in the mouse allows a normally benign (amyocarditic) cloned and sequenced Coxsackievirus to cause significant heart damage. Furthermore, Coxsackievirus recovered from the hearts of selenium-deficient mice inoculated into selenium-adequate mice still induced significant heart damage, suggesting that the amyocarditic Coxsackievirus had mutated to a virulent phenotype. Here we report that sequence analysis revealed six nucleotide changes between the virulent virus recovered from the selenium-deficient host and the avirulent input virus. These nucleotide changes are consistent with known differences in base composition between virulent and avirulent strains of Coxsackievirus. To the best of our knowledge, this is the first report of a specific nutritional deficiency driving changes in a viral genome, permitting an avirulent virus to acquire virulence due to genetic mutation.	USDA ARS,BELTSVILLE HUMAN NUTR RES CTR,NUTRIENT REQUIREMENTS & FUNCT LAB,BELTSVILLE,MD 20705	United States Department of Agriculture (USDA)	BECK, MA (corresponding author), UNIV N CAROLINA,FRANK PORTER GRAHAM CHILD DEV CTR,CB 8180,105 SMITH LEVEL RD,CHAPEL HILL,NC 27599, USA.							ALMOND JW, 1987, ANNU REV MICROBIOL, V41, P153; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAI J, 1984, ACTA ACAD MED SIN, V2, P29; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; CAGGANA M, 1993, J VIROL, V67, P4797, DOI 10.1128/JVI.67.8.4797-4803.1993; CHAPMAN NM, 1994, ARCH VIROL, V135, P115, DOI 10.1007/BF01309769; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; HALL BG, 1990, GENETICS, V126, P5; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; KHUMP WM, 1990, J VIROL, V64, P1573; LEVANDER OA, 1985, FED PROC, V44, P2579; MACADAM AJ, 1991, J VIROL, V65, P5225, DOI 10.1128/JVI.65.10.5225-5231.1991; MINOR PD, 1989, J GEN VIROL, V70, P1117, DOI 10.1099/0022-1317-70-5-1117; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; OCONNELL JB, 1985, POSTGRAD MED J, V61, P1127, DOI 10.1136/pgmj.61.722.1127; Su C, 1979, CHIN MED J, V59, P466; TRACY S, 1993, ARCH VIROL, V122, P399; VANDERPAS JB, 1990, AM J CLIN NUTR, V52, P1087, DOI 10.1093/ajcn/52.6.1087; WOODRUFF JF, 1980, AM J PATHOL, V101, P426; Yang G Q, 1988, World Rev Nutr Diet, V55, P98; ZHANG HY, 1993, J MED VIROL, V41, P129, DOI 10.1002/jmv.1890410208	22	290	306	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					433	436		10.1038/nm0595-433	http://dx.doi.org/10.1038/nm0595-433			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585090				2022-12-27	WOS:A1995RN10000033
J	SKINNER, MP; YUAN, C; MITSUMORI, L; HAYES, CE; RAINES, EW; NELSON, JA; ROSS, R				SKINNER, MP; YUAN, C; MITSUMORI, L; HAYES, CE; RAINES, EW; NELSON, JA; ROSS, R			SERIAL MAGNETIC-RESONANCE-IMAGING OF EXPERIMENTAL ATHEROSCLEROSIS DETECTS LESION FINE-STRUCTURE, PROGRESSION AND COMPLICATIONS IN-VIVO	NATURE MEDICINE			English	Article							ACUTE CORONARY SYNDROMES; LOW-LEVEL HYPERCHOLESTEROLEMIA; FATTY STREAK CONVERSION; NONHUMAN PRIMATE; MEDICAL PROGRESS; FIBROUS PLAQUE; ARTERY DISEASE; FOAM CELLS; ATHEROGENESIS; PATHOGENESIS	A major problem in the study of lesions of atherosclerosis is the difficulty of imaging noninvasively the lesions and following their progression in vivo. To address this problem, we have developed advanced magnetic resonance techniques to noninvasively and serially image advanced lesions of atherosclerosis in the rabbit abdominal aorta. Both lumen and wail were imaged with high resolution. Progression of disease, resulting in increase in lesion mass, decrease in arterial lumen, or stenosis, and intralesion complications, can be detected. Images acquired in vivo correlate with the fine structure of the lesions of atherosclerosis, including the fibrous cap, necrotic core, and lesion fissures, as verified by gross examination, dissection microscopy, and histology. The ability to noninvasively identify the features of atherosclerotic plaques, has significant implications for determining risks and benefits associated with different therapeutic approaches.	UNIV WASHINGTON, DEPT PATHOL SM30, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT RADIOL SB05, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					PHS HHS [18645] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CONSTANT.P, 1966, J ATHEROSCLER RES, V6, P1, DOI 10.1016/S0368-1319(66)80056-X; DAVIES MJ, 1993, BRIT HEART J, V69, pS3; DAVIES MJ, 1984, NEW ENGL J MED, V310, P137; EDELMAN RR, 1993, NEW ENGL J MED, V328, P785, DOI 10.1056/NEJM199303183281109; EDELMAN RR, 1993, NEW ENGL J MED, V328, P708, DOI 10.1056/NEJM199303113281008; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FORRESTER JS, 1991, ANNU REV MED, V42, P35, DOI 10.1146/annurev.med.42.1.35; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GOLD GE, 1993, JMRI-J MAGN RESON IM, V3, P399, DOI 10.1002/jmri.1880030216; HAYES C, IN PRESS J MAGN RESO; HERFKENS RJ, 1983, RADIOLOGY, V148, P161, DOI 10.1148/radiology.148.1.6856827; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MATWIYOFF NA, 1990, MAGN RESON IMAGING, V8, P295, DOI 10.1016/0730-725X(90)90102-8; MAYNOR CH, 1989, INVEST RADIOL, V24, P52, DOI 10.1097/00004424-198901000-00012; MERICKEL MB, 1993, ARTERIOSCLER THROMB, V13, P1180, DOI 10.1161/01.ATV.13.8.1180; MERICKEL MB, 1988, COMPUT BIOL MED, V18, P89, DOI 10.1016/0010-4825(88)90035-2; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MOHIADDIN RH, 1993, CIRCULATION, V88, P264, DOI 10.1161/01.CIR.88.1.264; MOHIADDIN RH, 1989, BRIT MED BULL, V45, P968, DOI 10.1093/oxfordjournals.bmb.a072377; PEARLMAN JD, 1988, MAGN RESON MED, V7, P262, DOI 10.1002/mrm.1910070303; PEARLMAN JD, 1991, ANGIOLOGY, V42, P726, DOI 10.1177/000331979104200906; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Stary HC, 1989, ARTERIOSCLER, V99, pI19; Topol EJ., 1994, TXB INTERVENTIONAL C, V1; VINITSKI S, 1991, INVEST RADIOL, V26, P703, DOI 10.1097/00004424-199108000-00001	33	162	165	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					69	73		10.1038/nm0195-69	http://dx.doi.org/10.1038/nm0195-69			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584956				2022-12-27	WOS:A1995QX55700029
J	Grainger, DJ; Metcalfe, JC				Grainger, DJ; Metcalfe, JC			Tamoxifen: Teaching an old drug new tricks?	NATURE MEDICINE			English	Editorial Material											Grainger, DJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.							BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BUTTA A, 1992, CANCER RES, V52, P4261; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/j.1469-185X.1995.tb01652.x; JENG MH, 1993, MOL CELL ENDOCRINOL, V97, P115, DOI 10.1016/0303-7207(93)90217-8; KARNIK PS, 1994, CANCER RES, V54, P349; LANGDAHL BL, 1995, J BONE MINERAL RES, V10; MACDONALD CC, 1995, BRIT MED J, V311, P977; MACDONALD CC, 1991, BRIT MED J, V303, P435; Magarian R., 1994, CURR MED CHEM, V1, P61; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; POTTER GA, 1994, CARCINOGENESIS, V15, P439, DOI 10.1093/carcin/15.3.439; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P116; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WARD RL, 1993, BONE MINER, V22, P87, DOI 10.1016/S0169-6009(08)80220-6	23	113	122	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					381	385		10.1038/nm0496-381	http://dx.doi.org/10.1038/nm0496-381			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597938				2022-12-27	WOS:A1996UD31400030
J	Murray, GI; Duncan, ME; ONeil, P; Melvin, WT; Fothergill, JE				Murray, GI; Duncan, ME; ONeil, P; Melvin, WT; Fothergill, JE			Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer	NATURE MEDICINE			English	Article							COLLAGENOLYTIC ACTIVITY; MONOCLONAL-ANTIBODIES; COLLAGENASE; METASTASIS; EXPRESSION; NEOPLASIA; ENOLASE; TUMORS	Colorectal cancer is one of the commonest malignant tumors and has a relatively poor prognosis. The outcome depends on the extent of local and particularly metastatic tumor spread. The matrix metalloproteinases (MMPs) are a family of closely related enzymes that degrade the extracellular matrix and are considered to be important in facilitating tumor invasion and spread(1-3). Using immunohistochemistry we have investigated the occurrence in colorectal cancer of MMP-1 (interstitial collagenase). Our monoclonal antibody was prepared against a synthetic peptide corresponding to an amino acid sequence specific for MMP-1 and was selected to react in formalin-fixed wax-embedded sections, thus allowing use in diagnostic histopathology and also enabling access to archival material. We found that the presence of MMP-1 in colorectal cancer is associated with a poor prognosis (P = 0.006) and has prognostic value independent of Dukes stage. One MMP inhibitor that strongly inhibits MMP-1 has already been shown to inhibit growth of human colon cancer xenografts in nude mice(4). Our results suggest that treatment of those individuals whose colon tumors produce MMP-1 with MMP inhibitors is a therapeutic strategy worth pursuing.	UNIV ABERDEEN,DEPT MOLEC & CELL BIOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	Murray, GI (corresponding author), UNIV ABERDEEN,DEPT PATHOL,ABERDEEN AB9 2ZD,SCOTLAND.							BROWN PD, 1993, CURR OPIN INVEST DR, V2, P617; DUNCAN ME, 1992, J IMMUNOL METHODS, V151, P227, DOI 10.1016/0022-1759(92)90121-9; FENOGLIOPREISER CM, 1995, GASTROINTESTINAL OES, P833; GRAY ST, 1993, AM J PATHOL, V143, P663; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; IRIMURA T, 1987, INT J CANCER, V40, P24, DOI 10.1002/ijc.2910400106; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; STETLERSTEVENSO.WG, 1992, FASEB J, V7, P1434; URBANSKI SJ, 1993, DIAGN MOL PATHOL, V2, P81; VANDERSTAPPEN JWJ, 1990, INT J CANCER, V45, P1071; WANG X, 1994, CANCER RES, V54, P4726	13	421	430	1	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					461	462		10.1038/nm0496461	http://dx.doi.org/10.1038/nm0496461			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597958				2022-12-27	WOS:A1996UD31400050
J	Gabizon, R; Telling, G; Meiner, Z; Halimi, H; Kahana, I; Prusiner, SB				Gabizon, R; Telling, G; Meiner, Z; Halimi, H; Kahana, I; Prusiner, SB			Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; AMYLOID PRECURSOR GENE; LIBYAN JEWS; MISSENSE VARIANT; PRP ACCUMULATION; SCRAPIE; MUTATION; CODON-200; REPLICATION	We studied prion proteins (PrP) in skin and brains of Libyan Jews carrying the E200K mutation who died of familial Creutzfeldt-Jakob disease (CJD). Unexpectedly, studies with brain showed that PrP molecules encoded both by the wild-type (wt) and mutant alleles exhibit altered properties characteristic of the prion protein associated with prion diseases (PrPSc). Using monospecific antisera, we found that wtPrP was insoluble in the brains of three patients who were heterozygous for the E200K mutation, whereas mutant PrP was both insoluble and protease-resistant. Our results argue that both wild-type and mutant PrP undergo conformational changes and are particularly intriguing, because the normal isoform PrPC is soluble in nondenaturing detergents and is readily digested by proteases, whereas PrPSc is insoluble and resistant to proteolytic digestion. Our findings indicate that insoluble wtPrP represents a conformational intermediate, the first to be identified, within a pathway in which PrPC is converted to PrPSc.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gabizon, R (corresponding author), HADASSAH UNIV HOSP,DEPT NEUROL,IL-91120 JERUSALEM,ISRAEL.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BERTONI J M, 1992, Neurology, V42, P350; BROWN P, 1992, J NEUROL SCI, V112, P65, DOI 10.1016/0022-510X(92)90133-6; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CHAPMAN J, 1994, NEUROLOGY, V44, P1683, DOI 10.1212/WNL.44.9.1683; COLLINGE J, 1993, BRIT MED J, V306, P391; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DIRINGER H, 1991, J GEN VIROL, V72, P457, DOI 10.1099/0022-1317-72-2-457; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1993, AM J HUM GENET, V33, P828; GABIZON R, 1993, J CELL PHYSL, V157; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KAHANA E, 1974, SCIENCE, V183, P90, DOI 10.1126/science.183.4120.90; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1983, ARCH VIROL, V78, P9, DOI 10.1007/BF01310854; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MEINER Z, 1992, NEUROLOGY, V42, P1355, DOI 10.1212/WNL.42.7.1355; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936	47	82	82	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					59	64		10.1038/nm0196-59	http://dx.doi.org/10.1038/nm0196-59			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564843				2022-12-27	WOS:A1996TP57900038
J	MIKECZ, K; BRENNAN, FR; KIM, JH; GLANT, TT				MIKECZ, K; BRENNAN, FR; KIM, JH; GLANT, TT			ANTI-CD44 TREATMENT ABROGATES TISSUE EDEMA AND LEUKOCYTE INFILTRATION IN MURINE ARTHRITIS	NATURE MEDICINE			English	Article							HYALURONIC-ACID BINDING; ADHESION MOLECULE; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; CD44; RECEPTOR; CELLS; GLYCOPROTEINS; CARTILAGE; EPITOPES	A ubiquitous cell adhesion receptor, CD44 preferentially binds hyaluronan, a polysaccharide macromolecule that is present in most extracellular matrices. Hyaluronan molecules have large hydrodynamic volumes that entrap substantial amounts of water and can therefore control tissue hydration (swelling). CD44 Is overexpressed by jynovial cells and leukocytes, and hyaluronan is overproduced in the rheumatoid synovial and in other inflammatory sites. Nevertheless, the role of the CD44-hyaluronan interaction during inflammation is unclear. Our evidence shows that the CD44 receptor plays a critical role in governing the migration of inflammatory leukocytes into the extravascular compartment of the synovium in murine arthritis. An anti-CD44 antibody induces a rapid loss of CD44 from both leukocytes and synovial cells and displays an inhibitory effect on cell-extracellular matrix interactions In the synovium. As a result, the administration of such an antibody abrogates tissue swelling and leukocyte infiltration, two major components of inflammation.	RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH MED COLL, DEPT BIOCHEM, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH MED COLL, RUSH ARTHRITIS & ORTHOPED INST, CHICAGO, IL 60612 USA	Rush University; Rush University	MIKECZ, K (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH MED COLL, DEPT ORTHOPED SURG, CHICAGO, IL 60612 USA.			Mikecz, Katalin/0000-0003-1506-4296	NIAMS NIH HHS [AR 40310] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040310] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; BRENNAN FR, 1995, CLIN EXP IMMUNOL, V100, P104; BUZAS EI, 1994, CELL IMMUNOL, V158, P292, DOI 10.1006/cimm.1994.1277; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; CAMPBELL RD, 1982, INFLAMMATION, V6, P235, DOI 10.1007/BF00916405; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; ENGSTROMLAURENT A, 1987, ARTHRITIS RHEUM, V30, P1333, DOI 10.1002/art.1780301203; GLANT TT, 1987, ARTHRITIS RHEUM-US, V30, P201, DOI 10.1002/art.1780300211; GLANT TT, 1982, BIOCHEM BIOPH RES CO, V106, P158, DOI 10.1016/0006-291X(82)92071-X; GLANT TT, 1986, BIOCHEM J, V234, P31, DOI 10.1042/bj2340031; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HATHCOCK KS, 1993, J IMMUNOL, V151, P6712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; KAKIMOTO K, 1992, CELL IMMUNOL, V142, P326, DOI 10.1016/0008-8749(92)90294-Y; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIKECZ K, 1994, ARTHRITIS RHEUM-US, V37, P1395, DOI 10.1002/art.1780370919; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NETTELBLADT O, 1989, AM J PHYSIOL, V257, pL379, DOI 10.1152/ajplung.1989.257.6.L379; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PITSILLIDES AA, 1994, BRIT J RHEUMATOL, V33, P5; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SZABO GC, IN PRESS ARTHRITIS R; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; UNDERHILL C, 1992, J CELL SCI, V103, P293; WILLIAMS JM, 1993, J ORTHOPAED RES, V11, P172, DOI 10.1002/jor.1100110204; 1985, SAS USERS GUIDE STAT, P113	38	257	266	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1995	1	6					558	563		10.1038/nm0695-558	http://dx.doi.org/10.1038/nm0695-558			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585123				2022-12-27	WOS:A1995RN10100040
J	ELLIS, JRM; KEATING, PJ; BAIRD, J; HOUNSELL, EF; RENOUF, DV; ROWE, M; HOPKINS, D; DUGGANKEEN, MF; BARTHOLOMEW, JS; YOUNG, LS; STERN, PL				ELLIS, JRM; KEATING, PJ; BAIRD, J; HOUNSELL, EF; RENOUF, DV; ROWE, M; HOPKINS, D; DUGGANKEEN, MF; BARTHOLOMEW, JS; YOUNG, LS; STERN, PL			THE ASSOCIATION OF AN HPV16 ONCOGENE VARIANT WITH HLA-B7 HAS IMPLICATIONS FOR VACCINE DESIGN IN CERVICAL-CANCER	NATURE MEDICINE			English	Article							PAPILLOMAVIRUS INFECTION; MHC MOLECULES; PEPTIDES; BINDING; RECOGNITION; CARCINOMA; ANTIGENS; EPITOPES; RISK	HLA-restricted cytotoxic T-lymphocyte (CTL) recognition of human papillomavirus (HPV) oncogene products may be important in the control of the HPV infections associated with the development of cervical cancer. We have identified, in HLA-B7 individuals, a consistent variation in the HPV16 E6 oncoprotein sequence, which alters an HLA-B7 peptide binding epitope in a way likely to influence immune recognition by CTLs. These results illustrate a biologically relevant mechanism for escape from immune surveillance of HPV16 in HLA-B7 individuals. Thus, both HLA type and HPV16 strain variation need to be considered in the screening of at-risk individuals and for the rational design of anti-HPV vaccines.	UNIV BIRMINGHAM, SCH MED, CRC, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, CRC, DEPT IMMUNOL, MANCHESTER M20 9BX, LANCS, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON, ENGLAND	University of Birmingham; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of London; University College London			Young, Lawrence S/B-7213-2009; Rowe, Martin/B-2880-2009; Hounsell, Elizabeth F/C-5177-2008	Young, Lawrence S/0000-0003-3919-4298; Rowe, Martin/0000-0003-4139-7326; 				APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BARTHOLOMEW JS, 1994, EUR J IMMUNOL, V24, P3175, DOI 10.1002/eji.1830241239; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; BURROWS SR, 1990, J EXP MED, V171, P345, DOI 10.1084/jem.171.1.345; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; ELVIN J, 1993, J IMMUNOL METHODS, V158, P161, DOI 10.1016/0022-1759(93)90210-X; Engelhard V H, 1993, Chem Immunol, V57, P39; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; GLEW SS, 1992, NATURE, V356, P22, DOI 10.1038/356022a0; HAN R, 1992, NATURE, V356, P66, DOI 10.1038/356066a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HELLAND A, 1992, NATURE, V356, P23, DOI 10.1038/356023a0; HILL A, 1995, EUR J IMMUNOL, V25, P18, DOI 10.1002/eji.1830250105; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HONMA S, 1994, INT J CANCER, V57, P650, DOI 10.1002/ijc.2910570507; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; KEATING PJ, IN PRESS BR J CANCER; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LORINCZ AT, 1990, AM J OBSTET GYNECOL, V162, P645, DOI 10.1016/0002-9378(90)90974-C; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MAIER R, 1994, IMMUNOGENETICS, V40, P306, DOI 10.1007/BF00189978; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SADOVNIKOVA E, 1994, INT IMMUNOL, V6, P289, DOI 10.1093/intimm/6.2.289; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0	33	163	164	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					464	470		10.1038/nm0595-464	http://dx.doi.org/10.1038/nm0595-464			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585096				2022-12-27	WOS:A1995RN10000039
J	MCFADDEN, G				MCFADDEN, G			GETTING TO KNOW YOU - VIRUSES MEET CD40 LIGAND	NATURE MEDICINE			English	Editorial Material							VIRAL INHIBITION	The coevolution of viruses and their hosts has given rise in both to elaborate molecular attack and defence mechanisms (pages 437-441).			MCFADDEN, G (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA.							ALCAMI A, 1995, VIROCEPTORS VIROKINE, P17; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Fenner Frank, 1994, P205; GOODING LR, 1992, CELL, V71, P5; MCFADDEN G, 1995, HUMAN CYTOKINES THEI, P401; MCNAIR ANB, 1992, PHARMACOL THERAPEUT, V56, P79, DOI 10.1016/0163-7258(92)90038-2; MOSSMAN K, 1995, VIROCEPTORS VIROKINE, P41; MURPHY PM, 1994, INFECT AGENT DIS, V3, P137; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUBY J, 1995, NAT MED, V1, P437, DOI 10.1038/nm0595-437; SCHALL TJ, 1995, VIROCEPTORS VIROKINE, P201; SMITH CA, 1995, VIROCEPTORS VIROKINE, P29; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; SPRIGGS MK, 1994, CURR OPIN IMMUNOL, V6, P526, DOI 10.1016/0952-7915(94)90136-8; SYMONS JA, COMMUNICATION; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WOLD WSM, 1995, VIROCEPTORS VIROKINE, P147	18	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					408	409		10.1038/nm0595-408	http://dx.doi.org/10.1038/nm0595-408			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585082				2022-12-27	WOS:A1995RN10000025
J	MCLEAN, M; BISITS, A; DAVIES, J; WOODS, R; LOWRY, P; SMITH, R				MCLEAN, M; BISITS, A; DAVIES, J; WOODS, R; LOWRY, P; SMITH, R			A PLACENTAL CLOCK CONTROLLING THE LENGTH OF HUMAN-PREGNANCY	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; HUMAN-FETAL MEMBRANES; BETA-ENDORPHIN; PRETERM LABOR; PLASMA; PARTURITION; MODULATE; CORTISOL; CELLS	We report the existence of a 'placental clock', which is active from an early stage in human pregnancy and determines the length of gestation and the timing of parturition and delivery. Using a prospective, longitudinal cohort study of 485 pregnant women we have demonstrated that placental secretion of corticotropin-releasing hormone (CRH) is a marker of this process and that measurement of the maternal plasma CRH concentration as early as 16-20 weeks of gestation identifies groups of women who ale destined to experience normal term, preterm or post-term delivery. Further, we report that the exponential rise in maternal plasma CRH concentrations with advancing pregnancy is associated with a concomitant fall in concentrations of the specific CRH binding protein in late pregnancy, leading to a rapid increase in circulating levels of bioavailable CRH at a time that coincides with the onset of parturition, suggesting that CRH may ad directly as a trigger for parturition in humans.	JOHN HUNTER HOSP,MATERNAL HLTH RES CTR,NEWCASTLE,NSW 2310,AUSTRALIA; UNIV READING,SCH ANIM & MICROBIAL SCI,READING RG6 2AJ,BERKS,ENGLAND	John Hunter Hospital; University of Reading				Smith, Roger/0000-0003-4720-0280				BALDUCCI J, 1993, AM J OBSTET GYNECOL, V168, P1609, DOI 10.1016/S0002-9378(11)90806-0; BENEDETTO C, 1994, AM J OBSTET GYNECOL, V171, P126, DOI 10.1016/0002-9378(94)90457-X; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; CHALLIS JRG, 1989, BAILLIERE CLIN ENDOC, V3, P781, DOI 10.1016/S0950-351X(89)80053-9; CHAN EC, 1993, ACTA ENDOCRINOL-COP, V128, P339, DOI 10.1530/acta.0.1280339; Cunningham F., 1993, WILLIAMS OBSTETRICS, P297; HILLHOUSE EW, 1993, J CLIN ENDOCR METAB, V76, P736, DOI 10.1210/jc.76.3.736; JONES SA, 1989, BIOCHEM BIOPH RES CO, V159, P192, DOI 10.1016/0006-291X(89)92422-4; JONES SA, 1989, J CLIN ENDOCR METAB, V68, P825, DOI 10.1210/jcem-68-4-825; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P263; KURKI T, 1991, BRIT J OBSTET GYNAEC, V98, P685, DOI 10.1111/j.1471-0528.1991.tb13456.x; LINTON EA, 1993, J CLIN ENDOCR METAB, V76, P260, DOI 10.1210/jc.76.1.260; MCLEAN M, 1994, EUR J ENDOCRINOL, V131, P167, DOI 10.1530/eje.0.1310167; MCNUTT CM, 1994, J ENDOCRINOL, V141, P195, DOI 10.1677/joe.0.1410195; PETRAGLIA F, 1989, AM J OBSTET GYNECOL, V160, P247, DOI 10.1016/0002-9378(89)90130-0; PETRAGLIA F, 1990, OBSTET GYNECOL, V75, P784; PETRAGLIA F, 1990, AM J OBSTET GYNECOL, V163, P1307, DOI 10.1016/0002-9378(90)90711-F; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; QUARTERO HWP, 1989, PLACENTA, V10, P439, DOI 10.1016/0143-4004(89)90054-4; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; SANGHA RK, 1994, J CLIN ENDOCR METAB, V78, P982, DOI 10.1210/jc.78.4.982; SASAKI A, 1987, J CLIN ENDOCR METAB, V64, P224, DOI 10.1210/jcem-64-2-224; SMITH R, 1993, J CLIN ENDOCR METAB, V76, P1063, DOI 10.1210/jc.76.4.1063; SMITH R, 1990, J PSYCHOSOM RES, V34, P53, DOI 10.1016/0022-3999(90)90008-R; SUN K, 1994, J CLIN ENDOCR METAB, V79, P519, DOI 10.1210/jc.79.2.519; THORBURN GD, 1991, REPROD FERT DEVELOP, V3, P277, DOI 10.1071/RD9910277; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VANWAGENEN G, 1943, SURG GYNECOL OBSTET, V77, P539; WARREN WB, 1992, AM J OBSTET GYNECOL, V166, P1198, DOI 10.1016/S0002-9378(11)90606-1; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; WOODS RJ, 1994, J CLIN ENDOCR METAB, V78, P73, DOI 10.1210/jc.78.1.73	31	692	713	2	42	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					460	463		10.1038/nm0595-460	http://dx.doi.org/10.1038/nm0595-460			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585095				2022-12-27	WOS:A1995RN10000038
J	MATHIESON, BJ				MATHIESON, BJ			CTL TO HIV-1 - SURROGATES OR SIRENS	NATURE MEDICINE			English	Editorial Material							CYTOTOXIC LYMPHOCYTES-T; IMMUNODEFICIENCY-VIRUS TYPE-1; RHESUS-MONKEYS; SEROPOSITIVE INDIVIDUALS; IMMUNE-RESPONSES; EPITOPES; VACCINES				MATHIESON, BJ (corresponding author), NIAID,DIV AIDS,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALDHOUS MC, 1994, CLIN EXP IMMUNOL, V97, P61; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; JOHNSON RP, 1992, J EXP MED, V175, P961, DOI 10.1084/jem.175.4.961; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LIEBERMAN J, 1992, J IMMUNOL, V148, P2738; LOHMAN BL, 1994, J VIROL, V68, P7021, DOI 10.1128/JVI.68.11.7021-7029.1994; MILLER MD, 1992, J EXP MED, V176, P1739, DOI 10.1084/jem.176.6.1739; NEWMAN MJ, 1994, AIDS RES HUM RETROV, V10, P853, DOI 10.1089/aid.1994.10.853; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; YASUTOMI Y, 1993, J IMMUNOL, V150, P3101; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; [No title captured]	24	5	5	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					304	305		10.1038/nm0495-304	http://dx.doi.org/10.1038/nm0495-304			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585057	Bronze			2022-12-27	WOS:A1995RN09800023
J	BAKER, T				BAKER, T			THE MINOR ISSUE OF ELECTROCONVULSIVE-THERAPY	NATURE MEDICINE			English	Editorial Material											BAKER, T (corresponding author), ASHWOOD CTR CHILD CARE CONSULTANTS,ASHWOOD RD WOKING,SURREY GU22 7JR,ENGLAND.							ENDLER NS, 1988, CONVULSIVE THER, V4, P5; PIPPARD J, 1992, BRIT J PSYCHIAT, V160, P621, DOI 10.1192/bjp.160.5.621; PIPPARD J, 1992, PSYCHIAT B, V16, P59; SACKEIM H, 1987, ARCH GEN PSYCHIAT, V44, P355; 1994, PRACTICAL ADM ELECTR; 1990, PRACTICE ELECTROCONV; 1989, PRRACTICAL ADM ELECT; 1977, BRIT J PSYCHIAT, V131, P261	8	7	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					199	200		10.1038/nm0395-199	http://dx.doi.org/10.1038/nm0395-199			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585028				2022-12-27	WOS:A1995QX55900018
J	Leonard, WJ				Leonard, WJ			STATs and cytokine specificity	NATURE MEDICINE			English	Editorial Material							PHOSPHORYLATION; TRANSCRIPTION; RECEPTOR; TYROSINE; IL-4				Leonard, WJ (corresponding author), NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892, USA.		Leonard, Warren/AAA-1397-2022					Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Leonard WJ, 1996, ANNU REV MED, V47, P229; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MUI A, 1995, EMBO J, V15, P2425; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P686; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	20	39	46	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					968	969		10.1038/nm0996-968	http://dx.doi.org/10.1038/nm0996-968			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782447				2022-12-27	WOS:A1996VF49700024
J	Scheuner, D; Eckman, C; Jensen, M; Song, X; Citron, M; Suzuki, N; Bird, TD; Hardy, J; Hutton, M; Kukull, W; Larson, E; LevyLahad, E; Viitanen, M; Peskind, E; Poorkaj, P; Schellenberg, G; Tanzi, R; Wasco, W; Lannfelt, L; Selkoe, D; Younkin, S				Scheuner, D; Eckman, C; Jensen, M; Song, X; Citron, M; Suzuki, N; Bird, TD; Hardy, J; Hutton, M; Kukull, W; Larson, E; LevyLahad, E; Viitanen, M; Peskind, E; Poorkaj, P; Schellenberg, G; Tanzi, R; Wasco, W; Lannfelt, L; Selkoe, D; Younkin, S			Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease	NATURE MEDICINE			English	Article							PRECURSOR PROTEIN; APOLIPOPROTEIN-E; MISSENSE MUTATIONS; A-BETA; GENE; PEPTIDE; CELLS; CHROMOSOME-1; A-BETA-42(43); PATHOGENESIS	To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0007), PS2(N141I) (P = 0.009), APP(K670N,M671L) (P < 0.0001), and APP(Y717I) (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzheimer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.	CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN NEUROSCI & FAMILY MED,NOVUM KFC,S-14186 HUDDINGE,SWEDEN; CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106; HARVARD UNIV,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; TAKEDA CHEM IND LTD,DIV DISCOVERY RES,TSUKUBA,IBARAKI 30042,JAPAN; UNIV WASHINGTON,DEPT NEUROL,SEATTLE,WA 98185; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98185; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98185; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98185; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98185; VET AFFAIRS PUGET SOUND HLTH CARE SYST,NEUROL SERV,SEATTLE,WA 98108; VET AFFAIRS PUGET SOUND HLTH CARE SYST,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; UNIV S FLORIDA,DEPT PSYCHIAT,SUNCOAST ALZHEIMERS DIS LABS,TAMPA,FL 33613; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02129	Case Western Reserve University; Mayo Clinic; Karolinska Institutet; Case Western Reserve University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Takeda Chemical Industries; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; State University System of Florida; University of South Florida; Harvard University; Massachusetts General Hospital			Tanzi, Rudolph/AAE-9622-2019; Hardy, John/C-2451-2009; Levy-Lahad, Ephrat/F-2186-2018	Tanzi, Rudolph/0000-0002-7032-1454; Hardy, John/0000-0002-3122-0423; Levy-Lahad, Ephrat/0000-0002-2637-1921; Kukull, Walter/0000-0001-8761-9014				BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; GRUBB A, 1984, NEW ENGL J MED, V311, P1547, DOI 10.1056/NEJM198412133112406; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARDY J, 1991, LANCET, V337, P1342; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KUKULL WA, 1995, AM J EPIDEMIOL, V141, P1059, DOI 10.1093/oxfordjournals.aje.a117370; KUKULL WA, 1996, AM J EPIDEMIOL, V142, P450; Larson E B, 1990, Aging (Milano), V2, P404; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P19965; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	40	2174	2302	1	256	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					864	870		10.1038/nm0896-864	http://dx.doi.org/10.1038/nm0896-864			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705854				2022-12-27	WOS:A1996UZ80400031
J	Anand, P; Terenghi, G; Warner, G; Kopelman, P; WilliamsChestnut, RE; Sinicropi, DV				Anand, P; Terenghi, G; Warner, G; Kopelman, P; WilliamsChestnut, RE; Sinicropi, DV			The role of endogenous nerve growth factor in human diabetic neuropathy	NATURE MEDICINE			English	Article							SKIN; RAT; NGF; NEUROPEPTIDES; EXPRESSION; MELLITUS; SYSTEM; VIP	Nerve growth factor (NGF) is trophic to sensory and sympathetic fibers(1-3). In animal models, NGF is depleted in diabetic nerves(4) and NGF deprivation produces hypoalgesia(5). Exogenous NCF can reverse some of the pathological changes in diabetic nerves(1,6) and NGF excess leads to hyperalgesia(5). We have quantified sensory and autonomic function in early diabetic polyneuropathy and correlated changes with levels of NCF and neuropeptides in affected skin. We describe an early length-dependent dysfunction of sensory small-diameter fibers, prior to dysfunction of sympathetic fibers, with depletion of skin NCF and the sensory neuropeptide substance P. We describe a significant correlation between NCF depletion and decreased skin axon-reflex vasodilation, mediated by small sensory fibers partly via substance P release(3). Immunostaining shows depletion of NGF in keratinocytes in diabetic skin. We propose that a decrease in endogenous skin-derived NCF influences the presentation of diabetic polyneuropathy, although metabolic or vascular abnormalites may be the cause of the neuropathy(7,8). As loss of nociception and axon-reflex vasodilation contribute to diabetic foot ulceration(9), early and prolonged NGF treatment at an appropriate dose may provide rational prophylaxis for this condition.	UNIV LONDON LONDON HOSP,ROYAL LONDON HOSP,COLL MED,DEPT MED,LONDON E1 1BB,ENGLAND; QUEEN VICTORIA HOSP,BLOND MCINDOE CTR,E GRINSTEAD RH19 3DZ,ENGLAND; GENENTECH INC,DEPT BIOANALYT TECHNOL,SAN FRANCISCO,CA 94080	Barts Health NHS Trust; Royal London Hospital; University of London; University College London; Roche Holding; Genentech	Anand, P (corresponding author), UNIV LONDON LONDON HOSP,ROYAL LONDON HOSP,COLL MED,DEPT NEUROL,LONDON E1 1BB,ENGLAND.							ANAND P, 1995, BRIT J ANAESTH, V75, P201, DOI 10.1093/bja/75.2.201; ANAND P, 1995, NEUROSCI LETT, V184, P157, DOI 10.1016/0304-3940(94)11195-O; ANAND P, 1994, LANCET, V344, P129, DOI 10.1016/S0140-6736(94)91316-1; ANAND P, 1988, J NEUROL SCI, V83, P167, DOI 10.1016/0022-510X(88)90066-4; ANAND P, 1983, NATURE, V305, P143, DOI 10.1038/305143a0; ANAND P, 1995, NAT MED, V2, P168; ANAND P, 1991, LANCET, V337, P1353; APFEL SC, 1994, BRAIN RES, V634, P7, DOI 10.1016/0006-8993(94)90252-6; Bell-Krotoski J, 1993, J Hand Ther, V6, P114; DIAMOND J, 1992, J NEUROSCI, V12, P1454; FERNYHOUGH P, 1994, NEUROSCIENCE, V62, P337, DOI 10.1016/0306-4522(94)90368-9; GUY RJC, 1985, DIABETOLOGIA, V28, P131; HELLWEG R, 1994, EXP NEUROL, V130, P24, DOI 10.1006/exnr.1994.1181; HELLWEG R, 1991, NEUROSCI LETT, V125, P1, DOI 10.1016/0304-3940(91)90114-9; HORNYAK ME, 1990, ACTA PHYSIOL SCAND, V139, P77, DOI 10.1111/j.1748-1716.1990.tb08899.x; JOLLIFFE VA, 1995, ANN RHEUM DIS, V54, P251, DOI 10.1136/ard.54.4.251; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVY DM, 1992, DIABETOLOGIA, V35, P889, DOI 10.1007/BF00399938; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; LINDBERGER M, 1989, J NEUROL SCI, V93, P289, DOI 10.1016/0022-510X(89)90198-6; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Loughlin, 1993, NEUROTROPHIC FACTORS, P209; MEAROW KM, 1993, NEUROREPORT, V4, P351, DOI 10.1097/00001756-199304000-00002; PARKHOUSE N, 1988, NEW ENGL J MED, V318, P1306, DOI 10.1056/NEJM198805193182005; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; PROPERZI G, 1993, J PATHOL, V169, P269, DOI 10.1002/path.1711690215; SCHMIDT RE, 1985, DIABETES, V34, P1230, DOI 10.2337/diabetes.34.12.1230; SOHRABJI F, 1994, J NEUROSCI, V14, P459; Thomas P.K., 1993, PERIPHERAL NEUROPATH, V3rd ed., P1219; WINTER J, 1988, NEURON, V1, P937; YAJIMA Y, 1991, JPN J DERMATOL, V10, P129; ZANONE MM, 1994, DIABETIC MED, V11, P378, DOI 10.1111/j.1464-5491.1994.tb00289.x	32	246	255	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					703	707		10.1038/nm0696-703	http://dx.doi.org/10.1038/nm0696-703			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640566				2022-12-27	WOS:A1996UN69100043
J	Avarbock, MR; Brinster, CJ; Brinster, RL				Avarbock, MR; Brinster, CJ; Brinster, RL			Reconstitution of spermatogenesis from frozen spermatogonial stem cells	NATURE MEDICINE			English	Article							MOUSE	Spermatozoa from a number of species can be cryopreserved and then subsequently used to fertilize eggs'. However, this technique has several limitations. First, the freezing protocol varies for each species and must be determined empirically, and for some species appropriate methods have not yet been identified(1,2). Second, because these cells are fully differentiated, they will not undergo replication when thawed, and recombination of genetic information cannot occur. We now demonstrate, by using the recently developed spermatogonial transplantation technique(3,4), that male germline stem cells can be successfully cryopreserved. Donor testis cells isolated from prepubertal or adult mice and frozen from 4 to 156 days at -196 degrees C were able to generate spermatogenesis in recipient seminiferous tubules. Relatively standard preservation techniques were used, suggesting that male germ cells from other species can also be stored for long periods. Because transplanted testis stem cells will ultimately undergo replication and meiotic recombination during spermatogenesis, one might consider these preserved male germ lines as biologically immortal.	UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104	University of Pennsylvania				Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aitken RJ, 1996, NATURE, V379, P493, DOI 10.1038/379493a0; Baker TG., 1972, REPROD BIOL, P398; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; BUCCI LR, 1987, MUTAT RES, V176, P259, DOI 10.1016/0027-5107(87)90057-1; Clermont Y., 1993, FRONT ENDOCRINOL, P332; CLOUTHIER DE, IN PRESS NATURE, P381; De Rooij DG, 1992, ANN NY ACAD SCI, V364, P140; DEANESLY R, 1954, J ENDOCRINOL, V11, P201, DOI 10.1677/joe.0.0110201; DYM M, 1993, HISTOLOGY CELL TISSU, P1000; EWING LL, 1980, INT REV PHYSL, P41; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; Freshney R.I., 1994, CULTURE ANIMAL CELLS, P253; GOSDEN RG, 1992, FETAL TISSUE TRANSPL, P253; Hafez E. S. E., 1993, P503; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Setchell B.P., 1982, P63; TADA N, 1990, J REPROD FERTIL, V89, P511, DOI 10.1530/jrf.0.0890511; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; ZAMBROWICZ BP, 1994, DEVELOPMENT, V120, P1549	25	236	266	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					693	696		10.1038/nm0696-693	http://dx.doi.org/10.1038/nm0696-693			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640563	Green Accepted			2022-12-27	WOS:A1996UN69100040
J	Monia, BP; Johnston, JF; Geiger, T; Muller, M; Fabbro, D				Monia, BP; Johnston, JF; Geiger, T; Muller, M; Fabbro, D			Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase	NATURE MEDICINE			English	Article							TRANSFORMING SEQUENCE; BIOLOGICAL-ACTIVITY; MESSENGER-RNA; V-RAF; OLIGONUCLEOTIDES; ACTIVATION; EXPRESSION; ONCOGENE; HYBRIDIZATION; MECHANISMS	Substantial evidence exists supporting a direct role for raf kinases in the development and maintenance of certain human malignancies. Here we test the potential of phosphorothioate antisense oligodeoxynucleotides targeted against human C-raf-l kinase to specifically inhibit C-raf-l kinase gene expression and tumor progression in cell culture and in vivo, using human tumor xenograft mouse models. Treatment of human tumor cells with appropriate phosphorothioate antisense oligodeoxynucleotides led to specific inhibition of C-raf kinase gene expression in cell culture and in vivo at well-tolerated doses. Moreover, oligodeoxynucleotide treatment resulted in potent antiproliferative effects in cell culture and potent antitumor effects in vivo against a variety of tumor types that were highly consistent with an antisense mechanism of action for these compounds. These studies strongly suggest that antisense inhibitors targeted against C-raf-l kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well-tolerated doses.	CIBA GEIGY AG,DEPT ONCOL,CH-4002 BASEL,SWITZERLAND	Novartis	Monia, BP (corresponding author), ISIS PHARMACEUT,DEPT MOLEC PHARMACOL,2280 FARADAY AVE,CARLSBAD,CA 92008, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACON TA, 1991, ONCOGENE RES, V6, P13; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, IN PRESS J PHARM EXP; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE RM, 1995, J PHARMACOL EXP THER, V275, P462; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; CROOKE ST, IN PRESS J PHARM EXP; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FABLAN JR, 1984, P NATL ACAD SCI USA, V91, P5982; FREIER SM, 1975, BIOCHEMISTRY-US, V14, P3310, DOI 10.1021/bi00686a004; FUKUI M, 1985, P NATL ACAD SCI USA, V81, P5954; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; KURAMOTO E, 1992, JPN J CANCER RES, V83, P1128, DOI 10.1111/j.1349-7006.1992.tb02734.x; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, P MODERN TRENDS LEUK, V7, P69; RAPP UR, 1987, P INT C HORM GROWTH, P122; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STEPKOWSKI SM, 1994, J IMMUNOL, V153, P5336; UHLENBECK OC, 1972, J MOL BIOL, V65, P25, DOI 10.1016/0022-2836(72)90489-5; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P844; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x; YAMAMOTO T, 1994, MICROBIOL IMMUNOL, V38, P831, DOI 10.1111/j.1348-0421.1994.tb01867.x; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	421	504	1	22	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					668	675		10.1038/nm0696-668	http://dx.doi.org/10.1038/nm0696-668			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640558				2022-12-27	WOS:A1996UN69100035
J	Druker, BJ; Tamura, S; Buchdunger, E; Ohno, S; Segal, GM; Fanning, S; Zimmermann, J; Lydon, NB				Druker, BJ; Tamura, S; Buchdunger, E; Ohno, S; Segal, GM; Fanning, S; Zimmermann, J; Lydon, NB			Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells	NATURE MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; SIGNAL-TRANSDUCTION; V-ABL; ONCOGENE; EXPRESSION; INDUCTION; MICE; LINE	The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.	CIBA GEIGY AG, ONCOL RES DEPT, CIBA PHARMACEUT DIV, CH-4002 BASEL, SWITZERLAND	Novartis	Druker, BJ (corresponding author), OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, 3181 S W SAN JACKSON PK RD, PORTLAND, OR 97201 USA.		Califano, Andrea/F-7239-2012	Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [K08CA001422] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN NC, 1994, BLOOD, V84, pA382; ANAFI M, 1993, BLOOD, V82, P3524; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEDI A, 1994, BLOOD, V83, P2038; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; ERWIN JL, 1992, ONCOGENE, V7, P1101; EVANS BD, 1982, BRIT J CANCER, V45, P466, DOI 10.1038/bjc.1982.75; EVANS CA, 1993, CANCER RES, V53, P1735; Furet P, 1995, J COMPUT AID MOL DES, V9, P465, DOI 10.1007/BF00124317; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERNANDEZ A, 1990, EXP HEMATOL, V18, P1142; HONMA Y, 1989, CANCER RES, V49, P331; KANAKURA Y, 1990, BLOOD, V76, P706; KANTARJIAN HM, 1993, BLOOD, V82, P691; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARTIAT P, 1993, BLOOD, V81, P502; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NOWELL PC, 1960, SCIENCE, V132, P1497; OBRIEN SG, 1994, BLOOD REV, V8, P63, DOI 10.1016/S0268-960X(05)80009-8; OBRIEN SG, 1995, J CLIN ONCOL, V13, P541, DOI 10.1200/JCO.1995.13.3.541; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OZER H, 1993, BLOOD, V82, P2975; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SEGAL GM, 1994, J CLIN INVEST, V94, P846, DOI 10.1172/JCI117405; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TURA S, 1994, NEW ENGL J MED, V330, P820; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	52	2821	2965	3	194	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					561	566		10.1038/nm0596-561	http://dx.doi.org/10.1038/nm0596-561			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616716				2022-12-27	WOS:A1996UJ23000040
J	Giordano, FJ; Ping, PP; McKirnan, MD; Nozaki, S; DeMaria, AN; Dillmann, WH; MathieuCostello, O; Hammond, HK				Giordano, FJ; Ping, PP; McKirnan, MD; Nozaki, S; DeMaria, AN; Dillmann, WH; MathieuCostello, O; Hammond, HK			Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart	NATURE MEDICINE			English	Article							CORONARY COLLATERAL DEVELOPMENT; SKELETAL-MUSCLES; ARTERY OCCLUSION; DOWN-REGULATION; MYOCARDIUM; LOCALIZATION; CIRCULATION; EXPRESSION; EXERCISE; MODEL	Increased coronary blood vessel development could potentially benefit patients with ischemic heart disease. In a model of stress-induced myocardial ischemia, intracoronary injection of a recombinant adenovirus expressing human fibroblast growth factor-5 (FGF-5) resulted in messenger RNA and protein expression of the transferred gene. Two weeks after gene transfer, regional abnormalities in stress-induced function and blood flow were improved, effects that persisted for 12 weeks. Improved blood flow and function were associated with evidence of angiogenesis. This report documents, for the first time, successful amelioration of abnormalities in myocardial blood flow and function following in vivo gene transfer.	VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego								BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BARR E, 1994, GENE THER, V1, P51; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BERNOTATDANIELOWSKI S, 1993, CARDIOVASC RES, V27, P1220, DOI 10.1093/cvr/27.7.1220; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; GOTO F, 1993, LAB INVEST, V69, P508; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; HAMMOND HK, 1993, J CLIN INVEST, V92, P2644, DOI 10.1172/JCI116880; HAMMOND HK, 1994, J AM COLL CARDIOL, V23, P475, DOI 10.1016/0735-1097(94)90436-7; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; KAJSTURA J, 1994, CIRC RES, V74, P383, DOI 10.1161/01.RES.74.3.383; KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498; KITAOKA T, 1994, INVEST OPHTH VIS SCI, V35, P3189; MATHIEUCOSTELLO O, 1987, MICROVASC RES, V33, P98, DOI 10.1016/0026-2862(87)90010-0; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORROW NG, 1990, J CLIN INVEST, V85, P1816, DOI 10.1172/JCI114640; MOULLIER P, 1994, KIDNEY INT, V45, P1220, DOI 10.1038/ki.1994.162; NIENABER CA, 1990, AM J CARDIOL, V65, P991, DOI 10.1016/0002-9149(90)91002-N; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; PING PP, 1994, AM J PHYSIOL-HEART C, V267, pH2079, DOI 10.1152/ajpheart.1994.267.5.H2079; POOLE DC, 1990, AM J PHYSIOL, V259, pH204, DOI 10.1152/ajpheart.1990.259.1.H204; ROTH DA, 1993, J CLIN INVEST, V91, P939, DOI 10.1172/JCI116315; ROTH DM, 1990, CIRCULATION, V82, P1778, DOI 10.1161/01.CIR.82.5.1778; ROTH DM, 1987, AM J PHYSIOL, V253, pH1279, DOI 10.1152/ajpheart.1987.253.5.H1279; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SKYBA DM, 1994, CIRCULATION, V90, P1513, DOI 10.1161/01.CIR.90.3.1513; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; TSAI PS, 1995, ENDOCRINOLOGY, V136, P3831, DOI 10.1210/en.136.9.3831; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; WHITE FC, 1992, CIRC RES, V71, P1490, DOI 10.1161/01.RES.71.6.1490; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	36	364	449	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					534	539		10.1038/nm0596-534	http://dx.doi.org/10.1038/nm0596-534			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616711				2022-12-27	WOS:A1996UJ23000035
J	Ross, R				Ross, R			Genetically modified mice as models of transplant atherosclerosis	NATURE MEDICINE			English	Editorial Material							REJECTION; ARTERIOSCLEROSIS; PATHOGENESIS; ALLOGRAFTS				Ross, R (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PATHOL,BOX 357470,SEATTLE,WA 98195, USA.							ALONSO DR, 1977, AM J PATHOL, V87, P415; HANSSON GK, 1996, ATHEROSCLEROSIS CORO, P557; HAYRY P, 1993, IMMUNOL REV, V134, P33, DOI 10.1111/j.1600-065X.1993.tb00639.x; ISIK FF, 1992, AM J PATHOL, V141, P1139; PAUL LC, 1993, TRANSPLANT P, V25, P2024; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051	8	32	34	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					527	528		10.1038/nm0596-527	http://dx.doi.org/10.1038/nm0596-527			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616709				2022-12-27	WOS:A1996UJ23000033
J	Walsh, GP; Tan, EV; delaCruz, EC; Abalos, RM; Villahermosa, LG; Young, LJ; Cellona, RV; Nazareno, JB; Horwitz, MA				Walsh, GP; Tan, EV; delaCruz, EC; Abalos, RM; Villahermosa, LG; Young, LJ; Cellona, RV; Nazareno, JB; Horwitz, MA			The Philippine cynomolgus monkey (Macaca fascicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease	NATURE MEDICINE			English	Article							PULMONARY TUBERCULOSIS	A nonhuman primate model of tuberculosis that closely resembles human disease is urgently needed. We have evaluated the Philippine cynomolgus monkey, Macaca fasicularis, as a model of TB. Cynomolgus monkeys challenged intratracheally with extremely high doses of Mycobocterium tuberculosis (10(5) or 10(4) CFU) developed an acute, rapidly progressive, highly fatal multilobar pneumonia. However, monkeys challenged with moderate or low doses of M. tuberculosis (less than or equal to 10(3) CFU) developed a chronic, slowly progressive, localized form of pulmonary TB, akin to the disease in humans, that was frequently accompanied by such clinical syndromes as ocular tuberculosis, meningitis and tuberculous spondylitis. A significant proportion of monkeys challenged with 10(2) or 10(1) CFU contained the infection in a subclinical state. The Philippine cynomolgus monkey model is an excellent model of chronic TB and provides an opportunity to study subclinical and potentially latent disease in an animal model.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095; LEONARD WOOD MEM RES CTR,CEBU,PHILIPPINES; SIMIAN CONSERVAT & BREEDING CORP,TANAY,PHILIPPINES	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035189] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH O, 1951, AM REV TUBERC PULM, V64, P419; BARRETTC.E, 1967, SOUTH MED J, V60, P1061, DOI 10.1097/00007611-196710000-00008; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; CHAPARAS SD, 1975, AM REV RESPIR DIS, V112, P43; CHAPARAS SD, 1970, AM J VET RES, V31, P1437; CORCORAN KD, 1991, LAB ANIM SCI, V41, P57; DONAHUE HC, 1967, AM J OPHTHALMOL, V64, P742, DOI 10.1016/0002-9394(67)92860-7; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GOOD RC, 1968, ANN NY ACAD SCI, V154, P200, DOI 10.1111/j.1749-6632.1968.tb16710.x; Good RC., 1984, MYCOBACTERIA SOURCEB, P903; GOOD RC, 1978, NONHUMAN PRIMATES ME, P39; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; MUSCOPLAT CC, 1975, AM J VET RES, V36, P699; PAL PG, 1992, INFECT IMMUN, V60, P4781, DOI 10.1128/IAI.60.11.4781-4792.1992; SCHMIDT LH, 1956, AM REV TUBERC PULM, V74, P138; SCHMIDT LH, 1972, AM REV RESPIR DIS, V105, P183; SCHMIDT LH, 1962, B INT UNION TUBERC, V32, P487; TRIBE G W, 1976, Laboratory Animals (London), V10, P39, DOI 10.1258/002367776780948970; WARD GS, 1985, LAB ANIM SCI, V35, P395; WURTZ R, 1993, CLIN INFECT DIS, V16, P806, DOI 10.1093/clind/16.6.806	20	172	179	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					430	436		10.1038/nm0496-430	http://dx.doi.org/10.1038/nm0496-430			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597953				2022-12-27	WOS:A1996UD31400045
J	Bergh, C; Sodersten, P				Bergh, C; Sodersten, P			Anorexia nervosa, self-starvation and the reward of stress	NATURE MEDICINE			English	Editorial Material							RESPONSES		KAROLINSKA INST, NOVUM, CTR EATING DISORDERS, S-14157 HUDDINGE, SWEDEN	Karolinska Institutet	Bergh, C (corresponding author), KAROLINSKA INST, NOVUM, DEPT CLIN NEUROSCI, DIV APPL NEUROENDOCRINOL, S-14157 HUDDINGE, SWEDEN.			Sodersten, Per/0000-0002-4713-4490				BURDEN VR, 1993, J NUTR, V123, P1217, DOI 10.1093/jn/123.7.1217; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; DAVIS C, 1994, PSYCHOL MED, V24, P957, DOI 10.1017/S0033291700029044; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; ECKERT ED, 1995, PSYCHOL MED, V25, P143, DOI 10.1017/S0033291700028166; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; GRATTON A, 1994, J NEUROSCI, V14, P4130; Gull W., 1874, CLIN SOC T, V7, P22; HOTTA M, 1986, J CLIN ENDOCR METAB, V62, P319, DOI 10.1210/jcem-62-2-319; LEE S, 1993, PSYCHOL MED, V23, P999, DOI 10.1017/S0033291700026465; LIU JP, 1994, J CLIN INVEST, V93, P1439, DOI 10.1172/JCI117121; NOVIN D, 1995, OBESITY RES S3, V3, pA373; PIAZZA PV, 1993, P NATL ACAD SCI USA, V90, P11738, DOI 10.1073/pnas.90.24.11738	13	101	102	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1996	2	1					21	22		10.1038/nm0196-21	http://dx.doi.org/10.1038/nm0196-21			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564826				2022-12-27	WOS:A1996TP57900026
J	Gillespie, PG				Gillespie, PG			Deaf and dizzy mice with mutated myosin motors	NATURE MEDICINE			English	Editorial Material							HAIR-CELLS		JOHNS HOPKINS UNIV, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University	Gillespie, PG (corresponding author), JOHNS HOPKINS UNIV, DEPT PHYSIOL, BALTIMORE, MD 21205 USA.			Barr-Gillespie, Peter/0000-0002-9787-5860				AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; DEOL MS, 1966, GENET RES, V8, P339, DOI 10.1017/S0016672300010193; EATOCK RA, 1987, J NEUROSCI, V7, P2821; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Lyon M., 1989, GENETIC VARIANTS STR; MARKIN VS, 1995, ANNU REV BIOPH BIOM, V24, P59, DOI 10.1146/annurev.bb.24.060195.000423; METCALF AB, 1994, P NATL ACAD SCI USA, V91, P11821, DOI 10.1073/pnas.91.25.11821; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	13	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1996	2	1					27	29		10.1038/nm0196-27	http://dx.doi.org/10.1038/nm0196-27			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564830				2022-12-27	WOS:A1996TP57900030
J	Zhang, W; Lee, WH; Triarhou, LC				Zhang, W; Lee, WH; Triarhou, LC			Grafted cerebellar cells in a mouse model of hereditary ataxia express IGF-I system genes and partially restore behavioral function	NATURE MEDICINE			English	Article							GROWTH FACTOR-I; DEGENERATION MUTANT MICE; PURKINJE-CELLS; RAT-BRAIN; INSULIN; SUSPENSIONS; NEURONS; PCD; DIFFERENTIATION; TRANSPLANTATION	Fetal grafts of normal cerebellar tissue were implanted into the cerebellum of Purkinje cell degeneration mutant mice (pcd/pcd), a model of adult-onset recessively inherited cerebello-olivary atrophy, in an attempt at correcting their cellular and motor impairment. Donor cerebellar cells engrafted in the appropriate sites, as evidenced by the pattern of expression of insulin-like growth factor-I (ICF-I) system genes. Bilateral cerebellar grafts led to an improvement of motor behaviors in balance rod tests and in the open field, providing evidence for functional integration into the atrophic mouse cerebellum and underscoring the potential of neural transplantation for counteracting the human cerebellar ataxias.	INDIANA UNIV, SCH MED, DEPT PATHOL & LAB MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT ANAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, HERMAN B WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, PROGRAM MED NEUROBIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Triarhou, Lazaros/ABE-4651-2020		NINDS NIH HHS [R29-NS29283] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029283] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVARADOMALLART RM, 1982, J COMP NEUROL, V212, P247, DOI 10.1002/cne.902120304; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY C, 1993, J NEUROSCI, V13, P5092, DOI 10.1523/JNEUROSCI.13-12-05092.1993; Bondy C.A., 1992, NEUROPROTOCOLS, V1, P240, DOI 10.1016/1058-6741(92)90034-U; BONDY CA, 1991, J NEUROSCI, V11, P3442; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; Bures J., 1976, TECHNIQUES BASIC EXP, P37; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CASTROALAMANCOS MA, 1993, P NATL ACAD SCI USA, V90, P7386, DOI 10.1073/pnas.90.15.7386; DAS GD, 1971, SCIENCE, V173, P637, DOI 10.1126/science.173.3997.637; DUNNETT SB, 1994, FUNCTIONAL NEURAL TR; GARDETTE R, 1988, NEUROSCIENCE, V24, P777, DOI 10.1016/0306-4522(88)90066-8; Ghetti B., 1992, CEREBELLAR DEGENERAT, P159; GREER CA, 1982, BRAIN RES, V235, P156, DOI 10.1016/0006-8993(82)90206-2; HARDING AE, 1993, ADV NEUROL, V61, P1; HEPLER JE, 1990, MOL NEUROBIOL, V4, P93, DOI 10.1007/BF02935586; HOLMES G, 1907, BRAIN, V30, P467; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; LANDIS SC, 1978, J COMP NEUROL, V177, P125, DOI 10.1002/cne.901770109; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LEE WH, 1992, J NEUROSCI, V12, P4737; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; LEROITH D, 1993, NEUROTROPHIC FACTORS, P391; MULLEN RJ, 1975, NATURE, V258, P528, DOI 10.1038/258528a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NIETOBONA MP, 1993, J NEUROSCI RES, V36, P520, DOI 10.1002/jnr.490360504; OBATA K, 1969, EXPERIENTIA, V25, P1285; OGORMAN S, 1985, J COMP NEUROL, V234, P277, DOI 10.1002/cne.902340302; POIRIER J, 1990, MANUAL BASIC NEUROPA, P151; Sokal R. R, 1981, BIOMETRY; SOTELO C, 1987, NEUROSCIENCE, V20, P1, DOI 10.1016/0306-4522(87)90002-9; SOTELO C, 1986, P NATL ACAD SCI USA, V83, P1135, DOI 10.1073/pnas.83.4.1135; Thach WT, 1992, CEREBELLUM REVISITED, P283; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; TRIARHOU LC, 1992, ANAT EMBRYOL, V185, P409; TRIARHOU LC, 1987, ANAT EMBRYOL, V176, P145, DOI 10.1007/BF00310047; TRIARHOU LC, 1992, NEUROCHEM RES, V17, P475, DOI 10.1007/BF00969895; WELLS J, 1982, DEV BRAIN RES, V4, P167, DOI 10.1016/0165-3806(82)90040-2; WETTS R, 1985, Society for Neuroscience Abstracts, V11, P1037; YUASA S, 1991, ANAT EMBRYOL, V184, P195, DOI 10.1007/BF01673256	40	46	47	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1996	2	1					65	71		10.1038/nm0196-65	http://dx.doi.org/10.1038/nm0196-65			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564845				2022-12-27	WOS:A1996TP57900039
J	MANDELBOIM, O; VADAI, E; FRIDKIN, M; KATZHILLEL, A; FELDMAN, M; BERKE, G; EISENBACH, L				MANDELBOIM, O; VADAI, E; FRIDKIN, M; KATZHILLEL, A; FELDMAN, M; BERKE, G; EISENBACH, L			REGRESSION OF ESTABLISHED MURINE CARCINOMA METASTASES FOLLOWING VACCINATION WITH TUMOR-ASSOCIATED ANTIGEN PEPTIDES	NATURE MEDICINE			English	Article							SUPPRESSOR T-CELLS; ANTIVIRAL PROTECTION; LYMPHOCYTES	The cure of micrometastases following surgery is the major goal of cancer immunotherapy. We have recently isolated tumour-associated antigen (TAA) peptides, MUT 1 and MUT 2, derived from a mutated connexin 37 gap-junction protein, from the malignant 3LL-D122 murine lung carcinoma. We now report that synthetic MUT 1 or MUT 2 induces effective antitumour cytoxic T lymphocytes. Peptide vaccines protect mice from spontaneous metastases of 3LL-D122 tumours. Moreover, peptide vaccines reduce metastatic loads in mice carrying pre-established micrometastases. Tumour-specific immunity was primarily mediated by CD8(+) T cells. This is the first evidence that peptide therapy may be effective in treatment of residual tumours and provides a rationale for the development of peptide vaccines as a modality for cancer therapy.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968; Mandelboim, Ofer/0000-0002-9354-1855				AWWAD M, 1989, CANCER RES, V49, P1649; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GELBER C, 1992, CANCER RES, V52, P6507; KAST WM, 1993, EUR J IMMUNOL, V23, P1189, DOI 10.1002/eji.1830230534; KOVACSOVICSBANK.M, 1995, SCIENCE, V267, P243; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; NORTH RJ, 1990, IMMUNOLOGY, V71, P90; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; RAKMILEVICH AL, 1994, CANCER IMMUNOL IMMUN, V38, P197; RAKMILLEVICH AL, 1993, INT J CANCER, V53, P338; ROCK KL, 1993, J IMMUNOL, V150, P438; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SCHULZ M, 1991, P NATL ACAD SCI USA, V88, P991, DOI 10.1073/pnas.88.3.991; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; URBAN JL, 1992, ANNU REV IMMUNOL, V10, P617, DOI 10.1146/annurev.iy.10.040192.003153	21	134	154	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1179	1183		10.1038/nm1195-1179	http://dx.doi.org/10.1038/nm1195-1179			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584991				2022-12-27	WOS:A1995TC53700043
J	WALLMAN, J; MCFADDEN, S				WALLMAN, J; MCFADDEN, S			MONKEY EYES GROW INTO FOCUS	NATURE MEDICINE			English	Editorial Material							CHILDREN	Previous studies that suggested that lens-wearing may affect eye growth are supported now by primate studies, which raises questions about the use of eyeglasses in children.	UNIV NEWCASTLE,DEPT PSYCHOL,NEWCASTLE,NSW 2308,AUSTRALIA; UNIV NEWCASTLE,DEPT PSYCHOL,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle; University of Newcastle			MCFADDEN, SALLY/G-7164-2013	McFadden, Sally/0000-0001-6761-1592				CHEN CJ, 1985, OPHTHALMIC PAED GEN, V6, P113, DOI 10.3109/13816818509004128; GOLDSCHMIDT E, 1968, ETIOLOGY MYOPIA EPID; GWIAZDA J, 1993, INVEST OPHTH VIS SCI, V34, P690; HUNG LF, 1995, NAT MED, V1, P761, DOI 10.1038/nm0895-761; IRVING EL, 1992, OPHTHAL PHYSL OPT, V12, P448, DOI 10.1111/j.1475-1313.1992.tb00315.x; JUDGE SJ, 1995, J PHYSIOL-LONDON, V485P, pP27; McFadden SA, 1995, INVEST OPHTHALMOL  S, V36, P758; RICHLER A, 1980, ACTA OPHTHALMOL, V58, P468; SCHAEFFEL F, 1988, VISION RES, V28, P639, DOI 10.1016/0042-6989(88)90113-7; SIEGWART JT, 1993, INVEST OPHTH VIS SCI, V34, P1208; SMITH EL, 1994, VISION RES, V34, P293, DOI 10.1016/0042-6989(94)90088-4; WILDSOET C, 1995, VISION RES, V35, P1175, DOI 10.1016/0042-6989(94)00233-C	12	30	30	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					737	739		10.1038/nm0895-737	http://dx.doi.org/10.1038/nm0895-737			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585168				2022-12-27	WOS:A1995RM63500022
J	COOPER, DL; DOUGHERTY, GJ				COOPER, DL; DOUGHERTY, GJ			TO METASTASIZE OR NOT - SELECTION OF CD44 SPLICE SITES	NATURE MEDICINE			English	Editorial Material							ADHESION MOLECULE; HYALURONATE; RECEPTOR; CELLS; EXONS; FORM		BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	British Columbia Cancer Agency	COOPER, DL (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261, USA.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASMAN DC, IN PRESS J NEUROONCO; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; DOUGHERTY G J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P35; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HOFMANN M, 1991, CANCER RES, V51, P5295; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; LABARRIERE N, 1994, CANCER RES, V54, P6275; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MERZAK A, 1994, CANCER RES, V54, P3988; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TARIN D, IN PRESS J NEUROONCO; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; IN PRESS J NEUROONCO	23	84	84	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					635	637		10.1038/nm0795-635	http://dx.doi.org/10.1038/nm0795-635			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585142				2022-12-27	WOS:A1995RQ06600035
J	DONNELLY, JJ; FRIEDMAN, A; MARTINEZ, D; MONTGOMERY, DL; SHIVER, JW; MOTZEL, SL; ULMER, JB; LIU, MA				DONNELLY, JJ; FRIEDMAN, A; MARTINEZ, D; MONTGOMERY, DL; SHIVER, JW; MOTZEL, SL; ULMER, JB; LIU, MA			PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS	NATURE MEDICINE			English	Article							A VIRUS; PLASMID DNA; REASSORTANT VIRUSES; IMMUNE-RESPONSES; SQUIRREL-MONKEYS; HUMAN VOLUNTEERS; GENE-EXPRESSION; HEMAGGLUTININ; H1N1; LIVE	Vaccination with plasmid DNA expression vectors encoding foreign proteins elicits antibodies and cell-mediated immunity and protects against disease in animal models. We report a comparison of DNA vaccines, using contemporary human strains of virus, and clinically licensed (inactivated virus or subvirion) vaccines in preclinical animal models, to better predict their efficacy in humans. Influenza DNA vaccines elicited antibodies in both non-human primates and ferrets and protected ferrets against challenge with an antigenically distinct epidemic human influenza virus more effectively than the contemporary clinically licensed vaccine. These studies demonstrate that DNA vaccines may be more effective, particularly against different strains of virus, than inactivated virus or subvirion vaccines.	MERCK SHARP & DOHME LTD, DEPT VIRUS & CELL BIOL, RES LABS, West Point, PA 19486 USA; MERCK SHARP & DOHME LTD, DEPT LAB ANIM RESOURCES, RES LABS, West Point, PA 19486 USA	Merck & Company; Merck & Company								ASANO Y, 1994, PEDIATRICS, V94, P524; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BERENDT RF, 1977, INFECT IMMUN, V16, P476, DOI 10.1128/IAI.16.2.476-479.1977; BERENDT RF, 1977, J INFECT DIS, V136, pS712, DOI 10.1093/infdis/136.Supplement_3.S712; BOTH GW, 1983, J VIROL, V48, P52, DOI 10.1128/JVI.48.1.52-60.1983; Chakraverty M., 1993, Morbidity and Mortality Weekly Report, V42, P177; CLEMENTS ML, 1992, J CLIN MICROBIOL, V30, P655, DOI 10.1128/JCM.30.3.655-662.1992; CLEMENTS ML, 1990, J INFECT DIS, V161, P869, DOI 10.1093/infdis/161.5.869; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; FRIES LF, 1993, J INFECT DIS, V167, P593, DOI 10.1093/infdis/167.3.593; Graham F L, 1992, Biotechnology, V20, P363; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; KATZ JM, 1989, J INFECT DIS, V160, P191, DOI 10.1093/infdis/160.2.191; KUWANO K, 1989, J EXP MED, V169, P1361, DOI 10.1084/jem.169.4.1361; MAHR A, 1992, IMMUNOBIOLOGY, V184, P126, DOI 10.1016/S0171-2985(11)80471-7; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; MBAWUIKE IN, 1994, VACCINE, V12, P1340, DOI 10.1016/S0264-410X(94)80063-6; MONTGOMERY DL, 1993, DNA CELL BIOL, V12, P777, DOI 10.1089/dna.1993.12.777; MURPHY BR, 1973, J INFECT DIS, V128, P479, DOI 10.1093/infdis/128.4.479; MURPHY BR, 1980, INFECT IMMUN, V28, P688; NEWMAN RW, 1993, VACCINE, V11, P400, DOI 10.1016/0264-410X(93)90279-7; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; POWERS DC, 1991, J CLIN MICROBIOL, V29, P498, DOI 10.1128/JCM.29.3.498-505.1991; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROCHA EP, 1993, J GEN VIROL, V74, P2513, DOI 10.1099/0022-1317-74-11-2513; SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994; SEARS SD, 1988, J INFECT DIS, V158, P1209, DOI 10.1093/infdis/158.6.1209; SHU LL, 1993, J VIROL, V67, P2723, DOI 10.1128/JVI.67.5.2723-2729.1993; SMITH H, 1988, REV INFECT DIS, V10, P56; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YETTER RA, 1980, INFECT IMMUN, V29, P650	37	270	290	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1995	1	6					583	587		10.1038/nm0695-583	http://dx.doi.org/10.1038/nm0695-583			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585127				2022-12-27	WOS:A1995RN10100044
J	INDOLFI, C; AVVEDIMENTO, EV; RAPACCIUOLO, A; DILORENZO, E; ESPOSITO, G; STABILE, E; FELICIELLO, A; MELE, E; GIULIANO, P; CONDORELLI, G; CHIARIELLO, M				INDOLFI, C; AVVEDIMENTO, EV; RAPACCIUOLO, A; DILORENZO, E; ESPOSITO, G; STABILE, E; FELICIELLO, A; MELE, E; GIULIANO, P; CONDORELLI, G; CHIARIELLO, M			INHIBITION OF CELLULAR RAS PREVENTS SMOOTH-MUSCLE CELL-PROLIFERATION AFTER VASCULAR INJURY IN-VIVO	NATURE MEDICINE			English	Article							SUCCESSFUL CORONARY ANGIOPLASTY; H-RAS; GROWTH; RESTENOSIS; PROTEIN; PHOSPHORYLATION; MICROINJECTION; NIH-3T3-CELLS; MUTANTS	Proliferation of smooth muscle cells of the arterial wall in response to local injury is an important aetiologic factor of vascular proliferative disorders such as atherosclerosis and restenosis after angioplasty. Ras proteins are key transducers of mitogenic signals from membrane to nucleus in many cell types. We investigated the role of ros proteins in the vascular response to arterial injury by inactivating cellular ras of rats in which the common carotid artery was subjected to balloon injury. DNA vectors expressing ros transdominant negative mutants, which interfere with ros function, reduced neointimal formation after injury. Our results indicate a key role for ras in smooth muscle cell proliferation and show that the local delivery of transdominant negative mutants of ras in vivo might prevent some of the acute vascular injury caused by balloon injury.	UNIV NAPLES FEDERICO II,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE CLIN,I-88100 CANTANZARO,ITALY; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	INDOLFI, C (corresponding author), UNIV NAPLES FEDERICO II,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CATTEDRA CARDIOL,VIA PANSINI 5,I-80131 NAPLES,ITALY.		Esposito, Giovanni/F-2880-2010; Rapacciuolo, Antonio/AAR-8012-2020; Condorelli, Gianluigi/Q-6736-2017	Esposito, Giovanni/0000-0003-0565-7127; Rapacciuolo, Antonio/0000-0002-4739-7004; stabile, eugenio/0000-0002-4544-3142; Condorelli, Gianluigi/0000-0003-0481-6843; INDOLFI, Ciro/0000-0003-1241-6487; stabile, eugenio/0000-0001-9763-6010				BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURASSA MG, 1992, J AM COLL CARDIOL, V19, P1410, DOI 10.1016/0735-1097(92)90595-E; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CLOWES AW, 1983, LAB INVEST, V49, P327; DIXON WJ, 1969, INTRO STATISTICAL AN; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERRMAN JPR, 1993, DRUGS, V46, P249, DOI 10.2165/00003495-199346020-00003; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; INDOLFI C, 1995, IN PRESS CIRCULATION; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MADRI JA, 1989, LAB INVEST, V60, P755; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VIRMANI R, 1994, AM HEART J, V127, P163, DOI 10.1016/0002-8703(94)90522-3; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; 1991, CIRCULATION, V86, P100	40	219	238	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					541	545		10.1038/nm0695-541	http://dx.doi.org/10.1038/nm0695-541			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585120				2022-12-27	WOS:A1995RN10100037
J	GAUNTT, C; TRACY, S				GAUNTT, C; TRACY, S			DEFICIENT DIET EVOKES NASTY HEART VIRUS	NATURE MEDICINE			English	Editorial Material							NEUROVIRULENCE	Infection of mice on a selenium-deficient diet with a nonvirulent Coxsackievirus selects a stable cardiovirulent strain (pages 433-436).	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center	GAUNTT, C (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284, USA.							ALMOND JW, 1987, ANNU REV MICROBIOL, V41, P153; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; BECK MA, 1995, NATURE MED, V1, pR30; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; CAGGANA M, 1993, J VIROL, V67, P4797, DOI 10.1128/JVI.67.8.4797-4803.1993; CHAPMAN NM, 1994, ARCH VIROL, V135, P115, DOI 10.1007/BF01309769; CHRISTENSEN MJ, 1994, BBA-MOL BASIS DIS, V1225, P338, DOI 10.1016/0925-4439(94)90015-9; EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0; GAUNTT CJ, 1995, J IMMUNOL, V154, P2983; Ge KY, 1987, SELENIUM BIOL MED B, P761; KAPLAN MH, 1983, REV INFECT DIS, V5, P1019; KONZ KH, 1989, J MOL CELL CARDIOL, V21, P789, DOI 10.1016/0022-2828(89)90718-9; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; PALLANSCH MA, 1988, COXSACKIEVIRUSES GEN, P399; PETER G, 1994, MEASLES 1994 RED BOO, P310; SCHRAUZER GN, 1992, BIOL TRACE ELEM RES, V33, P51, DOI 10.1007/BF02783992; ZURBRIGGEN A, 1991, J VIROL, V65, P1929, DOI 10.1128/JVI.65.4.1929-1937.1991	18	10	12	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					405	406		10.1038/nm0595-405	http://dx.doi.org/10.1038/nm0595-405			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585080				2022-12-27	WOS:A1995RN10000023
J	MCCURRY, KR; KOOYMAN, DL; ALVARADO, CG; COTTERELL, AH; MARTIN, MJ; LOGAN, JS; PLATT, JL				MCCURRY, KR; KOOYMAN, DL; ALVARADO, CG; COTTERELL, AH; MARTIN, MJ; LOGAN, JS; PLATT, JL			HUMAN-COMPLEMENT REGULATORY PROTEINS PROTECT SWINE-TO-PRIMATE CARDIAC XENOGRAFTS FROM HUMORAL INJURY	NATURE MEDICINE			English	Article							HYPERACUTE REJECTION; ACTIVATION; ANTIBODIES; MECHANISM; CELLS; CD59; C8; C9	The susceptibility of xenografts to hyperacute rejection is postulated to reflect in part failure of complement regulatory proteins (CRPs) to control activation of heterologous complement on graft endothelium. To test this concept, transgenic swine expressing the human CRP decay accelerating factor and CD59 were developed using a novel expression system involving transfer of the proteins from erythrocytes to endothelial cells. Hearts from transgenic swine transplanted into baboons had markedly less vascular injury and functioned for prolonged periods compared to hearts from nontransgenic swine. These results indicate that expression of human CRPs in xenogeneic organs may contribute to successful xenografting and suggest that intercellular protein transfer might be a useful approach for expression of heterologous proteins in endothelial cells.	DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA; NEXTRAN, PRINCETON, NJ 08540 USA	Duke University; Duke University; Duke University			Platt, Jeffrey/AHB-0480-2022	Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL 52297, HL 50985, HL 46810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985, R37HL052297, R01HL052297, R01HL046810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDRE GPJ, 1985, TRANSPLANT P, V17, P138; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; COOPER DKC, 1991, XENOTRANSPLANTATION, pR11; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FALK RJ, 1983, J CLIN INVEST, V72, P560, DOI 10.1172/JCI111004; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; KAPLON RJ, 1995, TRANSPLANTATION, V59, P1, DOI 10.1097/00007890-199501150-00001; KOOYMAN D, 1994, TRANSPLANT P, V26, P1241; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; LOGAN JS, 1994, METHOD ENZYMOL, V231, P435; MCCURRY KR, IN PRESS TRANSPLANTA; MICHLER RE, 1985, J MED PRIMATOL, V14, P357; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; PLATT JL, 1982, J EXP MED, V155, P17, DOI 10.1084/jem.155.1.17; PLATT JL, 1991, TRANSPLANTATION, V52, P214, DOI 10.1097/00007890-199108000-00006; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PLATT JL, 1990, TRANSPLANTATION, V49, P1000, DOI 10.1097/00007890-199005000-00033; PLATT JL, 1995, HYPERACUTE XENOGRAFT; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SHIN ML, 1986, J IMMUNOL, V136, P1777; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; WHITE D, 1993, LANCET, V342, P879, DOI 10.1016/0140-6736(93)91939-J	25	459	475	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					423	427		10.1038/nm0595-423	http://dx.doi.org/10.1038/nm0595-423			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585088				2022-12-27	WOS:A1995RN10000031
J	GERHAUSER, C; MAR, W; LEE, SK; SUH, N; LUO, YD; KOSMEDER, J; LUYENGI, L; FONG, HHS; KINGHORN, AD; MORIARTY, RM; MEHTA, RG; CONSTANTINOU, A; MOON, RC; PEZZUTO, JM				GERHAUSER, C; MAR, W; LEE, SK; SUH, N; LUO, YD; KOSMEDER, J; LUYENGI, L; FONG, HHS; KINGHORN, AD; MORIARTY, RM; MEHTA, RG; CONSTANTINOU, A; MOON, RC; PEZZUTO, JM			ROTENOIDS MEDIATE POTENT CANCER CHEMOPREVENTIVE ACTIVITY THROUGH TRANSCRIPTIONAL REGULATION OF ORNITHINE DECARBOXYLASE	NATURE MEDICINE			English	Article							SKIN TUMOR PROMOTION; PROTEIN KINASE-C; MESSENGER-RNA; RAT-BRAIN; INHIBITION; ACTIVATION; EXPRESSION; CELLS; GENE; ACID	For the discovery of new cancer chemopreventive agents, we have studied the potential of plant extracts to inhibit phorbol ester-induced ornithine decarboxylase (ODC) activity in cell culture. Four active rotenoids were obtained from the African plant Mundulea sericea (Leguminosae). These isolates were highly potent when evaluated for inhibition of chemically induced preneoplastic lesions in mammary organ culture and inhibition of papillomas in the two-stage mouse skin model, and they appear to function by a unique mechanism at the level of ODC messenger RNA expression. Based on our findings, rotenoids can be regarded as promising new chemopreventive OF anticancer agents.	UNIV ILLINOIS, COLL PHARM, DEPT MED CHEM & PHARMACOGNOSY, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL LIBERAL ARTS & SCI, DEPT CHEM, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL MED, DEPT SURG ONCOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Kinghorn, A. Douglas/0000-0002-6647-8707; Constantinou, Andreas/0000-0003-0365-1821	NCI NIH HHS [R01 CA48112] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZEVENO PB, 1979, J ORG CHEM, V44, P2578, DOI 10.1021/jo01328a056; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; Boutwel R. K., 1978, CARCINOGENESIS, V2, P49; BURGOS J, 1965, BIOCHIM BIOPHYS ACTA, V110, P475, DOI 10.1016/S0926-6593(65)80060-1; CHEN IS, 1994, J NAT PROD, V57, P1206, DOI 10.1021/np50111a003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DASILVA C, 1990, CANCER RES, V50, P2081; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; Fukami H, 1971, NATURALLY OCCURRING, P71; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85; KONOSHIMA T, 1993, J NAT PROD, V56, P843, DOI 10.1021/np50096a006; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LICHTI U, 1982, J CELL PHYSIOL, V113, P433, DOI 10.1002/jcp.1041130312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU YP, 1993, CARCINOGENESIS, V14, P293, DOI 10.1093/carcin/14.2.293; LUYENGI L, 1994, PHYTOCHEMISTRY, V36, P1523, DOI 10.1016/S0031-9422(00)89755-1; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MCCORMICK DL, 1986, CANCER LETT, V31, P133, DOI 10.1016/0304-3835(86)90003-0; MEHTA RG, 1991, ANTICANCER RES, V11, P587; O'Brien RD., 1967, INSECTICIDES ACTION, P159; OBRIEN TG, 1976, CANCER RES, V36, P2644; PEFIA A, 1993, J BIOL CHEM, V268, P27277; PEZZUTO JM, 1993, ACS SYM SER, V534, P205; PEZZUTO JM, IN PRESS RECENT ADV, V29; SPORN MB, 1979, FED PROC, V38, P2528; SZARKA CE, 1994, CURR PROB CANCER, V18, P1; TALALAY P, 1992, CANCER CHEMOPREVENTION, P469; VERMA AK, 1988, CANCER RES, V48, P2168; VERMA AK, 1986, CANCER RES, V46, P6149; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATTENBERG LW, 1985, CANCER RES, V45, P1; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843	35	129	132	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1995	1	3					260	266		10.1038/nm0395-260	http://dx.doi.org/10.1038/nm0395-260			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585044				2022-12-27	WOS:A1995QX55900034
J	FOLKMAN, J				FOLKMAN, J			ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; BREAST-CARCINOMA; METASTASIS; CELLS; INHIBITION; EXPRESSION; BINDING; VASCULOGENESIS; AFFINITY	Recent discoveries of endogenous negative regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all associated with neovascularized tumours, suggest a new paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth. The extent to which the negative regulators are decreased during this switch may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	FOLKMAN, J (corresponding author), HARVARD UNIV,CHILDRENS HOSP,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Stoeltzing, Oliver/E-5324-2010					ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; BACHARACHBUHLES M, 1994, J INVEST DERMATOL, V103, P263; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; Brem Harold, 1994, Surgical Forum, V45, P674; CROWLEY NJ, 1992, ARCH SURG-CHICAGO, V127, P1303; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; EZEKOWITZ RAB, 1994, NEW ENGL J MED, V33, P300; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1994, COMMUNICATION; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FIDLER IJ, 1994, CELL, V79, P1185; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1994, IN PRESS NEW ENGL J; FOLKMAN J, 1994, MOL BASIS CANCER; FOLKMAN J, UNPUB; FOLKMAN J, 1992, STEROID HORMONES UTE, P144; Greenwald GS, 1989, BIOL REPROD, V40, P175; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HOLMGREN L, 1994, IN PRESS; HULL MA, 1994, GASTROENTEROLOGY, V106, pA97; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; Kohn E., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P244; KRIPKE ML, 1988, JNCI-J NATL CANCER I, V80, P722, DOI 10.1093/jnci/80.10.722; LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7; LIOTTA LA, 1974, CANCER RES, V34, P997; LIOTTA LA, 1994, COMMUNICATION; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER JW, 1994, AM J PATHOL, V145, P574; MORROW M, 1993, CANCER SURV, V18, P211; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; NICKOLOFF BJ, 1994, AM J PATHOL, V44, P820; NICOSIA RF, 1986, CLIN EXP METASTAS, V4, P91, DOI 10.1007/BF00119076; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; ORIELLY MS, UNPUB; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PREHN RT, 1991, CANCER RES, V51, P2; RAK JW, 1994, J CELL PHYSIOL, V159, P245, DOI 10.1002/jcp.1041590208; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; REDMER DA, 1991, J ANIM SCI, V69, P237; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; RISAU W, 1986, J CELL BIOL, V103, P1101, DOI 10.1083/jcb.103.3.1101; Schaper W, 1993, COLLATERAL CIRCULATI; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sugarbaker E V, 1979, Curr Probl Cancer, V3, P1, DOI 10.1016/S0147-0272(79)80008-2; SZABO S, 1974, AM J PATHOL, V93, P273; SZABO S, 1989, DIGEST DIS SCI, V34, P1323; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WATANABE H, 1992, MOL BIOL CELL, V3, pA324; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; WOLFE MM, 1994, GASTROENTEROLOGY, V106, pA212; YUHAS JM, 1974, CANCER RES, V34, P2005; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	73	6690	7329	7	848	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					27	31		10.1038/nm0195-27	http://dx.doi.org/10.1038/nm0195-27			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584949				2022-12-27	WOS:A1995QX55700022
J	Johns, DR				Johns, DR			The other human genome: Mitochondrial DNA and disease	NATURE MEDICINE			English	Editorial Material							HEREDITARY OPTIC NEUROPATHY; MELAS MUTATION; DELETIONS; DEFECTS								NEI NIH HHS [R01 EY10864] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010864] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CULLOM ME, 1993, ARCH OPHTHALMOL-CHIC, V111, P1482, DOI 10.1001/archopht.1993.01090110048021; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; Ivanov PL, 1996, NAT GENET, V12, P417, DOI 10.1038/ng0496-417; JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P1491, DOI 10.1001/archopht.1993.01090110057023; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; JOHNS DR, 1994, CLIN NEUROSCI, V2, P146; MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P2291; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231	20	65	67	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1065	1068		10.1038/nm1096-1065	http://dx.doi.org/10.1038/nm1096-1065			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837595				2022-12-27	WOS:A1996VK99500017
J	Schwab, ME				Schwab, ME			Bridging the gap in spinal cord regeneration	NATURE MEDICINE			English	Editorial Material							AXONS; INJURY; RAT; METHYLPREDNISOLONE; LESION; GRAFTS; CELLS				Schwab, ME (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,POB 732,CH-8029 ZURICH,SWITZERLAND.		Schwab, Martin E/B-6818-2016					BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; KAO CC, 1983, SPINAL CORD RECONSTR; KEIRSTEAD HS, 1992, P NATL ACAD SCI USA, V89, P11664, DOI 10.1073/pnas.89.24.11664; MORRISSEY TK, 1995, J NEUROBIOL, V28, P190, DOI 10.1002/neu.480280206; RICHARDSON PM, 1984, J NEUROCYTOL, V13, P165, DOI 10.1007/BF01148324; SAUVE Y, 1995, J NEUROSCI, V15, P665; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Tello J.F., 1911, TRAB LAB INVEST BIOL, V9, P123; THANOS S, 1992, EUR J NEUROSCI, V4, P691, DOI 10.1111/j.1460-9568.1992.tb00178.x; VARGA ZM, 1995, EUR J NEUROSCI, V7, P2119, DOI 10.1111/j.1460-9568.1995.tb00634.x; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056	16	16	16	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					976	977		10.1038/nm0996-976	http://dx.doi.org/10.1038/nm0996-976			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782452				2022-12-27	WOS:A1996VF49700029
J	Boyer, K; Solem, JC; Longworth, JW; Borisov, AB; Rhodes, CK				Boyer, K; Solem, JC; Longworth, JW; Borisov, AB; Rhodes, CK			Biomedical three-dimensional holographic microimaging at visible, ultraviolet and X-ray wavelengths	NATURE MEDICINE			English	Article									UNIV ILLINOIS,DEPT PHYS,CHICAGO,IL 60607; MCR TECHNOL CORP,CHICAGO,IL 60610; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; IIT,DEPT PHYS,CHICAGO,IL 60616; UNIV TSUKUBA,TSUKUBA,IBARAKI 305,JAPAN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Los Alamos National Laboratory; Illinois Institute of Technology; University of Tsukuba								BORISOV AB, 1995, J PHYS B-AT MOL OPT, V28, P2143, DOI 10.1088/0953-4075/28/11/013; HADDAD WS, 1992, APPL OPTICS, V31, P4973, DOI 10.1364/AO.31.004973; HADDAD WS, 1989, P WORKSH XRAY MICR L, P81; KONDRATENKO A, 1978, OPTICAL INFORMATION, V2, P1; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Rhodes C K, 1994, OPT PHOTONICS NEWS, V5, P8; SOLEM JC, 1982, SCIENCE, V218, P229, DOI 10.1126/science.218.4569.229; SOLEM JC, 1984, OPT ENG, V23, P193, DOI 10.1117/12.7973410; SOLEM JC, 1981, P INT C LAS NEW ORL, P293; STROKE GW, 1965, APPL PHYS LETT, V7, P229, DOI 10.1063/1.1754392; WINTHROP JT, 1966, PHYS LETT, V21, P413, DOI 10.1016/0031-9163(66)90510-5	11	30	33	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					939	941		10.1038/nm0896-939	http://dx.doi.org/10.1038/nm0896-939			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705867				2022-12-27	WOS:A1996UZ80400044
J	Kedes, DH; Operskalski, E; Busch, M; Kohn, R; Flood, J; Ganem, D				Kedes, DH; Operskalski, E; Busch, M; Kohn, R; Flood, J; Ganem, D			The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission	NATURE MEDICINE			English	Article							DNA-SEQUENCES; HOMOSEXUAL MEN; AIDS; FORMS	Striking differences in Kaposi's sarcoma (KS) risk for AIDS patients who acquire HIV via homosexual activity and those whose HIV infections derive from blood product exposure suggest the presence of a sexually transmitted agent other than HIV in the development of KS. Using an immunofluorescence assay, we examined serum samples from 913 patients for the presence of antibody specific for infection by human herpesvirus 8 (HHV8), an agent whose genome is regularly found in KS tissue. The distribution of HHV8 seropositivity conforms to that expected for a sexually transmitted pathogen and tracks closely with the risk for KS development. Our data support the inference that this virus is the etiologic cofactor predicted by the epidemiology of KS.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; TRANSFUS SAFETY STUDY,LOS ANGELES,CA 90032; UNIV SO CALIF,LOS ANGELES,CA 90032; UNIV CALIF SAN FRANCISCO,IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,DIV SEXUALLY TRANSMITTED DIS,SAN FRANCISCO,CA 94103	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco Department of Public Health					NHLBI NIH HHS [N01-HB-97074, N01-HB-4-7003, N01-HB-4-7002] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097074, N01HB047003, N01HB047002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams V, 1995, LANCET, V346, P1715, DOI 10.1016/S0140-6736(95)92887-1; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; HENLE G, 1974, J INFECT DIS, V130, P231, DOI 10.1093/infdis/130.3.231; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KIEFF E, 1995, VIROLOGY, P2343; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MOORE P, 1995, AIDS, V10, P175; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICKINSON AB, 1995, VIROLOGY, P2397; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STRAUSS S, 1995, PRINCIPLES PRACTICE, P1330; WITBY D, 1995, LANCET, V346, P799; ZIEGLER JL, 1984, SEMIN ONCOL, V11, P47	30	614	634	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					918	924		10.1038/nm0896-918	http://dx.doi.org/10.1038/nm0896-918			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705863				2022-12-27	WOS:A1996UZ80400040
J	Yankner, BA				Yankner, BA			New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau	NATURE MEDICINE			English	Editorial Material							BETA-PROTEIN-PRECURSOR; MICROTUBULE-BINDING; PHOSPHORYLATION; GENE; MUTATION		CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115	Harvard University; Boston Children's Hospital	Yankner, BA (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.							Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Martins RH, 1995, NEUROREPORT, V7, P217, DOI 10.1097/00001756-199512290-00052; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	22	102	113	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					850	852		10.1038/nm0896-850	http://dx.doi.org/10.1038/nm0896-850			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705846				2022-12-27	WOS:A1996UZ80400023
J	Schwartz, MW; Peskind, E; Raskind, M; Boyko, EJ; Porte, D				Schwartz, MW; Peskind, E; Raskind, M; Boyko, EJ; Porte, D			Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; INSULIN; BRAIN; TRANSPORT	The adipocyte hormone, leptin (OB protein), is proposed to be an ''adiposity signal'' that acts in the brain to lower food intake and adiposity(1-5). As plasma leptin levels are elevated in most overweight individuals, obesity may be associated with leptin resistance(6,7). To investigate the mechanisms underlying brain leptin uptake and to determine whether reduced uptake may contribute to leptin resistance, we measured immunoreactive leptin levels in plasma and cerebrospinal fluid (CSF) of 53 human subjects. Leptin concentrations in CSF were strongly correlated to the plasma level in a nonlinear manner (r = 0.92; P = 0.0001). Like levels in plasma, CSF leptin levels were correlated to body mass index (r = 0.43; P = 0.001), demonstrating that plasma leptin enters human cerebrospinal fluid in proportion to body adiposity. However, the efficiency of this uptake (measured as the CSF:plasma leptin ratio) was lower among those in the highest as compared with the lowest plasma leptin quintile (5.4-fold difference). We hypothesize that a saturable mechanism mediates CSF leptin transport, and that reduced efficiency of brain leptin delivery among obese individuals with high plasma leptin levels results in apparent leptin resistance.	UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,EDUC & CLIN CTR,SEATTLE,WA 98105; UNIV WASHINGTON,SCH MED,DEPT GERIATR RES,EDUC & CLIN CTR,SEATTLE,WA 98105; VET AFFAIRS PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98108	University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Schwartz, MW (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98105, USA.		Boyko, Edward J/G-2484-2017; Schwartz, Michael W/H-9950-2012	Boyko, Edward J/0000-0002-3695-192X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032273, R29NS032273] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05136] Funding Source: Medline; NIDDK NIH HHS [DK 12829] Funding Source: Medline; NINDS NIH HHS [NS 32273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DAVSON H, 1996, PHYSL CSF BLOOD BRAI, P573; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P232; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WOODS SC, 1985, AM J CLIN NUTR, V42, P1063, DOI 10.1093/ajcn/42.5.1063	18	823	842	1	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					589	593		10.1038/nm0596-589	http://dx.doi.org/10.1038/nm0596-589			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616722				2022-12-27	WOS:A1996UJ23000046
J	Ernfors, P; Duan, ML; ElShamy, WM; Canlon, B				Ernfors, P; Duan, ML; ElShamy, WM; Canlon, B			Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3	NATURE MEDICINE			English	Article							INNER-EAR; COCHLEOVESTIBULAR GANGLION; SENSORY NEURONS; MESSENGER-RNAS; GUINEA-PIG; OTOTOXICITY; RAT; DEGENERATION; EXPRESSION; GENTAMICIN	Hearing is conveyed from the auditory receptors, the hair cells in the organ of Corti, to the brain via the spiral ganglion neurons. Damage or loss of either spiral ganglion neurons or hair cells causes hearing impairment. Such hearing disorders are often permanent and can be caused by therapeutic agents, such as aminoglycoside antibiotics and cisplatin, or by aging, loud sounds, infections and mechanical injury(1). Brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), members of the neurotrophin family of neurotrophic factors that also include nerve growth factor (NGF) and neurotrophin-4/5 (NT-4), are important in development of the neuronal components of the inner ear. We report here that the loss of target innervation and the degeneration of approximately 90% of the adult spiral ganglion neurons caused by aminoglycoside toxicity can be prevented by infusion of the neurotrophic factor, neurotrophin-3 (NT-3) in the membranous labyrinth in guinea pigs. The potency of NT-3 in protecting spiral ganglion neurons from degenerating suggests that neurotrophins may be useful for the treatment of hearing disorders.	KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Ernfors, P (corresponding author), KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,DOKTORSRINGEN 12A,S-17177 STOCKHOLM,SWEDEN.		ElShamy, Wael M./L-1090-2018; ElShamy, Wael/AAF-2867-2019	Ernfors, Patrik/0000-0002-1140-3986				ARVIDSSON J, 1995, SOC NEUR ABSTR; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; AXDORPH U, 1993, J INTERN MED, V233, P401, DOI 10.1111/j.1365-2796.1993.tb00691.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BICHLER E, 1983, ARCH OTO-RHINO-LARYN, V237, P201, DOI 10.1007/BF00453725; CANLON B, 1992, J ACOUST SOC AM, V94, P1140; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1986, J NEUROSCI, V6, P1897; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1995, NEURON, V14, P1153, DOI 10.1016/0896-6273(95)90263-5; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; ESTREM SA, 1981, OTOLARYNG HEAD NECK, V89, P638, DOI 10.1177/019459988108900424; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FLEISCHMAN RW, 1975, TOXICOL APPL PHARM, V33, P320, DOI 10.1016/0041-008X(75)90098-8; GAO WQ, 1995, ANN NEUROL, V38, P30, DOI 10.1002/ana.410380108; HENLEY CM, 1993, OTOLARYNG CLIN N AM, V26, P857; HINOJOSA R, 1987, J INFECT DIS, V156, P449, DOI 10.1093/infdis/156.3.449; HORYLEE F, 1993, P NATL ACAD SCI USA, V90, P2613, DOI 10.1073/pnas.90.7.2613; HUY PTB, 1981, J INFECT DIS, V143, P476; HUY PTB, 1986, J CLIN INVEST, V77, P1492, DOI 10.1172/JCI112463; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KOITCHEV K, 1982, ACTA OTO-LARYNGOL, V94, P431, DOI 10.3109/00016488209128931; KONISHI T, 1983, AM J OTOLARYNG, V4, P18, DOI 10.1016/S0196-0709(83)80003-9; KUMANA CR, 1994, DRUGS, V47, P902, DOI 10.2165/00003495-199447060-00004; LEFEBVRE PP, 1994, NEUROREPORT, V5, P865, DOI 10.1097/00001756-199404000-00003; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LUO L, 1993, HEARING RES, V69, P182; MATZ GJ, 1993, OTOLARYNGOL CLIN N A, V26, P706; NAKAI Y, 1982, ACTA OTO-LARYNGOL, V93, P227, DOI 10.3109/00016488209130876; OAKLEY RA, 1995, DEVELOPMENT, V121, P1341; PAPARELLA MM, 1980, OTOLARYNGOLOGY, P1817; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; PIRVOLA U, 1995, P NATL ACAD SCI USA, V92, P9269, DOI 10.1073/pnas.92.20.9269; REPRESA J, 1993, DEV BIOL, V159, P257, DOI 10.1006/dbio.1993.1238; THOMPSON SW, 1984, CANCER, V54, P1269, DOI 10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9; VAZQUEZ E, 1994, ANAT EMBRYOL, V189, P157; YLIKOSKI J, 1993, HEARING RES, V65, P69, DOI 10.1016/0378-5955(93)90202-C; ZHENG JL, 1995, J NEUROSCI, V15, P5079	40	204	214	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					463	467		10.1038/nm0496-463	http://dx.doi.org/10.1038/nm0496-463			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597959				2022-12-27	WOS:A1996UD31400051
J	Ellis, TM; Atkinson, MA				Ellis, TM; Atkinson, MA			The clinical significance of an autoimmune response against glutamic acid decarboxylase	NATURE MEDICINE			English	Article							STIFF-MAN SYNDROME; DEPENDENT DIABETES-MELLITUS; GAMMA-AMINOBUTYRIC-ACID; 2 FORMS; AUTOANTIBODIES; IDENTIFICATION; HETEROGENEITY; ANTIBODIES; CELLS	Glutamic acid decarboxylase is attracting much interest because of its putative involvement in two clinical disorders: stiff-man syndrome and insulin-dependent diabetes. Here we discuss the clinical significance of an autoimmune response against GAD and consider how such information may help identify the disease mechanisms of these disorders.			Ellis, TM (corresponding author), UNIV FLORIDA,COLL MED,DEPT LAB MED & PATHOL,GAINESVILLE,FL 32610, USA.							AANSTOOT H, 1993, MOTOR UNIT HYPERACTI, P53; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; ATKINSON MA, 1993, J CLIN INVEST, V91, P350, DOI 10.1172/JCI116192; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BUTLER MH, 1993, J EXP MED, V178, P2097, DOI 10.1084/jem.178.6.2097; ERDO SL, 1990, J NEUROCHEM, V54, P363, DOI 10.1111/j.1471-4159.1990.tb01882.x; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; JONES DB, 1995, NAT MED, V1, P284, DOI 10.1038/nm0495-284; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1994, J EXP MED, V180, P595, DOI 10.1084/jem.180.2.595; Layzer R B, 1988, N Engl J Med, V318, P1060, DOI 10.1056/NEJM198804213181610; LOHMANN T, 1994, LANCET, V343, P1606; MOERSCH FP, 1957, MAYO CLIN P, V31, P421; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TISH R, 1993, NATURE, V366, P72; TUOMILEHTO J, 1994, LANCET, V343, P1383, DOI 10.1016/S0140-6736(94)92521-6; UJIHARA N, 1994, DIABETES, V43, P968, DOI 10.2337/diabetes.43.8.968	30	96	98	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					148	153		10.1038/nm0296-148	http://dx.doi.org/10.1038/nm0296-148			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574952				2022-12-27	WOS:A1996TU06000027
J	Golino, P; Ragni, M; Cirillo, P; Avvedimento, VE; Feliciello, A; Esposito, N; Scognamiglio, A; Trimarco, B; Iaccarino, G; Condorelli, M; Chiariello, M; Ambrosio, G				Golino, P; Ragni, M; Cirillo, P; Avvedimento, VE; Feliciello, A; Esposito, N; Scognamiglio, A; Trimarco, B; Iaccarino, G; Condorelli, M; Chiariello, M; Ambrosio, G			Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion	NATURE MEDICINE			English	Article							HUMAN-ENDOTHELIAL-CELLS; FACTOR MESSENGER-RNA; PLATELET-AGGREGATION; BLOOD-FLOW; PROSTAGLANDIN ENDOPEROXIDES; ARTERY OCCLUSION; PROCOAGULANT; RABBIT; GENERATION; INJURY	Tissue factor is a transmembrane protein that activates the extrinsic coagulation pathway by binding factor VII. Endothelial cells, being in contact with circulating blood, do not normally express tissue factor. Here we provide evidence that oxygen free radicals induce tissue factor messenger RNA transcription and expression of tissue factor procoagulant activity in endothelial cells in culture. Isolated, perfused rabbit hearts exposed to exogenous oxygen free radicals also showed a marked increase in tissue factor activity within the coronary circulation. Furthermore, in ex vivo and in vivo hearts subjected to ischemia and reperfusion, a condition associated with a production of oxygen free radicals in large amounts, a marked increase in tissue factor activity occurred. This phenomenon could be abolished by oxygen radical scavengers. This increase in tissue factor activity during postischemic reperfusion was accompanied by a significant decrease in coronary flow, suggesting that increase in tissue factor activity with the consequent activation of the coagulation cascade might impair coronary flow during reperfusion and possibly contribute to the occurrence of reperfusion injury.	UNIV NAPLES,SCH MED 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80138 NAPLES,ITALY; UNIV REGGIO CALABRIA,SCH MED CATANZARO,DEPT EXPTL MED,CALABRIA,ITALY; UNIV PERUGIA,SCH MED,DIV CARDIOL,I-06100 PERUGIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; University of Perugia	Golino, P (corresponding author), UNIV NAPLES,SCH MED 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,DEPT INTERNAL MED,DIV CARDIOL,I-80138 NAPLES,ITALY.		IACCARINO, Guido/A-7702-2010; Iaccarino, Guido/D-4540-2009; Ambrosio, Giuseppe/C-6596-2013; Trimarco, Bruno BT/K-7851-2016; CIRILLO, Plinio/K-9263-2016	IACCARINO, Guido/0000-0002-8997-835X; Iaccarino, Guido/0000-0002-8997-835X; Ambrosio, Giuseppe/0000-0002-9677-980X; Trimarco, Bruno BT/0000-0002-0701-6449; CIRILLO, Plinio/0000-0001-7818-4952; GOLINO, Paolo/0000-0002-3590-6983				AMBROSIO G, 1994, AM J PHYSIOL, V267, pH308, DOI 10.1152/ajpheart.1994.267.1.H308; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; AMBROSIO G, 1989, CIRCULATION, V80, P1846, DOI 10.1161/01.CIR.80.6.1846; AMBROSIO G, 1987, J MOL CELL CARDIOL, V19, P953, DOI 10.1016/S0022-2828(87)80568-0; AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BLOEM LJ, 1989, J CELL PHYSIOL, V139, P418, DOI 10.1002/jcp.1041390226; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; CONNELLY C, 1982, AM J PHYSIOL, V243, pH682, DOI 10.1152/ajpheart.1982.243.5.H682; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; GOLINO P, 1992, CIRC RES, V71, P1447, DOI 10.1161/01.RES.71.6.1447; GOLINO P, 1993, J AM COLL CARDIOL, V21, P493, DOI 10.1016/0735-1097(93)90694-V; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; JAFFE EA, 1991, HEMATOLOGY BASIC PRI, P1198; KAO J, 1992, J BIOL CHEM, V267, P20239; KOWALLIK P, 1991, CIRCULATION, V83, P974, DOI 10.1161/01.CIR.83.3.974; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEMERSON Y, 1988, BLOOD, V71, P1; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PAWASHE A, 1991, THROMB HAEMOSTASIS, V66, P315; PAWASHE AB, 1994, CIRC RES, V74, P56, DOI 10.1161/01.RES.74.1.56; SCHOSSER R, 1979, COMPUT PROG BIOMED, V9, P19, DOI 10.1016/0010-468X(79)90014-X; SIES H, 1985, PHILOS T ROY SOC B, V311, P617, DOI 10.1098/rstb.1985.0168; YAO SK, 1993, CIRC RES, V73, P952, DOI 10.1161/01.RES.73.5.952; YUZAWA Y, 1993, J IMMUNOL, V150, P5633; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	36	157	161	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					35	40		10.1038/nm0196-35	http://dx.doi.org/10.1038/nm0196-35			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564835				2022-12-27	WOS:A1996TP57900034
J	GROSSMAN, M; RADER, DJ; MULLER, DWM; KOLANSKY, DM; KOZARSKY, K; CLARK, BJ; STEIN, EA; LUPIEN, PJ; BREWER, HB; RAPER, SE; WILSON, JM				GROSSMAN, M; RADER, DJ; MULLER, DWM; KOLANSKY, DM; KOZARSKY, K; CLARK, BJ; STEIN, EA; LUPIEN, PJ; BREWER, HB; RAPER, SE; WILSON, JM			A PILOT-STUDY OF EX-VIVO GENE-THERAPY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	NATURE MEDICINE			English	Article							LIVER-TRANSPLANTATION; LIPOPROTEIN RECEPTORS; HUMAN HEPATOCYTES; CHOLESTEROL; LOVASTATIN	The outcome of the first pilot study of liver-directed gene therapy is reported here. Five patients with homozygous familial hypercholesterolaemia (FH) ranging in age from 7 to 41 years were enrolled; each patient tolerated the procedure well without significant complications. Transgene expression was detected in a limited number of hepatocytes of liver tissue harvested four months after gene transfer from all five patients. Significant and prolonged reductions in low density lipoprotein (LDL) cholesterol were demonstrated in three of five patients; in vivo LDL catabolism was increased 53% following gene therapy in a receptor negative patient, who realized a reduction in serum LDL equal to similar to 150 mg dl(-1). This study demonstrates the feasibility of engrafting limited numbers of retrovirus-transduced hepatocytes without morbidity and achieving persistent gene expression lasting at least four months after gene therapy. The variable metabolic responses observed following low-level genetic reconstitution in the five patients studied precludes a broader application of liver-directed gene therapy without modifications that consistently effect substantially greater gene transfer.	UNIV PENN,MED CTR,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT SURG,PHILADELPHIA,PA 19104; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV PENN,MED CTR,DEPT PEDIAT,DIV CARDIOL,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104; CHRIST HOSP,CARDIOVASC RES CTR,DIV LIPID METAB & PREVENT ATHEROSCLEROSIS,CINCINNATI,OH 45219; CHRIST HOSP,CARDIOVASC RES CTR,MED RES LABS,CINCINNATI,OH 45219; LAVAL UNIV HOSP,MED RES CTR,LIPID RES CTR,QUEBEC CITY,PQ G1V 4G2,CANADA; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Christ Hospital - Ohio; Christ Hospital - Ohio; Laval University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ADAMS RM, 1992, P NATL ACAD SCI USA, V89, P8981, DOI 10.1073/pnas.89.19.8981; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BROWN MS, 1994, NAT GENET, V7, P349, DOI 10.1038/ng0794-349; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; DECKELBAUM RJ, 1977, NEW ENGL J MED, V296, P465, DOI 10.1056/NEJM197703032960901; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GORDON BR, 1992, AM J CARDIOL, V70, P1010, DOI 10.1016/0002-9149(92)90352-Y; GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501; GROSSMAN M, 1991, SOMAT CELL MOLEC GEN, V17, P601, DOI 10.1007/BF01233625; GROSSMAN M, 1993, J LAB CLIN MED, V121, P472; GROSSMAN M, 1994, NAT GENET, V6, P335, DOI 10.1038/ng0494-335; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MALLOY MJ, 1987, ANN INTERN MED, V107, P616, DOI 10.7326/0003-4819-107-5-616; RADER DJ, 1995, J CLIN INVEST, V95, P1403, DOI 10.1172/JCI117794; RAPER SE, IN PRESS ANN SURG; STARZL TE, 1983, ANN SURG, V198, P273, DOI 10.1097/00000658-198309000-00004; THOMPSON GR, 1989, ARTERIOSCLER, V9, P152; UAUY R, 1988, J PEDIATR-US, V113, P387, DOI 10.1016/S0022-3476(88)80289-0; WILSON JM, 1992, HUM GENE THER, V3, P179, DOI 10.1089/hum.1992.3.2-179	25	415	429	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1148	1154		10.1038/nm1195-1148	http://dx.doi.org/10.1038/nm1195-1148			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584986				2022-12-27	WOS:A1995TC53700038
J	COUTELLE, C; DOUAR, AM; COLLEDGE, WH; FROSTER, U				COUTELLE, C; DOUAR, AM; COLLEDGE, WH; FROSTER, U			THE CHALLENGE OF FETAL GENE-THERAPY	NATURE MEDICINE			English	Editorial Material							CYSTIC-FIBROSIS; EXPRESSION; TISSUES		UNIV LUBECK,D-23538 LUBECK,GERMANY; UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	University of Lubeck; University of Cambridge	COUTELLE, C (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429				CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; Clothier C., 1992, REPORT COMMITTEE ETH; Coutelle C, 1994, CYSTIC FIBROSIS CURR, V2, P33; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Gillman Joseph, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P81; MCCRAY PB, 1995, J CLIN INVEST, V95, P2620, DOI 10.1172/JCI117964; PITT BR, 1995, GENE THER, V2, P344; REECE EA, 1995, ULTRASOUND OBST GYN, V5, P281, DOI 10.1046/j.1469-0705.1995.05040281.x; ROUE A, 1986, HUM GENET, V74, P288; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TOURAINE JL, 1992, BONE MARROW TRANSPL, V9, P121; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	14	66	66	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					864	866		10.1038/nm0995-864	http://dx.doi.org/10.1038/nm0995-864			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585202				2022-12-27	WOS:A1995RT30300030
J	DALGLEISH, A				DALGLEISH, A			HIV AND CD26	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS; CD4+; RECEPTOR; CELLS; LYMPHOCYTES; INFECTION; ANTIGEN; GENE				DALGLEISH, A (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.		Dalgleish, Angus/AAZ-4450-2020	Dalgleish, Angus/0000-0003-3511-3059				ALIZON M, 1994, SCIENCE, V264, P1161, DOI 10.1126/science.7909962; BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004; BRODER CC, 1994, SCIENCE, V264, P1156, DOI 10.1126/science.7909959; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEVAUX C, 1990, RES IMMUNOL, V141, P357, DOI 10.1016/0923-2494(90)90026-U; DUKES CS, 1995, J VIROL, V69, P4000, DOI 10.1128/JVI.69.7.4000-4005.1995; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P3301, DOI 10.1073/pnas.86.9.3301; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; KIDO H, 1990, J BIOL CHEM, V265, P21979; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PATIENCE C, 1994, SCIENCE, V264, P1159, DOI 10.1126/science.7909960; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749	20	6	13	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					881	882		10.1038/nm0995-881	http://dx.doi.org/10.1038/nm0995-881			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585208				2022-12-27	WOS:A1995RT30300036
J	MILNER, J				MILNER, J			DNA-DAMAGE, P53 AND ANTICANCER THERAPIES	NATURE MEDICINE			English	Editorial Material											MILNER, J (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Crawford L V, 1984, Mol Biol Med, V2, P261; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; MEDCALF EA, ONCOGENE, V8, P2847; MOLINARI M, 1995, ONCOGENE, V10, P1849; ROLLEY N, IN PRESS ONCOGENE; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	8	71	92	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					879	880		10.1038/nm0995-879	http://dx.doi.org/10.1038/nm0995-879			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585207				2022-12-27	WOS:A1995RT30300035
J	HOLMBERG, L; BAUM, M				HOLMBERG, L; BAUM, M			CAN RESULTS FROM CLINICAL-TRIALS BE GENERALIZED	NATURE MEDICINE			English	Editorial Material								Randomized clinical trials are powerful tools to refute old prejudices and establish new therapeutic regimes. We propose that they should be afforded a more widespread application in modern clinical medicine.	UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN; ROYAL MARSDEN HOSP,ACAD DEPT SURG,LONDON SW3 6JJ,ENGLAND	Uppsala University; Uppsala University Hospital; Royal Marsden NHS Foundation Trust	HOLMBERG, L (corresponding author), UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN.							BRESLOW NE, 1980, STAT METHODS CANC RE, V1, P59; COOPER RG, 1969, P AM ASSOC CANC RES, V10, P15; COOPER RG, 1979, CANCER, V44, P793, DOI 10.1002/1097-0142(197909)44:3<793::AID-CNCR2820440302>3.0.CO;2-Y; HAAGENSE.CD, 1969, ANN SURG, V170, P875, DOI 10.1097/00000658-196912000-00001; HAAGENSEN CD, 1959, ANN SURG, V149, P159; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Popper K.R., 1959, LOGIC SCI DISCOVERY; SHAPIRO SH, 1983, CLIN TRIALS ISSUES A; WIESS NS, 1986, CLIN EPIDEMIOLOGY ST, P49	9	12	12	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					734	736		10.1038/nm0895-734	http://dx.doi.org/10.1038/nm0895-734			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585167				2022-12-27	WOS:A1995RM63500021
J	WALL, PD				WALL, PD			INDEPENDENT MECHANISMS CONVERGE ON PAIN	NATURE MEDICINE			English	Editorial Material							DORSAL	The molecular and neural bases for pain have proven elusive, but new studies approach an explanation from different directions.			WALL, PD (corresponding author), UNITED MED & DENT SCH,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.							BERKLEY KJ, 1995, NAT MED, V1, P766, DOI 10.1038/nm0895-766; COOK AJ, 1987, NATURE, V325, P151, DOI 10.1038/325151a0; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; GYBELS JM, 1989, NEUROSURGICAL TREATM; HANDWERKER HO, 1994, PAIN MEASUREMENTS, P116; Levine J.D., 1994, TXB PAIN, P45; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; MCMAHON SB, 1994, TXB PAIN, P129; TOREBJORK HE, 1992, J PHYSL, V448, P763	11	9	9	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					740	741		10.1038/nm0895-740	http://dx.doi.org/10.1038/nm0895-740			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585170				2022-12-27	WOS:A1995RM63500024
J	MERLO, A; HERMAN, JG; MAO, L; LEE, DJ; GABRIELSON, E; BURGER, PC; BAYLIN, SB; SIDRANSKY, D				MERLO, A; HERMAN, JG; MAO, L; LEE, DJ; GABRIELSON, E; BURGER, PC; BAYLIN, SB; SIDRANSKY, D			5' CPG ISLAND METHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL SILENCING OF THE TUMOR-SUPPRESSOR P16/CDKN2/MTS1 IN HUMAN CANCERS	NATURE MEDICINE			English	Article							DNA METHYLATION; HUMAN NEOPLASIA; BLADDER-CANCER; CELL-LINES; SHORT ARM; GENE; RETINOBLASTOMA; HYPERMETHYLATION; IDENTIFICATION; CHROMOSOME-9	Loss of heterozygosity on chromosome 9p21 is one of the most frequent genetic: alterations identified in human cancer. The rate of point mutations of p16, a candidate suppressor gene of this area, is low in most primary tumours with allelic loss of 9p21. Monosomic cell lines with structurally unaltered p16 show methylation of the 5' CpG island of p16. This distinct methylation pattern was associated with a complete transcriptional block that was reversible upon treatment with 5-deoxyazacytidine. Moreover, de novo methylation of the 5' CpG island of p16 was also found in approximately 20% of different primary neoplasms, but not in normal tissues, potentially representing a common pathway of tumour suppressor gene inactivation in human cancers.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; JOHNS HOPKINS MED INST,DEPT PATHOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Lee, Daniel/N-5422-2019; Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [CA-58184-01, CA-43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARAP W, 1995, CANCER RES, V55, P1351; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LATIF F, 1992, CANCER RES, V52, P1451; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; MAO L, IN PRESS CANCER RES; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MIGEON BR, 1990, GENET RES, V56, P91, DOI 10.1017/S0016672300035151; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; RYGAARD K, 1990, CANCER RES, V50, P5312; SAKAI T, 1991, AM J HUM GENET, V48, P880; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SPRUCK CH, 1994, NATURE, V370, P180; VANDERRIET P, 1994, CANCER RES, V54, P1156; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050	47	1772	1843	0	76	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					686	692		10.1038/nm0795-686	http://dx.doi.org/10.1038/nm0795-686			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585152				2022-12-27	WOS:A1995RQ06600045
J	AKHTAR, S; JAMES, H; GIBSON, I				AKHTAR, S; JAMES, H; GIBSON, I			MOLECULAR DIY WITH HAIRPINS AND HAMMERHEADS	NATURE MEDICINE			English	Editorial Material									UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND	University of East Anglia	AKHTAR, S (corresponding author), UNIV ASTON,INST PHARMACEUT SCI,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND.			Akhtar, Saghir/0000-0003-3177-946X				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; ELKINS DA, 1995, DELIVERY STRATEGIES; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0	3	5	7	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					300	302		10.1038/nm0495-300	http://dx.doi.org/10.1038/nm0495-300			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585055				2022-12-27	WOS:A1995RN09800021
J	NAKAO, N; FRODL, EM; WIDNER, H; CARLSON, E; EGGERDING, FA; EPSTEIN, CJ; BRUNDIN, P				NAKAO, N; FRODL, EM; WIDNER, H; CARLSON, E; EGGERDING, FA; EPSTEIN, CJ; BRUNDIN, P			OVEREXPRESSING CU/ZN SUPEROXIDE-DISMUTASE ENHANCES SURVIVAL OF TRANSPLANTED NEURONS IN A RAT MODEL OF PARKINSONS-DISEASE	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MICE; LIPID-PEROXIDATION; SUBSTANTIA-NIGRA; NERVOUS-SYSTEM; NITRIC-OXIDE; GLUTATHIONE; BRAINS; IRON	A high survival rate of grafted dopamine neurons is crucial for reversing neurological deficits following brain tissue transplantation in Parkinson's disease. For unknown rea-sons the survival rate of transplanted dopamine neurons is only around 10% in experimental animals. The hypothesis that oxidative stress causes the loss of transplanted neurons was tested by grafting neurons from transgenic mice that overexpress Cu/Zn superoxide dismutase. Compared with the survival of those taken from non-transgenic littermates, the survival was 4 times higher for the transgenic dopamine neurons with a concomitant more extensive functional recovery. The results provide direct support for the free radical hypothesis of dopaminergic neuron death in brain tissue grafting.	WAKAYAMA MED COLL,DEPT NEUROL SURG,WAKAYAMA,JAPAN; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	Wakayama Medical University; University of California System; University of California San Francisco	NAKAO, N (corresponding author), LUND UNIV,DEPT MED CELL RES,NEURONAL SURVIVAL SECT,BISKOPSGATAN 5,LUND,SWEDEN.				NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER; NIA NIH HHS [AG-08938] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; BAKER H, 1980, P NATL ACAD SCI-BIOL, V77, P4369, DOI 10.1073/pnas.77.7.4369; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; BRUNDIN P, 1985, BRAIN RES, V331, P251, DOI 10.1016/0006-8993(85)91550-1; CADET JL, 1994, J NEUROCHEM, V62, P380; CHADI G, 1993, EXP BRAIN RES, V97, P145; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1994, ANN NEUROL, V35, P298, DOI 10.1002/ana.410350309; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; DEXTER DT, 1994, NEUROREPORT, V5, P1773, DOI 10.1097/00001756-199409080-00022; DUAN WM, IN PRESS EXP BRAIN R; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRODL EM, 1994, BRAIN RES, V647, P286, DOI 10.1016/0006-8993(94)91328-5; GERMAN DC, 1983, J NEURAL TRANSM, V57, P243, DOI 10.1007/BF01248996; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KINOUCHI H, 1992, P NATL ACAD SCI USA, V88, P11158; LIEMANHURWITZ J, 1982, P NATL ACAD SCI-BIOL, V79, P2808, DOI 10.1073/pnas.79.9.2808; LINDVALL O, 1994, FUNCTIONAL NEURAL TR, P103; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; OLANOW CW, 1994, TRENDS NEUROSCI, V16, P439; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAUER H, 1991, RESTOR NEUROL NEUROS, V2, P123, DOI 10.3233/RNN-1991-2302; SCHMIDT RH, 1983, ACTA PHYSL SCAND S, V522, P19; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; TRIARHOU LC, 1988, EXP BRAIN RES, V70, P256; UNGERSTEDT U, 1970, BRAIN RES, V24, P486	40	123	136	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					226	231		10.1038/nm0395-226	http://dx.doi.org/10.1038/nm0395-226			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585038				2022-12-27	WOS:A1995QX55900028
J	ANAND, P; PARRETT, A; MARTIN, J; ZEMAN, S; FOLEY, P; SWASH, M; LEIGH, PN; CEDARBAUM, JM; LINDSAY, RM; WILLIAMSCHESTNUT, RE; SINICROPI, DV				ANAND, P; PARRETT, A; MARTIN, J; ZEMAN, S; FOLEY, P; SWASH, M; LEIGH, PN; CEDARBAUM, JM; LINDSAY, RM; WILLIAMSCHESTNUT, RE; SINICROPI, DV			REGIONAL CHANGES OF CILIARY NEUROTROPHIC FACTOR AND NERVE GROWTH-FACTOR LEVELS IN POST-MORTEM SPINAL-CORD AND CEREBRAL-CORTEX FROM PATIENTS WITH MOTOR DISEASE	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ADULT-RAT BRAIN; CHOLINERGIC PHENOTYPE; FACTOR PREVENTS; MESSENGER-RNA; SCIATIC-NERVE; NEURONS; DEGENERATION; INJURY; INVIVO	Ciliary neurotrophic factor (CNTF) rescues motor neurons in animal models of injury and neurodegeneration, and disruption of the mouse CNTF gene results in motor neuron degeneration in mature adults. Glial cells increase nerve growth factor (NGF) expression in neuropathological conditions, and the sensory system can be affected in the amyotrophic lateral sclerosis (ALS) type of motor neuronic disease. We therefore studied CNTF and NGF levels in post mortem spinal cord and cerebral cortex from patients with ALS and matched controls. We report a marked decrease of CNTF in the ventral horn of spinal cord in ALS, with no change in cerebral motor cortex. In contrast NGF levels were decreased in ALS cerebral motor cortex, where the corticospinal tract originates, but increased in the lateral column of spinal cord, which includes the region of corticospinal tract degeneration in ALS. Both CNTF and NGF levels were decreased in ALS dorsal spinal cord.	ROYAL LONDON HOSP, COLL MED, DEPT MORBID ANAT, LONDON E1 1BB, ENGLAND; INST PSYCHIAT, LONDON, ENGLAND; REGENERON PHARMACEUT INC, TARRYTOWN, NY USA; GENENTECH INC, DEPT MED & ANALYT CHEM, San Francisco, CA USA	Barts Health NHS Trust; Royal London Hospital; University of London; King's College London; Regeneron; Roche Holding; Genentech	ANAND, P (corresponding author), ROYAL LONDON HOSP, COLL MED, DEPT NEUROL, WHITECHAPEL, LONDON E1 1BB, ENGLAND.		Lindsay, Ronald/GQP-8001-2022; Leigh, Peter/AAD-5638-2019	Swash, Michael/0000-0002-8717-8914	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTAR CA, 1992, J NEUROCHEM, V59, P2167; ANAND P, 1983, NATURE, V305, P143, DOI 10.1038/305143a0; BAKHIT C, 1991, BRAIN RES, V554, P264, DOI 10.1016/0006-8993(91)90199-6; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; Davison C, 1941, ARCH NEURO PSYCHIATR, V46, P1039, DOI 10.1001/archneurpsyc.1941.02280240094006; DYCK PJ, 1975, NEUROLOGY, V25, P781, DOI 10.1212/WNL.25.8.781; FERNANDEZ E, 1993, NEUROSURGERY, V33, P889; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GREGORY R, 1993, J NEUROL, V240, P309, DOI 10.1007/BF00838169; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; Hughes J T, 1982, Adv Neurol, V36, P61; IKEDA K, IN PRESS ANN NEUROL; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; LOREZ H, 1989, NEUROSCI LETT, V98, P339, DOI 10.1016/0304-3940(89)90425-4; MAGAL E, 1993, NEUROREPORT, V4, P779, DOI 10.1097/00001756-199306000-00046; MALESSA S, 1991, J NEUROL NEUROSUR PS, V54, P984, DOI 10.1136/jnnp.54.11.984; Manthorpe M, 1993, NEUROTROPHIC FACTORS, P443; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MITSUMOTO H, 1994, ANN NEUROL, V36, P142, DOI 10.1002/ana.410360205; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; SWASH M, 1988, J NEUROL NEUROSUR PS, V51, P785, DOI 10.1136/jnnp.51.6.785; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; TANDAN R, 1985, ANN NEUROL, V18, P271, DOI 10.1002/ana.410180302; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x	34	63	64	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1995	1	2					168	172		10.1038/nm0295-168	http://dx.doi.org/10.1038/nm0295-168			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585015				2022-12-27	WOS:A1995QX55800029
J	PANTALEO, G; FAUCI, AS				PANTALEO, G; FAUCI, AS			APOPTOSIS IN HIV-INFECTION	NATURE MEDICINE			English	Editorial Material							T-CELLS; DEATH; LYMPHOCYTES; ACTIVATION; AIDS; HYPOTHESIS	It is reported that DNA fragmentation (indicating apoptosis) is rarely observed in HIV-1 or SIV-producing infected cells, and HIV-1 or SIV RNA is rarely (0-1%) observed in apoptotic cells. What is the role of apoptosis in the pathogenicity of HIV infection? (pages 129-134).			PANTALEO, G (corresponding author), NIAID, IMMUNOREGULAT LAB, BLDG 10, BETHESDA, MD 20892 USA.		Pantaleo, Giuseppe/K-6163-2016					AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; COHEN JJ, 1992, ANN REV IMMUNOL; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; PANTALEO G, 1994, CURR OPIN IMMUNOL, V6, P600, DOI 10.1016/0952-7915(94)90148-1; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WESSELBORG S, 1993, J IMMUNOL, V150, P4338	16	64	68	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1995	1	2					118	120		10.1038/nm0295-118	http://dx.doi.org/10.1038/nm0295-118			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585004				2022-12-27	WOS:A1995QX55800017
J	FUKUSHIMA, M				FUKUSHIMA, M			CLINICAL-TRIALS IN JAPAN	NATURE MEDICINE			English	Editorial Material								Although Japan's clinical trial system mimics that of the United States, there are certain flaws in the Japanese regulations that prevent it from working effectively.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center	FUKUSHIMA, M (corresponding author), AICHI CANC CTR,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.								0	6	7	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					12	13		10.1038/nm0195-12	http://dx.doi.org/10.1038/nm0195-12			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584938				2022-12-27	WOS:A1995QX55700013
J	Begent, RHJ; Verhaar, MJ; Chester, KA; Casey, JL; Green, AJ; Napier, MP; HopeStone, LD; Cushen, N; Keep, PA; Johnson, CJ; Hawkins, RE; Hilson, AJW; Robson, L				Begent, RHJ; Verhaar, MJ; Chester, KA; Casey, JL; Green, AJ; Napier, MP; HopeStone, LD; Cushen, N; Keep, PA; Johnson, CJ; Hawkins, RE; Hilson, AJW; Robson, L			Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library	NATURE MEDICINE			English	Article							CARCINOEMBRYONIC ANTIGEN; RADIOLABELED ANTIBODY; AFFINITY MATURATION; COLORECTAL-CANCER; PHAGE ANTIBODIES; GENERATION; THERAPY; CONSTRUCTION; PROTEIN	We present a system for cancer targeting based on single-chain Fv (scFv) antibodies selected from combinatorial libraries, produced in bacteria and purified by using an engineered tag. Combinatorial libraries of scFv genes contain great diversity, and scFv antibodies with characteristics optimized for a particular task can be selected from them using filamentous bacteriophage. We illustrate the benefits of this system by imaging patients with carcinoembryonic antigen (CEA)-producing cancers using an iodine-123 labeled scFv anti-CEA selected for high affinity. All known tumor deposits were located, and advantages over current imaging technology are illustrated. ScFvs are produced in a cloned form and can be readily engineered to have localizing and therapeutic functions that will be applicable in cancer and other diseases.	CTR PROTEIN ENGN,CRC PHASE TRAILS COMM 3,CAMBRIDGE CP2 2QH,ENGLAND; CTR PROTEIN ENGN,CRC PHASE TRAILS COMM 3,CAMBRIDGE CP2 2QH,ENGLAND	University of Cambridge; University of Cambridge	Begent, RHJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT CLIN ONCOL,CANC RES CAMPAIGN,TARGETING & IMAGING GRP,LONDON NW3 2PF,ENGLAND.		Chester, Kerry/AAE-2856-2020; Hilson, Andrew J W/C-8554-2009					Bagsgawe K., 1995, TUMOUR TARGETING, V1, P17; BARBAS CF, 1995, NAT MED, V1, P837, DOI 10.1038/nm0895-837; BEGENT RHJ, 1989, BRIT J CANCER, V60, P406, DOI 10.1038/bjc.1989.295; BEGENT RHJ, 1993, EUR J CANCER, V29A, P1907, DOI 10.1016/0959-8049(93)90549-U; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; CASEY JL, 1995, J IMMUNOL METHODS, V179, P105, DOI 10.1016/0022-1759(94)00278-5; CHESTER KA, 1995, TRENDS BIOTECHNOL, V13, P294, DOI 10.1016/S0167-7799(00)88968-4; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; GLIMELLUS B, 1991, EUR J CANC S S2, V82, P462; GREEN AJ, 1990, EUR J NUCL MED, V16, P361, DOI 10.1007/BF00842793; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; LANE DM, 1994, BRIT J CANCER, V70, P521, DOI 10.1038/bjc.1994.338; LEDERMANN JA, 1991, INT J CANCER, V47, P659, DOI 10.1002/ijc.2910470505; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MELTON RG, 1993, J IMMUNOL METHODS, V158, P49, DOI 10.1016/0022-1759(93)90257-8; Michael NP, 1996, IMMUNOTECHNOLOGY, V2, P47, DOI 10.1016/1380-2933(96)00033-4; MILENIC DE, 1991, CANCER RES, V51, P6363; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; SAVAGE P, 1993, BRIT J CANCER, V68, P738, DOI 10.1038/bjc.1993.420; TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VERHAAR MJ, 1995, INT J CANCER, V61, P497, DOI 10.1002/ijc.2910610412; Verhaar MJ, 1996, J NUCL MED, V37, P868; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; YOKOTA T, 1992, CANCER RES, V52, P3402; 1986, BRIT J CANCER, V54, P557	33	218	235	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					979	984		10.1038/nm0996-979	http://dx.doi.org/10.1038/nm0996-979			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782454				2022-12-27	WOS:A1996VF49700031
J	Jones, R				Jones, R			The impact of molecular medicine on health services	NATURE MEDICINE			English	Editorial Material							PREVALENCE; DYSPEPSIA; CARE				Jones, R (corresponding author), UNITED MED & DENT SCH, DEPT GEN PRACTICE, 5 LAMBETH WALK, LONDON SE11 6SP, ENGLAND.							CROSLAND A, 1995, BRIT MED J, V311, P486, DOI 10.1136/bmj.311.7003.486; DIXON AS, 1986, J ROY COLL GEN PRACT, V36, P468; FREER CB, 1980, MED CARE, V18, P853, DOI 10.1097/00005650-198008000-00006; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; Jonsen AR, 1996, NAT MED, V2, P622, DOI 10.1038/nm0696-622; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MARINKER M, 1992, GREENING WHITE PAPER; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; THOMAS KB, 1978, BRIT MED J, V1, P1327, DOI 10.1136/bmj.1.6123.1327; THOMAS KB, 1974, BRIT MED J, V1, P625, DOI 10.1136/bmj.1.5908.625	11	8	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					959	960		10.1038/nm0996-959	http://dx.doi.org/10.1038/nm0996-959			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782443				2022-12-27	WOS:A1996VF49700020
J	Hanenberg, H; Xiao, XL; Dilloo, D; Hashino, K; Kato, I; Williams, DA				Hanenberg, H; Xiao, XL; Dilloo, D; Hashino, K; Kato, I; Williams, DA			Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; CORD-BLOOD-CELLS; BONE-MARROW; PERIPHERAL-BLOOD; RECEPTOR; EXPRESSION; PROGENITORS; THERAPY; BINDING; ALPHA-4-BETA-1	Hematopoietic cells are important targets for genetic modification with retroviral vectors. Attempts at human gene therapy of stem cells have achieved limited success partly because of low gene transfer efficiency. Chymotryptic fragments of the extracellular matrix molecule fibronectin used during infection have been shown to increase transduction of human hematopoietic progenitor cells. Here, we demonstrate that this enhanced gene transfer into mammalian target cells is due to direct binding of retroviral particles to sequences within the fibronectin molecule. Transduction of mammalian cells, including murine long-term repopulating hematopoietic cells, is greatly enhanced when cells are adherent to chimeric fragments containing these retroviral binding sequences. In addition, colocalization of retrovirus and target cells on fibronectin peptides allows targeted transduction of specific cell types by exploiting unique ligand/receptor interactions.	INDIANA UNIV, SCH MED, SECT PEDIAT HEMATOL ONCOL, JAMES WHITCOMB RILEY HOSP CHILDREN, INDIANAPOLIS, IN 46202 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN; INDIANA UNIV, SCH MED, HOWARD HUGHES MED INST, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; St Jude Children's Research Hospital; Takara Holdings Inc.; Howard Hughes Medical Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [P01CA059348] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 59348] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53586] Funding Source: Medline; NIDDK NIH HHS [P50 DK 49218] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1996, B MED ETHICS; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BODINE DM, 1991, EXP HEMATOL, V19, P206; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; BORK P, 1993, PROTEIN SCI, V2, P1185, DOI 10.1002/pro.5560020714; BRADLEY TR, 1979, BLOOD, V54, P1446; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; CLAPP DW, 1995, EXP HEMATOL, V23, P630; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; DHAWAN S, 1993, VIROLOGY, V197, P778, DOI 10.1006/viro.1993.1656; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KIMIZUKA F, 1991, J BIOCH, V110, P281; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LIM B, 1987, MOL CELL BIOL, V7, P3549; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122; MORITZ T, 1993, J EXP MED, V178, P529, DOI 10.1084/jem.178.2.529; MORITZ T, 1996, IN PRESS BLOOD; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RIDER CC, 1994, BIOCHEMISTRY-US, V33, P6974, DOI 10.1021/bi00188a029; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; TSAI S, 1987, BLOOD, V69, P1587; VERFAILLIE CM, 1994, BLOOD, V84, P1802; VERFAILLIE CM, 1991, J EXP MED, V174, P693, DOI 10.1084/jem.174.3.693; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; YODER MC, 1995, EXP HEMATOL, V23, P961	39	468	504	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					876	882		10.1038/nm0896-876	http://dx.doi.org/10.1038/nm0896-876			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705856				2022-12-27	WOS:A1996UZ80400033
J	Miller, CJ; McGhee, JR				Miller, CJ; McGhee, JR			Progress towards a vaccine to prevent sexual transmission of HIV	NATURE MEDICINE			English	Editorial Material							MACAQUES		UNIV ALABAMA,DEPT MICROBIOL,MUCOSAL IMMUNIZAT RES GRP,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	Miller, CJ (corresponding author), UNIV CALIF DAVIS,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616, USA.							BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; COPELAND KFT, 1995, AIDS RES HUM RETROV, V11, P1321, DOI 10.1089/aid.1995.11.1321; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; LOHMAN BL, 1995, J IMMUNOL, V155, P5855; MARTHAS ML, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P117; Miller C. J., 1992, Laboratory Investigation, V68, P129; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; OTSYULA MG, IN PRESS VIROLOGY; THAPAR MA, 1990, IMMUNOLOGY, V70, P121	12	13	13	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					751	752		10.1038/nm0796-751	http://dx.doi.org/10.1038/nm0796-751			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673919	Bronze			2022-12-27	WOS:A1996UU68000029
J	Indolfi, C; Chiariello, M; Avvedimento, EV				Indolfi, C; Chiariello, M; Avvedimento, EV			Selective gene therapy for proliferative disorders: Sense and antisense	NATURE MEDICINE			English	Editorial Material							INHIBITION		UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL MOL & CELLULARE,NAPLES,ITALY	University of Naples Federico II	Indolfi, C (corresponding author), UNIV NAPLES FEDERICO II,DIV CARDIOL,NAPLES,ITALY.							Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HOLT JT, 1995, NAT MED, V1, P407, DOI 10.1038/nm0595-407; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KRONTIRIS TG, 1995, NEW ENGL J MED, V333, P303, DOI 10.1056/NEJM199508033330508; LUDWIG S, 1995, NAT MED, V1, P513, DOI 10.1038/nm0695-513; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; YOKOZAKI H, 1992, CANCER RES, V52, P2504	11	29	29	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					634	635		10.1038/nm0696-634	http://dx.doi.org/10.1038/nm0696-634			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640548				2022-12-27	WOS:A1996UN69100025
J	Jones, JT; Lee, SW; Sullenger, BA				Jones, JT; Lee, SW; Sullenger, BA			Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells	NATURE MEDICINE			English	Article							TETRAHYMENA RIBOZYME; BINDING-SITE; RNA; SEQUENCE; SPECIFICITY; EXPRESSION; CLEAVAGE	In mammalian cells, genetic instructions are usually revised by RNA splicing before they are translated to proteins. Here we demonstrate that a trans-splicing group I ribozyme can be employed to intentionally modify the sequence of targeted transcripts in tissue culture cells. By analyzing the ribozyme reaction products, we demonstrate that targeted trans-splicing can proceed in murine fibroblasts with high fidelity, providing direct evidence that ribozymes function as anticipated in a therapeutically relevant setting. Trans-splicing is not very specific however, and the ribozyme reacted with and tagged a variety of cellular transcripts with its 3' exon sequence. RNA tagging provides a unique approach to study RNA catalysis in mammalian cells. Such analysis should facilitate the logical development of safe, therapeutic ribozymes that can repair mutant RNAs associated with a variety of inherited diseases.	DUKE UNIV,MED CTR,DEPT GENET,PROGRAM MOL THERAPEUT,DURHAM,NC 27710	Duke University	Jones, JT (corresponding author), DUKE UNIV,MED CTR,DEPT EXPTL SURG,BOX 2601,DURHAM,NC 27710, USA.			Lee, Seong-Wook/0000-0003-1718-7601	NIGMS NIH HHS [1 RO1 GM 53525-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMATANO D, 1987, J VIROL, V61, P1647; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FORESTER AC, 1990, SCIENCE, V249, P783; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HASSELOFF J, 1988, NATURE, V334, pS85; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; KRAMER A, 1995, RNA, V1, P260; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1989, BIOCHEMISTRY-US, V28, P980, DOI 10.1021/bi00429a010; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	32	110	126	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					643	648		10.1038/nm0696-643	http://dx.doi.org/10.1038/nm0696-643			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640554				2022-12-27	WOS:A1996UN69100031
J	Jamison, KR; McInnis, MG				Jamison, KR; McInnis, MG			Genetic studies of manic-depressive illness	NATURE MEDICINE			English	Editorial Material							DISORDERS				Jamison, KR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21287, USA.		McInnis, Melvin G/F-6963-2012	McInnis, Melvin G/0000-0002-0375-6247				ANGST J, 1986, NEW RESULTS DEPRESSI; BAXTER LR, 1985, ARCH GEN PSYCHIAT, V42, P441; BERRETTINI WH, 1994, P NATL ACAD SCI USA, V91, P5918, DOI 10.1073/pnas.91.13.5918; Blackwood DHR, 1996, NAT GENET, V12, P427, DOI 10.1038/ng0496-427; Freimer NB, 1996, NAT GENET, V12, P436, DOI 10.1038/ng0496-436; Ginns EI, 1996, NAT GENET, V12, P431, DOI 10.1038/ng0496-431; Goodwin F, 1990, MANIC DEPRESSIVE ILL; Jamison K.R., 1993, TOUCHED FIRE MANIC D; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; POE EA, 1986, FALL OF HOUSE OF USH; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARDS RL, 1981, GENET PSYCHOL MONOGR, V103, P261; ROYBYRNE P, 1985, ACTA PSYCHIAT SCAND, V71, P1, DOI 10.1111/j.1600-0447.1985.tb10510.x; STINE OC, 1995, AM J HUM GENET, V57, P1384; WYATT RJ, 1995, SOC PSYCH PSYCH EPID, V30, P213	16	6	6	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					521	522		10.1038/nm0596-521	http://dx.doi.org/10.1038/nm0596-521			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616706				2022-12-27	WOS:A1996UJ23000030
J	Paxton, WA; Martin, SR; Tse, D; OBrien, TR; Skurnick, J; VanDevanter, NL; Padian, N; Braun, JF; Kotler, DP; Wolinsky, SM; Koup, RA				Paxton, WA; Martin, SR; Tse, D; OBrien, TR; Skurnick, J; VanDevanter, NL; Padian, N; Braun, JF; Kotler, DP; Wolinsky, SM; Koup, RA			Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; IMMUNE-RESPONSE; REPLICATION; ANTIGEN; ENTRY; DECLINE; CELLS	Some individuals remain uninfected with human immunodeficiency virus type-1 (HIV-1) despite multiple high-risk sexual exposures. We studied a cohort of 25 subjects with histories of multiple high-risk sexual exposures to HIV-1 and found that their CD8(+) lymphocytes had greater anti-HIV-1 activity than did CD8(+) lymphocytes from nonexposed controls. further studies indicated that their purified CD4(+) lymphocytes were less susceptible to infection with multiple primary isolates of HIV-1 than were CD4(+) lymphocytes from the nonexposed controls. This relative resistance to HIV-1 infection did not extend to T-cell line-adapted strains, was restricted by the envelope glycoprotein, was not explained by the cell surface density of CD4 molecules, but was associated with the activity of the C-C chemokines RANTES, MIP-1 alpha, and MIP-1 beta. This relative resistance of CD4(+) lymphocytes may contribute to protection from HIV-1 in multiply exposed persons.	AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; NYU, SCH MED, NEW YORK, NY 10016 USA; NCI, VIRAL EPIDEMIOL BRANCH, NIH, ROCKVILLE, MD 20852 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT PREVENT MED & COMMUNITY HLTH, NEWARK, NJ 07103 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV SOCIOMED SCI, NEW YORK, NY 10032 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94110 USA; ST LUKES ROOSEVELT HOSP, GASTROINTESTINAL IMMUNOL DIV, NEW YORK, NY 10025 USA; NORTHWESTERN UNIV, DIV INFECT DIS, CHICAGO, IL 60611 USA	New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; University of California System; University of California San Francisco; Mount Sinai St. Luke's; Mount Sinai West; Northwestern University			paxton, william/R-9747-2019; Wolinsky, Steven/B-2893-2012	Paxton, William/0000-0002-2654-5186; Wolinsky, Steven/0000-0002-9625-6697; Paxton, William/0000-0001-5200-0801	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035522, R01AI030358, R37AI035522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35522, AI 45218, AI 30358] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; BRAND D, 1995, J VIROL, V69, P166, DOI 10.1128/JVI.69.1.166-171.1995; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; DETELS R, 1994, J ACQ IMMUN DEF SYND, V7, P1263; GHABANBASANI MZ, 1994, CLIN EXP IMMUNOL, V97, P517; HARROWE G, 1995, VIROLOGY, V210, P490, DOI 10.1006/viro.1995.1367; HODGE TW, 1991, HUM IMMUNOL, V30, P99, DOI 10.1016/0198-8859(91)90077-M; Just J, 1992, Paediatr Perinat Epidemiol, V6, P215, DOI 10.1111/j.1365-3016.1992.tb00762.x; KABAT D, 1994, J VIROL, V68, P2570, DOI 10.1128/JVI.68.4.2570-2577.1994; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KILPATRICK DC, 1991, DIS MARKERS, V9, P21; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1990, TECHNIQUES HIV RES, P107; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LEDERMAN MM, 1995, J INFECT DIS, V172, P228, DOI 10.1093/infdis/172.1.228; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MOORE JP, 1994, J VIROL, V68, P8350, DOI 10.1128/JVI.68.12.8350-8364.1994; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705; OMETTO L, 1995, AIDS, V9, P427, DOI 10.1097/00002030-199509050-00003; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PREVOTS DR, 1994, AIDS S1, V8, pS109; REED L. J., 1938, AMER JOUR HYG, V27, P493; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STEEL CM, 1988, LANCET, V1, P1185; STEFANO KA, 1993, J VIROL, V67, P6707, DOI 10.1128/JVI.67.11.6707-6715.1993; TAYLOR R, 1994, J NIH RES, V6, P29; VYAKARNAM A, 1995, IMMUNOLOGY, V86, P85; WAINBERG MA, 1987, CLIN EXP IMMUNOL, V70, P136; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; [No title captured]	48	581	602	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					412	417		10.1038/nm0496-412	http://dx.doi.org/10.1038/nm0496-412			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597950				2022-12-27	WOS:A1996UD31400042
J	Axelrod, N				Axelrod, N			Of telomeres and tumors	NATURE MEDICINE			English	Editorial Material							CHROMOSOME											BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BLASCO MA, 1996, NAT GENET, V12, P1; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1995, TELOMERES, P265; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H	15	22	23	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					158	159		10.1038/nm0296-158	http://dx.doi.org/10.1038/nm0296-158			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574955				2022-12-27	WOS:A1996TU06000030
J	Neurath, AR; Jiang, SB; Strick, N; Lin, K; Li, YY; Debnath, AK				Neurath, AR; Jiang, SB; Strick, N; Lin, K; Li, YY; Debnath, AK			Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; BINDING; INFECTION; COMPLEX; DOCKING	Sexual transmission is the most frequent (86%) route of adult HIV-1 transmission worldwide(1). In the absence of a prophylactic anti-HIV vaccine, other methods of preventing infection should be implemented. Virucidal spermicides have been considered for this purpose, but their application is contraindicated by adverse effects(2). Anti-HIV drugs(3) or virus-neutralizing monoclonal antibodies(4) are expensive, suggesting that their wide use in topical chemoprophylaxis is unlikely. This emphasizes the importance of developing other methods for preventing HIV transmission. The target cells for sexual and mucosal HIV transmission include T lymphocytes, monocytes/macrophages and dendritic cells(5). Therefore, compounds blocking HIV-CD4 binding are expected to inhibit virus transmission. In exploring the possibility that chemical modification of food proteins might lead to compounds with anti-HIV-1 activity, we found that bovine beta-lactoglobulin (P-LG) modified by 3-hydroxyphthalic anhydride (3HP-beta-LG) (1) blocked at nanomolar concentrations the binding to CD4 of human (HIV) and simian (SIV) immunodeficiency virus surface glycoproteins and monoclonal antibodies specific for the HIV binding site on CD4 and (2) inhibited infection by HIV-1, including primary virus isolates, by HIV-2 and by SIV. The inexpensive and widely available source (whey) for production of 3HP-beta-LG suggests its potential application (nonparenteral) for diminishing the frequency of HIV transmission.			Neurath, AR (corresponding author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,LAB BIOCHEM VIROL,NEW YORK,NY 10021, USA.		Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135	NCI NIH HHS [CA 43315] Funding Source: Medline; NIAID NIH HHS [AI 29373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; [Anonymous], 1992, AIDS WORLD; BIRD KD, 1991, AIDS, V5, P791, DOI 10.1097/00002030-199107000-00001; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FORTHAL DN, 1995, AIDS RES HUM RETROV, V11, P1095, DOI 10.1089/aid.1995.11.1095; GARRETT TPJ, 1993, J MOL BIOL, V234, P763, DOI 10.1006/jmbi.1993.1625; GARTNER S, 1990, TECHNIQUES HIV RES, P53; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Miller C. J., 1992, Laboratory Investigation, V68, P129; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; MORR CV, 1993, CRIT REV FOOD SCI, V33, P431, DOI 10.1080/10408399309527643; MULLER R, 1983, METHOD ENZYMOL, V92, P589; NEURATH AR, 1992, ANTIVIR CHEM CHEMOTH, V3, P55, DOI 10.1177/095632029200300108; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; SATTENTAU QJ, 1988, AIDS, V2, P101, DOI 10.1097/00002030-198804000-00005; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; STEELE F, 1995, NAT MED, V1, P285, DOI 10.1038/nm0495-285; STODDARD BL, 1992, NATURE, V358, P774, DOI 10.1038/358774a0	23	72	80	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					230	234		10.1038/nm0296-230	http://dx.doi.org/10.1038/nm0296-230			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574970				2022-12-27	WOS:A1996TU06000045
J	ZWEIER, JL; WANG, PH; SAMOUILOV, A; KUPPUSAMY, P				ZWEIER, JL; WANG, PH; SAMOUILOV, A; KUPPUSAMY, P			ENZYME-INDEPENDENT FORMATION OF NITRIC-OXIDE IN BIOLOGICAL TISSUES	NATURE MEDICINE			English	Article							RELAXING FACTOR; PERFUSED HEART; L-ARGININE; SUPEROXIDE; SYNTHASE; NITRATE; INJURY	The gaseous free radical nitric oxide (NO.) is an important regulator of a variety of biological functions and also has a role in the pathogenesis of cellular injury. It has been generally accepted that NO. is solely generated in biological tissues by specific nitric oxide synthases, NOSs, which metabolize arginine to citrulline with the formation of NO.. We report that NO. can also be generated in the ischaemic heart by direct reduction of nitrite to NO. under the acidotic and highly reduced conditions that occur. This NO. formation is not blocked by NOS inhibitors, and with long periods of ischaemia progressing to necrosis, this mechanism of NO. formation predominates. We observe that enzyme-independent NO. generation results in myocardial injury with a loss of contractile function. The existence of this enzyme-independent mechanism of NO. formation has important implications in our understanding of the pathogenesis and treatment of tissue injury.	JOHNS HOPKINS MED INST,JOHNS HOPKINS BAYVIEW MED CTR,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine	ZWEIER, JL (corresponding author), JOHNS HOPKINS MED INST,JOHNS HOPKINS BAYVIEW MED CTR,CTR ELECTRON PARAMAGNET RESONANACE,BALTIMORE,MD 21224, USA.		Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011		NHLBI NIH HHS [HL-17655, HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324, P50HL017655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHZHAN M, 1993, J MAGN RESON SER A, V105, P49, DOI 10.1006/jmra.1993.1246; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARSIDE C, 1982, MAR CHEM, V11, P159, DOI 10.1016/0304-4203(82)90039-1; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANGREHR JM, 1993, TRANSPLANTATION, V55, P1205, DOI 10.1097/00007890-199306000-00001; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	22	657	679	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					804	809		10.1038/nm0895-804	http://dx.doi.org/10.1038/nm0895-804			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585184				2022-12-27	WOS:A1995RM63500038
J	CLONINGER, CR				CLONINGER, CR			THE PSYCHOBIOLOGICAL REGULATION OF SOCIAL COOPERATION	NATURE MEDICINE			English	Editorial Material							FLUID MONOAMINE METABOLITES; PARKINSONS-DISEASE; PERSONALITY; ALCOHOLICS; ACID; CSF		WASHINGTON UNIV,SCH MED,CTR PSYCHOBIOL PERSONAL,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL)	CLONINGER, CR (corresponding author), WASHINGTON UNIV,SCH MED,CTR PSYCHOBIOL PERSONAL,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.		Cloninger, Claude/F-5357-2012	Cloninger, Claude/0000-0003-3096-4807				AGREN H, 1986, J PSYCHIAT RES, V20, P175, DOI 10.1016/0022-3956(86)90002-6; BENKELFAT C, 1991, ARCH GEN PSYCHIAT, V48, P383; Cloninger C. R., 1994, TEMPERAMENT CHARACTE; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; CLONINGER CR, ALCOHOLISM, V13, P494; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; HIGLEY JD, 1993, ARCH GEN PSYCHIAT, V50, P615; JIBSON M, 1990, BIOL PSYCHIAT, V28, P595, DOI 10.1016/0006-3223(90)90397-K; KRUESI MJP, 1990, ARCH GEN PSYCHIAT, V47, P419; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P898; LIMSON R, 1991, ARCH GEN PSYCHIAT, V48, P437; MENZA MA, 1993, NEUROPSY NEUROPSY BE, V6, P214; MENZA MA, 1993, NEUROLOGY, V43, P505, DOI 10.1212/WNL.43.3_Part_1.505; MENZA MA, IN PRESS J NEUROPSYC; SIMONSSON P, ALCOHOL ALCOHOLISM, V27, P607; STALLINGS M, IN PRESS J PERS SOC; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; SVRAKIC N, IN PRESS DEV PSYCHOP; TIIHONEN J, 1995, NAT MED, V1, P654, DOI 10.1038/nm0795-654; VIRKKUNEN M, 1994, ARCH GEN PSYCHIAT, V51, P28	21	74	74	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					623	625		10.1038/nm0795-623	http://dx.doi.org/10.1038/nm0795-623			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585135				2022-12-27	WOS:A1995RQ06600028
J	HOHNE, KH; PFLESSER, B; POMMERT, A; RIEMER, M; SCHIEMANN, T; SCHUBERT, R; TIEDE, U				HOHNE, KH; PFLESSER, B; POMMERT, A; RIEMER, M; SCHIEMANN, T; SCHUBERT, R; TIEDE, U			A NEW REPRESENTATION OF KNOWLEDGE CONCERNING HUMAN ANATOMY AND FUNCTION	NATURE MEDICINE			English	Editorial Material							ATLAS; BRAIN; MRI; IMAGES				HOHNE, KH (corresponding author), MED UNIV HAMBURG,INST MATH & DATENVERARBEITUNG,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Schubert, Rainer/E-7320-2015	Schubert, Rainer/0000-0002-8026-7500				Ackerman M J, 1991, J Biocommun, V18, P14; BLOOM FE, 1990, 3 DIMENSIONAL NEUROI, P273; Bookstein F.L., 1991, MORPHOMETRIC TOOLS L; BRECHBUHLER C, 1992, 1ST P C VIS BIOM COM, P80; BRINKLEY JF, 1993, COMPUT METH PROG BIO, V40, P131, DOI 10.1016/0169-2607(93)90007-8; Carlsen I. C., 1991, Computer Assisted Radiology. Proceedings of the International Symposium. CAR '91 Computer Assisted Radiology, P277; DECLERCK J, 1995, 1ST P INT C COMP VIS, P153; Dev P, 1992, RADIOLOGY P, V185, P413; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; Fox P.T., 1994, FUNCTIONAL NEUROIMAG, P95; GEE JC, 1993, J COMPUT ASSIST TOMO, V17, P225, DOI 10.1097/00004728-199303000-00011; GREITZ T, 1991, J COMPUT ASSIST TOMO, V15, P26, DOI 10.1097/00004728-199101000-00003; Hohne K. H., 1990, Visual Computer, V6, P28, DOI 10.1007/BF01902627; HOHNE KH, 1992, IEEE COMPUT GRAPH, V12, P72, DOI 10.1109/38.144829; HOHNE KH, 1992, J COMPUT ASSIST TOMO, V16, P285, DOI 10.1097/00004728-199203000-00019; KEYSERLINGK DG, 1989, PSYCHIAT RES, V29, P461; LEHMANN ED, 1991, MED INFORM, V16, P151, DOI 10.3109/14639239109012124; LIPSCOMB K, 1991, PHYSICIANS COMPUT, V9, P14; Mano I, 1990, Radiat Med, V8, P50; NIEMANN H, 1990, IEEE T PATTERN ANAL, V12, P883, DOI 10.1109/34.57683; NIEMANN K, 1988, ACTA NEUROCHIR, V93, P61, DOI 10.1007/BF01409904; POMMERT A, 1994, P SOC PHOTO-OPT INS, V2359, P412; ROBINSON GP, 1994, IMAGE VISION COMPUT, V12, P499, DOI 10.1016/0262-8856(94)90003-5; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; SCHIEMANN T, 1992, P SOC PHOTO-OPT INS, V1808, P376, DOI 10.1117/12.131092; SCHUBERT R, 1994, ACTA ANAT, V150, P69; Talairach J., 1988, COPLANAR STEREOTAXIC; TIEDE U, 1990, IEEE COMPUT GRAPH, V10, P41, DOI 10.1109/38.50672; TIEDE U, 1993, AM J NEURORADIOL, V14, P551; WAHLERLUCK M, 1991, GRAEF ARCH CLIN EXP, V229, P201, DOI 10.1007/BF00167867; WERTHEIM SI, 1989, 13TH ANN S COMP APPL, P399; Winston P.H., 1992, ARTIFICIAL INTELLIGE; 1995, VOXEL MAN BRAIN SKUL	33	88	91	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					506	511		10.1038/nm0695-506	http://dx.doi.org/10.1038/nm0695-506			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585108				2022-12-27	WOS:A1995RN10100025
J	BUONOCORE, MH; HECHT, ST				BUONOCORE, MH; HECHT, ST			FUNCTIONAL MAGNETIC-RESONANCE-IMAGING DEPICTS THE BRAIN IN ACTION	NATURE MEDICINE			English	Article							SENSORY STIMULATION; VISUAL-CORTEX; MOTOR CORTEX; ACTIVATION; MRI				BUONOCORE, MH (corresponding author), UNIV CALIF DAVIS,MED CTR,DEPT RADIOL,SACRAMENTO,CA 95817, USA.							ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Aronen H J, 1993, Top Magn Reson Imaging, V5, P14; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BELLIVEAU JW, 1992, INVEST RADIOL, V27, pS59, DOI 10.1097/00004424-199212002-00011; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BUONOCORE MH, 1994, RADIOLOGY, V193, P137; BUONOCORE MH, 1994, RADIOLOGY, V193, P136; CAO Y, 1993, JMRI-J MAGN RESON IM, V3, P869, DOI 10.1002/jmri.1880030613; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Edelman R., 1994, JMRI-J MAGN RESON IM, V4, P68; FRAHM J, 1993, MAGNET RESON MED, V29, P139, DOI 10.1002/mrm.1910290126; FRAHM J, 1994, NMR BIOMED, V7, P45, DOI 10.1002/nbm.1940070108; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; MADDOCK RJ, 1995, 2ND P ANN M COGN NEU; MENON RS, 1992, INVEST RADIOL, V27, pS47, DOI 10.1097/00004424-199212002-00009; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; RAO SM, 1994, AUG P SOC MAGN RES, V1, P325; ROSEN BR, 1991, MAGNET RESON MED, V22, P293, DOI 10.1002/mrm.1910220227; ROSEN BR, 1991, MAGN RESON MED, V22, P300; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560	27	8	9	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					379	381		10.1038/nm0495-379	http://dx.doi.org/10.1038/nm0495-379			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585071				2022-12-27	WOS:A1995RN09800037
J	HIYAMA, E; HIYAMA, K; YOKOYAMA, T; MATSUURA, Y; PIATYSZEK, MA; SHAY, JW				HIYAMA, E; HIYAMA, K; YOKOYAMA, T; MATSUURA, Y; PIATYSZEK, MA; SHAY, JW			CORRELATING TELOMERASE ACTIVITY LEVELS WITH HUMAN NEUROBLASTOMA OUTCOMES	NATURE MEDICINE			English	Article							NEURO-BLASTOMA; HUMAN FIBROBLASTS; N-MYC; CELLULAR SENESCENCE; CHILDRENS CANCER; PROGNOSIS; STAGE; CELLS; DNA; IMMORTALIZATION	Telomerase activity was analysed in 100 neuroblastoma cases. Although telomerase activity was not detected in normal adrenal tissues or benign ganglioneuromas, almost all neuroblastomas (94%) did express it, suggesting an important role for telomerase in neuroblastoma development. Neuroblastomas with high telomerase activity had other genetic changes (for example, N-myc amplification) and an unfavourable prognosis, whereas tumours with low telomerase activity were devoid of such genetic alterations and were associated with a favourable prognosis. Three neuroblastomas lacking telomerase activity regressed (stage IVS). Thus telomerase expression may be required as a critical step in the multigenetic process of tumorigenesis, and two different pathways may exist for the development of neuroblastoma.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; HIROSHIMA UNIV,SCH MED,DEPT GEN MED,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT INTERNAL MED 2,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT SURG 1,HIROSHIMA 734,JAPAN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Hiroshima University; Hiroshima University; Hiroshima University			Shay, Jerry W/F-7878-2011; Piatyszek, Mieczyslaw A./F-9365-2015; Hiyama, Eiso/A-2013-2019	Piatyszek, Mieczyslaw A./0000-0003-0502-3239; Hiyama, Eiso/0000-0001-9179-5037	NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DANGIO GJ, 1971, LANCET, V1, P1046; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1981, ARCH DIS CHILD, V56, P271, DOI 10.1136/adc.56.4.271; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FINKLESTEIN JZ, 1979, MED PEDIATR ONCOL, V6, P179, DOI 10.1002/mpo.2950060211; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HELLSTROM IE, 1968, P NATL ACAD SCI USA, V60, P1231, DOI 10.1073/pnas.60.4.1231; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA E, 1995, INT J ONCOL, V6, P13; IKEDA Y, 1981, J PEDIATR SURG, V16, P636, DOI 10.1016/0022-3468(81)90019-1; JAMES DH, 1965, J AMER MED ASSOC, V194, P123, DOI 10.1001/jama.1965.03090150015003; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRETSCHMAR CS, 1984, J CLIN ONCOL, V2, P799, DOI 10.1200/JCO.1984.2.7.799; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MEHLE C, 1994, CANCER RES, V54, P236; MOTIN GB, 1989, CELL, V59, P521; NURNBERG P, 1993, HUM GENET, V91, P190; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PRICHARD J, 1994, LANCET, V344, P869; RANGECROFT L, 1978, ARCH DIS CHILD, V52, P815; SAWADA T, 1991, AM J PEDIAT HEMATOL, V13, P3; SAWAGUCHI S, 1990, CANCER, V66, P1879, DOI 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L; SCHMITT H, 1994, GENE CHROMOSOME CANC, V11, P171, DOI 10.1002/gcc.2870110306; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SHAY JW, 1994, CELL DIFFER, V2, P1; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; TURKEL SB, 1974, AM J PATHOL, V76, P225; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WOODS WG, 1992, PEDIATRICS, V89, P114; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; YOUNG JL, 1986, CANCER, V56, P598; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	56	608	631	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					249	255		10.1038/nm0395-249	http://dx.doi.org/10.1038/nm0395-249			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585042				2022-12-27	WOS:A1995QX55900032
J	BOHACEK, RS; MCMARTIN, C				BOHACEK, RS; MCMARTIN, C			EXPLORING THE UNIVERSE OF MOLECULES FOR NEW DRUGS	NATURE MEDICINE			English	Editorial Material							DISPLAY											BOHACEK RS, 1992, J MED CHEM, V35, P1671, DOI 10.1021/jm00088a002; BOHACEK RS, 1994, J AM CHEM SOC, V116, P5560, DOI 10.1021/ja00092a006; RODERICK SL, 1989, BIOCHEMISTRY-US, V28, P1493, DOI 10.1021/bi00430a011; THAISRIVONGS S, 1994, J MED CHEM, V37, P3200, DOI 10.1021/jm00046a002	4	5	5	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					177	178		10.1038/nm0295-177	http://dx.doi.org/10.1038/nm0295-177			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585016				2022-12-27	WOS:A1995QX55800030
J	Kierszenbaum, F				Kierszenbaum, F			Can a killer be arrested?	NATURE MEDICINE			English	Editorial Material							TRYPANOSOMA SCHIZOTRYPANUM CRUZI; CHAGAS-DISEASE; AUTOIMMUNITY; ICI-195,739				Kierszenbaum, F (corresponding author), MICHIGAN STATE UNIV, DEPT MICROBIOL, E LANSING, MI 48824 USA.							BRENER Z, 1979, TRYPANOSOMA CRUZI DO, P199; Kierszenbaum F., 1989, Vaccination strategies of tropical diseases., P173; KIERSZENBAUM F, 1986, J PARASITOL, V72, P201, DOI 10.2307/3281592; Kierszenbaum F., 1994, Parasitic infections and the immune system., P53; KIERSZENBAUM F, 1984, PARASITIC DISEASES C, V2, P133; LAZARDI K, 1991, ANTIMICROB AGENTS CH, V35, P736, DOI 10.1128/AAC.35.4.736; TAKLE GB, 1989, CURR TOP MICROBIOL, V145, P79; URBINA JA, 1991, ANTIMICROB AGENTS CH, V35, P730, DOI 10.1128/AAC.35.4.730; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; 1992, TDR NEWS, V39, P2	10	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1071	1072		10.1038/nm1096-1071	http://dx.doi.org/10.1038/nm1096-1071			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837597				2022-12-27	WOS:A1996VK99500019
J	Chen, XQ; Stroun, M; Magnenat, JL; Nicod, LP; Kurt, AM; Lyautey, J; Lederrey, C; Anker, P				Chen, XQ; Stroun, M; Magnenat, JL; Nicod, LP; Kurt, AM; Lyautey, J; Lederrey, C; Anker, P			Microsatellite alterations in plasma DNA of small cell lung cancer patients	NATURE MEDICINE			English	Article							INSTABILITY; MUTATIONS; MARKERS	Microsatellite instability is an important characteristic of many tumor types(1-8) especially those associated with hereditary non-polyposis colorectal carcinoma (HNPCC) syndrome(6-8). Microsatellite alterations in 50% of primary small cell lung carcinoma (SCLC) have been found. These alterations were also found in the sputum(4). Because neoplastic characteristics such as decreased strand stability(9) and ras mutations(10-12) have been found in the plasma DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients. A microsatellite alteration was present in 16 out of 21 (76%) SCLC tumors and in 15 out of 21 (71%) plasma samples. In one case, the alteration was present only in the plasma DNA. If confirmed in larger studies, microsatellite analysis of plasma DNA might constitute a new tool for tumor staging, management and, possibly, detection.	FAC SCI GENEVA,LAB PLANT BIOCHEM & PHYSIOL,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,FAC MED,DEPT MED,DIV RESP,CH-1205 GENEVA,SWITZERLAND; UNIV GENEVA,FAC MED,DEPT PATHOL,CH-1205 GENEVA,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva			Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X				KOLODNER RD, 1995, CANCER RES, V55, P242; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MERLO A, 1994, CANCER RES, V54, P2098; NAGEL S, 1995, CANCER RES, V55, P2866; NAWROZ H, 1996, NAT MED, V2, P1036; PELTOMAKI P, 1993, CANCER RES, V53, P5853; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; STROUN M, 1989, ONCOLOGY, V46, P318; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASYUKHIN V, 1994, CHALLENGES MODERN ME, P141; VASYUKHIN V, 1994, BRIT J HAEMATOL, V86, P774; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	14	534	665	1	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1033	1035						3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782463				2022-12-27	WOS:A1996VF49700040
J	Snyder, SH				Snyder, SH			No NO prevents Parkinsonism	NATURE MEDICINE			English	Editorial Material							NITRIC-OXIDE SYNTHASE; NEUROTOXICITY; INHIBITION; MPTP				Snyder, SH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; Dawson VL, 1996, J NEUROSCI, V16, P2479; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; INNIS RB, 1993, P NATL ACAD SCI USA, V90, P11965, DOI 10.1073/pnas.90.24.11965; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	13	24	24	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					965	966		10.1038/nm0996-965	http://dx.doi.org/10.1038/nm0996-965			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782445				2022-12-27	WOS:A1996VF49700022
J	Putnam, AJ; Mooney, DJ				Putnam, AJ; Mooney, DJ			Tissue engineering using synthetic extracellular matrices	NATURE MEDICINE			English	Editorial Material									UNIV MICHIGAN,DEPT CHEM ENGN,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL & MAT SCI,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Putnam, Andrew J./E-8643-2010	Putnam, Andrew J./0000-0002-1262-4377; Mooney, David/0000-0001-6299-1194				Alberts B., 1994, MOL BIOL CELL, P971; ATALA A, 1994, J UROLOGY, V152, P641, DOI 10.1016/S0022-5347(17)32671-X; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; GILDING DK, 1981, BIOCOMPATIBILITY CLI, V2, P209; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; KIM WS, 1994, PLAST RECONSTR SURG, V94, P233, DOI 10.1097/00006534-199408000-00001; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lo H, 1995, Tissue Eng, V1, P15, DOI 10.1089/ten.1995.1.15; MIKOS AG, 1994, POLYMER, V35, P1068, DOI 10.1016/0032-3861(94)90953-9; Mooney D J, 1995, Tissue Eng, V1, P107, DOI 10.1089/ten.1995.1.107; Mooney DJ, 1996, BIOTECHNOL BIOENG, V50, P422, DOI 10.1002/(SICI)1097-0290(19960520)50:4<422::AID-BIT9>3.0.CO;2-N; MOONEY DJ, 1995, J BIOMED MATER RES, V29, P959, DOI 10.1002/jbm.820290807; MOONEY DJ, 1994, CELL TRANSPLANT, V3, P203, DOI 10.1177/096368979400300209; MOONEY DJ, IN PRESS BIOMATERIAL; Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5; Nerem R M, 1995, Tissue Eng, V1, P3, DOI 10.1089/ten.1995.1.3; ORGAN GM, 1992, TRANSPLANT P, V24, P3008; PUELACHER WC, 1994, BIOMATERIALS, V15, P774, DOI 10.1016/0142-9612(94)90031-0; PUELACHER WC, 1994, INT J ORAL MAX SURG, V23, P49, DOI 10.1016/S0901-5027(05)80328-5	19	180	193	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					824	826		10.1038/nm0796-824	http://dx.doi.org/10.1038/nm0796-824			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673932				2022-12-27	WOS:A1996UU68000044
J	GarciaZepeda, EA; Rothenberg, ME; Ownbey, RT; Celestin, J; Leder, P; Luster, AD				GarciaZepeda, EA; Rothenberg, ME; Ownbey, RT; Celestin, J; Leder, P; Luster, AD			Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; FUNCTIONAL-PROPERTIES; BLOOD EOSINOPHILS; CROHNS-DISEASE; LEUKOCYTE; INTERLEUKIN-3; SURVIVAL; RELEASE; BOWEL	Eotaxin is an eosinophil-specific chemoattractant that has been recently identified in rodent models of asthma and host response against tumors. To determine whether a similar molecule might play a role in human inflammatory diseases characterized by eosinophilia, we isolated the human eotaxin gene. We demonstrate that human eotaxin is an early response gene of cytokine-stimulated epithelial and endothelial cells, and is induced in peripheral blood eosinophils by interleukin-3. Eotaxin is directly chemotactic for eosinophils, but not mononuclear cells or neutrophils. Eotaxin messenger RNA accumulates markedly in the lesions of patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease), but not in the lesions of patients with diverticulitis. These results now provide a mechanism involving eotaxin to explain the eosinophil infiltration seen in a variety of human diseases; as such, an eotaxin antagonist may be a novel therapy for certain human diseases characterized by tissue eosinophilia.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital			Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUCKLEY MG, 1995, IMMUNOLOGY, V84, P410; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DUBUCQUOI S, 1995, GUT, V37, P242, DOI 10.1136/gut.37.2.242; DVORAK AM, 1980, J IMMUNOL, V125, P460; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FUGGLE WJ, 1984, J CLIN PATHOL, V37, P267, DOI 10.1136/jcp.37.3.267; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; HALLGREN R, 1989, AM J MED, V86, P56, DOI 10.1016/0002-9343(89)90230-1; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; JIANG YL, 1990, J BIOL CHEM, V265, P18318; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; SARIN SK, 1987, DIGEST DIS SCI, V32, P363, DOI 10.1007/BF01296289; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRY CJF, 1971, CELL TISSUE KINET, V4, P351, DOI 10.1111/j.1365-2184.1971.tb01545.x; TOMONAGA M, 1986, BLOOD, V67, P1433; WALSH RE, 1991, SCAND J GASTROENTERO, V26, P1217, DOI 10.3109/00365529108998617; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WILLOUGHBY CP, 1979, SCAND J GASTROENTERO, V14, P394; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	38	589	608	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					449	456		10.1038/nm0496-449	http://dx.doi.org/10.1038/nm0496-449			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597956				2022-12-27	WOS:A1996UD31400048
J	Jacobson, BS; Stolz, DB; Schnitzer, JE				Jacobson, BS; Stolz, DB; Schnitzer, JE			Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease	NATURE MEDICINE			English	Editorial Material							DISCOIDEUM PLASMA-MEMBRANE; GEL-ELECTROPHORESIS; ANGIOGENESIS; CYTOSKELETON; VASCULATURE; INVITRO		UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Jacobson, BS (corresponding author), UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003, USA.							BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUCK CA, 1995, MOL BASIS CANC, P172; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; CHANEY LK, 1983, J BIOL CHEM, V258, P62; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; PATTON WF, 1989, ANAL BIOCHEM, V179, P37, DOI 10.1016/0003-2697(89)90197-8; PATTON WF, 1989, J CELL SCI, V92, P85; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHWARTZ LM, 1995, METHOD CELL BIOL, V46, P107; SHIOZAWA JA, 1987, BIOCHEMISTRY-US, V26, P4884, DOI 10.1021/bi00389a041; STOLZ DB, 1991, IN VITRO CELL DEV B, V27, P169; STOLZ DB, 1992, J CELL SCI, V103, P53; STOLZ DB, IN PRESS CELL BIOL L	22	39	42	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					482	484		10.1038/nm0496-482	http://dx.doi.org/10.1038/nm0496-482			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597963				2022-12-27	WOS:A1996UD31400056
J	Momose, A; Takeda, T; Itai, Y; Hirano, K				Momose, A; Takeda, T; Itai, Y; Hirano, K			Phase-contrast X-ray computed tomography for observing biological soft tissues	NATURE MEDICINE			English	Article								Biological soft tissues are almost transparent to hard X rays and therefore cannot be investigated without enhancement with a contrast medium, such as iodine. On the other hand, phase-contrast X-ray imaging is sensitive to light elements(1-8). This is because the X-ray phase shift cross section is almost a thousand times larger than the X-ray absorption cross section for light elements such as hydrogen, carbon, nitrogen and oxygen(4,5). Hence, phase-contrast X-ray imaging is a promising technique for observing the structure inside biological soft tissues without the need for staining and without serious radiation exposure. We have devised a means of observing biological tissues in three dimensions using a novel X-ray computed tomography (CT) by modifying the phase-contrast technique. To generate appropriate CT input data, we used phase-mapping images obtained using an X-ray interferometer(6) and computer analysis of interference patterns(9). Now, we present a three-dimensional observation result of a nonstained sample of a cancerous rabbit liver, using a synchrotron X-ray source. Phase-contrast X-ray CT was able to clearly differentiate the cancer lesion from the normal tissue. Moreover, fine structures corresponding to cancerous degeneration and fibrous tissues were clearly depicted.	UNIV TSUKUBA, INST CLIN MED, TSUKUBA, IBARAKI 305, JAPAN; NATL LAB HIGH ENERGY PHYS, PHOTON FACTORY, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; High Energy Accelerator Research Organization (KEK)	Momose, A (corresponding author), HITACHI LTD, ADV RES LAB, HATOYAMA, SAITAMA 35003, JAPAN.		Momose, Atsushi/T-4873-2019	Hirano, Keiichi/0000-0001-9105-3746				ANDO M, 1972, 6TH P INT C XRAY OPT, P63; BECKER P, 1981, PHYS REV LETT, V46, P1540, DOI 10.1103/PhysRevLett.46.1540; BONSE U, 1965, APPL PHYS LETT, V7, P99, DOI 10.1063/1.1754330; BONSE U, 1965, APPL PHYS LETT, V6, P155, DOI 10.1063/1.1754212; BRUNING JH, 1974, APPL OPTICS, V13, P2693, DOI 10.1364/AO.13.002693; DESLATTES RD, 1973, PHYS REV LETT, V31, P972, DOI 10.1103/PhysRevLett.31.972; HART M, 1975, P ROY SOC LOND A MAT, V346, P1, DOI 10.1098/rspa.1975.0163; MCNULTY I, 1994, NUCL INSTRUM METH A, V347, P170, DOI 10.1016/0168-9002(94)91874-0; MOMOSE A, 1995, ACAD RADIOL, V2, P883, DOI 10.1016/S1076-6332(05)80067-4; MOMOSE A, 1995, MED PHYS, V22, P375, DOI 10.1118/1.597472; MOMOSE A, 1995, NUCL INSTRUM METH A, V352, P622, DOI 10.1016/0168-9002(95)90017-9; MOMOSE A, 1995, REV SCI INSTRUM, V66, P1434, DOI 10.1063/1.1145931; SUZUKI Y, 1989, REV SCI INSTRUM, V60, P2299, DOI 10.1063/1.1140798; TAKEDA T, 1995, ACAD RADIOL, V2, P799, DOI 10.1016/S1076-6332(05)80490-8	14	716	744	6	129	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					473	475		10.1038/nm0496-473	http://dx.doi.org/10.1038/nm0496-473			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597962				2022-12-27	WOS:A1996UD31400054
J	MATIS, LA; ROLLINS, SA				MATIS, LA; ROLLINS, SA			COMPLEMENT SPECIFIC ANTIBODIES - DESIGNING NOVEL ANTIINFLAMMATORIES	NATURE MEDICINE			English	Editorial Material											MATIS, LA (corresponding author), ALEXION PHARMACEUT INC,PROGRAM IMMUNOL,25 SCI PK,SUITE 360,NEW HAVEN,CT 06511, USA.							BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; EVANS MJ, IN PRESS MOL IMMUN; EVANS RW, 1993, TRANSPLANTATION, V55, P1297, DOI 10.1097/00007890-199306000-00017; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1992, IMMUNOL REV, V130, P41, DOI 10.1111/j.1600-065X.1992.tb01520.x; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JIANG HX, 1994, J IMMUNOL, V152, P5050; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; MORGAN BP, 1994, EUR J CLIN INVEST, V24, P219, DOI 10.1111/j.1365-2362.1994.tb01078.x; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NEAL CE, 1994, SEMIN NUCL MED, V24, P272, DOI 10.1016/S0001-2998(05)80019-4; NICHOLSONWELLER A, 1993, IMMUNOL RES, V12, P244, DOI 10.1007/BF02918256; PIETERSZ GA, 1994, J DRUG TARGET, V2, P183, DOI 10.3109/10611869408996804; RINDER CS, IN PRESS J CLIN INVE; TCHENG JE, 1994, CIRCULATION, V90, P1757, DOI 10.1161/01.CIR.90.4.1757; WANG Y, IN PRESS P NATN ACAD; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	18	68	78	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					839	842		10.1038/nm0895-839	http://dx.doi.org/10.1038/nm0895-839			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585191	Green Published			2022-12-27	WOS:A1995RM63500045
J	ABIMIKU, AG; FRANCHINI, G; TARTAGLIA, J; ALDRICH, K; MYAGKIKH, M; MARKHAM, PD; CHONG, PL; KLEIN, M; KIENY, MP; PAOLETTI, E; GALLO, RC; ROBERTGUROFF, M				ABIMIKU, AG; FRANCHINI, G; TARTAGLIA, J; ALDRICH, K; MYAGKIKH, M; MARKHAM, PD; CHONG, PL; KLEIN, M; KIENY, MP; PAOLETTI, E; GALLO, RC; ROBERTGUROFF, M			HIV-1 RECOMBINANT POXVIRUS VACCINE INDUCES CROSS-PROTECTION AGAINST HIV-2 CHALLENGE IN RHESUS MACAQUES	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TOXIC LYMPHOCYTES-T; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDES; INFECTION; TYPE-1; NEUTRALIZATION; ANTIBODIES; EXPRESSION; EPITOPE	Rhesus macaques were immunized with attenuated vaccinia or canarypox human immunodeficiency virus type 1 (HIV-1) recombinants and boosted with HIV-1 protein subunits formulated in alum. Following challenge with HIV-2(SBL6669), three out of eight immunized macaques resisted infection for six months and another exhibited significantly delayed infection, whereas all three naive controls became infected. Immunizations elicited both humoral and cellular immune responses; however, no clear correlates of protection were discerned. Although more extensive studies are now called for, this first demonstration of cross-protection between HIV-1 and -2 suggests that viral variability may not be an insurmountable problem in the design of a global AIDS vaccine.	VIROGENET CORP,TROY,NY 12180; ADV BIOSCI LABS INC,KENSINGTON,MD 20895; CONNAUGHT LABS,N YORK,ON M2R 3T4,CANADA; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Transgene SA	ABIMIKU, AG (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,ROOM 6A09,37 CONVENT DR MSC 4255,BETHESDA,MD 20892, USA.		Kieny, Marie-Paule/N-3914-2017; Kieny, Marie-Paule/Q-1238-2019; Chong, Pele/E-3855-2010	Kieny, Marie-Paule/0000-0002-5943-6488; 				ABIMIKU AG, 1995, AIDS RES HUM RETROV, V11, P383, DOI 10.1089/aid.1995.11.383; ACHOUR A, 1990, P NATL ACAD SCI USA, V87, P7045, DOI 10.1073/pnas.87.18.7045; AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; BERZOFSKY JA, 1991, J ACQ IMMUN DEF SYND, V4, P451; BOTTIGER B, 1990, J VIROL, V64, P3492; BOTTIGER B, 1990, AIDS RES HUM RETROV, V5, P525; CADOZ M, 1992, LANCET, V339, P1429, DOI 10.1016/0140-6736(92)92027-D; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHONG P, 1990, FEBS LETT, V264, P231, DOI 10.1016/0014-5793(90)80255-H; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671; DORMONT D, 1989, INTERVIROLOGY, V30, P59, DOI 10.1159/000150125; FRANCHINI G, 1990, J VIROL, V64, P4462, DOI 10.1128/JVI.64.9.4462-4467.1990; FRANCHINI G, 1995, AIDS RES HUM RETROV, V11, P307, DOI 10.1089/aid.1995.11.307; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MYERS G, 1994, HUMAN RETROVIRUSES A; NAIR BC, 1994, J CLIN MICROBIOL, V32, P1449, DOI 10.1128/JCM.32.6.1449-1456.1994; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; NISHANIAN PG, 1988, J IMMUNOL METHODS, V107, P261, DOI 10.1016/0022-1759(88)90227-X; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NORLEY SG, 1990, J IMMUNOL, V145, P1700; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PERKUS ME, 1989, J VIROL, V63, P3829, DOI 10.1128/JVI.63.9.3829-3836.1989; PICCINI A, 1987, METHOD ENZYMOL, V153, P545; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROBERTGUROFF M, 1990, TECHNIQUES HIV RES, P179; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; TARTAGLIA J, 1993, J VIROL, V67, P2370, DOI 10.1128/JVI.67.4.2370-2375.1993; TARTAGLIA J, 1993, AIDS RES REV, V3, P361; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WANG CY, 1991, SCIENCE, V254, P285, DOI 10.1126/science.1925584; WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004	50	63	66	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					321	329		10.1038/nm0495-321	http://dx.doi.org/10.1038/nm0495-321			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585061				2022-12-27	WOS:A1995RN09800027
J	RAINE, CS				RAINE, CS			MULTIPLE-SCLEROSIS - TNF REVISITED, WITH PROMISE	NATURE MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRANSFORMING GROWTH FACTOR-BETA-1; AUTOIMMUNE DEMYELINATION; LYMPHOTOXIN; MICE		YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,ROSE F KENNEDY CTR RES MENTAL RETARDAT & HUMAN DE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	RAINE, CS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL NEUROPATHOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							BAKER D, 1994, EUR J IMMUNOL, V24, P2040, DOI 10.1002/eji.1830240916; BILLIAU A, 1988, J IMMUNOL, V140, P1506; BROSNAN CF, 1980, NATURE, V285, P235, DOI 10.1038/285235a0; GENAIN CP, IN PRESS P NATN ACAD; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; JACOBS CA, 1991, J IMMUNOL, V146, P2983; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; MASSACESI L, IN PRESS ANN NEUROL; MONASTRA G, 1993, NEUROLOGY, V43, P153, DOI 10.1212/WNL.43.1_Part_1.153; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; RACKE MK, 1991, J IMMUNOL, V146, P3012; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Raine C., 1984, MYELIN, P1, DOI 10.1007/978-1-4757-1830-0_1; RAINE CS, 1990, TXB NEUROPATHOLOGY, P535; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; RUDDLE NH, 1968, J EXP MED, V128, P1237, DOI 10.1084/jem.128.6.1237; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ K, IN PRESS J NEUROIMMU; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SELMAJ KW, 1990, J IMMUNOL, V147, P129; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; TSUKADA N, 1993, NEUROLOGY, V43, P2679, DOI 10.1212/WNL.43.12.2679	28	87	89	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					211	214		10.1038/nm0395-211	http://dx.doi.org/10.1038/nm0395-211			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585035				2022-12-27	WOS:A1995QX55900025
J	MOSER, HW				MOSER, HW			A QUESTION OF CULTURE	NATURE MEDICINE			English	Editorial Material							SCHWANN-CELLS; NERVOUS-SYSTEM	The demonstration, by Rutkowski et al. (page 80), that human Schwann cells can now be expanded to around 1 x 10(8) cells, provides a new opportunity for the study and therapy of myelin disorders.	JOHNS HOPKINS UNIV,DEPT NEUROL & PEDIAT,BALTIMORE,MD 21218	Johns Hopkins University	MOSER, HW (corresponding author), JOHNS HOPKINS UNIV,CTR RES MENTAL RETARDAT & RELATED ASPECTS HUMAN D,BALTIMORE,MD 21218, USA.							ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; ASKANAS V, 1980, ARCH NEUROL-CHICAGO, V37, P329, DOI 10.1001/archneur.1980.00500550031001; BARONVANEVERCOO.A, 1992, J NEUROIMMUNOL, V40, P235; BLAKEMORE WF, 1985, J NEUROL SCI, V7, P207; BOLIN LM, 1993, J CELL BIOL, V123, P237, DOI 10.1083/jcb.123.1.237; BOYER PJ, 1994, EXP NEUROL, V13, P1; DUNCAN ID, 1988, J NEUROCYTOL, V17, P351, DOI 10.1007/BF01187857; GOODEARL ADJ, 1993, J BIOL CHEM, V262, P18095; HARRISON BM, 1980, J NEUROL SCI, V46, P63, DOI 10.1016/0022-510X(80)90044-1; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; RAO BB, 1993, NEW ENGL J MED, V329, P96; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; RUTKOWSKI JL, 1992, ANN NEUROL, V3, P580; WHITCOMB RW, 1988, J CLIN INVEST, V8, P185	16	4	4	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					24	25		10.1038/nm0195-24	http://dx.doi.org/10.1038/nm0195-24			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584947				2022-12-27	WOS:A1995QX55700020
J	Hamill, MB; Koch, DD				Hamill, MB; Koch, DD			Refractive surgery - The cutting edge	NATURE MEDICINE			English	Editorial Material											Hamill, MB (corresponding author), BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030, USA.							BRINT SF, 1996, ASCRS JUN; DURNEV VV, 1976, 5TH ALL UN C INV RAT, P106; FLANDER DC, 1995, J REFRACT SURG S, V11, pS234; Fyodorov SN, 1977, PRESSING PROBLEMS OP, P47; LESHER M, 1996, ASCRS JUN; Nose W, 1996, J REFRACT SURG, V12, P20; SCHANZLIN DJ, 1996, ASCRS JUN; Verity SM, 1995, OPHTHALMOLOGY, V102, P1908, DOI 10.1016/S0161-6420(95)30776-2; WARING GO, 1994, ARCH OPHTHALMOL-CHIC, V112, P1298, DOI 10.1001/archopht.1994.01090220048022	9	2	2	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					740	741		10.1038/nm0796-740	http://dx.doi.org/10.1038/nm0796-740			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673912				2022-12-27	WOS:A1996UU68000022
J	Lutzker, SG; Levine, AJ				Lutzker, SG; Levine, AJ			A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation	NATURE MEDICINE			English	Article							WILD-TYPE P53; TESTICULAR CANCER; MDM-2 ONCOGENE; TUMOR-ANTIGEN; C-MYC; APOPTOSIS; GENE; EXPRESSION; TRANSFORMATION; MUTATIONS	Testicular teratocarcinomas never contain p53 gene mutations even though these tumors express high levels of nuclear p53 protein. We have characterized two murine teratocarcinoma cell lines and find no evidence that endogenous p53-regulated genes are correspondingly upregulated. Differentiation of these teratocarcinoma cells with retinoic acid results in a marked decrease in p53 protein levels but is accompanied by a marked increase in p53-mediated transcriptional activity. Together these results support the hypothesis that the p53 protein in undifferentiated teratocarcinoma cells is transcriptionally inactive and accounts for the lack of selection for p53 gene mutations in this tumor type. These teratocarcinoma cells undergo p53-mediated apoptosis in response to DNA damage, which may explain the routine cures of human testicular tumors with combination chemotherapy.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,NEW BRUNSWICK,NJ 08901	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Lutzker, SG (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08540, USA.				PHS HHS [P01 41086] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHAMPLIN R, 1987, BLOOD, V69, P1551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KASTAN MB, 1991, CANCER RES, V51, P6304; LANGLEY RE, 1994, INT J RADIAT BIOL, V65, P605, DOI 10.1080/09553009414550691; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEWIS DJ, 1994, J UROLOGY, V152, P418, DOI 10.1016/S0022-5347(17)32753-2; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCJEHUHLE C, 1991, INT J CANCER, V47, P461; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MURTY VVVS, 1994, ONCOGENE, V9, P2245; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PENG HQ, 1993, CANCER RES, V53, P3574; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; POTTERN LM, 1986, PRINCIPLES MANAGEMEN, P108; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHENKMAN NS, 1995, J UROLOGY, V154, P617, DOI 10.1016/S0022-5347(01)67122-2; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; STRICKLAND S, 1980, CELL, V21; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	57	194	199	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					804	810		10.1038/nm0796-804	http://dx.doi.org/10.1038/nm0796-804			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673928				2022-12-27	WOS:A1996UU68000038
J	Rubin, H				Rubin, H			Serine protease inhibitors (serpins): Where mechanism meets medicine	NATURE MEDICINE			English	Editorial Material											Rubin, H (corresponding author), UNIV PENN,MED CTR,PHILADELPHIA,PA 19104, USA.							CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; PLOTNICK MI, IN PRESS BIOCH; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	14	47	49	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					632	633		10.1038/nm0696-632	http://dx.doi.org/10.1038/nm0696-632			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640547				2022-12-27	WOS:A1996UN69100024
J	Shibata, D; Navidi, W; Salovaara, R; Li, ZH; Aaltonen, LA				Shibata, D; Navidi, W; Salovaara, R; Li, ZH; Aaltonen, LA			Somatic microsatellite mutations as molecular tumor clocks	NATURE MEDICINE			English	Article							CARCINOGENESIS; CANCER; MODEL	Microsatellite (MS) mutations can potentially unravel the past of mutator phenotype tumors, with greater genetic diversity expected in older regions. Rapid clonal expansions of xenografts were characterized by relatively homogenous MS alleles, whereas greater diversity was observed in a colorectal cancer with the greatest variation in its adjacent adenoma. A subcutaneous lung cancer metastasis demonstrated diversity consistent with its one-month clinical duration and evidence of active mitosis during dormancy. The genetic legacy inherent to multistep tumorigenesis provides direct estimates of tumor ages, with up to thousands of cell divisions and high death rates necessary to yield the observed diversities. MS molecular tumor clocks have the unique potential to systematically reconstruct the early and occult evolution of individual human mutator phenotype tumors.	UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90033; HAARTMAN INST,DEPT PATHOL,FIN-00014 HELSINKI,FINLAND; HAARTMAN INST,DEPT MED GENET,FIN-00014 HELSINKI,FINLAND	University of Southern California	Shibata, D (corresponding author), UNIV SO CALIF,SCH MED,DEPT PATHOL,1200 N STATE ST,LOS ANGELES,CA 90033, USA.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286	NATIONAL CANCER INSTITUTE [R01CA058704, P30CA014089] Funding Source: NIH RePORTER; NCI NIH HHS [CA58704, 5 P30 CA14089-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GOLDSTEIN DB, 1995, GENETICS, V139, P463; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIMURA M, 1978, P NATL ACAD SCI USA, V75, P2868, DOI 10.1073/pnas.75.6.2868; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5322; LOEB LA, 1991, CANCER RES, V51, P3075; MANOUKIAN EB, 1986, MODERN CONCEPTS THEO, P126; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SHIBATA D, 1992, AM J PATHOL, V141, P539; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SLATKIN M, 1995, GENETICS, V139, P457; STEEL G. G., 1967, EUR J CANCER, V3, P381, DOI 10.1016/0014-2964(67)90022-9; STEEL GG, 1977, GROWTH KINETICS TUMO, P185; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VALDES AM, 1993, GENETICS, V133, P737; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WELIN S, 1963, AMER J ROENTGENOL RA, V90, P673; Wheelock E F, 1981, Adv Cancer Res, V34, P107; ZUCKERKANDL EMILE, 1965, P97	30	89	90	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					676	681		10.1038/nm0696-676	http://dx.doi.org/10.1038/nm0696-676			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640559				2022-12-27	WOS:A1996UN69100036
J	Manome, Y; Wen, PY; Dong, YH; Tanaka, T; Mitchell, BS; Kufe, DW; Fine, HA				Manome, Y; Wen, PY; Dong, YH; Tanaka, T; Mitchell, BS; Kufe, DW; Fine, HA			Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo	NATURE MEDICINE			English	Article							HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ACUTE MYELOCYTIC-LEUKEMIA; HUMAN ADENOVIRUS TYPE-5; DNA POLYMERASE; GENE-TRANSFER; RAT MODEL; ARA-C; ADRIAMYCIN; TRANSPORT; TOXICITY	Cytosine arabinoside (ara-C) is a cytidine analog that incorporates into replicating DNA and induces lethal DNA strand breaks. Although ara-C is a potent antitumor agent for hematologic malignancies, it has only minimal activity against most solid tumors. The rate-limiting step in intracellular ara-C activation is phosphorylation of the prodrug by deoxycytidine kinase (dCK). The present results demonstrate that both retroviral and adenoviral vector-mediated transduction of the dCK cDNA results in marked sensitization of glioma cell lines to the cytotoxic effects of ara-C in vitro. We also demonstrate that ara-C treatment of established intradermal and intracerebral gliomas transduced with dCK results in significant antitumor effects in vivo. These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy.	DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27599	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wen, Patrick/AAE-3776-2022	Manome, Yoshinobu/0000-0002-8755-8976				ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; CADMAN E, 1977, CANCER TREAT REP, V61, P1109; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; COLLY LP, 1984, LEUKEMIA RES, V8, P945, DOI 10.1016/0145-2126(84)90048-1; COLLY LP, 1986, CANCER RES, V46, P3825; COLLY LP, 1982, MED PEDIAT ONCOL S1, V209, P209; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; EARLY AP, 1982, CANCER RES, V42, P1587; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; FREEMAN SM, 1993, CANCER RES, V53, P5274; GRAHAM FL, 1970, CANCER RES, V30, P2636; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KOBAYASHI N, 1980, J NEUROSURG, V53, P808, DOI 10.3171/jns.1980.53.6.0808; KUFE D, 1984, BLOOD, V64, P54; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MANOME Y, 1994, CANCER RES, V54, P5408; MANOME Y, 1993, BIOCHEM PHARMACOL, V45, P1677, DOI 10.1016/0006-2952(93)90309-K; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; OHNO Y, 1988, CANCER RES, V48, P1494; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; TAPSCOTT SJ, 1994, P NATL ACAD SCI USA, V91, P8185, DOI 10.1073/pnas.91.17.8185; VAUGHAN WP, 1983, CANCER RES, V43, P2005; WILEY JS, 1982, J CLIN INVEST, V69, P479, DOI 10.1172/JCI110472	35	102	108	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					567	573		10.1038/nm0596-567	http://dx.doi.org/10.1038/nm0596-567			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616717				2022-12-27	WOS:A1996UJ23000041
J	Gupta, S; Maiden, MCJ; Feavers, IM; Nee, S; May, RM; Anderson, RM				Gupta, S; Maiden, MCJ; Feavers, IM; Nee, S; May, RM; Anderson, RM			The maintenance of strain structure in populations of recombining infectious agents	NATURE MEDICINE			English	Article							HORIZONTAL GENETIC EXCHANGE; OUTER-MEMBRANE PROTEINS; PLASMODIUM-FALCIPARUM; TRANSMISSION DYNAMICS; NEISSERIA-MENINGITIDIS; ANTIGENIC DIVERSITY; ESCHERICHIA-COLI; IMMUNE-RESPONSE; SURFACE; MALARIA	Using mathematical models that combine population genetic and epidemiological processes, we resolve the paradox that many important pathogens appear to persist as discrete strains despite the constant exchange of genetic material. We show that dominant polymorphic determinants (that is, those that elicit the most effective immune responses) will be organized into nonoverlapping combinations as a result of selection by the host immune system, thereby defining a set of discrete independently transmitted strains. By analysing 222 isolates of Neisseria meningitidis, we show that two highly polymorphic epitopes of the outer membrane protein PorA exist in nonoverlapping combinations as predicted by this general framework. The model indicates that dominant polymorphic determinants will be in linkage disequilibrium, despite frequent genetic exchange, even though they may be encoded by several unlinked genes. This suggests that the detection of nonrandom associations between epitope regions can be employed as a novel strategem for identifying dominant polymorphic antigens.	NATL INST BIOL STAND & CONTROLS, DIV BACTERIOL, POTTERS BAR EN6 3QG, HERTS, ENGLAND	National Institute for Biological Standards & Control	Gupta, S (corresponding author), UNIV OXFORD, DEPT ZOOL, WELLCOME CTR EPIDEMIOL INFECT DIC, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Maiden, Martin/N-6805-2019; Maiden, Martin C J/C-5055-2014	Maiden, Martin/0000-0001-6321-5138; Maiden, Martin C J/0000-0001-6321-5138; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BOLLYKY PL, IN PRESS J MOL EVOL; CARMAN WF, 1993, VIRAL HEPATITIS SCI, P115; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; CRAVEN DE, 1980, J INFECT DIS, V142, P556, DOI 10.1093/infdis/142.4.556; DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993; DESJARDINS P, 1995, J MOL EVOL, V41, P440, DOI 10.1007/BF00160315; FEAVERS IM, 1992, MOL MICROBIOL, V6, P489, DOI 10.1111/j.1365-2958.1992.tb01493.x; FEAVERS IM, IN PRESS CLIN DIAGN; GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367; GUPTA S, 1994, PARASITOL TODAY, V10, P476, DOI 10.1016/0169-4758(94)90160-0; GUPTA S, 1994, P ROY SOC B-BIOL SCI, V256, P231, DOI 10.1098/rspb.1994.0075; GUPTA S, 1994, PARASITE IMMUNOL, V16, P361, DOI 10.1111/j.1365-3024.1994.tb00361.x; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Hartl D., 1989, PRINCIPLES POPULATIO; HAYES LJ, 1995, J INFECT DIS, V172, P268, DOI 10.1093/infdis/172.1.268; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HUGHES AL, 1992, MOL BIOL EVOL, V9, P381; Jones T R, 1993, Prog Clin Parasitol, V3, P103; LEVIN BR, 1981, GENETICS, V99, P1; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MAIDEN MCJ, 1991, MOL MICROBIOL, V5, P727, DOI 10.1111/j.1365-2958.1991.tb00743.x; MAIDEN MCJ, 1993, FEMS MICROBIOL LETT, V112, P243, DOI 10.1111/j.1574-6968.1993.tb06457.x; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; MANDRELL RE, 1989, INFECT IMMUN, V57, P1590, DOI 10.1128/IAI.57.5.1590-1598.1989; NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; SPRATT BG, 1995, SYMP SOC GEN MICROBI, V52, P143; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUKER J, 1994, MOL MICROBIOL, V12, P253, DOI 10.1111/j.1365-2958.1994.tb01014.x; TIBAYRENC M, 1994, PARASITOL TODAY, V10, P456, DOI 10.1016/0169-4758(94)90152-X; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; WALLIKER D, 1989, EXP PARASITOL, V69, P303, DOI 10.1016/0014-4894(89)90078-7; WIERTZ EJHJ, 1991, J IMMUNOL, V147, P2012; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514	41	213	214	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1996	2	4					437	442		10.1038/nm0496-437	http://dx.doi.org/10.1038/nm0496-437			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597954				2022-12-27	WOS:A1996UD31400046
J	Serra, R; Moses, HL				Serra, R; Moses, HL			Tumor suppressor genes in the TGF-beta signaling pathway?	NATURE MEDICINE			English	Editorial Material									VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37323	Vanderbilt University	Serra, R (corresponding author), VANDERBILT UNIV,MED CTR,VANDERBILT CANC CTR,NASHVILLE,TN 37323, USA.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616	15	43	47	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					390	391		10.1038/nm0496-390	http://dx.doi.org/10.1038/nm0496-390			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597940				2022-12-27	WOS:A1996UD31400032
J	Hamilton, BS				Hamilton, BS			A new role for a fat actor	NATURE MEDICINE			English	Editorial Material											Hamilton, BS (corresponding author), SUNNYBROOK HLTH SCI CTR,N YORK,ON M4N 3M5,CANADA.							BARINAGA M, 1995, SCIENCE, V269, P475, DOI 10.1126/science.7624769; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MCLACHLAN RI, 1987, ENDOCRINOL METAB, P957; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	13	6	8	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					272	273		10.1038/nm0396-272	http://dx.doi.org/10.1038/nm0396-272			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612218				2022-12-27	WOS:A1996TY64000028
J	Pai, LH; Wittes, R; Setser, A; Willingham, MC; Pastan, I				Pai, LH; Wittes, R; Setser, A; Willingham, MC; Pastan, I			Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; PHASE-I; THERAPY; CANCER	Immunotoxin LMB-1 is composed of monoclonal antibody B3 chemically linked to PE38, a genetically engineered form of Pseudomonas exotoxin. B3 recognizes a carbohydrate antigen (Le(Y)) present on many human solid tumors(1). LMB-1 has excellent antitumor activity in nude mice bearing Le(Y)-positive tumors(2). We conducted a phase I study of 38 patients with solid tumors who failed conventional therapy and whose tumors expressed the Le(Y) antigen. Objective antitumor activity was observed in 5 patients, 18 had stable disease, 15 progressed. A complete remission was observed in a patient with metastatic breast cancer to supraclavicular nodes. A greater than 75% tumor reduction and resolution of all clinical symptoms lasting for more than six months was observed in a colon cancer patient with extensive retroperitoneal and cervical metastasis. Three patients (two colon, one breast cancer) had minor responses. The maximum tolerated dose of LMB-1 is 75 mu g/kg given intravenously three times every other day. The major toxicity is vascular leak syndrome manifested by hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary edema. Although immunotoxins have been evaluated in clinical studies for more than two decades, this is the first report of antitumor activity in epithelial tumors.	NCI,NIH,MED BRANCH,BETHESDA,MD 20892; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina	Pai, LH (corresponding author), NCI,NIH,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; FRENCH RR, 1995, LANCET, V346, P223, DOI 10.1016/S0140-6736(95)91271-1; GOULD BJ, 1989, J NATL CANCER I, V81, P775, DOI 10.1093/jnci/81.10.775; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JAIN RK, 1988, CANCER RES, V48, P7022; KONDO T, 1988, J BIOL CHEM, V263, P9470; KUAN CT, IN PRESS CLIN CANC R; PAI LH, 1993, JAMA-J AM MED ASSOC, V269, P78, DOI 10.1001/jama.269.1.78; PAI LH, 1995, BIOL THERAPY CANC, P521; PASTAN I, 1991, CANCER RES, V51, P3781; PASTAN IH, 1995, ANN NY ACAD SCI, V758, P345, DOI 10.1111/j.1749-6632.1995.tb24840.x; ROSCOE DM, 1994, INFECT IMMUN, V62, P5055, DOI 10.1128/IAI.62.11.5055-5065.1994; VITETTA ES, 1991, CANCER RES, V51, P4052; WANG QC, 1993, CANCER RES, V53, P4588; WILLINGHAM MC, 1990, FOCUS, V12, P62; YOSHIMOTO T, 1986, JPN J CANCER RES, V77, P1264	17	194	206	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					350	353		10.1038/nm0396-350	http://dx.doi.org/10.1038/nm0396-350			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612238				2022-12-27	WOS:A1996TY64000048
J	Kovacs, DM; Fausett, HJ; Page, KJ; Kim, TW; Moir, RD; Merriam, DE; Hollister, RD; Hallmark, OG; Mancini, R; Felsenstein, KM; Hyman, BT; Tanzi, RE; Wasco, W				Kovacs, DM; Fausett, HJ; Page, KJ; Kim, TW; Moir, RD; Merriam, DE; Hollister, RD; Hallmark, OG; Mancini, R; Felsenstein, KM; Hyman, BT; Tanzi, RE; Wasco, W			Alzheimer-associated presenilins 1 and 2: Neuronal expression in brain and localization to intracellular membranes in mammalian cells	NATURE MEDICINE			English	Article							BETA-PROTEIN PRECURSOR; DISEASE	Mutations in two recently identified genes appear to cause the majority of early-onset familial Alzheimer's disease (FAD). These two novel genes, presenilin 1 (PS1) and presenilin 2 (PS2) are members of an evolutionarily conserved gene family. The normal biological role(s) of the presenilins and the mechanism(s) by which the FAD-associated mutations exert their effect remain unknown. Employing in situ hybridization, we demonstrate that the expression patterns of PS1 and PS2 in the brain are extremely similar to each other and that messages for both are primarily detectable in neuronal populations. Immunochemical analyses indicate that PS1 and PS2 are similar in size and localized to similar intracellular compartments (endoplasmic reticulum and Golgi complex). FAD-associated mutations in PS1 and PS2 do not significantly modify either their migration patterns on SDS-polyacrylamide gel electrophoresis or their overall subcellular localization, although subtle differences in perinuclear staining were noted for mutant PS1.	HARVARD UNIV,MASSACHUSETTS GEN HOSP EAST,SCH MED,GENET & AGING UNIT,BOSTON,MA 02129; HARVARD UNIV,MASSACHUSETTS GEN HOSP EAST,SCH MED,DEPT NEUROL,BOSTON,MA 02129; BRISTOL MYERS SQUIBB CO,DEPT 405,WALLINGFORD,CT 06492	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Bristol-Myers Squibb			Tanzi, Rudolph/AAE-9622-2019; Moir, Robert D./M-7612-2017	Tanzi, Rudolph/0000-0002-7032-1454; Moir, Robert D./0000-0001-5431-3553				CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P337; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HYMAN BT, 1993, MOL BRAIN RES, V18, P253, DOI 10.1016/0169-328X(93)90197-W; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D., 1995, Society for Neuroscience Abstracts, V21, P1500; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIRINATHSINGHJI DS, 1993, MOL IMAGING NEUROSCI; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SORBI S, 1995, LANCET, V346, P439, DOI 10.1016/S0140-6736(95)92809-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANAHASHI H, 1995, LANCET, V346, P440, DOI 10.1016/S0140-6736(95)92810-3; TANZI RE, 1993, MOL BRAIN RES, V18, P246, DOI 10.1016/0169-328X(93)90196-V; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wasco W., 1995, NEUROBIOLOGY ALZHEIM, P51; WISDEN W, 1991, MOL NEUROBIOLOGY PRA; 1995, NAT GENET, V11, P219	24	517	534	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					224	229		10.1038/nm0296-224	http://dx.doi.org/10.1038/nm0296-224			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574969				2022-12-27	WOS:A1996TU06000044
J	Starzl, TE; Murase, N; Thomson, A; Demetris, AJ				Starzl, TE; Murase, N; Thomson, A; Demetris, AJ			Liver transplants contribute to their own success	NATURE MEDICINE			English	Editorial Material							BONE-MARROW; GRAFT ACCEPTANCE; CELL-MIGRATION; RECIPIENTS; CHIMERISM				Starzl, TE (corresponding author), PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BURLINGHAM WJ, 1995, TRANSPLANTATION, V59, P1147, DOI 10.1097/00007890-199504270-00013; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; DECKER T, 1988, EUR J IMMUNOL, V18, P697, DOI 10.1002/eji.1830180507; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; HAYS EF, 1978, EXP HEMATOL, V6, P18; KAMADA N, 1981, NATURE, V292, P840, DOI 10.1038/292840a0; LU L, 1995, J EXP MED, V182, P379, DOI 10.1084/jem.182.2.379; MONACO AP, 1976, SURGERY, V79, P384; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Murase N, 1996, TRANSPLANTATION, V61, P1, DOI 10.1097/00007890-199601150-00001; PRZEPIORKA D, 1991, AM J CLIN PATHOL, V95, P201, DOI 10.1093/ajcp/95.2.201; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1965, SURGERY, V58, P131; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; THOMSON AW, 1995, STEM CELLS, V13, P622, DOI 10.1002/stem.5530130607	22	49	52	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					163	165		10.1038/nm0296-163	http://dx.doi.org/10.1038/nm0296-163			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574958	Green Accepted			2022-12-27	WOS:A1996TU06000033
J	Nash, J; Pini, A				Nash, J; Pini, A			Making the connections in nerve regeneration	NATURE MEDICINE			English	Editorial Material							NEURITE OUTGROWTH; OPTIC-NERVE; ADHESION; MYELIN; GROWTH				Nash, J (corresponding author), UCL, DEPT BIOL, MORTIMER ST, LONDON NW1 2HE, ENGLAND.		Pini, Adrian PJ/C-5342-2009					BARTSCH U, 1995, ABSTR SOC NEUR; BEDI KS, 1992, EUR J NEUROSCI, V4, P193, DOI 10.1111/j.1460-9568.1992.tb00867.x; BJORKLUND A, 1994, NATURE, V367, P112, DOI 10.1038/367112a0; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; DEMEDINACELI L, 1989, MICROSURG, V10, P56, DOI 10.1002/micr.1920100111; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KEYNES RJ, 1990, ABSTR SOC NEUR, V16; KIERSTEAD SA, 1989, SCIENCE, V246, P255; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHAFER M, 1995, ABSTR SOC NEUR; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SHEWAN D, 1993, EUR J NEUROSCI, V5, P809, DOI 10.1111/j.1460-9568.1993.tb00932.x; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103	19	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					25	26		10.1038/nm0196-25	http://dx.doi.org/10.1038/nm0196-25			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564828				2022-12-27	WOS:A1996TP57900028
J	LAWFORD, BR; YOUNG, RM; ROWELL, JA; QUALICHEFSKI, J; FLETCHER, BH; SYNDULKO, K; RITCHIE, T; NOBLE, EP				LAWFORD, BR; YOUNG, RM; ROWELL, JA; QUALICHEFSKI, J; FLETCHER, BH; SYNDULKO, K; RITCHIE, T; NOBLE, EP			BROMOCRIPTINE IN THE TREATMENT OF ALCOHOLICS WITH THE D-2 DOPAMINE-RECEPTOR A1 ALLELE	NATURE MEDICINE			English	Article							NEUROENDOCRINE EVIDENCE; NUCLEUS-ACCUMBENS; PREFERRING P; D2 RECEPTOR; GENE; RATS; ASSOCIATION; ETHANOL; ABUSE; VULNERABILITY	Various types of alcoholics have been described and heredity has been shown to be involved in some of these types. An important role of the mesolimbic dopamine system has been suggested in the reinforcing effects of alcohol and recent molecular genetic studies are implicating the gene for the D-2 dopamine receptor (DRD2) in alcoholism. In a double-blind study, bromocriptine, a DRD2 agonist, or placebo was administered to alcoholics with either the Al (A1/A1 and A1/A2 genotypes) or only the A2 (A2/A2 genotype) allele of the DRD2 gene. The greatest improvement in craving and anxiety occurred in the bromocriptine-treated A1 alcoholics and attrition was highest in the placebo-treated A1 alcoholics. The feasibility of a pharmacogenetic approach in treating certain types of alcoholics is suggested.	UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; ROYAL BRISBANE HOSP,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT PSYCHIAT,ST LUCIA,QLD 4072,AUSTRALIA; WOLSTON PK HOSP,WACOL 4076,AUSTRALIA; DEPT VET AFFAIRS MED CTR,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; Royal Brisbane & Women's Hospital; University of Queensland			Young, Ross/AAF-2082-2021	Young, Ross/0000-0002-6806-6503				BALLDIN J, 1993, DRUG ALCOHOL DEPEN, V32, P159, DOI 10.1016/0376-8716(93)80008-3; BALLDIN JI, 1992, ALCOHOL CLIN EXP RES, V16, P71, DOI 10.1111/j.1530-0277.1992.tb00639.x; Beck AT, 1978, DEPRESSION INVENTORY; BERMAN SM, 1995, BEHAV GENET, V25, P45, DOI 10.1007/BF02197241; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BORG V, 1983, ACTA PSYCHIAT SCAND, V68, P100, DOI 10.1111/j.1600-0447.1983.tb06987.x; BORG V, 1980, CURR THER RES CLIN E, V27, P170; BRODIE MS, 1990, BRAIN RES, V580, P65; CARLSSON C, 1977, INT J CLIN PHARM BI, V15, P211; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS DE, 1994, DRUG ALCOHOL DEPEN, V34, P175, DOI 10.1016/0376-8716(94)90154-6; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; COOK CCH, 1994, J ROY SOC MED, V87, P400; DONGIER M, 1991, ALCOHOL CLIN EXP RES, V15, P970, DOI 10.1111/j.1530-0277.1991.tb05197.x; DYR W, 1993, ALCOHOL, V10, P207, DOI 10.1016/0741-8329(93)90037-O; FELDMANN HS, 1983, PSYCHIAT J U OTTAWA, V8, P30; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; Gorwood P., 1994, European Psychiatry, V9, P63; IMPERATO A, 1986, J PHARMACOL EXP THER, V239, P219; JELLINEK EM, 1960, DISEASE CONCEPT ALCO; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LEVY AD, 1991, ALCOHOL ALCOHOLISM, P417; MCBRIDE WJ, 1990, ALCOHOL, V7, P199, DOI 10.1016/0741-8329(90)90005-W; MCBRIDE WJ, 1993, ALCOHOL, V10, P387, DOI 10.1016/0741-8329(93)90025-J; MORGAN MY, 1980, GASTROENTEROLOGY, V78, P663; NOBLE EP, 1993, JAMA-J AM MED ASSOC, V270, P1547, DOI 10.1001/jama.270.13.1547; NOBLE EP, 1993, BEHAV GENET, V23, P119, DOI 10.1007/BF01067416; NOBLE EP, 1994, AM J HUM GENET, V54, P658; NOBLE EP, 1993, DRUG ALCOHOL DEPEN, V33, P271, DOI 10.1016/0376-8716(93)90113-5; NOBLE EP, 1994, INT J EAT DISORDER, V15, P205, DOI 10.1002/1098-108X(199404)15:3&lt;205::AID-EAT2260150303&gt;3.0.CO;2-P; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; PATO CN, 1993, AM J MED GENET, V48, P78, DOI 10.1002/ajmg.1320480204; RASSNICK S, 1993, ALCOHOL, V10, P127, DOI 10.1016/0741-8329(93)90091-2; REES DW, 1986, J STUD ALCOHOL, V47, P436, DOI 10.15288/jsa.1986.47.435; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; STEFANINI E, 1992, ALCOHOL ALCOHOLISM, V27, P127; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; WEISS F, 1990, PSYCHOPHARMACOLOGY, V101, P178, DOI 10.1007/BF02244123; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250	43	120	126	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					337	341		10.1038/nm0495-337	http://dx.doi.org/10.1038/nm0495-337			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585063				2022-12-27	WOS:A1995RN09800029
J	HASSAN, N; WU, GY				HASSAN, N; WU, GY			GETTING TO THE CORE OF THE MATTER	NATURE MEDICINE			English	Editorial Material							VIRUS-DNA SYNTHESIS; ASIALOGLYCOPROTEIN RECEPTOR; HEPATOCYTES; ASIALOFETUIN; INHIBITION; DELIVERY; RESCUE; MODEL; CELLS				HASSAN, N (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.							ASHWELL G, 1974, ADV ENZYMOL, V4, P99; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; CERENZIA MRT, 1994, J HEPATOL, V20, P307, DOI 10.1016/S0168-8278(05)80076-5; FIUME L, 1979, FEBS LETT, V103, P47, DOI 10.1016/0014-5793(79)81247-8; FIUME L, 1980, FEBS LETT, V116, P185, DOI 10.1016/0014-5793(80)80639-9; FLOREN CH, 1978, BIOCHEM J, V168, P493; GREGORIADIS G, 1993, DRUGS, V45, P15, DOI 10.2165/00003495-199345010-00003; HUBER BE, 1992, MOL PHARMACOL, V41, P639; MOMMAASKIENHUIS AM, 1985, EUR J CELL BIOL, V38, P42; MU JZ, 1993, AM J PHYSIOL, V264, pG752, DOI 10.1152/ajpgi.1993.264.4.G752; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; VANDERSLUIJS P, 1990, HEPATOLOGY, V6, P723; WU GY, 1985, HEPATOLOGY, V5, P709, DOI 10.1002/hep.1840050502; WU GY, 1983, P NATL ACAD SCI-BIOL, V80, P3078, DOI 10.1073/pnas.80.10.3078	14	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					210	211		10.1038/nm0395-210	http://dx.doi.org/10.1038/nm0395-210			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585034				2022-12-27	WOS:A1995QX55900024
J	HOLMGREN, L; OREILLY, MS; FOLKMAN, J				HOLMGREN, L; OREILLY, MS; FOLKMAN, J			DORMANCY OF MICROMETASTASES - BALANCED PROLIFERATION AND APOPTOSIS IN THE PRESENCE OF ANGIOGENESIS SUPPRESSION	NATURE MEDICINE			English	Article							TUMOR-GROWTH; MONOCLONAL-ANTIBODY; CELL-DEATH; METASTASIS; INDUCTION; SURVIVAL; PROTEIN; CANCER; RATS; MICE	In cancer patients, dormant micrometastases are often asymptomatic and clinically undetectable, for months or years, until relapse. We have studied dormant lung metastases under angiogenesis suppression in mice. The metastases exhibited rapid growth when the inhibition of angiogenesis was removed. Tumour cell proliferation, as measured by bromodeoxyuridine incorporation and immunohistochemical staining proliferating cell nuclear antigen, was not significantly different in dormant and growing metastases. However, tumour cells of dormant metastases exhibited a more than threefold higher incidence of apoptosis. These data show that metastases remain dormant when tumour cell proliferation is balanced by an equivalent rate of cell death and suggest that angiogenesis inhibitors control metastatic growth by indirectly increasing apoptosis in tumour cells.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	HOLMGREN, L (corresponding author), HARVARD UNIV,CHILDRENS HOSP,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							ANTOINE N, 1994, CANCER RES, V54, P2073; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BREM H, 1993, J PEDIATR SURG, V28, P445, DOI 10.1016/0022-3468(93)90246-H; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CROWLEY NJ, 1992, ARCH SURG-CHICAGO, V127, P1303; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; DEVITA VT, 1993, CANCER PRINCIPLES PR, P134; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HORI A, 1991, CANCER RES, V51, P6180; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MELTZER A, 1990, J SURG ONCOL, V43, P181, DOI 10.1002/jso.2930430312; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NICOSIA RF, 1983, CANCER RES, V43, P2159; NOBLE RL, 1975, CANCER RES, V35, P2935; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAFFMC, 1992, NATURE, V356, P397; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; Wheelock E F, 1981, Adv Cancer Res, V34, P107; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WOODRUFF M, 1982, BRIT J CANCER, V46, P313, DOI 10.1038/bjc.1982.206; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057	37	1535	1602	2	41	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					149	153		10.1038/nm0295-149	http://dx.doi.org/10.1038/nm0295-149			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585012				2022-12-27	WOS:A1995QX55800026
J	LICHTENBERGER, LM; WANG, ZM; ROMERO, JJ; ULLOA, C; PEREZ, JC; GIRAUD, MN; BARRETO, JC				LICHTENBERGER, LM; WANG, ZM; ROMERO, JJ; ULLOA, C; PEREZ, JC; GIRAUD, MN; BARRETO, JC			NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) ASSOCIATE WITH ZWITTERIONIC PHOSPHOLIPIDS - INSIGHT INTO THE MECHANISM AND REVERSAL OF NSAID-INDUCED GASTROINTESTINAL INJURY	NATURE MEDICINE			English	Article							CANINE GASTRIC-MUCOSA; SURFACE HYDROPHOBICITY; RAT; ASPIRIN; PROSTAGLANDIN; ABSORPTION; INHIBITION; ORGANELLES; CELLS	The molecular basis of the injurious actions of non-steroidal anti-inflammatory drugs (NSAIDs) on the gastrointestinal (GI) tract is only partly understood. In this study we have obtained evidence, employing both in vitro and in vivo systems, that five NSAIDs have the ability to form a chemical association with zwitterionic phospholipids. Since this same class of phospholipids line the luminal aspects of the mucus gel layer to provide it with non-wettable properties, this intermolecular association may be the mechanism by which NSAIDs attenuate the hydrophobic barrier properties of the upper GI tract. Preassociating a number of NSAIDs with exogenous zwitterionic phospholipids prevented this increase in surface wettability of the mucus gel layer and protected rats against the injurious GI side-effects of these drugs, while enhancing their lipid permeability, antipyretic and anti-inflammatory activity.	UNIV TEXAS,SCH MED,DEPT SURG,HOUSTON,TX 77030	University of Texas System	LICHTENBERGER, LM (corresponding author), UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77030, USA.		gf, mn/N-1593-2016	gf, mn/0000-0003-3228-6827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS SS, 1968, J PHARM PHARMACOL, V20, P305, DOI 10.1111/j.2042-7158.1968.tb09744.x; ALEXANDER AM, 1985, J CLIN HOSP PHARM, V10, P89; ALLISON MC, 1992, NEW ENGL J MED, V32, P749; ALPSTEN M, 1982, EUR J CLIN PHARMACOL, V22, P57, DOI 10.1007/BF00606426; CASTRO GA, 1980, J PARASITOL, V66, P407, DOI 10.2307/3280739; CHEN, 1993, GASTROENTEROLOGY, V104, pA53; CLATWORTHY AL, 1994, J NEUROSCI, V14, P3263; GODDARD PJ, 1987, AM J PHYSIOL, V252, pG421, DOI 10.1152/ajpgi.1987.252.3.G421; GODDARD PJ, 1990, GASTROENTEROLOGY, V98, P361, DOI 10.1016/0016-5085(90)90826-M; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P675, DOI 10.1016/S0016-5085(89)80064-2; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; JOLOBE OMP, 1984, DIGESTION, V29, P164, DOI 10.1159/000199027; KAO YCJ, 1991, GASTROENTEROLOGY, V101, P7, DOI 10.1016/0016-5085(91)90454-S; KAO YCJ, 1990, GASTROENTEROLOGY, V98, P592, DOI 10.1016/0016-5085(90)90278-9; KAO YCJ, 1993, GASTROENTEROLOGY, V104, P103, DOI 10.1016/0016-5085(93)90841-Y; LICHTENBERGER LM, 1983, SCIENCE, V219, P1327, DOI 10.1126/science.6828859; LIGUMSKY M, 1982, AM J PHYSIOL, V242, pG337, DOI 10.1152/ajpgi.1982.242.4.G337; MCCORMACK K, 1987, ARCH TOXICOL, V60, P261, DOI 10.1007/BF01234664; MOJAVERIAN P, 1987, CLIN PHARMACOL THER, V41, P11, DOI 10.1038/clpt.1987.3; RAINSFORD KD, 1989, SCAND J GASTROENTERO, V24, P9, DOI 10.3109/00365528909091169; RAINSFORDKD, 1985, ANTI INFLAMMATORY AN, V1; UCELAY M, 1988, ARZNEIMITTELFORSCH, V38-1, P546; WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0; WHITTLE BJR, 1981, GASTROENTEROLOGY, V80, P94	24	259	276	2	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					154	158		10.1038/nm0295-154	http://dx.doi.org/10.1038/nm0295-154			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585013				2022-12-27	WOS:A1995QX55800027
J	SIMERLY, C; WU, GJ; ZORAN, S; ORD, T; RAWLINS, R; JONES, J; NAVARA, C; GERRITY, M; RINEHART, J; BINOR, Z; ASCH, R; SCHATTEN, G				SIMERLY, C; WU, GJ; ZORAN, S; ORD, T; RAWLINS, R; JONES, J; NAVARA, C; GERRITY, M; RINEHART, J; BINOR, Z; ASCH, R; SCHATTEN, G			THE PATERNAL INHERITANCE OF THE CENTROSOME, THE CELLS MICROTUBULE-ORGANIZING CENTER, IN HUMANS, AND THE IMPLICATIONS FOR INFERTILITY	NATURE MEDICINE			English	Article							GAMMA-TUBULIN; MOUSE OOCYTES; SEA-URCHIN; FERTILIZATION; CENTRIOLES; RABBIT; CYCLE	Successful fertilization in humans, achieved when parental chromosomes intermix at first mitosis, requires centrosome restoration and microtubule-mediated motility. Imaging of inseminated human oocytes reveals that the sperm introduces the centrosome. The centrosome then nucleates the new microtubule assembly to form the sperm aster - a step essential for successful fertilization. Oocytes from some infertile patients failed to complete fertilization because of defects in uniting the sperm and egg nuclei, indicating that failure to properly effect the cytoplasmic motions uniting the nuclei results in human infertility. These discoveries have important implications for infertility diagnosis and managing reproduction.	UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV WISCONSIN,WISCONSIN REG PRIMATE RES CTR,MADISON,WI 53706; UNIV WISCONSIN,DEPT OBSTET & GYNECOL,MADISON,WI 53706; UNIV CALIF IRVINE,IRVINE MED CTR,CTR REPROD HLTH,ORANGE,CA 92668; RUSH UNIV,REPROD ENDOCRINOL & INFERTIL SECT,CHICAGO,IL 60612; GLENBROOK HOSP,ASSISTED REPROD TECHNOL PROGRAM,GLENVIEW,IL 60025	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine; Rush University; NorthShore University Health System			simerly, Calvin/AAC-9564-2021; Navara, Christopher/C-2813-2011; Schatten, Gerald/B-3253-2009	Schatten, Gerald/0000-0001-5206-7782				ARCHER J, 1994, CELL, V76, P589, DOI 10.1016/0092-8674(94)90496-0; BORRERO C, 1989, HUM REPROD, V4, P275, DOI 10.1093/oxfordjournals.humrep.a136887; BOVERI T, 1901, ZELIEN STUDIEN NATUR, V4; BREED W, 1994, DEV BIOL B, P230; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; FUKUI Y, 1988, J REPROD FERTIL, V82, P337, DOI 10.1530/jrf.0.0820337; HILL DP, 1993, DEV BIOL, V1136, P154; KIMBLE M, 1992, INT REV CYTOL, V136, P1, DOI 10.1016/S0074-7696(08)62049-5; LEGUEN P, 1989, EUR J CELL BIOL, V48, P239; LONG CR, 1993, MOL REPROD DEV, V36, P23, DOI 10.1002/mrd.1080360105; LONGO FJ, 1976, J CELL BIOL, V69, P539, DOI 10.1083/jcb.69.3.539; MARO B, 1985, J CELL BIOL, V101, P1665, DOI 10.1083/jcb.101.5.1665; MAZIA D, 1987, INT REV CYTOL, V100, P49; NAVARA CS, 1994, DEV BIOL, V162, P29, DOI 10.1006/dbio.1994.1064; PALACIOS MJ, 1993, J CELL SCI, V104, P383; PALERMO G, 1994, HUM REPROD, V9, P1220, DOI 10.1093/oxfordjournals.humrep.a138682; PICKERING SJ, 1988, HUM REPROD, V3, P978, DOI 10.1093/oxfordjournals.humrep.a136828; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; Rose MD, 1993, CURR OPIN CELL BIOL, V5, P105, DOI 10.1016/S0955-0674(05)80015-8; SATHANANTHAN AH, 1991, P NATL ACAD SCI USA, V88, P4806, DOI 10.1073/pnas.88.11.4806; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4152, DOI 10.1073/pnas.82.12.4152; SCHATTEN H, 1989, GAMETE RES, V23, P309, DOI 10.1002/mrd.1120230308; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; SIMERLY C, 1993, METHOD ENZYMOL, V225, P516; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SZOLLOSI D, 1991, BIOL CELL, V72, P61, DOI 10.1016/0248-4900(91)90079-3; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; WINSTON N, 1991, FERTIL STERIL, V56, P204; YLLERAFERNANDEZ MD, 1992, MOL REPROD DEV, V32, P271, DOI 10.1002/mrd.1080320313; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	36	214	222	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					47	52		10.1038/nm0195-47	http://dx.doi.org/10.1038/nm0195-47			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584952				2022-12-27	WOS:A1995QX55700025
J	Hantraye, P; Brouillet, E; Ferrante, R; Palfi, S; Dolan, R; Matthews, RT; Beal, MF				Hantraye, P; Brouillet, E; Ferrante, R; Palfi, S; Dolan, R; Matthews, RT; Beal, MF			Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons	NATURE MEDICINE			English	Article							DOPAMINERGIC-NEURONS; SUPEROXIDE-DISMUTASE; 7-NITRO INDAZOLE; RAT STRIATUM; NEUROTOXICITY; DISEASE; LESIONS; MODEL; PEROXYNITRITE; MECHANISMS	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces clinical, biochemical and neuropathologic changes reminiscent of those which occur in idiopathic Parkinson's disease. 7-Nitroindazole (7-NI) is a relatively selective inhibitor of the neuronal isoform of nitric oxide synthase (NOS) that blocks MPTP neurotoxicity in mice. We now show that 7-NI protects against profound striatal dopamine depletions and loss of tyrosine hydroxylase-positive neurons in the substantia nigra in MPTP-treated baboons. Furthermore, 7-NI protected against MPTP-induced motor and frontal-type cognitive deficits. These results strongly implicate a role of nitric oxide in MPTP neurotoxicity and suggest that inhibitors of neuronal NOS might be useful in treating Parkinson's disease.	MASSACHUSETTS GEN HOSP, NEUROL SERV, NEUROCHEM LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; SERV HOSP FREDERIC JOLIOT, CEA, CNRS URA 2210, ORSAY, FRANCE; VET AFFAIRS MED CTR, GERIATR RES EDUC CLIN CTR, BEDFORD, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University			Brouillet, Emmanuel/B-4784-2014	Brouillet, Emmanuel/0000-0001-6322-7403	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P01NS016367, P50NS016367, P50NS010828] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12922-01] Funding Source: Medline; NINDS NIH HHS [NS 16367, NS 10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BEAL MF, 1990, NEUROSCI LETT, V108, P36; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; FORNO LS, 1986, ANN NEUROL, V20, P449, DOI 10.1002/ana.410200403; GERMAN DC, 1988, NEUROSCIENCE, V24, P161, DOI 10.1016/0306-4522(88)90320-X; HANTRAYE P, 1993, NEUROSCIENCE, V53, P169, DOI 10.1016/0306-4522(93)90295-Q; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LIN AMY, 1995, J NEUROCHEM, V65, P2043; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LONART G, 1994, J NEUROCHEM, V63, P2108; PALFI S, IN PRESS J NEUROSCI; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; SCHNEIDER JS, 1992, VULN BRAIN ENV, P293; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Schulz JB, 1995, J NEUROSCI, V15, P8419; SILVA MT, 1995, BRIT J PHARMACOL, V114, P257, DOI 10.1111/j.1476-5381.1995.tb13219.x; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; VARASTET M, 1994, NEUROSCIENCE, V63, P47, DOI 10.1016/0306-4522(94)90006-X; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241	29	382	388	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					1017	1021		10.1038/nm0996-1017	http://dx.doi.org/10.1038/nm0996-1017			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782460				2022-12-27	WOS:A1996VF49700037
J	Wilson, JM				Wilson, JM			A pharmacologic rheostat for gene therapy	NATURE MEDICINE			English	Editorial Material											Wilson, JM (corresponding author), UNIV PENN HLTH SYST,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SCHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904	4	4	5	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					977	978		10.1038/nm0996-977	http://dx.doi.org/10.1038/nm0996-977			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782453				2022-12-27	WOS:A1996VF49700030
J	Waisman, A; Ruiz, PJ; Hirschberg, DL; Gelman, A; Oksenberg, JR; Brocke, S; Mor, F; Cohen, IR; Steinman, L				Waisman, A; Ruiz, PJ; Hirschberg, DL; Gelman, A; Oksenberg, JR; Brocke, S; Mor, F; Cohen, IR; Steinman, L			Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity	NATURE MEDICINE			English	Article							MYELIN-BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; V-BETA-6.1 CDR2 PEPTIDES; MULTIPLE-SCLEROSIS; LYMPHOCYTE-T; TCR PEPTIDES; IMMUNIZATION; DISEASE; ANTIBODY; THERAPY	A variable region gene of the T-cell receptor, V beta 8.2, is rearranged, and its product is expressed on pathogenic T cells that induce experimental autoimmune encephalomyelitis (EAE) in H-2(u) mice after immunization with myelin basic protein (MBP). Vaccination of these mice with naked DNA encoding V beta 8.2 protected mice from EAE. Analysis of T cells reacting to the pathogenic portion of the MBP molecule indicated that in the vaccinated mice there was a reduction in the Th1 cytokines interleukin-2 (IL-2) and interferon-gamma. In parallel, there was an elevation in the production of IL-4, a Th2 cytokine associated with suppression of disease. A novel feature of DNA immunization for autoimmune disease, reversal of the autoimmune response from Th1 to Th2, may make this approach attractive for treatment of Th1-mediated diseases like multiple sclerosis, juvenile diabetes and rheumatoid arthritis.	WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; STANFORD UNIV,DEPT NEUROL,STANFORD,CA 94305; STANFORD UNIV,DEPT NEUROL SCI,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	Weizmann Institute of Science; Weizmann Institute of Science; Stanford University; Stanford University; University of California System; University of California San Francisco			Waisman, Ari/C-7383-2015; Cohen, Irun R/B-3542-2009; Mor, Felix/K-1093-2012	Waisman, Ari/0000-0003-4304-8234; Steinman, Lawrence/0000-0002-2437-2250	NINDS NIH HHS [NS 18235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018235] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBAS AK, 1991, IMMUNOL REV, V123, P5, DOI 10.1111/j.1600-065X.1991.tb00603.x; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BOURDETTE DN, 1994, J IMMUNOL, V152, P2510; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHOU YK, 1994, J IMMUNOL, V152, P2520; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DAVIS HL, 1993, FEBS LETT, V333, P146, DOI 10.1016/0014-5793(93)80393-9; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MEDAER R, 1995, LANCET, V346, P807, DOI 10.1016/S0140-6736(95)91622-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; Sambrook J., 2002, MOL CLONING LAB MANU; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; STEINMAN L, 1995, MOL MED TODAY, V1, P79, DOI 10.1016/S1357-4310(95)92366-7; STEINMAN L, 1995, NATURE, V375, P739, DOI 10.1038/375739b0; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015; XU D, 1995, IMMUNOLOGY, V84, P173; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	37	225	241	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					899	905		10.1038/nm0896-899	http://dx.doi.org/10.1038/nm0896-899			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705860				2022-12-27	WOS:A1996UZ80400037
J	Mao, L; Lee, JS; Fan, YH; Ro, JY; Batsakis, JG; Lippman, S; Hittelman, W; Hong, WK				Mao, L; Lee, JS; Fan, YH; Ro, JY; Batsakis, JG; Lippman, S; Hittelman, W; Hong, WK			Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment	NATURE MEDICINE			English	Article							LEUKOPLAKIA	To better understand genetic alterations in oral premalignant lesions, we examined 84 oral leukoplakia samples from 37 patients who had been enrolled in a chemoprevention trial. The samples were analyzed for two microsatellite markers located at chromosomes 9p21 and 3p14. Loss of heterozygosity (LOH) at either or both loci was identified in 19 of the 37 (51%) patients. Of these 19 patients, seven (37%) have developed head and neck squamous cell carcinoma (HNSCC) while only one of 18 (6%) of patients without LOH developed HNSCC. Our data suggest that clonal genetic alterations are common in oral premalignant lesions; that multiple genetic alterations have already occurred in oral premalignant lesions, allowing at least a focal clonal expansion; and that losses of the 9p21 and 3p14 regions may be related to early processes of tumorigenesis in HNSCC. These genetic alterations in premalignant tissues may serve as markers for cancer risk assessment.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CLIN INVEST,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC HEAD & NECK MED ONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [P01 CA 52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANOCZY J, 1972, CANCER, V29, P1230, DOI 10.1002/1097-0142(197205)29:5<1230::AID-CNCR2820290515>3.0.CO;2-3; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; MAESTRO R, 1993, CANCER RES, V53, P5775; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SILVERMAN S, 1984, CANCER, V53, P563; VANDERRIET P, 1994, CANCER RES, V54, P1156; ZHANG S, 1994, CANCER RES, V54, P5060	17	411	414	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					682	685		10.1038/nm0696-682	http://dx.doi.org/10.1038/nm0696-682			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640560				2022-12-27	WOS:A1996UN69100037
J	Muthupillai, R; Ehman, RL				Muthupillai, R; Ehman, RL			Magnetic resonance elastography	NATURE MEDICINE			English	Editorial Material							TISSUE		MAYO CLIN & MAYO FDN,DEPT DIAGNOST RADIOL,ROCHESTER,MN 55905	Mayo Clinic			Qureshi, Muhammad Yasir/I-3719-2012; Muthupillai, Raja/D-6544-2017	Qureshi, Muhammad Yasir/0000-0002-9898-2318; Muthupillai, Raja/0000-0001-5041-2562				DUCK FA, 1990, PHYSICAL PROPERTIES, P225; FOWLKES JB, 1995, MED PHYS, V22, P1771, DOI 10.1118/1.597633; Krouskop T A, 1987, J Rehabil Res Dev, V24, P1; LEWA CJ, 1994, ULTRASON IEEE S CANN, V1, P691; LEWA CJ, 1995, P SOC MAGN RES NIC F, V1, P690; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; MUTHUPILLAI R, 1995, P SOC MAGN RES NIC F, V1, P189; MUTHUPILLAI R, IN PRESS MAGN RESONM; ODONNELL M, 1994, IEEE T ULTRASON FERR, V41, P314, DOI 10.1109/58.285465; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; PARKER KJ, 1990, ULTRASOUND MED BIOL, V16, P241, DOI 10.1016/0301-5629(90)90003-U; Plewes DB, 1995, JMRI-J MAGN RESON IM, V5, P733, DOI 10.1002/jmri.1880050620; SARVAZYAN A, 1994, P INT WORKSH INT ULT, V1, P69; Sarvazyan A., 1993, J ACOUST SOC AM, V93, P2329, DOI [10.1121/1.406353, DOI 10.1121/1.406353]; SKOVORODA AR, 1994, IEEE T ULTRASON FERR, V41, P302, DOI 10.1109/58.285463; YAMAKOSHI Y, 1990, IEEE T ULTRASON FERR, V37, P45, DOI 10.1109/58.46969	16	177	178	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					601	603		10.1038/nm0596-601	http://dx.doi.org/10.1038/nm0596-601			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616724				2022-12-27	WOS:A1996UJ23000049
J	Freimer, NB; Blower, S; Slatkin, M				Freimer, NB; Blower, S; Slatkin, M			Pathogens and strain diversity: Is sex disruptive?	NATURE MEDICINE			English	Editorial Material									UNIV CALIF SAN FRANCISCO,GENET PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT INTEGRAT BIOL,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Freimer, NB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,CTR NEUROBIOL & PSYCHIAT,NEUROGENET LAB,SAN FRANCISCO,CA 94143, USA.							DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HUDSON RR, 1994, J EVOLUTION BIOL, V7, P535, DOI 10.1046/j.1420-9101.1994.7050535.x; LURIA SE, 1943, GENETICS, V28, P499; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; PETERSON AC, 1995, HUM MOL GENET, V4, P887, DOI 10.1093/hmg/4.5.887; PETERSON SN, 1995, P NATL ACAD SCI USA, V92, P11829, DOI 10.1073/pnas.92.25.11829; SMITH JM, 1994, J EVOLUTION BIOL, V7, P525, DOI 10.1046/j.1420-9101.1994.7050525.x; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384	13	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					401	403		10.1038/nm0496-401	http://dx.doi.org/10.1038/nm0496-401			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597947				2022-12-27	WOS:A1996UD31400039
J	Dimitroulakos, J; Yeger, H				Dimitroulakos, J; Yeger, H			HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells	NATURE MEDICINE			English	Article							HUMAN NEURO-BLASTOMA; COENZYME-A REDUCTASE; MOLECULAR CHARACTERIZATION; COMPETITIVE INHIBITOR; MULTIDRUG-RESISTANCE; MESSENGER-RNA; GROWTH; LINE; DIFFERENTIATION; MORPHOLOGY	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, involved in de novo cholesterol synthesis and cell-cycle progression, was identified as a potential mediator of the growth inhibitory effects of retinoic acid on human neuroblastoma. a nonreversible inhibitor of HMG-CoA reductase, induced extensive that was restricted to drug-resistant P-glycoprotein-expressing neuroblastoma cell lines. This response was potentiated by dibutyryl cyclic AMP but not retinoic acid. Patients with advanced-stage metastatic neuroblastoma often display an acquired chemoresistant phenotype, which may in part be mediated by P-glycoprotein. Our studies support the application or use of HMG-CoA reductase inhibitors as potential therapeutic agents in the treatment of these patients who are refractory to chemotherapy.	HOSP SICK CHILDREN,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Dimitroulakos, Jim/AAK-3398-2020					ABERMAYOR E, 1992, LARYNGOSCOPE, V102, P1133; ADAM A, 1983, CANCER, V47, P373; AREY JB, 1975, J CLIN LAB SCI, V5, P475; BARDOW SB, 1994, CANCER RES, V54, P5036; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOLANDE RP, 1985, SURV SYN PATHOL RES, V4, P296; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHERVINSKY DS, 1993, ANTICANCER RES, V13, P93; COHN SL, 1991, PROG CLIN BIOL RES, V366, P21; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; DE LUCA LM, 1991, FASEB J, V5, P2924; DIMITROULAKOS J, 1994, CELL GROWTH DIFFER, V5, P373; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; GAETANO C, 1992, CANCER RES, V52, P4402; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GOTTESMAN MM, 1986, CANCER SURV, V5, P291; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HELSON L, 1976, J NATL CANCER I, V57, P727, DOI 10.1093/jnci/57.3.727; HOLMBERG M, 1994, ANTI-CANCER DRUG, V5, P598, DOI 10.1097/00001813-199410000-00012; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KLEINERT R, 1991, ACTA NEUROPATHOL, V82, P502, DOI 10.1007/BF00293385; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MALTESE WA, 1983, NEUROLOGY, V33, P1294, DOI 10.1212/WNL.33.10.1294; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI T, 1991, PROG CLIN BIOL RES, V366, P65; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P231; PIACENTINI M, 1993, FEBS LETT, V320, P150, DOI 10.1016/0014-5793(93)80081-5; RAMANI P, 1995, J PATHOL, V175, P13, DOI 10.1002/path.1711750104; RAMHARACK R, 1990, DNA CELL BIOL, V9, P677, DOI 10.1089/dna.1990.9.677; ROCCHI P, 1992, ANTICANCER RES, V12, P917; SEEGER RC, 1977, CANCER RES, V37, P1364; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOKOS M, 1987, AM J PATHOL, V128, P484; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WIRNALASENA J, 1991, GYNECOL ONCOL, V41, P56; WOODS WG, 1992, PEDIATRICS, V89, P114; YEGER H, 1990, CANCER RES, V50, P2794; YEGER H, 1988, DIFFERENTIATION, V39, P216, DOI 10.1111/j.1432-0436.1988.tb00095.x	51	106	108	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					326	333		10.1038/nm0396-326	http://dx.doi.org/10.1038/nm0396-326			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612233				2022-12-27	WOS:A1996TY64000043
J	SWIFT, M				SWIFT, M			SUBJECTIVE ATTACKS ON STATISTICAL SIGNIFICANCE	NATURE MEDICINE			English	Editorial Material											SWIFT, M (corresponding author), NEW YORK MED COLL,INST GENET ANAL COMMON DIS,HAWTHORNE,NY 10532, USA.							ARMITAGE P, 1971, STATISTICAL METHODS; BOICE JD, 1992, NEW ENGL J MED, V326, P1357; Fisher RA., 1925, STAT METHOD RES WORK, V11th; Fleiss JL, 1981, STAT METHODS RATES P; KOLATA G, 1991, NY TIMES        1227, pA18; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; [No title captured]	7	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1134	1134		10.1038/nm1195-1134	http://dx.doi.org/10.1038/nm1195-1134			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584979	Bronze			2022-12-27	WOS:A1995TC53700031
J	RUBY, J; BLUETHMANN, H; AGUET, M; RAMSHAW, IA				RUBY, J; BLUETHMANN, H; AGUET, M; RAMSHAW, IA			CD40 LIGAND HAS POTENT ANTIVIRAL ACTIVITY	NATURE MEDICINE			English	Article							RECOMBINANT VACCINIA VIRUS; B-CELL PROLIFERATION; INTERFERON-GAMMA; T-CELLS; DEPENDENT ACTIVATION; VIRAL REPLICATION; IMMUNE-RESPONSE; GENE FAMILY; MICE; EXPRESSION	For B cells to make antibodies against most antigens, they require help from T cells. T cell help is delivered as two signals to the B cell, one of which is via CD40 and the other can be through receptors for any of a variety of soluble cytokines. We have constructed recombinant vaccinia viruses that express the ligand for CD40 and have shown that the growth of these viruses is dramatically controlled in vivo, even in mice that lack T or B cells. In this paper, we also describe our attempts to analyse the CD40 ligand-mediated antiviral activity by studying the clearance of these viruses in mice that are deficient in important antiviral mechanisms. Thus, the antiviral activity of CD40L may represent a surprising and potent effector mechanism of T cells activated during a virus infection.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,DEPT BIOL,CH-1002 BASEL,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Roche Holding; Genentech	RUBY, J (corresponding author), JOHN CURTIN SCH MED RES,DIV CELL BIOL,VIRAL ENGN & CYTOKINES GRP,POB 334,CANBERRA,ACT 2601,AUSTRALIA.							ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; FOY TM, 1993, J EXP MED, V178, P1567, DOI 10.1084/jem.178.5.1567; GALY AHM, 1992, J IMMUNOL, V149, P775; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; HODGKIN PD, 1990, J IMMUNOL, V145, P2025; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KARUPIAH G, 1990, J IMMUNOL, V144, P290; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEDERMAN S, 1993, CURR OPIN IMMUNOL, V5, P439, DOI 10.1016/0952-7915(93)90066-2; MOHLER KM, 1993, J IMMUNOL, V151, P1548; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PAULIE S, 1989, J IMMUNOL, V142, P590; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RAMSHAW IA, 1987, NATURE, V329, P545, DOI 10.1038/329545a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUBY J, 1991, CYTOKINE, V3, P92, DOI 10.1016/1043-4666(91)90028-C; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAO X, 1993, EUR J IMMUNOL, V23, P2916, DOI 10.1002/eji.1830231128; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0	33	48	54	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					437	441		10.1038/nm0595-437	http://dx.doi.org/10.1038/nm0595-437			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585091				2022-12-27	WOS:A1995RN10000034
J	FINKEL, TH; TUDORWILLIAMS, G; BANDA, NK; COTTON, MF; CURIEL, T; MONKS, C; BABA, TW; RUPRECHT, RM; KUPFER, A				FINKEL, TH; TUDORWILLIAMS, G; BANDA, NK; COTTON, MF; CURIEL, T; MONKS, C; BABA, TW; RUPRECHT, RM; KUPFER, A			APOPTOSIS OCCURS PREDOMINANTLY IN BYSTANDER CELLS AND NOT IN PRODUCTIVELY INFECTED-CELLS OF HIV-INFECTED AND SIV-INFECTED LYMPH-NODES	NATURE MEDICINE			English	Article							CD4+ T-CELLS; ENVELOPE GLYCOPROTEIN; DEATH; AIDS; MECHANISM; DNA; LYMPHOCYTES; DEPLETION; RNA; PCR	Although 13 years have passed since identification of human immunodeficiency virus-1 (HIV-1) as the cause of AIDS, we do not yet know how HIV kills its primary target, the T cell that carries the CD4 antigen. We and others have shown an increase in the percentage of apoptotic cells among circulating CD4(+) (and CD8(+)) T cells of HIV-seropositive individuals and an increase in frequency of apoptosis with disease progression. However, it is not known if this apoptosis occurs in infected or uninfected T cells. We show here, using in situ labelling of lymph nodes from HIV-infected children and SIV-infected macaques, that apoptosis occurs predominantly in bystander cells and not in the productively infected cells themselves. These data have implications for pathogenesis and therapy, namely, arguing that rational drug therapy may involve combination agents targeting viral replication in infected cells and apoptosis of uninfected cells.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT INFECT DIS, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT CELL & STRUCT BIOL, DENVER, CO 80262 USA; NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, VIRAL PATHOGENESIS LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DIV NEWBORN MED, DEPT PEDIAT, BOSTON, MA 02111 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University	FINKEL, TH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.		Serei, Virian D/B-4616-2015; Cotton, Mark/AAQ-9936-2020	Cotton, Mark/0000-0003-2559-6034	NIAID NIH HHS [P01-AI29903A, R01-AI35513] Funding Source: Medline; PHS HHS [R01-A130575A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035513, P01AI029903] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; FOX CH, 1994, CURR PROT IMMUN; GOEBEL WS, 1992, FASEB J, V6, pA1335; GORCZYCA W, 1992, INT J ONCOL, V1, P639; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; GREENE WC, 1993, SCI AM, V269, P98, DOI 10.1038/scientificamerican0993-98; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; Kuby J., 1994, IMMUNOLOGY; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LEWIS DE, 1994, J IMMUNOL, V153, P412; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; STEIN H, 1982, CLIN HAEMATOL, V11, P531; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091	34	782	804	0	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1995	1	2					129	134		10.1038/nm0295-129	http://dx.doi.org/10.1038/nm0295-129			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585008				2022-12-27	WOS:A1995QX55800022
J	KERR, E				KERR, E			TOO MANY SCIENTISTS, TOO FEW ACADEMIC JOBS	NATURE MEDICINE			English	Editorial Material								Graduate education in the sciences is not doing its job. By preparing students only for academic research, the system neglects the range of opportunities for work in science that young scientists want and society needs.			KERR, E (corresponding author), STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,BECKMAN CTR B202,STANFORD,CA 94305, USA.								0	5	5	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					14	14		10.1038/nm0195-14	http://dx.doi.org/10.1038/nm0195-14			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584939				2022-12-27	WOS:A1995QX55700014
J	Fox, AJ; Lalloo, UG; Belvisi, MG; Bernareggi, M; Chung, KF; Barnes, PJ				Fox, AJ; Lalloo, UG; Belvisi, MG; Bernareggi, M; Chung, KF; Barnes, PJ			Bradykinin-evoked sensitization of airway sensory nerves: A mechanism for ACE-inhibitor cough	NATURE MEDICINE			English	Article							BRONCHIAL HYPERREACTIVITY; GUINEA-PIG; REFLEX	Cough accompanied by an increased sensitivity of the cough reflex is the most common symptom of inflammatory airway disease(1,5). This symptom is also frequently reported in patients receiving angiotensin-converting converting enzyme (ACE) inhibitors as therapy for heart failure or hypertension(2-4), although the underlying mechanism is unknown. We have investigated the possibility that the inflammatory peptide bradykinin, normally degraded by ACE, causes sensitization of airway sensory nerves and an enhancement of the cough reflex in conscious guinea pigs. Treatment of guinea pigs for two weeks with captopril led to an increased cough response to inhaled citric acid, which was prevented by concomitant treatment with the bradykinin receptor antagonist icatibant. A similar icatibant-sensitive enhancement of citric acid-evoked cough was seen in untreated animals after prior inhalation of bradykinin, although cough evoked by hypertonic saline was unaffected. In electrophysiological studies performed in vitro, responses of single vagal C fibers to capsaicin, applied to receptive fields of single-fiber units in the trachea, were also markedly increased after perfusion with bradykinin, whereas A delta fiber responses to hypertonic saline were unaffected. These results indicate that bradykinin-evoked sensitization of airway sensory nerves may underlie the pathogenesis of ACE-inhibitor cough. Bradykinin receptor antagonists may be of benefit in treating chronic cough seen with this and other inflammatory conditions.	NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London			Chung, Kian Fan/B-1872-2012; Belvisi, Maria G/A-3055-2009; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; CHOUDRY NB, 1992, EUR RESPIR J, V5, P296; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Forsberg K, 1988, Pulm Pharmacol, V1, P33, DOI 10.1016/0952-0600(88)90008-7; FOX AJ, 1995, NEUROSCIENCE, V67, P741, DOI 10.1016/0306-4522(95)00115-Y; FOX AJ, 1995, J PHYSIOL-LONDON, V482, P179, DOI 10.1113/jphysiol.1995.sp020508; FOX AJ, 1993, J PHYSIOL-LONDON, V469, P21, DOI 10.1113/jphysiol.1993.sp019802; HARGREAVES MR, 1995, LANCET, V345, P13, DOI 10.1016/S0140-6736(95)91151-0; HOLZER P, 1991, PHARMACOL REV, V43, P143; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082, DOI 10.1152/jappl.1995.79.4.1082; MCEWAN JR, 1989, BMJ-BRIT MED J, V299, P13, DOI 10.1136/bmj.299.6690.13; MOHAMMED SP, 1993, J PHYSIOL-LONDON, V469, P51, DOI 10.1113/jphysiol.1993.sp019804; OCONNELL F, 1995, AM J RESP CRIT CARE, V152, P2068, DOI 10.1164/ajrccm.152.6.8520777; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; TSUBONE H, 1991, RESP PHYSIOL, V86, P215, DOI 10.1016/0034-5687(91)90082-T; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193	20	197	210	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					814	817		10.1038/nm0796-814	http://dx.doi.org/10.1038/nm0796-814			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673930				2022-12-27	WOS:A1996UU68000040
J	Jonsen, AR; Durfy, SJ; Burke, W; Motulsky, AG				Jonsen, AR; Durfy, SJ; Burke, W; Motulsky, AG			The advent of the 'unpatients'	NATURE MEDICINE			English	Editorial Material							HUNTINGTON DISEASE; CANADA; RISK		UNIV WASHINGTON,WOMENS HLTH CARE CTR,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Jonsen, AR (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED HIST & ETH,BOX 357120,SEATTLE,WA 98195, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000477] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG 00477] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; Cook-Deegan R M, 1991, Mol Genet Med, V1, P1; Dunlop M G, 1992, Semin Cancer Biol, V3, P131; FANOS JH, 1995, AM J HUM GENET, V57, P431; GROOP LC, 1993, NEW ENGL J MED, V328, P10, DOI 10.1056/NEJM199301073280102; HIPPOCRATES, 1923, ART, P204; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; Jones WH, 1923, EPIDEMICS, V1, P165; Kevles Daniel J., 1985, NAME EUGENICS GENETI; MARSHALL E, 1993, SCIENCE, V262, P23, DOI 10.1126/science.8211123; MEHLMAN MJ, 1994, AM J HUM GENET, V55, P1054; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOSELEY R, 1993, ETHICAL LEGAL SOCIAL; MOTULSKY AG, 1992, GENETIC BASIS COMMON, P150; MYERS MF, 1994, AM J HUM GENET, V54, P719; Proctor Robert N., 1988, RACIAL HYGIENE MED N; ROTTER JI, 1992, GENETIC BASIS COMMON, P413; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YESLEY MS, 1993, ELSI BIBLIO ETHICAL; 1993, GENETIC INFORMATION	22	67	67	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					622	624		10.1038/nm0696-622	http://dx.doi.org/10.1038/nm0696-622			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640544				2022-12-27	WOS:A1996UN69100021
J	Morison, IM; Becroft, DM; Taniguchi, T; Woods, CG; Reeve, AE				Morison, IM; Becroft, DM; Taniguchi, T; Woods, CG; Reeve, AE			Somatic overgrowth associated with overexpression of insulin-like growth factor II	NATURE MEDICINE			English	Article							BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; DOMINANT INHERITANCE; HUMAN-FETUS; GENE; EXPRESSION; RELAXATION; CHROMOSOME-11; POLYMORPHISM; CANCER	Overexpression of the normally imprinted fetal insulin-like growth factor II (IGF2) has been implicated in the pathogenesis of the cancer-predisposing Beckwith-Wiedemann syndrome (BWS). We have detected constitutional relaxation of imprinting of IGF2 in four children with somatic overgrowth who do not show diagnostic features of BWS. Three children showed constitutional abnormalities of H19 methylation. All four children showed nephromegaly and two developed Wilms' tumors. Gene methylation is known to be associated with gene silencing, and three children showed constitutional abnormalities of H19 gene methylation. Disruption of H19 methylation, and concomitant relaxation of IGF2 imprinting, provides another mechanism that can increase IGF2 expression in children with overgrowth. The accumulated data on normal and pathologic IGF2 expression are now sufficient to define an entity, ''IGF2 overgrowth disorder,'' of which BWS may be one extreme manifestation. These findings have broad implications for the characterization of idiopathic overgrowth.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND; UNIV AUCKLAND,DEPT OBSTET & GYNAECOL,AUCKLAND,NEW ZEALAND; ST JAMESS UNIV HOSP,YORKSHIRE REG GENET SERV,LEEDS,W YORKSHIRE,ENGLAND	University of Otago; University of Auckland; Saint James's University Hospital; University of Leeds			Morison, Ian M/A-1236-2008; woods, christopher g/A-1361-2010	Morison, Ian M/0000-0003-3616-0025; 				ALECK KA, 1989, AM J MED GENET, V33, P155, DOI 10.1002/ajmg.1320330202; BECKWITH J B, 1969, Birth Defects Original Article Series, V5, P188; BECKWITH JB, 1978, CANCER, V41, P1937; Bove K E, 1976, Perspect Pediatr Pathol, V3, P185; BRICE AL, 1989, DEVELOPMENT, V106, P543; BROWN KW, 1992, CANCER GENET CYTOGEN, V58, P66, DOI 10.1016/0165-4608(92)90136-V; CHAO LY, 1993, NAT GENET, V3, P127, DOI 10.1038/ng0293-127; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLES HSR, 1993, DEVELOPMENT, V118, P777; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DITTRICH B, 1992, HUM GENET, V90, P313; DRUT R, 1988, Pediatric Pathology, V8, P331; EDWARDS A, 1991, AM J HUM GENET, V49, P746; ELLIOTT M, 1994, J MED GENET, V31, P560, DOI 10.1136/jmg.31.7.560; GIANNOUKAKIS N, 1994, AM J HUM GENET S, V55, P323; GLOUDEMANS T, 1993, CANCER RES, V53, P5754; GRUNDY P, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91937-P; HAN BK, 1985, AM J ROENTGENOL, V145, P611, DOI 10.2214/ajr.145.3.611; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEDBORG F, 1994, AM J PATHOL, V145, P802; Henry I., 1993, European Journal of Human Genetics, V1, P19; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Mannens M., 1994, European Journal of Human Genetics, V2, P3; MATSUMOTO T, 1994, JPN J HUM GENET, V39, P225, DOI 10.1007/BF01876842; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NIIKAWA N, 1986, AM J MED GENET, V24, P41, DOI 10.1002/ajmg.1320240107; NORDENSKJOLD A, 1993, HUM GENET, V92, P296; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Romero R., 1988, PRENATAL DIAGNOSIS C; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCOTT J, 1985, NATURE, V317, P261; SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749; SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TURLEAU C, 1985, ANN GENET-PARIS, V28, P93; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807; WITTE DP, 1994, AM J PATHOL, V145, P762; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	52	116	118	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					311	316		10.1038/nm0396-311	http://dx.doi.org/10.1038/nm0396-311			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612230				2022-12-27	WOS:A1996TY64000040
J	Vassalli, JD; Saurat, JH				Vassalli, JD; Saurat, JH			Cuts and scrapes? Plasmin heals!	NATURE MEDICINE			English	Editorial Material							UROKINASE-TYPE; KERATINOCYTES; ACTIVATOR; ULCERS		UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Vassalli, JD (corresponding author), UNIV GENEVA,SCH MED,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.							BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; MULDER G, 1993, INT J DERMATOL, V32, P304, DOI 10.1111/j.1365-4362.1993.tb04275.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WESTERHOF W, 1990, DERMATOLOGICA, V181, P293, DOI 10.1159/000247828	13	15	15	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					284	285		10.1038/nm0396-284	http://dx.doi.org/10.1038/nm0396-284			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612225				2022-12-27	WOS:A1996TY64000035
J	SEKHON, HS; LARSON, JE				SEKHON, HS; LARSON, JE			IN-UTERO GENE-TRANSFER INTO THE PULMONARY EPITHELIUM	NATURE MEDICINE			English	Article							RAT LUNG	In early gestation the internal surface of the lung is structurally simple and an ideal target for somatic gene transfer(1-3). The transfer of genes into the growing lung would be particularly useful in the prenatal correction of cystic fibrosis, which has devastating pulmonary complications. In addition, in utero gene therapy has the potential to immunotolerize the individual, and thereby to avoid the immune reactions now seen with the current generation of adenoviral vectors(4,5). We injected a replication-defective adenoviral vector containing the lacZ reporter gene (Ad5.CMVlacZ) into the amniotic fluid of rat pups on the 16th day of gestation(6-9). At 16 days of gestation, rat lungs are equivalent in maturity to those of a 22-week human fetus as their airways are lined with undifferentiated multipotential stem cells. The pups showed high-level reporter gene expression in their airways a week following birth (13 days following infection). The expression was maintained during a time when the lung volume increased approximately 20-fold, alveolarization occurred, and the epithelial cells differentiated(2,3). These data establish gene targeting of undifferentiated fetal cells as an effective means of gene therapy.	TULANE UNIV,MED CTR,NEW ORLEANS,LA 70121; ALTON OCHSNER MED FDN & OCHSNER CLIN,MOLEC GENET LAB,NEW ORLEANS,LA 70121	Tulane University; Ochsner Health System					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD000880] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 00880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMSON IYR, 1975, LAB INVEST, V32, P736; ADAMSON IYR, 1984, LAB INVEST, V50, P456; ADAMSON IYR, 1984, AM REV RESPIR DIS, V129, P130; ADAMSON IYR, 1991, LUNG SCI F, P663; BOLDUC P, 1976, AM REV RESPIR DIS, V114, P1121; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; HISLOP A, 1974, THORAX, V29, P90, DOI 10.1136/thx.29.1.90; Kauffman S L, 1980, Int Rev Exp Pathol, V22, P131; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; STRATFORDPERRIC.LD, 1992, J CLIN INVEST, V90, P626; TENHAVEOPBROEK AAW, 1981, AM J ANAT, V162, P201, DOI 10.1002/aja.1001620303; WINICK M, 1965, DEV BIOL, V12, P451, DOI 10.1016/0012-1606(65)90009-6; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	15	82	84	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1201	1203		10.1038/nm1195-1201	http://dx.doi.org/10.1038/nm1195-1201			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584996				2022-12-27	WOS:A1995TC53700048
J	PRICE, DD				PRICE, DD			UNPLEASANT PAIN EVOKED BY THALAMIC-STIMULATION	NATURE MEDICINE			English	Editorial Material											PRICE, DD (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT ANESTHESIOL,RICHMOND,VA 23298, USA.		Price, Donald D./A-3094-2008	Price, Donald D./0000-0002-8971-7184				APPLEBAUM AE, 1975, J NEUROPHYSIOL, V38, P572, DOI 10.1152/jn.1975.38.3.572; COGHILL RC, 1994, NEUROSCIENCE, V14, P4095; DAVIS KD, 1995, NEUROREPORT, V6, P369, DOI 10.1097/00001756-199501000-00035; Fields H. L., 1987, PAIN; KATZ J, 1990, PAIN, V43, P319, DOI 10.1016/0304-3959(90)90029-D; LENZ FA, 1995, NAT MED, V1, P910, DOI 10.1038/nm0995-910; MAO J, 1992, BRAIN RES, V584, P18, DOI 10.1016/0006-8993(92)90873-8; MELZACK R, 1968, P423; Mountcastle V.B., 1968, MED PHYSL; PRICE D, 1992, APS J, V4, P229; Price DD, 1988, PSYCHOL NEURAL MECHA; Willis William D., 1985, PAIN SYSTEM	12	3	3	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					885	887		10.1038/nm0995-885	http://dx.doi.org/10.1038/nm0995-885			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585211				2022-12-27	WOS:A1995RT30300039
J	SCHROEDER, SA; GAUGHAN, DM; SWIFT, M				SCHROEDER, SA; GAUGHAN, DM; SWIFT, M			PROTECTION AGAINST BRONCHIAL-ASTHMA BY CFTR DELTA-F508 MUTATION - A HETEROZYGOTE ADVANTAGE IN CYSTIC-FIBROSIS	NATURE MEDICINE			English	Article							DISEASE; GENE	Cystic fibrosis (CF) is a multisystem autosomal recessive disorder caused by mutations of the cystic fibrosis transmembrane regulator (CFTR), a protein that regulates cyclic-AMP-mediated chloride conductance at the apical membrane of secretory epithelia(1). Mutations in the CFTR gene are common in many populations. In North America, 4-5% Of the general population are heterozygous for a CFTR mutation(2). Although there are over 400 known CFTR mutations, a single mutation, a deletion of the phenylalanine at position 508 (Delta F508) in exon 10, accounts for about 70% of all CF chromosomes worldwide(3). The reasons for the high frequency of the Delta F508 CFTR allele - the selective advantage associated with CF heterozygosity - are unknown(1). Many physiological abnormalities have been observed in CF heterozygotes(4-6), although the clinical significance of these observations is unknown. Preliminary unpublished data and anecdotal information from CF families suggested that, remarkably, the Delta F508 allele might protect heterozygotes against bronchial asthma prompted us to further investigate this possibility. Here we present evidence that the Delta F508 CF allele protects against asthma in childhood and early adult life.	NEW YORK MED COLL,INST GENET ANAL COMMON DIS,HAWTHORNE,NY 10523; NEW YORK MED COLL,DEPT PEDIAT,DIV PULM DIS,HAWTHORNE,NY 10523; NEW YORK MED COLL,DEPT PEDIAT,DIV HUMAN MOLEC GENET,HAWTHORNE,NY 10523	New York Medical College; New York Medical College; New York Medical College								BAXTER PS, 1988, NATURE, V335, P211, DOI 10.1038/335211a0; BONFORTE RJ, 1993, PEDIATRIC RESPIRATOR, P263; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; DAVIS PB, 1989, J APPL PHYSIOL, V66, P2124, DOI 10.1152/jappl.1989.66.5.2124; DAVIS PB, 1987, THORAX, V42, P120, DOI 10.1136/thx.42.2.120; FRIEDMAN KJ, 1991, CLIN CHEM, V37, P753; GYURKOVITS K, 1977, LANCET, V1, P203; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; PIGNATTI PF, 1995, HUM MOL GENET, V4, P635, DOI 10.1093/hmg/4.4.635; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SWIFT M, 1990, AM J HUM GENET, V47, P266; TIZZANO EF, 1992, J PEDIATR-US, V120, P337, DOI 10.1016/S0022-3476(05)80895-9; 1977, AM REV RESPIR DIS, V136, P225; 1991, DHMS NIH913042 PUBL	15	106	108	0	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					703	705		10.1038/nm0795-703	http://dx.doi.org/10.1038/nm0795-703			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585155				2022-12-27	WOS:A1995RQ06600048
J	PALABRICA, TM; LIU, AC; ARONOVITZ, MJ; FURIE, B; LAWN, RM; FURIE, BC				PALABRICA, TM; LIU, AC; ARONOVITZ, MJ; FURIE, B; LAWN, RM; FURIE, BC			ANTIFIBRINOLYTIC ACTIVITY OF APOLIPOPROTEIN(A) IN-VIVO - HUMAN APOLIPOPROTEIN(A) TRANSGENIC MICE ARE RESISTANT TO TISSUE-PLASMINOGEN ACTIVATOR-MEDIATED THROMBOLYSIS	NATURE MEDICINE			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); PLASMA LIPOPROTEIN(A); MYOCARDIAL-INFARCTION; MONOCLONAL-ANTIBODY; FIBRIN BINDING; ATHEROSCLEROSIS; HETEROGENEITY; HEMOSTASIS; THROMBOSIS; INHIBITION	The extensive homology between apolipoprotein(a) and plasminogen has led to the hypothesis that the increased risk for atherosclerosis, cardiac disease and stroke associated with elevated levels of apolipoprotein(a) may reflect modulation of fibrinolysis. We have investigated the role of apolipoprotein(a) on clot lysis in transgenic mice expressing the human apolipoprotein(a) gene. These mice develop fatty streak lesions resembling early lesions of human atherosclerosis. Pulmonary emboli were generated in mice by injection, through the right jugular vein, of a human platelet-rich plasma clot radiolabelled with technetium-99m-labelled antifibrin antibodies. Tissue plasminogen activator was introduced continuously via the right jugular vein. Clot lysis, determined by ex vivo imaging, was depressed in mice carrying the apolipoprotein(a) transgene relative to their sex-matched normal littermates. These results directly demonstrate an in vivo effect of apolipoprotein(a) on fibrinolysis, an effect that may contribute to the pathology associated with elevated levels of this protein.	TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV CARDIOL, BOSTON, MA 02111 USA; STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts Medical Center; Stanford University								CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CHIESA G, 1992, J BIOL CHEM, V267, P24369; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; FRADE LJG, 1991, THROMB RES, V63, P407, DOI 10.1016/0049-3848(91)90227-N; GLUECK CJ, 1993, METABOLISM, V42, P236, DOI 10.1016/0026-0495(93)90042-M; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HALVORSEN S, 1992, THROMB RES, V68, P223, DOI 10.1016/0049-3848(92)90080-T; HEINRICH J, 1991, CLIN CHEM, V37, P1950; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; LIU JN, 1993, BIOCHEMISTRY-US, V32, P9694, DOI 10.1021/bi00088a022; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOLITERNO DJ, 1993, CIRCULATION, V88, P935, DOI 10.1161/01.CIR.88.3.935; OSHIMA S, 1991, ARTERIOSCLER THROMB, V11, P1772, DOI 10.1161/01.ATV.11.6.1772; ROSEBROUGH SF, 1988, J NUCL MED, V29, P1212; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; STASSEN JM, 1991, CIRCULATION, V83, P65; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VONHODENBERG E, 1991, AM J CARDIOL, V67, P1349, DOI 10.1016/0002-9149(91)90464-V; Zysow Bernice R., 1993, Current Opinion in Lipidology, V4, P484, DOI 10.1097/00041433-199312000-00010	25	126	128	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1995	1	3					256	259		10.1038/nm0395-256	http://dx.doi.org/10.1038/nm0395-256			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585043				2022-12-27	WOS:A1995QX55900033
J	Srivastava, D; Olson, EN				Srivastava, D; Olson, EN			Neurotrophin-3 knocks heart off trk	NATURE MEDICINE			English	Editorial Material							NERVOUS-SYSTEM; NEURAL CREST; MORPHOGENESIS; AFFERENTS; MUTATION; NEURONS		UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Srivastava, D (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV CARDIOL,DALLAS,TX 75235, USA.							CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARLNAS I, 1994, NATURE, V369, P658; FLAKE AW, 1995, ANNU REV MED, V46, P67; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; OLSON, 1996, SCIENCE, V272, P671; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852	17	15	15	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1069	1071		10.1038/nm1096-1069	http://dx.doi.org/10.1038/nm1096-1069			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837596				2022-12-27	WOS:A1996VK99500018
J	Ferrara, N				Ferrara, N			Natural killer cells, adhesion and tumor angiogenesis	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; INVITRO; INVIVO				Ferrara, N (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080, USA.							ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Berke Gideon, 1993, P965; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; MELDER RJ, 1993, CANCER RES, V53, P5876; PARMIANI G, 1990, IMMUNOL TODAY, V11, P113, DOI 10.1016/0167-5699(90)90046-C; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; ROSENBERG SA, 1990, SCI AM, V262, P62, DOI 10.1038/scientificamerican0590-62; SASAKI A, 1991, JNCI-J NATL CANCER I, V83, P433, DOI 10.1093/jnci/83.6.433; WINTER BK, 1992, CANCER RES, V52, P6279	13	10	10	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					971	972		10.1038/nm0996-971	http://dx.doi.org/10.1038/nm0996-971			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782449				2022-12-27	WOS:A1996VF49700026
J	Kuhl, PR; GriffithCima, LG				Kuhl, PR; GriffithCima, LG			Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase	NATURE MEDICINE			English	Article							FACTOR RECEPTOR; TYROSINE KINASE; RAT HEPATOCYTES; CELLS; MITOGENESIS; CULTURE; ADULT; INTERNALIZATION; TRANSIENT; BINDING	We have tethered epidermal growth factor (EGF) to a solid substrate in a manner permitting the factor to retain its biological activity as assessed by both mitogenic and morphological assays. Mouse EGF was covalently coupled to aminosilane-modified glass via star poly(ethylene oxide) (PEG), which allows the ligand to retain significant mobility and active conformation. Tethered EGF was as effective as soluble EGF in eliciting DNA synthesis and cell rounding responses of primary rat hepatocytes under different surface conditions. In contrast, physically adsorbed EGF at comparable surface concentrations showed no activity. Presentation of growth factors in this manner may help to expedite their clinical use by permitting greater control of temporal and spatial availability in the extracellular environment.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,CTR BIOMED ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Griffith, Linda/0000-0002-1801-5548	NIGMS NIH HHS [GM 50047] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050047] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARONOV A, 1978, J BIOL CHEM, V253, P3970; ALLGOR SS, 1996, THESIS MIT; BLANC P, 1992, GASTROENTEROLOGY, V102, P1340; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CIMA LG, 1991, BIOTECHNOL BIOENG, V38, P145, DOI 10.1002/bit.260380207; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; GLADHAUG IP, 1987, EUR J BIOCHEM, V164, P267, DOI 10.1111/j.1432-1033.1987.tb11054.x; KNAUER DJ, 1984, J BIOL CHEM, V269, P5623; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; MORIARITY DM, 1980, ARCH BIOCHEM BIOPHYS, V203, P506, DOI 10.1016/0003-9861(80)90208-8; PIERCE GF, 1995, ANNU REV MED, V46, P467; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; SCHAUDIES RP, 1985, J CELL PHYSIOL, V124, P493, DOI 10.1002/jcp.1041240320; SMITH KA, 1988, INTERLEUKIN, V2, P1; STENGER DA, 1992, J AM CHEM SOC, V114, P8435, DOI 10.1021/ja00048a013; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; TOMOMURA A, 1987, J CELL PHYSIOL, V130, P221, DOI 10.1002/jcp.1041300208; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; WILEY HS, 1989, J BIOL CHEM, V264, P912	28	260	269	0	26	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1022	1027		10.1038/nm0996-1022	http://dx.doi.org/10.1038/nm0996-1022			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782461				2022-12-27	WOS:A1996VF49700038
J	Callan, MFC; Steven, J; Krausa, P; Wilson, JDK; Moss, PAH; Gillespie, GM; Bell, JI; Rickinson, AB; McMichael, AJ				Callan, MFC; Steven, J; Krausa, P; Wilson, JDK; Moss, PAH; Gillespie, GM; Bell, JI; Rickinson, AB; McMichael, AJ			Large clonal expansions of CD8(+) T cells in acute infectious mononucleosis	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; VARIABLE REGION GENES; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIGEN RECEPTOR GENES; MONOCLONAL-ANTIBODIES; CHAIN; LYMPHOCYTES; EXPRESSION; IDENTIFICATION; PERSISTENCE	Primary infection with Epstein-Barr virus often results in the clinical syndrome of acute infectious mononucleosis (glandular fever). This illness is characterized by a striking lymphocytosis, the nature of which has been controversial. We show that large monoclonal or oligoclonal populations of CD8(+) T cells account for a significant proportion of the lymphocytosis and provide molecular evidence that these populations have been driven by antigen. The results suggest that the selective and massive expansion of a few dominant clones of CD8(+) T cells is an important feature of the primary response to this virus.	UNIV BIRMINGHAM,CRC,INST CANC STUDIES,SCH MED,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	University of Birmingham	Callan, MFC (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,MOL IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; CALLAN MFC, 1993, P NATL ACAD SCI USA, V90, P10454, DOI 10.1073/pnas.90.22.10454; CALLAN MFC, 1995, EUR J IMMUNOL, V25, P1529, DOI 10.1002/eji.1830250609; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CARREL S, 1986, EUR J IMMUNOL, V16, P649, DOI 10.1002/eji.1830160610; CHEN ZW, 1995, J EXP MED, V182, P21, DOI 10.1084/jem.182.1.21; CHOI YW, 1991, P NATL ACAD SCI USA, V88, P8357, DOI 10.1073/pnas.88.19.8357; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CLARKE GR, 1994, EUR J IMMUNOL, V24, P837, DOI 10.1002/eji.1830240410; CONCANNON P, 1986, P NATL ACAD SCI USA, V83, P6598, DOI 10.1073/pnas.83.17.6598; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DIU A, 1993, EUR J IMMUNOL, V23, P1422, DOI 10.1002/eji.1830230703; FERRADINI L, 1991, EUR J IMMUNOL, V21, P935, DOI 10.1002/eji.1830210412; HESSE J, 1983, SCAND J INFECT DIS, V15, P335, DOI 10.3109/inf.1983.15.issue-4.03; HINGORANI R, 1993, J IMMUNOL, V151, P5762; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; LAI PK, 1975, J HYG-CAMBRIDGE, V74, P329, DOI 10.1017/S0022172400046842; LEE SP, 1993, J VIROL, V67, P7428, DOI 10.1128/JVI.67.12.7428-7435.1993; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; LI YX, 1991, J EXP MED, V174, P1537, DOI 10.1084/jem.174.6.1537; MAKENSEN A, 1994, J CLIN INVEST, V98, P1397; Maryanski JL, 1996, IMMUNITY, V4, P47, DOI 10.1016/S1074-7613(00)80297-6; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MORLEY JK, 1995, J IMMUNOL, V154, P6182; MOSKOPHIDIS D, 1993, EUR J IMMUNOL, V23, P3306, DOI 10.1002/eji.1830231237; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; ROMAGNE F, 1992, EUR J IMMUNOL, V22, P2749, DOI 10.1002/eji.1830221043; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SADLER AM, 1994, TISSUE ANTIGENS, V44, P148, DOI 10.1111/j.1399-0039.1994.tb02372.x; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; SMITH TJ, 1993, BLOOD, V81, P1521; STRANG G, 1987, EUR J IMMUNOL, V17, P1007, DOI 10.1002/eji.1830170717; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; UEHARA T, 1992, BLOOD, V80, P452; VENKITARAMAN AR, 1985, J MED VIROL, V15, P11, DOI 10.1002/jmv.1890150103; VINEY JL, 1992, HYBRIDOMA, V11, P701, DOI 10.1089/hyb.1992.11.701	43	382	387	1	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					906	911		10.1038/nm0896-906	http://dx.doi.org/10.1038/nm0896-906			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705861				2022-12-27	WOS:A1996UZ80400038
J	Lee, SW				Lee, SW			H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer	NATURE MEDICINE			English	Article							CELL-ADHESION MOLECULES; TUMOR-SUPPRESSOR GENES; ASSOCIATION; METASTASIS; CARCINOMAS; MUTATIONS; SURVIVAL; INVASION	A newly identified gene, H-cadherin, is reported. H-cadherin encodes a protein related to the cadherin superfamily of cell adhesion molecules, and its expression is shown to be significantly reduced in human breast carcinoma cell lines and breast cancer specimens. H-cadherin was localized to chromosome 16q24 and is highly expressed in the heart. Introduction of H-cadherin cDNA markedly diminished tumor cell growth and resulted in a significant change from invasive morphology to a normal cell-like morphology in the Matrigel outgrowth assay. These studies indicate that downregulation of H-cadherin may be frequent in the breast malignant progression and suggest that it may have prognostic value as a marker for breast cancer development.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02215; HARVARD UNIV,INST MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University	Lee, SW (corresponding author), BETH ISRAEL HOSP,DEPT MED,ROOM 921,77 AVE LOUIS PASTEUR,BOSTON,MA 02215, USA.				NCI NIH HHS [1R01 CA 66271-01] Funding Source: Medline; NIA NIH HHS [AG 08812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BONGIORNO PF, 1995, BRIT J CANCER, V71, P166, DOI 10.1038/bjc.1995.34; BRINGUIER PP, 1993, CANCER RES, V53, P3241; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GISHOP JM, 1995, GENE DEV, V9, P1309; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KINSELLA AR, 1992, BRIT J CANCER, V67, P804; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDBLOM A, 1993, CANCER RES, V53, P3707; Liotta L A, 1991, Important Adv Oncol, P85; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MAYER B, 1993, CANCER RES, V53, P1690; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NAVARRO P, 1993, J CELL SCI, V105, P923; OKA H, 1993, CANCER RES, V53, P1696; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SAINSBURY JRC, 1987, LANCET, V1, P1398; SATO T, 1991, CANCER RES, V51, P5794; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SOMMERS CL, 1994, CANCER RES, V54, P3544; Stappert J, 1993, Curr Opin Neurobiol, V3, P60, DOI 10.1016/0959-4388(93)90036-X; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; THOMSON RB, 1995, J BIOL CHEM, V270, P17594, DOI 10.1074/jbc.270.29.17594; TSUDA H, 1992, CANCER RES, V52, P1504; TSUDA H, 1995, CANCER RES, V55, P3395; TSUDA H, 1994, CANCER RES, V54, P513; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	51	185	197	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					776	782		10.1038/nm0796-776	http://dx.doi.org/10.1038/nm0796-776			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673923				2022-12-27	WOS:A1996UU68000033
J	LovellBadge, R				LovellBadge, R			Banking on spermatogonial stem cells: Frozen assets and foreign investments	NATURE MEDICINE			English	Editorial Material											LovellBadge, R (corresponding author), NATL INST MED RES,MRC,DIV DEV GENET,LONDON NW7 1AA,ENGLAND.			Lovell-Badge, Robin/0000-0001-9364-4179				ALVING BM, 1995, TRANSFUSION, V35, P783, DOI 10.1046/j.1537-2995.1995.35996029166.x; ENGELSEN SJ, 1996, CAMBRIDGE S, V1, P26; GREISLER HP, 1996, CAMBRIDGE S, V1, P28; JACKSON MR, 1996, CAMBRIDGE S, V1, P26; LEVITSKY S, 1994, FIBRIN SEALANT CHARA; MILNE AA, 1995, EUR J VASC ENDOVASC, V10, P91, DOI 10.1016/S1078-5884(05)80203-5; NICHOLS WL, 1993, BLOOD, V82, P59; ROUSOU J, 1989, J THORAC CARDIOV SUR, V97, P194; SIERRA DH, 1996, CAMBRIDGE S, V1, P24; WOOLVERTON CJ, 1996, CAMBRIDGE S, V1, P30; ZEHNDER JL, 1990, BLOOD, V76, P2011	11	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					638	639		10.1038/nm0696-638	http://dx.doi.org/10.1038/nm0696-638			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640551				2022-12-27	WOS:A1996UN69100028
J	Brash, DE				Brash, DE			Cellular proofreading	NATURE MEDICINE			English	Editorial Material							MICE; FERTILITY		YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,YALE COMPREHENS CANC CTR,NEW HAVEN,CT 06510	Yale University; Yale University	Brash, DE (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							Allan D.J., 1987, P229; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; Buss LW, 1987, EVOLUTION INDIVIDUAL, P201; COUCOUVANIS EC, 1993, EXP CELL RES, V209, P238, DOI 10.1006/excr.1993.1307; MATSUDA Y, 1991, P NATL ACAD SCI USA, V88, P4850, DOI 10.1073/pnas.88.11.4850; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Russell LB, 1963, REPAIR GENETIC RADIA, P313; Russell WL, 1954, RADIAT BIOL, V1, P825; SUTCLIFFE MJ, 1991, MOL REPROD DEV, V30, P81, DOI 10.1002/mrd.1080300202; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	15	44	45	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					525	526		10.1038/nm0596-525	http://dx.doi.org/10.1038/nm0596-525			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616708				2022-12-27	WOS:A1996UJ23000032
J	Hammes, HP; Brownlee, M; Jonczyk, A; Sutter, A; Preissner, KT				Hammes, HP; Brownlee, M; Jonczyk, A; Sutter, A; Preissner, KT			Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS	Retinal neovascularization is a major cause of blindness in such disorders as retinopathy of prematurity, proliferative diabetic retinopathy and senile macular degeneration. Because ligation of vitronectin receptor-type integrins appears to be required for the survival and maturation of newly formed but not quiescent blood vessels in several vascular beds including the retina, blockade of this downstream adhesion receptor system was investigated. In a mouse model of hypoxia-induced retinal neovascularization twice daily administration of 1 to 20 mg cyclic alpha(nu)-integrin antagonist peptide per kilogram of body weight reduced capillary proliferation in a dose-dependent fashion - maximum 76% - without obvious side effects. A cyclic control peptide displayed no inhibitory effect on neovascularization. These findings indicate that systemic application of vitronectin receptor antagonists appears to be clinically feasible and is efficient in preventing retinal neovascularization and superior to cytokine-blocking strategies.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIABET RES CTR, BRONX, NY 10461 USA; MERCK KGAA, D-64293 DARMSTADT, GERMANY; KERCKHOFF KLIN, MPI, HAEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY	Yeshiva University; Albert Einstein College of Medicine; Merck KGaA; Kerckhoff Clinic; Max Planck Society	Hammes, HP (corresponding author), UNIV GIESSEN, MED KLIN & POLIKLIN, DEPT INTERNAL MED 3, RODTHOHL 6, D-35385 GIESSEN, GERMANY.		Hammes, Hans-Peter/S-3719-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN GC, 1987, INT OPHTHALMOL, V11, P41, DOI 10.1007/BF02027896; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; JONCZYK A, 1993, Patent No. 632053; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MARANO RPC, 1995, EXP EYE RES, V60, P5, DOI 10.1016/S0014-4835(05)80079-X; MARANO RPC, 1994, INVEST OPHTH VIS SCI, V35, P2791; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PEER J, 1995, LAB INVEST, V72, P638; PFEIFFER A, 1995, EXP CLIN ENDOCR DIAB, V103, P7, DOI 10.1055/s-0029-1211323; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PREISSNER KT, 1988, BLOOD, V71, P1581; PROST M, 1988, BRIT J OPHTHALMOL, V72, P363, DOI 10.1136/bjo.72.5.363; ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SCHULTZ G S, 1991, Eye (London), V5, P170; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SPRANGER J, 1995, MED KLIN, V90, P134; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115	34	290	331	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					529	533		10.1038/nm0596-529	http://dx.doi.org/10.1038/nm0596-529			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616710				2022-12-27	WOS:A1996UJ23000034
J	Moffatt, M; Cookson, W				Moffatt, M; Cookson, W			Naked DNA: New shots for allergy?	NATURE MEDICINE			English	Editorial Material											Moffatt, M (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,ASTHMA GENET GRP,OXFORD OX3 9DU,ENGLAND.		Cookson, William/HHC-1790-2022					DAVIS HL, 1995, MOL CELL BIOL HUMAN, P368; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; KRISHNAN S, 1995, NAT MED, V1, P521, DOI 10.1038/nm0695-521; Noon L, 1911, LANCET, V1, P1572; RENZ H, 1994, J IMMUNOL, V152, P351; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1994, VACCINE, V12, P1541, DOI 10.1016/0264-410X(94)90081-7; VARNEY VA, 1993, J CLIN INVEST, V92, P664; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	9	1	3	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					515	516		10.1038/nm0596-515	http://dx.doi.org/10.1038/nm0596-515			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616703				2022-12-27	WOS:A1996UJ23000027
J	Auger, I; Escola, JM; Gorvel, JP; Roudier, J				Auger, I; Escola, JM; Gorvel, JP; Roudier, J			HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins	NATURE MEDICINE			English	Article							SHARED-EPITOPE HYPOTHESIS; NUCLEOTIDE-SEQUENCE; CELL; GENE; DISEASE; ASSOCIATION; PEPTIDE; CHAIN; DNAK	Most patients with rheumatoid arthritis express particular HLA-DR alleles. The DR beta 1 chains of these alleles share a highly homologous amino acid motif, in their third hypervariable (HV3) region, and this motif seems to help the development of rheumatoid arthritis via unknown mechanisms. In an attempt to identify a ligand of this motif, we screened bacterial proteins. HV3 peptides from HLA-DRB1 alleles containing a QKRAA or RRRAA motif bound the 70-kD heat shock protein (HSP) from Escherichia coli, dnaK. In lymphoblastoid cells homozygous for these same HLA-DRB1 alleles the constitutive 70-kD HSP, HSP73, that targets selected proteins to lysosomes coprecipitated with HLA-DR. Thus, the QKRAA and RRRAA amino acid motifs of HLA-DR mediate binding of HLA-DR to HSP73. This property may influence the intracellular route, processing or peptide associations of the HLA-DR beta 1 chain in these two rheumatoid arthritis-associated alleles.	CTR IMMUNOL,INSERM,CNRS MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Auger, I (corresponding author), FAC MED MARSEILLE,LAB IMMUNORHUMATOL,F-13005 MARSEILLE,FRANCE.		AUGER, ISABELLE/P-6294-2016; roudier, jean/A-8654-2011; Gorvel, Jean-Pierre/O-1332-2018	AUGER, ISABELLE/0000-0002-1414-8095; roudier, jean/0000-0001-5435-8567; Gorvel, Jean-Pierre/0000-0002-2829-9804				ALBANI, 1995, NATURE MED, V1, P448; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BOKI KA, 1992, ARTHRITIS RHEUM, V35, P749, DOI 10.1002/art.1780350706; CELLIER MF, 1992, J BACTERIOL, V174, P8032; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; ESCOLA JM, 1995, J CELL SCI, V108, P2337; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; GOYERT SM, 1983, P NATL ACAD SCI-BIOL, V80, P5719, DOI 10.1073/pnas.80.18.5719; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HOUGHTEN RA, 1980, INT J PEPT PROT RES, V16, P311; KRISHNAN HB, 1991, MOL MICROBIOL, V3, P737; OLLIER W, 1992, RHEUM DIS CLIN N AM, V18, P761; ROUDIER J, 1989, P NATL ACAD SCI USA, V86, P5104, DOI 10.1073/pnas.86.13.5104; ROUDIER J, 1991, EUR J IMMUNOL, V21, P2063, DOI 10.1002/eji.1830210914; SALVAT S, 1994, J IMMUNOL, V153, P5321; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; VANASSELDONK M, 1993, J BACTERIOL, V175, P1637, DOI 10.1128/JB.175.6.1637-1644.1993; WEYAND CM, 1995, J CLIN INVEST, V95, P2120, DOI 10.1172/JCI117900; WEYAND CM, 1992, ARTHRITIS RHEUM-US, V35, P990, DOI 10.1002/art.1780350903; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597	25	88	101	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					306	310		10.1038/nm0396-306	http://dx.doi.org/10.1038/nm0396-306			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612229				2022-12-27	WOS:A1996TY64000039
J	Contrino, J; Hair, G; Kreutzer, DL; Rickles, FR				Contrino, J; Hair, G; Kreutzer, DL; Rickles, FR			In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease	NATURE MEDICINE			English	Article							TUMOR-DERIVED POLYPEPTIDE; FACTOR MESSENGER-RNA; PERMEABILITY FACTOR; PROCOAGULANT ACTIVITY; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; EXPRESSION; IDENTIFICATION; CARCINOMA; CANCER	Expression of tissue factor (TF) in the endothelium has been observed only rarely in human disease and has been thought to be elaborated on the surface of vascular endothelial cells (VECs) in vitro as an artifact of tissue culture. Using monoclonal antibodies and a novel probe for functional TF, we have localized TF to the VECs (and tumor cells) within the tumors of seven patients with invasive breast cancer but not in the VECs (or tumor cells) of benign tumors from ten patients with fibrocystic disease of the breast. The potent procoagulant TF was shown to be a marker of the initiation of angiogenesis in human breast cancer. Further evidence that the TF was the demonstration of a similar distribution of cross-linked fibrin only in the VECs of the malignant tumors. We interpret these data as further support for the concept that tumor cells can activate nearby VECs and regulate blood vessel growth in vivo. Large clinical-pathologic studies will be necessary to determine whether TF is a useful marker for the ''switch to the angiogenic phenotype'' in human breast disease and/or correlates with the thromboembolic complications of breast cancer.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS MSD02,ATLANTA,GA 30333; UNIV CONNECTICUT,SCH MED,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH MED,DEPT SURG,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH MED,DEPT PATHOL,FARMINGTON,CT 06032; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; VET ADM MED CTR,NEWINGTON,CT 06111	Centers for Disease Control & Prevention - USA; University of Connecticut; University of Connecticut; University of Connecticut; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System					NCI NIH HHS [CA 22202] Funding Source: Medline; NEI NIH HHS [EYE 04131] Funding Source: Medline; NHLBI NIH HHS [HL 25015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022202] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004131] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; BROWN LF, 1993, CANCER RES, V53, P4727; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; CONTRINO J, 1994, AM J PATHOL, V145, P1315; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; COSTANTINI V, 1991, CANCER RES, V51, P349; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DRAKE TA, 1993, AM J PATHOL, V142, P1458; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DVORAK HF, 1981, J NATL CANCER I, V67, P335; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; FAULK WP, 1990, BLOOD, V76, P86; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HOFFMAN M, 1994, BLOOD, V83, P38; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; KAO J, 1992, J BIOL CHEM, V267, P20239; KIRCHHOFER D, 1993, BLOOD, V81, P2050; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; KUDRYK B, 1988, FIBRINOGEN, V3, P129; LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7; LYBERG T, 1983, BRIT J HAEMATOL, V53, P85, DOI 10.1111/j.1365-2141.1983.tb01989.x; MAYNARD JR, 1977, BLOOD, V50, P387; MCKEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MIYAUCHI S, 1988, IN VITRO CELL DEV B, V24, P753; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NEMERSON Y, 1988, BLOOD, V71, P1; NOGUCHI M, 1989, BIOCHEM BIOPH RES CO, V160, P222, DOI 10.1016/0006-291X(89)91644-6; RICKLES FR, 1988, SEMIN THROMB HEMOST, V14, P126, DOI 10.1055/s-2007-1002765; RICKLES FR, 1992, CANCER METAST REV, V11, P237, DOI 10.1007/BF01307180; RICKLES FR, 1994, HEMOSTASIS THROMBOSI, P1164; RUENING U, 1993, THROMB HAEMOSTASIS, V69, P197; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; SATO Y, 1986, AM J PATHOL, V125, P431; STERN DM, 1982, P NATL ACAD SCI USA, V82, P2523; TANNENBAUM SH, 1986, J IMMUNOL, V137, P1532; Trousseau A, 1865, CLIN MED HOTEL DIEU, P654; VANHOEF MEHM, 1993, EUR J CANCER, V29A, P1141; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1993, AM J PATHOL, V143, P401; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	52	511	538	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					209	215		10.1038/nm0296-209	http://dx.doi.org/10.1038/nm0296-209			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574967				2022-12-27	WOS:A1996TU06000042
J	MUNDY, GR				MUNDY, GR			NO BONES ABOUT FLUORIDE	NATURE MEDICINE			English	Editorial Material							OSTEOPOROSIS				MUNDY, GR (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED ENDOCRINOL & METAB, SAN ANTONIO, TX 78284 USA.							CHAVASSIEUX PM, 1985, CALCIFIED TISSUE INT, V37, P345, DOI 10.1007/BF02553699; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; LAU KHW, 1989, METABOLISM, V38, P858; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O	8	8	8	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1995	1	11					1130	1131		10.1038/nm1195-1130	http://dx.doi.org/10.1038/nm1195-1130			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584977				2022-12-27	WOS:A1995TC53700029
J	LENZ, FA; GRACELY, RH; ROMANOSKI, AJ; HOPE, EJ; ROWALAND, LH; DOUGHERTY, PM				LENZ, FA; GRACELY, RH; ROMANOSKI, AJ; HOPE, EJ; ROWALAND, LH; DOUGHERTY, PM			STIMULATION IN THE HUMAN SOMATOSENSORY THALAMUS CAN REPRODUCE BOTH THE AFFECTIVE AND SENSORY DIMENSIONS OF PREVIOUSLY EXPERIENCED PAIN	NATURE MEDICINE			English	Article							RESPONSES; NEURONS; MICROSTIMULATION; SENSATIONS; NUCLEUS; MONKEYS; AREA	Thalamic structures involved in the unpleasant emotional or affective aspect of pain are poorly understood. We now describe studies of the region of the thalamic principal somatosensory nucleus (Vc) performed before thalamotomy for tremor in a patient who also had panic disorder. Microstimulation in the region posterior to Vc evoked chest pain, including a strong affective dimension, almost identical to that occurring during his panic attacks, as measured using a questionnaire. Results in our other patients indicate that stimulation-associated pain with a strong affective dimension occurred only in those patients who had previously experienced spontaneous pain with a strong affective component. These results are consistent with stimulation-evoked activation of limbic structures, which are connected through cortex with the region posterior to Vc and involved in the affective dimension of pain through conditioning by previous experience.	JOHNS HOPKINS UNIV, DEPT PSYCHIAT, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, DEPT CARDIOL, BALTIMORE, MD 21287 USA; NIDR, NEUROBIOL & ANESTHESIOL BRANCH, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	LENZ, FA (corresponding author), JOHNS HOPKINS UNIV, DEPT NEUROSURG, MEYER BLDG 7-113, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.			Dougherty, Patrick/0000-0002-2177-2734	NINDS NIH HHS [P01 NS 32386, NS 28598, K08 NS 01384] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS032386, K08NS001384, R29NS028598] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEITMAN BD, 1987, ARCH INTERN MED, V147, P1548, DOI 10.1001/archinte.147.9.1548; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; BRAUNWALD E, 1988, HEART DISEASE TXB CA, V3, P1; BURTON H, 1976, J COMP NEUROL, V168, P249, DOI 10.1002/cne.901680204; Burton H., 1986, SENSORY MOTOR AREAS, P31, DOI 10.1007/978-1-4613-2149-1_2; Cannon R O 3rd, 1991, Cardiol Clin, V9, P157; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CASEY KL, 1978, NEUROSCI RES PROGRAM, V16, P9; CHATRIAN GE, 1975, NEUROLOGY, V25, P745, DOI 10.1212/WNL.25.8.745; COGHILL RC, 1994, J NEUROSCI, V14, P4095; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; DAVIS KD, 1995, NEUROREPORT, V6, P369, DOI 10.1097/00001756-199501000-00035; DONG W, 1994, J NEUROPHYSIOL, V72, P1; DONG WK, 1989, BRAIN RES, V484, P314, DOI 10.1016/0006-8993(89)90375-2; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; FRIESINGER GS, 1985, ANGINA PECTORIS, V2, P25; GRACELY RH, 1979, SCIENCE, V203, P1261, DOI 10.1126/science.424753; GREENSPAN J, 1992, PAIN, V60, P29; HAUSER AM, 1985, J AM COLL CARDIOL, V5, P193, DOI 10.1016/S0735-1097(85)80036-X; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; LENZ FA, 1994, PAIN, V59, P119, DOI 10.1016/0304-3959(94)90055-8; LENZ FA, 1993, J NEUROPHYSIOL, V70, P200, DOI 10.1152/jn.1993.70.1.200; LENZ FA, 1988, J NEUROSURG, V68, P630, DOI 10.3171/jns.1988.68.4.0630; LENZ FA, 1988, J NEUROPHYSIOL, V59, P299, DOI 10.1152/jn.1988.59.2.299; LENZ FA, 1993, BRAIN RES, V623, P235, DOI 10.1016/0006-8993(93)91433-S; LENZ FA, IN PRESS HUMAN THALA; LOCKE S, 1961, ANAT REC, V139, P249; MATTHEWS MB, 1985, ANGINA PECTORIS, V2, P62; Mehler W., 1962, BASIC RES PARAPLEGIA, P26; MISHKIN M, 1979, NEUROPSYCHOLOGIA, V17, P139, DOI 10.1016/0028-3932(79)90005-8; PASTERNAK RC, 1992, CARDIAC DISEASE, V4, P1200; PRICE D, 1992, APS J, V4, P229; PROCACCI P, 1989, TXB PAIN, V2, P410; ROUGHGARDEN JW, 1966, AM J MED, V41, P947, DOI 10.1016/0002-9343(66)90052-0; Schaltenbrand G., 1959, INTRO STEREOTAXIS AT; TORGERSON WS, 1988, 5TH P WORLD C PAIN, P368; Van Buren JM, 1972, VARIATIONS CONNECTIO; 1987, APA DIAGNOSTIC STATI	38	68	70	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1995	1	9					910	913		10.1038/nm0995-910	http://dx.doi.org/10.1038/nm0995-910			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585216				2022-12-27	WOS:A1995RT30300044
J	CHEN, J; WILLINGHAM, T; MARGRAF, LR; SCHREIBERAGUS, N; DEPINHO, RA; NISEN, PD				CHEN, J; WILLINGHAM, T; MARGRAF, LR; SCHREIBERAGUS, N; DEPINHO, RA; NISEN, PD			EFFECTS OF THE MYC ONCOGENE ANTAGONIST, MAD, ON PROLIFERATION, CELL CYCLING AND THE MALIGNANT PHENOTYPE OF HUMAN BRAIN-TUMOR CELLS	NATURE MEDICINE			English	Article							C-MYC; DNA-BINDING; PROTEIN; TRANSFORMATION; EXPRESSION; GROWTH; G0; G1	To investigate how overexpression of MAD, an antagonist of MYC oncogenes influences the malignant phenotype of human cancer cells, an adenovirus vector system was used to transfer the human MAD gene (AdMAD) into human astrocytoma cells. Decreased growth potential of AdMAD-infected cells was evidenced by a decrease In [H-3]thymidine incorporation, an increase in cell doubling time and alteration of cell-cycle distribution. Diminished malignant potential of AdMAD-infected cells was manifested by their loss of anchorage-independent growth in soft agar and by their inability, in general, to induce tumorigenesis in a xenograft animal model. These studies indicate that adenovirus constructs encoding MAD dramatically inhibit the proliferation and tumorigenicity of human astrocytoma cells and support the use of MAD for gene therapy of human tumours.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PATHOL, DALLAS, TX 75235 USA; ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, NEW YORK, NY 10461 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University				DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P20CA060173] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60173] Funding Source: Medline; NEI NIH HHS [EY 09300] Funding Source: Medline; NICHD NIH HHS [HD 28317] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANDREW ME, 1981, J IMMUNOL, V127, P1201; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KOHL NE, 1987, ONCOGENE, V2, P41; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	31	99	102	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1995	1	7					638	643		10.1038/nm0795-638	http://dx.doi.org/10.1038/nm0795-638			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585143				2022-12-27	WOS:A1995RQ06600036
J	SCHEFFER, GL; WIJNGAARD, PLJ; FLENS, MJ; IZQUIERDO, MA; SLOVAK, ML; PINEDO, HM; MEIJER, CJLM; CLEVERS, HC; SCHEPER, RJ				SCHEFFER, GL; WIJNGAARD, PLJ; FLENS, MJ; IZQUIERDO, MA; SLOVAK, ML; PINEDO, HM; MEIJER, CJLM; CLEVERS, HC; SCHEPER, RJ			THE DRUG RESISTANCE-RELATED PROTEIN LRP IS THE HUMAN MAJOR VAULT PROTEIN	NATURE MEDICINE			English	Article							TUMOR-CELL-LINES; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; GENE; OVEREXPRESSION; INHIBITORS; CLONING; CDNA	Multidrug-resistant cancer cells frequently overexpress the 110-kD LRP protein (originally named Lung Resistance-related Protein). LRP overexpression has been found to predict a poor response to chemotherapy in acute myeloid leukaemia and ovarian carcinoma. We describe the cloning and chromosome localization of the gene coding for this novel protein. The deduced LRP amino acid sequence shows 87.7% identity with the 104-kD rat major vault protein Vault's are multi-subunit structures that may be involved in nucleo-cytoplasmic transport. The LRP gene is located on chromosome 16, close to the genes coding for multidrug resistance-associated protein and protein kinase C-beta, and may mediate drug resistance, perhaps via a transport process.	FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT ONCOL,1081 HV AMSTERDAM,NETHERLANDS; ACAD UNIV HOSP UTRECHT,DEPT IMMUNOL,3584 CX UTRECHT,NETHERLANDS; CITY HOPE NATL MED CTR,DEPT CYTOGENET,DUARTE,CA 91010	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center; City of Hope								ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHUGANI DC, 1993, J CELL SCI, V106, P23; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DIETEL M, 1990, CANCER RES, V50, P6100; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FUTSCHER BW, 1994, BIOCHEM PHARMACOL, V47, P1601, DOI 10.1016/0006-2952(94)90538-X; IZQUIERDO MA, 1994, ANN ONCOL, V5, P98; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; Kuiper C. M., 1990, J CELL PHARM, V1, P35; KUSS BJ, 1994, LANCET, V343, P1531, DOI 10.1016/S0140-6736(94)92938-6; LIST AF, 1993, BLOOD, V82, pA443; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPER RJ, 1993, CANCER RES, V53, P1475; SCHUURHUIS GJ, 1991, BRIT J CANCER, V64, P857, DOI 10.1038/bjc.1991.413; SLAPAK CA, 1994, CANCER RES, V54, P5607; SLOVAK ML, 1988, CANCER RES, V48, P2793; SLOVAK ML, 1993, CANCER RES, V53, P3221; TAKEDA Y, 1994, INT J CANCER, V57, P229, DOI 10.1002/ijc.2910570217; VASU SK, 1993, J BIOL CHEM, V268, P15356; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273; WU L, 1992, CANCER RES, V52, P3029; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	33	557	601	1	25	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					578	582		10.1038/nm0695-578	http://dx.doi.org/10.1038/nm0695-578			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585126	Green Submitted			2022-12-27	WOS:A1995RN10100043
J	TAKAYAMA, H; RAY, J; RAYMON, HK; BAIRD, A; HOGG, J; FISHER, LJ; GAGE, FH				TAKAYAMA, H; RAY, J; RAYMON, HK; BAIRD, A; HOGG, J; FISHER, LJ; GAGE, FH			BASIC FIBROBLAST GROWTH-FACTOR INCREASES DOPAMINERGIC GRAFT-SURVIVAL AND FUNCTION IN A RAT MODEL OF PARKINSONS-DISEASE	NATURE MEDICINE			English	Article							EXTRACELLULAR-MATRIX; NIGRAL TRANSPLANTS; FACTOR PROMOTES; NEURONS; ASTROCYTES; SECRETION; INVITRO; STIMULATION; PROSPECTS; TISSUE	The clinical use of fetal neural grafts as an intracerebral source of dopamine for patients with Parkinson's disease has, met with limited success. Since basic fibroblast growth factor (bFGF) enhances the survival and growth of dopaminergic neurons in vitro, we explored whether cells genetically modified to produce bFGF would improve the functional efficacy of dopaminergic neurons implanted into rats with experimental Parkinson's disease. Results show that bFGF-producing cells grafted together with fetal dopamine neurons have potent growth-promoting effects on the implanted neurons in vivo. Moreover, rats implanted with such co-grafts display the most pronounced behavioural improvements post-grafting. These findings not only provide insight into the function of bFGF in situ, but also suggest an approach for enhancing the survival and function of dopamine neurons grafted into the damaged brain.	UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; WHITTIER INST DIABET & ENDOCRINOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego				Baird, Andrew/0000-0003-0027-9905	NIA NIH HHS [AG10435, AG08514] Funding Source: Medline; NIDDK NIH HHS [DK18811] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008514, P01AG010435, R37AG008514] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AHLSKOG JE, 1993, MAYO CLIN PROC, V68, P578, DOI 10.1016/S0025-6196(12)60373-5; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; Baird A., 1991, PEPTIDE GROWTH FACTO, V1, P369; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; BLAM SB, 1988, ONCOGENE, V3, P129; BRUNDIN P, 1985, BRAIN RES, V331, P251, DOI 10.1016/0006-8993(85)91550-1; Brundin P, 1987, PROG BRAIN RES <D>, V71, P293; ENGELE J, 1991, J NEUROSCI, V11, P3070; FINGER S, 1989, EXP NEUROL, V104, P1, DOI 10.1016/0014-4886(89)90001-0; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; GONZALEZ AM, IN PRESS BRAIN RES; KAWAJA MD, 1992, J COMP NEUROL, V317, P102, DOI 10.1002/cne.903170108; KAWAJA MD, 1992, NEURAL TRANSPLANTATI, P21; KNUSEL B, 1990, J NEUROSCI, V10, P558; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1991, TRENDS NEUROSCI, V14, P376, DOI 10.1016/0166-2236(91)90167-S; MATSUDA S, 1992, JAPAN J PHARM, V69, P365; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; RAY J, 1995, J NEUROCHEM, V64, P503; REDMOND DE, 1990, LANCET, V336, P820, DOI 10.1016/0140-6736(90)93294-Y; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; SCHMIDT RH, 1983, ACTA PHYSIOL SCAND, P19; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; STEINBUSCH HWM, 1990, PROG BRAIN RES, V82, P81; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	31	175	185	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1995	1	1					53	58		10.1038/nm0195-53	http://dx.doi.org/10.1038/nm0195-53			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584953				2022-12-27	WOS:A1995QX55700026
J	Syrengelas, AD; Chen, TT; Levy, R				Syrengelas, AD; Chen, TT; Levy, R			DNA immunization induces protective immunity against B-cell lymphoma	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; IDIOTYPIC VACCINATION; GENE IMMUNIZATION; FUSION PROTEIN; INDUCTION; VACCINES; ANTIGEN; RESPONSES; ANTIBODY; REGION	Idiotypic determinants of the immunoglobulin expressed on the surface of B-cell lymphomas are tumor-specific antigens (TSAs), which can be targeted by immunotherapy. Immunization with DNA constructs encoding the idiotype (Id) of a murine B-cell lymphoma induced specific anti-id antibody responses and protected mice against tumor challenge. Use of DNA encoding an Id/CM-CSF (idiotype/granuiocyte-macrophage colony-stimulating factor) fusion protein improved vaccine efficacy, and xenogeneic immunoglobulin constant region determinants were required for immunogenicity. These results indicate that DNA may be a simple and efficacious means of inducing immune responses against a weak, otherwise unrecognized tumor antigen, provided that additional stimuli are included with the DNA.			Syrengelas, AD (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV ONCOL,ROOM M207,STANFORD,CA 94305, USA.			Levy, Ronald/0000-0003-2061-0650	NCI NIH HHS [CA 33399] Funding Source: Medline; NIAID NIH HHS [5T32 AI 07290] Funding Source: Medline; NIGMS NIH HHS [GM 07365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033399, R37CA033399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGMAN Y, 1977, EUR J IMMUNOL, V7, P413, DOI 10.1002/eji.1830070702; CHEN TT, 1994, J IMMUNOL, V153, P4775; CHEN TT, 1995, J IMMUNOL, V154, P3105; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HAWKINS RE, 1994, BLOOD, V83, P3279; HAWKINS RE, 1993, J IMMUNOTHER, V14, P273, DOI 10.1097/00002371-199311000-00004; Irvine KR, 1996, J IMMUNOL, V156, P238; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; REFF ME, 1994, BLOOD, V83, P435; REITAN SK, 1995, EUR J IMMUNOL, V25, P1601, DOI 10.1002/eji.1830250620; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SLAVIN S, 1978, NATURE, V272, P624, DOI 10.1038/272624a0; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WATANABE A, 1993, J IMMUNOL, V151, P2871; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105	23	226	248	1	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1038	1041		10.1038/nm0996-1038	http://dx.doi.org/10.1038/nm0996-1038			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782465				2022-12-27	WOS:A1996VF49700042
J	McCarthy, PM				McCarthy, PM			Ventricular remodeling: Hype or hope?	NATURE MEDICINE			English	Editorial Material											McCarthy, PM (corresponding author), CLEVELAND CLIN FDN,DEPT THORAC & CARDIOVASC SURG,9500 EUCLID AVE,F-25,CLEVELAND,OH 44195, USA.								0	18	18	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					859	860		10.1038/nm0896-859	http://dx.doi.org/10.1038/nm0896-859			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705851				2022-12-27	WOS:A1996UZ80400028
J	Wang, Q; Finer, MH				Wang, Q; Finer, MH			Second-generation adenovirus vectors	NATURE MEDICINE			English	Editorial Material							LATE GENE-EXPRESSION; EARLY REGION-4; DNA-REPLICATION; PRODUCT; PROMOTER; MUTANTS; SHUTOFF; CELLS; E4		CELL GENESYS INC,FOSTER CITY,CA 94404	Cell Genesys Inc								AYUMI F, 1995, J VIROL, V69, P6180; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; COUTURE LA, 1992, PEDIATR PULM S, V8, P237; Dong JY, 1996, HUM GENE THER, V7, P319, DOI 10.1089/hum.1996.7.3-319; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; Fang B, 1996, GENE THER, V3, P217; FLINT J, 1980, LYTIC INFECTIONS ADE, P443; GOLKMAN MJ, 1995, HUM GENE THER, V6, P839; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HIERHOLZER JC, 1973, J INFECT DIS, V128, P541, DOI 10.1093/infdis/128.4.541; HORWITZ MS, 1994, VIROLOGY, P1679; HRISSE J, 1981, NUCLEIC ACIDS RES, V9, P4022; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KassEisler A, 1996, GENE THER, V3, P154; KETNER G, 1989, NUCLEIC ACIDS RES, V17, P3037, DOI 10.1093/nar/17.8.3037; KIM KS, 1993, J BIOL CHEM, V268, P15689; KLESSIG DF, 1984, MOL CELL BIOL, V4, P1354, DOI 10.1128/MCB.4.7.1354; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; LOCHMULLER H, 1994, HUM GENE THER, V5, P1485, DOI 10.1089/hum.1994.5.12-1485; NEVINS JR, 1987, MICROBIOL REV, V51, P419, DOI 10.1128/MMBR.51.4.419-430.1987; NORRBY E, 1966, VIROLOGY, V28, P236, DOI 10.1016/0042-6822(66)90148-6; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; VALENTINE RC, 1965, J MOL BIOL, V13, P13, DOI 10.1016/S0022-2836(65)80076-6; VANGINKEL FW, 1995, HUM GENE THER, V6, P895, DOI 10.1089/hum.1995.6.7-895; WANG Q, 1993, MOL CELL BIOL, V13, P918, DOI 10.1128/MCB.13.2.918; Wang Q, 1995, GENE THER, V2, P775; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; YANG NS, 1992, CRIT REV BIOTECHNOL, V12, P335, DOI 10.3109/07388559209040627; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	36	92	129	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					714	716		10.1038/nm0696-714	http://dx.doi.org/10.1038/nm0696-714			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640568				2022-12-27	WOS:A1996UN69100045
J	Howard, M; Frizzell, DM; Bedwell, DM				Howard, M; Frizzell, DM; Bedwell, DM			Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations	NATURE MEDICINE			English	Article							CYSTIC-FIBROSIS; PHENOTYPIC SUPPRESSION; ESCHERICHIA-COLI; CODONS; CELLS; UAG	Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). A single recessive mutation, the deletion of phenylalanine 508 (Delta F508), causes severe CF and resides on 70% of mutant chromosomes. Severe CF is also caused by premature stop mutations, which are found on 5% of CF chromosomes. Here we report that two common, disease-associated stop mutations can be suppressed by treating cells with low doses of the aminoglycoside antibiotic G-418. Aminoglycoside treatment resulted in the expression of full-length CFTR and restored its cyclic AMP-activated chloride channel activity. Another aminoglycoside, gentamicin, also promoted the expression of full-length CFTR. These results suggest that treatment with aminoglycosides may provide a means of restoring CFTR function in CF patients with this class of mutation.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Bedwell, David/0000-0002-6605-818X				BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1993, J BIOENERG BIOMEMBR, V25, P7, DOI 10.1007/BF00768062; DAVIES J, 1965, MOL PHARMACOL, V1, P93; EGGERTSSON G, 1988, MICROBIOL REV, V52, P354, DOI 10.1128/MMBR.52.3.354-374.1988; FEARON K, 1994, J BIOL CHEM, V269, P17802; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606; HOWARD M, 1995, AM J PHYSIOL, V38, pC1565; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; SHERMAN F, 1982, MOL BIOL YEAST SACCH, P463; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; SKUZESKI JM, 1991, J MOL BIOL, V218, P365, DOI 10.1016/0022-2836(91)90718-L; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; 1994, HUM MUTAT, V4, P167	20	363	381	1	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					467	469		10.1038/nm0496-467	http://dx.doi.org/10.1038/nm0496-467			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597960				2022-12-27	WOS:A1996UD31400052
J	Tanaka, M; Suda, T; Haze, K; Nakamura, N; Sato, K; Kimura, F; Motoyoshi, K; Mizuki, M; Tagawa, S; Ohga, S; Hatake, K; Drummond, AH; Nagata, S				Tanaka, M; Suda, T; Haze, K; Nakamura, N; Sato, K; Kimura, F; Motoyoshi, K; Mizuki, M; Tagawa, S; Ohga, S; Hatake, K; Drummond, AH; Nagata, S			Fas ligand in human serum	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; GRANULAR LYMPHOCYTIC-LEUKEMIA; GROWTH-FACTOR; EXPRESSION; CELLS; ANTIGEN; APO-1; RECEPTOR; MEMBER; LEVEL	The Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis in Fas-bearing cells. The membrane-bound human Fast was found to be converted to a soluble form (sFasL) by the action of a matrix metalloproteinase-like enzyme. Two neutralizing monoclonal anti-human Fast antibodies were identified, and an enzyme-linked immunosorbent assay (ELISA) for sFasL in human sera was established. Sera from healthy persons did not contain a detectable level of sFasL, whereas those from patients with large granular lymphocytic (LGL) leukemia and natural killer (NK) cell lymphoma did. These malignant cells constitutively expressed Fast, whereas peripheral NK cells from healthy persons expressed Fast only on activation. These results suggested that the systemic tissue damage seen in most patients with LGL leukemia and NK-type lymphoma is due to sFasL produced by these malignant cells. Neutralizing anti-Fast antibodies or matrix metalloproteinase inhibitors may be of use in modulating such tissue damage.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT CLIN RES,SUITA,OSAKA 565,JAPAN; MOCHIDA PHARMACEUT CO,BIOSCI RES LAB,TOKYO 115,JAPAN; NATL DEF MED COLL,DEPT INTERNAL MED 3,TOKOROZAWA,SAITAMA 359,JAPAN; OSAKA CITY UNIV,SCH MED,DEPT CLIN HEMATOL,ABENO,OSAKA 545,JAPAN; TENRI HOSP,DIV HEMATOL,TENRI,NARA 632,JAPAN; JICHI MED SCH,DEPT MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; BRITISH BIOTECH PHARMACEUT,OXFORD OX4 5LY,ENGLAND	Osaka University; Osaka University; Mochida Pharmaceutical Co Ltd; National Defense Medical College - Japan; Osaka Metropolitan University; Tenri Hospital; Jichi Medical University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ADACHI M, IN PRESS P NATL ACAD; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P9; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FALK MH, 1992, BLOOD, V79, P3300; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gougeon M L, 1995, Cell Death Differ, V2, P1; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; IWAI K, 1994, BLOOD, V84, P1201; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KATAOKA T, 1994, J IMMUNOL, V153, P3938; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOUGHRAN TP, 1993, BLOOD, V82, P1; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAGAWA S, 1988, BLOOD, V71, P1161; TAGAWA S, 1992, LEUKEMIA, V6, P465; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081	50	638	654	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					317	322		10.1038/nm0396-317	http://dx.doi.org/10.1038/nm0396-317			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612231				2022-12-27	WOS:A1996TY64000041
J	Noishiki, Y; Tomizawa, Y; Yamane, Y; Matsumoto, A				Noishiki, Y; Tomizawa, Y; Yamane, Y; Matsumoto, A			Autocrine angiogenic vascular prosthesis with bone marrow transplantation	NATURE MEDICINE			English	Article							VENOUS TISSUE FRAGMENTS; GRAFT; INVITRO	Synthetic vascular prostheses are foreign bodies, so that blood coagulation can occur on their luminal surfaces, causing graft occlusion very frequently in prostheses of small diameter. A vascular prosthesis needs angiogenesis for endothelialization of the luminal surface, as endothelial cells have natural and permanent antithrombogenic properties'. To induce capillary growth into the graft, we developed a method of transplanting bone marrow cells, which are primitive, strong enough to survive, and create blood cells, resulting in the inducement of,capillary growth. In an animal experiment, marrow cells were infiltrated into the walls of long-fibril expanded polytetrafluoroethylene (ePTFE) vascular grafts. The grafts were implanted in the abdominal aortic position of 24 dogs autologously. Marrow cells survived and continued exogenous hemopoiesis for up to six months and were immunohistochemically reactive to basic fibroblast growth factor (bFGF). All the grafts older than three weeks had complete endothelialization and maintained their patency. Twenty grafts without bone marrow were implanted as controls. Endothelialization was present at anastomotic sites, but other areas were covered with fresh thrombi. Four out of seven control grafts were patent with endothelial cell lining at six months, but three were occluded and one of the four grafts was still covered with a thrombus layer. Bone marrow with its unique native properties produced autocrine angiogenicity in the graft.	TOKYO WOMENS MED COLL,DEPT CARDIOVASC SURG,SHINJUKU KU,TOKYO 162,JAPAN; TOKYO UNIV AGR & TECHNOL,FAC AGR SCI,DEPT VET MED,FUCHU,TOKYO 183,JAPAN	Tokyo Women's Medical University; Tokyo University of Agriculture & Technology	Noishiki, Y (corresponding author), YOKOHAMA CITY UNIV,SCH MED,DEPT SURG 1,KANAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.							BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BIKFALVI A, 1994, LEUKEMIA, V8, P523; BURGER K, 1972, ANN SURG, V175, P118; CLOWES AW, 1986, AM J PATHOL, V123, P220; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GOLDEN PB, 1983, IN VITRO CELL DEV, V19, P661; HARKESS JW, 1991, ROCKWOOD GREENS FRAC, P145; MIWA AY, 1992, SCIENCE, V267, P1401; NOISHIKI Y, 1993, J THORAC CARDIOV SUR, V105, P796; NOISHIKI Y, 1992, J THORAC CARDIOV SUR, V104, P770; NOISHIKI Y, 1994, J VASC SURG, V20, P279, DOI 10.1016/0741-5214(94)90017-5; NOISHIKI Y, 1995, ARTIF ORGANS, V19, P17, DOI 10.1111/j.1525-1594.1995.tb02239.x; NOISHIKI Y, 1995, ARTIF ORGANS, V19, P7, DOI 10.1111/j.1525-1594.1995.tb02238.x; PARK PK, 1990, J VASC SURG, V11, P468, DOI 10.1067/mva.1990.17242; RADOMSKI JS, 1989, J SURG RES, V47, P173, DOI 10.1016/0022-4804(89)90084-X; Rudolph R, 1990, PLAST SURG-CHIR PLAS, V1, P221; SAUVAGE LR, 1969, SURGERY, V65, P78; TILG H, 1994, BLOOD, V83, P113; WANG CL, 1978, BIOCHIM BIOPHYS ACTA, V68, P544; 1985, NIH8023 PUBL	20	115	135	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					90	93		10.1038/nm0196-90	http://dx.doi.org/10.1038/nm0196-90			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564850				2022-12-27	WOS:A1996TP57900043
J	KRAMER, R; ZHANG, YP; GEHRMANN, J; GOLD, R; THOENEN, H; WEKERLE, H				KRAMER, R; ZHANG, YP; GEHRMANN, J; GOLD, R; THOENEN, H; WEKERLE, H			GENE-TRANSFER THROUGH THE BLOOD-NERVE BARRIER - NGF-ENGINEERED NEURITOGENIC T-LYMPHOCYTES ATTENUATE EXPERIMENTAL AUTOIMMUNE NEURITIS	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC NEURITIS; GROWTH-FACTOR; CELL LINE; MESSENGER-RNA; EXPRESSION; RAT; INVIVO; SYSTEM; CDNA; TRK	Nerve-specific autoimmune T lymphocytes were used as vehicles to deliver therapeutically useful neurotrophic factors across the endothelial blood-nerve barrier. P-2 protein-reactive T-lymphocyte lines from Lewis rats were transduced with a recombinant retrovirus containing the mouse nerve growth factor (NGF) gene. The engineered T cells released high amounts of NGF dependent on antigenic stimulation in vitro. After intravenous injection, the T cells infiltrated the rat peripheral nervous system and persisted there for at least two weeks. Local release of NGF from engineered T cells was demonstrable by immunocytochemistry and by an anti-inflammatory effect on infiltrating macrophages.	MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY; UNIV ZURICH HOSP,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	Max Planck Society; University of Zurich; University Zurich Hospital								CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUMOYER D, 1993, ANNU REV IMMUNOL, V11, P297; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; GEHRMANN J, 1992, LAB INVEST, V67, P100; HARTUNG HP, 1993, PERIPHERAL NEUROPATH, P418; HEININGER K, 1988, ANN NEUROL, V23, P326, DOI 10.1002/ana.410230403; HEININGER K, 1986, ANN NEUROL, V19, P44, DOI 10.1002/ana.410190109; HWU P, 1993, J IMMUNOL, V150, P4104; IZUMO S, 1985, LAB INVEST, V53, P209; KAWAJA MD, 1992, J NEUROSCI, V12, P2849; KORSCHING S, 1983, P NATL ACAD SCI-BIOL, V80, P3513, DOI 10.1073/pnas.80.11.3513; LAMPERT P, 1977, ACTA NEUROPATHOL, V40, P103, DOI 10.1007/BF00688697; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; LININGTON C, 1984, J IMMUNOL, V133, P1946; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SEBERT ME, 1993, J NEUROSCI RES, V36, P357, DOI 10.1002/jnr.490360402; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9	22	70	76	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1162	1166		10.1038/nm1195-1162	http://dx.doi.org/10.1038/nm1195-1162			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584988				2022-12-27	WOS:A1995TC53700040
J	TAMADA, JA; BOHANNON, NJV; POTTS, RO				TAMADA, JA; BOHANNON, NJV; POTTS, RO			MEASUREMENT OF GLUCOSE IN DIABETIC SUBJECTS USING NONINVASIVE TRANSDERMAL EXTRACTION	NATURE MEDICINE			English	Article							SUBCUTANEOUS TISSUE	Results from the Diabetes Care and Complications Trial show that tight blood glucose control significantly reduces the long-term complications of diabetes mellitus(1). In that study, frequent self-testing of glucose and insulin administration resulted in a significant reduction in long-term complications. This protocol, however, also resulted in a threefold increase in the frequency of hypoglycaemic incidents. Currently, self-testing requires a drop of blood for each measurement. The pain and inconvenience of self-testing, along with the fear and danger of hypoglycaemia has led to poor patient acceptance of a tight control regimen, despite the clear long-term advantages. A continuously worn, noninvasive method to periodically measure glucose would provide a convenient and comfortable means of frequent self-testing(2,3). A continuously worn device could also alert the user of low glucose levels, thereby reducing the incidence of hypoglycaemia(4,5). Guy et al. demonstrated a noninvasive method to transport glucose through the skin using low-level electrical current(6,7). To provide a quantitative measurement, the flux of glucose extracted across the skin must correlate with serum glucose in a predictive manner. The results presented here show a quantitative relationship between serum and transdermally extracted glucose in diabetics.	MONTEAGLE MED CTR,SAN FRANCISCO,CA 94110		TAMADA, JA (corresponding author), CYGNUS THERAPEUT SYST,400 PENOBSCOT DR,REDWOOD CITY,CA 94063, USA.							CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; GLIKFELD P, 1989, PHARMACEUT RES, V6, P988, DOI 10.1023/A:1015957816254; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; MOATTISIRAT D, 1992, DIABETOLOGIA, V35, P224, DOI 10.1007/BF00400921; OSHEA TJ, 1992, ANAL CHEM, V64, P381; RAO G, IN PRESS PHARM RES; REACH G, 1992, Analytical Chemistry, V64, P381; REACH G, 1993, DIABETES ANN, P332; 1993, NEW ENGL J MED, V329, P977	9	146	156	1	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1198	1201		10.1038/nm1195-1198	http://dx.doi.org/10.1038/nm1195-1198			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584995				2022-12-27	WOS:A1995TC53700047
J	Aas, T; Borresen, AL; Geisler, S; SmithSorensen, B; Johnsen, H; Varhaug, JE; Akslen, LA; Lonning, PE				Aas, T; Borresen, AL; Geisler, S; SmithSorensen, B; Johnsen, H; Varhaug, JE; Akslen, LA; Lonning, PE			Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients	NATURE MEDICINE			English	Article							EXPRESSION	The mechanisms causing resistance to chemotherapeutic drugs in cancer patients are poorly understood. Recent evidence suggests that different forms of chemotherapy may exert their cytotoxic effects by inducing apoptosis(1). The tumor suppressor gene P53 has a pivotal role inducing apoptosis in response to cellular damage. In vitro investigations have shown intact p53 to play a critical role executing cell death in response to treatment with cytotoxic drugs like 5-fluorouracil, etoposide and doxorubicin(2). Recently, mutations in the P53 gene were found to confer resistance to anthracyclines in a mouse sarcoma tumor model(3) and overexpression of the p53 protein (which, in most cases, is due to a mutated gene) was found to be associated with lack of response to cisplatin-based chemotherapy in non-small cell lung cancer(4). Previous studies have shown mutations in the P53 gene or overexpression of the p53 protein to predict a poor prognosis(5-7), but also a beneficial effect of adjuvant radiotherapy(8) or chemotherapy(9) in breast cancer. In this study we present data linking specific mutations in the P53 gene to primary resistance to doxorubicin therapy and early relapse in breast cancer patients.	NORWEGIAN RADIUMHOSP,DEPT GENET,N-0310 MONTEBELLO,OSLO,NORWAY; HAUKELAND UNIV HOSP,DEPT ONCOL,N-5021 BERGEN,NORWAY; GADE INST,DEPT SURG,N-5021 BERGEN,NORWAY; GADE INST,DEPT PATHOL,N-5021 BERGEN,NORWAY	University of Bergen; Haukeland University Hospital			Akslen, Lars A./AAG-6097-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543; Lonning, Per Eystein/0000-0002-8890-6303				ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ANDERSEN TI, 1995, DIAGN MOL PATHOL, V4, P203, DOI 10.1097/00019606-199509000-00008; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAVEL M, 1993, EUR J CANCER, V29A, P598, DOI 10.1016/S0959-8049(05)80161-3; DIXON WJ, 1995, BMDP STATISTICAL SOF; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; GUNDERSEN S, 1994, EUR J CANCER, V30A, P1775, DOI 10.1016/0959-8049(94)00213-O; HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42; JANSSON T, 1995, J CLIN ONCOL, V13, P2745, DOI 10.1200/JCO.1995.13.11.2745; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Pocard M, 1996, ONCOGENE, V12, P875; PREUDHOMME C, 1993, LEUKEMIA, V7, P1888; RUSCH V, 1995, CANCER RES, V55, P5038; STAL O, 1995, ACTA ONCOL, V34, P767, DOI 10.3109/02841869509127184	18	654	667	0	46	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					811	814		10.1038/nm0796-811	http://dx.doi.org/10.1038/nm0796-811			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673929				2022-12-27	WOS:A1996UU68000039
J	Burke, JR; Enghild, JJ; Martin, ME; Jou, YS; Myers, RM; Roses, AD; Vance, JM; Strittmatter, WJ				Burke, JR; Enghild, JJ; Martin, ME; Jou, YS; Myers, RM; Roses, AD; Vance, JM; Strittmatter, WJ			Huntington and DRPLA proteins selectively interact with the enzyme GAPDH	NATURE MEDICINE			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GLYCOLYTIC-ENZYMES; BINDING PROTEINS; IDENTIFICATION; CELLS	At least five adult-onset neurodegenerative diseases, including Huntington disease (HD), and dentatorubral-pallidoluysian atrophy (DRPLA) are produced by genes containing a variably increased CAG repeat within the coding region(1-4). The size range of the repeats is similar in all diseases; unaffected individuals have fewer than 30 CAG repeats, whereas affected patients usually have more than 40 repeats. The size of the inherited CAG repeat correlates with the severity and age of disease onset(1,5-7). The CAG triplet repeat produces a polyglutamine domain in the expressed proteins(3,8-10). All of these diseases are inherited in a dominant fashion, and a pathologic gain of function in gene carriers has been proposed. We sought to identify proteins in the brain that selectively interact with polyglutamine domain proteins, hypothesizing that the polyglutamine domain may determine protein-protein interactions.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEANE LAB, DURHAM, NC 27710 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	Duke University; Duke University; Duke University; Duke University; Stanford University	Burke, JR (corresponding author), DUKE UNIV, MED CTR, DEPT MED NEUROL, DURHAM, NC 27710 USA.		Jou, Yuh-Shan/O-5921-2018; Burke, James R/E-4245-2016	Jou, Yuh-Shan/0000-0001-5090-3732; Burke, James R/0000-0002-3408-7787; Vance, Jeffery/0000-0003-3815-8199; Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001533, P01NS026630] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01533, NS 26630] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; HOOGEVEEN AT, 1993, HUM MOL GENET, V2, P2069, DOI 10.1093/hmg/2.12.2069; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KNULL HR, 1985, COMP BIOCHEM PHYS B, V81, P349, DOI 10.1016/0305-0491(85)90324-4; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MINASCHEK G, 1992, EUR J CELL BIOL, V58, P418; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAI A, 1991, BIOCHEM BIOPH RES CO, V176, P59, DOI 10.1016/0006-291X(91)90889-F; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; RANUM LPW, 1994, AM J HUM GENET, V55, P244; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SCHULZE H, 1993, J NEUROCHEM, V60, P1915, DOI 10.1111/j.1471-4159.1993.tb13420.x; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; [No title captured]	32	380	394	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1996	2	3					347	350		10.1038/nm0396-347	http://dx.doi.org/10.1038/nm0396-347			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612237				2022-12-27	WOS:A1996TY64000047
J	Issa, JPJ; Baylin, SB				Issa, JPJ; Baylin, SB			Epigenetics and human disease	NATURE MEDICINE			English	Editorial Material							DNA METHYLATION; RELAXATION; TUMOR				Issa, JPJ (corresponding author), JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231, USA.			Issa, Jean-Pierre/0000-0003-2258-5030				BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; ELLIOTT M, 1994, J MED GENET, V31, P560, DOI 10.1136/jmg.31.7.560; FEY MF, 1994, BLOOD, V83, P931; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; LEISENRING WM, 1994, CANCER RES, V54, P4680; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	18	34	35	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					281	282		10.1038/nm0396-281	http://dx.doi.org/10.1038/nm0396-281			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612223				2022-12-27	WOS:A1996TY64000033
J	Koenig, S				Koenig, S			A lesson from the HIV patient: The immune response is still the bane (or promise) of gene therapy	NATURE MEDICINE			English	Editorial Material											Koenig, S (corresponding author), MEDIMMUNE INC,35 W WATKINS MILL RD,GAITHERSBURG,MD 20878, USA.							CHAVIN KD, 1993, J IMMUNOL, V151, P7249; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; GREENSTEIN JL, 1995, CYBERCONGRESS TRANSP; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; MORRIS RE, 1993, J HEART LUNG TRANSPL, V12, pS275; REDFIELD R, 1992, AIDS RES HUM RETROV, V8, P1333, DOI 10.1089/aid.1992.8.1333; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; ROBERTS MR, 1994, BLOOD, V84, P2878; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SOULILLOU JP, 1994, KIDNEY INT, V46, P540, DOI 10.1038/ki.1994.306; THOMPSON JS, 1995, RECENT DEV TRANSPLAN, P139; TURKA LA, 1995, RECENT DEV TRANSPLAN, P139; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wilson JM, 1995, J CLIN INVEST, V96, P2547, DOI 10.1172/JCI118318; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YU M, 1994, GENE THER, V1, P13	18	4	8	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					165	167		10.1038/nm0296-165	http://dx.doi.org/10.1038/nm0296-165			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574959				2022-12-27	WOS:A1996TU06000034
J	GALLIMORE, A; CRANAGE, M; COOK, N; ALMOND, N; BOOTMAN, J; RUD, E; SILVERA, P; DENNIS, M; CORCORAN, T; STOTT, J; MCMICHAEL, A; GOTCH, F				GALLIMORE, A; CRANAGE, M; COOK, N; ALMOND, N; BOOTMAN, J; RUD, E; SILVERA, P; DENNIS, M; CORCORAN, T; STOTT, J; MCMICHAEL, A; GOTCH, F			EARLY SUPPRESSION OF SIV REPLICATION BY CD8+ NEF-SPECIFIC CYTOTOXIC T-CELLS IN VACCINATED MACAQUES	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTES-T; MONKEYS; GENE; INVITRO; PROTEIN; AIDS	In order to develop a successful subunit vaccine against infection with the human immunodeficiency virus (HIV), protective immune effector functions must be identified. Until now, there has been only indirect evidence that HIV-specific cytotoxic T lymphocytes (CTLs) fulfill this role. Using the macaque simian immunodeficiency virus (SIV) model, the protective potential of nef-specific CTLs, stimulated by vaccination, was examined in animals challenged with a high intravenous dose of the pathogenic simian immunodeficiency virus, SIVmac251(32H)(pJ5). An inverse correlation was found between the vaccine-induced nef-specific CTL precursor frequency and virus load measured after challenge. In addition, the early decline in viraemia, observed in both vaccinated and unvaccinated control animals was associated with the development of virus-specific CTL activity and not with the presence of virus-specific neutralizing; antibodies. The results imply that vaccines that stimulate strong CTL responses could protect against HIV infection.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; CTR APPL MICROBIOL & RES,SALISBURY SP4 0JG,WILTS,ENGLAND; NATL INST BIOL STAND & CONTROLS,AIDS COLLABORATING CTR,POTTERS BAR EN6 3QG,HERTS,ENGLAND; NATL INST BIOL STAND & CONTROLS,DIV IMMUNOBIOL,POTTERS BAR EN6 3QG,HERTS,ENGLAND; DEPT HLTH & WELF,LAB CTR DIS CONTROL,BUR HIV AIDS,OTTAWA,ON K1A 0L2,CANADA	University of Oxford; National Institute for Biological Standards & Control; National Institute for Biological Standards & Control			Rud, Erling/P-5359-2016	Rud, Erling/0000-0001-8615-0277; Gallimore, Awen/0000-0001-6675-7004; Almond, Neil/0000-0001-6105-0616				ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; AN SF, 1992, MOL CELL PROBE, V6, P193, DOI 10.1016/0890-8508(92)90016-Q; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2228, DOI 10.1002/eji.1830240944; BANGHAM CRM, 1989, T CELLS; BOOTMAN JS, 1992, J VIROL METHODS, V37, P23, DOI 10.1016/0166-0934(92)90018-9; BOOTMAN JS, 1994, J VIROL METHODS, V49, P1, DOI 10.1016/0166-0934(94)90050-7; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CULMANN B, 1991, J IMMUNOL, V146, P1560; CULMANNPENCIOLE.B, 1994, J VIROL, V68, P7336; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; GOTCH FM, 1991, AIDS, V5, P317, DOI 10.1097/00002030-199103000-00012; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LAMHAMEDICHERRA.S, 1992, AIDS, V6, P1249; LEFKOVITS I, 1979, LIMITING DILUTION AN; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; NORUSIS MJ, 1988, SPSS PCPLUS V2 0; NOWAK MA, IN PRESS NATURE; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; ROSE J, 1995, J VIROL METHODS, V51, P229, DOI 10.1016/0166-0934(94)00109-T; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES S, IN PRESS CURR TOPICS; RUD E, 1994, VACCINES 92 MODERN A, V75, P529; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; Sambrook J, 1989, MOL CLONING LABORATO; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	39	182	187	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1167	1173		10.1038/nm1195-1167	http://dx.doi.org/10.1038/nm1195-1167			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584989				2022-12-27	WOS:A1995TC53700041
J	BERKLEY, KJ; HUBSCHER, CH				BERKLEY, KJ; HUBSCHER, CH			ARE THERE SEPARATE CENTRAL-NERVOUS-SYSTEM PATHWAYS FOR TOUCH AND PAIN	NATURE MEDICINE			English	Article							DORSAL COLUMN NUCLEI; RAT CUNEATE NUCLEUS; AFFERENT-FIBERS; SPINAL-CORD; GRACILE NUCLEUS; NEURONS; STIMULATION; RESPONSES; PROJECTIONS; LESIONS	Information about bodily events is conveyed by primary sensory fibres to higher brain centres through neurons in the dorsal column nuclei (DCN) and spinal dorsal horn. The DCN route is commonly considered a 'touch pathway', separate from the spinal 'pain pathway', in part because DCN neurons respond to gentle tactile stimulation of small skin areas. Here we report that DCN neurons can additionally respond to gentle and noxious stimulation of viscera and widespread skin regions. These and other experimental and clinical data suggest that the DCN and spinal routes cooperate, rather than operate separately, to produce the many perceptions of touch and pain, an ensemble view that encourages novel approaches to health care and research.			BERKLEY, KJ (corresponding author), FLORIDA STATE UNIV, NEUROSCI PROGRAM, TALLAHASSEE, FL 32306 USA.				NINDS NIH HHS [NS 11892] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011892] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APKARIAN AV, 1995, PROG PAIN RES MANAG, V5, P217; BANNA NR, 1989, SOMATOSENS MOT RES, V6, P237, DOI 10.3109/08990228909144675; BARBARESI P, 1986, BRAIN RES, V382, P305, DOI 10.1016/0006-8993(86)91340-5; BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; BERKLEY KJ, 1995, PAIN, V61, P121, DOI 10.1016/0304-3959(94)00150-D; BERKLEY KJ, 1993, J NEUROPHYSIOL, V69, P545, DOI 10.1152/jn.1993.69.2.545; BERKLEY KJ, 1993, J NEUROPHYSIOL, V69, P533, DOI 10.1152/jn.1993.69.2.533; BERKLEY KJ, 1993, J NEUROPHYSIOL, V69, P557, DOI 10.1152/jn.1993.69.2.557; BERKLEY KJ, 1986, BRAIN RES REV, V11, P199, DOI 10.1016/0165-0173(86)90012-3; BERKLEY KJ, 1991, J CARDIOVASC ELECTR, V2, pS13; CECHETTO DF, 1987, FASEB J, V46, P17; CLIFFER KD, 1989, J NEUROSCI, V9, P3146; CLIFFER KD, 1992, J NEUROPHYSIOL, V68, P818, DOI 10.1152/jn.1992.68.3.818; COGGESHALL RE, 1990, RECENT ACHIEVEMENTS, V3, P128; DAMASSIO AR, 1994, DESCARTES ERROR; DAVIDSON N, 1971, J PHYSIOL-LONDON, V219, P689, DOI 10.1113/jphysiol.1971.sp009683; Delorey Timothy M., 1994, P389; DEPOMMERY J, 1984, NEUROSCI LETT, V50, P319, DOI 10.1016/0304-3940(84)90506-8; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; DOSTROVSKY JO, 1977, EXP NEUROL, V56, P610, DOI 10.1016/0014-4886(77)90324-7; FELDMAN SG, 1980, J COMP NEUROL, V192, P427, DOI 10.1002/cne.901920305; FIELDS HL, 1994, PHARM APPROACHES TRE; FRYE CA, 1993, PHARMACOL BIOCHEM BE, V45, P255, DOI 10.1016/0091-3057(93)90116-B; GAHERY Y, 1974, BRAIN RES, V75, P241, DOI 10.1016/0006-8993(74)90744-6; GILDENBERG PL, 1984, J NEUROL NEUROSUR PS, V47, P94, DOI 10.1136/jnnp.47.1.94; GIUFFRIDA R, 1992, J COMP NEUROL, V316, P206, DOI 10.1002/cne.903160206; Gybels J M, 1989, Pain Headache, V11, P1; HUBSCHER CH, 1994, BRAIN RES, V664, P1, DOI 10.1016/0006-8993(94)91946-1; KRIANICK JU, 1994, TXB PAIN, P1219; LAHUERTA J, 1994, J NEUROSURG, V80, P975, DOI 10.3171/jns.1994.80.6.0975; MASLANY S, 1991, BRAIN RES, V564, P56, DOI 10.1016/0006-8993(91)91351-Z; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; MCMAHON SB, 1983, EXP NEUROL, V80, P195, DOI 10.1016/0014-4886(83)90016-X; MELZACK R, 1989, CAN PSYCHOL, V30, P1, DOI 10.1037/h0079793; NATHAN PW, 1986, BRAIN, V109, P1003, DOI 10.1093/brain/109.5.1003; NEUHUBER W, 1982, ANAT EMBRYOL, V164, P413, DOI 10.1007/BF00315762; PETTIT MJ, 1993, SCIENCE, V262, P2054, DOI 10.1126/science.8266104; PFAFF DW, 1994, PHYSL REPRODUCTION, V2, P107; RANCE NE, 1988, NEUROLOGY, V38, P265, DOI 10.1212/WNL.38.2.265; RIGAMONTI DD, 1978, EXP NEUROL, V61, P337, DOI 10.1016/0014-4886(78)90251-0; SAADE NE, 1986, BRAIN RES, V369, P307, DOI 10.1016/0006-8993(86)90540-8; SAADE NE, 1990, PAIN, V42, P313, DOI 10.1016/0304-3959(90)91144-8; Spiller WG, 1912, J AMER MED ASSOC, V58, P1489; TRIGGS WJ, 1994, J NEUROL NEUROSUR PS, V57, P1077, DOI 10.1136/jnnp.57.9.1077; Wall P. D., 1994, TXB PAIN, P1; WALL PD, 1977, BRAIN, V100, P641, DOI 10.1093/brain/100.4.641; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y; WEINBERG RJ, 1989, J COMP NEUROL, V282, P142, DOI 10.1002/cne.902820111; WEINBERG RJ, 1990, J COMP NEUROL, V300, P113, DOI 10.1002/cne.903000108; White JC., 1969, PAIN NEUROSURGEON, P6; Willis WD, 1991, SENSORY MECH SPINAL	51	94	97	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					766	773		10.1038/nm0895-766	http://dx.doi.org/10.1038/nm0895-766			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585178				2022-12-27	WOS:A1995RM63500032
J	MARGOLICK, JB; MUNOZ, A; DONNENBERG, AD; PARK, LP; GALAI, N; GIORGI, JV; OGORMAN, MRG; FERBAS, J				MARGOLICK, JB; MUNOZ, A; DONNENBERG, AD; PARK, LP; GALAI, N; GIORGI, JV; OGORMAN, MRG; FERBAS, J			FAILURE OF T-CELL HOMEOSTASIS PRECEDING AIDS IN HIV-1 INFECTION	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD; LYMPHOCYTES-T; DISEASE; SEROCONVERSION; PROGRESSION; RESPONSES	We and others have postulated that a constant number of T lymphocytes is normally maintained without regard to CD4(+) or CD8(+) phenotype ('blind' T-cell homeostasis). Here we confirm essentially constant T-cell levels (despite marked decline in CD4(+) T cells and increase in CD8(+) T cells) in homosexual men with incident human immunodeficiency virus, type 1 (HIV-1), infection who remained free of acquired immunodeficiency syndrome (AIDS) for up to eight years after seroconversion. In contrast, seroconverters who developed AIDS exhibited rapidly declining T cells (both CD4(+) and CD8(+)) for approximately two years before AIDS, independent of the time between seroconversion and AIDS, suggesting that homeostasis failure is an important landmark in HIV disease progression. Given the high rate of T-cell turnover in HIV-1 infection, blind T-cell homeostasis may contribute to HIV pathogenesis through a CD8(+) T lymphocytosis that interferes with regeneration of lost CD4(+) T cells.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; MONTEFIORE UNIV HOSP,PITTSBURGH,PA 15213; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT ECOL MED,IL-91120 JERUSALEM,ISRAEL; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; NORTHWESTERN UNIV,DEPT PEDIAT,CHICAGO,IL 60614	Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Hebrew University of Jerusalem; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Northwestern University	MARGOLICK, JB (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC BIOL & IMMUNOL,ROOM 7032,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Galai, Noya/HII-8086-2022; Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072631, N01AI072634, N01AI032535] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32535, AI 72631, AI 72634] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; ALDEMAN LM, 1993, 1ST NATN C HUM RETR; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; DONNENBERG AD, 1995, RES IMMUNOL, V146, P11, DOI 10.1016/0923-2494(96)80236-7; DONNENBERG AD, IN PRESS ANN NY ACAD; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GALAI N, 1993, STAT MED, V12, P2133, DOI 10.1002/sim.4780122207; GIORGI JV, 1994, AIDS S1, V8, pS183; GIORGI JV, 1900, CLIN IMMUNOL IMMUNOP, V55, P173; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; HAUSNER MA, 1993, J IMMUNOL METHODS, V157, P181, DOI 10.1016/0022-1759(93)90085-L; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO HN, 1993, J IMMUNOL, V150, P3070; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOOVER DR, 1992, AM J PUBLIC HEALTH, V82, P1538, DOI 10.2105/AJPH.82.11.1538; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARGOLICK JB, 1993, J ACQ IMMUN DEF SYND, V6, P153; MARGOLICK JB, 1994, J ACQUIR IMMUN DEFIC, V8, P415; MEUER SC, 1982, J IMMUNOL, V129, P1076; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SCHENKER EL, 1993, CYTOMETRY, V14, P307, DOI 10.1002/cyto.990140311; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404; 1987, MMWR-MORBID MORTAL W, V36, pS3	29	211	226	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					674	680		10.1038/nm0795-674	http://dx.doi.org/10.1038/nm0795-674			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585150	Bronze			2022-12-27	WOS:A1995RQ06600043
J	WAINBERG, MA; GU, ZX				WAINBERG, MA; GU, ZX			TARGETING HIV REVERSE-TRANSCRIPTASE IN NOVEL WAYS	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANCE; MUTATION; AZT				WAINBERG, MA (corresponding author), MCGILL UNIV,JEWISH GEN HOSP,CTR AIDS,MONTREAL,PQ H3T 1E2,CANADA.							GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; Katlama C., 1994, AIDS (Philadelphia), V8, pS6; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Staszewski S., 1994, AIDS (Philadelphia), V8, pS7; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; WU J, 1993, J BIOL CHEM, V268, P9980; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	13	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					628	629		10.1038/nm0795-628	http://dx.doi.org/10.1038/nm0795-628			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585138				2022-12-27	WOS:A1995RQ06600031
J	JONESCARSON, J; VAZQUEZTORRES, A; VANDERHEYDE, HC; WARNER, T; WAGNER, RD; BALISH, E				JONESCARSON, J; VAZQUEZTORRES, A; VANDERHEYDE, HC; WARNER, T; WAGNER, RD; BALISH, E			GAMMA-DELTA T-CELL-INDUCED NITRIC-OXIDE PRODUCTION ENHANCES RESISTANCE TO MUCOSAL CANDIDIASIS	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BLOOD-STAGE MALARIA; GASTROINTESTINAL CANDIDIASIS; LISTERIA-MONOCYTOGENES; MACROPHAGE ACTIVATION; SYSTEMIC CANDIDIASIS; GNOTOBIOTIC MICE; INFECTED MICE; ALPHA-BETA; SCID MICE	Despite the prevalence of gamma delta T cells in mucosae that are typically colonized by Candida albicans, little is known of the possible role of these cells in resistance to candidiasis. A sharp increase in the number of gamma delta T cells and macrophages following intraperitoneal inoculation of mice with C. albicons led us to examine the role of these cells in the immune response to C, albicans. We show that the gamma delta T cells enhance macrophage nitric oxide (NO) production and anti-candida activity, in vitro. We also propose that the gamma delta T cells regulate macrophage function during candidiasis in vivo as well, because depletion of these cells abrogated inducible NO synthase expression in mucosae and enhanced murine susceptibility to candidiasis.	UNIV WISCONSIN,SCH MED,DEPT SURG,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED MICROBIOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT IMMUNOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT SURG PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009659] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-09659] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALISH E, 1993, J MED VET MYCOL, V31, P143; BALISH E, 1990, INFECT IMMUN, V58, P107, DOI 10.1128/IAI.58.1.107-113.1990; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BISTONI F, 1993, J INFECT DIS, V168, P1449, DOI 10.1093/infdis/168.6.1449; BODEY GP, 1992, SEMIN HEMATOL, V19, P196; BOOCKVAR KS, 1994, INFECT IMMUN, V62, P1089, DOI 10.1128/IAI.62.3.1089-1100.1994; CANTORNA M, 1990, INFECT IMMUN, V58, P3813, DOI 10.1128/IAI.58.11.3813-3815.1990; CANTORNA MT, 1991, INFECT IMMUN, V59, P2447, DOI 10.1128/IAI.59.7.2447-2455.1991; CENCI E, 1993, EUR J IMMUNOL, V23, P1034, DOI 10.1002/eji.1830230508; CHAKIR J, 1994, ORAL MICROBIOL IMMUN, V9, P88, DOI 10.1111/j.1399-302X.1994.tb00040.x; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; COLE GT, 1992, INFECT IMMUN, V60, P4168, DOI 10.1128/IAI.60.10.4168-4178.1992; CUTLER JE, 1976, J RETICULOENDOTH SOC, V19, P121; Di Rosa R, 1991, Boll Ist Sieroter Milan, V70, P499; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FIDEL PL, 1994, INFECT IMMUN, V62, P1032, DOI 10.1128/IAI.62.3.1032-1038.1994; FOLLOWS GA, 1992, INFECT IMMUN, V60, P1229, DOI 10.1128/IAI.60.3.1229-1231.1992; FU YX, 1994, J IMMUNOL, V153, P3101; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENFIELD RA, 1993, INFECT IMMUN, V61, P2520, DOI 10.1128/IAI.61.6.2520-2525.1993; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; JENSEN J, 1992, INFECT IMMUN, V60, P4549, DOI 10.1128/IAI.60.11.4549-4557.1992; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEFRANCOIS L, 1989, SCIENCE, V243, P1716, DOI 10.1126/science.2564701; LORSBACH RB, 1992, INFECT IMMUN, V60, P2133, DOI 10.1128/IAI.60.5.2133-2135.1992; LUNDQVIST C, 1994, J IMMUNOL, V153, P2302; MARODI L, 1993, J CLIN INVEST, V91, P2596, DOI 10.1172/JCI116498; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MIXTER PF, 1994, INFECT IMMUN, V62, P4618, DOI 10.1128/IAI.62.10.4618-4621.1994; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; NARAYANAN R, 1991, INFECT IMMUN, V59, P2116, DOI 10.1128/IAI.59.6.2116-2119.1991; ROMANI L, 1994, J IMMUNOL, V152, P3514; ROMANI L, 1993, INFECT IMMUN, V61, P3769, DOI 10.1128/IAI.61.9.3769-3774.1993; ROSAT JP, 1993, J IMMUNOL, V150, P550; SKEEN MJ, 1993, J EXP MED, V178, P985, DOI 10.1084/jem.178.3.985; STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783; STERNBERG S, 1994, SCIENCE, V266, P1632, DOI 10.1126/science.7702654; TANOWITZ HB, 1992, MED CLIN N AM, V76, P45, DOI 10.1016/S0025-7125(16)30370-4; TAO X, 1993, EUR J IMMUNOL, V23, P2916, DOI 10.1002/eji.1830231128; VANDERHEYDE HC, 1993, EUR J IMMUNOL, V23, P1846, DOI 10.1002/eji.1830230817; VANDERHEYDE HC, 1993, J IMMUNOL, V151, P6311; VASQUEZTORRES A, IN PRESS J INFECT DI; VAZQUEZTORRES A, 1994, J INFECT DIS, V170, P180, DOI 10.1093/infdis/170.1.180; YAMAMOTO S, 1993, INFECT IMMUN, V61, P2154, DOI 10.1128/IAI.61.5.2154-2161.1993	46	102	104	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					552	557		10.1038/nm0695-552	http://dx.doi.org/10.1038/nm0695-552			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585122				2022-12-27	WOS:A1995RN10100039
J	THOMPSON, VP				THOMPSON, VP			ANATOMICAL RESEARCH LIVES	NATURE MEDICINE			English	Editorial Material											THOMPSON, VP (corresponding author), UNIV MARYLAND,SCH DENT,DEPT RESTORAT DENT,BALTIMORE,MD 21201, USA.							BOGDUK N, 1992, J MANIP PHYSIOL THER, V15, P67; KIMMEL DL, 1960, NEUROLOGY, V10, P800; RAY BS, 1942, ARCH SURG-CHICAGO, V41, P813	3	7	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					297	298		10.1038/nm0495-297	http://dx.doi.org/10.1038/nm0495-297			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585053				2022-12-27	WOS:A1995RN09800019
J	FRIEDMANN, T; YEE, JK				FRIEDMANN, T; YEE, JK			PSEUDOTYPED RETROVIRAL VECTORS FOR STUDIES OF HUMAN GENE-THERAPY	NATURE MEDICINE			English	Editorial Material							VESICULAR STOMATITIS-VIRUS; EXPRESSION; INVIVO; RECEPTOR; PROTEIN; CELLS		CITY HOPE NATL MED CTR,DEPT PEDIAT,DUARTE,CA 91010	City of Hope	FRIEDMANN, T (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PEDIAT,LA JOLLA,CA 92093, USA.				NCI NIH HHS [CA58317] Funding Source: Medline; NHLBI NIH HHS [HLHL47119] Funding Source: Medline; NICHD NIH HHS [HD20034] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020034] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BURNS JC, 1994, DEV BIOL, V165, P285, DOI 10.1006/dbio.1994.1253; CORDOSO JE, 1993, HUM GENE THER, V4, P411; EIDEN MV, 1993, J VIROL, V67, P4056, DOI 10.1128/JVI.67.7.4056-4061.1993; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949; FRIEDMANN T, 1992, NAT GENET, V2, P93, DOI 10.1038/ng1092-93; HUANG AS, 1973, J VIROL, V12, P659, DOI 10.1128/JVI.12.3.659-662.1973; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; KOLODKA TM, 1993, SOMAT CELL MOLEC GEN, V19, P491, DOI 10.1007/BF01233254; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; LIVINGSTON DM, 1976, VIROLOGY, V70, P432, DOI 10.1016/0042-6822(76)90284-1; LOVE DN, 1974, VIROLOGY, V57, P217; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER DG, 1994, J VIROL, V68, P8270, DOI 10.1128/JVI.68.12.8270-8276.1994; MIYANOHARA A, IN PRESS GENE THERAP; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Weiss R., 1980, RTE, P52; WEISS RA, 1977, VIROLOGY, V76, P808, DOI 10.1016/0042-6822(77)90261-6; WITTE ON, 1977, CELL, V11, P505, DOI 10.1016/0092-8674(77)90068-X; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZAVADA J, 1972, J GEN VIROL, V125, P183	29	46	49	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					275	277		10.1038/nm0395-275	http://dx.doi.org/10.1038/nm0395-275			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585046				2022-12-27	WOS:A1995QX55900039
J	KINGSTON, IB; CASTRO, MJM; ANDERSON, S				KINGSTON, IB; CASTRO, MJM; ANDERSON, S			IN-VITRO STIMULATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY ALZHEIMER AMYLOID BETA-PEPTIDE ANALOGS	NATURE MEDICINE			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; DISEASE; PROTEIN; ANGIOPATHY; BRAIN; PRECURSOR; FIBRIN; CHAIN	We have studied the effects of amyloid beta-peptide analogues on the activity of tissue-type plasminogen activator (t-PA) in vitro. We have found that these peptides have a marked stimulatory effect upon plasminogen activation by t-PA, comparable to that of known stimulators of t-PA. This stimulatory activity appears to increase when beta-peptides form aggregated fibrillar structures similar to those found in amyloid deposits. This finding is significant in that it may provide insights into the pathogenesis of hereditary cerebral haemorrhage with amyloidosis-Dutch type (HCHWA-D) and cerebral amyloid angiopathy-related cerebral haemorrhage. It may also provide an explanation for the deaths resulting from intracerebral haemorrhage that have occurred in patients undergoing t-PA treatment for acute myocardial infarction.	UNIV CAMBRIDGE, DEPT PATHOL, CAMBRIDGE CB2 1QP, ENGLAND; RUTGERS STATE UNIV, DEPT MICROBIOL, NEW BRUNSWICK, NJ 08903 USA; RUTGERS STATE UNIV, DEPT MOLEC BIOL & BIOCHEM, NEW BRUNSWICK, NJ 08903 USA	University of Cambridge; Rutgers State University New Brunswick; Rutgers State University New Brunswick	KINGSTON, IB (corresponding author), CTR ADV BIOTECHNOL & MED, 679 HOES LANE, PISCATAWAY, NJ 08854 USA.				NIA NIH HHS [R01-AG10462, R01-AG11525] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010462, R01AG011525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CASTRO MJM, IN PRESS ANAL BIOCH; CHIEN TT, 1984, BLOOD, V63, P1331; CORIA F, 1987, AM J PATHOL, V129, P422; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOUST JM, 1984, J NEUROPATH EXP NEUR, V43, P481, DOI 10.1097/00005072-198409000-00003; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HIGGINS DL, 1990, THROMB RES, V57, P527, DOI 10.1016/0049-3848(90)90070-S; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KASE CS, 1990, ANN INTERN MED, V112, P17, DOI 10.7326/0003-4819-112-1-17; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LIJNEN HR, 1982, SEMIN THROMB HEMOST, V8, P2, DOI 10.1055/s-2007-1005038; LUYENDIJK W, 1988, J NEUROL SCI, V85, P267, DOI 10.1016/0022-510X(88)90186-4; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; PENDLEBURY WW, 1991, ANN NEUROL, V29, P210, DOI 10.1002/ana.410290216; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POWERS JM, 1981, J NEUROPATH EXP NEUR, V40, P592, DOI 10.1097/00005072-198111000-00002; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHIELEN WJG, 1993, FIBRINOLYSIS, V7, P63, DOI 10.1016/0268-9499(93)90057-3; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; STERN RA, 1990, FEBS LETT, V264, P43; TAGLIAVINI F, 1990, LAB INVEST, V62, P761; Tomlinson B.E., 1992, GREENFIELDS NEUROPAT, P1284; TORACK RM, 1975, AM J PATHOL, V81, P349; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; WATTENDORFF AR, 1982, J NEUROL SCI, V55, P121, DOI 10.1016/0022-510X(82)90094-6; WIJDICKS EFM, 1993, STROKE, V24, P554, DOI 10.1161/01.STR.24.4.554; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249	36	101	108	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1995	1	2					138	142						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585010				2022-12-27	WOS:A1995QX55800024
J	NICOLL, JAR; ROBERTS, GW; GRAHAM, DI				NICOLL, JAR; ROBERTS, GW; GRAHAM, DI			APOLIPOPROTEIN-E EPSILON-4 ALLELE IS ASSOCIATED WITH DEPOSITION OF AMYLOID BETA-PROTEIN FOLLOWING HEAD-INJURY	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; TYPE-4 ALLELE; BRAIN; BINDING; STAGE; RISK; PCR	Deposition of amyloid beta-protein (A beta) in the brain plays a key role in the pathogenesis of Alzheimer's disease. Apolipoprotein E epsilon 4 allele (apo E-epsilon 4) is a strong risk factor for Alzheimer's disease, and there is in vitro evidence that apo E is directly involved in A beta deposition. Head injury is an epidemiological risk factor for Alzheimer's disease and deposition of A beta occurs in approximately one-third of individuals dying after a severe head injury. We report here that the frequency of apo E-epsilon 4 in those individuals with A beta deposition following head injury (0.52) is higher than in most studies of Alzheimer's disease, while in those head-injured individuals without A beta deposition the apo E-epsilon 4 frequency (0.16) is similar to controls without Alzheimer's disease (P < 0.00001). This finding provides further evidence linking apo E-epsilon 4 with A beta deposition in vivo and suggests that known environmental and genetic risk factors for Alzheimer's disease may act additively. In addition our finding indicates a genetic susceptibility to the effects of a head injury.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC NEUROPATHOL,HARLOW CM19 5AW,ESSEX,ENGLAND	GlaxoSmithKline	NICOLL, JAR (corresponding author), SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,LANARK,SCOTLAND.		Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246				ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MAYEUX R, 1994, NEUROBIOL AGING, pS73; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NICOLL JAR, 1992, J NEUROL SCI, V113, P144, DOI 10.1016/0022-510X(92)90242-D; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; TSAI MS, 1994, AM J HUM GENET, V54, P643; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Younkin SG, 1991, BRAIN PATHOL, V1, P253, DOI 10.1111/j.1750-3639.1991.tb00668.x	26	416	429	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					135	137		10.1038/nm0295-135	http://dx.doi.org/10.1038/nm0295-135			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585009				2022-12-27	WOS:A1995QX55800023
J	SHORT, N				SHORT, N			A FIGHT TO THE DEATH	NATURE MEDICINE			English	Editorial Material							INFECTION; HIV	Examination of the effects of three new drugs shows that the destruction of the immune system in AIDS reflects fulminant HIV production, which eventually overwhelms the immune system's prodigious powers of regeneration.			SHORT, N (corresponding author), NATURE,4 LITTLE ESSEX ST,LONDON WCZR 3LF,ENGLAND.							CAO Y, NEWENGL J MED   0126, P332; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINKEL TF, 1995, NATURE MED, P1; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KEMPF D, IN PRESS P NATN ACAD; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NAJERA I, 1995, J VIROL, V69, P23; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, NEW ENGL J MED  0126, P332; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	13	4	4	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					122	124		10.1038/nm0295-122	http://dx.doi.org/10.1038/nm0295-122			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585006				2022-12-27	WOS:A1995QX55800020
J	Friesen, C; Herr, I; Krammer, PH; Debatin, KM				Friesen, C; Herr, I; Krammer, PH; Debatin, KM			Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CONTINUOUS-INFUSION; MOLECULAR-CLONING; DEATH APOPTOSIS; SURFACE ANTIGEN; FAS; PHARMACOKINETICS; DOXORUBICIN; ACTIVATION; ADRIAMYCIN	Cytotoxic drugs used in chemotherapy of leukemias and solid tumors cause apoptosis in target cells(1,2). In lymphoid cells the CD95 (APO-1/Fas)/CD95 ligand (CD95-L) system is a key regulator of apoptosis(3-6). Here we describe that doxorbicin induces apoptosis via the CD95/CD95-L system in human leukemia T-cell lines. Doxorubicin-induced apoptosis was completely blocked by inhibition of gene expression and protein synthesis. Also, doxorbicin strongly stimulated CD95-L messenger RNA expression in vitro at concentrations relevant for therapy in vivo. CEM and jurkat cells resistant to CD95-mediated apoptosis were also resistant to doxorbicin-induced apoptosis. Furthermore, doxorbicin-induced apoptosis was inhibited by blocking F(ab')(2)anti-APO-1 (anti-CD95) antibody fragments; Expression of CD95-L mRNA and protein in vitro was also stimulated by other cytotoxic drugs such as methotrexate. The finding that apoptosis caused by anticancer drugs may be mediated via the CD95 system provides a new molecular insight into resistance and sensitivity toward chemotherapy in malignancies.	UNIV HEIDELBERG,CHILDRENS HOSP,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,DIV MOLEC ONCOL,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,DIV IMMUNOGENET,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886				BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CARBONARI M, 1994, BLOOD, V83, P1268; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CUSACK BJ, 1993, CANCER CHEMOTH PHARM, V32, P53, DOI 10.1007/BF00685876; DEBATIN KM, 1995, LEUKEMIA, V9, P815; DEBATIN KM, 1993, BLOOD, V81, P2972; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; HERR I, IN PRESS CELL DEATH; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, IN PRESS EMBO J; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MULLER C, 1993, CANCER CHEMOTH PHARM, V32, P379, DOI 10.1007/BF00735923; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; THAKKAR NS, 1992, BIOCHEM PHARMACOL, V43, P1683, DOI 10.1016/0006-2952(92)90697-H; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530	25	932	957	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					574	577		10.1038/nm0596-574	http://dx.doi.org/10.1038/nm0596-574			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616718				2022-12-27	WOS:A1996UJ23000042
J	Goetz, CG; Diederich, NJ				Goetz, CG; Diederich, NJ			There is a renaissance of interest in pallidotomy for Parkinson's disease	NATURE MEDICINE			English	Editorial Material							SUBTHALAMIC NUCLEUS; LESIONS		CTR HOSP LUXEMBOURG, DEPT NEUROSCI, L-1210 LUXEMBOURG, LUXEMBOURG	Luxembourg Hospital Center	Goetz, CG (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT NEUROL SCI, CHICAGO, IL 60612 USA.		Diederich, Nico J/AAX-4467-2020					AEBISCHER P, 1991, SCIENCE, V252, P133, DOI 10.1126/science.2011750; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Cooper IS, 1953, PSYCHIAT QUART, V27, P317, DOI 10.1007/BF01562492; DIEDERICH N, 1992, NEUROLOGY, V42, P1311, DOI 10.1212/WNL.42.7.1311; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GOETZ CG, 1993, NEUROLOGY, V43, P1; GRAFTON ST, 1995, ANN NEUROL, V37, P776, DOI 10.1002/ana.410370611; Hassler R, 1954, NERVENARZT, V25, P441; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; JANKOVIC J, 1995, NEUROSURGERY, V37, P680, DOI 10.1227/00006123-199510000-00011; LAITINEN LV, 1985, J NEUROSURG, V62, P349, DOI 10.3171/jns.1985.62.3.0349; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; POLLAK P, 1993, REV NEUROL, V149, P175; SPIEGEL EA, 1947, SCIENCE, V106, P349, DOI 10.1126/science.106.2754.349; STERIO D, 1994, ANN NEUROL, V35, P586, DOI 10.1002/ana.410350512; SUTTON JP, 1995, NEUROSURGERY, V36, P1112; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x	21	34	34	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1996	2	5					510	514		10.1038/nm0596-510	http://dx.doi.org/10.1038/nm0596-510			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616702				2022-12-27	WOS:A1996UJ23000026
J	Mecenas, CA; Giussani, DA; Owiny, JR; Jenkins, SL; Wu, WX; Honnebier, MBOM; Lockwood, CJ; Kong, L; Guller, S; Nathanielsz, PW				Mecenas, CA; Giussani, DA; Owiny, JR; Jenkins, SL; Wu, WX; Honnebier, MBOM; Lockwood, CJ; Kong, L; Guller, S; Nathanielsz, PW			Production of premature delivery in pregnant rhesus monkeys by androstenedione infusion	NATURE MEDICINE			English	Article							FIBRONECTIN EXPRESSION; PLASMA-CONCENTRATIONS; OXYTOCIN ANTAGONIST; PERIPHERAL PLASMA; AMNIOTIC-FLUID; LATE GESTATION; FETAL SHEEP; LAST 3RD; PARTURITION; ESTRADIOL	The endocrine mechanisms involved in term and preterm delivery in primates, including pregnant women, are poorly understood. In the term monkey, fetal plasma androgen concentration rises to two hundred times the maternal concentration which remains unchanged. Placental conversion of androgen to estrogen results in increased maternal plasma estrogen concentration at term in both pregnant nonhuman primates and women. In the present study, continuous infusion of androstenedione to 0.8 gestation monkeys resulted in the premature occurrence of labor-type myometrial activity and increases in maternal plasma estrogen, oxytocin and amnion fibronectin concentrations similar to those measured at normal-term labor. Androstenedione induction of these normal-term biochemical and endocrine changes accompanied by fetal membrane rupture, cervical dilatation and live delivery provides a rich opportunity to study the molecular and physiological mechanisms of both term and preterm labor in primates.	CORNELL UNIV,COLL VET MED,DEPT PHYSIOL,LAB PREGNANCY & NEWBORN RES,ITHACA,NY 14853; MT SINAI SCH MED,DEPT OBSTET & GYNECOL,NEW YORK,NY 10029	Cornell University; Icahn School of Medicine at Mount Sinai				Nathanielsz, Peter/0000-0001-8410-6280; Giussani, Dino/0000-0002-1308-1204	NICHD NIH HHS [HD 21350] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBRECHT ED, 1989, AM J OBSTET GYNECOL, V160, P237, DOI 10.1016/0002-9378(89)90128-2; AMICO JA, 1990, NEUROENDOCRINOLOGY, V51, P437, DOI 10.1159/000125371; ANDERSON ABM, 1975, J ENDOCRINOL, V66, P61, DOI 10.1677/joe.0.0660061; BINIENDA Z, 1989, J CLIN ENDOCR METAB, V68, P1184, DOI 10.1210/jcem-68-6-1184; BUSTER JE, 1979, J CLIN ENDOCR METAB, V48, P139, DOI 10.1210/jcem-48-1-139; CHALLIS JRG, 1974, ENDOCRINOLOGY, V95, P547, DOI 10.1210/endo-95-2-547; CHALLIS JRG, 1975, ENDOCRINOLOGY, V96, P185, DOI 10.1210/endo-96-1-185; CHALLIS JRG, 1977, J ENDOCRINOL, V73, P355, DOI 10.1677/joe.0.0730355; CHALLIS JRG, 1971, NATURE, V229, P208, DOI 10.1038/229208a0; CHALLIS JRG, 1974, ENDOCRINOLOGY, V95, P1300, DOI 10.1210/endo-95-5-1300; CHALLIS JRG, 1977, CIBA F S, V47, P211; ELSNER CW, 1979, J CLIN ENDOCR METAB, V49, P30, DOI 10.1210/jcem-49-1-30; FIGUEROA JP, 1989, AM J OBSTET GYNECOL, V161, P481, DOI 10.1016/0002-9378(89)90545-0; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; GARFIELD RE, 1980, AM J PHYSIOL, V238, P81; GULLER S, 1993, ENDOCRINOLOGY, V133, P1139, DOI 10.1210/en.133.3.1139; GULLER S, 1992, ENDOCRINOLOGY, V130, P2609, DOI 10.1210/en.130.5.2609; HALUSKA GJ, 1987, AM J OBSTET GYNECOL, V157, P1487, DOI 10.1016/S0002-9378(87)80249-1; HIRST J J, 1991, American Journal of Obstetrics and Gynecology, V164, P252; HONNEBIER MBOM, 1989, J DEV PHYSIOL, V12, P225; HSU HW, 1989, AM J OBSTET GYNECOL, V161, P467; Liggins G C, 1973, Recent Prog Horm Res, V29, P111; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; LYE SJ, 1994, SEMIN REPROD ENDOCR, V12, P284, DOI 10.1055/s-2007-1016409; MAGYAR DM, 1980, ENDOCRINOLOGY, V107, P155, DOI 10.1210/endo-107-1-155; MAZOR M, 1994, AM J OBSTET GYNECOL, V171, P231, DOI 10.1016/0002-9378(94)90474-X; MCDONALD TJ, 1991, AM J OBSTET GYNECOL, V165, P764, DOI 10.1016/0002-9378(91)90325-L; MILLER FD, 1993, REGUL PEPTIDES, V45, P247, DOI 10.1016/0167-0115(93)90214-S; NATHANIELSZ PW, 1990, AM J OBSTET GYNECOL, V166, P1529; NATHANIELSZ PW, 1984, RES PERINATAL MED, V1, P887; NOVY MJ, 1983, AM J OBSTET GYNECOL, V145, P920, DOI 10.1016/0002-9378(83)90841-4; NOVY MJ, 1981, FETAL ENDOCRINOLOGY, P66; RADETSKY P, 1994, SCIENCE, V266, P1486, DOI 10.1126/science.7985015; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SIITERI PK, 1981, FETAL ENDOCRINOLOGY, P1; TAYLOR NF, 1983, AM J OBSTET GYNECOL, V146, P557, DOI 10.1016/0002-9378(83)90803-7; THOMAS AL, 1978, ENDOCRINOLOGY, V103, P17, DOI 10.1210/endo-103-1-17; TRIBOLLET E, 1990, BRAIN RES, V511, P129, DOI 10.1016/0006-8993(90)90232-Z; TURNBULL AC, 1974, LANCET, P101; WALSH SW, 1984, J CLIN ENDOCR METAB, V58, P629, DOI 10.1210/jcem-58-4-629; WILSON L, 1991, AM J OBSTET GYNECOL, V165, P1487; WILSON L, 1990, AM J OBSTET GYNECOL, V163, P1875, DOI 10.1016/0002-9378(90)90767-2; ZHANG J, 1991, BIOL REPROD, V45, P395, DOI 10.1095/biolreprod45.3.395	44	91	93	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					443	448		10.1038/nm0496-443	http://dx.doi.org/10.1038/nm0496-443			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597955				2022-12-27	WOS:A1996UD31400047
J	Markotic, A; LeDuc, JW; Hlaca, D; Rabatic, S; Sarcevic, A; Dasic, G; Gagro, A; Kuzman, I; Barac, V; AvsicZupanc, T; Beus, I; Dekaris, D				Markotic, A; LeDuc, JW; Hlaca, D; Rabatic, S; Sarcevic, A; Dasic, G; Gagro, A; Kuzman, I; Barac, V; AvsicZupanc, T; Beus, I; Dekaris, D			Hantaviruses are a likely threat to NATO forces in bosnia and Herzegovina and Croatia	NATURE MEDICINE			English	Editorial Material							HEMORRHAGIC-FEVER; RENAL SYNDROME		WHO,CH-1211 GENEVA,SWITZERLAND; UNIV SARAJEVO,SCH MED,SARAJEVO,BOSNIA & HERCEG; UNIV ZAGREB,HOSP INFECT DIS,ZAGREB 1000,CROATIA; HLTH CTR ZADAR,ZADAR 23000,CROATIA; UNIV LJUBLJANA,SCH MED,LJUBLJANA,SLOVENIA	World Health Organization; University of Sarajevo; University of Zagreb; University of Ljubljana	Markotic, A (corresponding author), INST IMMUNOL,ROCKEFELLEROVA 10,ZAGREB 10000,CROATIA.			AVSIC ZUPANC, TATJANA/0000-0001-6243-0688				Borcic B, 1991, Lijec Vjesn, V113, P320; CLEMENT J, 1994, LANCET, V344, P131, DOI 10.1016/S0140-6736(94)91319-6; GAJDUSEK DC, 1962, J PEDIATR-US, V60, P841, DOI 10.1016/S0022-3476(62)80170-X; GAON J, 1968, FOLIA MED FM U SARAE, V3, P23; GLIGIC A, 1989, AM J TROP MED HYG, V41, P102, DOI 10.4269/ajtmh.1989.41.102; GRESIKOVA M, 1968, FOLIA MED SAR, V3, P161; Hlaca D., 1984, FOLIA MED SAR, V19, P99; LEDUC JW, 1990, J INFECT DIS, V162, P1182, DOI 10.1093/infdis/162.5.1182; LEDUC JW, 1989, REV INFECT DIS S4, V11, P730; MARKOTIC A, 1995, NAT MED, V1, P977, DOI 10.1038/nm1095-977a; Markotic A, 1994, Med Arh, V48, P109; NIKLASSON B, 1992, RES VIROLOGY, V143, P211, DOI 10.1016/S0923-2516(06)80106-8; PON E, 1990, AM J TROP MED HYG, V42, P612, DOI 10.4269/ajtmh.1990.42.612; RADOSEVIC Z, 1954, ACTA MED SCAND, V149, P221; Vesenjak-Hirjan J, 1986, Lijec Vjesn, V108, P197; VESENJAK-HIRJAN J, 1971, Folia Parasitologica (Ceske Budejovice), V18, P275; VONSTUHLFAUTH K, 1943, DEUT MED WOCHENSCHR, V69, P439; *WHO, 1983, B WORLD HEALTH ORGAN, V61, P269	18	32	32	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					269	270		10.1038/nm0396-269	http://dx.doi.org/10.1038/nm0396-269			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612216				2022-12-27	WOS:A1996TY64000026
J	Liu, B; Parsons, R; Papadopoulos, N; Nicolaides, NC; Lynch, HT; Watson, P; Jass, JR; Dunlop, M; Wyllie, A; Peltomaki, P; delaChapelle, A; Hamilton, SR; Vogelstein, B; Kinzler, KW				Liu, B; Parsons, R; Papadopoulos, N; Nicolaides, NC; Lynch, HT; Watson, P; Jass, JR; Dunlop, M; Wyllie, A; Peltomaki, P; delaChapelle, A; Hamilton, SR; Vogelstein, B; Kinzler, KW			Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients	NATURE MEDICINE			English	Article							NONPOLYPOSIS COLON-CANCER; MUTATIONS; HOMOLOG	Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disorder characterized by the early onset of colorectal cancer and linked to germline defects in at least four mismatch repair genes. Although much has been learned about the molecular pathogenesis of this disease, questions related to effective presymptomatic diagnosis are largely unanswered because of its genetic complexity. In this study, we evaluated tumors from 74 HNPCC kindreds for genomic instability characteristic of a mismatch repair deficiency and found such instability in 92% of the kindreds. The entire coding regions of the five known human mismatch repair genes were evaluated in 48 kindreds with instability, and mutations were identified in 70%. This study demonstrates that a combination of techniques can be used to genetically diagnose tumor susceptibility in the majority of HNPCC kindreds and lays the foundation for genetic testing of this relatively common disease.	JOHNS HOPKINS ONCOL CTR,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; CREIGHTON UNIV,SCH MED,OMAHA,NE 68178; UNIV AUCKLAND,SCH MED,DEPT PATHOL,AUCKLAND,NEW ZEALAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LAB,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV HELSINKI,DEPT MED GENET,SF-00014 HELSINKI,FINLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Creighton University; University of Auckland; University of Edinburgh; University of Edinburgh; University of Helsinki; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			Dunlop, Malcolm G/F-1973-2011; Papadopoulos, Nickolas/K-7272-2012	Dunlop, Malcolm G/0000-0002-3033-5851; Peltomaki, Paivi/0000-0001-8819-2980; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R37CA035494, P50CA062924, R01CA047527, R01CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47527, CA 62924, CA 35494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BONNER CE, 1994, NATURE, V368, P258; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HALL NR, 1994, EUR J CANCER, V30A, P180, DOI 10.1016/0959-8049(94)90083-3; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; NYSTROMLAHTI M, 1995, NATURE MED, V1, P1202; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TURCOT J, 1959, DIS COLON RECTUM, V2, P456; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Warthin AS, 1913, ARCH INTERN MED, V12, P546	36	795	843	0	51	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					169	174		10.1038/nm0296-169	http://dx.doi.org/10.1038/nm0296-169			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574961				2022-12-27	WOS:A1996TU06000036
J	Weinberg, AD; Bourdette, DN; Sullivan, TJ; Lemon, M; Wallin, JJ; Maziarz, R; Davey, M; Palida, F; Godfrey, W; Engleman, E; Fulton, RJ; Offner, H; Vandenbark, AA				Weinberg, AD; Bourdette, DN; Sullivan, TJ; Lemon, M; Wallin, JJ; Maziarz, R; Davey, M; Palida, F; Godfrey, W; Engleman, E; Fulton, RJ; Offner, H; Vandenbark, AA			Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; ANTIGENS; RAT; DISEASE; PEPTIDE; LESIONS	The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4(+)T. cells that does not require prior knowledge of the pathogenic autoantigen.	VET AFFAIRS MED CTR,PORTLAND,OR 97207; OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; PHARMINGEN,SAN DIEGO,CA 92121; INLAND LAB,DESOTO,TX 75115; STANFORD UNIV,DEPT PATHOL,PALO ALTO,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Stanford University			Godfrey, Wayne/AAL-7219-2020	Wallin, Jeffrey/0000-0002-5952-3813				BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BOURDETTE DN, 1991, J NEUROSCI RES, V30, P308, DOI 10.1002/jnr.490300205; CASPI RR, 1988, J IMMUNOL, V140, P1490; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; CUSH JJ, 1988, ARTHRITIS RHEUM-US, V31, P1230, DOI 10.1002/art.1780311003; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; HINTZEN RQ, 1994, IMMUNOL TODAY, V15, P307, DOI 10.1016/0167-5699(94)90077-9; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KRUISBEEK AM, 1992, CURRENT PROTOCOLS IM; LATZA U, 1994, EUR J IMMUNOL, V24, P677, DOI 10.1002/eji.1830240329; MATSUMOTO Y, 1988, IMMUNOLOGY, V65, P23; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; ORTIZORTIZ L, 1976, J IMMUNOL, V117, P576; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; PATERSON PY, 1981, J CHRON DIS, V26, P119; PRESS OW, 1986, CELL IMMUNOL, V102, P10, DOI 10.1016/0008-8749(86)90321-7; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; SWANBORG RH, 1983, J IMMUNOL, V130, P1503; VANDENBARK AA, 1985, J IMMUNOL, V135, P223; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WEINBERG AD, 1992, J IMMUNOL, V148, P2109; WEINBERG AD, 1994, J IMMUNOL, V152, P4712; WEINBERG AD, IN PRESS J NEUROSCI; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	26	133	146	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					183	189		10.1038/nm0296-183	http://dx.doi.org/10.1038/nm0296-183			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574963				2022-12-27	WOS:A1996TU06000038
J	Freedman, AR; Zhu, HH; Levine, JD; Kalams, S; Scadden, DT				Freedman, AR; Zhu, HH; Levine, JD; Kalams, S; Scadden, DT			Generation of human T lymphocytes from bone marrow CD34(+) cells in vitro	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; HUMAN FETAL THYMOCYTES; EARLY EVENTS; HUMAN THYMUS; PRECURSORS; INFECTION; INVITRO; DIFFERENTIATION; DEPLETION; INVIVO	Analysis of the events that regulate development of red blood cells or granulocytes has led to therapies altering clinical conditions associated with anemia or neutropenia. The development of therapeutic approaches to target conditions associated with lymphopenia, such as AIDS, has been thwarted by limited techniques for studying T-lymphocyte development. We describe an in vitro system in which human bone marrow CD34 cells proliferate, acquire the expression of the lymphoid-specific RAG-2 gene and a broad repertoire of rearranged T-cell receptor genes, develop the ability to produce T cell-specific interleukin-2 and achieve a range of T-cell immunophenotypes. The cells also become susceptible to infection with the T-lymphotropic strain of human immunodeficiency virus-1, HIV-1(IIB). This culture system induces human T lymphopoiesis and may permit further analysis of the events regulating human T-lineage differentiation. It provides a preclinical model for screening stem cell gene therapies directed toward AIDS.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,AIDS RES CTR,INFECT DIS UNIT,BOSTON,MA 02129; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 44851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKINA RK, 1994, BLOOD, V84, P1393; ALDROVANDI GM, 1993, NATURE, V363; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; GALY A, 1993, J EXP MED, V178, P391, DOI 10.1084/jem.178.2.391; GODFREY DI, 1994, J IMMUNOL, V152, P2729; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061; HIRAYAMA F, 1994, BLOOD, V83, P92; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; JACOBSEN SEW, 1993, J EXP MED, V178, P413, DOI 10.1084/jem.178.2.413; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; KURTZBERG J, 1989, P NATL ACAD SCI USA, V86, P7575, DOI 10.1073/pnas.86.19.7575; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEAULT B, 1991, J EXP MED, V174, P1283, DOI 10.1084/jem.174.5.1283; ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; TANAKA KE, 1992, J ACQ IMMUN DEF SYND, V5, P94; TERSTAPPEN IWW, 1992, BLOOD, V79, P666; TJONNFJORD GE, 1993, J EXP MED, V177, P1531, DOI 10.1084/jem.177.6.1531; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WOLF SF, 1994, STEM CELLS, V12, P154, DOI 10.1002/stem.5530120203; YEOMAN H, 1993, IMMUNOLOGY, V90, P10778	30	57	66	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					46	51		10.1038/nm0196-46	http://dx.doi.org/10.1038/nm0196-46			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564838				2022-12-27	WOS:A1996TP57900036
J	LEWIS, DL; ARENS, M				LEWIS, DL; ARENS, M			RESISTANCE OF MICROORGANISMS TO DISINFECTION IN DENTAL AND MEDICAL DEVICES	NATURE MEDICINE			English	Article							INFECTION; STERILIZATION; ENDOSCOPES	The U.S. Centers for Disease Control and Prevention (CDC) recommends that only heat sterilization be used for all reusable devices entering the oral cavity(1). However, chemical disinfection is still employed for reprocessing dental devices in many areas of the world. In an analysis of a Florida dental practice responsible for nosocomial human immunodeficiency virus (HIV) transmissions, the possible role of contaminated devices was deemed unlikely in part because they were subjected to high-level disinfection with 2% glutaraldehyde(2). Disease transmissions have, however, been documented for endoscopes used in diagnostic and surgical procedures even after this treatment(3). In some dental devices, lubricants mix with potentially infectious patient materials, and organic debris has been observed in endoscopes after cleaning(4-6). We have investigated whether lubricants can render high-level chemical disinfection procedures ineffective and have addressed the role that some common devices may play in disease transmission. We report here that HIV in whole-blood samples and Pseudomonas aeruginosa in blood and plasma survived high-level disinfection when entrapped in lubricants used in dental handpieces and endoscopes. We also found that lubricated dental devices used to clean and polish teeth (prophylaxis angles) have the potential to transfer sufficient amounts of blood to infect human lymphocyte cultures with HIV. These results emphasize the need to subject reusable dental devices to a heat-sterilization protocol that penetrates the lubricant(7).	UNIV GEORGIA, DEPT ECOL, ATHENS, GA 30602 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	University System of Georgia; University of Georgia; Washington University (WUSTL)				Lewis, David/0000-0003-0777-2460				[Anonymous], 1993, MMWR Recomm Rep, V42, P1; Barnes Caren M., 1994, General Dentistry, V42, P456; BOND WW, 1991, DISINFECTION STERILI, P1097; ERICE A, 1992, J CLIN MICROBIOL, V30, P444, DOI 10.1128/JCM.30.2.444-448.1992; FAVERO MS, 1991, INFECT CONT HOSP EP, V12, P279; GERBERDING JL, 1991, HOSP PRACT, V26, P103; GOOCH B, 1993, J AM DENT ASSOC, V124, P38, DOI 10.14219/jada.archive.1993.0006; Lewis D L, 1995, Trends Tech Contemp Dent Lab, V12, P30; LEWIS DL, 1992, LANCET, V340, P1252, DOI 10.1016/0140-6736(92)92950-K; LEWIS DL, 1995, ANN INTERN MED, V122, P960, DOI 10.7326/0003-4819-122-12-199506150-00015; LEWIS DL, 1992, J CLIN MICROBIOL, V30, P401, DOI 10.1128/JCM.30.2.401-406.1992; MARTIN E, 1995, AGD IMPACT, V23, P6; SPACH DH, 1993, ANN INTERN MED, V118, P117, DOI 10.7326/0003-4819-118-2-199301150-00008; VESLEY D, 1992, AM J INFECT CONTROL, V20, P291, DOI 10.1016/S0196-6553(05)80232-9	14	25	25	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1995	1	9					956	958		10.1038/nm0995-956	http://dx.doi.org/10.1038/nm0995-956			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585225				2022-12-27	WOS:A1995RT30300053
J	RICHARDS, JR				RICHARDS, JR			EUTHANASIA	NATURE MEDICINE			English	Editorial Material											RICHARDS, JR (corresponding author), OPEN UNIV,DEPT PHILOSOPHY,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					618	620		10.1038/nm0795-618	http://dx.doi.org/10.1038/nm0795-618			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585133				2022-12-27	WOS:A1995RQ06600026
J	SPIEGEL, AM				SPIEGEL, AM			G-PROTEIN GENE KNOCKOUT HITS THE GUT	NATURE MEDICINE			English	Editorial Material							MUTATIONS				SPIEGEL, AM (corresponding author), NIDDKD,BETHESDA,MD 20892, USA.							BICHET DG, 1994, AM J HUM GENET, V55, P278; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; ELSON CO, 1994, INFLAMM BOWEL DIS, P81; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; IISMA TP, 1995, PROTEIN COUPLED RECE; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; RAYMOND JR, 1994, J BIOL CHEM, V269, P13073; RUDOLPH U, 1995, NAT GENET, V10, P141; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; SPIEGEL AM, 1994, PROTEINS; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	17	7	8	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					522	524		10.1038/nm0695-522	http://dx.doi.org/10.1038/nm0695-522			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585115				2022-12-27	WOS:A1995RN10100032
J	LEWIS, W; DALAKAS, MC				LEWIS, W; DALAKAS, MC			MITOCHONDRIAL TOXICITY OF ANTIVIRAL DRUGS	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-POLYMERASES; MUSCLE MITOCHONDRIA; ZIDOVUDINE THERAPY; AIDS; AZIDOTHYMIDINE; MYOPATHY; AZT; DISORDERS; 2',3'-DIDEOXYCYTIDINE	Long-term treatment with antiviral nucleoside analogue drugs, such as AZT, can give rise to delayed and at times severe mitochondrial toxicity. Although these toxic effects are manifest in many tissues, a common disease mechanism can explain the diverse clinical events. A better understanding of these disorders will shed light on genetic mitochondrial diseases and lead to the design of safer and more effective antiviral drugs.	NINCDS, MED NEUROL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS)	LEWIS, W (corresponding author), UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, CINCINNATI, OH 45267 USA.							ANDERSON TD, 1994, LAB INVEST, V70, P724; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CHANG CN, 1992, J BIOL CHEM, V267, P22414; Chariot P, 1991, Neuromuscul Disord, V1, P357, DOI 10.1016/0960-8966(91)90122-9; CHARIOT P, 1994, ARTHRITIS RHEUM, V37, P583, DOI 10.1002/art.1780370421; CHATTHA G, 1993, ANN INTERN MED, V118, P37, DOI 10.7326/0003-4819-118-1-199301010-00007; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; d'Amati G, 1992, Cardiovasc Pathol, V1, P317, DOI 10.1016/1054-8807(92)90042-M; DAINIAK N, 1988, BRIT J HAEMATOL, V69, P299, DOI 10.1111/j.1365-2141.1988.tb02366.x; DALAKAS MC, 1994, ANN NEUROL, V35, P482, DOI 10.1002/ana.410350418; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALAKAS MC, 1994, ANN NEUROL, V36, P680, DOI 10.1002/ana.410360428; DAMATI G, 1994, LAB INVEST, V71, P879; Dixon M., 1979, ENZYMES, Vthird; DUBINSKY RM, 1989, MUSCLE NERVE, V12, P856, DOI 10.1002/mus.880121012; ELION GB, 1993, J MED VIROL, P2; FALCONE A, 1990, BLOOD, V76, P2216; FOUREL I, 1992, J MED VIROL, V37, P122, DOI 10.1002/jmv.1890370209; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FRY M, 1986, ANIMAL CELL DNA POLY; HAMBURGER AW, 1994, EXP HEMATOL, V22, P348; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; JAY C, 1994, J ACQ IMMUN DEF SYND, V7, P630; JAY C, 1994, MYOPATHIES NEUROPATH; JOLLIET P, 1990, LANCET, V335, P1457, DOI 10.1016/0140-6736(90)91481-O; KEILBAUGH SA, 1991, BIOCHEM PHARMACOL, V42, pR5, DOI 10.1016/0006-2952(91)90672-R; LAMPERTH L, 1991, LAB INVEST, V65, P742; LEWIS W, 1991, LAB INVEST, V65, P228; LEWIS W, 1994, BIOCHEMISTRY-US, V33, P14620, DOI 10.1021/bi00252a030; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; LIPSHULTZ SE, 1992, NEW ENGL J MED, V327, P1260, DOI 10.1056/NEJM199210293271802; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MACILWAIN C, 1994, NATURE, V369, P433, DOI 10.1038/369433a0; MARSHALL E, 1994, SCIENCE, V264, P1530, DOI 10.1126/science.8202706; MCGOWAN JJ, 1990, REV INFECT DIS, V12, pS513; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; Moraes Carlos T., 1993, P97; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORGANHUGHES JA, 1994, MYOLOGY, V1, P1610; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; NICKEL W, 1992, J BIOL CHEM, V267, P848; PETERS BS, 1993, Q J MED, V86, P5; PEZESHKPOUR G, 1991, HUM PATHOL, V22, P1281, DOI 10.1016/0046-8177(91)90112-3; PRUSOFF W, 1993, PHARMACOL THERAPEUT, V60, P315, DOI 10.1016/0163-7258(93)90013-4; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RICHARDSON FC, 1994, P NATL ACAD SCI USA, V91, P12003, DOI 10.1073/pnas.91.25.12003; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; ROZENCWEIG M, 1990, REV INFECT DIS, V12, pS570; SATO T, 1991, PROGR NEUROPATHY, V7; SCADDEN DT, 1989, BLOOD, V74, P1455; SEMINOMORA MC, 1994, LAB INVEST, V71, P102; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISSMAN JD, 1992, NEUROLOGY, V42, P619, DOI 10.1212/WNL.42.3.619; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YOSHIDA Y, 1990, AIDS RES HUM RETROV, V6, P929, DOI 10.1089/aid.1990.6.929	66	613	631	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					417	422		10.1038/nm0595-417	http://dx.doi.org/10.1038/nm0595-417			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585087				2022-12-27	WOS:A1995RN10000030
J	REISS, AL; ABRAMS, MT; GREENLAW, R; FREUND, L; DENCKLA, MB				REISS, AL; ABRAMS, MT; GREENLAW, R; FREUND, L; DENCKLA, MB			NEURODEVELOPMENTAL EFFECTS OF THE FMR-1 FULL MUTATION IN HUMANS	NATURE MEDICINE			English	Article							FRAGILE-X-SYNDROME; FRA(X) SYNDROME; CAENORHABDITIS-ELEGANS; COGNITIVE PROFILES; POSTERIOR-FOSSA; CGG-REPEAT; CELL-DEATH; MALES; GENE; BEHAVIOR	Brain dysfunction is the most important sequelae of the fragile X (FMR-1) mutation, the most common heritable cause of developmental disability. Using magnetic-resonance imaging (MRI) and quantitative morphometry, we have compared the neuroanatomy of 51 individuals with an FMR-1 mutation with matched controls and showed that subjects with an FMR-1 mutation have increased volume of the caudate nucleus and, in males, the lateral ventricle. Both caudate and lateral ventricular volumes are correlated with IQ. Caudate volume is also correlated with the methylation status of the FMR-1 gene. Neuroanatomical differences between two monozygotic twins with an FMR-1 mutation who are discordant for mental retardation are localized to the cerebellum, lateral ventricles and subcortical nuclei. These findings suggest that the FMR-1 mutation causing the fragile X syndrome leads to observable changes in neuroanatomy that may be relevant to the neurodevelopmental disability and behavioural problems observed in affected individuals.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	REISS, AL (corresponding author), KENNEDY KRIEGER INST,707 N BROADWAY,BALTIMORE,MD 21205, USA.		Freund, Lisa/ABD-8855-2020	Freund, Lisa/0000-0003-2095-4023	NICHD NIH HHS [HD24061, HD25806] Funding Source: Medline; NIMH NIH HHS [MH01142] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD025806] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAMS MT, 1994, AM J MED GENET, V51, P317, DOI 10.1002/ajmg.1320510407; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; BAMGARDNER T, IN PRESS PEDIATRICS; BAUMGARDNER T, 1992, Current Opinion in Pediatrics, V4, P609, DOI 10.1097/00008480-199208000-00008; Bayley N, 1993, BAYLEY SCALES INFANT; BREGMAN JD, 1988, J AUTISM DEV DISORD, V18, P343, DOI 10.1007/BF02212191; COHEN IL, 1988, AM J MENT RETARD, V92, P436; COHEN IL, 1991, AM J HUM GENET, V48, P195; COTE L, 1991, PRINCIPLES NEURAL SC, P647; CROWE SF, 1990, NEUROPSYCHOLOGIA, V28, P9, DOI 10.1016/0028-3932(90)90082-Y; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; CURFS LMG, 1989, J MED GENET, V26, P443, DOI 10.1136/jmg.26.7.443; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; DYKENS EM, 1989, J AM ACAD CHILD PSY, V28, P422, DOI 10.1097/00004583-198905000-00020; EICHLER EE, 1993, HUM MOL GENET, V2, P1147, DOI 10.1093/hmg/2.8.1147; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FILIPEK PA, IN PRESS CEREBRAL CO; FISCH GS, 1994, AM J MED GENET, V51, P353, DOI 10.1002/ajmg.1320510411; FREUND LS, 1993, PEDIATRICS, V91, P321; FREUND LS, 1991, AM J MED GENET, V38, P542, DOI 10.1002/ajmg.1320380409; FREUND LS, IN PRESS DEVNEUROPSY; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; Hagerman R, 1991, FRAGILE X SYNDROME D, P3; Hagerman R. J., 1991, FRAGILE X SYNDROME D, P173; HAGERMAN RJ, 1989, AM J MED GENET, V33, P513, DOI 10.1002/ajmg.1320330422; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; HODAPP RM, 1990, J AM ACAD CHILD PSY, V29, P214, DOI 10.1097/00004583-199003000-00009; JACK CR, 1994, EPILEPSIA, V35, pS21, DOI 10.1111/j.1528-1157.1994.tb05986.x; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KEMPER MB, 1988, AM J MED GENET, V30, P191, DOI 10.1002/ajmg.1320300118; LACHIEWICZ AM, 1987, AM J MENT RETARD, V92, P272; LACHIEWICZ AM, 1994, AM J MED GENET, V51, P364, DOI 10.1002/ajmg.1320510413; MARGOLIS RL, 1994, BIOL PSYCHIAT, V35, P946, DOI 10.1016/0006-3223(94)91241-6; Mesulam M. M., 1985, PRINCIPLES BEHAVIORA, P1; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PROUTY LA, 1988, AM J MED GENET, V30, P123, DOI 10.1002/ajmg.1320300111; REISS A L, 1990, Brain Dysfunction, V3, P9; REISS AL, 1992, AM J MED GENET, V43, P35, DOI 10.1002/ajmg.1320430106; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; REISS AL, 1994, NEUROLOGY, V44, P1317, DOI 10.1212/WNL.44.7.1317; REISS AL, 1991, AM J HUM GENET, V49, P279; REISS AL, 1991, ANN NEUROL, V29, P26, DOI 10.1002/ana.410290107; REISS AL, ANN NEUROL, V34; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; RUDELLI RD, 1985, ACTA NEUROPATHOL, V67, P289, DOI 10.1007/BF00687814; Sherman S., 1991, FRAGILE X SYNDROME D, P69; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SUDHALTER V, 1991, AM J MED GENET, V38, P493, DOI 10.1002/ajmg.1320380270; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAYLOR A E, 1990, Alzheimer Disease and Associated Disorders, V4, P150, DOI 10.1097/00002093-199040300-00003; THEOBALD TM, 1987, AM J MED GENET, V28, P1, DOI 10.1002/ajmg.1320280102; THORNDIKE R, 1986, GUIDE ADM SCORING 4T; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wechsler D, 1974, WECHSLER ADULT INTEL	60	179	179	1	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					159	167		10.1038/nm0295-159	http://dx.doi.org/10.1038/nm0295-159			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585014				2022-12-27	WOS:A1995QX55800028
J	CALNE, RY				CALNE, RY			AN OPPORTUNITY IN ORGAN-TRANSPLANTATION	NATURE MEDICINE			English	Editorial Material								Further progress in organ transplantation must overcome two key problems: a shortage of organs and long term immunological tolerance. Xenografts and immunological conditioning may help.			CALNE, RY (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT SURG,LEVEL 9,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.							BILLINGHAM RE, 1956, PHILOS T ROY SOC B, V239, P375; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE RY, 1978, LANCET, V2, P1323; CALNE RY, 1994, TRANSPLANTATION, V57, P1433; CALNE RY, 1961, TRANSPLAN B, V28, P445; CALNE RY, 1960, SURG FORUM, V11, P470; Gibson T, 1943, J ANAT, V77, P299; GROTH CG, 1994, LANCET, V344, P6; MERRILL JP, 1956, JAMA-J AM MED ASSOC, V160, P227; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P10; TERASAKI P, 1993, 3RD C AS SOC TRANSPL	12	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					20	22		10.1038/nm0195-20	http://dx.doi.org/10.1038/nm0195-20			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584945				2022-12-27	WOS:A1995QX55700018
J	LIBBY, P				LIBBY, P			LESION VERSUS LUMEN	NATURE MEDICINE			English	Editorial Material								Skinner and colleagues (pages 69-73) show that MRI can be used to evaluate atherosclerotic lesions, non-invasively and in vivo.	HARVARD UNIV,SCH MED,BOSTON,MA 02134	Harvard University; Harvard Medical School	LIBBY, P (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,VASC MED & ATHEROSCLEROSIS UNIT,221 LONGWOOD AVE,BOSTON,MA 02134, USA.		Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X				BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; DAVIES MJ, 1993, BRIT HEART J, V69, P377; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; GALIS Z, IN PRESS J CLIN INVE; GALIS Z, IN PRESS P NATN ACAD; Glagov S., 1987, NEW ENGL J MED, V316, P371; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; TOUSSAINT JF, IN PRESS ARTERIOSCLE	8	27	28	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					17	18		10.1038/nm0195-17	http://dx.doi.org/10.1038/nm0195-17			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584941				2022-12-27	WOS:A1995QX55700016
J	MILLER, PL				MILLER, PL			MEDICAL INFORMATICS IN CLINICAL MEDICINE AND THE BIOSCIENCES	NATURE MEDICINE			English	Editorial Material									YALE UNIV,SCH MED,DEPT ANESTHESIOL,NEW HAVEN,CT 06520	Yale University	MILLER, PL (corresponding author), YALE UNIV,SCH MED,CTR MED INFORMAT,POB 208009,NEW HAVEN,CT 06520, USA.							GREENES RA, 1990, JAMA-J AM MED ASSOC, V263, P1114; PECHURA CM, 1991, ENABLING TECHNOLOGIE; SHORTLIFFE EH, 1990, MED INFORMATICS COMP; VANBEMMEL J, 1992, YB MED INFORMATICS; VANBEMMEL JH, 1994, YB MED INFORMATICS; VANBEMMEL JH, 1993, YB MED INFORMATICS; 1991, COMPUTER BASED PATIE; 1990, DOEER0452P US DEP CO	8	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					93	94		10.1038/nm0195-93	http://dx.doi.org/10.1038/nm0195-93			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584961				2022-12-27	WOS:A1995QX55700033
J	Goldstein, G				Goldstein, G			HIV-1 Tat protein as a potential AIDS vaccine	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; GENE-EXPRESSION; NATURAL ANTIBODIES; TYPE-1; INFECTION; ACTIVATION; APOPTOSIS; RNA; PROGRESSION		THYMON LLC, SHORT HILLS, NJ 07078 USA		Goldstein, G (corresponding author), NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10003 USA.							BRAKE DA, 1990, J VIROL, V64, P962, DOI 10.1128/JVI.64.2.962-965.1990; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; JEANG HT, 1994, HUMAN RETROVIRUSES 3, P11; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KRONE WJA, 1988, J MED VIROL, V26, P261, DOI 10.1002/jmv.1890260306; KUSUMI K, 1992, J VIROL, V66, P875, DOI 10.1128/JVI.66.2.875-885.1992; LEVEY JA, 1994, HIV PATHOGENESIS AID, P27; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MASOOD R, 1994, BIOCHEM BIOPH RES CO, V202, P374, DOI 10.1006/bbrc.1994.1938; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; REISS P, 1990, J MED VIROL, V30, P163, DOI 10.1002/jmv.1890300303; RODMAN TC, 1993, P NATL ACAD SCI USA, V90, P7719, DOI 10.1073/pnas.90.16.7719; RUBEN S, 1989, J VIROL, V63, P1; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; STEINAA L, 1994, ARCH VIROL, V139, P263, DOI 10.1007/BF01310790; THOMAS CA, 1994, J IMMUNOL, V153, P3831; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; ZAULI G, 1992, BLOOD, V80, P3036	34	122	141	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					960	964		10.1038/nm0996-960	http://dx.doi.org/10.1038/nm0996-960			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782444				2022-12-27	WOS:A1996VF49700021
J	Sharpe, P				Sharpe, P			HOX gene mutations - The wait is over	NATURE MEDICINE			English	Editorial Material											Sharpe, P (corresponding author), UNITED MED & DENT SCH,GUYS HOSP,DEPT CRANIOFACIAL DEV,LONDON SE1 9RT,ENGLAND.							Brunelli S, 1996, NAT GENET, V12, P94, DOI 10.1038/ng0196-94; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509	10	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					748	749		10.1038/nm0796-748	http://dx.doi.org/10.1038/nm0796-748			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673917				2022-12-27	WOS:A1996UU68000027
J	Cioffi, JA; Shafer, AW; Zupancic, TJ; SmithGbur, J; Mikhail, A; Platika, D; Snodgrass, HR				Cioffi, JA; Shafer, AW; Zupancic, TJ; SmithGbur, J; Mikhail, A; Platika, D; Snodgrass, HR			Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction	NATURE MEDICINE			English	Article							IL-6 SIGNAL TRANSDUCER; STEM-CELLS; MOUSE; EXPRESSION; CLONING; ENRICHMENT; IMMUNE; GP130	Hematopoietic development is a complex process that involves a large number of growth factors and cytokines. Many cytokines are known to act on more mature, lineage-restricted cells of the hematopoietic system(1,2). However, no specific factors have yet been identified that induce the expansion of the most primitive hematopoietic cells without also inducing differentiation. To search for such factors, we isolated novel cell lines from the yolk sac in order to identify genes important in early hematopoietic and endothelial development. This approach led to the discovery of B219, a sequence that is expressed in at least four isoforms in very primitive hematopoietic cell populations and which may represent a novel hemopoietin receptor. The recently published receptor(3) for the obesity (ob) gene product (leptin)(4) is an isoform of B219 with a nearly identical ligand binding domain. B279/obr is expressed in the yolk sac, early fetal liver, enriched hematopoietic stem cells and in a variety of lymphohematopoietic cell lines. B279/obr is also expressed at high levels in adult reproductive organs. B279/obr maps to human chromosome 1p32, a region syntenic with the recently reported location of obr on murine chromosome 4 (ref. 5).	PROGENITOR INC,COLUMBUS,OH 43212; OHIO STATE UNIV,SCH MED,DIV BONE MARROW TRANSPLANTAT,DEPT INTERNAL MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BARRACLOUGH CA, HDB PHYSL 7 1, P29; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BJORNTORP P, 1993, ANN NY ACAD SCI, V676, P242; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CARLSSON L, 1995, EUR J IMMUNOL, V25, P2308, DOI 10.1002/eji.1830250829; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Civin C I, 1993, J Hematother, V2, P137, DOI 10.1089/scd.1.1993.2.137; FERNANDES G, 1978, J CLIN INVEST, V61, P243, DOI 10.1172/JCI108933; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GARRIS DR, 1986, ANAT RECORD, V216, P359, DOI 10.1002/ar.1092160304; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; JORDAN CT, 1995, EXP HEMATOL, V23, P1011; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEITER EH, 1994, J CLIN INVEST, V93, P2007, DOI 10.1172/JCI117194; LEITER EH, 1989, ENDOCRINOLOGY, V124, P912, DOI 10.1210/endo-124-2-912; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; METCALF D, 1993, BLOOD, V82, P3515; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; ONO M, 1987, NUCLEIC ACIDS RES, V15, P8725, DOI 10.1093/nar/15.21.8725; SPANGRUDE GJ, 1990, EXP HEMATOL, V18, P920; SZILVASSY SJ, 1993, BLOOD, V81, P2310; TARTAGLIA, 1995, CELL, V83, P1263; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	589	637	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					585	589		10.1038/nm0596-585	http://dx.doi.org/10.1038/nm0596-585			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616721				2022-12-27	WOS:A1996UJ23000045
J	Delaney, SJ; Wainwright, BJ				Delaney, SJ; Wainwright, BJ			New pharmaceutical approaches to the treatment of cystic fibrosis	NATURE MEDICINE			English	Editorial Material											Delaney, SJ (corresponding author), UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,BRISBANE,QLD,AUSTRALIA.			Wainwright, Brandon/0000-0003-0406-2092				BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Delaney SJ, 1996, EMBO J, V15, P955, DOI 10.1002/j.1460-2075.1996.tb00432.x; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; NOONE PG, 1994, ANNU REV MED, V45, P421; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1995, SCI AM, V273, P52, DOI 10.1038/scientificamerican1295-52; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253	14	8	8	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					392	393		10.1038/nm0496-392	http://dx.doi.org/10.1038/nm0496-392			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597941				2022-12-27	WOS:A1996UD31400033
J	Lacorazza, HD; Flax, JD; Snyder, EY; Jendoubi, M				Lacorazza, HD; Flax, JD; Snyder, EY; Jendoubi, M			Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells	NATURE MEDICINE			English	Article							TRANSPLANTATION; BIOSYNTHESIS; FIBROBLASTS; LINE	In humans, beta-hexosaminidase alpha-subunit deficiency prevents the formation of a functional beta-hexosaminidase A heterodimer resulting in the severe neurodegenerative disorder, Tay-Sachs disease. To explore the feasibility of using ex vivo gene transfer in this lysosomal storage disease, we produced ecotropic retroviruses encoding the human beta-hexosaminidase alpha-subunit cDNA and transduced multipotent neural cell lines. Transduced progenitors stably expressed and secreted high levels of biologically active beta-hexosaminidase A in vitro and cross-corrected the metabolic defect in a human Tay-Sachs fibroblasts cell line in vitro. These genetically engineered CNS progenitors were transplanted into the brains of both normal fetal and newborn mice. Engrafted brains, analyzed at various ages after transplant, produced substantial amounts of human beta-hexosaminidase alpha-subunit transcript and protein, which was enzymatically active throughout the brain at a level reported to be therapeutic in Tay-Sachs disease. These results have implications for treating neurologic diseases characterized by inherited single gene mutations.	NEI,GENET & MOLEC IMMUNOL SECT,IMMUNOL LAB,NIH,BETHESDA,MD 20892; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School								ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; BRAUN SE, 1993, P NATL ACAD SCI USA, V90, P11830, DOI 10.1073/pnas.90.24.11830; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GIESELMANN V, 1995, BBA-MOL BASIS DIS, V1270, P103, DOI 10.1016/0925-4439(94)00075-2; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HASILIK A, 1980, J BIOL CHEM, V255, P4937; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KRESSE H, 1981, J BIOL CHEM, V256, P2926; LACORAZZA HD, 1995, BIOTECHNIQUES, V19, P434; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; ONIFER SM, 1993, EXP NEUROL, V122, P130, DOI 10.1006/exnr.1993.1114; PROIA RL, 1984, J BIOL CHEM, V259, P3350; REUFRAZ PJ, 1991, CELL, V66, P713; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; SUHR ST, 1993, ARCH NEUROL-CHICAGO, V50, P1252, DOI 10.1001/archneur.1993.00540110122012; WILEMAN T, 1985, BIOCHEM J, V232, P1; YAMANAKA S, 1994, GENOMICS, V21, P588, DOI 10.1006/geno.1994.1318; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	24	164	177	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					424	429		10.1038/nm0496-424	http://dx.doi.org/10.1038/nm0496-424			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597952				2022-12-27	WOS:A1996UD31400044
J	Tanzi, RE				Tanzi, RE			Neuropathology in the Down's syndrome brain	NATURE MEDICINE			English	Editorial Material							ALZHEIMERS-DISEASE; PROTEIN				Tanzi, RE (corresponding author), MASSACHUSETTS GEN HOSP, GENET & AGING UNIT, BOSTON, MA 02129 USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	Telethon [C.23 BIS] Funding Source: Medline	Telethon(Fondazione Telethon)		GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANN DMA, 1992, NEURODEGENERATION, V1, P201; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93	11	16	19	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1996	2	1					31	32		10.1038/nm0196-31	http://dx.doi.org/10.1038/nm0196-31			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564833				2022-12-27	WOS:A1996TP57900032
J	ISACSON, O; DEACON, TW; PAKZABAN, P; GALPERN, WR; DINSMORE, J; BURNS, LH				ISACSON, O; DEACON, TW; PAKZABAN, P; GALPERN, WR; DINSMORE, J; BURNS, LH			TRANSPLANTED XENOGENEIC NEURAL CELLS IN NEURODEGENERATIVE DISEASE-MODELS EXHIBIT REMARKABLE AXONAL TARGET SPECIFICITY AND DISTINCT GROWTH-PATTERNS OF GLIAL AND AXONAL FIBERS	NATURE MEDICINE			English	Article							CD44 EXPRESSION; NERVOUS-SYSTEM; NEUROBLASTS; ASTROCYTES; NEURONS; OLIGODENDROCYTES; GLYCOPROTEIN; SURVIVAL; PATHWAYS; SUBSETS	Clinical trials are under way using fetal cells to repair damaged neuronal circuitry. However, little is known about how transplanted immature neurons can grow anatomically correct connections in the adult central nervous system (CNS). We transplanted embryonic porcine neural cells in vivo into adult rat brains with neuronal and axonal loss typical of Parkinson's or Huntington's disease. Using complementary species-specific cellular markers, we found donor axons and CD44(+) astroglial fibres in host white matter tracts up to 8 mm from CNS transplant sites, although only donor axons were capable of reaching correct gray matter target regions. This work demonstrates that adult host brain can orient growth of transplanted neurons and that there are differences in transplant donor glial and axonal growth patterns in cellular repair of the mature CNS.	MCLEAN HOSP,NEUROGENERAT LAB,BELMONT,MA 02178; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BELMONT,MA 02178; MASSACHUSETTS GEN HOSP,DEPT NEUROSURG,BELMONT,MA 02178; DIACRIN INC,BOSTON,MA 02129	Harvard University; McLean Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	ISACSON, O (corresponding author), HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115, USA.			Pakzaban, Peyman/0000-0001-7541-2286; Isacson, Ole/0000-0001-8091-8302	NINDS NIH HHS [NS29178, 5T32 NS07340, NS30064] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029178, T32NS007340, R01NS030064] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1984, NEUROSCI LETT, V45, P53, DOI 10.1016/0304-3940(84)90328-8; ASHER R, 1992, EXP CELL RES, V203, P80, DOI 10.1016/0014-4827(92)90042-7; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; Bjorklund A, 1988, Adv Neurol, V47, P455; BRUNDIN P, 1985, BRAIN RES, V331, P251, DOI 10.1016/0006-8993(85)91550-1; BURDENGULLEY SM, 1995, J NEUROSCI, V15, P4370; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COON HG, 1989, P NATL ACAD SCI USA, V86, P1703, DOI 10.1073/pnas.86.5.1703; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; DEACON TW, 1994, BRAIN RES, V668, P211, DOI 10.1016/0006-8993(94)90526-6; DEACON TW, 1994, EXP NEUROL, V130, P151, DOI 10.1006/exnr.1994.1194; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FORSSMAN J, 1898, THESIS LUND U; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GALPERN WR, 1995, J NEUROSURG P AANS, P38; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; GIRGRAH N, 1992, EXP CELL RES, V203, P80; GOODMAN CS, 1993, CELL S, V10, P77; HAMBURGER V, 1939, J EXP ZOOL, V80, P147; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MORETTO G, 1993, J NEUROPATH EXP NEUR, V52, P419, DOI 10.1097/00005072-199307000-00009; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; SACHER GA, 1974, AM NAT, V108, P593, DOI 10.1086/282938; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SNOW MHL, 1980, NATURE, V286, P107, DOI 10.1038/286107a0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403; ZHOU HF, 1993, EXP NEUROL, V122, P155, DOI 10.1006/exnr.1993.1116	37	179	184	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1189	1194		10.1038/nm1195-1189	http://dx.doi.org/10.1038/nm1195-1189			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584993				2022-12-27	WOS:A1995TC53700045
J	WILSON, C; KAY, MA				WILSON, C; KAY, MA			IMMUNOMODULATION TO ENHANCE GENE-THERAPY	NATURE MEDICINE			English	Editorial Material									UNIV WASHINGTON,SCH MED,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	WILSON, C (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195, USA.							BARR D, 1995, GENE THER, V2, P151; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; FOY TM, 1994, J EXP MED, V178, P1567; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GLUESTONE JA, 1995, IMMUNITY, V2, P555; KAY MA, IN PRESS NATURE GENE; MCELVANEY NG, 1995, NAT MED, V1, P182, DOI 10.1038/nm0395-182b; MCINTYRE TM, 1995, J IMMUNOL, V154, P3156; RIZZO LV, 1995, EUR J IMMUNOL, V25, P708, DOI 10.1002/eji.1830250312; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; VANGINKEL FW, 1995, HUM GENE THER, V6, P895, DOI 10.1089/hum.1995.6.7-895; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	16	33	36	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					887	889		10.1038/nm0995-887	http://dx.doi.org/10.1038/nm0995-887			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585212				2022-12-27	WOS:A1995RT30300040
J	HYNES, NE; GRONER, B				HYNES, NE; GRONER, B			A TARGET FOR TUMOR-DIRECTED THERAPY	NATURE MEDICINE			English	Editorial Material							MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; ERBB-2 RECEPTOR; CELL GROWTH; ONCOGENE; INHIBITION		INST EXPTL CANC RES,D-79106 FREIBURG,GERMANY		HYNES, NE (corresponding author), FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND.							ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1992, CANCER RES, V52, P2580; BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; BEERLI RR, 1994, J BIOL CHEM, V39, P23931; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; DESHANE J, 1994, GENE THER, V1, P332; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; JESCHKE M, 1995, INT J CANCER, V60, P739; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; MARTE BM, 1995, ONCOGENE, V10, P167; MASUI H, 1984, CANCER RES, V44, P1002; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WELS W, 1992, CANCER RES, V52, P6310	19	5	7	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					631	632		10.1038/nm0795-631	http://dx.doi.org/10.1038/nm0795-631			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585140				2022-12-27	WOS:A1995RQ06600033
J	NESTEROVA, M; CHOCHUNG, YS				NESTEROVA, M; CHOCHUNG, YS			A SINGLE-INJECTION PROTEIN-KINASE A-DIRECTED ANTISENSE TREATMENT TO INHIBIT TUMOR-GROWTH	NATURE MEDICINE			English	Article							I REGULATORY SUBUNIT; HL-60 LEUKEMIA-CELLS; AMINO-ACID SEQUENCE; RI-ALPHA-SUBUNIT; CATALYTIC SUBUNIT; MOLECULAR-CLONING; HUMAN TESTIS; MESSENGER-RNA; CANCER-CELLS; CAMP	Expression of the RI(alpha) subunit of cAMP-dependent protein kinase type I is enhanced in human cancer cell lines, in primary tumours, in cells after transformation and in cells upon stimulation of growth. We have investigated the effect of sequence-specific inhibition of RI(alpha) gene expression on in vivo tumour growth. We report that single injection RI(alpha) antisense treatment results in a reduction in RI(alpha) expression and inhibition of tumour growth. Tumour cells behaved like untransformed cells by making less protein kinase type I. The RI(alpha) antisense, which produces a biochemical imprint for growth control, requires infrequent dosing to halt neoplastic growth in vivo.	NCI, TUMOR IMMUNOL & BIOL LAB, CELLULAR BIOCHEM SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COBB CE, 1987, J BIOL CHEM, V262, P16566; CONNELLY PA, 1986, J BIOL CHEM, V261, P2325; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; KAPOOR CL, 1983, CANCER RES, V43, P295; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NESTEROVA M, 1994, FASEB J, V8, pA1328; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; OYEN O, 1988, FEBS LETT, V229, P391, DOI 10.1016/0014-5793(88)81163-3; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SRIVASTAVA AK, 1978, J BIOL CHEM, V253, P1752; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047; YOKOZAKI H, 1993, CANCER RES, V53, P868	31	130	139	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1995	1	6					528	533		10.1038/nm0695-528	http://dx.doi.org/10.1038/nm0695-528			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585118				2022-12-27	WOS:A1995RN10100035
J	CHALLIS, JRG				CHALLIS, JRG			CRH, A PLACENTAL CLOCK AND PRETERM LABOR	NATURE MEDICINE			English	Editorial Material							PREGNANCY	The existence of a placental clock controlling the term of pregnancy has long been hypothesized. Now scientists may have uncovered what makes it tick (pages 460-463).			CHALLIS, JRG (corresponding author), ST JOSEPHS HLTH CTR,LAWSON RES INST,LONDON,ON N6A 4V2,CANADA.		Challis, John RG/E-7419-2014					CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; CASEY ML, 1988, NIH WORKSHOP INITIAT, P141; CHALLIS JRG, 1994, RES CLIN FORUMS, V16, P39; CHALLIS JRG, 1989, PERINATAL ENDOCRINOL, P781; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; PERKINS AV, 1993, J ENDOCRINOL, V138, P149, DOI 10.1677/joe.0.1380149; Thorburn G. D., 1990, Eicosanoids in reproduction., P73; WARREN WB, 1992, AM J OBSTET GYNECOL, V166, P1198, DOI 10.1016/S0002-9378(11)90606-1; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x	9	36	37	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					416	416		10.1038/nm0595-416	http://dx.doi.org/10.1038/nm0595-416			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585086	Bronze			2022-12-27	WOS:A1995RN10000029
J	NORTH, TW; LACASSE, RA				NORTH, TW; LACASSE, RA			TESTING ANTI-HIV DRUGS IN THE FIV MODEL	NATURE MEDICINE			English	Editorial Material							FELINE IMMUNODEFICIENCY VIRUS; CATS; INFECTION; AIDS	Viral resistance is a major problem with current AIDS drugs. The feline immunodeficiency virus model may provide a way to test new drugs and strategies before human trials.			NORTH, TW (corresponding author), UNIV MONTANA,DIV BIOL SCI,MISSOULA,MT 59812, USA.							ACKLEY CD, 1990, J VIROL, V64, P5652, DOI 10.1128/JVI.64.11.5652-5655.1990; BARLOUGH JE, 1991, J ACQ IMMUN DEF SYND, V4, P219; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; DAVIDSON MG, 1993, AM J PATHOL, V143, P1486; ENGLISH RV, 1994, J INFECT DIS, V120, P543; GOBERT JM, 1994, ANTIMICROB AGENTS CH, V38, P861, DOI 10.1128/AAC.38.4.861; ISHIDA T, 1990, JPN J VET SCI, V52, P645; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; Pedersen N. C., 1993, The Retroviridae, volume 2., P181; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PHILLIPS TR, 1994, J GEN VIROL, V75, P979, DOI 10.1099/0022-1317-75-5-979; PODELL M, 1993, J ACQ IMMUN DEF SYND, V6, P758; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; WAINBERG MA, 1993, J ACQ IMMUN DEF SYND, V6, pS36; 1990, RETROVIR PACKAGE INS	16	20	20	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					410	411		10.1038/nm0595-410	http://dx.doi.org/10.1038/nm0595-410			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585083				2022-12-27	WOS:A1995RN10000026
J	ROTH, GS; INGRAM, DK; LANE, MA				ROTH, GS; INGRAM, DK; LANE, MA			SLOWING AGING BY CALORIC RESTRICTION	NATURE MEDICINE			English	Editorial Material							DIETARY RESTRICTION	Dietary caloric restriction is the only intervention conclusively shown to slow ageing, delay the onset of age-related diseases, maintain function and extend both median and maximal life span in mammals.			ROTH, GS (corresponding author), JOHNS HOPKINS UNIV,NIA,GERONTOL RES CTR,BAYVIEW CAMPUS,BALTIMORE,MD 21224, USA.							BEREGI E, 1990, CENTENARIANS HUNGARY; BODKIN N, IN PRESS J GERONT BI; DARK J, 1994, AM J PHYSIOL, V267, pR496, DOI 10.1152/ajpregu.1994.267.2.R496; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HEYDARI AR, IN PRESS J NUTR; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; KEMITZ JW, 1993, J GERONTOL A-BIOL, V48, pB17; LANE MA, IN PRESS J NUTR; LEE AS, 1983, J BIOL CHEM, V258, P597; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; PAHLAVANI MA, 1994, MODULATION AGING PRO, P143; REISER KM, 1994, J GERONTOL, V49, pB71, DOI 10.1093/geronj/49.2.B71; ROTH GS, 1994, AGING-CLIN EXP RES, V6, P139, DOI 10.1007/BF03324227; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; WEINDRUCH R, 1988, RETARDATION AGING DI; Yu BP, 1993, FREE RADICALS AGING; [No title captured]	17	44	48	1	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					414	415		10.1038/nm0595-414	http://dx.doi.org/10.1038/nm0595-414			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585085				2022-12-27	WOS:A1995RN10000028
J	HAYDEN, MR; REIDY, H				HAYDEN, MR; REIDY, H			MANY ROADS LEAD TO ATHEROMA	NATURE MEDICINE			English	Editorial Material							GROWTH-FACTOR-BETA; LIPOPROTEIN; PLASMINOGEN; ATHEROSCLEROSIS; PATHOGENESIS; ACTIVATION; MECHANISM; INHIBITOR; CELLS	For many years cholesterol was seen as the worst enemy of coronary arteries. Recent advances show that interactions between lipoproteins, coagulation and growth factors are important in atherosclerosis.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	HAYDEN, MR (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,416-2125 E MALL,VANCOUVER,BC V6T 1Z4,CANADA.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; DAHLEN G, 1975, CLIN GENET, V7, P334; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; 1994, LANCET, V344, P1389	18	15	15	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					22	23		10.1038/nm0195-22	http://dx.doi.org/10.1038/nm0195-22			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584946				2022-12-27	WOS:A1995QX55700019
J	SOLIMENA, M; DECAMILLI, P				SOLIMENA, M; DECAMILLI, P			COXSACKIEVIRUSES AND DIABETES	NATURE MEDICINE			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; MELLITUS	Two recent reports provide further evidence for a link between coxsackieviruses and the onset of IDDM, although a careful examination suggests it is still too early to conclude a definitive role.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	SOLIMENA, M (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ENDOCRINOL SECT,NEW HAVEN,CT 06510, USA.		Solimena, Michele/GVS-5990-2022; Solimena, Michele/E-1275-2011					ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BAEKKESKOV S, 1990, NATURE, V347, P130; BANATVALA JE, 1985, LANCET, V1, P149; DALESSIO DJ, 1992, AM J EPIDEMIOL, V135, P1331, DOI 10.1093/oxfordjournals.aje.a116244; FRISK G, 1985, J MED VIROL, V17, P219, DOI 10.1002/jmv.1890170303; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; SCHMIDT WAK, 1978, MED MICROBIOL IMMUN, V164, P291, DOI 10.1007/BF02125498; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; SOLIMENA M, 1994, NATURE, V366, P15; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0	14	20	21	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					25	26		10.1038/nm0195-25	http://dx.doi.org/10.1038/nm0195-25			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584948				2022-12-27	WOS:A1995QX55700021
J	Neurath, MF; Pettersson, S; zumBuschenfelde, KHM; Strober, W				Neurath, MF; Pettersson, S; zumBuschenfelde, KHM; Strober, W			Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; RECEPTOR MUTANT MICE; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; ULCERATIVE-COLITIS; GENE INHIBITION; EXPRESSION; ALPHA; DNA	Chronic intestinal inflammation induced by 2,4,6,-trinitrobenzene sulfonic acid (TNBS) is characterized by a transmural granulomatous colitis that mimics some characteristics of human Crohn's disease. Here, we show that the transcription factor NF-kappa S p65 was strongly activated in TNBS-induced colitis and in colitis of interleukin-10-deficient mice. Local administration of p65 antisense phosphorothioate oligonucleotides abrogated clinical and histological signs of colitis and was more effective in treating TNBS-induced colitis than single or daily administration of glucocorticoids. The data provide direct evidence for the central importance of p65 in chronic intestinal inflammation and suggest a potential therapeutic utility of p65 antisense oligonucleotides as a novel molecular approach for the treatment of patients with Crohn's disease.	KAROLINSKA INST, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; NIAID, CLIN INVEST LAB, MUCOSAL IMMUN SECT, BETHESDA, MD 20892 USA	Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Neurath, MF (corresponding author), UNIV MAINZ, MED CLIN 1, IMMUNOL LAB, LANGENBECKSTR 1, D-55101 MAINZ, GERMANY.		Pettersson, Sven/F-9511-2015					AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HOLT JT, 1995, NAT MED, V1, P407, DOI 10.1038/nm0595-407; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; STROBER W, 1995, CLIN IMMUNOLOGY, P1401; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; VALTIERI M, 1991, BLOOD, V77, P1181; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	47	720	750	1	33	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					998	1004		10.1038/nm0996-998	http://dx.doi.org/10.1038/nm0996-998			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782457				2022-12-27	WOS:A1996VF49700034
J	Self, CH; Thompson, S				Self, CH; Thompson, S			Light activatable antibodies: Models for remotely activatable proteins	NATURE MEDICINE			English	Article							ACID	The ability to activate biological macromolecules remotely, at specific locations and times, will allow the manipulation of a wide range of cellular activities and give rise to many practical applications. Interest has been shown in the theoretical possibility of accomplishing this by means of photochemical approaches(1). Photochemical changes of the guest-binding cavity of cyclodextrins has been suggested(2); however, these changes require organic solvent. What is needed is a widely and readily applicable method allowing activation under physiological conditions. We have developed such a method. This is based on our demonstration that relatively large amounts of the a-methyl substituted 2-nitrobenzyl alcohol, namely, 1-(2-nitrophenyl)ethanol (NPE) can be coupled to proteins using diphosgene(3,4). Previous work involved ''caging'' of small molecules such as ATP (ref. 5-9) and blocking amino acids(10) in peptide synthesis(11,12) with 2-nitrobenzyl compounds. For large molecules, site-specific reversible inactivation of T4-lysozyme has been reported following introduction of an aspartyl beta-nibenzyl ester into its active site by mutagenesis(13) In contrast, the present simple procedure allows an existing protein to be deactivated and then, when and where required, reactivated by exposure to ultraviolet-A (UV-A) light. We have employed antibodies as models for both receptors and ligands and have successfully modulated: antibody binding sites for antigen; antigen binding sites for antibody, and antibody Fc binding sites for Protein A.			Self, CH (corresponding author), UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT CLIN BIOCHEM, FRAMLINGTON PL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND.							ARADYELLIN R, 1994, NATURE, V371, P320, DOI 10.1038/371320a0; DANZIG JA, 1991, J PHYSIOL-LONDON, V432, P639; GOLDMACHER VS, 1992, BIOCONJUGATE CHEM, V3, P104, DOI 10.1021/bc00014a003; HENRIKSEN DB, 1992, PEPTIDE RES, V5, P321; MARRIOTT G, 1992, BIOCHEM INT, V26, P943; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MORRISON H, 1993, BIOORGANIC PHOTOCHEM, V2; PILLAI VNR, 1980, SYNTHESIS-STUTTGART, P1; SELF CH, 1995, BIOCHEM SOC T, V23, pS156, DOI 10.1042/bst023156s; SENTER PD, 1985, PHOTOCHEM PHOTOBIOL, V42, P231, DOI 10.1111/j.1751-1097.1985.tb08936.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMPSON S, 1994, BIOCHEM BIOPH RES CO, V201, P1213, DOI 10.1006/bbrc.1994.1834; THOMPSON S, 1995, BIOCHEM SOC T, V23, pS155, DOI 10.1042/bst023155s; THOMPSON S, 1982, RED CELL MEMBRANES M, P67; TJOENG FS, 1977, BIOCHIM BIOPHYS ACTA, V490, P489, DOI 10.1016/0005-2795(77)90025-3; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; WOOTTON JF, 1989, NATO ADV SCI I C-MAT, V272, P277	18	41	48	3	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1996	2	7					817	820		10.1038/nm0796-817	http://dx.doi.org/10.1038/nm0796-817			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673931				2022-12-27	WOS:A1996UU68000041
J	Preul, MC; Caramanos, Z; Collins, DL; Villemure, JG; Leblanc, R; Olivier, A; Pokrupa, R; Arnold, DL				Preul, MC; Caramanos, Z; Collins, DL; Villemure, JG; Leblanc, R; Olivier, A; Pokrupa, R; Arnold, DL			Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy	NATURE MEDICINE			English	Article							H-1 MR SPECTROSCOPY; INTRACRANIAL TUMORS; INVIVO	Although conventional proton magnetic resonance imaging has increased our ability to detect brain tumors, it has not enhanced to nearly the same degree our ability to diagnose tumor type(1). Proton magnetic resonance spectroscopy is a safe, noninvasive means of performing biochemical analyses in vivo(2). Using this technique, we characterized and classified tissue from normal brains, as well as tissue from the five most common types of adult supratentorial brain tumors. These six tissue types differed in their pattern across the six metabolites measured. 'Leaving-one-out' linear discriminant analyses based on these resonance profiles correctly classified 104 of 105 spectra, and, whereas conventional preoperative clinical diagnosis misclassified 20 of 91 tumors, the linear discriminant analysis approach missed only 1. Thus, we have found that a pattern-recognition analysis of the biochemical information obtained from proton magnetic resonance spectroscopy can enable accurate, noninvasive diagnosis of the most prevalent types of supratentorial brain tumors.	MCGILL UNIV,MONTREAL NEUROL INST & HOSP,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,MONTREAL NEUROL INST & HOSP,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University; McGill University			Caramanos, Zografos/A-9553-2011; Collins, D. Louis/ABD-7708-2021	Collins, D. Louis/0000-0002-8432-7021; Arnold, Douglas/0000-0003-4266-0106				Arnold D L, 1990, NMR Biomed, V3, P184, DOI 10.1002/nbm.1940030407; Arnold DL, 1996, MR SPECTROSCOPY CLIN, P139; ATLAS SW, 1991, MAGNETIC RESONANCE I, P223; BEHAR KL, 1994, MAGNET RESON MED, V32, P294, DOI 10.1002/mrm.1910320304; BROOKS DJ, 1985, CARRIER MEDIATED TRA, P195; BRUHN H, 1989, RADIOLOGY, V172, P541, DOI 10.1148/radiology.172.2.2748837; BURGER PC, 1991, SURGICAL PATHOLOGY N; BURGER PC, 1994, ATLAS TUMOR PATHOLOG; CHANDRASOMA PT, 1990, MALIGNANT CEREBRAL G, P129; DICHIRO G, 1985, BRAIN IMAGING BRAIN, P185; GILL SS, 1990, J COMPUT ASSIST TOMO, V14, P497, DOI 10.1097/00004728-199007000-00001; Hand D. J, 1981, WILEY SERIES PROBABI; KAUPPINEN RA, 1994, PROG NEUROBIOL, V44, P87, DOI 10.1016/0301-0082(94)90058-2; KONDZIOLKA D, 1993, J NEUROSURG, V79, P553; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; LACHENBRUCH PA, 1975, DISCRIMINANT ANAL; PEELING J, 1992, MAGNET RESON MED, V24, P123, DOI 10.1002/mrm.1910240113; PREUL MC, 1993, MAGNETIC RESONANCE S, P299; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; 1992, SYSTAT WINDOWS STAT	21	431	438	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					323	325		10.1038/nm0396-323	http://dx.doi.org/10.1038/nm0396-323			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612232				2022-12-27	WOS:A1996TY64000042
J	EVERALL, IP; HUDSON, L; ALSARRAJ, S; HONAVAR, M; LANTOS, P; KERWIN, R				EVERALL, IP; HUDSON, L; ALSARRAJ, S; HONAVAR, M; LANTOS, P; KERWIN, R			DECREASED EXPRESSION OF AMPA RECEPTOR MESSENGER-RNA AND PROTEIN IN AIDS - A MODEL FOR HIV-ASSOCIATED NEUROTOXICITY	NATURE MEDICINE			English	Article							ENVELOPE PROTEIN; NEURONAL LOSS; GLUTAMATE; CHANNELS; INFECTION; DAMAGE; FAMILY	HIV infection can cause extensive neuronal loss and clinically a severe dementia. The cause of the neurotoxicity remains unclear as neurons are not infected, but disturbance of glutamate-linked calcium entry has been implicated. In this study, we have shown a decrease in HIV-infected brain of the expression of mRNA and protein of the GluR-A flop subtype of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor in cerebellar Purkinje cells. Although Purkinje cells are relatively resistant to loss, the observed disturbance of AMPA receptors may contribute to the neurotoxic process in other vulnerable brain regions and clinically to the development of dementia.			EVERALL, IP (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.							BAUDE A, 1994, J NEUROSCI, V14, P2830; BENKE TA, 1993, P NATL ACAD SCI USA, V90, P7819, DOI 10.1073/pnas.90.16.7819; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CLARK PJ, 1954, ECOLOGY, V35, P445, DOI 10.2307/1931034; DAY NC, 1995, MOL BRAIN RES, V31, P17, DOI 10.1016/0169-328X(95)00021-J; DIOP AG, 1994, NEUROSCI LETT, V165, P187, DOI 10.1016/0304-3940(94)90741-2; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EVERALL I, 1992, LANCET, V340, P1413, DOI 10.1016/0140-6736(92)92603-D; EVERALL IP, 1994, ACTA NEUROPATHOL, V88, P538; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; EVERALL IP, 1993, J NEUROL NEUROSUR PS, V56, P481, DOI 10.1136/jnnp.56.5.481; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GARCIALADONA FJ, 1994, MOL BRAIN RES, V21, P75, DOI 10.1016/0169-328X(94)90380-8; GARRY RF, 1991, AIDS, V5, P1381, DOI 10.1097/00002030-199111000-00017; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALL TC, 1975, NEUROPATH APPL NEURO, V1, P267, DOI 10.1111/j.1365-2990.1975.tb00652.x; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HILL JM, 1993, BRAIN RES, V603, P222, DOI 10.1016/0006-8993(93)91241-J; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LIPTON SA, 1991, ANN NEUROL, V30, P111; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P585; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; WERNER T, 1991, AIDS, V5, P1301, DOI 10.1097/00002030-199111000-00003; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613	30	35	35	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1174	1178		10.1038/nm1195-1174	http://dx.doi.org/10.1038/nm1195-1174			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584990				2022-12-27	WOS:A1995TC53700042
J	MCBRIDE, WH; DOUGHERTY, GJ				MCBRIDE, WH; DOUGHERTY, GJ			RADIOTHERAPY FOR GENES THAT CAUSE CANCER	NATURE MEDICINE			English	Editorial Material							ONCOGENE; CELLS; RAS		UNIV CALIF LOS ANGELES,JONSSON CANC CTR,LOS ANGELES,CA 90095; BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; British Columbia Cancer Agency	MCBRIDE, WH (corresponding author), UNIV CALIF LOS ANGELES,DEPT RADIAT ONCOL,10833 LECONTE AVE,LOS ANGELES,CA 90095, USA.							AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; BOOTHMAN DA, 1994, RADIAT RES, V138, pS68, DOI 10.2307/3578765; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CHENG X, 1995, INT J RADIAT BIOL, V67, P261, DOI 10.1080/09553009514550311; CHU THT, 1995, J VIROL, V69, P2659, DOI 10.1128/JVI.69.4.2659-2663.1995; CULVER KW, 1995, BRIT MED BULL, V51, P192, DOI 10.1093/oxfordjournals.bmb.a072946; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Hallahan D E, 1993, Important Adv Oncol, P71; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; ILIAKIS G, 1991, RADIAT RES, V125, P56, DOI 10.2307/3577982; JUNG M, 1994, CANCER RES, V54, P5194; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KIM JH, 1994, CANCER RES, V54, P6053; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MCBRIDE WH, 1995, ACTA ONCOL, V34, P447, DOI 10.3109/02841869509094007; MCKENNA WG, 1990, CANCER RES, V50, P97; MILAS L, 1987, CANCER RES, V47, P1069; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MIYASHITA T, 1994, ONCOGENE, V9, P1799; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; STONE HB, 1993, RADIAT RES, V136, P422, DOI 10.2307/3578556; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VILE RG, 1994, SEMIN CANCER BIOL, V5, P429; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266	29	31	33	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1215	1217		10.1038/nm1195-1215	http://dx.doi.org/10.1038/nm1195-1215			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584999				2022-12-27	WOS:A1995TC53700051
J	PUTKONEN, P; WALTHER, L; ZHANG, YJ; LI, SL; NILSSON, C; ALBERT, J; BIBERFELD, P; THORSTENSSON, R; BIBERFELD, G				PUTKONEN, P; WALTHER, L; ZHANG, YJ; LI, SL; NILSSON, C; ALBERT, J; BIBERFELD, P; THORSTENSSON, R; BIBERFELD, G			LONG-TERM PROTECTION AGAINST SIV-INDUCED DISEASE IN MACAQUES VACCINATED WITH A LIVE ATTENUATED HIV-2 VACCINE	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; CYNOMOLGUS MONKEYS; INFECTION; IMMUNIZATION	The aim of this study was to test the ability of a live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine to protect cynomolgus monkeys against superinfection with a pathogenic simian immunodeficiency virus (SIVsm) This report is an update on our previously reported observation period of nine months. The new data here show that three of four monkeys vaccinated with live HIV-2 were protected against immunosuppression and SIV-induced disease during more than five years of follow-up. The quality of the immunity was permissive for infection, but monkeys that survived showed restricted viral replication in peripheral blood and lymph nodes. This study shows that it is possible to induce protection against a pathogenic heterologous primate lentivirus and to prevent disease in vaccinated monkeys even if infection is not prevented. These findings provide evidence that protection against AIDS can be achieved by immunization.	KAROLINSKA INST,CTR MICROBIOL & TUMOURBIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,IMMUNOPATHOL LAB,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,SWEDISH INST INFECT DIS CONTROL,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control	PUTKONEN, P (corresponding author), KAROLINSKA INST,SWEDISH INST INFECT DIS CONTROL,DEPT IMMUNOL,S-10521 STOCKHOLM,SWEDEN.			Walther-Jallow, Lilian/0000-0001-8731-1917				ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; AHMAD S, 1994, AIDS RES HUM RETROV, V10, P195, DOI 10.1089/aid.1994.10.195; ALBERT J, 1987, AIDS RES HUM RETROV, V3, P3, DOI 10.1089/aid.1987.3.3; ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BOTTIGER B, 1989, AIDS RES HUM RETROV, V5, P511; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; HIRSCH VM, 1994, J INFECT DIS, V170, P51, DOI 10.1093/infdis/170.1.51; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; ISRAEL ZR, 1994, J VIROL, V68, P1843, DOI 10.1128/JVI.68.3.1843-1853.1994; MARTHAS ML, 1990, J VIROL, V64, P3694, DOI 10.1128/JVI.64.8.3694-3700.1990; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PUTKONEN P, 1991, NATURE, V352, P436, DOI 10.1038/352436a0; PUTKONEN P, 1992, AIDS, V6, P257, DOI 10.1097/00002030-199203000-00001; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P359; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P368; SCHAFERMAN A, 1993, VACCINE, V11, P848; SCHULTZ AM, 1994, AIDS S1, V8, P203; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; SUJIPTO S, 1990, J VIROL, V64, P2290; WIGZELL H, 1991, FASEB J, V5, P2406, DOI 10.1096/fasebj.5.10.2065889; ZHANG YJ, 1994, VIROLOGY, V200, P583, DOI 10.1006/viro.1994.1221	26	62	63	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					914	918		10.1038/nm0995-914	http://dx.doi.org/10.1038/nm0995-914			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585217				2022-12-27	WOS:A1995RT30300045
J	ILIOPOULOS, O; KIBEL, A; GRAY, S; KAELIN, WG				ILIOPOULOS, O; KIBEL, A; GRAY, S; KAELIN, WG			TUMOR SUPPRESSION BY THE HUMAN VON HIPPEL-LINDAU GENE-PRODUCT	NATURE MEDICINE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; BINDING; DNA; IDENTIFICATION; TRANSLATION; COMPLEX; DOMAIN	A partial cDNA sequence for the gene linked to the von Hippel-Lindau (VHL) syndrome was reported in 1993. Mutation or loss of both VHL alleles has been documented in sporadic renal cell carcinomas and in the neoplasms that arise in von Hippel-Lindau kindreds. We have determined that the protein product of the VHL gene is an approximately 30 kilodalton cytoplasmic protein. The renal carcinoma cell line 786-0 is known to harbour a VHL mutation and, as shown here, fails to produce a wild-type VHL protein. Reintroduction of wild-type, but not mutant, VHL into these cells had no demonstrable effect on their growth in vitro but inhibited their ability to form tumours in nude mice.	DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOLDE DW, 1981, ANN INTERN MED, V95, P71, DOI 10.7326/0003-4819-95-1-71; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1988, ANTIBODIES LABORATOR; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNO H, 1994, CANCER RES, V54, P4845; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KUZMIN I, IN PRESS ONCOGENE; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKusick V.A., 1992, MENDELIAN INHERITANC; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; SHIMIZU M, 1990, ONCOGENE, V5, P185; SHUIN T, 1994, CANCER RES, V54, P2852; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303	30	555	567	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					822	826		10.1038/nm0895-822	http://dx.doi.org/10.1038/nm0895-822			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585187				2022-12-27	WOS:A1995RM63500041
J	LITTLE, M; WAINWRIGHT, B				LITTLE, M; WAINWRIGHT, B			METHYLATION AND P16 - SUPPRESSING THE SUPPRESSOR	NATURE MEDICINE			English	Editorial Material											LITTLE, M (corresponding author), UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA.		Little, Melissa H/A-6170-2010	Little, Melissa H/0000-0003-0380-2263; Wainwright, Brandon/0000-0003-0406-2092				CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; GRUIS NA, IN PRESS NATURE GENE; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; WHITAKER NJ, IN PRESS ONCOGENE	7	37	38	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					633	634		10.1038/nm0795-633	http://dx.doi.org/10.1038/nm0795-633			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585141				2022-12-27	WOS:A1995RQ06600034
J	Holmberg, L; Baum, M				Holmberg, L; Baum, M			Work on your theories!	NATURE MEDICINE			English	Editorial Material							BREAST-CANCER; SURGERY		UNIV UPPSALA HOSP, DEPT SURG, S-75185 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital	Holmberg, L (corresponding author), UCL, SCH MED, INST SURG STUDIES, LONDON W1P 7LD, ENGLAND.							ABE O, 1992, LANCET, V339, P71; Baum, 1995, Breast Cancer, V2, P9, DOI 10.1007/BF02966891; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1980, CANCER RES, V40, P3863; GAGE I, 1995, INT J RADIAT ONCOL, V33, P245, DOI 10.1016/0360-3016(95)02001-R; OLIVER RTD, 1995, LANCET, V346, P1506, DOI 10.1016/S0140-6736(95)92046-3; Popper K., 1979, OBJECTIVE KNOWLEDGE, P106; Popper K., 1979, OBJECTIVE KNOWLEDGE, P32; POPPER KR, 1994, MYTH FRAMEWORK, P102; POPPER KR, 1994, MYTH FRAMEWORK, P86; POPPER KR, 1979, OBJECTIVE KNOWLEDGE, P202; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19	12	17	18	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					844	846		10.1038/nm0896-844	http://dx.doi.org/10.1038/nm0896-844			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705844				2022-12-27	WOS:A1996UZ80400021
J	Molla, A; Korneyeva, M; Gao, Q; Vasavanonda, S; Schipper, PJ; Mo, HM; Markowitz, M; Chernyavskiy, T; Niu, P; Lyons, N; Hsu, A; Granneman, GR; Ho, DD; Boucher, CAB; Leonard, JM; Norbeck, DW; Kempf, DJ				Molla, A; Korneyeva, M; Gao, Q; Vasavanonda, S; Schipper, PJ; Mo, HM; Markowitz, M; Chernyavskiy, T; Niu, P; Lyons, N; Hsu, A; Granneman, GR; Ho, DD; Boucher, CAB; Leonard, JM; Norbeck, DW; Kempf, DJ			Ordered accumulation of mutations in HIV protease confers resistance to ritonavir	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ASSAY	Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine-82, although insufficient to confer resistance, appeared first in most patients. Significant phenotypic resistance required multiple mutations in HIV protease, which emerged subsequently in an ordered, stepwise fashion. The appearance of resistance mutations was delayed in patients with higher plasma levels of ritonavir. Early mutants retained susceptibility to structurally diverse protease inhibitors, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.	ABBOTT LABS,DEPT ANTIINFECT RES,ABBOTT PK,IL 60064; ABBOTT LABS,DEPT PHARMACOKINET,ABBOTT PK,IL 60064; ABBOTT LABS,DEPT ANTIVIRAL VENTURE,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064; UNIV UTRECHT,EIJKMAN WINKLER INST MED & CLIN MICROBIOL,3584 CX UTRECHT,NETHERLANDS; NYU,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016	Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Utrecht University; New York University								CAMERON B, 1996, 3 C RETR OPP INF WAS; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; GULICK R, 1996, 3 C RETR OPP INF WAS; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HEATHCHIOZZI M, 1996, 3 C RETR OPP INF WAS; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; JACOBSEN H, 1995, AIDS RES HUM RETROV, V11, pS169; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MASCHERA B, 1995, J VIROL, V69, P5431, DOI 10.1128/JVI.69.9.5431-5436.1995; MYERS G, 1993, HUMAN RETROVIRUSES A; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PARTALEDIS JA, 1995, J VIROL, V69, P5228, DOI 10.1128/JVI.69.9.5228-5235.1995; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; RICHMAN DD, 1990, REV INFECT DIS, V12, pS507; SCHAPIRO JM, IN PRESS ANN INTERN; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	26	626	642	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					760	766		10.1038/nm0796-760	http://dx.doi.org/10.1038/nm0796-760			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673921				2022-12-27	WOS:A1996UU68000031
J	Aebischer, P; Schluep, M; Deglon, N; Joseph, JM; Hirt, L; Heyd, B; Goddard, M; Hammang, JP; Zurn, AD; Kato, AC; Regli, F; Baetge, EE				Aebischer, P; Schluep, M; Deglon, N; Joseph, JM; Hirt, L; Heyd, B; Goddard, M; Hammang, JP; Zurn, AD; Kato, AC; Regli, F; Baetge, EE			Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients	NATURE MEDICINE			English	Article							NEUROTROPHIC FACTOR PREVENTS; MOTOR-NEURONS; MOTONEURONS	Neuronal growth factors hold promise for providing therapeutic benefits in various neurological disorders. As a means of ensuring adequate central nervous system delivery of growth factors and minimizing significant adverse side effects associated with systemic delivery methods, we have developed an ex vivo gene therapy approach for protein delivery using encapsulated genetically modified xenogeneic cells. Ciliary neurotrophic factor (CNTF) has been shown in various rodent models to reduce the motor neuron cell death similar to that seen in amyotrophic lateral sclerosis (ALS)(1-3). The initial trials focusing on the systemic administration of CNTF for ALS have been discontinued as a result of major side effects, thus preventing determination of the potential efficacy of the molecule(4,5). In order to deliver CNTF directly to the nervous system, we conducted a phase I study in which six ALS patients were implanted with polymer capsules containing genetically engineered baby hamster kidney cells releasing approximately 0.5 mu g of human CNTF per day in vitro. The CNTF-releasing implants were surgically placed within the lumbar intrathecal space. Nanogram levels of CNTF were measured within the patients' cerebrospinal fluid (CSF) for at least 17 weeks post-transplantation, whereas it was undetectable before implantation. Intrathecal delivery of CNTF was not associated with the limiting side effects observed with systemic delivery. These results demonstrate that neurotrophic factors can be continuously delivered within the CSF of humans by an ex vivo gene therapy approach, opening new avenues for the treatment of neurological diseases.	UNIV LAUSANNE,CHU VAUDOIS,SCH MED,DIV SURG RES,CH-1011 LAUSANNE,SWITZERLAND; UNIV LAUSANNE,CHU VAUDOIS,SCH MED,DEPT NEUROL,CH-1011 LAUSANNE,SWITZERLAND; CYTOTHERAPEUT INC,PROVIDENCE,RI 02906; CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND; CTR MED UNIV GENEVA,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva	Aebischer, P (corresponding author), UNIV LAUSANNE,CHU VAUDOIS,SCH MED,GENE THERAPY CTR,CH-1011 LAUSANNE,SWITZERLAND.		Hirt, Lorenz/G-3553-2010; Deglon, Nicole/A-2265-2012; Aebischer, Patrick/E-1387-2013	Hirt, Lorenz/0000-0002-2921-5000; Deglon, Nicole/0000-0003-4475-9476; 				Aebischer P, 1996, HUM GENE THER, V7, P851, DOI 10.1089/hum.1996.7.7-851; AEBISCHER P, 1995, XENO, V3, P43; ANDRES PL, 1986, NEUROLOGY, V36, P937, DOI 10.1212/WNL.36.7.937; CEDERBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P500; CEDERBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; KATO AC, 1994, EXP NEUROL, V130, P196, DOI 10.1006/exnr.1994.1198; LEWIS ME, 1993, EXP NEUROL, V124, P73, DOI 10.1006/exnr.1993.1177; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NORRIS FH, 1974, NEUROLOGY, V24, P721, DOI 10.1212/WNL.24.8.721; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; ZURN AD, 1994, NEUROREPORT, V6, P133	17	365	393	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					696	699		10.1038/nm0696-696	http://dx.doi.org/10.1038/nm0696-696			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640564				2022-12-27	WOS:A1996UN69100041
J	Beutler, E				Beutler, E			The cost of treating Gaucher disease	NATURE MEDICINE			English	Editorial Material											Beutler, E (corresponding author), SCRIPPS RES INST, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							BALLCKI D, 1995, MEDICINE, V74, P305; BEUTLER E, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91422-6; BEUTLER E, 1995, BLOOD CELL MOL DIS, V21, P86, DOI 10.1006/bcmd.1995.0012; COHEN Y, 1994, AM J HEMATOL, V47, P235, DOI 10.1002/ajh.2830470317; HOLLAK CEM, 1995, LANCET, V345, P1474, DOI 10.1016/S0140-6736(95)91037-9; *NATL I HLTH TECHN, 1995, GAUCH DIS CURR ISS D; ROBINSON ML, 1996, BIOWORLD TODAY, V7, P1; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	8	13	13	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					523	524		10.1038/nm0596-523	http://dx.doi.org/10.1038/nm0596-523			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616707				2022-12-27	WOS:A1996UJ23000031
J	Hsu, CH; Chua, KY; Tao, MH; Lai, YL; Wu, HD; Huang, SK; Hsieh, KH				Hsu, CH; Chua, KY; Tao, MH; Lai, YL; Wu, HD; Huang, SK; Hsieh, KH			Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization	NATURE MEDICINE			English	Article							ASTHMATIC-CHILDREN; IMMUNE-RESPONSE; IGE RESPONSES; MOUSE MUSCLE; SERUM IGE; T-CELLS; ANTIGEN; RESPONSIVENESS; INHALATION; RATS	The efficacy of an ''allergen-gene immunization'' protocol in altering allergic response was examined. Intramuscular injection of rats with a plasmid DNA encoding a house dust mite allergen into the muscle results in its long-term expression and the induction of specific immune responses. Significantly, this approach prevents the induction of immunoglobulin E synthesis, histamine release in bronchoalveolar fluids, and airway hyperresponsiveness in rats challenged with aerosolized allergen. Furthermore, this suppression is persistent and can be transferred into naive rats by CD8(+) T cells from gene-immunized rats. These findings suggest that allergen-gene immunization is effective in modulating allergic responses, and may provide a novel therapeutic approach for allergic diseases.	NATL TAIWAN UNIV,COLL MED,GRAD INST MICROBIOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,GRAD INST IMMUNOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,GRAD INST PHYSIOL,TAIPEI,TAIWAN; ACAD SINICA,INST BIOMED SCI,TAIPEI,TAIWAN; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224; NATL TAIWAN UNIV HOSP,DEPT PEDIAT,TAIPEI 10016,TAIWAN	National Taiwan University; National Taiwan University; National Taiwan University; Academia Sinica - Taiwan; Johns Hopkins University; Johns Hopkins Medicine; National Taiwan University; National Taiwan University Hospital			Huang, Shau-Ku/F-5509-2010; Tao, Mi-Hua/S-7020-2018	Tao, Mi-Hua/0000-0002-4307-5729	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; ELWOOD W, 1991, J ALLERGY CLIN IMMUN, V88, P951, DOI 10.1016/0091-6749(91)90253-K; EMANUEL MB, 1995, CLIN EXP ALLERGY, V25, P15, DOI 10.1111/j.1365-2222.1995.tb00998.x; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P6800; GRAINGER DN, 1990, CLIN EXP ALLERGY, V20, P181, DOI 10.1111/j.1365-2222.1990.tb02665.x; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HSIEH KH, 1987, J ASTHMA, V24, P19, DOI 10.3109/02770908709073189; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; KEMENY DM, 1991, INT ARCH ALLER A IMM, V94, P99, DOI 10.1159/000235337; KUS J, 1985, CLIN ALLERGY, V15, P523, DOI 10.1111/j.1365-2222.1985.tb02305.x; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; PAUWELS R, 1979, IMMUNOLOGY, V36, P151; RENZ H, 1994, J IMMUNOL, V152, P351; ROUNDTRESS S, 1985, ARCH DIS CHILD, V60, P727; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEDGWICK JD, 1985, CELL IMMUNOL, V94, P182, DOI 10.1016/0008-8749(85)90095-4; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8	29	261	281	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					540	544		10.1038/nm0596-540	http://dx.doi.org/10.1038/nm0596-540			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616712				2022-12-27	WOS:A1996UJ23000036
J	Barry, MA; Dower, WJ; Johnston, SA				Barry, MA; Dower, WJ; Johnston, SA			Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries	NATURE MEDICINE			English	Article							PROTEIN; ADENOVIRUS; INVIVO	Ideal gene therapy vectors would be delivered intravenously to transfect only specific cells. Existing vectors only transfect cells in vivo in a manner determined by blood flow and the site of introduction. As a general and systematic approach for generating cell-targeting ligands for gene therapy vectors, we have used peptide-presenting phage libraries to select peptides that bind and enter several different cell types. Because of their small size, cell-binding peptides such as these could be incorporated into biological or physical gene therapy vectors. In addition, peptide-presenting phage themselves may also be candidates for gene therapy vectors.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; AFFYMAX RES INST,PALO ALTO,CA 94304	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FONG S, 1994, DRUG DEVELOP RES, V33, P64, DOI 10.1002/ddr.430330203; GOTTSCHALK S, 1995, GENE THER, V2, P498; HART SL, 1994, J BIOL CHEM, V269, P12468; HART SL, 1995, GENE THER, V2, P552; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; MARKLAND W, 1991, GENE, V109, P13, DOI 10.1016/0378-1119(91)90583-W; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; YOKOYAMAKOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V192, P935, DOI 10.1006/bbrc.1993.1505	18	293	341	1	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					299	305		10.1038/nm0396-299	http://dx.doi.org/10.1038/nm0396-299			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612228				2022-12-27	WOS:A1996TY64000038
J	Mellors, JW				Mellors, JW			Closing in on human immunodeficiency virus-1	NATURE MEDICINE			English	Editorial Material							MULTIDRUG-RESISTANCE; THERAPY		DEPT VET AFFAIRS MED CTR,PITTSBURGH,PA 15213		Mellors, JW (corresponding author), UNIV PITTSBURGH,MED CTR,PITTSBURGH,PA 15213, USA.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; Cameron Bill, 1996, P162; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DANNER SA, 1993, 9 INT C AIDS BERL, P69; DELFRAISSY JF, 1993, 9 INT C AIDS BERL, P69; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; Freimuth W. W., 1996, P162; Gulick R., 1996, P162; Hammer S. M., 1996, P175; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Mathez D., 1996, P106; MELLORS J, 1995, 35 INT C ANT AG CHEM, P235; MELLORS JW, 1996, 3 C RETR OPP INF WAS, P175; Perelson Alan S., 1996, P174; SCHAPIRO JM, 1995, 35 INT C ANT AG CHEM, pS8; STEIGBIGEL RT, 1993, 3 C RETR OPP INF WAS, P80; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	23	27	37	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					274	275		10.1038/nm0396-274	http://dx.doi.org/10.1038/nm0396-274			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612219				2022-12-27	WOS:A1996TY64000029
J	Crameri, A; Cwirla, S; Stemmer, WPC				Crameri, A; Cwirla, S; Stemmer, WPC			Construction and evolution of antibody-phage libraries by DNA shuffling	NATURE MEDICINE			English	Editorial Material											Crameri, A (corresponding author), AFFYMAX RES INST,4001 MIRANDA AVE,PALO ALTO,CA 94304, USA.							CRAMERI A, 1995, BIOTECHNIQUES, V18, P194; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; KABAT EA, 1991, NIH913242 PUBL; SMITH GP, 1994, NATURE, V370, P324, DOI 10.1038/370324a0; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; STEMMER WPC, IN PRESS SCIENCE; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	11	83	179	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					100	102		10.1038/nm0196-100	http://dx.doi.org/10.1038/nm0196-100			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564822				2022-12-27	WOS:A1996TP57900045
J	BANERJEE, S; LIVANOS, E; VOS, JMH				BANERJEE, S; LIVANOS, E; VOS, JMH			THERAPEUTIC GENE DELIVERY IN HUMAN BETA-LYMPHOBLASTOID CELLS BY ENGINEERED NON-TRANSFORMING INFECTIOUS EPSTEIN-BARR-VIRUS	NATURE MEDICINE			English	Article							FANCONIS ANEMIA; REPLICATION; DNA	The B-lymphotrophic human herpes Epstein-Barr virus (EBV) is a 160-kilobase double-stranded DNA episomal virus carried in a persistent asymptomatic state by more than 90% of the worldwide adult population. We engineered a helper-dependent mini-EBV, with the minimal cis-EBV elements for episomal replication, viral amplification and packaging, for use as a gene delivery system. The therapeutic potential of this system was established by stably transducing B-lymphoblastoid cells from a Fanconi anaemia group C (FA-C) patient with a mini-EBV constitutively expressing the normal FACC cDNA and showing in vitro correction of the FA phenotype. In the absence of selective pressure, episomal expression persisted with a half-life of 30 days in actively growing transduced cells, indicating a retention rate of 98% expression per cell doubling. This work demonstrates the generation of an infectious non-transforming viral vector that can potentially deliver large therapeutic genes efficiently and selectively into human B cells.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051818] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-POI-HL51818-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAESE RM, 1990, HUM GENE THER, V1, P327; BLOSS TA, 1994, J VIROL, V68, P8217, DOI 10.1128/JVI.68.12.8217-8222.1994; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; COHEN JI, 1992, J VIROL, V66, P7555, DOI 10.1128/JVI.66.12.7555-7559.1992; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; DILLON N, 1994, CURR OPIN GENET DEV, V4, P260, DOI 10.1016/S0959-437X(05)80053-X; DUNBAR CE, 1994, STEM CELLS, V12, P563, DOI 10.1002/stem.5530120604; EDVARDSMITH CI, 1994, IMMUNOL REV, V138, P159; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; FARELL PJ, 1989, ADV VIRAL ONCOL, V8, P103; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KELLEHER ZT, 1994, BIOTECHNIQUES, V17, P1110; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; KIEFF E, 1990, VIROLOGY, P1889; KINCADE PW, 1992, FUNDAMENTAL IMMUNOLO, P41; KRAUSS JC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P193, DOI 10.1016/0304-419X(92)90015-Q; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; MATSUMOTO A, 1989, MUTAT RES, V217, P185, DOI 10.1016/0921-8777(89)90070-0; MILLER G, 1990, VIROLOGY, P1921; MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8; MORGAN RA, 1994, ANN REV BIOCH, V62, P191; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROBERTSON E, 1995, J VIROL, V69, P983, DOI 10.1128/JVI.69.2.983-993.1995; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; STRATHDEE CA, 1992, AM J PEDIAT HEMATOL, V5, P177; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; SUN TQ, 1992, INT J GENOME RES, V1, P45; VOS JM, 1994, VIRUSES HUMAN GENE T, P108; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	33	62	64	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1995	1	12					1303	1308		10.1038/nm1295-1303	http://dx.doi.org/10.1038/nm1295-1303			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TH786	7489413				2022-12-27	WOS:A1995TH78600044
J	HILLEMAN, MR				HILLEMAN, MR			WHETHER AND WHEN AN AIDS VACCINE	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION				HILLEMAN, MR (corresponding author), MERCK SHARP & DOHME RES LABS,THERAPEUT RES INST,WP26-331,W POINT,PA 19486, USA.							BABA TW, 1995, SCIENCE, V427, P1820; CLERICI M, 1993, IMMUNOL TODAY, V114, P107; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; GRIFFIN DE, 1994, J INFECT DIS, V170, pS24, DOI 10.1093/infdis/170.Supplement_1.S24; HILLEMAN MR, 1994, AIDS RES HUM RETROV, V10, P1409, DOI 10.1089/aid.1994.10.1409; HILLEMAN MR, 1992, VACCINE, V10, P1053, DOI 10.1016/0264-410X(92)90115-Z; HILLEMAN MR, 1994, AIDS RES HUM RETROV, V10, P3, DOI 10.1089/aid.1994.10.3; HILLEMAN MR, IN PRESS VACCINE; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kurth Reinhard, 1993, P39; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MOSMANN TR, 1994, SCIENCE, V265, P193, DOI 10.1126/science.8023139; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAUL WE, 1995, SCIENCE, V267, P633, DOI 10.1126/science.7839138; RIMMELZWAAN GF, 1995, VACCINE, V13, P703; SIMONMOFFAT A, 1995, SCIENCE, V268, P658; 1995, AIDS, V9, pWHO1	20	12	12	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1126	1129		10.1038/nm1195-1126	http://dx.doi.org/10.1038/nm1195-1126			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584976	Bronze			2022-12-27	WOS:A1995TC53700028
J	MAFFEI, M; HALAAS, J; RAVUSSIN, E; PRATLEY, RE; LEE, GH; ZHANG, Y; FEI, H; KIM, S; LALLONE, R; RANGANATHAN, S; KERN, PA; FRIEDMAN, JM				MAFFEI, M; HALAAS, J; RAVUSSIN, E; PRATLEY, RE; LEE, GH; ZHANG, Y; FEI, H; KIM, S; LALLONE, R; RANGANATHAN, S; KERN, PA; FRIEDMAN, JM			LEPTIN LEVELS IN HUMAN AND RODENT - MEASUREMENT OF PLASMA LEPTIN AND OB RNA IN OBESE AND WEIGHT-REDUCED SUBJECTS	NATURE MEDICINE			English	Article							LIPOPROTEIN-LIPASE; ADIPOSE-TISSUE; PIMA-INDIANS; MOUSE; MUTATION; MICE; RAT	Leptin, the gene product of the obese gene, may play an important role in regulating body weight by signalling the size of the adipose tissue mass. Plasma leptin was found to be highly correlated with body mass index (BMI) in rodents and in 87 lean and obese humans. In humans, there was variability in plasma leptin at each BMI suggesting that there are differences in its secretion rate from fat. Weight loss due to food restriction was associated with a decrease in plasma leptin in samples from mice and obese humans.	ROCKEFELLER UNIV, MOLEC GENET LAB, NEW YORK, NY 10021 USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; BROOKWOOD BIOMED ACC, BIRMINGHAM, AL 35209 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cedars Sinai Medical Center; Howard Hughes Medical Institute; Rockefeller University			sheng, jian/E-9474-2012; Steib, Lori/B-6628-2014; Ravussin, Eric/N-1985-2017	Steib, Lori/0000-0001-8274-318X; Ravussin, Eric/0000-0003-2129-547X	NCRR NIH HHS [RR00862] Funding Source: Medline; NIDDK NIH HHS [DK39176, DK41096] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096, R29DK039176, R01DK039176] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; BARROWS CH, 1977, ADV NUTR RES, V1, P253; BENNETT WI, 1995, NEW ENGL J MED, V332, P673, DOI 10.1056/NEJM199503093321009; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; DEBONS AF, 1977, FED PROC, V36, P143; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GOLDMAN RF, 1959, TECHNIQUES MEASURING, P78; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HARLOW E, 1988, ANTIBODIES LABORATOR; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KERN PA, 1990, NEW ENGL J MED, V322, P1053, DOI 10.1056/NEJM199004123221506; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBEL RL, 1977, J THEOR BIOL, V66, P297, DOI 10.1016/0022-5193(77)90173-4; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P679, DOI 10.1056/NEJM199503093321012; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MACDOUGALD OA, IN PRESS P NATN ACAD; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P637, DOI 10.1210/jc.80.2.637; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; SIMSOLO RB, 1993, J CLIN INVEST, V92, P2124, DOI 10.1172/JCI116813; SIRI WE, 1959, TECHNIQUES MEASURING, P223; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1985, WHO TECH REP, V727, P796	47	3086	3166	1	148	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1995	1	11					1155	1161		10.1038/nm1195-1155	http://dx.doi.org/10.1038/nm1195-1155			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584987				2022-12-27	WOS:A1995TC53700039
J	STROMINGER, JL				STROMINGER, JL			PEPTIDE VACCINATION AGAINST CANCER	NATURE MEDICINE			English	Editorial Material									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	STROMINGER, JL (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; CASTELLI C, 1995, J EXP MED, V181, P363, DOI 10.1084/jem.181.1.363; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MELIEF CJM, 1995, IMMUNOL REV, V146, P167; MOLLER G, 1995, IMMUNOL REV, V145, P5; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; RESSING ME, 1995, J IMMUNOL, V154, P5934; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	14	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1140	1140		10.1038/nm1195-1140	http://dx.doi.org/10.1038/nm1195-1140			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584983				2022-12-27	WOS:A1995TC53700035
J	ORAVECZ, T; RODERIQUEZ, G; KOFFI, J; WANG, JH; DITTO, M; BOUHABIB, DC; LUSSO, P; NORCROSS, MA				ORAVECZ, T; RODERIQUEZ, G; KOFFI, J; WANG, JH; DITTO, M; BOUHABIB, DC; LUSSO, P; NORCROSS, MA			CD26 EXPRESSION CORRELATES WITH ENTRY, REPLICATION AND CYTOPATHICITY OF MONOCYTOTROPIC HIV-1 STRAINS IN A T-CELL LINE	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DIPEPTIDYL PEPTIDASE-IV; ACTIVATION ANTIGEN; BIOLOGICAL PHENOTYPE; AIDS VIRUS; HTLV-III; INFECTION; SURFACE; CD4; INDIVIDUALS	Experiments to identify cell determinants involved in HIV-1 tropism revealed a specific decrease in the expression of the T-cell activation antigen CD26 after monocytotropic (M-tropic) but not T-cell line-tropic (T-tropic) virus infection of the PM1 T-cell line. The level of CD26 expression in single-cell clones of PM1 correlated with the entry rate and cytopathicity of M-tropic HIV-1 variants, resulting in preferential survival of cells with low CD26 levels after infection. Experiments with recombinant viruses showed that the third hypervariable region of the envelope gp120 plays an important role in this selection process. This study identifies CD26 as a key marker for M-tropic human immunodeficiency virus type 1 (HIV-1) infection and suggests a mechanism for the early loss of CD26-expressing cells in HIV-1-infected individuals.	NIH,FOOD & DRUG ADM,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BETHESDA,MD 20892; UNIV MILAN,OSPED L SACCO,INST MALATTIE INFETT,I-20132 MILAN,ITALY	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); University of Milan; Luigi Sacco Hospital				Bou-Habib, Dumith/0000-0003-0552-9045				ANSORGE S, 1987, ADV BIOSCI, P3; BEDNARCZYK JL, 1991, J CELL BIOCHEM, V46, P206, DOI 10.1002/jcb.240460304; BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; BRODER CC, 1994, SCIENCE, V264, P1156, DOI 10.1126/science.7909959; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CALLEBAUT C, 1994, SCIENCE, V264, P1162, DOI 10.1126/science.264.5162.1162; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HAFLER DA, 1986, J IMMUNOL, V137, P414; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KIDO H, 1990, J BIOL CHEM, V265, P21979; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Maniatis T., 1982, MOL CLONING; MEERLOO T, 1992, AIDS, V6, P1105, DOI 10.1097/00002030-199210000-00007; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; ORAVECZ T, 1991, SCAND J IMMUNOL, V34, P531, DOI 10.1111/j.1365-3083.1991.tb01576.x; ORAVECZ T, 1994, IMMUNOL LETT, V40, P7, DOI 10.1016/0165-2478(94)90198-8; ORAVECZ T, 1993, AIDS RES HUM RETROV, V9, P945, DOI 10.1089/aid.1993.9.945; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SERPENTE N, 1993, INT IMMUNOL, V5, P939, DOI 10.1093/intimm/5.8.939; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; TANAKA T, 1992, J IMMUNOL, V149, P481; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	45	61	62	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					919	926		10.1038/nm0995-919	http://dx.doi.org/10.1038/nm0995-919			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585218				2022-12-27	WOS:A1995RT30300046
J	VANOMMEN, GJ				VANOMMEN, GJ			A FOUNDATION FOR LIMB-GIRDLE MUSCULAR-DYSTROPHY	NATURE MEDICINE			English	Editorial Material							GENETIC-HETEROGENEITY; MOLECULAR-CLONING; LINKAGE; CALPAIN; CHROMOSOME-15; CONFIRMATION; AUTOLYSIS; SUBUNIT; MUSCLE	Recent work suggests that the molecular basis for one form of limb-girdle muscular dystrophy is neither a single gene nor many genes: Enter the digenic model.			VANOMMEN, GJ (corresponding author), LEIDEN UNIV, DEPT HUMAN GENET, 2300 RA LEIDEN, NETHERLANDS.							ALLAMAND V, IN PRESS AM J HUM GE; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; Bushby K.M.D., 1994, DIAGNOSTIC CRITERIA, P25; BUSHBY KMD, IN PRESS NEUROMUSC D; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SPEER MC, 1992, AM J HUM GENET, V50, P1211; YOUNG K, 1992, GENOMICS, V13, P1370, DOI 10.1016/0888-7543(92)90074-3	18	16	16	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1995	1	5					412	414						3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585084				2022-12-27	WOS:A1995RN10000027
J	LYNCH, HT; MARCUS, JN				LYNCH, HT; MARCUS, JN			GENETICS AND ENVIRONMENT IN HODGKINS-DISEASE	NATURE MEDICINE			English	Editorial Material							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; LOCUS; CHROMOSOME-5Q21; MUTATIONS; HOMOLOG; FAMILY; GENES; FAP		ST LUKES HOSP,DEPT PATHOL,ST LOUIS,MO 63017	Saint Luke's Hospital - Missouri	LYNCH, HT (corresponding author), CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178, USA.							Anderson Robert J., 1993, Current Opinion in Oncology, V5, P75; BJERRUM OW, 1986, SCAND J HAEMATOL, V46, P398; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUEHLER SK, 1975, LANCET, V1, P195; CIMINO G, 1988, EUR J CANCER CLIN ON, V24, P1595, DOI 10.1016/0277-5379(88)90051-X; CREAGAN ET, 1972, LANCET, V2, P547; DONHUIJSENANT R, 1988, ANN INTERN MED, V109, P946, DOI 10.7326/0003-4819-109-12-946; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRAUMENI JF, 1974, CANCER RES, V34, P1164; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LYNCH HT, 1989, BRIT J CANCER, V59, P622, DOI 10.1038/bjc.1989.126; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1990, BREAST COMPREHENSIVE, P262; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NAROD SA, 1991, LANCET, V338, P82; NICOLAIDES NC, 1994, NATURE, V271, P75; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAPADOPOULOS N, 1994, SCIENCE, V262, P1625; PYRIESLER A, 1926, VIRCHOWS ARCH PATH A, V262, P749; SALIMONU LS, 1980, INT ARCH ALLER A IMM, V63, P52, DOI 10.1159/000232609	24	2	2	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1995	1	4					298	300		10.1038/nm0495-298	http://dx.doi.org/10.1038/nm0495-298			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN098	7585054				2022-12-27	WOS:A1995RN09800020
J	RUTKOWSKI, JL; KIRK, CJ; LERNER, MA; TENNEKOON, GI				RUTKOWSKI, JL; KIRK, CJ; LERNER, MA; TENNEKOON, GI			PURIFICATION AND EXPANSION OF HUMAN SCHWANN-CELLS IN-VITRO	NATURE MEDICINE			English	Article							PERIPHERAL-NERVE REGENERATION; GLIAL GROWTH-FACTOR; WALLERIAN DEGENERATION; TISSUE-CULTURE; PROLIFERATION; SYSTEM	The ability to culture cells from the human nervous system provides new insight into the pathophysiology of neurological diseases and could be crucial to the development of gene replacement therapies and neural transplantation. We report that the proliferation of human Schwann cells isolated from paediatric and adult nerves is sustained in vitro by recombinant glial growth factor. Agents that increase intracellular cyclic cAMP were also mitogenic towards Schwann cells but suppress growth of contaminating fibroblasts. As the lifespan of highly enriched cultures can be extended for up to twelve population doublings, large numbers of cells can be generated from nerve biopsies.	CAMBRIDGE NEUROSCI INC,CAMBRIDGE,MA 02139		RUTKOWSKI, JL (corresponding author), UNIV MICHIGAN,DIV PEDIAT NEUROL,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029710] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-29710] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AICARDI J, 1993, J INHERIT METAB DIS, V16, P733, DOI 10.1007/BF00711905; ASKANAS V, 1980, ARCH NEUROL-CHICAGO, V37, P329, DOI 10.1001/archneur.1980.00500550031001; BOLIN LM, 1992, J NEUROSCI RES, V33, P231, DOI 10.1002/jnr.490330206; BOYER PJ, 1994, EXP NEUROL, V130, P53, DOI 10.1006/exnr.1994.1184; BROCKES JP, 1987, METHOD ENZYMOL, V147, P217; BUNGE RP, 1988, PROG BRAIN RES, V78, P312; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHANCE PF, 1993, ARCH NEUROL-CHICAGO, V50, P1180, DOI 10.1001/archneur.1993.00540110060006; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; ESPINOZA B, 1986, AM J PHYSIOL, V251, pC238, DOI 10.1152/ajpcell.1986.251.2.C238; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FISHER LJ, 1993, PHYSIOL REV, V73, P583, DOI 10.1152/physrev.1993.73.3.583; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; GUTMANN DH, 1994, CURR OPIN NEUROL, V7, P166, DOI 10.1097/00019052-199404000-00014; HUGHES RAC, 1994, ACTA NEUROL BELG, V94, P128; KIM SU, 1989, J NEUROSCI RES, V22, P50, DOI 10.1002/jnr.490220107; LEVI ADO, 1994, J NEUROSCI, V14, P1309, DOI 10.1523/JNEUROSCI.14-03-01309.1994; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MORETTO G, 1984, ACTA NEUROPATHOL, V64, P15, DOI 10.1007/BF00695601; MUIR D, 1990, J CELL BIOL, V111, P2663, DOI 10.1083/jcb.111.6.2663; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; RAIVICH G, 1993, INT J DEV NEUROSCI, V11, P311, DOI 10.1016/0736-5748(93)90003-V; RUTKOWSKI JL, 1992, ANN NEUROL, V31, P580, DOI 10.1002/ana.410310603; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCARPINI E, 1988, BRAIN RES, V440, P261, DOI 10.1016/0006-8993(88)90994-8; ZAGER EL, 1988, SURG NEUROL, V29, P350, DOI 10.1016/0090-3019(88)90044-4	29	130	132	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					80	83		10.1038/nm0195-80	http://dx.doi.org/10.1038/nm0195-80			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584959				2022-12-27	WOS:A1995QX55700031
J	Capron, L				Capron, L			Chlamydia in coronary plaques - Hidden culprit or harmless hobo?	NATURE MEDICINE			English	Editorial Material							PNEUMONIAE TWAR; ATHEROSCLEROSIS; ARTERIES; LESIONS				Capron, L (corresponding author), HOP HOTEL DIEU,SERV MED INTERNE,F-75181 PARIS 04,FRANCE.							FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Moazed TC, 1996, AM J PATHOL, V148, P667; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6	9	47	48	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					856	857		10.1038/nm0896-856	http://dx.doi.org/10.1038/nm0896-856			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705849				2022-12-27	WOS:A1996UZ80400026
J	Wang, JZ; GrundkeIqbal, I; Iqbal, K				Wang, JZ; GrundkeIqbal, I; Iqbal, K			Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer's disease	NATURE MEDICINE			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; MISSENSE MUTATIONS; OXIDANT STRESS; GLYCATED-TAU; GENE; BRAIN; PHOSPHORYLATION; PHOSPHATASE-2A; PATHOLOGY	Alzheimer's disease (AD) is characterized by the presence of numerous neurons with neurofibrillary tangles of paired helical filaments (PHFs). The microtubule-associated protein tau in abnormally hyperphosphorylated form is the major protein subunit of the PHF. We now show that PHF tangles isolated from AD brains are glycosylated, whereas no glycan is detected in normal tau. Deglycosylation of PHF tangles by endoglycosidase F/N-glycosidase F converts them into bundles of straight filaments 2.5 +/- 0.5 nm in diameter, similar to those generated by the interaction of normal tau and abnormally hyperphosphorylated tau (AD P-tau). Deglycosylation plus dephosphorylation, but not deglycosylation alone, of AD P-tau and tau from PHF tangles restores their microtubule polymerization activity. Dephosphorylation of deglycosylated PHF tangles results in increased tan release. Thus, although the abnormal phosphorylation might promote aggregation of tau and inhibition of the assembly of microtubules, glycosylation appears to be responsible for the maintenance of the PHF structure.	NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Institute for Basic Research in Developmental Disabilities					NIA NIH HHS [AG 05892, AG 08076] Funding Source: Medline; NIMH NIH HHS [MH/NS 31862] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005892, R01AG008076] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALAFUZOFF I, 1987, ACTA NEUROPATHOL, V74, P209, DOI 10.1007/BF00688184; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DELALONSO AC, 1996, NAT MED, V2, P783; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUX WJ, 1995, FEBS LETT, V366, P81, DOI 10.1016/0014-5793(95)00486-S; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KOPKE E, 1993, J BIOL CHEM, V268, P24374; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEDESMA MD, 1995, J NEUROCHEM, V65, P1658; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; RUBEN GC, 1992, BRAIN RES, V590, P164, DOI 10.1016/0006-8993(92)91092-S; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; TANAKA S, 1988, J MOL BIOL, V203, P495, DOI 10.1016/0022-2836(88)90015-0; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; ZUBENKO GS, 1988, ALZ DIS ASSOC DIS, V2, P179	33	282	302	1	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					871	875		10.1038/nm0896-871	http://dx.doi.org/10.1038/nm0896-871			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705855				2022-12-27	WOS:A1996UZ80400032
J	Langer, R				Langer, R			Controlled release of a therapeutic protein	NATURE MEDICINE			English	Editorial Material							DELIVERY		GENENTECH INC,SAN FRANCISCO,CA 94080	Roche Holding; Genentech	Langer, R (corresponding author), MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02134, USA.							COSTANTINO HR, 1994, J PHARM SCI-US, V83, P1662, DOI 10.1002/jps.2600831205; HAGEMAN MJ, 1992, J AGR FOOD CHEM, V40, P348, DOI 10.1021/jf00014a036; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317; OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; SCHOR AM, 1979, INT J CANCER, V245, P225; Stannett V. T., 1979, RECENT ADV MEMBRANE, P69	10	22	22	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					742	743		10.1038/nm0796-742	http://dx.doi.org/10.1038/nm0796-742			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673913				2022-12-27	WOS:A1996UU68000023
J	Dodds, MWJ				Dodds, MWJ			Dental caries diagnosis - Toward the 21st century	NATURE MEDICINE			English	Editorial Material											Dodds, MWJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT COMMUNITY DENT,SAN ANTONIO,TX 78284, USA.							Longbottom C, 1996, NAT MED, V2, P235, DOI 10.1038/nm0296-235; LUSSI A, 1993, CARIES RES, V27, P409, DOI 10.1159/000261572	2	8	8	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1996	2	3					283	283		10.1038/nm0396-283	http://dx.doi.org/10.1038/nm0396-283			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TY640	8612224	Bronze			2022-12-27	WOS:A1996TY64000034
J	Blau, CA; Stamatoyannopoulos, G				Blau, CA; Stamatoyannopoulos, G			Preemptive therapy for genetic disease	NATURE MEDICINE			English	Editorial Material							MARROW TRANSPLANTATION		UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Blau, CA (corresponding author), UNIV WASHINGTON,DIV HEMATOL,SEATTLE,WA 98195, USA.							BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; COWAN MJ, 1994, AM J PEDIAT HEMATOL, V16, P35; Flake A. W., 1995, Blood, V86, p125A; KAPELUSHNIK J, 1995, BLOOD, V86, P3241, DOI 10.1182/blood.V86.8.3241.bloodjournal8683241; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; NESCI S, 1992, BONE MARROW TRANSPL, V10, P143; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O	7	10	10	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					161	162		10.1038/nm0296-161	http://dx.doi.org/10.1038/nm0296-161			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574957				2022-12-27	WOS:A1996TU06000032
J	McInnes, IB; AlMughales, J; Field, M; Leung, BP; Huang, FP; Dixon, R; Sturrock, RD; Wilkinson, PC; Liew, FY				McInnes, IB; AlMughales, J; Field, M; Leung, BP; Huang, FP; Dixon, R; Sturrock, RD; Wilkinson, PC; Liew, FY			The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis	NATURE MEDICINE			English	Article							CARTILAGE PANNUS JUNCTION; SYNOVIAL TISSUE; INFLAMMATORY ARTHRITIS; PERIPHERAL-BLOOD; MACROPHAGE; EXPRESSION; CYTOKINES; FLUID; CLASSIFICATION; LOCALIZATION	Interleukin 15 (IL-15) is a novel cytokine with interleukin-2-like activity. It is also a potent T-lymphocyte chemoattractant. Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the presence of activated T lymphocytes, macrophages and synoviocytes in the synovial membrane. The mechanisms of T-cell activation in RA are currently unclear. We report the presence of high concentrations of IL-15 in rheumatoid arthritis (RA) synovial fluid and have demonstrated its expression in the synovial membrane lining layer by immunohistochemistry. RA synovial fluids were found to contain chemotactic activity, which was attributable in part to the presence of IL-15. Moreover, in a murine model, injection of recombinant IL-15 was found to induce a local tissue inflammatory infiltrate consisting predominantly of T lymphocytes. Synovial fluid T lymphocytes proliferate in response to IL-15, demonstrating that continued responsiveness to IL-15 is a feature of T cells after entry into the synovial compartment, These data suggest that IL-15 can recruit and activate T lymphocytes into the synovial membrane, thereby contributing to RA pathogenesis.	UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,DEPT MED,CTR RHEUMAT DIS,GLASGOW G11 6NT,LANARK,SCOTLAND; LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND	University of Glasgow; University of Glasgow			Leung, Bernard/O-2409-2013	Leung, Bernard/0000-0002-1119-4934; Al-Mughales, Jamil/0000-0001-6893-0691; McInnes, Iain/0000-0002-6462-4280	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BRENNAN FM, 1991, BR J RHEUM S2, V30, P75; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; CHU CQ, 1992, BRIT J RHEUMATOL, V31, P653; COMBE B, 1985, CLIN EXP IMMUNOL, V59, P520; DELEURAN B, 1994, SCAND J RHEUMATOL, V23, P2, DOI 10.3109/03009749409102126; DELEURAN BW, 1992, BRIT J RHEUMATOL, V31, P801; DUFF GW, 1993, BRIT J RHEUMATOL, V32, P15; DUKE O, 1982, CLIN EXP IMMUNOL, V49, P22; FERNANDEZGUTIERREZ B, 1995, J RHEUMATOL, V22, P413; FIELD M, 1991, RHEUMATOL INT, V11, P45, DOI 10.1007/BF00291144; FIRESTEIN GS, 1987, ARTHRITIS RHEUM, V30, P864, DOI 10.1002/art.1780300804; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARRISON WB, 1992, 2ND LINE AGENTS TREA; HASTON WS, 1985, J IMMUNOL METHODS, V81, P229, DOI 10.1016/0022-1759(85)90208-X; HORNEFF G, 1991, ARTHRITIS RHEUM, V34, P129, DOI 10.1002/art.1780340202; IANNONE F, 1994, EUR J IMMUNOL, V24, P2706, DOI 10.1002/eji.1830241120; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KOCH AE, 1991, J IMMUNOL, V147, P2187; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; MAINI RN, 1995, MECHANISMS MODELS RH, P25; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; PITZALIS C, 1987, J RHEUMATOL, V14, P662; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; THOMAS R, 1992, ARTHRITIS RHEUM-US, V35, P1455, DOI 10.1002/art.1780351209; ULFGREN AK, 1995, ANN RHEUM DIS, V54, P654, DOI 10.1136/ard.54.8.654; WENDLING D, 1991, J RHEUMATOL, V18, P325; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	41	406	425	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					175	182		10.1038/nm0296-175	http://dx.doi.org/10.1038/nm0296-175			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574962				2022-12-27	WOS:A1996TU06000037
J	Willis, D; Moore, AR; Frederick, R; Willoughby, DA				Willis, D; Moore, AR; Frederick, R; Willoughby, DA			Heme oxygenase: A novel target for the modulation of the inflammatory response	NATURE MEDICINE			English	Article							BILIRUBIN	Chronic inflammatory diseases place a heavy social and economic burden on the resources of many nations, but the number of safe and effective treatments is limited. To date, the major research effort has concentrated on those mediators responsible for the initiation and maintenance of the pathological process. In contrast, little attention has been focused on endogenous factors responsible for the resolution of the inflammation. Heme oxygenase ((HO); EC 1.14.99.3) is the rate-limiting enzyme in the catabolism of heme to biliverdin (which is converted to bilirubin by biliverdin reductase), free iron and carbon monoxide (CO), Two isoforms of HO have been characterized, the constitutive isoform, HO-2, which is the major isoform present under physiological conditions, and the stress-induced isoform, HO-1, which has also been classified as heat-shock protein 32K (ref. 1). Increases in HO activity have been implicated in tissue protection against oxidative stress(2). In this communication, we describe the effects of modulating HO during an acute complement-dependent inflammatory response. Elevation of this enzyme resulted in a striking suppression, whereas inhibition of the enzyme led to a potentiation of the inflammatory response. Such novel enzyme modulation has application on the one hand to the treatment of inflammatory diseases and on the other hand to immunosuppressed states in which the impaired ability to mount an adequate inflammatory response may result in death from opportunistic infections.			Willis, D (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WILLIAM HARVEY RES INST,DEPT EXPTL PATHOL,LONDON EC1M 6BQ,ENGLAND.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; CAPASSO F, 1975, J PATHOL, V116, P117, DOI 10.1002/path.1711160208; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; LEVERE RD, 1993, AM J HEMATOL, V43, P19, DOI 10.1002/ajh.2830430106; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MARTASEK P, 1991, J AM SOC NEPHROL, V2, P1078; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; POLLA BS, 1995, INFLAMMATION, V19, P363, DOI 10.1007/BF01534393; SIERRA EE, 1992, ANAL BIOCHEM, V200, P27, DOI 10.1016/0003-2697(92)90271-8; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILLIS D, 1995, BIOCHEM BIOPH RES CO, V214, P1152, DOI 10.1006/bbrc.1995.2406	18	688	718	0	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					87	90		10.1038/nm0196-87	http://dx.doi.org/10.1038/nm0196-87			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564848				2022-12-27	WOS:A1996TP57900042
J	FUJIMOTO, JG; BREZINSKI, ME; TEARNEY, GJ; BOPPART, SA; BOUMA, B; HEE, MR; SOUTHERN, JF; SWANSON, EA				FUJIMOTO, JG; BREZINSKI, ME; TEARNEY, GJ; BOPPART, SA; BOUMA, B; HEE, MR; SOUTHERN, JF; SWANSON, EA			OPTICAL BIOPSY AND IMAGING USING OPTICAL COHERENCE TOMOGRAPHY	NATURE MEDICINE			English	Editorial Material							BIOLOGICAL TISSUES; REFLECTOMETRY		MIT,COMP SCI RES LAB ELECTR,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; MIT,LINCOLN LAB,LEXINGTON,MA 02173	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Lincoln Laboratory; Massachusetts Institute of Technology (MIT)	FUJIMOTO, JG (corresponding author), MIT,DEPT ELECT ENGN,30 VASSAR ST,CAMBRIDGE,MA 02139, USA.		Boppart, Stephen A/C-7338-2009	Boppart, Stephen/0000-0002-9386-5630				BOUMA B, 1995, OPT LETT, V20, P1486, DOI 10.1364/OL.20.001486; CLIVAZ X, 1992, OPT LETT, V17, P4, DOI 10.1364/OL.17.000004; CLIVAZ X, 1994, EUROPEAN BIOMEDICAL, P2083; DAVIES MJ, 1983, BRIT HEART J, V53, P363; FALK E, 1983, BRIT HEART J, V50, P127; FERCHER AF, 1988, OPT LETT, V13, P1867; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GILGEN HH, 1989, IEEE J LIGHTWAVE TEC, V8, P1225; HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HITZENBERGER CK, 1992, INVEST OPHTH VIS SCI, V33, P98; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; IZATT JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P1584, DOI 10.1001/archopht.1994.01090240090031; POLIAFITO CA, IN PRESS OPTICAL COH; PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217; RICHARDSON PD, 1989, LANCET, V1, P941; SCHMITT JM, 1994, PHYS MED BIOL, V39, P1705, DOI 10.1088/0031-9155/39/10/013; SCHMITT JM, 1993, APPL OPTICS, V32, P6032, DOI 10.1364/AO.32.006032; SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864; TAKADA K, 1987, APPL OPTICS, V26, P1603, DOI 10.1364/AO.26.001603; YOUNGQUIST RC, 1987, OPT LETT, V12, P158, DOI 10.1364/OL.12.000158	21	683	780	5	70	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					970	972		10.1038/nm0995-970	http://dx.doi.org/10.1038/nm0995-970			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585229				2022-12-27	WOS:A1995RT30300057
J	GOTTLIEB, SL; GILLEAUDEAU, P; JOHNSON, R; ESTES, L; WOODWORTH, TG; GOTTLIEB, AB; KRUEGER, JG				GOTTLIEB, SL; GILLEAUDEAU, P; JOHNSON, R; ESTES, L; WOODWORTH, TG; GOTTLIEB, AB; KRUEGER, JG			RESPONSE OF PSORIASIS TO A LYMPHOCYTE-SELECTIVE TOXIN (DAB(389)IL-2) SUGGESTS A PRIMARY IMMUNE, BUT NOT KERATINOCYTE, PATHOGENIC BASIS	NATURE MEDICINE			English	Article							GROWTH FACTOR-ALPHA; INTERLEUKIN-2 FUSION PROTEIN; RECEPTOR; CYCLOSPORINE; EXPRESSION; CELLS; MATURATION; PLAQUES; MODEL; SKIN	Psoriasis is a hyperproliferative and inflammatory skin disorder of unknown aetiology. A fusion protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB(389)IL-2), which selectively blocks the growth of activated lymphocytes but not keratinocytes, was administered systemically to ten patients to gauge the contribution of activated T cells to the disease. Four patients showed striking clinical improvement and four moderate improvement, after two cycles of low dose IL-2-toxin. The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3(-) and CD8(+) T cells, suggesting a primary immunological basis for this widespread disorder.	ROCKEFELLER UNIV,INVEST DERMATOL LAB,NEW YORK,NY 10021; SERAGEN INC,HOPKINTON,MA 01748	Rockefeller University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007525] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54215] Funding Source: Medline; NCRR NIH HHS [RR 00102] Funding Source: Medline; NIAMS NIH HHS [AR 07525] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACKERMAN C, 1991, J INVEST DERMATOL, V96, P536; BAADSGARD O, 1990, J INVEST DERMATOL, V95, P325; BACHA PA, 1991, INT J CANCER, V49, P96, DOI 10.1002/ijc.2910490118; BAKER BS, 1987, BRIT J DERMATOL, V116, P503, DOI 10.1111/j.1365-2133.1987.tb05869.x; BATACSORGO Z, 1995, J CLIN INVEST, V95, P317, DOI 10.1172/JCI117659; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; CARNAUD C, 1993, IMMUNOL RES, V12, P131, DOI 10.1007/BF02918300; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GOTTLIEB AB, 1986, J EXP MED, V164, P1013, DOI 10.1084/jem.164.4.1013; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P302, DOI 10.1111/1523-1747.ep12499782; GOTTLIEB AB, 1994, PSORIASIS, P63; GOTTLIEB SI, IN PRESS J AM ACAD D; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; KHANDKE L, 1991, ARCH DERMATOL, V127, P1172, DOI 10.1001/archderm.127.8.1172; KRANE JF, 1991, J INVEST DERMATOL, V96, P983, DOI 10.1111/1523-1747.ep12476485; KRUEGER JG, 1994, PSORIASIS, P18; LEMAISTRE CF, 1992, BLOOD, V79, P2547; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; ONUMA A, 1994, J DERMATOL, V21, P223; PAUKKONEN K, 1992, ARCH DERMATOL RES, V284, P375, DOI 10.1007/BF00372065; PETZELBAUER P, 1991, J INVEST DERMATOL, V96, P362, DOI 10.1111/1523-1747.ep12465404; PRINZ JC, 1994, EUR J IMMUNOL, V24, P593, DOI 10.1002/eji.1830240315; Rizova Helena, 1994, Journal of Dermatological Science, V7, P1, DOI 10.1016/0923-1811(94)90016-7; SHAW JP, 1991, J BIOL CHEM, V266, P21118; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; VALLAT VP, 1994, J EXP MED, V180, P283, DOI 10.1084/jem.180.1.283; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; Weinstein GD, 1993, THERAPY OF MODERATE-TO-SEVERE PSORIASIS, P1; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493	36	507	534	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1995	1	5					442	447		10.1038/nm0595-442	http://dx.doi.org/10.1038/nm0595-442			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN100	7585092				2022-12-27	WOS:A1995RN10000035
J	ROWLANDJONES, S; SUTTON, J; ARIYOSHI, K; DONG, T; GOTCH, F; MCADAM, S; WHITBY, D; SABALLY, S; GALLIMORE, A; CORRAH, T; TAKIGUCHI, M; SCHULTZ, T; MCMICHAEL, A; WHITTLE, H				ROWLANDJONES, S; SUTTON, J; ARIYOSHI, K; DONG, T; GOTCH, F; MCADAM, S; WHITBY, D; SABALLY, S; GALLIMORE, A; CORRAH, T; TAKIGUCHI, M; SCHULTZ, T; MCMICHAEL, A; WHITTLE, H			HIV-SPECIFIC CYTOTOXIC T-CELLS IN HIV-EXPOSED BUT UNINFECTED GAMBIAN WOMEN	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TOXIC LYMPHOCYTES-T; POLYMERASE CHAIN-REACTION; CLASS-I ANTIGENS; CONSERVED REGION; COTE-DIVOIRE; INFECTION; AIDS; RESPONSES; PEPTIDE	A crucial requirement in the rational design of a prophylactic vaccine against the huuman immunodeficiency virus (HIV) is to establish whether or not protective immunity can occur following natural infection. The immune response to HIV infection is characterized by very vigorous HIV-specific cytotoxic T-lymphocyte (CTL) activity. We have identified four HIV-1 and HIV-2 cross-reactive peptide epitopes, presented to CTL from HIV-infected Gambians by HLA-B35 (the most common Gambian class I HLA molecule). These peptides were used to elicit HIV-specific CTLs from three out of six repeatedly exposed but HIV-seronegative female prostitutes with HLA-B35. These women remain seronegative with no evidence of HIV infection by polymerase chain reaction or viral culture. Their CTL activity may represent protective immunity against HIV infection.	MRC LABS,FAJARA,SENEGAL; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; UNIV TOKYO,INST MED SCI,DEPT TUMOR BIOL,TOKYO 108,JAPAN	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Tokyo	ROWLANDJONES, S (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		Takiguchi, Masafumi/E-7468-2013	Dong, Tao/0000-0003-3545-3758; Gallimore, Awen/0000-0001-6675-7004				ALDHOUS MC, 1994, CLIN EXP IMMUNOL, V97, P61; ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; BERRY NJ, 1994, RETROVIRUSES, V8, P1031; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; CARBONE FR, 1989, J EXP MED, V167, P1767; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1992, J INFECT DIS, V1165, P1012; CULMANN B, 1991, J IMMUNOL, V146, P1560; DEBRUIJN MLH, 1992, EUR J IMMUNOL, V22, P3013, DOI 10.1002/eji.1830221137; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GOTCH F, 1993, J IMMUNOL, V151, P3361; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JOHNSON RP, 1993, J VIROL, V67, P438, DOI 10.1128/JVI.67.1.438-445.1993; JOHNSON RP, 1992, J EXP MED, V175, P961, DOI 10.1084/jem.175.4.961; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOS FJ, 1992, EUR J IMMUNOL, V22, P3183, DOI 10.1002/eji.1830221224; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEE S, IN PRESS EV J IMMUNO; LEONARD G, 1993, AIDS, V7, P1185, DOI 10.1097/00002030-199309000-00006; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; MABEY DCW, 1988, BRIT MED J, V296, P83, DOI 10.1136/bmj.296.6615.83; MACATONIA SE, 1989, J EXP MED, P1255; MARKOVITZ DM, 1993, ANN INTERN MED, V118, P211, DOI 10.7326/0003-4819-118-3-199302010-00010; MARTINSON F, 1990, EUR J IMMUNOL, V21, P2171; MIEDEMA F, 1993, SCIENCE, V262, P1074, DOI 10.1126/science.8235627; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PICKERING H, 1993, AIDS, V7, P271, DOI 10.1097/00002030-199302000-00017; PINTO LA, 1993, AIDS, V7, P1389, DOI 10.1097/00002030-199310000-00016; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SALK J, 1993, SCIENCE, V262, P1075, DOI 10.1126/science.262.5136.1075; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCHECHTER MT, 1993, LANCET, V341, P658, DOI 10.1016/0140-6736(93)90421-C; SCHILD H, 1991, J EXP MED, V174, P1665, DOI 10.1084/jem.174.6.1665; SCHULZ TF, 1990, J VIROL, V64, P5177, DOI 10.1128/JVI.64.10.5177-5182.1990; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018	60	675	706	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					59	64		10.1038/nm0195-59	http://dx.doi.org/10.1038/nm0195-59			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584954	Bronze			2022-12-27	WOS:A1995QX55700027
J	Rivera, VM; Clackson, T; Natesan, S; Pollock, R; Amara, JF; Keenan, T; Magari, SR; Phillips, T; Courage, NL; Cerasoli, F; Holt, DA; Gilman, M				Rivera, VM; Clackson, T; Natesan, S; Pollock, R; Amara, JF; Keenan, T; Magari, SR; Phillips, T; Courage, NL; Cerasoli, F; Holt, DA; Gilman, M			A humanized system for pharmacologic control of gene expression	NATURE MEDICINE			English	Article							HUMAN GROWTH-HORMONE; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; RAPAMYCIN; COMPLEX; CELLS; YEAST; CLONING; FKBP12; DESIGN	Gene therapy was originally conceived as a medical intervention to replace or correct defective genes in patients with inherited disorders. However, it may have much broader potential as an alternative delivery platform for protein therapeutics, such as cytokines, hormones, antibodies and novel engineered proteins. One key technical barrier to the widespread implementation of this form of therapy is the need for precise control over the level of protein production. A suitable system for pharmacologic control of therapeutic gene expression would permit precise titration of gene product dosage, intermittent or pulsatile treatment, and ready termination of therapy by withdrawal of the activating drug. We set out to design such a system with the following properties: (1) low baseline expression and high induction ratio; (2) positive control by an orally bioavailable small-molecule drug; (3) reduced potential for immune recognition through the exclusive use of human proteins; and (4) modularity to allow the independent optimization of each component using the tools of protein engineering. We report here the properties of this system and demonstrate its use to control circulating levels of human growth hormone in mice implanted with engineered human cells.	ARIAD PHARMACEUT INC,GENE THERAPEUT,CAMBRIDGE,MA 02139	Takeda Pharmaceutical Company Ltd; Takeda Oncology			Wilson, Matthew H/K-3193-2013	Rivera, Victor/0000-0002-7258-3001				ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; Austin D J, 1994, Chem Biol, V1, P131, DOI 10.1016/1074-5521(94)90002-7; BELSHAW PJ, 1995, ANGEW CHEM INT EDIT, V34, P2129, DOI 10.1002/anie.199521291; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HEARTLEIN MW, 1994, P NATL ACAD SCI USA, V91, P10967, DOI 10.1073/pnas.91.23.10967; HO SN, IN PRESS NATURE; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KAY JE, 1991, IMMUNOLOGY, V72, P544; LUENGO JI, 1995, CHEM BIOL, V2, P471, DOI 10.1016/1074-5521(95)90264-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Pruschy M N, 1994, Chem Biol, V1, P163, DOI 10.1016/1074-5521(94)90006-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; STAN R, 1994, J BIOL CHEM, V269, P32037; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEPKOWSKI SM, 1991, TRANSPLANTATION, V51, P22, DOI 10.1097/00007890-199101000-00002; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5	39	433	550	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1028	1032		10.1038/nm0996-1028	http://dx.doi.org/10.1038/nm0996-1028			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782462				2022-12-27	WOS:A1996VF49700039
J	Bruce, AJ; Boling, W; Kindy, MS; Peschon, J; Kraemer, PJ; Carpenter, MK; Holtsberg, FW; Mattson, MP				Bruce, AJ; Boling, W; Kindy, MS; Peschon, J; Kraemer, PJ; Carpenter, MK; Holtsberg, FW; Mattson, MP			Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RAT-BRAIN; MESSENGER-RNA; KAINIC ACID; ASTROCYTES; PROTECTION; CYTOKINES; OLIGODENDROCYTES; MODULATION	Brain injury, as occurs in stroke or head trauma, induces a dramatic increase in levels of tumor necrosis factor-alpha (TNF), but its role in brain injury response is unknown. We generated mice genetically deficient in TNF receptors (TNFR-KO) to determine the role of TNF in brain cell injury responses. Damage to neurons caused by focal cerebral ischemia and epileptic seizures was exacerbated in TNFR-KO mice, indicating that TNF serves a neuroprotective function. Oxidative stress was increased and levels of an antioxidant enzyme reduced in brain cells of TNFR-KO mice, indicating that INF protects neurons by stimulating antioxidant pathways. Injury-induced microglial activation was suppressed in TNFR-KO mice, demonstrating a key role for TNF in injury-induced immune response. Drugs that target TNF signaling pathways may prove beneficial in treating stroke and traumatic brain injury.	UNIV KENTUCKY, SANDERS BROWN RES CTR AGING, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT NEUROSURG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PSYCHOL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT BIOL SCI, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT ANAT & NEUROBIOL, LEXINGTON, KY 40536 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky			Mattson, Mark P/F-6038-2012; Bruce-Keller, Annadora/N-1954-2017		NIA NIH HHS [AG 12981] Funding Source: Medline; NINDS NIH HHS [NS 9001, NS 31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012981] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; BRUCE AJ, 1995, EXP NEUROL, V132, P209, DOI 10.1016/0014-4886(95)90026-8; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHUNG IY, 1990, J IMMUNOL, V144, P2999; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GAYOSO MJ, 1994, BRAIN RES, V653, P92, DOI 10.1016/0006-8993(94)90376-X; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LYDEN PD, 1992, EXP NEUROL, V116, P122, DOI 10.1016/0014-4886(92)90160-R; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1993, SEMIN NEUROSCI, V5, P295; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; PANEK RB, 1995, J IMMUNOL, V154, P2846; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STEINBEHRENS B, 1994, J NEUROSCI, V14, P5373; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VANDERPOLL T, 1995, SHOCK, V3, P1; WARNER BB, 1991, AM J PHYSIOL, V260, pL296, DOI 10.1152/ajplung.1991.260.4.L296; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WHITE BC, 1993, ACTA NEUROPATHOL, V86, P1, DOI 10.1007/BF00454891; WIESSNER C, 1993, ACTA NEUROPATHOL, V86, P439; WOLVERS DAW, 1993, EUR CYTOKINE NETW, V4, P377; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	49	815	833	1	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1996	2	7					788	794		10.1038/nm0796-788	http://dx.doi.org/10.1038/nm0796-788			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673925				2022-12-27	WOS:A1996UU68000035
J	Lehner, T; Wang, YF; Cranage, M; Bergmeier, LA; Mitchell, E; Tao, L; Hall, G; Dennis, M; Cook, N; Brookes, R; Klavinskis, L; Doyle, C; Ward, R				Lehner, T; Wang, YF; Cranage, M; Bergmeier, LA; Mitchell, E; Tao, L; Hall, G; Dennis, M; Cook, N; Brookes, R; Klavinskis, L; Doyle, C; Ward, R			Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; TOXIC LYMPHOCYTES-T; HIV-INFECTION; RECTAL MUCOSA; CELL; ANTIBODY; ANTIGEN; TRANSMISSION; PATHOGENESIS; REPLICATION	Prevention of sexually transmitted HIV infection was investigated in macaques by immunization with a recombinant SIV (simian immunodeficiency virus) envelope gp120 and core p27 vaccine. In two independent series of experiments, we used the novel targeted iliac lymph node (TILN) route of immunization, aiming close to the iliac lymph nodes draining the genitorectal mucosa. Rectal challenge with the SIVmac 32H J5 molecular clone in two series induced total protection in four out of seven macaques immunized by TILN, compared with infection in 13 of 14 unimmunized macaques or immunized by other routes (P = 0.025). The remaining three macaques showed either a decrease in viral load (>90%) or transient viremia, indicating that all seven TILN-immunized macaques showed total or partial protection (P = 0.001). Protection was associated with significant increase in the iliac lymph nodes of IgA antibody-secreting cells to p27 (P < 0.02), CD8-suppressor factor (P < 0.01), and the chemokines RANTES and MIP-1 beta (P < 0.01).	PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,SALISBURY SP4 0JG,WILTS,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Lehner, T (corresponding author), UNITED MED & DENT SCH,DEPT IMMUNOL,LONDON SE1 9RT,ENGLAND.			Brookes, Roger/0000-0002-5361-0617; Klavinskis, Linda S./0000-0001-5828-6978				ADACHI A, 1987, J VIROL, V61, P209, DOI 10.1128/JVI.61.1.209-213.1987; AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; ASHWORTH LAE, 1995, J INFECT DIS, V172, P1261, DOI 10.1093/infdis/172.5.1261; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BEAVIS AJ, 1994, J IMMUNOL METHODS, V170, P57, DOI 10.1016/0022-1759(94)90245-3; BERGMEIER LA, 1995, CLIN IMMUNOL IMMUNOP, V76, pS107; BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DOYLE CB, 1995, J VIROL, V69, P1256, DOI 10.1128/JVI.69.2.1256-1260.1995; ERIKSSON K, 1992, J IMMUNOL METHODS, V153, P107, DOI 10.1016/0022-1759(92)90312-H; FURUTA Y, 1994, P NATL ACAD SCI USA, V91, P12559, DOI 10.1073/pnas.91.26.12559; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; HUSSAIN L, 1996, CLIN EXP IMMUNOL, V102, P384; HUSSAIN LA, 1991, AIDS, V5, P1089, DOI 10.1097/00002030-199109000-00004; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; KLAVINSKIS L, 1995, CLIN IMMUNOL IMMUNOP, V76, pS82; LEHNER T, 1994, J IMMUNOL, V153, P1858; LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CELL IMMUNOL, V153, P329, DOI 10.1006/cimm.1994.1032; MATHIJS JM, 1988, LANCET, V1, P1111; MAYER KH, 1987, AM J MED, V80, P327; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; ROSE J, 1995, J VIROL METHODS, V51, P229, DOI 10.1016/0166-0934(94)00109-T; RUD EW, 1994, J GEN VIROL, V75, P529, DOI 10.1099/0022-1317-75-3-529; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; THAPAR MA, 1990, IMMUNOLOGY, V70, P121; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YAHI N, 1992, J VIROL, V66, P2848; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173; 1995, WEEKLY EPIDEMIOL REC, V70, P5	49	287	297	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					767	775		10.1038/nm0796-767	http://dx.doi.org/10.1038/nm0796-767			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673922				2022-12-27	WOS:A1996UU68000032
J	Maciunas, RJ				Maciunas, RJ			Stereotactic radiosurgery	NATURE MEDICINE			English	Editorial Material							LINEAR-ACCELERATOR; ARTERIOVENOUS-MALFORMATIONS; BRAIN; THERAPY; BASE				Maciunas, RJ (corresponding author), VANDERBILT UNIV,MED CTR,DEPT NEUROL SURG,T-4224 MED CTR N,NASHVILLE,TN 37232, USA.							BETTI OO, 1984, ACTA NEUROCHIRURGI S, V33, P385; Coffey R J, 1991, Acta Neurochir Suppl (Wien), V52, P90; COLOMBO F, 1985, NEUROSURGERY, V16, P154, DOI 10.1227/00006123-198502000-00005; DAWSON RC, 1990, AM J NEURORADIOL, V11, P857; DEGERBLAD M, 1986, ACTA ENDOCRINOL-COP, V112, P310, DOI 10.1530/acta.0.1120310; FLICKINGER JC, 1989, INT J RADIAT ONCOL, V17, P879, DOI 10.1016/0360-3016(89)90082-5; FLICKINGER JC, 1991, CANCER, V67, P345, DOI 10.1002/1097-0142(19910115)67:2<345::AID-CNCR2820670205>3.0.CO;2-M; FRIEDMAN WA, 1992, J NEUROSURG, V77, P832, DOI 10.3171/jns.1992.77.6.0832; GILL SS, 1991, INT J RADIAT ONCOL, V20, P599, DOI 10.1016/0360-3016(91)90076-G; Horsley V, 1908, BRAIN, V31, P45, DOI 10.1093/brain/31.1.45; HOSOBUCHI Y, 1987, APPL NEUROPHYSIOL, V50, P248; KAPLAN ID, 1992, CANCER, V70, P1980, DOI 10.1002/1097-0142(19921001)70:7<1980::AID-CNCR2820700728>3.0.CO;2-L; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; KONDZIOLKA D, 1991, NEUROSURGERY, V29, P38, DOI 10.1227/00006123-199107000-00007; KONDZIOLKA D, 1991, J NEUROSURG, V74, P552, DOI 10.3171/jns.1991.74.4.0552; KONZIOLKA D, 1990, NEUROSURGERY, V27, P892; LARSSON B, 1958, NATURE, V182, P1222, DOI 10.1038/1821222a0; LEKSELL L, 1971, ACTA CHIR SCAND, V137, P311; LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316; LEKSELL L, 1960, ACTA RADIOL, V54, P251, DOI 10.3109/00016926009172547; LEKSELL L, 1968, ACTA CHIR SCAND, V134, P585; LOEFFLER JS, 1990, J CLIN ONCOL, V8, P576, DOI 10.1200/JCO.1990.8.4.576; LUNSFORD LD, 1989, NEUROSURGERY, V24, P151; LUTZ W, 1988, INT J RADIAT ONCOL, V14, P373, DOI 10.1016/0360-3016(88)90446-4; OZKAN M, 1995, P INT AUT SYST C KAR, P27; PODGORSAK EB, 1988, INT J RADIAT ONCOL, V14, P115, DOI 10.1016/0360-3016(88)90059-4; SOUHAMI L, 1991, CANCER-AM CANCER SOC, V68, P2101, DOI 10.1002/1097-0142(19911115)68:10<2101::AID-CNCR2820681003>3.0.CO;2-C; SPIEGELMANN R, 1992, NEUROSURGERY, V30, P619; STEINER L, 1980, ACTA NEUROCHIR, V52, P173, DOI 10.1007/BF01402072; WINSTON KR, 1988, NEUROSURGERY, V22, P454, DOI 10.1227/00006123-198803000-00002	30	3	3	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					712	713		10.1038/nm0696-712	http://dx.doi.org/10.1038/nm0696-712			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640567				2022-12-27	WOS:A1996UN69100044
J	Mitchison, DA				Mitchison, DA			Pyrazinamide - On the antituberculosis drug frontline	NATURE MEDICINE			English	Editorial Material							CHEMOTHERAPY; TUBERCULOSIS				Mitchison, DA (corresponding author), ST GEORGE HOSP, SCH MED, DEPT MED MICROBIOL, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.							BRANDER E, 1972, Tubercle, V53, P128, DOI 10.1016/0041-3879(72)90029-3; Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; CYNAMON MH, 1995, J MED CHEM, V38, P3902, DOI 10.1021/jm00020a003; KONNO K, 1967, AM REV RESPIR DIS, V95, P461; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; MITCHISON DA, 1992, J ANTIMICROB CHEMOTH, V29, P477, DOI 10.1093/jac/29.5.477; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662	10	18	18	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1996	2	6					635	636		10.1038/nm0696-635	http://dx.doi.org/10.1038/nm0696-635			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640549				2022-12-27	WOS:A1996UN69100026
J	OReilly, MS; Holmgren, L; Chen, C; Folkman, J				OReilly, MS; Holmgren, L; Chen, C; Folkman, J			Angiostatin induces and sustains dormancy of human primary tumors in mice	NATURE MEDICINE			English	Article							GROWTH-FACTOR; PLASMA; CELLS	There is now considerable direct evidence that tumor growth is angiogenesis-dependent(1-4). The most compelling evidence is based on the discovery of angiostatin, an angiogenesis inhibitor that selectively instructs endothelium to become refractory to angiogenic stimuli(5). Angiostatin, which specifically inhibits endothelial proliferation, induced dormancy of metastases defined by a balance of apoptosis and proliferation(6). We now show that systemic administration of human angiostatin potently inhibits the growth of three human and three murine primary carcinomas in mice. An almost complete inhibition of tumor growth was observed without detectable toxicity or resistance. The human carcinomas regressed to microscopic dormant foci in which tumor cell proliferation was balanced by apoptosis in the presence of blocked angiogenesis. This regression of primary tumors without toxicity has not been previously described. This is also the first demonstration of dormancy therapy, a novel anticancer strategy in which malignant tumors are regressed by prolonged blockade of angiogenesis.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	OReilly, MS (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,DEPT CELLULAR BIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA064481] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FOLKMAN J, 1976, SCI AM, V234, P58, DOI 10.1038/scientificamerican0576-58; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HORI A, 1991, CANCER RES, V51, P6180; KENYON BM, IN PRESS INVEST OPTH; KEY G, 1993, LAB INVEST, V68, P629; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NICOSIA RF, 1986, CLIN EXP METASTAS, V4, P91, DOI 10.1007/BF00119076; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; TEICHER BA, 1994, INT J CANCER, V57, P1; [No title captured]	19	1034	1107	0	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					689	692		10.1038/nm0696-689	http://dx.doi.org/10.1038/nm0696-689			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640562				2022-12-27	WOS:A1996UN69100039
J	McCully, KS				McCully, KS			Homocysteine and vascular disease	NATURE MEDICINE			English	Editorial Material							ATHEROSCLEROSIS; HOMOCYSTINURIA; RISK				McCully, KS (corresponding author), VET AFFAIRS MED CTR,PATHOL & LAB MED SERV,830 CHALKSTONE AVE,PROVIDENCE,RI 02908, USA.							BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CLOPATH P, 1976, SCIENCE, V192, P372, DOI 10.1126/science.1257770; ELLIS JM, 1995, RES COMMUN MOL PATH, V89, P208; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KANWAR YS, 1976, PEDIATR RES, V10, P598, DOI 10.1203/00006450-197606000-00008; MATTHIAS D, IN PRESS ATHEROSCLER; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MCCULLY KS, 1990, AM J MED SCI, V299, P217, DOI 10.1097/00000441-199004000-00001; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P27; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P134; MCCULLY KS, 1970, NATURE, V231, P391; MUDD SH, 1981, AM J HUM GENET, V33, P883; MUDD SH, 1982, AM J HUM GENET, V34, P1016; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NILSSON J, 1992, HERZ, V17, P263; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SHIPCHANDLER MT, 1995, CLIN CHEM, V41, P991; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; UBBINK JB, 1995, AM J CLIN NUTR, V62, P802, DOI 10.1093/ajcn/62.4.802; UBBINK JB, 1993, CLIN INVESTIGATOR, V71, P993, DOI 10.1007/BF00180030	23	623	653	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					386	389		10.1038/nm0496-386	http://dx.doi.org/10.1038/nm0496-386			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597939				2022-12-27	WOS:A1996UD31400031
J	Friedmann, T				Friedmann, T			Human gene therapy - An immature genie, but certainly out of the bottle	NATURE MEDICINE			English	Article								The gene therapy community has swung from an excited and overoptimistic mood to one of disillusionment with the apparent slowness of progress and with the absence of truly therapeutic applications. Although gene therapy is yet to come of age, there can be no doubt that, in time, it will bear fruit.			Friedmann, T (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093, USA.							BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; BRENNER MK, 1995, J INTERN MED, V237, P229, DOI 10.1111/j.1365-2796.1995.tb01171.x; CULVER K, 1994, GENE THERAPY HDB PHY; FRIEDMANN T, 1994, GENE THER, V1, P217; GROSSMAN M, 1995, NAT MED, V1, P1148, DOI 10.1038/nm1195-1148; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; RIGBY PWJ, 1995, CURR OPIN GENET DEV, V5, P397, DOI 10.1016/0959-437X(95)80056-5; THAYER AM, 1995, CHEM ENG NEWS, V73, P15; VERMA IM, 1994, MOL MED, V1, P2; WEATHERALL DJ, 1995, BRIT MED BULL, V51, P1	15	115	137	1	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					144	147		10.1038/nm0296-144	http://dx.doi.org/10.1038/nm0296-144			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574951				2022-12-27	WOS:A1996TU06000026
J	Riddell, SR; Elliott, M; Lewinsohn, DA; Gilbert, MJ; Wilson, L; Manley, SA; Lupton, SD; Overell, RW; Reynolds, TC; Corey, L; Greenberg, PD				Riddell, SR; Elliott, M; Lewinsohn, DA; Gilbert, MJ; Wilson, L; Manley, SA; Lupton, SD; Overell, RW; Reynolds, TC; Corey, L; Greenberg, PD			T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients	NATURE MEDICINE			English	Article							LONG-TERM EXPRESSION; ADENOSINE-DEAMINASE; RHESUS-MONKEYS; TRANSPLANTATION; THERAPY; PROTEIN; DISEASE; INVIVO; VIRUS; IMMUNOTHERAPY	The introduction and expression of genes in somatic cells is an innovative therapy for correcting genetic deficiency diseases and augmenting immune function. A potential obstacle to gene therapy is the elimination of such gene-modified cells by an immune response to novel protein products of the introduced genes. We are conducting an immunotherapy trial in which individuals seropositive for human immunodeficiency virus (HIV) receive CD8(+) HIV-specific cytotoxic T cells modified by retroviral transduction to express a gene permitting positive and negative selection. However, five of six subjects developed cytotoxic T-lymphocyte responses specific for the novel protein and eliminated the transduced cytotoxic T cells. The rejection of genetically modified cells by these immunocompromised hosts suggests that strategies to render gene-modified cells less susceptible to host immune surveillance will be required for successful gene therapy of immunocompetent hosts.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; TARGETED GENET CORP,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Riddell, SR (corresponding author), FRED HUTCHINSON CANC RES CTR,1174 COLUMBIA ST,SEATTLE,WA 98104, USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI036613] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI36613] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BLAESE RM, 1993, HUM GENE THER, V4, P521, DOI 10.1089/hum.1993.4.4-521; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRODY SL, 1994, HUM GENE THER, V5, P821, DOI 10.1089/hum.1994.5.7-821; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CULVER KW, 1990, HUM GENE THER, V1, P399, DOI 10.1089/hum.1990.1.4-399; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; DRANOFF G, 1995, ADV IMMUNOL, V58, P417, DOI 10.1016/S0065-2776(08)60624-0; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MERROUCHE Y, 1995, J CLIN ONCOL, V13, P410, DOI 10.1200/JCO.1995.13.2.410; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIDDELL SR, 1992, SCIENCE, V257, P238; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; STRIJBOSCH LWG, 1987, J IMMUNOL METHODS, V97, P133, DOI 10.1016/0022-1759(87)90115-3; TIGGES MA, 1992, J VIROL, V66, P1622, DOI 10.1128/JVI.66.3.1622-1634.1992; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YEI SP, 1994, GENE THER, V1, P192; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	51	486	558	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					216	223		10.1038/nm0296-216	http://dx.doi.org/10.1038/nm0296-216			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574968				2022-12-27	WOS:A1996TU06000043
J	Wang, XL; Sim, AS; Badenhop, RF; McCredie, RM; Wilcken, DEL				Wang, XL; Sim, AS; Badenhop, RF; McCredie, RM; Wilcken, DEL			A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene	NATURE MEDICINE			English	Article								Endothelium-dependent vasodilatation is mediated by release of nitric oxide formed by constitutively expressed endothelial nitric oxide synthase (ecNOS). We explored the distribution of polymorphism ecNOS4a/b in 549 subjects with, and 153 without, coronary artery disease in relation to smoking. In current and ex-cigarette smokers, but not nonsmokers, there was a significant excess of homozygotes for the rare ecNOS4a allele in patients with severely stenosed arteries, compared with those with no or mild stenosis. This genotype was also associated with a history of myocardial infarction. This smoking-dependent excess coronary risk in ecNOS4a homozygotes is consistent with predisposition to endothelial dysfunction.	UNIV NEW S WALES,PRINCE HENRY HOSP,DEPT CARDIOVASC MED,SYDNEY,NSW 2036,AUSTRALIA; UNIV NEW S WALES,PRINCE WALES HOSP,DEPT CARDIOVASC MED,SYDNEY,NSW 2036,AUSTRALIA	University of New South Wales Sydney; University of New South Wales Sydney								BONNARDEAUX A, 1995, CIRCULATION, V91, P96, DOI 10.1161/01.CIR.91.1.96; CELERMAJER DS, 1993, J AM COLL CARDIOL, V22, P854, DOI 10.1016/0735-1097(93)90203-D; Emery AEH, 1976, METHODOLOGY MED GENE, P3; HIGMAN DJ, 1994, BRIT J SURG, V81, P97798; KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27; LUSCHER TF, 1993, EUR J CLIN INVEST, V23, P670, DOI 10.1111/j.1365-2362.1993.tb01285.x; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MIYAHARA K, 1994, EUR J BIOCHEM, V223, P719, DOI 10.1111/j.1432-1033.1994.tb19045.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; POWELL JT, 1994, BRIT J SURG, V81, P785, DOI 10.1002/bjs.1800810602; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; WANG XL, 1994, CIRCULATION, V89, P1974, DOI 10.1161/01.CIR.89.5.1974; WARREN JB, 1994, CARDIOVASC RES, V28, P25, DOI 10.1093/cvr/28.1.25; WEINTRAUB WS, 1985, AM J CARDIOL, V55, P669, DOI 10.1016/0002-9149(85)90133-X; WILCKEN DEL, 1993, J PEDIATR-US, V123, P519, DOI 10.1016/S0022-3476(05)80944-8; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156; [No title captured]	22	509	549	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1996	2	1					41	45		10.1038/nm0196-41	http://dx.doi.org/10.1038/nm0196-41			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TP579	8564837				2022-12-27	WOS:A1996TP57900035
J	WANG, MZ; JIN, P; BUMCROT, DA; MARIGO, V; MCMAHON, AP; WANG, EA; WOOLF, T; PANG, K				WANG, MZ; JIN, P; BUMCROT, DA; MARIGO, V; MCMAHON, AP; WANG, EA; WOOLF, T; PANG, K			INDUCTION OF DOPAMINERGIC NEURON PHENOTYPE IN THE MIDBRAIN BY SONIC HEDGEHOG PROTEIN	NATURE MEDICINE			English	Article							CELL PATTERN; FLOOR PLATE; NOTOCHORD	Loss of substantia nigra dopaminergic neurons, which develop from the ventral region of the midbrain, is associated with Parkinson's disease. During embryogenesis, induction of these and other ventral neurons is influenced by interactions with the underlying mesoderm of the notochord and the floor plate, which lies at the ventral midline of the developing CNS. Sonic hedgehog encodes a secreted peptide, which is expressed in notochord and floor plate cells and can induce appropriate ventral cell types in the basal forebrain and spinal cord. Here we demonstrate that Sonic hedgehog is sufficient to induce dopaminergic and other neuronal phenotypes in chick mesencephalic explants in vitro. We find that Sonic hedgehog is a general ventralizing signal in the CNS, the specific response being determined by the receiving cells. These results suggest that Sonic hedgehog may have utility in the induction of clinically important cell types.	ONTOGENY INC,CAMBRIDGE,MA 02139; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Marigo, Valeria/B-7947-2015; McMahon, Andrew P/ABE-7520-2020	Marigo, Valeria/0000-0002-4428-2084; 				ANG SL, 1993, DEVELOPMENT, V119, P1301; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; DONLACH T, 1992, SCIENCE, V257, P542; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1995, CELL, V81, P1; FORBES AJ, 1993, DEVELOPMENT, P115; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LINDVALL O, 1994, FUNCTIONAL NEURAL TR, P103; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MITRANI E, 1990, SCIENCE, V247, P1092, DOI 10.1126/science.11032544; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V75, P761; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; METHODS APPLICATIONS, P39	29	141	154	1	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1184	1188		10.1038/nm1195-1184	http://dx.doi.org/10.1038/nm1195-1184			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584992				2022-12-27	WOS:A1995TC53700044
J	CHEN, HH; KONG, WP; ZHANG, L; WARD, PL; ROOS, RP				CHEN, HH; KONG, WP; ZHANG, L; WARD, PL; ROOS, RP			A PICORNAVIRAL PROTEIN SYNTHESIZED OUT OF FRAME WITH THE POLYPROTEIN PLAYS A KEY ROLE IN A VIRUS-INDUCED IMMUNE-MEDIATED DEMYELINATING DISEASE	NATURE MEDICINE			English	Article							MURINE ENCEPHALOMYELITIS VIRUS; THEILERS VIRUS; DA STRAIN; INITIATION SITE; TRANSLATION; RNA; NEUROVIRULENCE; INFECTION; MICE	The DA strain and other members of the TO subgroup of Theiler's murine encephalomyelitis virus (TMEV) induce a chronic demyelinating disease with a restricted virus expression. This disease serves as an experimental model of multiple sclerosis; in both diseases the immune system contributes to a similar demyelinating pathology. Like all picornaviruses, TMEV encodes a polyprotein translated from one long open reading frame. The polyprotein is then processed into structural and non-structural viral proteins. Here, we demonstrate that the DA strain of TMEV has an additional alternative open reading frame that encodes a protein called L* that is present in infected cells. Virus with a mutation of L* has a dramatically decreased demyelinating activity, indicating that L* plays a critical role in TO subgroup-induced demyelinating disease. L* is associated with membranes, suggesting that L* may interact with the immune system and thereby mediate the viral-induced demyelinating disease.	UNIV CHICAGO,MED CTR,DEPT NEUROL,CHICAGO,IL 60637; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV CHICAGO,MARJORIE B KOVLER VIRAL ONCOL LABS,CHICAGO,IL 60637	University of Chicago; University of Chicago Medical Center; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Chicago				Chen, Hsiao-Huei/0000-0003-2914-6057	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024575, P01NS021442] Funding Source: NIH RePORTER; NINDS NIH HHS [1 PO1 NS 24575, 1 PO1 NS 21442] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAINES JD, 1991, J VIROL, V65, P6414, DOI 10.1128/JVI.65.12.6414-6424.1991; CELMA ML, 1975, J MOL BIOL, V65, P3395; CLATCH RJ, 1986, J IMMUNOL, V136, P920; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; FU JL, 1990, P NATL ACAD SCI USA, V87, P4125, DOI 10.1073/pnas.87.11.4125; FUJINAMI RS, 1988, J NEUROIMMUNOL, V20, P25, DOI 10.1016/0165-5728(88)90110-5; GORDON J, 1994, IMMUNOL TODAY, V15, P411, DOI 10.1016/0167-5699(94)90270-4; HILL JR, 1992, J BIOL CHEM, V267, P21886; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; JAROUSSE N, 1994, J VIROL, V68, P3364, DOI 10.1128/JVI.68.5.3364-3368.1994; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; KONG WP, 1991, J VIROL, V65, P3395, DOI 10.1128/JVI.65.6.3395-3399.1991; NUNEZ R, 1993, PATHOBIOLOGY, V61, P128, DOI 10.1159/000163781; OLESZAK EL, 1988, J GEN VIROL, V69, P2413, DOI 10.1099/0022-1317-69-9-2413; PATICK AK, 1990, J GEN VIROL, V71, P2123, DOI 10.1099/0022-1317-71-9-2123; PHILLIPS BA, 1986, VIROLOGY, V148, P255, DOI 10.1016/0042-6822(86)90323-5; PRITCHARD AE, 1992, J VIROL, V66, P1951, DOI 10.1128/JVI.66.4.1951-1958.1992; RODRIGUEZ M, 1992, J VIROL, V66, P217, DOI 10.1128/JVI.66.1.217-225.1992; ROOS RP, 1989, J VIROL, V63, P5492, DOI 10.1128/JVI.63.12.5492-5496.1989; ROOS RP, 1989, J VIROL, V63, P5344, DOI 10.1128/JVI.63.12.5344-5353.1989; ROOS RP, 1989, J VIROL, V63, P4469, DOI 10.1128/JVI.63.10.4469-4473.1989; ROOS RP, 1992, MOL NEUROVIROLOGY, P283; SANGAR DV, 1987, NUCLEIC ACIDS RES, V15, P3305, DOI 10.1093/nar/15.8.3305; SPEAR PG, 1972, J VIROL, V9, P143, DOI 10.1128/JVI.9.1.143-159.1972; TESAR M, 1992, VIROLOGY, V186, P609, DOI 10.1016/0042-6822(92)90027-M; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; ZHANG L, 1995, J VIROL, V69, P3171, DOI 10.1128/JVI.69.5.3171-3175.1995; ZURBRIGGEN A, 1991, J VIROL, V65, P1929, DOI 10.1128/JVI.65.4.1929-1937.1991	29	62	62	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					927	931		10.1038/nm0995-927	http://dx.doi.org/10.1038/nm0995-927			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585219				2022-12-27	WOS:A1995RT30300047
J	YANG, YP; TRINCHIERI, G; WILSON, JM				YANG, YP; TRINCHIERI, G; WILSON, JM			RECOMBINANT IL-12 PREVENTS FORMATION OF BLOCKING IGA ANTIBODIES TO RECOMBINANT ADENOVIRUS AND ALLOWS REPEATED GENE-THERAPY TO MOUSE LUNG	NATURE MEDICINE			English	Article							STIMULATORY FACTOR INTERLEUKIN-12; MICE; CELLS	Enthusiasm for the use of recombinant adenoviruses in gene therapy has been tempered by the problematic immune responses that develop to the virus and virus-infected cells. Humoral immune responses to the input viral proteins generate neutralizing antibodies that thwart attempts to effectively administer the therapy more than once. Previous studies in murine models of gene therapy for cystic fibrosis (CF) have shown that the formation of adenoviral antibodies of the IgA subtype, a process that is dependent on T helper cells of the T-H2 subset, contributes to a block in gene transfer that occurs following a second administration of virus. We show in this report that coadministration of interferon-gamma (lFN-gamma) (or interleukin-12 which activates T-H1 cells to secrete IFN-gamma) with the recombinant adenovirus into the airway of C57BL/6 mice diminishes the activation of T-H2 cells and formation of neutralizing antibody, allowing for efficient readministration of recombinant virus. This suggests a strategy for gene therapy of CF in which administration of a short-acting immune modulator at the time of gene therapy may be sufficient to overcome the problems of humoral immunity.	UNIV PENN,MED CTR,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				DAI Y, IN PRESS P NATN ACAD; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; ENGELHARDT JF, 1994, HUM GENE THER, V5, P1217, DOI 10.1089/hum.1994.5.10-1217; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MORRIS SC, 1994, J IMMUNOL, V152, P1047; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUINN B, 1992, P NATL ACAD SCI USA, V89, P2581; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; YANG Y, IN PRESS P NATN ACAD; YANG Y, 1994, NAT GENET, V7, P363; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; YEI SP, 1994, GENE THER, V1, P192	21	223	231	1	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1995	1	9					890	893		10.1038/nm0995-890	http://dx.doi.org/10.1038/nm0995-890			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RT303	7585213				2022-12-27	WOS:A1995RT30300041
J	ELDADAH, ZA; GRIFO, JA; DIETZ, HC				ELDADAH, ZA; GRIFO, JA; DIETZ, HC			MARFAN-SYNDROME AS A PARADIGM FOR TRANSCRIPT-TARGETED PREIMPLANTATION DIAGNOSIS OF HETEROZYGOUS MUTATIONS	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; GENETIC DIAGNOSIS; CYSTIC-FIBROSIS; AMPLIFICATION; CELL; DNA	Among the many clinical applications of the polymerase chain reaction (PCR) is its potential use in preimplantation diagnosis of genetic disorders. Performing PCR on single blastomeres from early cleavage stage (six-to eight-cell) human embryos should, in principle, enable reliable determination of disease status for certain inherited conditions. However, reports of misdiagnoses using this technique have diminished enthusiasm for its widespread clinical use. One principal source of error is the propensity for genome-targeted PCR to exclusively amplify one allele in reactions assaying a single heterozygous diploid cell. Complete reaction failure is also common. Employing the Marfan syndrome (MFS) as a paradigm, we have developed a reliable, reverse transcription-PCR-based method of genotyping single cells that overcomes these obstacles. The technique should facilitate accurate preimplantation diagnosis of MFS and other selected genetic diseases caused by heterozygous or compound-heterozygous mutations.	JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; CORNELL UNIV,COLL MED,CTR REPROD MED & INFERTIL,NEW YORK,NY 10021	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Cornell University				Grifo, James/0000-0003-0439-2374				ARNHEIM N, 1992, HUM REPROD, V7, P1481, DOI 10.1093/oxfordjournals.humrep.a137599; BOEHNKE M, 1989, AM J HUM GENET, V45, P21; BRIDGES AB, 1992, J MED GENET, V29, P81, DOI 10.1136/jmg.29.2.81; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; CUI X, 1993, P NATL ACAD SCI USA, V86, P9389; CUL KH, 1994, LANCET, V343, P972; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GRIFO JA, 1994, HUM REPROD, V9, P912, DOI 10.1093/oxfordjournals.humrep.a138616; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; HANDYSIDE A, 1992, HUM REPROD, V7, P1481, DOI 10.1093/oxfordjournals.humrep.a137600; Handyside A.H., 1993, PREIMPLANTATION DIAG, P239; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HANDYSIDE AH, 1989, LANCET, V2, P532; HEWETT DR, 1994, AM J HUM GENET, V52, P447; KONTOGIANNI EH, 1991, 1ST P S PREIMPL GEN, P139; KRISTJANSSON K, 1994, NAT GENET, V6, P19, DOI 10.1038/ng0194-19; LI A, 1988, NATURE, V335, P414; LIU J, 1994, HUM REPROD, V9, P716, DOI 10.1093/oxfordjournals.humrep.a138576; MCKUSICK VA, 1993, MENDELIAN INHERITANC; MCKUSICK VA, 1977, HERITABLE DISORDERS; MUGGLETONHARRIS AL, 1994, INT REV CYTOL, V151, P1, DOI 10.1016/S0074-7696(08)62629-7; NAVIDI W, 1991, HUM REPROD, V6, P836, DOI 10.1093/oxfordjournals.humrep.a137438; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; PEREIRA L, 1994, NEW ENGL J MED, V331, P148, DOI 10.1056/NEJM199407213310302; PICKERING SJ, 1992, HUM REPROD, V7, P630, DOI 10.1093/oxfordjournals.humrep.a137710; PYERITZ RE, 1977, NEW ENGL J MED, V300, P772; SNABES MC, 1994, P NATL ACAD SCI USA, V91, P6181, DOI 10.1073/pnas.91.13.6181; TROUNSON AL, 1992, HUM REPROD, V7, P583; VERLINSKY Y, 1992, PRENATAL DIAG, V12, P103, DOI 10.1002/pd.1970120205; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	32	37	37	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					798	803		10.1038/nm0895-798	http://dx.doi.org/10.1038/nm0895-798			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585183				2022-12-27	WOS:A1995RM63500037
J	HUNG, LF; CRAWFORD, MLJ; SMITH, EL				HUNG, LF; CRAWFORD, MLJ; SMITH, EL			SPECTACLE LENSES ALTER EYE GROWTH AND THE REFRACTIVE STATUS OF YOUNG MONKEYS	NATURE MEDICINE			English	Article							CHROMATIC ABERRATION; OPTICAL DEFOCUS; VISUAL-ACUITY; EMMETROPIZATION; ACCOMMODATION; CHICKEN; MODEL; MYOPIA; DEPRIVATION; PROGRESSION	The influence of visual experience on ocular development in higher primates is not well understood. To investigate the possible role of defocus in regulating ocular growth, spectacle lenses were used to optically simulate refractive anomalies in young monkeys (for example, myopia or nearsightedness). Both positive and negative lenses produced compensating ocular growth that reduced the lens-induced refractive errors and, at least for low lens powers, minimized any refractive-error differences between the two eyes. These results indicate that the developing primate visual system can detect the presence of refractive anomalies and alter each eye's growth to eliminate these refractive errors. Moreover, these results support the hypothesis that spectacle lenses can alter eye development in young children.	UNIV HOUSTON,COLL OPTOMETRY,HOUSTON,TX 77204; UNIV TEXAS,GRAD SCH BIOMED SCI,CTR SENSORY SCI,HOUSTON,TX 77030	University of Houston System; University of Houston; University of Texas System					NATIONAL EYE INSTITUTE [R01EY003611, P30EY007551] Funding Source: NIH RePORTER; NEI NIH HHS [EY 03611, EY 07551] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Atkinson J., 1993, EARLY VISUAL DEV NOR, P335; BOOTHE RG, 1985, ANNU REV NEUROSCI, V8, P495, DOI 10.1146/annurev.ne.08.030185.002431; CHARMAN WN, 1991, VISION VISUAL DYSFUN, V1, P1; CHUNG KM, 1993, OPTOMETRY VISION SCI, V70, P228, DOI 10.1097/00006324-199303000-00010; CRAWFORD MLJ, 1979, T OPHTHAL SOC UK, V99, P369; CREWTHER SG, 1988, CLIN VISION SCI, V3, P221; GREEN DG, 1980, VISION RES, V20, P827, DOI 10.1016/0042-6989(80)90063-2; GWIAZDA J, 1993, CLIN VISION SCI, V8, P337; HENDRICKSON P, 1985, INVEST OPHTH VIS SCI, V26, P343; HOWLAND HC, 1985, AM J OPTOM PHYS OPT, V62, P621; INGRAM RM, 1991, BRIT J OPHTHALMOL, V75, P414, DOI 10.1136/bjo.75.7.414; IRVING EL, 1992, OPHTHAL PHYSL OPT, V12, P448, DOI 10.1111/j.1475-1313.1992.tb00315.x; IRVING EL, 1991, OPTOMETRY VISION SCI, V68, P364, DOI 10.1097/00006324-199105000-00007; KIELY PM, 1987, CLIN VISION SCI, V1, P269; KIORPES L, 1995, VISION RES, V35, P1289, DOI 10.1016/0042-6989(94)00239-I; MEDINA A, 1987, ACTA OPHTHALMOL, V65, P565; MEDINA A, 1987, OPHTHALMOLOGICA, V194, P133, DOI 10.1159/000309750; NI JR, 1989, VISION RES, V29, P929, DOI 10.1016/0042-6989(89)90107-7; RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505; ROHRER B, 1992, J PHYSIOL-LONDON, V449, P363, DOI 10.1113/jphysiol.1992.sp019090; SCHAEFFEL F, 1990, VISUAL NEUROSCI, V4, P177, DOI 10.1017/S0952523800002327; SCHAEFFEL F, 1988, VISION RES, V28, P639, DOI 10.1016/0042-6989(88)90113-7; SCHAEFFEL F, 1988, J OPT SOC AM A, V5, P2080, DOI 10.1364/JOSAA.5.002080; SCHAEFFEL F, 1991, VISION RES, V31, P717, DOI 10.1016/0042-6989(91)90011-S; SCHAEFFEL F, 1987, APPL OPTICS, V26, P1505, DOI 10.1364/AO.26.001505; SCHAEFFEL F, 1986, VISION RES, V26, P1977, DOI 10.1016/0042-6989(86)90123-9; SMITH EL, 1985, INVEST OPHTH VIS SCI, V26, P330; SMITH EL, 1987, INVEST OPHTH VIS SCI, V28, P1236; SMITH EL, 1994, VISION RES, V34, P293, DOI 10.1016/0042-6989(94)90088-4; TROILO D, 1991, VISION RES, V31, P1237, DOI 10.1016/0042-6989(91)90048-A; WALLMAN J, 1987, SCIENCE, V237, P73, DOI 10.1126/science.3603011; WILDSOET CF, 1993, VISION RES, V33, P1593, DOI 10.1016/0042-6989(93)90026-S	32	359	369	2	46	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1995	1	8					761	765		10.1038/nm0895-761	http://dx.doi.org/10.1038/nm0895-761			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585177				2022-12-27	WOS:A1995RM63500031
J	YAN, SD; YAN, SF; CHEN, X; FU, J; CHEN, M; KUPPUSAMY, P; SMITH, MA; PERRY, G; GODMAN, GC; NAWROTH, P; ZWEITER, JL; STERN, D				YAN, SD; YAN, SF; CHEN, X; FU, J; CHEN, M; KUPPUSAMY, P; SMITH, MA; PERRY, G; GODMAN, GC; NAWROTH, P; ZWEITER, JL; STERN, D			NONENZYMATICALLY GLYCATED-TAU IN ALZHEIMERS-DISEASE INDUCES NEURONAL OXIDANT STRESS RESULTING IN CYTOKINE GENE-EXPRESSION AND RELEASE OF AMYLOID BETA-PEPTIDE	NATURE MEDICINE			English	Article							KAPPA-B; PROTEIN; IMMUNOREACTIVITY; INTERLEUKIN-6; ACTIVATION; INITIATION; CELLS	Paired helical filament (PHF) tau is the principal component of neurofibrillary tangles, a characteristic feature of the neurodegenerative pathology in Alzheimer's disease (AD). Post-translational modification of tau, especially phosphorylation, has been considered a major factor in aggregation and diminished microtubule interactions of PHF-tau. Recently, it has been recognized that PHF-tau is also subject to non-enzymatic glycation, with formation of advanced glycation end products (AGEs). We now show that as a consequence of glycation, PHF-tau from AD and ACE-tau generate oxygen free radicals, thereby activating transcription via nuclear factor-kappa B, increasing amyloid beta-protein precursor and release of similar to 4 kD amyloid beta-peptides. These data provide Insight into how PHF-tau disturbs neuronal function, and add to a growing body of evidence that oxidant stress contributes to the pathogenesis of AD.	COLUMBIA UNIV COLL PHYS & SURG, DEPT SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21224 USA; CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; UNIV HEIDELBERG, DEPT MED, W-6900 HEIDELBERG, GERMANY	Columbia University; Columbia University; Johns Hopkins University; Case Western Reserve University; Ruprecht Karls University Heidelberg	YAN, SD (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Perry, George/A-8611-2009; Fu, Jin/A-3510-2012; Smith, Mark A/A-9053-2009	Perry, George/0000-0002-6547-0172; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, P50HL017655, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42507, HL 21006, HL 17655] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; COLLINS T, 1993, LAB INVEST, V68, P499; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FRAPPIER TF, 1994, J NEUROCHEM, V63, P2288; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LIN MF, 1993, BIOCHEM BIOPH RES CO, V192, P413, DOI 10.1006/bbrc.1993.1431; LIU WK, 1991, J BIOL CHEM, V266, P21723; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STRAUSS S, 1992, LAB INVEST, V66, P223; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wischik CM, 1989, CURR OPIN CELL BIOL, V1, P115, DOI 10.1016/S0955-0674(89)80047-X; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1994, J BIOL CHEM, V269, P9889; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	32	353	368	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1995	1	7					693	699		10.1038/nm0795-693	http://dx.doi.org/10.1038/nm0795-693			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585153				2022-12-27	WOS:A1995RQ06600046
J	BENZAQUEN, LR; BRUGNARA, C; BYERS, HR; GATTONICELLI, S; HALPERIN, JA				BENZAQUEN, LR; BRUGNARA, C; BYERS, HR; GATTONICELLI, S; HALPERIN, JA			CLOTRIMAZOLE INHIBITS CELL-PROLIFERATION IN-VITRO AND IN-VIVO	NATURE MEDICINE			English	Article							CYTOCHROME-P-450 INHIBITORS; HUMAN NEUTROPHILS; GROWTH-FACTORS; CALCIUM; STORES; INFLUX; CHANNELS; ENTRY; RAT; MELANOMA	Cell proliferation is critically dependent on the regulated movement of ions across various cellular compartments. The antimycotic drug clotrimazole (CLT) has been shown to inhibit movement of Ca2+ and K+ across the plasma membrane. Our results show that CLT inhibits the rate of cell proliferation of normal and cancer cell fines in a reversible and dose-dependent manner in vitro. Moreover, CLT depletes the intracellular Ca2+ stores and prevents the rise in cytosolic Ca2+ that normally follows mitogenic stimulation. In mice with severe combined immunodeficiency disease (SCID) and inoculated intravenously with MM-RU human melanoma cells, daily subcutaneous injections of CLT induced a significant reduction in the number of lung metastases. Modulation of early ionic mitogenic: signals and potent inhibition of cell proliferation both in vitro and in vivo are new and potentially useful clinical effects of CLT.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02115; CHILDRENS HOSP,HEMATOL LAB,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02118; MED UNIV S CAROLINA,DEPT RADIAT ONCOL,CHARLESTON,SC 29425	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Boston University; Medical University of South Carolina			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BENZAQUEN L, 1993, J EXP MED, V179, P985; BERGER HJ, 1993, AM J PHYSIOL, V265, pH267, DOI 10.1152/ajpheart.1993.265.1.H267; BORZAK S, 1990, AM J PHYSIOL, V259, pH973, DOI 10.1152/ajpheart.1990.259.3.H973; BYERS HR, 1993, MELANOMA RES, V3, P247; BYERS HR, 1991, AM J PATHOL, V139, P423; CLAPHAM DE, 1993, NATURE, V364, P763, DOI 10.1038/364763a0; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; EGUCHI K, 1992, J RHEUMATOL, V19, P1925; FLOEGE J, 1993, J CLIN INVEST, V90, P2362; French J E, 1966, Int Rev Exp Pathol, V5, P253; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; LOGAN DM, 1993, INT C AIDS, V9, P399; LYTTON J, 1991, J BIOL CHEM, V66, P17067; MAGNI M, 1991, J BIOL CHEM, V261, P9321; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, BIOCHIM BIOPHYS ACTA, V1177, P127, DOI 10.1016/0167-4889(93)90031-J; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEO M, 1977, CURR MED RES OPIN, V5, P169, DOI 10.1185/03007997709110160; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; VOSTAL JG, 1993, BIOCHEM J, V295, P525, DOI 10.1042/bj2950525; WEUTA H, 1974, POSTGRAD MED J, V50, P45	32	143	153	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1995	1	6					534	540		10.1038/nm0695-534	http://dx.doi.org/10.1038/nm0695-534			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN101	7585119				2022-12-27	WOS:A1995RN10100036
J	GILLIAM, TC				GILLIAM, TC			IS THE SPINAL MUSCULAR-ATROPHY GENE FOUND	NATURE MEDICINE			English	Editorial Material							CONTIG	Three articles claim to have identified the spinal muscular atrophy gene, yet they do not appear to have enough in common to identify the same gene.			GILLIAM, TC (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032, USA.							BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; LEFEBVRE S, 1995, CELL, V80, P1; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; ROY N, 1995, CELL, V80, P21; SARGENT CA, 1991, CYTOGENET CELL GENET, V58, P1901; THOMPSON TG, 1995, NAT GENET, V9, P56, DOI 10.1038/ng0195-56	14	9	11	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					124	127		10.1038/nm0295-124	http://dx.doi.org/10.1038/nm0295-124			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585007				2022-12-27	WOS:A1995QX55800021
J	MURRAY, C				MURRAY, C			TUMOR DORMANCY - NOT SO SLEEPY AFTER ALL	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; CELL PROLIFERATION; ANGIOGENESIS; INVIVO; CANCER				MURRAY, C (corresponding author), CITY HOSP,CRC,DEPT CLIN ONCOL,MOLEC ONCOL LAB,NOTTINGHAM NG5 1PB,ENGLAND.							DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOX SB, 1993, CANCER RES, V53, P4161; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504	18	41	42	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					117	118		10.1038/nm0295-117	http://dx.doi.org/10.1038/nm0295-117			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585003				2022-12-27	WOS:A1995QX55800016
J	CRYSTAL, RG				CRYSTAL, RG			THE GENE AS THE DRUG	NATURE MEDICINE			English	Editorial Material							CYSTIC-FIBROSIS GENE; IDENTIFICATION	Caplen et al. (pages 39-46) demonstrate that it is feasible to use liposomes to transfer a human gene in vivo. Can this vector mimic the ability of viruses to effectively transfer genetic information into target cells?			CRYSTAL, RG (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV PULM & CRIT CARE MED,NEW YORK,NY 10021, USA.							CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1994, COMMUNICATION   1129; CRYSTAL RG, 1992, FED REGISTER, V58, P21737; FELGNER PL, 1993, LIPOSOME RES, V3, P3; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1994, HUM GENE THER, V5, P331, DOI 10.1089/hum.1994.5.3-331; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	15	123	138	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1995	1	1					15	17		10.1038/nm0195-15	http://dx.doi.org/10.1038/nm0195-15			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX557	7584940				2022-12-27	WOS:A1995QX55700015
